<SEC-DOCUMENT>0001069530-21-000020.txt : 20210323
<SEC-HEADER>0001069530-21-000020.hdr.sgml : 20210323
<ACCEPTANCE-DATETIME>20210323170523
ACCESSION NUMBER:		0001069530-21-000020
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		62
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210323
DATE AS OF CHANGE:		20210323

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CASSAVA SCIENCES INC
		CENTRAL INDEX KEY:			0001069530
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911911336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29959
		FILM NUMBER:		21765506

	BUSINESS ADDRESS:	
		STREET 1:		7801 N CAPITAL OF TEXAS HIGHWAY
		STREET 2:		SUITE 260
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78731
		BUSINESS PHONE:		512-501-2444

	MAIL ADDRESS:	
		STREET 1:		7801 N CAPITAL OF TEXAS HIGHWAY
		STREET 2:		SUITE 260
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78731

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PAIN THERAPEUTICS INC
		DATE OF NAME CHANGE:	20000309
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>sava-20201231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<!--HTML document created with Certent Disclosure Management 6.39.2.1-->
<!--Created on: 3/23/2021 3:59:06 PM-->
<html>
	<head>
		<title>
			20201231 10K
		</title>
	</head>
	<body><div style="margin-left:63pt;margin-right:49pt;">
		<p style="margin:0pt;border-bottom:2pt double #000000 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;font-size:6pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;font-size:6pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;font-weight:bold;font-size:14pt;">UNITED STATES</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;font-weight:bold;font-size:14pt;">SECURITIES AND EXCHANGE COMMISSION</font>
		</p>
		<p style="margin:0pt;text-align:center;font-weight:bold;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Washington, D.C. 20549</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">_______________</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;font-size:6pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 16pt">
			<font style="display: inline;font-weight:bold;font-size:16pt;">Form </font><font style="display: inline;font-weight:bold;font-size:16pt;">10-K</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">_______________</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 3pt">
			<font style="display: inline;font-size:3pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:05.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.6pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:94.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.6pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:05.40%;padding:0pt 6.6pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;"></font></p>
				</td>
				<td valign="top" style="width:94.60%;padding:0pt 6.6pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-size:9pt;">(Mark One)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:05.40%;padding:0pt 6.6pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#x2611;</font></p>
				</td>
				<td valign="top" style="width:94.60%;padding:0pt 6.6pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-size:9pt;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-weight:bold;font-size:9pt;">For the </font><font style="display: inline;font-weight:bold;font-size:9pt;">Fiscal Year</font><font style="display: inline;font-weight:bold;font-size:9pt;"> Ended </font><font style="display: inline;font-weight:bold;font-size:9pt;">December&nbsp;</font><font style="display: inline;font-weight:bold;font-size:9pt;">31, 20</font><font style="display: inline;font-weight:bold;font-size:9pt;">20</font>
		</p>
		<p style="margin:0pt;text-align:center;font-weight:bold;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">or</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:05.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.6pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:94.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.6pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:05.40%;padding:0pt 6.6pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#x2610;</font></p>
				</td>
				<td valign="top" style="width:94.60%;padding:0pt 6.6pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-size:9pt;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 5pt;border-bottom:1pt none #D9D9D9 ;text-align:center;font-weight:bold;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">For the transition period from </font><font style="display: inline;font-size:9pt;text-decoration:underline;">_____</font><font style="display: inline;font-size:9pt;"> to </font><font style="display: inline;font-size:9pt;text-decoration:underline;">_____</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:center;font-weight:bold;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Commission File Number: </font><font style="display: inline;">000-29959</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 3pt">
			<font style="display: inline;font-weight:bold;font-size:3pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 22pt">
			<font style="display: inline;font-family:Sansation;font-weight:bold;font-size:22pt;">Cassava</font><font style="display: inline;font-weight:bold;font-size:22pt;">&nbsp;</font><font style="display: inline;font-family:Sansation;font-weight:bold;font-size:22pt;">Sciences,</font><font style="display: inline;font-weight:bold;font-size:22pt;">&nbsp;</font><font style="display: inline;font-family:Sansation;font-weight:bold;font-size:22pt;">Inc.</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
			<font style="display: inline;font-size:8pt;">(Exact name of registrant as specified in its charter)</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:50.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.6pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:49.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.6pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.46%;padding:0pt 6.6pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-size:9pt;">Delaware </font></p>
				</td>
				<td valign="top" style="width:49.54%;padding:0pt 6.6pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-size:9pt;">91-1911336 </font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.46%;padding:0pt 6.6pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-style:italic;font-size:9pt;">(State or other jurisdiction of</font></p>
				</td>
				<td valign="top" style="width:49.54%;padding:0pt 6.6pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-style:italic;font-size:9pt;">(I.R.S. Employer</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.46%;padding:0pt 6.6pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-style:italic;font-size:9pt;">incorporation or organization)</font></p>
				</td>
				<td valign="top" style="width:49.54%;padding:0pt 6.6pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-style:italic;font-size:9pt;">Identification Number)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 3pt">
			<font style="display: inline;font-size:3pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">7801 N. Capital of Texas Highway</font><font style="display: inline;font-size:9pt;">, &nbsp;</font><font style="display: inline;font-size:9pt;">Suite 260</font><font style="display: inline;font-size:9pt;">, &nbsp;</font><font style="display: inline;font-size:9pt;">Austin</font><font style="display: inline;font-size:9pt;">, &nbsp;</font><font style="display: inline;font-size:9pt;">TX</font><font style="display: inline;font-size:9pt;">&nbsp;</font><font style="display: inline;font-size:9pt;">78731</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-weight:bold;font-size:9pt;"> &nbsp;(</font><font style="display: inline;font-weight:bold;font-size:9pt;">512</font><font style="display: inline;font-weight:bold;font-size:9pt;">) &nbsp;</font><font style="display: inline;font-weight:bold;font-size:9pt;">501-2444</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
			<font style="display: inline;font-style:italic;font-size:8pt;">(Address, including zip code, of registrant's principal executive offices and</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
			<font style="display: inline;font-style:italic;font-size:8pt;">telephone number, including area code)</font>
		</p>
		<p style="margin:0pt;text-indent:14.4pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">Securities registered pursuant to Section 12(b) of the Act:</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.20%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:41.36%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">0</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.10%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.44%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:42.20%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Title of each class</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Trading</font></p>
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Symbol(s)</font></p>
				</td>
				<td valign="bottom" style="width:00.44%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:42.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Name of each exchange on which registered</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">Common Stock, $0.001 par value</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">SAVA</font></p>
				</td>
				<td valign="bottom" style="width:00.44%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:42.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">NASDAQ</font><font style="display: inline;font-size:9pt;"> Capital Market</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 3pt">
			<font style="display: inline;font-style:italic;font-size:3pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-weight:bold;font-size:9pt;">Securities registered pursuant to Section 12(g) of the Act:&nbsp;&nbsp;None</font>
		</p>
		<p style="margin:6pt 0pt 0.5pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
			<font style="display: inline;font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes&nbsp;</font><font style="display: inline;font-size:8pt;">&#x2611;</font><font style="display: inline;font-size:8pt;"> &nbsp;No&nbsp;</font><font style="display: inline;font-size:8pt;">&#x2610;</font>
		</p>
		<p style="margin:0pt 0pt 0.5pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
			<font style="display: inline;font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes&nbsp;</font><font style="display: inline;font-size:8pt;">&#x2610;</font><font style="display: inline;font-size:8pt;"> &nbsp;No&nbsp;</font><font style="display: inline;font-size:8pt;">&#x2611;</font>
		</p>
		<p style="margin:0pt 0pt 0.5pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
			<font style="display: inline;font-size:8pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;Yes&nbsp;</font><font style="display: inline;font-size:8pt;">&#x2611;</font><font style="display: inline;font-size:8pt;"> &nbsp;No&nbsp;</font><font style="display: inline;font-size:8pt;">&#x2610;</font>
		</p>
		<p style="margin:0pt 0pt 0.5pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
			<font style="display: inline;font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#xA7;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&nbsp;&nbsp;Yes&nbsp;</font><font style="display: inline;font-size:8pt;">&#x2611;</font><font style="display: inline;font-size:8pt;"> &nbsp;No&nbsp;</font><font style="display: inline;font-size:8pt;">&#x2610;</font><font style="display: inline;font-size:8pt;">.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
			<font style="display: inline;font-size:8pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201C;large accelerated filer,&#x201D; &#x201C;accelerated filer,&#x201D; &#x201C;smaller reporting company,&#x201D; and &#x201C;emerging growth company&#x201D; in Rule 12b-2 of the Exchange Act.&nbsp;&nbsp;(Check one): </font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">Large accelerated filer&nbsp; </font><font style="display: inline;font-size:8pt;">&#x2610;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">Accelerated filer&nbsp; </font><font style="display: inline;font-size:8pt;">&#x2610;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">Non-accelerated filer</font><font style="display: inline;font-size:8pt;"> &nbsp; &nbsp;</font><font style="display: inline;font-size:8pt;">&#x2611;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">Smaller reporting company&nbsp; </font><font style="display: inline;font-size:8pt;">&#x2611;</font><font style="display: inline;font-size:8pt;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">Emerging growth company&nbsp; </font><font style="display: inline;font-size:8pt;">&#x2610;</font><font style="display: inline;font-size:8pt;"></font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 4pt">
			<font style="display: inline;font-size:4pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
			<font style="display: inline;font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;</font><font style="display: inline;font-size:8pt;">&#x2610;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
			<font style="display: inline;color:#2B2B2B;font-size:8pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the&nbsp;Sarbanes-Oxley Act (15 USC. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.</font><font style="display: inline;color:#2B2B2B;font-size:8pt;">&nbsp;</font><font style="display: inline;font-size:8pt;">&#x2610;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
			<font style="display: inline;font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).&nbsp;&nbsp;Yes&nbsp;</font><font style="display: inline;font-size:8pt;">&#x2610;</font><font style="display: inline;font-size:8pt;"> &nbsp;No&nbsp;</font><font style="display: inline;font-size:8pt;">&#x2611;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
			<font style="display: inline;font-size:8pt;">The aggregate market value of the voting and non-voting common equity held by non-affiliates was </font><font style="display: inline;font-size:8pt;">$</font><font style="display: inline;font-size:8pt;">71</font><font style="display: inline;font-size:8pt;">,</font><font style="display: inline;font-size:8pt;">146</font><font style="display: inline;font-size:8pt;">,</font><font style="display: inline;font-size:8pt;">906</font><font style="display: inline;font-size:8pt;"> computed by reference to the last sales price of $</font><font style="display: inline;font-size:8pt;">3</font><font style="display: inline;font-size:8pt;">.</font><font style="display: inline;font-size:8pt;">08</font><font style="display: inline;font-size:8pt;"> as reported on the Nasdaq Capital Market, as of the last business day of the Registrant's most recently completed second fiscal quarter, </font><font style="display: inline;font-size:8pt;">June&nbsp;</font><font style="display: inline;font-size:8pt;">30</font><font style="display: inline;font-size:8pt;">, 20</font><font style="display: inline;font-size:8pt;">20</font><font style="display: inline;font-size:8pt;">. The number of shares outstanding of the Registrant's common stock on </font><font style="display: inline;font-size:8pt;">March&nbsp;</font><font style="display: inline;font-size:8pt;">18</font><font style="display: inline;font-size:8pt;">, 202</font><font style="display: inline;font-size:8pt;">1</font><font style="display: inline;font-size:8pt;"> was </font><font style="display: inline;font-size:8pt;">3</font><font style="display: inline;font-size:8pt;">9,89</font><font style="display: inline;font-size:8pt;">8,325</font><font style="display: inline;font-size:8pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 0.5pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-weight:bold;font-size:9pt;">DOCUMENTS INCORPORATED BY REFERENCE</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
			<font style="display: inline;font-size:8pt;">Portions of the Registrant's Proxy Statement for its 202</font><font style="display: inline;font-size:8pt;">1</font><font style="display: inline;font-size:8pt;"> Annual Meeting of Stockholders (the Proxy Statement), to be filed with the U.S. Securities and Exchange Commission, are incorporated by reference to Part III of this Form 10-K Report.</font>
		</p>
		<p style="margin:0pt;border-bottom:2pt double #000000 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;font-size:6pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">1</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-weight:bold;">CASSAVA SCIENCES, INC.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 5pt">
			<font style="display: inline;font-weight:bold;font-size:5pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">FORM 10-K</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">INDEX</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 5pt">
			<font style="display: inline;font-size:5pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:81.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.54%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:81.86%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:07.60%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;text-decoration:underline;">Page</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="top" style="width:100.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;">PART I</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.54%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Item 1.</font></p>
				</td>
				<td valign="top" style="width:81.86%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="#Business"><font style="display: inline;">Business</font></a></p>
				</td>
				<td valign="bottom" style="width:07.60%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;">4</font><font style="display: inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.54%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Item 1A.</font></p>
				</td>
				<td valign="top" style="width:81.86%;padding:0pt 6.5pt">
					<p style="margin:0pt 4.5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="#Risk_Factors"><font style="display: inline;">Risk Factors</font></a></p>
				</td>
				<td valign="bottom" style="width:07.60%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;">31</font><font style="display: inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.54%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Item 1B.</font></p>
				</td>
				<td valign="top" style="width:81.86%;padding:0pt 6.5pt">
					<p style="margin:0pt 4.5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="#Unresolved_Staff_Comments"><font style="display: inline;">Unresolved Staff Comments</font></a></p>
				</td>
				<td valign="bottom" style="width:07.60%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;">64</font><font style="display: inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.54%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Item 2.</font></p>
				</td>
				<td valign="top" style="width:81.86%;padding:0pt 6.5pt">
					<p style="margin:0pt 4.5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="#Properties"><font style="display: inline;">Properties</font></a></p>
				</td>
				<td valign="bottom" style="width:07.60%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;">64</font><font style="display: inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.54%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Item 3.</font></p>
				</td>
				<td valign="top" style="width:81.86%;padding:0pt 6.5pt">
					<p style="margin:0pt 4.5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="#Legal_Proceedings"><font style="display: inline;">Legal Proceedings</font></a></p>
				</td>
				<td valign="bottom" style="width:07.60%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;">64</font><font style="display: inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.54%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Item 4.</font></p>
				</td>
				<td valign="top" style="width:81.86%;padding:0pt 6.5pt">
					<p style="margin:0pt 4.5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="#Mine_Safety_Disclosures"><font style="display: inline;">Mine Safety Disclosures</font></a></p>
				</td>
				<td valign="bottom" style="width:07.60%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;">64</font><font style="display: inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.54%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:81.86%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:07.60%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="top" style="width:100.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;">PART II</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.54%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Item 5.</font></p>
				</td>
				<td valign="top" style="width:81.86%;padding:0pt 6.5pt">
					<p style="margin:0pt 4.5pt 0pt 0.75pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="#Market_For_Registrants_Common_Equity"><font style="display: inline;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></p>
				</td>
				<td valign="bottom" style="width:07.60%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;">65</font><font style="display: inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.54%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Item 6.</font></p>
				</td>
				<td valign="top" style="width:81.86%;padding:0pt 6.5pt">
					<p style="margin:0pt 4.5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="#Selected_Financial_Data"><font style="display: inline;">Selected Financial Data</font></a></p>
				</td>
				<td valign="bottom" style="width:07.60%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;">65</font><font style="display: inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.54%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Item 7.</font></p>
				</td>
				<td valign="top" style="width:81.86%;padding:0pt 6.5pt">
					<p style="margin:0pt 4.5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="#MDA"><font style="display: inline;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></p>
				</td>
				<td valign="bottom" style="width:07.60%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;">66</font><font style="display: inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.54%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Item 7A.</font></p>
				</td>
				<td valign="top" style="width:81.86%;padding:0pt 6.5pt">
					<p style="margin:0pt 4.5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="#Quantitative_And_Qualitative_Disclosures"><font style="display: inline;">Quantitative and Qualitative Disclosures About Market Risk</font></a></p>
				</td>
				<td valign="bottom" style="width:07.60%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;">73</font><font style="display: inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.54%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Item 8.</font></p>
				</td>
				<td valign="top" style="width:81.86%;padding:0pt 6.5pt">
					<p style="margin:0pt 4.5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="#Financial_Statements_Supplementary_Data"><font style="display: inline;">Financial Statements and Supplementary Data</font></a></p>
				</td>
				<td valign="bottom" style="width:07.60%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;">74</font><font style="display: inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.54%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Item 9.</font></p>
				</td>
				<td valign="top" style="width:81.86%;padding:0pt 6.5pt">
					<p style="margin:0pt 4.5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="#Changes_And_Disagreements"><font style="display: inline;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</font></a></p>
				</td>
				<td valign="bottom" style="width:07.60%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;">92</font><font style="display: inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.54%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Item 9A.</font></p>
				</td>
				<td valign="top" style="width:81.86%;padding:0pt 6.5pt">
					<p style="margin:0pt 4.5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="#Controls_And_Procedures"><font style="display: inline;">Controls and Procedures</font></a><font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.60%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;">92</font><font style="display: inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.54%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Item 9B.</font></p>
				</td>
				<td valign="top" style="width:81.86%;padding:0pt 6.5pt">
					<p style="margin:0pt 4.5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="#Other_Information"><font style="display: inline;">Other Information</font></a><font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.60%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;">93</font><font style="display: inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.54%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:81.86%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:07.60%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="top" style="width:100.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;">PART III</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.54%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Item 10.</font></p>
				</td>
				<td valign="top" style="width:81.86%;padding:0pt 6.5pt">
					<p style="margin:0pt 4.5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="#Directors_And_Executive_Officers"><font style="display: inline;">Directors and Executive Officers and Corporate Governance</font></a></p>
				</td>
				<td valign="bottom" style="width:07.60%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;">93</font><font style="display: inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.54%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Item 11.</font></p>
				</td>
				<td valign="top" style="width:81.86%;padding:0pt 6.5pt">
					<p style="margin:0pt 4.5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="#Executive_Compensation"><font style="display: inline;">Executive Compensation</font></a></p>
				</td>
				<td valign="bottom" style="width:07.60%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;">93</font><font style="display: inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.54%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Item 12.</font></p>
				</td>
				<td valign="top" style="width:81.86%;padding:0pt 6.5pt">
					<p style="margin:0pt 4.5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="#Security_Ownership"><font style="display: inline;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></p>
				</td>
				<td valign="bottom" style="width:07.60%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;">93</font><font style="display: inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.54%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Item 13.</font></p>
				</td>
				<td valign="top" style="width:81.86%;padding:0pt 6.5pt">
					<p style="margin:0pt 4.5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="#Certain_Relationships"><font style="display: inline;">Certain Relationships and Related Transactions and Director Independence</font></a></p>
				</td>
				<td valign="bottom" style="width:07.60%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;">94</font><font style="display: inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.54%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Item 14.</font></p>
				</td>
				<td valign="top" style="width:81.86%;padding:0pt 6.5pt">
					<p style="margin:0pt 4.5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="#Principal_Accountant_Fees"><font style="display: inline;">Principal Accountant Fees and Services</font></a></p>
				</td>
				<td valign="bottom" style="width:07.60%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;">94</font><font style="display: inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.54%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:81.86%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:07.60%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="top" style="width:100.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;">PART IV</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.54%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Item 15.</font></p>
				</td>
				<td valign="top" style="width:81.86%;padding:0pt 6.5pt">
					<p style="margin:0pt 4.5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="#Exhibits"><font style="display: inline;">Exhibits and Financial Statement Schedules</font></a></p>
				</td>
				<td valign="top" style="width:07.60%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;">95</font><font style="display: inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.54%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Item 16.</font></p>
				</td>
				<td valign="top" style="width:81.86%;padding:0pt 6.5pt">
					<p style="margin:0pt 4.5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="#Form10KSummary"><font style="display: inline;">Form 10-K Summary</font></a></p>
				</td>
				<td valign="top" style="width:07.60%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;">96</font><font style="display: inline;"></font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">2</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;"></font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">PART I</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">FORWARD-LOOKING STATEMENTS</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">This Annual Report on Form 10-K contains forward-looking statements within the meaning of the Private Securities Reform Act of 1995. All statements other than statements of historical facts contained in this Annual Report are forward-looking statements. We intend that such statements be protected by the safe harbor created thereby. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by terms such as &#x201C;anticipate,&#x201D; &#x201C;believe,&#x201D; &#x201C;could,&#x201D; &#x201C;estimate,&#x201D; &#x201C;expect,&#x201D; &#x201C;intend,&#x201D; &#x201C;may,&#x201D; &#x201C;plan,&#x201D; &#x201C;potential,&#x201D; &#x201C;should,&#x201D; &#x201C;will&#x201D; and &#x201C;would&#x201D; or the negatives of these terms or other comparable terminology.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The forward-looking statements are based on our beliefs, assumptions and expectations of our future performance, taking into account all information currently available to us. Forward-looking statements involve risks and uncertainties and our actual results and the timing of events may differ significantly from the resu</font><font style="display: inline;">lts discussed in the forward-looking statements. Such forward-looking statements and our business are subject to numerous risks and uncertainties that you should consider before investing in our Company. These risks are described more fully in the section titled &#x201C;Risk Factors.&#x201D; </font><font style="display: inline;">Accordingly, you should not rely upon forward-looking statements as predictions of future events.</font><font style="display: inline;"> Examples of such forward-looking statements include, but are not limited to statements about:</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">our intention to initiate a pivotal Phase 3 clinical program with simufilam in Alzheimer&#x2019;s disease, the anticipated scope of Phase 3 studies and our estimated timeline for doing so;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">our reliance on third-party contractors to make drug supply on a large-scale for our Phase 3 clinical program, or their ability to do so on-time or on-budget;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">our intention to initiate a cognition maintenance study with simufilam in Alzheimer&#x2019;s disease;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">limitations around the interpretation of cognitive results from a long-term open-label study design, as compared to efficacy results from a fully completed, randomized controlled study design;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the expected rate of cognitive decline over time in untreated Alzheimer&#x2019;s patients;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the ability of the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog), Neuropsychiatric Inventory (NPI), CANTAB or other clinical scales to assess cognition or health in our trials of Alzheimer&#x2019;s disease;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">announcements or plans regarding any future interim analyses of our open-label study of simufilam and our estimated timeline for doing so;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">any significant changes we have made, or anticipate making, to the design of an on-going open-label study of simufilam;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">announcements regarding an End-of-Phase 2 meeting held </font><font style="display: inline;color:#000000;">January 202</font><font style="display: inline;color:#000000;">1 with the U.S. Food and Drug Administration (FDA);</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">our ability to initiate, conduct or analyze additional clinical and non-clinical studies with our product candidates targeted at Alzheimer&#x2019;s disease and other neurodegenerative diseases;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the interpretation of results from our Phase 2 clinical studies;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">our estimated timeline for publishing in a peer-reviewed technical journal clinical results of our Phase 2b study of simufilam;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">our plans to initiate a validation study of SavaDx, our investigational blood-based diagnostic, and our estimated timeline for doing so;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the safety, efficacy, or potential therapeutic benefits of our product candidates;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the utility of protection, or the sufficiency, of our intellectual property;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">our potential competitors or competitive products;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">expected future sources of revenue and capital and increasing cash needs;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">our use of Clinical Research Organizations (CROs) to conduct clinical studies of our product candidates;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">expectations regarding trade secrets, technological innovations, licensing agreements and outsourcing of certain business functions;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">our expenses increasing or fluctuations in our financial or operating results;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">our operating losses and anticipated operating and capital expenditures;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">expectations regarding the issuance of shares of common stock to employees pursuant to equity compensation awards, net of employment taxes;</font></p></td></tr></table></div>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">3</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the development and maintenance of our internal information systems and infrastructure;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">our need to hire additional personnel and our ability to attract and retain such personnel;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">existing regulations and regulatory developments in the United States and other jurisdictions;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">our need to expand the size and scope of our physical facilities;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the sufficiency of our current resources to continue to fund our operations;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the accuracy of our estimates regarding expenses, capital requirements, and needs for additional financing;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">assumptions and estimates used for our disclosures regarding stock-based compensation; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the long-term impact of COVID-19, a novel coronavirus first detected in 2019, on our operations and financial condition.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">We cannot assure you that we will realize the results or developments we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our operations in the way we expect. The forward-looking statements included in this Annual Report on Form 10-K are made only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as required by law.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">In addition, statements that &#x201C;we believe&#x201D; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Our research programs in neurodegeneration benefit from longstanding scientific and financial support from the National </font><font style="display: inline;color:#000000;">Institutes</font><font style="display: inline;color:#000000;"> of Health (NIH). The contents of this Annual Report are solely our responsibility and do not necessarily represent any official views of NIH.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<a name="Item_1_Business"></a><font style="display: inline;font-weight:bold;color:#000000;">Item 1.&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Business</font><a name="Business"></a>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">Overview</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<a name="_Hlk32321201"></a><font style="display: inline;color:#000000;">Cassava Sciences, Inc. is a clinical-stage biotechnology company. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer&#x2019;s disease. Our novel science is based on stabilizing &#x2013; but not removing &#x2013; a critical protein in the brain.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Over the past 10 years, we have combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer&#x2019;s disease and other neurodegenerative diseases. </font><font style="display: inline;color:#000000;">Our strategy is to leverage our unique scientific/clinical platform to develop a first-in-class program for </font><font style="display: inline;color:#000000;">treating neurodegenerative diseases, such as Alzheimer&#x2019;s</font><font style="display: inline;color:#000000;">. &nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">We currently have two clinical-stage </font><font style="display: inline;color:#000000;">biopharmaceutical </font><font style="display: inline;color:#000000;">assets under development: </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">our lead therapeutic product candidate</font><font style="display: inline;color:#000000;"> is</font><font style="display: inline;color:#000000;"> called simufilam, </font><font style="display: inline;color:#000000;">and it is a novel</font><font style="display: inline;color:#000000;"> treatment </font><font style="display: inline;color:#000000;">for</font><font style="display: inline;color:#000000;"> Alzheimer&#x2019;s disease; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">our lead investigational diagnostic product candidate</font><font style="display: inline;color:#000000;"> is</font><font style="display: inline;color:#000000;"> called SavaDx, </font><font style="display: inline;color:#000000;">and it is a novel way </font><font style="display: inline;color:#000000;">to detect </font><font style="display: inline;color:#000000;">the presence of </font><font style="display: inline;color:#000000;">Alzheimer&#x2019;s disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Our scientific approach for the treatment of Alzheimer&#x2019;s disease seeks to simultaneously improve </font><font style="display: inline;font-style:italic;color:#000000;">both</font><font style="display: inline;color:#000000;"> neurodegeneration and neuroinflammation. We believe our ability to improve multiple vital functions in the brain represents a new, different and crucial approach to address Alzheimer&#x2019;s disease. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Our lead therapeutic product candidate, simufilam, is a proprietary small molecule (oral) drug. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimer&#x2019;s brain. Published studies have demonstrated that the altered form of FLNA causes neuronal dysfunction, neuronal degeneration and neuroinflammation.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">We believe simufilam improves brain health by reverting altered FLNA back to its native, healthy conformation, thus countering the downstream toxic effects of altered FLNA. We have generated and published experimental and clinical </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">4</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;">evidence of improved brain health with simufilam. </font><font style="display: inline;">Importantly, </font><font style="display: inline;">simufilam</font><font style="display: inline;"> is not dependent on clearing amyloid from the brain. S</font><font style="display: inline;">ince simufilam has a unique mechanism of action, we believe its potential therapeutic effects may be additive or synergistic with that of other therapeutic candidates aiming to treat neurodegeneration.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Simufilam has demonstrated a multitude of beneficial effects in animal models of disease, including normalizing neurotransmission, decreasing neuroinflammation, suppressing neurodegeneration, and restoring memory and cognition.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In 2019</font><font style="display: inline;">, we completed a small, first-in-patient, clinical-proof-of-concept, open-label Phase 2a study of simufilam in the U.S., with substantial support from the </font><font style="display: inline;font-style:italic;">National Institute on Aging</font><font style="display: inline;"> (NIA), a division of the NIH. Treatment with simufilam for 28 days significantly improved key biomarkers of Alzheimer&#x2019;s pathology, neurodegeneration and neuroinflammation (</font><font style="display: inline;color:#000000;">p&lt;0.001)</font><font style="display: inline;">. &nbsp;</font><font style="display: inline;color:#000000;">Biomarkers effects were seen in all patients in both cerebrospinal fluid (CSF) and plasma.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">In </font><font style="display: inline;color:#000000;font-size:10pt;">September 202</font><font style="display: inline;color:#000000;font-size:10pt;">0, </font><font style="display: inline;font-size:10pt;">we</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">announced </font><font style="display: inline;font-size:10pt;">final</font><font style="display: inline;color:#000000;font-size:10pt;"> results of a Phase 2b study with </font><font style="display: inline;color:#000000;font-size:10pt;">simufilam</font><font style="display: inline;color:#000000;font-size:10pt;"> in Alzheimer&#x2019;s disease. </font><font style="display: inline;font-size:10pt;">In </font><font style="display: inline;font-size:10pt;">this</font><font style="display: inline;font-size:10pt;"> clinical study funded by the NIH, Alzheimer&#x2019;s </font><font style="font-style:italic;display: inline;font-style:normal;font-size:10pt;">patients</font><font style="font-style:italic;display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">treated with 50 mg or 100 mg of </font><font style="display: inline;font-size:10pt;">simufilam</font><font style="display: inline;font-size:10pt;"> twice-daily for 28 days showed statistically significant (p&lt;0.05) improvements in </font><font style="display: inline;font-size:10pt;">CSF </font><font style="display: inline;font-size:10pt;">biomarkers of </font><font style="font-style:italic;display: inline;font-style:normal;font-size:10pt;">disease pathology, neurodegeneration and neuroinflammation, versus</font><font style="font-style:italic;display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">Alzheimer&#x2019;s </font><font style="font-style:italic;display: inline;font-style:normal;font-size:10pt;">patients who took placebo</font><font style="font-style:italic;display: inline;font-size:10pt;">.</font><font style="display: inline;font-size:10pt;"> In addition, Alzheimer&#x2019;s </font><font style="font-style:italic;display: inline;font-style:normal;font-size:10pt;">patients</font><font style="font-style:italic;display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">treated with </font><font style="display: inline;font-size:10pt;">simufilam</font><font style="display: inline;font-size:10pt;"> showed improvements in validated tests of episodic memory and spatial working memory,</font><font style="font-style:italic;display: inline;font-size:10pt;">&nbsp;</font><font style="font-style:italic;display: inline;font-style:normal;font-size:10pt;">versus patients on placebo</font><font style="font-style:italic;display: inline;font-size:10pt;"> &nbsp;(</font><font style="display: inline;font-size:10pt;">Effect Size 17-46%). Cognitive improvements correlated most strongly (R</font><font style="display: inline;font-size:10pt;font-size:5pt;vertical-align:super;line-height:100%">2</font><font style="display: inline;font-size:10pt;">=0.5) with decreases in levels of P-tau181.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;background-color: #FFFFFF;">In </font><font style="display: inline;color:#000000;font-size:10pt;background-color: #FFFFFF;">March 202</font><font style="display: inline;color:#000000;font-size:10pt;background-color: #FFFFFF;">0, we initiated</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">a long-term</font><font style="display: inline;color:#000000;font-size:10pt;"> open-label extension study to evaluate&nbsp;simufilam&nbsp;in patients with Alzheimer&#x2019;s disease.&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;background-color: #FFFFFF;">This open-label, multi-center, </font><font style="display: inline;color:#000000;font-size:10pt;background-color: #FFFFFF;">extension study&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">is intended to monitor the long-term safety and tolerability of&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">simufilam</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;100 mg twice-daily for 12 </font><font style="display: inline;color:#000000;font-size:10pt;">or more </font><font style="display: inline;color:#000000;font-size:10pt;">months. The study&#x2019;s initial target enrollment was</font><font style="display: inline;color:#000000;font-size:10pt;"> approximately 100&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;background-color: #FFFFFF;">patients with m</font><font style="display: inline;color:#000000;font-size:10pt;">ild-to-moderate Alzheimer&#x2019;s </font><font style="display: inline;color:#000000;font-size:10pt;">disease</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">and, in </font><font style="display: inline;color:#000000;font-size:10pt;">February 202</font><font style="display: inline;color:#000000;font-size:10pt;">1, was increased to approximately 150</font><font style="display: inline;color:#000000;font-size:10pt;"> patients. This study</font><font style="display: inline;color:#000000;font-size:10pt;"> uses the</font><font style="display: inline;color:#000000;font-size:10pt;"> Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog-11) to assess</font><font style="display: inline;color:#000000;font-size:10pt;"> cognitive symptoms of </font><font style="display: inline;color:#000000;font-size:10pt;">dementia&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">and the Neuropsychiatric Inventory (NPI) to assess the presence and severity of dementia-related behavior. Both scales are widely used clinical tools </font><font style="display: inline;color:#000000;font-size:10pt;">in </font><font style="display: inline;color:#000000;font-size:10pt;">trials of Alzheimer&#x2019;s disease</font><font style="display: inline;color:#000000;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">On </font><font style="display: inline;color:#000000;font-size:10pt;">February&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">2, 2021, we </font><font style="display: inline;color:#000000;font-size:10pt;">announced results </font><font style="display: inline;color:#000000;font-size:10pt;">of </font><font style="display: inline;color:#000000;font-size:10pt;">the first of two</font><font style="display: inline;color:#000000;font-size:10pt;"> preplanned interim analysis </font><font style="display: inline;color:#000000;font-size:10pt;">of our</font><font style="display: inline;color:#000000;font-size:10pt;"> open-label study of simufilam. Th</font><font style="display: inline;color:#000000;font-size:10pt;">e</font><font style="display: inline;color:#000000;font-size:10pt;"> first</font><font style="display: inline;color:#000000;font-size:10pt;"> interim analysis summarizes clinical data at the midway point</font><font style="display: inline;color:#000000;font-size:10pt;"> of enrollment, i.e., the first</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">50 patients who have completed at least 6 months of drug treatment. Patients&#x2019; </font><font style="display: inline;color:#000000;font-size:10pt;">cognition and behavior scores both improved following six months of simufilam treatment, with no safety issues. </font><font style="display: inline;color:#000000;font-size:10pt;">S</font><font style="display: inline;font-size:10pt;">ix months of simufilam</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">treatment </font><font style="display: inline;color:#000000;font-size:10pt;">improved cognition scores by 1.6 points on ADAS-Cog11, a 10% mean improvement from baseline to month 6. In these same patients, simufilam also improved </font><font style="display: inline;font-size:10pt;">dementia-related</font><font style="display: inline;color:#000000;font-size:10pt;"> behavior, such as anxiety, delusions and agitation, by 1.3 points on the Neuropsychiatric Inventory, a 29% mean improvement from baseline to month 6.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">Based on the interim results and inbound</font><font style="display: inline;color:#000000;font-size:10pt;"> demand from Alzheimer&#x2019;s patients and their caregivers, </font><font style="display: inline;color:#000000;font-size:10pt;">we announced significant changes to the open-label program, including an increase in </font><font style="display: inline;color:#000000;font-size:10pt;">the enrollment target by up to 50 additional patients,</font><font style="display: inline;color:#000000;font-size:10pt;"> for</font><font style="display: inline;color:#000000;font-size:10pt;"> a total target of approximately 150 patients.</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">This study&nbsp;ha</font><font style="display: inline;color:#000000;font-size:10pt;">d enrolled</font><font style="display: inline;color:#000000;font-size:10pt;"> approximately</font><font style="display: inline;">&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">80</font><font style="display: inline;color:#000000;font-size:10pt;"> patients</font><font style="display: inline;color:#000000;font-size:10pt;"> as of </font><font style="display: inline;color:#000000;font-size:10pt;">February 202</font><font style="display: inline;color:#000000;font-size:10pt;">1.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">We expect to announce&nbsp;results of&nbsp;a second planned interim analysis on safety and cognition for our open-label study approximately mid-2021. The second interim analysis is intended to summarize clinical data on the first 50 patients who complete at least 12 months of open label drug treatment.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">On </font><font style="display: inline;">February&nbsp;</font><font style="display: inline;">22, 2021, we </font><font style="display: inline;">announced the successful completion of an End-of-Phase 2 (EOP2) meeting with the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">FDA for simufilam. Official EOP2 meeting minutes indicate</font><font style="display: inline;"> we and the</font><font style="display: inline;"> FDA agree on key elements of a pivotal Phase 3 clinical program in support of a New Drug Application (NDA) filing for simufilam in Alzheimer&#x2019;s disease. </font><font style="display: inline;">We believe agreements</font><font style="display: inline;"> reached during the EOP2 meeting show a clear path forward for advancing simufilam into Phase 3 studies</font><font style="display: inline;">. We expect to initiate a pivotal Phase 3 program with simufilam in Alzheimer&#x2019;s disease</font><font style="display: inline;"> in the second half of 2021.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Our diagnostic effort, called SavaDx, is an early-stage program focused on detecting </font><font style="display: inline;">the presence of </font><font style="display: inline;">Alzheimer&#x2019;s disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. We</font><font style="display: inline;"> are developing </font><font style="display: inline;">SavaDx</font><font style="display: inline;"> as a fast, accurate and quantitative blood-based investigational biomarker/diagnostic to detect and monitor Alzheimer's disease. T</font><font style="display: inline;">he goal is to make the detection of Alzheimer&#x2019;s disease as simple as getting a blood test. </font><font style="display: inline;color:#000000;">We expect to initiate a validation/disease specificity study&nbsp;of SavaDx&nbsp;in 2021.</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">5</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-weight:bold;font-size:10pt;">About Alzheimer&#x2019;s Disease</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Alzheimer&#x2019;s disease is a progressive neurodegenerative disorder that affects cognition, function and behavior. T</font><font style="display: inline;color:#000000;font-size:10pt;background-color: #FFFFFF;">here are no disease-modifying drug </font><font style="display: inline;color:#000000;font-size:10pt;background-color: #FFFFFF;">therapies to treat the disease.</font><font style="display: inline;color:#000000;font-size:10pt;background-color: #FFFFFF;">&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;background-color: #FFFFFF;">As such, c</font><font style="display: inline;color:#000000;font-size:10pt;background-color: #FFFFFF;">ognition will always </font><font style="display: inline;color:#000000;font-size:10pt;background-color: #FFFFFF;">continue to </font><font style="display: inline;color:#000000;font-size:10pt;background-color: #FFFFFF;">decline over time in patients with Alzheimer&#x2019;s.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;background-color: #FFFFFF;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">As of 2020, there were approximately 50</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> people worldwide living with dementia, a figure expected to increase to 150</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> by 2050</font><font style="display: inline;"> and t</font><font style="display: inline;">he annual global cost of dementia is now above </font><font style="font-weight:bold;display: inline;font-weight:normal;">$1 trillion</font><font style="display: inline;font-weight:bold;">,</font><font style="display: inline;"> according to </font><font style="display: inline;font-style:italic;">Alzheimer&#x2019;s Disease International</font><font style="display: inline;">, a charitable organization.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;color:#000000;background-color: #FFFFFF;"> &nbsp; &nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Our Scientific Approach is Different</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Over the last ten years, we have developed a new and</font><font style="display: inline;"> promising scientific approach for the treatment and diagnosis of neurodegenerative diseases, such as Alzheimer&#x2019;s disease. Importantly, we do not seek to clear amyloid out of the brain. Rather, we seek to stabilize a critical protein in the brain that has many downstream effects.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Our scientific approach is to treat neurodegeneration by targeting an altered form of a scaffold protein called FLNA. Through years of basic research, we and our academic collaborators identified FLNA as a structurally altered protein in the Alzheimer&#x2019;s brain. We have shown that the altered form of FLNA is pervasive in the Alzheimer&#x2019;s brain and undetectable in healthy control brains.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Using scientific insight and advanced techniques in molecular biochemistry, bioinformatics and imaging, we have elucidated this protein dysfunction. Through this work, we have produced experimental evidence that altered FLNA plays a critical role in Alzheimer&#x2019;s disease. We engineered a family of high-affinity, small molecules to target this structurally altered protein and restore its normal shape and function. This family of small molecules, including our lead therapeutic candidate, simufilam, was designed in-house and characterized by our academic collaborators. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Our lead therapeutic product candidate, simufilam, is a small molecule (oral) drug with a novel mechanism of action. The target of simufilam is altered FLNA, the brain protein we seek to stabilize</font><font style="display: inline;"> (simufilam does not bind to healthy, normal FLNA).</font><font style="display: inline;"> Importantly, since simufilam has a unique mechanism of action, we believe its potential therapeutic effects may be additive or synergistic with that of other therapeutic candidates aiming to treat neurodegeneration.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;background-color: #FFFFFF;">Given the biopharmaceutical industry&#x2019;s challenging track record </font><font style="display: inline;">in Alzheimer&#x2019;s research, we believe there is </font><font style="display: inline;color:#000000;background-color: #FFFFFF;">an urgent need to consider more recent and innovative approaches to combat this disease. We believe our scientific approach may broaden the range of possible </font><font style="display: inline;">treatment</font><font style="display: inline;color:#000000;background-color: #FFFFFF;"> approaches for this complex disease.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Our science is based on stabilizing a critical protein in the brain</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Proteins are essential for cell function because they participate in virtually every biological process. If protein function is impaired, the health consequences can be devastating. Technological advances in medicine and improvements in lifestyle are making our lives longer. But with age, genetic mutations and other factors conspire against healthy cells, resulting in altered proteins. Sometimes a cell can rid itself of altered proteins. However, when disease changes the shape and function of </font><font style="display: inline;">critical</font><font style="display: inline;"> proteins, multiple downstream processes are impaired. There are many clinical conditions in which proteins become structurally altered and impair the normal function of cells, tissues and organs, leading to disease.&nbsp;&nbsp;Conversely, restoring altered proteins back to health &#x2013;called proteostasis &#x2013; is a well-accepted therapeutic strategy in clinical medicine.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">For over 100 years, scientists have ascribed various neurodegenerative diseases to proteins that misfold and are rendered pathological. In Alzheimer&#x2019;s disease, certain proteins, such as amyloid and tau, lose their normal shape and function. Such misfolded proteins can breakdown or aggregate in clumps and form plaque in the brain. Destruction of neuronal synapses, accelerated nerve cell death, and dysfunction of the brain support cells, are all widely believed to be direct consequences of misfolded proteins. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">FLNA is a scaffolding protein widely found throughout the body. A healthy scaffolding protein brings multiple proteins together, initiating their interaction. However, an altered form of FLNA protein is found in the Alzheimer&#x2019;s brain. Our experimental evidence shows that altered FLNA protein contribute to Alzheimer&#x2019;s disease by disrupting the normal function of neurons, leading to neurodegeneration and brain inflammation. Our product candidate, simufilam, aims to counter the </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">6</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;">altered and toxic form of FLNA in the brain, thus restoring the normal function of this critical protein. Our novel science is based on stabilizing &#x2013; but not removing &#x2013; a critical protein in the brain.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">One drug, multiple effects </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Our lead therapeutic candidate, simufilam, binds to altered FLNA with very high (femtomolar) affinity. This drug effect restores the normal shape of FLNA and the normal function of key brain receptors</font><font style="display: inline;">, including</font><font style="display: inline;">: the alpha-7 nicotinic acetylcholine receptor; the </font><font style="display: inline;background-color: #FFFFFF;">N-methyl-D-aspartate</font><font style="display: inline;"> (NMDA) receptor; and the </font><font style="display: inline;">insulin</font><font style="display: inline;"> receptor. These receptors have pivotal roles in brain cell survival, cognition and memory.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In animal models, treatment with simufilam resulted in dramatic improvements in brain health, such as reduced amyloid and tau deposits, improved receptor signaling and improved learning and memory. In addition, simufilam has another beneficial treatment effect of significantly reducing inflammatory cytokines in the brain. In animal models of disease, treatment with simufilam greatly reduced levels of IL-6 and suppressed TNF-alpha and IL-1beta levels by 86% and 80%, respectively, illustrating a powerful anti-neuroinflammatory effect.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">By restoring function to multiple receptors and exerting powerful anti-inflammatory effects, we believe our approach has potential to slow the progression of neurodegeneration in patients. Thus, we have designed simufilam to slow or, potentially, even reverse the deterioration of brain cells.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In 2019, a small, first-in-patient, clinical proof-of-concept Phase 2a study funded by NIH, showed that open-label treatment with simufilam for 28 days significantly improved key biomarkers of Alzheimer&#x2019;s pathology, neuroinflammation and neurodegeneration (</font><font style="display: inline;color:#000000;">p&lt;0.001)</font><font style="display: inline;">. &nbsp;</font><font style="display: inline;color:#000000;">On </font><font style="display: inline;color:#000000;">July&nbsp;</font><font style="display: inline;color:#000000;">15, 2020,&nbsp;we presented&nbsp;additional&nbsp;Phase 2a clinical results at the&nbsp;</font><font style="display: inline;font-style:italic;color:#000000;">Biomarkers&nbsp;for Alzheimer&#x2019;s Disease Summit,&nbsp;</font><font style="display: inline;color:#000000;">a virtual scientific&nbsp;conference.&nbsp;In addition to showing that SavaDx could distinguish and stratify patients with Alzheimer&#x2019;s disease, this presentation provided direct evidence for target engagement and for the treatment effects of&nbsp;</font><font style="display: inline;">simufilam</font><font style="display: inline;color:#000000;">. Target engagement is a crucial step in drug research because it shows that our small molecule drug candidate binds to its intended site of action in cells and confirms that treatment effects are caused by the drug hitting its target.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">In </font><font style="display: inline;color:#000000;font-size:10pt;">March 202</font><font style="display: inline;color:#000000;font-size:10pt;">0, we completed a&nbsp;randomized, placebo-controlled, double-blind&nbsp;Phase 2b study </font><font style="display: inline;color:#000000;font-size:10pt;">of&nbsp;</font><font style="display: inline;font-size:10pt;">simufilam</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;in 64 patients</font><font style="display: inline;color:#000000;font-size:10pt;background-color: #FFFFFF;">&nbsp;with m</font><font style="display: inline;color:#000000;font-size:10pt;">ild-to-moderate Alzheimer&#x2019;s disease, 50-85 years of age, with MMSE scores 16 to 26. St</font><font style="display: inline;color:#000000;font-size:10pt;">udy&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;background-color: #FFFFFF;">participants received&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;background-color: #FFFFFF;">simufilam</font><font style="display: inline;color:#000000;font-size:10pt;background-color: #FFFFFF;">&nbsp;100 mg, 50 mg or matching placebo, twice-daily, for 28 continuous days.&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">This study was substantially funded by a research grant award from NIH.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">In </font><font style="display: inline;color:#000000;font-size:10pt;">September 202</font><font style="display: inline;color:#000000;font-size:10pt;">0,&nbsp;we&nbsp;reported positive&nbsp;final&nbsp;study&nbsp;results for our Phase 2b study.&nbsp;Drug was safe and well-tolerated. Simufilam significantly&nbsp;(P&lt;0.05)&nbsp;improved an entire panel of validated biomarkers of disease in patients with Alzheimer&#x2019;s disease&nbsp;compared to a placebo group. In addition, Alzheimer&#x2019;s patients treated with simufilam showed directional improvements in validated tests of episodic memory and spatial working memory,&nbsp;versus patients on placebo</font><font style="display: inline;">&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">(Effect Sizes 46-17%). Cognitive improvements correlated most strongly (R</font><font style="display: inline;color:#000000;font-size:10pt;font-size:5pt;vertical-align:super;line-height:100%">2</font><font style="display: inline;color:#000000;font-size:10pt;">=0.5) with decreases in levels of </font><font style="display: inline;color:#000000;font-size:10pt;">CSF </font><font style="display: inline;color:#000000;font-size:10pt;">P-tau181. The study achieved a 98% response rate, defined as the proportion of study participants taking simufilam who showed improvements in biomarkers. Importantly, we believe these data are consistent with prior clinical and preclinical results, the drug&#x2019;s mechanism of </font><font style="display: inline;color:#000000;font-size:10pt;">action and over 10 years of basic research.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;background-color: #FFFFFF;">To our knowledge, no competing drug candidate has demonstrated the ability to reduce an entire panel of biomarkers of disease in patients with Alzheimer&#x2019;s disease. For this reason, CSF biomarker data generated in our Phase 2a </font><font style="display: inline;color:#000000;font-size:10pt;background-color: #FFFFFF;">and Phase 2b </font><font style="display: inline;color:#000000;font-size:10pt;background-color: #FFFFFF;">stud</font><font style="display: inline;color:#000000;font-size:10pt;background-color: #FFFFFF;">ies</font><font style="display: inline;color:#000000;font-size:10pt;background-color: #FFFFFF;"> may not be directly comparable to clinical results generated by our competitors.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">On </font><font style="display: inline;color:#000000;font-size:10pt;">February&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">2, 2021, we announced results of </font><font style="display: inline;color:#000000;font-size:10pt;">a preplanned interim analysis of our open-label study of simufilam. This first interim analysis summarizes clinical data at the midway point of enrollment, i.e., the first</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">50 patients who have completed at least 6 months of drug treatment. Patients&#x2019; cognition and behavior scores both improved following six months of simufilam treatment, with no safety issues. S</font><font style="display: inline;font-size:10pt;">ix months of simufilam</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">treatment </font><font style="display: inline;color:#000000;font-size:10pt;">improved cognition scores by 1.6 points on ADAS-Cog11, a 10% mean improvement from baseline to month 6. In these same patients, simufilam also improved </font><font style="display: inline;font-size:10pt;">dementia-related</font><font style="display: inline;color:#000000;font-size:10pt;"> behavior, such as anxiety, delusions and agitation, by 1.3 points on the Neuropsychiatric Inventory, a 29% mean improvement from baseline to month 6.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">7</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;color:#000000;font-size:10pt;">We</font><font style="display: inline;color:#000000;font-size:10pt;"> expect to announce&nbsp;results of&nbsp;a second planned interim analysis on safety and cognition for this study in mid-2021.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">Based on</font><font style="display: inline;color:#000000;font-size:10pt;"> positive clinical results and inbound demand from clinical sites, patients, and their caregivers, we expand</font><font style="display: inline;color:#000000;font-size:10pt;">ed</font><font style="display: inline;color:#000000;font-size:10pt;"> the size of the ongoing open-label study of simufilam. </font><font style="display: inline;color:#000000;font-size:10pt;">In </font><font style="display: inline;color:#000000;font-size:10pt;">February 202</font><font style="display: inline;color:#000000;font-size:10pt;">0, we increased the</font><font style="display: inline;color:#000000;font-size:10pt;"> target enrollment by up to 50 additional patients with mild-to-moderate Alzheimer&#x2019;s disease, for a total target enrollment of up to 150 patients.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">We also plan to initiate a 6-month, double-blind, randomized, placebo-controlled study in patients with Alzheimer&#x2019;s disease who complete at least one year of open-label treatment with simufilam. This is a </font><font style="display: inline;font-style:italic;color:#000000;font-size:10pt;">Cognition Maintenance Study</font><font style="display: inline;color:#000000;font-size:10pt;"> (CMS), in which patients who complete one year of open-label treatment will subsequently be randomized (1:1) to simufilam or placebo for six months. The CMS is designed to compare simufilam&#x2019;s effects on cognition and behavior in patients who continue with drug treatment versus those who discontinue drug treatment. For ethical and other reasons, patients who successfully complete the six-month CMS will have the option to receive open-label simufilam. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Our science is published in multiple peer-reviewed journals. In addition, our research has been supported by NIH under multiple research grant awards. Each grant was awarded following an in-depth, peer-</font><font style="display: inline;">reviewed</font><font style="display: inline;"> evaluation of our approach for scientific and technical merit by a panel of outside experts in the field. Strong, long-term support from NIH has allowed us to advance our two product candidates for neurodegeneration, simufilam and SavaDx, into clinical development.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;font-size:10pt;">Overview of Alzheimer&#x2019;s disease</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Alzheimer&#x2019;s disease is a progressive neurodegenerative disorder that affects cognition, function and behavior. T</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">here are no disease-modifying drug therapies to treat the disease. </font><font style="display: inline;">As of 2020, there were approximately 50</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> people worldwide living with dementia, a figure expected to increase to 150</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> by 2050 and the annual global cost of dementia is now above </font><font style="font-weight:bold;display: inline;font-weight:normal;">$1 trillion</font><font style="display: inline;font-weight:bold;">,</font><font style="display: inline;"> according to </font><font style="display: inline;font-style:italic;">Alzheimer&#x2019;s Disease International</font><font style="display: inline;">, a charitable organization. </font><font style="display: inline;color:#000000;background-color: #FFFFFF;"> &nbsp; &nbsp;</font><font style="display: inline;">According to the non-profit </font><font style="display: inline;font-style:italic;">Alzheimer's Association</font><font style="display: inline;">, Alzheimer&#x2019;s disease is expected to nearly triple in the U.S. between now and 2050. If this occurs, there is potential for Alzheimer's disease to cause a major financial drain on the national economy.</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;font-size:10pt;">Currently marketed drug therapies for </font><font style="display: inline;font-style:italic;font-size:10pt;">Alzheimer&#x2019;s disease have limited therapeutic effect</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;background-color: #FFFFFF;">There are no disease-modifying drug therapies to treat Alzheimer&#x2019;s disease. The FDA has not approved any new drugs for Alzheimer&#x2019;s </font><font style="display: inline;">disease</font><font style="display: inline;background-color: #FFFFFF;"> since 2003. </font><font style="display: inline;">Biogen, Inc., a large biopharmaceutical company, is currently seeking FDA approval for an investigational drug, aducanumab, for the treatment of Alzheimer&#x2019;s disease.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Currently marketed drug therapies focus solely on treating symptoms, mostly in patients with mild-to-moderate Alzheimer's disease. At the time of diagnosis, patients are initiated on a class of drugs called cholinesterase inhibitors. The Alzheimer&#x2019;s brain</font><font style="display: inline;background-color: #FFFFFF;"> has low levels of a neurotransmitter called acetylcholine. C</font><font style="display: inline;">holinesterase inhibitors </font><font style="display: inline;background-color: #FFFFFF;">prevent an </font><font style="display: inline;">enzyme</font><font style="display: inline;background-color: #FFFFFF;"> in the brain, called&nbsp;</font><font style="display: inline;background-color: #FFFFFF;">acetylcholinesterase,</font><font style="display: inline;background-color: #FFFFFF;">&nbsp;from breaking down acetylcholine.</font><font style="display: inline;"> Currently marketed cholinesterase inhibitors include donepezil (marketed by Eisai&nbsp;Co.,&nbsp;Ltd. and Pfizer,&nbsp;Inc. as Aricept</font><font style="display: inline;font-size:5pt;vertical-align:super;line-height:100%">&#xAE;</font><font style="display: inline;">), rivastigmine (marketed by Novartis AG as Exelon</font><font style="display: inline;font-size:5pt;vertical-align:super;line-height:100%">&#xAE;</font><font style="display: inline;">) and galantamine (marketed by Janssen Pharmaceuticals, Inc. as Razadyne</font><font style="display: inline;font-size:5pt;vertical-align:super;line-height:100%">&#xAE;</font><font style="display: inline;">). Cholinesterase inhibitors may benefit some patients for several months, after which the targeted brain receptors are desensitized, and drug efficacy is lost. </font><font style="display: inline;">To our knowledge, no drug for Alzheimer&#x2019;s has shown an ability to stabilize cognition in patients, much less restore loss cognition, beyond a few months.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Simufilam is our Proprietary Drug for the Treatment of Alzheimer&#x2019;s Disease.</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We have generated and published experimental evidence of improved brain health by restoring altered FLNA with simufilam, our lead therapeutic product candidate. Simufilam is a proprietary small molecule drug that represents an entirely new scientific approach to treat neurodegeneration. Published studies have demonstrated that simufilam targets an altered form of a protein called FLNA that is </font><font style="display: inline;">pervasive</font><font style="display: inline;"> in the Alzheimer&#x2019;s brain. Altered FLNA causes neuronal dysfunction, neuronal degeneration and neuroinflammation. We believe our drug candidate, simufilam, improves brain health by reverting altered FLNA back to its native, healthy conformation, thus countering downstream toxic effects of altered FLNA. </font><font style="display: inline;">Importantly, </font><font style="display: inline;">simufilam</font><font style="display: inline;"> is not dependent on clearing amyloid from the brain. The following is a summary profile of </font><font style="display: inline;">simufilam</font><font style="display: inline;">&#x2019;s drug development program.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">8</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-style:italic;font-size:10pt;">IND submission to FDA</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Over the past ten years, we successfully conducted basic research, in vitro studies and preclinical studies in support of an Investigational New Drug (IND) submission to FDA for simufilam, including requisite studies around safety pharmacology, toxicology, genotoxicity and bioanalytical methods. In 2017 we filed an IND with FDA for simufilam.</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;font-size:10pt;">Clinical</font><font style="display: inline;font-style:italic;font-size:10pt;"> safety of simufilam in a Phase 1 study</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Following FDA acceptance of our IND in 2017, we investigated the safety, dosing and pharmacokinetic profile of simufilam in healthy </font><font style="display: inline;">human</font><font style="display: inline;"> volunteers. The design of our first-in-human Phase 1 study was based on regulatory feedback, clinical and scientific rationale and observations from previously conducted preclinical </font><font style="font-style:italic;display: inline;font-style:normal;">and</font><font style="display: inline;"> in vitro studies. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In a Phase 1 study, simufilam was evaluated in 24 healthy human volunteers in a single site in the U.S. for safety, tolerability and pharmacokinetics. Study subjects were administered a single oral dose of 50, 100 or 200 mg of simufilam. Drug was well-tolerated in all subjects. Importantly, simufilam showed no treatment-related adverse effects and no dose-limiting safety findings. Pharmacokinetic measurements demonstrated that simufilam, a small molecule, was rapidly absorbed. Dose-proportionality was observed over the full dose range of 50 to 200 mg. Results of this Phase 1 study were presented at the 10</font><font style="display: inline;font-size:5pt;vertical-align:super;line-height:100%">th</font><font style="display: inline;"> Annual International Conference on Clinical Studies on Alzheimer's Disease in 2017. </font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;color:#000000;text-align:justify;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;font-family:Calibri;color:#000000;text-justify:inter-ideograph;font-size: 1pt">
			<font style="display: inline;font-family:Times New Roman;color:#FFFFFF;font-size:1pt;">Mean PTI-125 Plasma Concentration Concentration (ng/mL) 0 500 100 1500 0 4 8 12 16 g 200 mg Time (</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Given the absence of any observable dose-limiting effects in healthy adults in a Phase 1 study, a strong scientific rationale, and </font><font style="display: inline;">multiple</font><font style="display: inline;"> peer-reviewed publications and research grant awards, we believe this program demonstrated favorable proof-of-principle for the development of simufilam in Alzheimer&#x2019;s disease. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;font-size:10pt;">Phase 2 clinical development program for simufilam</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In 2018, we mapped out, </font><font style="display: inline;">in collaboration with outside science advisors and medical experts, a strategic clinical plan to advance simufilam into a comprehensive Phase 2 clinical development program. The general objective of our Phase 2 program with simufilam was to gain an initial estimate of the safety, tolerability and biological activity of this drug candidate in patients with Alzheimer&#x2019;s disease. We believe m</font><font style="display: inline;">eaningful Phase 2 data now enable us to design and conduct a large-scale Phase 3 efficacy program for simufilam and may also enable us to seek one or more </font><font style="display: inline;">strategic</font><font style="display: inline;"> collaborations with pharmaceutical or biotechnology companies.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;text-decoration:underline;">Phase 2a Clinical Study</font><font style="display: inline;font-weight:bold;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In 2019, we completed a first-in-patient, clinical proof-of-concept study of simufilam</font><font style="display: inline;"> in the U.S. Our Phase</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">2a </font><font style="display: inline;">was an</font><font style="display: inline;"> open-label, multi-center, safety and pharmacokinetic study of simufilam. Thirteen (13) patients with mild-to-moderate Alzheimer&#x2019;s disease, age 50-85, received 100 mg oral simufilam twice daily for 28 days. A diagnosis of Alzheimer&#x2019;s disease was confirmed with Mini-Mental State Examination (MMSE) &#x2265; 16 and &#x2264; 24 and a </font><font style="display: inline;background-color: #FFFFFF;">c</font><font style="display: inline;">erebrospinal fluid (CSF) T-tau/A&#x3B2;</font><sub style="display: inline;">42 </sub><font style="display: inline;">ratio &#x2265; 0.30. Safety was assessed </font><font style="display: inline;color:#000000;">by ECGs, clinical labs, adverse event monitoring and physical examinations. </font><font style="display: inline;">CSF was drawn from patients before dosing started and again after 28 continuous days of dosing with simufilam. </font><font style="display: inline;color:#000000;">CSF samples were then analyzed for biomarkers of Alzheimer&#x2019;s pathology (T-tau, P-tau, A&#x3B2;</font><sub style="display: inline;color:#000000;">42</sub><font style="display: inline;color:#000000;">); neurodegeneration (NfL, neurogranin); and neuroinflammation (YKL-40, IL-6, IL-1&#x3B2; and TNF&#x3B1;). A</font><font style="display: inline;"> consulting</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">biostatistician</font><font style="display: inline;color:#000000;"> conducted an </font><font style="display: inline;">independent</font><font style="display: inline;">&nbsp;</font><font style="display: inline;color:#000000;">analysis of the data set.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-size:10pt;background-color: #FFFFFF;">A key objective of our Phase 2a study was to measure levels of CSF biomarkers in the brain</font><font style="display: inline;font-size:10pt;">. Key results of this study include (</font><font style="display: inline;font-weight:bold;font-size:10pt;">Figure </font><font style="display: inline;font-weight:bold;font-size:10pt;">1</font><font style="display: inline;font-size:10pt;">)</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">:</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Total tau (T-tau) decreased 20% (</font><font style="display: inline;color:#000000;">p&lt;0.001</font><font style="display: inline;color:#000000;">)</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Phosphorylated tau (P-tau) decreased 34% (</font><font style="display: inline;color:#000000;">p&lt;0.0001</font><font style="display: inline;color:#000000;">)</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Neurofilament light chain (NfL), a marker for neurodegeneration, decreased 22% (</font><font style="display: inline;color:#000000;">p&lt;0.0001</font><font style="display: inline;color:#000000;">)</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Neurogranin, a marker for cognitive decline, decreased 32% (</font><font style="display: inline;color:#000000;">p&lt;0.0001</font><font style="display: inline;color:#000000;">)</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Neuroinflammatory marker YKL-40, an indicator of microglial activation, decreased 9% (</font><font style="display: inline;color:#000000;">p&lt;0.0001</font><font style="display: inline;color:#000000;">)</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Proinflammatory Interleukin 6 (IL-6) decreased 14% (</font><font style="display: inline;color:#000000;">p&lt;0.0001)</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Proinflammatory Interleukin 1 beta (IL-1</font><font style="display: inline;color:#000000;">&#x3B2;) </font><font style="display: inline;color:#000000;">decreased 11% (</font><font style="display: inline;color:#000000;">p&lt;0.0001</font><font style="display: inline;color:#000000;">)</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Proinflammatory Tumor Necrosis Factor alpha (TNF&#x3B1;) decreased 5% (</font><font style="display: inline;color:#000000;">p&lt;0.001</font><font style="display: inline;color:#000000;">) &nbsp;</font></p></td></tr></table></div>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">9</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">The ratio of CSF P-tau to A</font><font style="display: inline;color:#000000;">&#x3B2;</font><sub style="display: inline;color:#000000;">42</sub><font style="display: inline;color:#000000;">, a widely accepted biochemical value of Alzheimer&#x2019;s disease, improved in all patients (p&lt;0.001)</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;font-size:10pt;">Figure </font><font style="display: inline;font-weight:bold;color:#000000;font-size:10pt;">1</font><font style="display: inline;font-weight:bold;color:#000000;font-size:10pt;">: Simufilam treatment reduces levels of CSF biomarkers in patients with Alzheimer&#x2019;s in a Phase 2a study.</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;text-align:justify;text-justify:inter-ideograph;margin-left:0pt;">
			<tr>
				<td valign="middle" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:81.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:22.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:72.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:45.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:49.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:54.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:45.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:61.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:81.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Calibri;font-weight:bold;color:#404040;">Neurogranin</font><font style="display: inline;color:#000000;">*</font></p>
				</td>
				<td valign="middle" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:22.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Calibri;font-weight:bold;color:#404040;">NfL</font><font style="display: inline;color:#000000;">*</font></p>
				</td>
				<td valign="middle" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:72.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Calibri;font-weight:bold;color:#404040;">T-tau</font><font style="display: inline;font-weight:bold;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:16pt;font-size:8pt;vertical-align:super;line-height:100%">+</font></p>
				</td>
				<td valign="middle" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:45.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Calibri;font-weight:bold;color:#404040;">P-tau</font><font style="display: inline;font-family:Calibri;font-weight:bold;color:#404040;font-size:5pt;vertical-align:super;line-height:100%">181</font><font style="display: inline;color:#000000;">*</font></p>
				</td>
				<td valign="middle" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:49.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Calibri;font-weight:bold;color:#404040;">YKL40</font><font style="display: inline;color:#000000;">*</font></p>
				</td>
				<td valign="middle" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:54.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Calibri;font-weight:bold;color:#404040;">IL-6</font><font style="display: inline;color:#000000;">*</font></p>
				</td>
				<td valign="middle" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:45.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Calibri;font-weight:bold;color:#404040;">IL-1</font><font style="display: inline;font-family:Calibri;font-weight:bold;color:#404040;">&#x3B2;</font><font style="display: inline;color:#000000;">*</font></p>
				</td>
				<td valign="middle" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:61.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Calibri;font-weight:bold;color:#404040;">TNF</font><font style="display: inline;font-family:Calibri;font-weight:bold;color:#404040;">&#x3B1;</font><font style="display: inline;font-weight:bold;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:16pt;font-size:8pt;vertical-align:super;line-height:100%">+</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:center;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;font-size:10pt;"><img src="sava-20201231x10kg001.jpg" style="width: 6.40625in; height: 2.375in" alt="Picture 5"></font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;color:#FFFFFF;font-size:1pt;">Neurogranin* NfL* T-tau+ P-tau181* YKL40* IL-6* IL-1</font><font style="display: inline;color:#FFFFFF;font-size:1pt;">&#x3B2;</font><font style="display: inline;color:#FFFFFF;font-size:1pt;">* TNF</font><font style="display: inline;color:#FFFFFF;font-size:1pt;">&#x3B1;</font><font style="display: inline;color:#FFFFFF;font-size:1pt;">+ -32% -22% -20% -34% -9% -14% -11% -5%</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:center;border-top:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;color:#FFFFFF;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">Figure </font><font style="display: inline;font-weight:bold;color:#000000;">1</font><font style="display: inline;font-weight:bold;color:#000000;">. Percent change from baseline in CSF biomarkers measured by ELISA.</font><font style="display: inline;color:#000000;"> Eight CSF biomarkers of disease in Alzheimer&#x2019;s patients were significantly reduced with simufilam treatment.&nbsp;&nbsp;*p &lt; 0.0001, +p &lt; 0.001 in paired </font><font style="display: inline;font-style:italic;color:#000000;">t</font><font style="display: inline;color:#000000;"> test comparing Day 28 to pre-dose baseline. </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">10</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In addition, visual line plots, which are also known as spaghetti plots, of each individual patient and each individual biomarker measurement show that all patients had a biomarker response to treatment with simufilam in our Phase 2a study (Figure </font><font style="display: inline;">2</font><font style="display: inline;">). </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="font-family:Palatino;color:#211D1E;font-size:7pt;display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Figure </font><font style="font-family:Palatino;color:#211D1E;font-size:7pt;display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">2</font><font style="font-family:Palatino;color:#211D1E;font-size:7pt;display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">. Individual patient response to treatment with simufilam in a Phase 2a study. CSF data are plotted as pg/mL.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;"><img src="sava-20201231x10kg002.jpg" style="width: 6.905387in; height: 1.885182in" alt="Picture 7"></font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;color:#FFFFFF;font-size:1pt;">0 200 400 600 800 1000 1200 Neurogranin 0 100 200 300 400 500 600 700 800 Neurofilament Light Chain 0 2 4 6 8 10 12 Phospho-tau (T181)</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;"><img src="sava-20201231x10kg003.jpg" style="width: 6.936633in; height: 4.072407in" alt="Picture 8"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="font-family:Palatino;color:#211D1E;font-size:7pt;display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="font-family:Palatino;color:#211D1E;font-size:7pt;display: inline;font-family:Times New Roman;font-weight:bold;color:#FFFFFF;font-size:1pt;">0 100 200 300 400 500 Total tau Screening Day 28 0 50 100 150 200 250 300 350 400 450 A42 Screening Day 28 0 10 20 30 40 50 60 70 80 90 YKL40 Screening Day 28 0 5 10 15 20 25 IL-6 Screning Day 28 0 10 20 30 40 50 60 IL-1 Screening Day 28 0 5 10 15 20 25 30 35 40 45 TNF Screening Day 28</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="font-family:Palatino;color:#211D1E;font-size:7pt;display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Figure </font><font style="font-family:Palatino;color:#211D1E;font-size:7pt;display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">2</font><font style="font-family:Palatino;color:#211D1E;font-size:7pt;display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">.</font><font style="font-family:Palatino;color:#211D1E;font-size:7pt;display: inline;font-family:Times New Roman;font-size:10pt;"> Each spaghetti plot shows change from baseline to Day 28 for each patient and each biomarker.</font>
		</p>
		<p style="margin:0pt;text-indent:9.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="font-style:italic;display: inline;font-style:normal;font-size:10pt;">Consistent with over 10 years of basic research and pre-clinical data, we believe our Phase 2a study showed clinical evidence of simufilam&#x2019;s mechanism of action and drug-target engagement, including:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;background-color: #FFFFFF;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="font-style:italic;display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="font-style:italic;display: inline;font-style:normal;color:#000000;">Impr</font><font style="display: inline;color:#000000;">ovements in biomarkers of Alzheimer&#x2019;s disease in CSF, plasma and lymphocytes;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Consistency across biomarker improvements in CSF, plasma, and lymphocytes; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Significant reductions (p&lt;0.01) in both nitrated and phosphorylated forms of tau protein;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Evidence that each individual patient showed biomarker responses to simufilam;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Evidence that simufilam reversed the shape of altered filamin A in lymphocytes;</font></p></td></tr></table></div>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">11</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Evidence that simufilam reduced levels of amyloid bound to alpha 7 nicotinic receptors in lymphocytes;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Early clinical validation of the drug target &#x2013; altered filamin A &#x2013; as a facilitator protein between amyloid beta and both neuroinflammation and tau pathology. </font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;background-color: #FFFFFF;">In </font><font style="display: inline;color:#000000;background-color: #FFFFFF;">December 201</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">9, we </font><font style="display: inline;color:#000000;">presented data</font><font style="display: inline;color:#000000;background-color: #FFFFFF;"> from our Phase 2a study at </font><font style="display: inline;color:#000000;">the </font><font style="display: inline;font-style:italic;color:#000000;">12</font><font style="display: inline;font-style:italic;color:#000000;font-size:5pt;vertical-align:super;line-height:100%">th</font><font style="display: inline;font-style:italic;color:#000000;"> International Conference on Clinical Trials on Alzheimer&#x2019;s Disease</font><font style="display: inline;">&nbsp;</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">(CTAD 2019), a conference for the medical and scientific community held in San Diego, CA. Our Phase 2a presentation was selected as a Late Breaking Oral Communication by CTAD 2019.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-indent:9.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;background-color: #FFFFFF;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;background-color: #FFFFFF;">In </font><font style="display: inline;color:#000000;background-color: #FFFFFF;">February 202</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">0, </font><font style="display: inline;color:#000000;">our Phase 2a study was published in</font><font style="display: inline;font-style:italic;color:#000000;"> The Journal of Prevention of Alzheimer&#x2019;s Disease</font><font style="display: inline;color:#000000;"> (JPAD), a technical journal for the research community. </font><font style="display: inline;color:#000000;">This </font><font style="display: inline;color:#000000;">peer-reviewed </font><font style="display: inline;color:#000000;">publication highlighted that </font><font style="display: inline;color:#000000;">biomarkers of Alzheimer&#x2019;s disease pathology (P-tau, total tau and A&#x3B2;</font><sub style="display: inline;color:#000000;">42</sub><font style="display: inline;color:#000000;">), neurodegeneration (NfL and neurogranin) and neuroinflammation (YKL-40, IL-6, IL-1&#x3B2; and TNF&#x3B1;) improved significantly after 28 days of treatment with simufilam.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">On </font><font style="display: inline;color:#000000;">July&nbsp;</font><font style="display: inline;color:#000000;">15, 2020,&nbsp;we presented&nbsp;additional&nbsp;Phase 2a clinical results at the&nbsp;</font><font style="display: inline;font-style:italic;color:#000000;">Biomarkers&nbsp;for Alzheimer&#x2019;s Disease Summit,&nbsp;</font><font style="display: inline;color:#000000;">a virtual scientific&nbsp;conference.&nbsp;In addition to showing that SavaDx, our investigational diagnostic product candidate, could distinguish and stratify patients with Alzheimer&#x2019;s disease, this presentation provided direct evidence for target engagement and for the treatment effects of&nbsp;</font><font style="display: inline;color:#000000;">simufilam</font><font style="display: inline;color:#000000;">. &nbsp;</font><font style="display: inline;color:#000000;">Presenting evidence of t</font><font style="display: inline;color:#000000;">arget engagement is a crucial step in drug research because it shows that </font><font style="display: inline;color:#000000;">a</font><font style="display: inline;color:#000000;"> drug candidate binds to its intended site of action in cells and confirms that treatment effects are caused by the drug hitting its target.</font>
		</p>
		<p style="margin:0pt;text-indent:9.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Cognition and function were not assessed in this small Phase 2a study. However, independent research has shown that high levels of CSF biomarkers of P-tau and total tau/</font><font style="display: inline;color:#000000;">A&#x3B2;</font><sub style="display: inline;color:#000000;">42</sub><font style="display: inline;color:#000000;"> ratio correlate with worse performance on a wide range of memory and attention tests. Conversely, </font><font style="display: inline;color:#000000;">we believe </font><font style="display: inline;color:#000000;">lowering</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">a pa</font><font style="display: inline;color:#000000;">nel of</font><font style="display: inline;color:#000000;"> CSF </font><font style="display: inline;color:#000000;">biomarkers of disease</font><font style="display: inline;color:#000000;"> may benefit patients. </font>
		</p>
		<p style="margin:0pt;text-indent:9.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;text-decoration:underline;color:#000000;">Phase 2b Clinical Study</font><font style="display: inline;font-weight:bold;font-size:10pt;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">In </font><font style="display: inline;color:#000000;font-size:10pt;">March 202</font><font style="display: inline;color:#000000;font-size:10pt;">0, we</font><font style="display: inline;color:#000000;font-size:10pt;"> announced the completion of a&nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">double-blind, randomized, placebo-controlled, multi-center clinical study of simufilam. Sixty-four patients with mild-to-moderate Alzheimer&#x2019;s disease, age 50-85, were randomized (1:1:1) to 100mg or 50 mg oral simufilam or matching placebo. Treatment was </font><font style="display: inline;font-size:10pt;color:#000000;">administered twice daily for 28 days. Nine U.S. </font><font style="display: inline;font-size:10pt;color:#000000;">study site</font><font style="display: inline;font-size:10pt;color:#000000;">s</font><font style="display: inline;font-size:10pt;color:#000000;"> enrolled patients. A clinical diagnosis was confirmed with the MMSE </font><font style="display: inline;font-size:10pt;color:#000000;">&#x2265;16 and &#x2264;26</font><font style="display: inline;font-size:10pt;color:#000000;"> and a CSF T-tau/</font><font style="display: inline;font-size:10pt;color:#000000;">A&#x3B2;</font><sub style="display: inline;font-size:10pt;color:#000000;">42</sub><font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">ratio </font><font style="display: inline;font-size:10pt;color:#000000;">&#x2265;</font><font style="display: inline;font-size:10pt;color:#000000;">0.28. Safety was assessed by ECGs, clinical labs, adverse event monitoring and physical examinations.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">This study was substantially funded by a research grant award from NIH.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">In </font><font style="display: inline;color:#000000;font-size:10pt;">May 202</font><font style="display: inline;color:#000000;font-size:10pt;">0, we </font><font style="display: inline;color:#000000;font-size:10pt;">announced that&nbsp;an outside lab with whom </font><font style="display: inline;color:#000000;font-size:10pt;">we</font><font style="display: inline;color:#000000;font-size:10pt;"> had no prior work experience had generated an initial bioanalysis </font><font style="display: inline;color:#000000;font-size:10pt;">of CSF samples from our Phase 2b study. The data set from the&nbsp;initial bioanalysis showed unnaturally high variability and other problems, such as no correlation among changes in levels of biomarkers over 28</font><font style="display: inline;color:#000000;font-size:10pt;"> days, even in the placebo group, and different biomarkers of disease moving in opposite directions in the same patient. </font><font style="display: inline;color:#000000;font-size:10pt;">Importantly, we later observed no statistical correlation between levels of simufilam in plasma and CSF, further indicating an invalid analysis. </font><font style="display: inline;color:#000000;font-size:10pt;">Overall</font><font style="display: inline;color:#000000;font-size:10pt;">, we believe data from the </font><font style="display: inline;color:#000000;font-size:10pt;">initial bioanalysis can be interpreted as anomalous and highly improbable.&nbsp;With its validity in question, the initial bioanalysis serves no useful purpose. </font><font style="display: inline;font-size:10pt;color:#000000;">Backup CSF samples were subsequently sent to a second</font><font style="display: inline;font-size:10pt;color:#000000;"> outside lab for bioanalysis. All bioanalyses were conducted under blinded conditions to eliminate any possibility of bias.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Tahoma;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">On </font><font style="display: inline;color:#000000;font-size:10pt;">September&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">14, 2020,&nbsp;we&nbsp;reported final positive&nbsp;Phase 2b&nbsp;clinical&nbsp;study&nbsp;results.&nbsp;Drug was safe and well-tolerated in this study. Simufilam significantly&nbsp;(P&lt;0.05)&nbsp;improved an entire panel of validated biomarkers of disease in patients with Alzheimer&#x2019;s disease&nbsp;compared to a placebo group. In addition, Alzheimer&#x2019;s patients treated with simufilam showed directional improvements in validated tests of episodic memory and spatial working memory,&nbsp;versus patients on placebo</font><font style="display: inline;">&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">(Effect Sizes 46-17%). Cognitive improvements correlated most strongly (R</font><font style="display: inline;color:#000000;font-size:5pt;font-size:3pt;vertical-align:super;line-height:100%">2</font><font style="display: inline;color:#000000;font-size:10pt;">=0.5) with decreases in levels of P-tau181 in CSF. The study achieved a 98% response rate, defined as the proportion of study participants taking simufilam who showed improvements in biomarkers. </font><font style="display: inline;color:#000000;font-size:10pt;">We later observed a direct correlation between levels of simufilam in plasma and CSF, which provides strong evidence </font><font style="display: inline;color:#000000;font-size:10pt;">of </font><font style="display: inline;color:#000000;font-size:10pt;">a valid analysis.</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">Importantly, we believe these data are </font><font style="display: inline;color:#000000;font-size:10pt;">consistent with prior clinical and preclinical</font><font style="display: inline;color:#000000;font-size:10pt;"> results, the drug&#x2019;s mechanism of action and over 10 years of basic research.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">Phase 2b&nbsp;results with&nbsp;simufilam were selected for a late</font><font style="display: inline;color:#000000;font-size:10pt;">-breaking oral presentation by the 13</font><font style="display: inline;color:#000000;font-size:10pt;font-size:5pt;vertical-align:super;line-height:100%">th</font><font style="display: inline;">&nbsp;</font><font style="display: inline;font-style:italic;color:#000000;font-size:10pt;">International Conference on</font><font style="display: inline;">&nbsp;</font><font style="display: inline;font-style:italic;color:#000000;font-size:10pt;">Clinical Trials on Alzheimer&#x2019;s Disease (CTAD 2020),&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">which</font><font style="display: inline;">&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">took&nbsp;place virtually </font><font style="display: inline;color:#000000;font-size:10pt;">November&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">4-7</font><font style="display: inline;color:#000000;font-size:10pt;font-size:5pt;vertical-align:super;line-height:100%">th</font><font style="display: inline;color:#000000;font-size:10pt;">, 2020. Members of CTAD 2020&#x2019;s scientific committee select research abstracts for late-breaking, oral presentation based on medical and scientific significance, quality of data and methodology.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">12</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">The ability to improve multiple biomarkers from distinct biological pathways with one drug has never been shown before in patients with Alzheimer&#x2019;s disease. Phase 2b study results are expected to be published in a peer-reviewed publication&nbsp;at a future date.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Th</font><font style="display: inline;font-size:10pt;">e</font><font style="display: inline;font-size:10pt;"> Phase 2b clinical study </font><font style="display: inline;font-size:10pt;">was</font><font style="display: inline;font-size:10pt;"> designed to evaluate safety, tolera</font><font style="display: inline;font-size:10pt;">bility and drug effects of </font><font style="display: inline;font-size:10pt;">simufilam on </font><font style="display: inline;font-size:10pt;">biomarkers of Alzheimer&#x2019;s disease. </font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">The primary endpoint </font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">was</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;"> improvement in biomarkers of Alzheimer&#x2019;s disease from baseline to Day 28. </font><font style="display: inline;font-size:10pt;">CSF was drawn from patients before dosing started and again after 28 continuous days of dosing with simufilam. </font><font style="display: inline;color:#000000;font-size:10pt;">CSF samples were then analyzed for biomarkers of Alzheimer&#x2019;s pathology (T-tau, P-tau, A&#x3B2;</font><sub style="display: inline;color:#000000;font-size:10pt;">42</sub><font style="display: inline;color:#000000;font-size:10pt;">); neurodegeneration (NfL, neurogranin); and neuroinflammation (YKL-40, IL-6,</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;</font><font style="font-style:italic;display: inline;font-style:normal;font-size:10pt;">sTREM2, HMGB1</font><font style="display: inline;color:#000000;font-size:10pt;">)</font><font style="display: inline;color:#000000;font-size:10pt;"> and BBB integrity (IgG, albumin)</font><font style="display: inline;color:#000000;font-size:10pt;">. A</font><font style="display: inline;font-size:10pt;"> consulting</font><font style="display: inline;">&nbsp;</font><font style="display: inline;font-size:10pt;">biostatistician</font><font style="display: inline;color:#000000;font-size:10pt;"> conducted an </font><font style="display: inline;font-size:10pt;">independent</font><font style="display: inline;">&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">analysis of the data set.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">A further objective of this study was to measure drug effects on cognition.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;font-size:10pt;">Patients were tested at baseline and again on Day 28. Changes in episodic memory and spatial working memory were assessed on CANTAB, a validated, computer-based battery of tests. CANTAB is designed to measure cognitive skills regardless of the subject&#x2019;s language skills, speed, gender or education.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;background-color: #FFFFFF;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:150%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Key biomarker results include the following (all p-values versus placebo)</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:10pt;">(Figure </font><font style="display: inline;font-weight:bold;font-size:10pt;">3</font><font style="display: inline;font-weight:bold;font-size:10pt;">)</font><font style="display: inline;font-size:10pt;">:</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:9pt;"><p style="width:9pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 09.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;font-size:10pt;text-align:justify;text-justify:inter-ideograph;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Core markers of Alzheimer&#x2019;s pathology are total tau (T-tau), phosphorylated tau (P-tau181), and amyloid beta42 (A&#x3B2;</font><sub style="display: inline;color:#000000;">42</sub><font style="display: inline;color:#000000;">). In Alzheimer&#x2019;s, tau and P-tau levels are elevated and A&#x3B2;</font><sub style="display: inline;color:#000000;">42</sub><font style="display: inline;color:#000000;"> is low.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 18.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 13.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;font-size:10pt;text-align:justify;text-justify:inter-ideograph;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">T-tau decreased 15% (p&lt;0.01) for patients in the 50 mg drug group. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 13.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;font-size:10pt;text-align:justify;text-justify:inter-ideograph;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">T-tau decreased 18% (p&lt;0.01) for patients in the 100 mg drug group.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 13.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;font-size:10pt;text-align:justify;text-justify:inter-ideograph;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">P-tau decreased 8% (p&lt;0.01) for patients in the 50 mg drug group. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 13.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;font-size:10pt;text-align:justify;text-justify:inter-ideograph;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">P-tau decreased 11% (p&lt;0.01) for patients in the 100 mg drug group. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 13.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;font-size:10pt;text-align:justify;text-justify:inter-ideograph;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">A&#x3B2;</font><sub style="display: inline;color:#000000;">42</sub><font style="display: inline;color:#000000;"> increased 17% (p&lt;0.01) for patients in the 50 mg drug group.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 13.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;font-size:10pt;text-align:justify;text-justify:inter-ideograph;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">A&#x3B2;</font><sub style="display: inline;color:#000000;">42</sub><font style="display: inline;color:#000000;"> increased 14% (p&lt;0.01) for patients in the 100 mg drug group. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:9pt;"><p style="width:9pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 09.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;font-size:10pt;text-align:justify;text-justify:inter-ideograph;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">Elevated CSF levels of two proteins, Neurogranin (Ng) and Neurofilament Light Chain (NfL) indicate neurodegeneration. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 13.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;font-size:10pt;text-align:justify;text-justify:inter-ideograph;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Ng decreased 36% (p&lt;0.01) for patients in the 50 mg drug group. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 13.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;font-size:10pt;text-align:justify;text-justify:inter-ideograph;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Ng decreased 43% (p&lt;0.01) for patients in the 100 mg drug group.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 13.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;font-size:10pt;text-align:justify;text-justify:inter-ideograph;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">NfL decreased 28% (p&lt;0.05) for patients in the 50 mg drug group. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 13.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;font-size:10pt;text-align:justify;text-justify:inter-ideograph;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">NfL decreased 34% (p&lt;0.01) for patients in the 100 mg drug group.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 49.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:9pt;"><p style="width:9pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 09.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;font-size:10pt;text-align:justify;text-justify:inter-ideograph;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">Proinflammatory IL-6 (Interleukin 6) is produced in response to tissue stress and injury.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 13.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;font-size:10pt;text-align:justify;text-justify:inter-ideograph;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">IL-6 decreased 10% (p&lt;0.01) for patients in the 50 mg drug group.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 13.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;font-size:10pt;text-align:justify;text-justify:inter-ideograph;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">IL-6 decreased 11% (p&lt;0.01) for patients in the 100 mg drug group.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 49.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:9pt;"><p style="width:9pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 09.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;font-size:10pt;text-align:justify;text-justify:inter-ideograph;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">Elevated levels of neuroinflammatory marker </font><font style="display: inline;color:#000000;">YKL-40 </font><font style="display: inline;color:#000000;">indicate microglial activation. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 13.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;font-size:10pt;text-align:justify;text-justify:inter-ideograph;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">YKL-40 decreased 10% (p&lt;0.01) for patients in the 50 mg drug group.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 13.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;font-size:10pt;text-align:justify;text-justify:inter-ideograph;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">YKL-40 decreased 12% (p&lt;0.01) for patients in the 100 mg drug group.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 49.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:9pt;"><p style="width:9pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 09.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;font-size:10pt;text-align:justify;text-justify:inter-ideograph;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="font-style:italic;display: inline;font-style:normal;color:#000000;">sTREM2 </font><font style="display: inline;color:#000000;">is a neuroinflammation biomarker that has commanded substantial recent attention from researchers</font><font style="font-style:italic;display: inline;color:#000000;">&nbsp;</font><font style="font-style:italic;display: inline;font-style:normal;color:#000000;">for its role in Alzheimer&#x2019;s disease and frontotemporal dementia.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 13.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;font-size:10pt;text-align:justify;text-justify:inter-ideograph;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="font-style:italic;display: inline;font-style:normal;color:#000000;">sTREM2 decreased 43% (p&lt;0.01)</font><font style="font-style:italic;display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">for patients in the 50 mg drug group.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 13.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;font-size:10pt;text-align:justify;text-justify:inter-ideograph;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">sTREM2</font><font style="font-style:italic;display: inline;color:#000000;">&nbsp;</font><font style="font-style:italic;display: inline;font-style:normal;color:#000000;">decreased 46% (P&lt;0.01) for</font><font style="font-style:italic;display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">patients in </font><font style="font-style:italic;display: inline;font-style:normal;color:#000000;">the 100 mg drug group.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 49.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="font-style:italic;display: inline;font-style:normal;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:9pt;"><p style="width:9pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 09.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;font-size:10pt;text-align:justify;text-justify:inter-ideograph;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="font-style:italic;display: inline;font-style:normal;color:#000000;">Simufilam</font><font style="font-style:italic;display: inline;font-style:normal;color:#000000;"> Significantly Reduced Levels of HMGB1 in Cerebrospinal Fluid (CSF)</font><font style="font-style:italic;display: inline;font-style:normal;color:#000000;">.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 13.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;font-size:10pt;text-align:justify;text-justify:inter-ideograph;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="font-style:italic;display: inline;font-style:normal;color:#000000;">HMGB1 decreased 33% (p&lt;0.001) in patients treated with 50 mg </font><font style="font-style:italic;display: inline;font-style:normal;color:#000000;">simufilam</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 13.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;font-size:10pt;text-align:justify;text-justify:inter-ideograph;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="font-style:italic;display: inline;font-style:normal;color:#000000;">HMGB1 decreased 32% (p&lt;0.001) in patients treated with 100 mg </font><font style="font-style:italic;display: inline;font-style:normal;color:#000000;">simufilam</font><font style="font-style:italic;display: inline;font-style:normal;color:#000000;"> &nbsp; &nbsp;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:150%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:9pt;"><p style="width:9pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 09.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;font-size:10pt;text-align:justify;text-justify:inter-ideograph;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="font-style:italic;display: inline;font-style:normal;color:#000000;">Simufilam</font><font style="font-style:italic;display: inline;font-style:normal;color:#000000;"> Significantly Improved the Integrity of the Blood-brain Barrier (BBB)</font><font style="font-style:italic;display: inline;font-style:normal;color:#000000;">.</font></p></td></tr></table></div>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">13</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 13.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;font-size:10pt;text-align:justify;text-justify:inter-ideograph;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="font-style:italic;display: inline;font-style:normal;color:#000000;">CSF IgG decreased 30% (p&lt;0.05) in patients treated with 50 mg </font><font style="font-style:italic;display: inline;font-style:normal;color:#000000;">simufilam</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 13.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;font-size:10pt;text-align:justify;text-justify:inter-ideograph;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="font-style:italic;display: inline;font-style:normal;color:#000000;">CSF IgG decreased 30% (p&lt;0.05) in patients treated with 100 mg </font><font style="font-style:italic;display: inline;font-style:normal;color:#000000;">simufilam</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 13.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;font-size:10pt;text-align:justify;text-justify:inter-ideograph;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="font-style:italic;display: inline;font-style:normal;color:#000000;">CSF albumin decreased 15% (p&lt;0.05) in patients treated with 50 mg </font><font style="font-style:italic;display: inline;font-style:normal;color:#000000;">simufilam</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 13.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;font-size:10pt;text-align:justify;text-justify:inter-ideograph;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="font-style:italic;display: inline;font-style:normal;color:#000000;">CSF albumin decreased 28% (p&lt;0.05) in patients treated with 100 mg </font><font style="font-style:italic;display: inline;font-style:normal;color:#000000;">simufilam</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:9pt;"><p style="width:9pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 09.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;font-size:10pt;text-align:justify;text-justify:inter-ideograph;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="font-style:italic;display: inline;font-style:normal;color:#000000;">Simufilam</font><font style="font-style:italic;display: inline;font-style:normal;color:#000000;"> Improved the Albumin Ratio, a Test of Blood-brain Barrier (BBB) Permeability:</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 13.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;font-size:10pt;text-align:justify;text-justify:inter-ideograph;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="font-style:italic;display: inline;font-style:normal;color:#000000;">BBB permeability can be clinically evaluated by comparing levels of albumin in CSF and plasma. The albumin ratio is a test for BBB permeability because albumin protein is not synthesized in CSF. Hence, albumin in CSF necessarily comes from plasma through the BBB. The albumin ratio is frequently elevated in patients with dementia and various other disorders.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 13.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;font-size:10pt;text-align:justify;text-justify:inter-ideograph;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="font-style:italic;display: inline;font-style:normal;color:#000000;">In the Phase 2b study, the albumin ratio was unchanged for Alzheimer&#x2019;s patients on placebo. The albumin ratio improved by approximately 5 and 7 points for patients treated with </font><font style="font-style:italic;display: inline;font-style:normal;color:#000000;">simufilam</font><font style="font-style:italic;display: inline;font-style:normal;color:#000000;">, 50 mg and 100 mg, respectively, over 28 days.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="font-style:italic;display: inline;font-style:normal;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">Changes in the Albumin Ratio by Treatment Group</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-size:12pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;text-align:justify;text-justify:inter-ideograph;margin-left:0pt;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:38.50%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.26%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.68%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:25.58%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:38.50%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.26%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.68%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:25.58%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:38.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Treatment</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.26%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Day 0</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.68%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Day 28</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:25.58%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Change-Day 0 to 28</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:38.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Placebo</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.26%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">24</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.68%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">24</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:25.58%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">No change</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:38.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">50 mg </font><font style="display: inline;color:#000000;">simufilam</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.26%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">25</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.68%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">20</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:25.58%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">- &nbsp;</font><font style="display: inline;color:#000000;">20%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:38.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">100 mg </font><font style="display: inline;color:#000000;">simufilam</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:19.26%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">25</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:16.68%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">18</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:25.58%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">- &nbsp;</font><font style="display: inline;color:#000000;">28%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="font-style:italic;display: inline;font-style:normal;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="font-style:italic;display: inline;font-weight:bold;font-style:normal;color:#000000;">Figure </font><font style="font-style:italic;display: inline;font-weight:bold;font-style:normal;color:#000000;">3</font><font style="font-style:italic;display: inline;font-weight:bold;font-style:normal;color:#000000;">.</font><font style="font-style:italic;display: inline;font-style:normal;color:#000000;">&nbsp;</font><font style="font-style:italic;display: inline;font-weight:bold;font-style:normal;color:#000000;">Simufilam improved levels of CSF biomarkers in patients with Alzheimer&#x2019;s in a Phase 2b study.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="font-style:italic;display: inline;font-style:normal;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;"><img src="sava-20201231x10kg004.jpg" style="width: 6.9375in; height: 3.301389in" alt="Picture 1"></font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;color:#FFFFFF;font-size:1pt;">% Change&nbsp;&nbsp;Baseline to Day 28 -55% -45% -35% -25% -15% -5% 5% 15% 25% A42 T-tau P-tau181 Nurogranin NfL YKL-40 IL-6 sTREM2 HMGB1 Albumin IgG Placebo 50 mg 100 mg +p &lt; 0.05 p &lt; 0.01, # p &lt; 0.001, p &lt; 0.0001 vs. placebo</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">14</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-weight:bold;background-color: #FFFFFF;">Figure </font><font style="display: inline;font-weight:bold;background-color: #FFFFFF;">4</font><font style="display: inline;font-weight:bold;background-color: #FFFFFF;">. &nbsp;</font><font style="display: inline;font-weight:bold;">Study response rate, defined as the proportion of study participants taking simufilam who showed improvements in biomarkers.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;"><img src="sava-20201231x10kg005.jpg" style="width: 6.9375in; height: 3.342361in" alt="Picture 2"></font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;color:#FFFFFF;font-size:1pt;">% of Patients Who Responded to Simufilam on CSF Biomarkets Tau/p- Tau Biomarkers 98% Biomarkers of Neuroinflammation 98% Biomarkers of Neurodegeneration 98% Biomarkers of BBB Integrity 95% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Key cognition results. Only directional trends are observed, due to limitations around study size (N=64). (</font><font style="display: inline;font-weight:bold;font-size:10pt;">Figure </font><font style="display: inline;font-weight:bold;font-size:10pt;">5</font><font style="display: inline;font-weight:bold;font-size:10pt;">)</font><font style="display: inline;font-size:10pt;">:</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Alzheimer&#x2019;s patients in both drug groups showed directional improvements on tests of episodic memory and spatial memory after 28 days of treatment, versus patients on placebo. Effect Sizes were 46-17% versus placebo.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Episodic memory improved by -5.7 (lower score is better) for Alzheimer&#x2019;s patients in the 50 mg drug group, versus -1.5 for patients on placebo. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Episodic memory improved by -4.3 (lower score is better) for Alzheimer&#x2019;s patients in the 100 mg drug group, versus -1.5 for patients on placebo. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Spatial memory improved by -1.6 (lower score is better) for Alzheimer&#x2019;s patients in the 50 mg drug group, versus -0.4 for patients on placebo. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Spatial memory improved by -3.3 (lower score is better) for Alzheimer&#x2019;s patients in the 100 mg drug group, versus -0.4 for patients on placebo. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Improvements in cognition correlated most strongly (statistical R</font><font style="display: inline;color:#000000;">2</font><font style="display: inline;color:#000000;">=0.5) with decreases in CSF P-tau181, a biomarker that, when elevated, leads to tangles in the brain. </font><font style="display: inline;color:#000000;">Simufilam</font><font style="display: inline;color:#000000;"> decreased brain levels of Ptau-181 by 8-11%, versus placebo.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:13.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">15</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-indent:13.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-weight:bold;background-color: #FFFFFF;">Figure </font><font style="display: inline;font-weight:bold;background-color: #FFFFFF;">5</font><font style="display: inline;font-weight:bold;background-color: #FFFFFF;">. &nbsp;</font><font style="display: inline;font-weight:bold;">Episodic Memory and Spatial Working Memory Improvements</font>
		</p>
		<p style="margin:0pt;text-indent:13.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;"><img src="sava-20201231x10kg006.jpg" style="width: 6.9375in; height: 2.993056in" alt="Picture 11"></font>
		</p>
		<p style="margin:0pt;text-align:center;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;text-decoration:underline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;color:#FFFFFF;font-size:1pt;">Change in Errors Baseline to Day 28 -6.0 -5.0 -4.0 -3.0 -2.0 -1.0 0.0 Placebo -1.5 50 mg -5.7 100 mg -4.5 37% Effect Size 2% Effect Size&nbsp;&nbsp;-3.5 -3.0 -2.5 -2.0 -1.5 -1.0 -0.5 0.0 Placebo -0.41 50 mg -1.65 100 mg -3.33</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;text-decoration:underline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:13.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;background-color: #FFFFFF;">Figure</font><font style="display: inline;font-weight:bold;">&nbsp;</font><font style="display: inline;font-weight:bold;">6</font><font style="display: inline;font-weight:bold;">. Improvements in cognition correlated most strongly (statistical R</font><font style="display: inline;font-weight:bold;font-size:5pt;vertical-align:super;line-height:100%">2</font><font style="display: inline;font-weight:bold;">=0.5) with decreases in CSF P-tau181.</font>
		</p>
		<p style="margin:0pt;text-align:center;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;"><img src="sava-20201231x10kg007.jpg" style="width: 4.620879in; height: 3.120833in" alt="Picture 9"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;text-decoration:underline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;color:#FFFFFF;font-size:1pt;">Cognition/Biomarker Correlations (R2) 1 YKL NfL T-tau Albumin II-6 P-tau181 0.30 0.36 0.37 0.37 0.41 0.48</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;text-decoration:underline;">Open-label Extension Clinical Study</font><font style="display: inline;font-weight:bold;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;background-color: #FFFFFF;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;background-color: #FFFFFF;">I</font><font style="display: inline;background-color: #FFFFFF;">n &nbsp;</font><font style="display: inline;background-color: #FFFFFF;">March 202</font><font style="display: inline;background-color: #FFFFFF;">0, we announced </font><font style="display: inline;">the initiation of an open-label extension study to evaluate simufilam in patients with Alzheimer&#x2019;s disease. </font><a name="_Hlk33446796"></a><font style="display: inline;background-color: #FFFFFF;">This open-label, multi-center, extension study </font><font style="display: inline;">is designed to monitor the long-term safety and tolerability of simufilam at 100 mg twice-daily for 12 months. The study&#x2019;s target enrollment is approximately 150 </font><font style="display: inline;background-color: #FFFFFF;">patients with m</font><font style="display: inline;">ild-to-moderate Alzheimer&#x2019;s disease</font><font style="display: inline;">, including patients from a prior study of simufilam</font><font style="display: inline;color:#000000;">. &nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">ADAS-Cog-11 is being used to assess cognitive symptoms of dementia&nbsp;in patients enrolled in the open-label study. </font><font style="display: inline;">The NPI is being used to assess the presence and severity of Alzheimer&#x2019;s related behavior.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">16</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;">On </font><font style="display: inline;">February&nbsp;</font><font style="display: inline;">2, 2021, we announced results of </font><font style="display: inline;">the first of two</font><font style="display: inline;"> preplanned interim analysis from </font><font style="display: inline;">our</font><font style="display: inline;"> open-label study of simufilam</font><font style="display: inline;">. The first interim analysis summarized</font><font style="display: inline;color:#000000;"> clinical data at the midway point of enrollment, i.e., the first</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">50 patients who have completed at least 6 months of drug treatment</font><font style="display: inline;">. Patients&#x2019; cognition and behavior scores both improved following six months of simufilam treatment, with no safety issues. In the study, six months of simufilam treatment improved cognition scores by 1.6 points on ADAS-Cog11, a 10% mean improvement from baseline to month 6. In these same patients, simufilam also improved dementia-related behavior, such as anxiety, delusions and agitation, by 1.3 points on the Neuropsychiatric Inventory, a 29% mean improvement from baseline to month 6. The safety profile of simufilam in the interim analysis was </font><font style="display: inline;">consistent with prior human studi</font><font style="display: inline;">es. There were no drug-related serious adverse events. Adverse events were mild and transient. </font><font style="display: inline;">Based on these results and other factors, we</font><font style="display: inline;"> announced significant changes to the design of our open-label study, including a 50% increase in the enrollment target and other potential enhancements to the study design. </font><font style="display: inline;color:#000000;">This study&nbsp;has approximately 80 patients enrolled as of </font><font style="display: inline;color:#000000;">February 202</font><font style="display: inline;color:#000000;">1.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">On </font><font style="display: inline;font-size:10pt;">February&nbsp;</font><font style="display: inline;font-size:10pt;">8, 2021, we announced additional changes to our open-label program with simufilam in Alzheimer&#x2019;s disease. We plan to initiate a 6-month, double-blind, randomized, placebo-controlled study in patients with Alzheimer&#x2019;s disease who complete at least one year of open-label treatment with simufilam. This is a cognition maintenance study (CMS), in which patients who complete one year of open-label treatment will subsequently be randomized (1:1) to simufilam or placebo for six months. The CMS is designed to compare simufilam&#x2019;s effects on cognition and behavior in patients who continue with drug treatment versus those who discontinue drug treatment.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Figure </font><font style="display: inline;font-weight:bold;font-size:10pt;">7</font><font style="display: inline;font-weight:bold;font-size:10pt;">. &nbsp;</font><font style="display: inline;font-weight:bold;font-size:10pt;">Cognition Maintenance Study Design</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;"><img src="sava-20201231x10kg008.jpg" style="width: 6.9375in; height: 2.261111in" alt="Picture 10"></font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;color:#FFFFFF;font-size:1pt;">SCREEN Ongoing Open-label Study simufilam 100 mg BID (n=up to 150) Month 12 Cognition study completers Radomization 1:1 COGNITION MAINTENANCE STUDY Double-blind, randomized, placebo-controlled study simufilam 100 mg BID placebo Month 6 cognition study completers Open-labe Treatment simufilam 100 mg BID Month 0 Month 12 Month 0 Month 6</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">We expect to announce&nbsp;results of&nbsp;a second interim analysis on safety and cognition for this study in the mid-2021, after approximately </font><font style="display: inline;color:#000000;">50 patients have completed at least 12 months of drug treatment</font><font style="display: inline;color:#000000;">. &nbsp;</font><font style="display: inline;">To our knowledge, no drug for Alzheimer&#x2019;s has shown an ability to stabilize cognition in patients, much less restore loss cognition, beyond a few months.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;text-decoration:underline;">Phase 3 Clinical </font><font style="display: inline;font-weight:bold;font-size:10pt;text-decoration:underline;">Strategy</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We held an end-of-phase 2 (EOP2) meeting with FDA in </font><font style="display: inline;">January 202</font><font style="display: inline;">1. An EOP2 meeting is a critical regulatory milestone to ensure that meaningful data will be generated during a Phase 3 clinical program.&nbsp;Our objectives for the&nbsp;EOP2 meeting </font><font style="display: inline;">were</font><font style="display: inline;"> to gain agreement around proposed Phase 3 clinical plans and protocols, and to identify outstanding requirements around safety, product development or manufacturing, or any other information needed to support the statutory requirements for a 505(b)(1) NDA submission and marketing approval of </font><font style="display: inline;">simufilam</font><font style="display: inline;"> for the treatment of mild-to-moderate Alzheimer&#x2019;s disease. </font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Official EOP2 meeting minutes</font><font style="display: inline;"> were issued by the FDA in </font><font style="display: inline;">February 202</font><font style="display: inline;">1. </font><font style="display: inline;">We</font><font style="display: inline;"> believe these</font><font style="display: inline;"> indicate FDA and </font><font style="display: inline;">Company agreement</font><font style="display: inline;"> on key elements of a pivotal Phase 3 clinical program in support of a New Drug Application (NDA) filing for simufilam in Alzheimer&#x2019;s disease. Agreements reached during the EOP2 meeting show a clear path forward for advancing simufilam into </font><font style="display: inline;">a pivotal </font><font style="display: inline;">Phase 3 </font><font style="display: inline;">program, which we</font><font style="display: inline;"> plan to </font><font style="display: inline;">initiate</font><font style="display: inline;"> in the second half of 2021.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">17</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;">Official EOP2 meeting minutes also indicate </font><font style="display: inline;">agreement that the use of separate clinical scales to assess cognition (ADAS-cog</font><font style="display: inline;font-size:5pt;vertical-align:super;line-height:100%">1</font><font style="display: inline;">) and function (ADCS-ADL</font><font style="display: inline;font-size:5pt;vertical-align:super;line-height:100%">2</font><font style="display: inline;">) are appropriate co-primary endpoints of efficacy. A clinical scale that combines cognition and function, such as iADRS</font><font style="display: inline;font-size:5pt;vertical-align:super;line-height:100%">3</font><font style="display: inline;">, is a secondary efficacy endpoint.</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Our</font><font style="display: inline;"> pivotal Phase 3 clinical program consists of two double-blind, randomized, placebo-controlled studies, each described below.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Our</font><font style="display: inline;"> first Phase 3 study is designed to evaluate </font><font style="display: inline;">disease-modifying</font><font style="display: inline;"> effects of simufilam in Alzheimer&#x2019;s disease. The goal is to demonstrate a slower rate of decline in cognition and health function in subjects treated with simufilam compared to placebo.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Details of the first Phase 3 study include:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Wingdings;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xD8;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Approximately 1,000 subjects with mild-to-moderate Alzheimer&#x2019;s disease to be enrolled.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Wingdings;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xD8;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Subjects to be randomized (1:1:1) to simufilam 100 mg, 50 mg, or placebo BID. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Wingdings;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xD8;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Subjects to be treated for 18 months.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Wingdings;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xD8;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">The co-primary efficacy endpoints are ADAS-Cog, a cognitive scale, and ADCS-ADL, a functional scale; both are widely used clinical tools in trials of Alzheimer&#x2019;s disease. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Wingdings;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xD8;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">A secondary efficacy endpoint is iADRS, a widely used clinical tool in trials of Alzheimer&#x2019;s disease that combines cognitive and functional scores from ADAS-Cog &amp; ADCS-ADL. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Wingdings;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xD8;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Other secondary endpoints include biomarkers of disease and NPI</font><font style="display: inline;color:#000000;font-size:5pt;vertical-align:super;line-height:100%">4</font><font style="display: inline;color:#000000;">, a clinical tool that assesses the presence and severity of dementia-related behavior.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Wingdings;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;font-size:10pt;;"> &#xD8;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">We</font><font style="display: inline;color:#000000;"> plan to initiate the first pivotal Phase 3 study </font><font style="display: inline;color:#000000;">approximately </font><font style="display: inline;color:#000000;">Q3 2021.</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:150%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Our</font><font style="display: inline;color:#000000;"> second Phase 3 study is designed to evaluate </font><font style="display: inline;font-style:italic;color:#000000;">symptomatic improvement</font><font style="display: inline;color:#000000;"> in Alzheimer&#x2019;s disease. The goal is to demonstrate improved cognition and health function in subjects treated with simufilam compared to placebo. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Details of the second Phase 3 study include:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Wingdings;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xD8;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Approximately 600 subjects with mild-to-moderate Alzheimer&#x2019;s disease to be enrolled.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Wingdings;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xD8;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Subjects to be randomized (1:1) to simufilam 100 mg or placebo BID. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Wingdings;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xD8;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Subjects to be treated for 9 to 12 months.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Wingdings;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xD8;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">The co-primary efficacy endpoints are ADAS-Cog, a cognitive scale, and ADCS-ADL, a functional scale; both are widely used clinical tools in trials of Alzheimer&#x2019;s disease. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Wingdings;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xD8;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">A secondary efficacy endpoint is iADRS, a widely used clinical tool in trials of Alzheimer&#x2019;s disease that combines cognitive and functional scores from ADAS-Cog &amp; ADCS-ADL. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Wingdings;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xD8;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Other secondary endpoints include biomarkers of disease and NPI, a clinical tool that assesses the presence and severity of dementia-related behavior.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:150%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Wingdings;line-height:150%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;font-size:10pt;;"> &#xD8;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:150%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">We</font><font style="display: inline;color:#000000;"> plan to initiate the second pivotal Phase 3 study </font><font style="display: inline;color:#000000;">approximately </font><font style="display: inline;color:#000000;">Q4 2021.</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:150%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">_____________________________</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;color:#000000;font-size:5pt;vertical-align:super;line-height:100%">1</font><font style="display: inline;font-style:italic;color:#000000;"> ADAS-Cog = The Alzheimer&#x2019;s Disease Assessment Scale &#x2013; Cognitive Subscale, a measure of cognition </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;color:#000000;font-size:5pt;vertical-align:super;line-height:100%">2</font><font style="display: inline;font-style:italic;color:#000000;"> ADCS-ADL = Alzheimer&#x2019;s Disease Cooperative Study &#x2013; Activities of Daily Living, a measure of health function</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;color:#000000;font-size:5pt;vertical-align:super;line-height:100%">3</font><font style="display: inline;font-style:italic;color:#000000;"> iADRS = integrated Alzheimer&#x2019;s Disease Rating Scale, a composite measure of cognition and health function</font>
		</p>
		<p style="margin:0pt;line-height:150%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;color:#000000;font-size:5pt;vertical-align:super;line-height:150%">4</font><font style="display: inline;font-style:italic;color:#000000;"> Neuropsychiatric Inventory (NPI)</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">18</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-style:italic;"></font>
		</p>
		<p style="margin:0pt;line-height:150%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Figure </font><font style="display: inline;font-weight:bold;font-size:10pt;">8</font><font style="display: inline;font-weight:bold;font-size:10pt;">. &nbsp;</font><font style="display: inline;font-weight:bold;font-size:10pt;">Phase 3 Program Design</font>
		</p>
		<p style="margin:0pt;line-height:150%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:150%;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;"><img src="sava-20201231x10kg009.jpg" style="width: 6.9375in; height: 1.204861in" alt="Picture 4"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">FDA has provided further flexibility to </font><font style="display: inline;">us</font><font style="display: inline;"> by agreeing to review the final version of each protocol for the two Phase 3 studies, and to conduct a Special Protocol Assessment (SPA) for each Phase 3 study. An SPA is a formal regulatory procedure that confirms certain critical details of a Phase 3 study protocol, such as the statistical analyses, meet FDA&#x2019;s standards of approvability.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;text-decoration:underline;">SavaDx</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Our diagnostic effort, called SavaDx, is an early-stage program focused on detecting Alzheimer&#x2019;s disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. </font><font style="display: inline;">T</font><font style="display: inline;">he goal of SavaDx, an early-stage product candidate, is to make the detection of Alzheimer&#x2019;s disease as simple as getting a blood test.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">We</font><font style="display: inline;"> are developing SavaDx as a fast, a</font><font style="display: inline;">ccurate and quantitative blood-based biomarker/diagnostic to detect and monitor Alzheimer's disease. </font><font style="display: inline;">If successful, we believe SavaDx has potential to make obsolete more invasive approaches for diagnosing Alzheimer&#x2019;s disease. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Over the past ten years, we discovered that altered FLNA is a hallmark feature of brain pathology in patients with Alzheimer&#x2019;s disease. We believe SavaDx, which is a complex and unique detection system for altered filamin A (FLNA), can reveal early traces of the disease, potentially even before the overt appearance of disease symptoms, such as memory loss.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In </font><font style="display: inline;">September 201</font><font style="display: inline;">7, we announced a $1.8</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> research grant award from the NIH for SavaDx. The NIH awarded us this research grant following a confidential, in-depth evaluation of SavaDx technology for scientific and technical merit. This technical milestone-based grant award enables us to work collaboratively with leaders in the field to collect clinical samples needed to develop our blood-based diagnostic for Alzheimer&#x2019;s disease.&nbsp;&nbsp;&nbsp; </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">A diagnostic test usually measures one or more biomarkers, which are biological indicators of disease. A deep understanding of the biology of disease is required to identify and develop a diagnostic. A valid diagnostic has certain baseline characteristics to be functional and useful for clinical practice. It must detect disease in patients and, conversely, not detect disease in healthy subjects; and it is preferably quantitative, giving some indication of severity or stage of disease. Collectively, the ability to selectively detect disease indicators can be useful to provide diagnostic information (i.e., detect the disease) or prognostic information (i.e., predict the disease or its future course). </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Currently, the most definitive method to diagnose Alzheimer&#x2019;s disease is through autopsy after death, which is not particularly helpful. </font><font style="display: inline;">Methods to detect </font><font style="display: inline;">Alzheimer&#x2019;s disease during its course can </font><font style="display: inline;">be expensive, invasive, subjective, risky or uncomfortable. Importantly, because of the expense and invasiveness of current </font><font style="display: inline;">tests</font><font style="display: inline;">,</font><font style="display: inline;"> most people are not tested until they show obvious cognitive decline.</font><font style="display: inline;font-style:italic;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Current approaches for diagnosing Alzheimer&#x2019;s disease include measurement of amyloid-&#x3B2; (specifically, A&#x3B2;</font><sub style="display: inline;">42</sub><font style="display: inline;">), total tau (T-tau) or phosphorylated tau (P-tau) levels in CSF; structural neuroimaging techniques, including magnetic resonance imaging (MRI) or computerized tomography (CT); positron-emission tomography (PET) imaging of brain amyloid (AmyVid</font><font style="display: inline;font-size:5pt;vertical-align:super;line-height:100%">&#xAE;</font><font style="display: inline;">); and batteries of cognitive tests. Usually, a combination of more than one test is necessary to provide a working diagnosis. When such tests and techniques are used together, the totality of data can be sensitive and specific for the detection of Alzheimer&#x2019;s disease. In practice, however, such tests and techniques are only used after overt symptoms of impaired memory.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">19</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;">We believe there is a profound need for a blood-based diagnostic test for Alzheimer&#x2019;s disease. A quick, simple, inexpensive test may benefit the medical community in many ways. Advantages may include confirming the presence of Alzheimer&#x2019;s disease earlier, when lifestyle changes and potential therapeutics may have the most impact, or conversely, to rule out Alzheimer&#x2019;s disease at such early stages. Other potential benefits include discriminating Alzheimer&#x2019;s disease from other causes of dementias; helping to identify stage of Alzheimer&#x2019;s disease; selection and enrollment of appropriate patients into clinical studies of experimental product candidates; and better alignment of a patient&#x2019;s specific diagnosis with a targeted therapeutic.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">It is widely accepted that in Alzheimer&#x2019;s disease, pathological changes in the brain occur at least 10-15 years before clinical </font><font style="display: inline;">symptoms</font><font style="display: inline;"> appear. These &#x201C;pre-symptomatic&#x201D; changes include deposits of certain misfolded or impaired proteins in the brain. </font><font style="display: inline;">Our</font><font style="display: inline;"> long-term goal </font><font style="display: inline;">with SavaDx is </font><font style="display: inline;">to identify people with </font><font style="display: inline;">Alzheimer&#x2019;s disease, potentially </font><font style="display: inline;">long before clinical symptoms occur. Early detection may be critical for any intervention to cease - or at least slow down - brain damage before it is too late. </font><font style="display: inline;">Importantly, a non-invasive screen for latent Alzheimer&#x2019;s disease prior to overt symptoms could be conducted as a general health screen, not just in patients at risk by family history or in patients already showing cognitive impairment. Once a disease-modifying treatment is found, early detection is likely to be critically important. Early detection and treatment may also be critical in identifying such a disease-modifying treatment, as many believe one reason for clinical study failures in Alzheimer&#x2019;s disease is that treatment has routinely started too late in the course of disease to make any impact.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Moreover, w</font><font style="display: inline;">ith repeat measurements over time, SavaDx may provide a probability of cognitive decline or disease progression. Even if SavaDx does not provide a precise numerical cutoff value for </font><font style="display: inline;">Alzheimer&#x2019;s disease</font><font style="display: inline;">, we believe it may be important to </font><font style="display: inline;">incorporate</font><font style="display: inline;"> data from SavaDx into the overall diagnostic framework for neurodegeneration, and </font><font style="display: inline;">Alzheimer&#x2019;s disease in particular</font><font style="display: inline;">. As with any diagnosis of disease, some people may embrace a way to detect Alzheimer&#x2019;s disease long before clinical symptoms appear, while others may prefer not to know &#x2013; at least until a treatment is found</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;font-size:10pt;">Diagnostic development program for SavaDx.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Diagnostic development differs from drug development in many important ways. As a result, diagnostic development requires substantial differences in planning, study design and study execution.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Some of the ways that diagnostic development differs from drug development include the following:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 31.5pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">We may need to choose among a wider range of regulatory pathways for approval of SavaDx, depending on factors such as intended use and user, test type and complexity and role in patient-care decisions;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Drug studies usually deal primarily with one office within FDA, but the regulatory pathway for SavaDx may require us to consider the policies of multiple federal or state regulatory agencies and offices;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Unlike drug programs, statistical analysis with SavaDx does not focus on efficacy and safety endpoints. Rather, study endpoints for SavaDx will focus on sensitivity (true positives), specificity (true negatives), positive predictive value (percentage of correct positive diagnoses of known positive cases) and negative predictive value (percentage of correct negative diagnoses of known negative cases);</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">SavaDx is an investigational diagnostic product candidate that has not yet been reviewed by FDA. Clinical testing consists of collecting blood samples on a limited scale to validate SavaDx. Our ability to test such samples depends on multiple factors, many of which are beyond our control. For example, optimal sample collection depends on risk of sample degradation, storage requirements to preserve samples, cost of sample storage and actual vs. predicted time of assay validation. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Over the past four years, we have conducted four such rounds of early validation tests, with funding from NIH. In three blinded studies of test samples, SavaDx detected more than a 10-fold separation between Alzheimer&#x2019;s patients and normal healthy control subjects (N=232 test samples). In these three proof-of-concept studies, SavaDx demonstrated nearly 100% accuracy and specificity. The three studies deployed a research grade antibody manufactured by an outside vendor.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">A fourth blinded study of SavaDx failed to generate meaningful diagnostic data. We believe the fourth study deployed a faulty research antibody sourced from an outside vendor. </font><font style="display: inline;color:#000000;">Commercially available research antibodies can present certain technical flaws, such as improper validation, significant batch-to-batch variations or inconsistent storage, any of which can jeopardize results of studies and experiments. For these reasons, </font><font style="display: inline;color:#000000;">and in order to increase consistency of quality, reliability and availability,</font><font style="display: inline;color:#000000;"> we are now developing and validating a</font><font style="display: inline;color:#000000;"> proprietary, </font><font style="display: inline;color:#000000;">fit-for-purpose, antibody system for use with SavaDx. </font><font style="display: inline;color:#000000;">NIH is funding the development expenses for this project. </font><font style="display: inline;color:#000000;">Such technical activities </font><font style="display: inline;color:#000000;">are</font><font style="display: inline;color:#000000;"> on-going.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">20</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">SavaDx was selected as a keynote presentation at the </font><font style="display: inline;font-style:italic;font-size:10pt;">Biomarkers </font><font style="display: inline;font-style:italic;font-size:10pt;">for Alzheimer&#x2019;s Disease Summit</font><font style="display: inline;font-size:10pt;">, a virtual conference, on </font><font style="display: inline;font-size:10pt;">July&nbsp;</font><font style="display: inline;font-size:10pt;">15, 2020</font><font style="display: inline;color:#000000;font-size:10pt;">. &nbsp;</font><font style="display: inline;font-size:10pt;">The </font><font style="font-weight:bold;display: inline;font-weight:normal;font-style:italic;font-size:10pt;">Biomarkers for Alzheimer&#x2019;s Disease Summit</font><font style="display: inline;font-size:10pt;"> is a scientific forum dedicated to solving the challenges of developing clinically validated biomarkers to detect Alzheimer&#x2019;s disease.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">We are prioritizing the development of simufilam for the treatment of Alzheimer&#x2019;s disease over the development of SavaDx for the detection of Alzheimer&#x2019;s disease in light of our assessment of each product candidate&#x2019;s ability to address unmet clinical needs, severity of disease burden, market potential, growth potential, and other factors.&nbsp;We expect to initiate a validation/disease specificity study&nbsp;of SavaDx&nbsp;in 2021.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The legal system for intellectual property around diagnostic methods is highly complex and uncertain. In the U.S., patent courts have struggled to define a clear means of patent eligibility for modern age diagnostics. Generally, a simple process involving correlations between blood test results and patient health is not eligible for patent claims because such processes incorporate &#x201C;laws of nature&#x201D;. However, different outcomes from different courts, including Federal Circuit, district court and Patent Trial and Appeal Board decisions, have continued to create a sometimes vague or conflicting legal framework for determining the eligibility of patent claims for diagnostic methods. As a result, we cannot be certain how SavaDx fits into the current U.S. legal framework for obtaining effective patent claims. Furthermore, </font><font style="display: inline;">claims for diagnostic methods can be complicated to enforce. </font><font style="display: inline;color:#000000;">We</font><font style="display: inline;color:#000000;"> currently ha</font><font style="display: inline;color:#000000;">ve</font><font style="display: inline;color:#000000;"> no patents or patent applications with respect to SavaDx, and is protected in the United States by trade secrets, know-how and other proprietary rights technology.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Expansion of our science to other indications.</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">It is well-known that protein misfolds occur in a wide variety of biological processes and diseases. We may leverage our scientific insights in neurodegeneration and advanced tools in biochemistry, bioinformatics and imaging to expand our science to other diseases. New indications and new drug development approaches may complement our initial focus on Alzheimer&#x2019;s disease.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Pre-clinical programs are always visionary, sometimes innovative and often of high biomedical potential. However, by definition such programs are exploratory and risky. Moreover, most pre-clinical programs fail for scientific or other reasons, regardless of the amount of effort or resources that are brought to bear upon such programs. For these reasons, in general we do not intend to disclose our pre-clinical programs until such time as they become material to our pipeline of product candidates.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">We own worldwide rights to our neurodegeneration program. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We own intellectual property, including patents, patent applications, technology, trade secrets and know-how in the U.S. and other countries. The protection of patents, designs, trademarks and other proprietary rights that we own or license is critical to our success and competitive position. We consider the overall protection of our patents and other intellectual property rights to be of material value and act to protect these rights from infringement. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We seek to protect our technology by, among other methods, filing and prosecuting U.S. and foreign patents and patent </font><font style="display: inline;">applications</font><font style="display: inline;"> with respect to our technology and products and their uses. The focus of our patent strategy is to secure and maintain intellectual property rights to technology for our program in neurodegeneration.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Simufilam and SavaDx were both discovered and designed in-house and were characterized by our academic collaborators during research activities that were conducted from approximately 2008 to date. We own exclusive, worldwide rights to these drug assets and related technologies, without royalty obligations to any third party. </font><font style="display: inline;color:#000000;">Our</font><font style="display: inline;color:#000000;"> patent protection with respect to simufilam and use of simufilam for Alzheimer&#x2019;s disease and other neurodegenerative disease currently runs through 2033 and includes six issued patents and related patent filings and applications. In addition, </font><font style="display: inline;color:#000000;">we</font><font style="display: inline;color:#000000;"> ha</font><font style="display: inline;color:#000000;">ve</font><font style="display: inline;color:#000000;"> patent protection with respect to simufilam for use in treating certain cancers that runs through 2034. </font><font style="display: inline;color:#000000;">We currently</font><font style="display: inline;color:#000000;"> ha</font><font style="display: inline;color:#000000;">ve</font><font style="display: inline;color:#000000;"> no patents or patent applications with respect to SavaDx, and is protected in the United States by trade secrets, know-how and other proprietary rights technology.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">21</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-weight:bold;">Our Development Team </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Our product development team is led by seasoned professionals with a proven track record of innovation in drug discovery and development, as well as substantial business expertise. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Our Founder and Chief Executive Officer, Remi Barbier, has over 25&nbsp;years of biopharmaceutical industry experience and has led teams responsible for pioneering several pharmaceutical innovations, including abuse-deterrent drugs; the clinical development of multiple pain drugs; an innovative antibody program in cancer; and other programs in </font><font style="display: inline;">neuroscience</font><font style="display: inline;"> and other therapeutics areas. Before founding Cassava Sciences (formerly known as Pain Therapeutics, Inc.), he held leadership roles and was founder or co-founder of four life science companies, three of which are now publicly traded.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Our Chief Medical Officer, Nadav Friedmann PhD, MD, has eight prior FDA drug approvals and previously served as CEO of Daiichi Pharmaceuticals USA and Head of Johnson &amp; Johnson&#x2019;s Biotechnology Research Center.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">James Kupiec, MD, has two prior FDA drug approvals and previously served as </font><font style="display: inline;color:#0A0A0A;">VP, Global Clinical Leader for Parkinson&#x2019;s Disease and Clinical Head of the Neuroscience Research Unit for Pfizer, Inc. and also held leadership roles at Sanofi and Ciba-Geigy Pharmaceuticals.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#0A0A0A;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Lindsay Burns, PhD, SVP, Neuroscience, worked on the development of several product candidates in neuroscience and other therapeutics areas while at Neurex (acquired by Elan Pharmaceuticals) and Abgenix (acquired by Amgen).</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Michael Zamloot, SVP of Technology Operations, has four prior FDA drug approvals and has worked in drug operations and supply chain management at Boehringer Mannheim (acquired by Roche Diagnostics), Athena Neuroscience (acquired by Elan Pharmaceuticals) and Ciba-Geigy (acquired by Novartis).</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">George (Ben) Thornton, PhD, SVP of Technology, has led research and development teams at Johnson &amp; Johnson as well as translated basic science to the clinical setting at biotechnology start-ups such as GeneMedicine and Apovia.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Our management </font><font style="display: inline;">team</font><font style="display: inline;"> is further supported by scientific advisors that share our commitment to advancing new treatments for Alzheimer&#x2019;s disease. Leading experts in the field who advise us include:</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Jeff Cummings, MD, Director of Cleveland Clinic Lou Ruvo Center for Brain Health and Professor of Neurother</font><font style="display: inline;color:#000000;">apeutics and Drug Development, Cleveland Clinic.&nbsp; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Hoau-Yan Wang, PhD, </font><font style="display: inline;color:#000000;">Tenured Medical Professor at CUNY Medical School; co-lead scientist on discovery &amp; development of simufilam and </font><font style="display: inline;color:#000000;">SavaDx</font><font style="display: inline;color:#000000;">.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Steven E. Arnold, MD, Translational Neurology Head of the Interdisciplinary Brain Center, Massachusetts General Hospital, Harvard Medical School. &nbsp;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Ba</font><font style="display: inline;color:#000000;">rbara Sahakian, FBA, FMedSci, </font><font style="display: inline;color:#000000;">Professor of Clinical Neuropsychology at the Department of Psychiatry and Medical </font><font style="display: inline;color:#000000;">Research Council /Wellcome Trust Behavioral and Clinical</font><font style="display: inline;color:#000000;"> Neuroscience Institute, University of </font><font style="display: inline;color:#000000;">Cambridge</font><font style="display: inline;color:#000000;">.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Trevor W. Robbins, CBE FRS FMedSci, P</font><font style="display: inline;color:#000000;">rofessor of Cognitive Neuroscience at the University of Cambridge and Past President of the British Neuroscience Association.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Our Strategy </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Our goal is to develop product candidates to diagnose and treat neurodegeneration, such as Alzheimer&#x2019;s disease. Key elements of our business strategy to achieve this mission include: </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">building a lean company that is narrowly focused on developing innovative product candidates for Alzheimer&#x2019;s disease and </font><font style="display: inline;color:#000000;">other</font><font style="display: inline;color:#000000;"> areas of neurodegeneration;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">validating our unique scientific approach with competitive research grants and publishing our scientific data in peer-reviewed </font><font style="display: inline;color:#000000;">journals</font><font style="display: inline;color:#000000;">;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">applying</font><font style="display: inline;color:#000000;"> our development capabilities to advance our product candidates through clinical proof-of-concept studies and beyond;</font></p></td></tr></table></div>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">22</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">using our expertise and experience to continue to focus on discovering new indications and product candidates, validated by </font><font style="display: inline;color:#000000;">experimental</font><font style="display: inline;color:#000000;"> evidence and leading experts in the field; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">continuing</font><font style="display: inline;color:#000000;"> to outsource preclinical studies, clinical studies and formulation development activities in order to allow more efficient deployment of our resources</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">We also conduct basic research and development in collaboration with academic and other partners. Our research and development expenses were $3.1</font><font style="display: inline;color:#000000;">&nbsp;million</font><font style="display: inline;color:#000000;"> and $1.6</font><font style="display: inline;color:#000000;">&nbsp;million</font><font style="display: inline;color:#000000;"> for the year ended </font><font style="display: inline;color:#000000;">December&nbsp;</font><font style="display: inline;color:#000000;">31, 2020 and 2019, respectively. These amounts are net of significant reimbursement received from NIH. See </font><font style="display: inline;font-style:italic;color:#000000;">&#x201C;Item 7 Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</font><font style="display: inline;color:#000000;">&#x201D; for additional details regarding our research and development activities.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">Competition</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The drug discovery and development industry is characterized by rapidly advancing technologies, intense competition and a strong </font><font style="display: inline;color:#000000;">emphasis</font><font style="display: inline;color:#000000;"> on proprietary products. We face potential competition from many different sources, including pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions. Any product candidates that we successfully develop and commercialize, such as simufilam or SavaDx, may compete with existing therapies and new therapies that may become available in the future.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Historically, the drug industry has attempted to treat Alzheimer&#x2019;s disease by developing drugs that block the synthesis of, or </font><font style="display: inline;color:#000000;">remove</font><font style="display: inline;color:#000000;"> or dis-aggregate, beta amyloid and, more recently another protein in the brain called tau. Essentially, the prevailing doctrine says amyloid must be cleared out of the brain. This scientific approach &#x2013; known as the amyloid hypothesis - has been repeatedly tested by our competitors in late stage clinical studies using a variety of antibody backbones, epitopes, target conformations, biomarkers and in various stages of disease. While this approach may yet work, to date the amyloid hypothesis has failed to generate unambiguous therapeutic benefit in patients with Alzheimer&#x2019;s disease. More recent competitors in Alzheimer&#x2019;s research are focused on modulating proteins in the brain that have anti-inflammatory or other properties, an approach known as immunotherapy. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;background-color: #FFFFFF;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">In contrast, our scientific approach seeks to simultaneously improve neurodegeneration and neuroinflammation. We believe improving multiple vital functions in the brain represents a new, different and crucial approach to address Alzheimer&#x2019;s disease.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="font-family:Palatino;color:#211D1E;font-size:10pt;display: inline;font-family:Times New Roman;color:#000000;">Regardless of scientific approach, improvements in cognition and function remains a key criterion for FDA approval of a new drug in Alzheimer&#x2019;s disease, a hurdle which, to date, no drug candidate has met with clear and compelling clinical data.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Our competitors may have significantly greater financial resources, an established presence in the market, expertise in research and </font><font style="display: inline;color:#000000;">development</font><font style="display: inline;color:#000000;">, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing-approved products. These competitors also compete with us in recruiting and retaining qualified scientific and </font><font style="display: inline;color:#000000;">technical</font><font style="display: inline;color:#000000;"> personnel, establishing clinical study sites and patient registration for clinical studies, as well as in acquiring or developing technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The key competitive factors affecting the success of simufilam, and any other product candidates that we develop to address neurodegenerative disorders, if approved, are likely to be their efficacy, safety, convenience, price, the level of generic competition, patient and physician acceptance and the availability of reimbursement from government and other third-party payors. Our commercial opportunity could be </font><font style="display: inline;color:#000000;">reduced</font><font style="display: inline;color:#000000;"> or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less severe side </font><font style="display: inline;color:#000000;">effects</font><font style="display: inline;color:#000000;">, are more convenient or are less expensive than any products that we may develop.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Our competitors also may obtain FDA approval for their products more rapidly than we may obtain approval for ours. For example, Biogen, Inc., a large biopharmaceutical company, is currently seeking regulatory approval in the U.S. for aducanumab. Aducanumab is a proprietary investigational drug candidate (human monoclonal antibody) that has been intensely studied for the treatment of Alzheimer&#x2019;s disease. The safety and efficacy data with aducanumab are complex and subject to debate. However, aducanumab may become the first therapy since 2003 to receive FDA approval in patients with Alzheimer&#x2019;s disease.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">23</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;">In recent years, we have observed ramped-up worldwide efforts aimed at developing blood-based techniques to detect and monitor Alzheimer&#x2019;s disease. The key competitive factors affecting the success of SavaDx, and any other product candidates that </font><font style="display: inline;">we</font><font style="display: inline;"> develop to diagnose neurodegeneration, if approved, are likely to be their measure of accuracy, such as specificity and sensitivity, as well as their convenience, patient acceptance, price and the availability of reimbursement from government and other third-party payors. Our competitors in the diagnostic area are pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions. Despite increased research effort, the field has generally been hampered by lack of reproducibility and an unclear path on how to move academic discoveries into clinical utilization. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In addition to blood-based techniques to detect Alzheimer&#x2019;s disease, competitors are examining the use of novel tracing agents and imaging techniques to map the course of neurodegeneration. In 2012, FDA approved Amyvid</font><font style="display: inline;font-size:5pt;vertical-align:super;line-height:100%">&#xAE;</font><font style="display: inline;"> (Eli Lilly Pharmaceuticals), which is a radioactive diagnostic agent for brain imaging of amyloid plaque. Amyvid can rule out Alzheimer&#x2019;s disease but does not confirm its presence. That is, a negative scan means little or no plaque is present; however, a positive </font><font style="display: inline;">scan</font><font style="display: inline;"> does not necessarily indicate Alzheimer&#x2019;s disease. In addition, Amyvid cannot be used to stage Alzheimer&#x2019;s disease because some people take years to show cognitive decline after amyloid plaque develops, while other others rapidly develop advanced Alzheimer&#x2019;s disease within months. Since its approval in 2012, Amyvid has had modest clinical utilization due to its high cost, lack of widespread reimbursement and need for specialized training.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Manufacturing</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We do not own or lease any manufacturing facilities. We outsource formulation, manufacturing and related activities to third parties. For the foreseeable future, we will continue to rely on third parties to conduct certain quality control and assurance testing, shipping or storage of our product candidates.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We currently rely on contract development and manufacturing organizations (CDMOs) for the manufacture of all our materials for preclinical and clinical studies and expect to continue to do so, and for commercial supply of any product candidates that we may develop. We currently have established relationships with several CDMOs for the manufacturing of our product candidates.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">We</font><font style="display: inline;color:#000000;"> believe </font><font style="display: inline;color:#000000;">our</font><font style="display: inline;color:#000000;"> manufacturing strategy is on-track to ensure sufficient drug supply for a Phase 3 program, including both drug substance (i.e., active ingredient) and drug product (i.e., oral tablets).</font><font style="display: inline;color:#000000;"> On </font><font style="display: inline;color:#000000;">March&nbsp;</font><font style="display: inline;color:#000000;">8, 2021, we entered into an agreement with Evonik Corporation to supply large-scale, clinical-grade quantities of drug substance for simufilam.</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">The goal is to ensure the integrity of the drug supply chain on a worldwide basis, in compliance with FDA standards.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">We believe raw</font><font style="display: inline;color:#000000;"> materials for our drug product are readily available from reliable sources. We have experienced no supply chain disruption</font><font style="display: inline;color:#000000;"> due to COVID-19.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Our suppliers must comply with </font><font style="display: inline;color:#000000;">current good manufacturing practices (cGMP)</font><font style="display: inline;"> enforced by FDA and other government agencies. Our suppliers </font><font style="display: inline;">are subject to unannounced inspection by regulators, including pre-approval inspections by FDA, to ensure they are in strict compliance with </font><font style="display: inline;">government</font><font style="display: inline;"> regulations and standards. </font><font style="display: inline;">Our suppliers </font><font style="display: inline;">may be forced to stop producing, storing, shipping or testing our drug products if they fall out of compliance with government regulations and standards. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We have no control over our suppliers&#x2019; compliance, or lack thereof, with the multitude of regulations and standards that affect our </font><font style="display: inline;">drug</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">products</font><font style="display: inline;">. We cannot control decisions by our suppliers that affect their ability or willingness to continue to supply us on acceptable terms, or at all.</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Strategic</font><font style="display: inline;font-weight:bold;"> Shift Away from Analgesic Drug Development</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Until approximately 2018, </font><font style="display: inline;">our</font><font style="display: inline;color:#000000;"> efforts in neurology drug development had focused on analgesic drugs. In late 2018, we announced a strategic shift away from analgesic drugs to focus exclusively on neurodegeneration.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Government</font><font style="display: inline;font-weight:bold;"> Regulation </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Government authorities in the U.S. at the federal, state and local level and in other countries regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, </font><font style="display: inline;">promotion</font><font style="display: inline;">, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug and </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">24</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;">diagnostic</font><font style="display: inline;"> products. Generally, before a new drug or diagnostic can be marketed, considerable data demonstrating its quality, safety and efficacy and/or specificity must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">U.S. Drug Development </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In the U.S., FDA regulates drugs under the Food, Drug, and Cosmetic Act (FDCA). Both drugs and diagnostics also are subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or post-market may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, FDA&#x2019;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, product recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Product candidates must be approved by FDA before they may be commercialized in the U.S. The drug approval process generally involves the following: </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Completion of extensive preclinical studies in accordance with applicable regulations, including studies conducted in accordance with good laboratory practice;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Submission to FDA of an IND, which must become effective before human clinical studies may begin;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Approval by an independent institutional review board (IRB) or ethics committee before each study may be initiated;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Performance of adequate and well-controlled human clinical studies in accordance with applicable IND regulations, code of good clinical practice (cGCP), requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Submission to FDA of an NDA;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">A determination by FDA within 60 days of its receipt of an NDA to accept the filing for review;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities where the drug will be produced to assess compliance with cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#x2019;s identity, strength, quality and purity;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Potential FDA audit of the preclinical study and/or clinical study sites that generated the data in support of the NDA;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">FDA review and approval of the NDA, including consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the drug in the U.S.; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Compliance with any post-approval requirements, including the potential requirement to conduct post-approval studies.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The data required to support an NDA are generated in two distinct developmental stages: preclinical and clinical. The </font><font style="display: inline;color:#000000;">preclinical</font><font style="display: inline;color:#000000;"> and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for any future product candidates will be granted on a timely basis, or at all. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Preclinical Studies and IND </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The preclinical developmental stage generally involves laboratory evaluations of drug chemistry, formulation and stability, as well as studies to evaluate toxicity in animals, which support subsequent clinical testing. As sponsor, we must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to FDA as part of the IND. An IND is a request for authorization from FDA to administer an investigational product to humans and must become effective before human clinical studies may begin. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Preclinical studies include laboratory evaluation of product chemistry and formulation, as well as</font><font style="display: inline;font-style:italic;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">in vitro</font><font style="display: inline;color:#000000;"> and animal studies to assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including cGCP regulations for safety/toxicology studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, to FDA as part of an IND. Some long-term preclinical testing, such as long-term toxicity tests, animal tests of reproductive adverse events and carcinogenicity, may </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">25</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;">continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by FDA, unless before that time FDA raises concerns or questions about any aspect of the program. In such a case, the IND sponsor and FDA must resolve any outstanding concerns before the clinical study can begin.</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">Clinical Studies </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The </font><font style="display: inline;">clinical</font><font style="display: inline;"> stage of development involves the administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the study sponsor&#x2019;s control, in accordance with cGCP requirements, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical studies are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to FDA as part of the IND. Furthermore, each clinical study must be reviewed and approved by an IRB for each institution at which the clinical study will be conducted to ensure that the risks to individuals participating in the clinical studies are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical study subject or his or her legal representative and must monitor the clinical study until completed. There also are requirements governing the reporting of ongoing clinical studies and completed clinical study results to public registries. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">A &nbsp;</font><font style="display: inline;">sponsor</font><font style="display: inline;"> who wishes to conduct a clinical study outside of the U.S. may, but need not, obtain FDA authorization to conduct the clinical study under an IND. If a foreign clinical study is not conducted under an IND, the sponsor may submit data from the clinical study to FDA in support of an NDA. The FDA may accept a well-designed and well-conducted foreign clinical study not conducted under an IND if the study was conducted in accordance with cGCP requirements and FDA is able to validate the data through an onsite inspection if deemed necessary. In 2020 we did not conduct any clinical studies outside of the U.S. We plan to launch clinical sites in Canada in 2021 and may perform additional clinical studies outside of the U.S. in the future.</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Clinical studies in the U.S. generally are conducted in three sequential phases, known as Phase&nbsp;1, Phase&nbsp;2 and Phase&nbsp;3, </font><font style="display: inline;">and</font><font style="display: inline;"> may overlap. </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Phase&nbsp;1 clinical studies generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical studies is to assess the metabolism, pharmacologic action, tolerability and safety of a drug candidate.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Phase&nbsp;2 clinical studies involve studies in disease-affected patients to determine the proper dose required to produce the desired benefits. At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety risks are identified, and a preliminary evaluation of efficacy may be observed.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Phase&nbsp;3 clinical studies generally involve many patients at multiple sites and are designed to provide the data necessary to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product approval. These studies may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Post-approval studies, sometimes referred to as Phase&nbsp;4 clinical studies, may be conducted after initial marketing approval. These studies are </font><font style="display: inline;color:#000000;">used</font><font style="display: inline;color:#000000;"> to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, FDA may mandate the performance of Phase&nbsp;4 clinical studies as a condition of approval of an NDA. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Progress reports detailing the results of the clinical studies, among other information, must be submitted at least annually to FDA. </font><font style="display: inline;color:#000000;">Written</font><font style="display: inline;color:#000000;"> safety reports and the investigators for serious and unexpected adverse events, or any other findings suggesting a significant risk to humans exposed to the drug must be submitted to FDA. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Phase&nbsp;1, Phase&nbsp;2, and Phase&nbsp;3 clinical studies may not be completed successfully within any specified period, if at all. The FDA or the sponsor may suspend or terminate a clinical study at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical study at its institution if the clinical study is not being conducted in accordance with the IRB&#x2019;s </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">26</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;">requirements or if the drug </font><font style="display: inline;">has</font><font style="display: inline;"> been associated with unexpected serious harm to patients. Additionally, some clinical studies are overseen by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a study may move forward at designated check-points based on access to certain data from the trial. Concurrent with clinical studies, companies usually complete additional animal studies and must develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among other things, companies must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that our product candidates do not undergo unacceptable deterioration over their shelf life.</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">NDA Review Process</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Following completion of the clinical studies, data is analyzed to assess whether the investigational product is safe and effective for the proposed indicated use or uses. The results of preclinical studies and clinical studies are then submitted to FDA as part of </font><font style="display: inline;">an</font><font style="display: inline;"> NDA, along with proposed labeling, chemistry and manufacturing information to ensure product quality and other relevant data. In short, the NDA is a request for approval to market a drug for one or more specified indication and must contain proof of safety and efficacy for a drug&#x2019;s purity and potency. The application may include both negative and ambiguous results of preclinical studies and clinical studies, as well as positive findings. Data may come from company-sponsored clinical studies intended to test the safety and efficacy of a product&#x2019;s use or from several alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of FDA. FDA approval of an NDA must be obtained before a drug may be marketed in the U.S. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Under the Prescription Drug User Fee Act (PDUFA), as amended, each NDA must be accompanied by a user fee. FDA adjusts the PDUFA user fees on an annual basis. According to FDA&#x2019;s fiscal year 2021 fee schedule, effective through </font><font style="display: inline;">September&nbsp;</font><font style="display: inline;">30, 2021, the user fee for an application requiring clinical data, such as an NDA, is approximately $2.9</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;">. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product also includes a non-orphan indication. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The FDA reviews all submitted NDAs before it accepts them for filing and may request additional information rather than accept the NDA for filing. The FDA must decide on accepting an NDA for filing within 60 days of receipt. Once the submission is accepted for filing, FDA begins an in-depth review of the NDA. Under the goals and policies agreed to by FDA under PDUFA, FDA has 10 months, from the filing date, in which to complete its initial review of a new molecular-entity NDA and respond to the applicant, and six months from the filing date of a new molecular-entity NDA designated for priority review. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs, and the review process is often extended by FDA requests for additional information or clarification. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Before approving an NDA, FDA may conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities fully comply with cGMP requirements and are adequate to assure consistent production of the product within required specifications. The FDA also may audit data from clinical studies to ensure compliance with cGCP requirements. Additionally, FDA may refer applications for novel product candidates which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it considers such recommendations when making decisions on approval. The FDA likely will reanalyze the clinical study data, which could result in extensive discussions between FDA and the applicant during the review process. After FDA evaluates an NDA, it will issue either an approval letter or a Complete Response Letter (CRL). An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A CRL indicates that FDA&#x2019;s review of the application is complete and the application cannot be approved in its present form. A CRL usually describes the specific deficiencies in the NDA identified by FDA. The CRL may require additional clinical data, additional pivotal Phase&nbsp;3 clinical trial(s) and/or other significant and time-consuming requirements related to clinical studies, preclinical studies or manufacturing. If a CRL is issued, the applicant may either resubmit the NDA, addressing all the deficiencies identified in the CRL, or withdraw the application. Even if such data and information are submitted, FDA may decide that the NDA does not satisfy the criteria for </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">27</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;">approval. Data obtained from clinical studies are not always conclusive and FDA may interpret data differently than we interpret the same data.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Advertising and Promotion</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The FDA and other federal regulatory agencies closely regulate the marketing and promotion of drugs through, among other things, standards and regulations for direct</font><font style="display: inline;">&#8209;to</font><font style="display: inline;">&#8209;consumer advertising, communications regarding unapproved uses, industry</font><font style="display: inline;">&#8209;</font><font style="display: inline;">sponsored</font><font style="display: inline;"> scientific and educational activities, and promotional activities involving the Internet. None of our product candidates can be commercially promoted before receiving FDA approval. After approval, product promotion can include only those claims relating to safety and effectiveness that are consistent with the labeling approved by FDA. Healthcare providers are permitted to prescribe drugs for &#x201C;off</font><font style="display: inline;">&#8209;label&#x201D; uses&nbsp;&#x2014; that is, uses not approved by FDA and therefore not described in the drug&#x2019;s labeling&nbsp;&#x2014; because FDA does not regulate the practice of medicine. However, FDA regulations impose stringent restrictions on manufacturers&#x2019; communications regarding off</font><font style="display: inline;">&#8209;label uses. Failure to comply with applicable FDA requirements and restrictions in this area may subject us to adverse publicity and enforcement action by FDA, the U.S. Department of Justice, or the Office of the Inspector General of Health and Human Services, as well as state authorities. This could subject us to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which we promote or distribute our product candidates.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Post</font><font style="display: inline;font-weight:bold;font-style:italic;">&#8209;Approval Requirements</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">After a product candidate receives regulatory approval, it is often subject to pervasive and continuing regulation by FDA, </font><font style="display: inline;">including</font><font style="display: inline;">, among other things, requirements relating to drug listing and registration, recordkeeping, periodic reporting, product sampling and distribution, adverse event reporting and advertising, marketing and promotion restrictions. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Adverse event reporting and submission of periodic reports is required following FDA approval of an NDA. The FDA also may require post</font><font style="display: inline;">&#8209;</font><font style="display: inline;">market testing, known as Phase 4 testing, or FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control, drug manufacture, packaging, and labeling procedures must continue to conform to cGMP after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with FDA and certain state agencies. Registration may result in periodic announced or unannounced inspections by FDA or these state agencies, during which the agency inspects manufacturing facilities to assess compliance with cGMP. Accordingly, manufacturers must continue to expend time, money, and effort in the areas of production and quality control to maintain compliance with cGMP. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered. In addition, other regulatory actions may be aken, including, among other things, warning letters, the seizure of products, injunctions, consent decrees placing significant restrictions on or suspending manufacturing operations, refusal to approve pending applications or supplements to approved applications, civil penalties, and criminal prosecution. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The FDA may require post</font><font style="display: inline;">&#8209;</font><font style="display: inline;">approval clinical studies to help assure continued safety or effectiveness of the approved drug. The FDA may also require a labeling change if it becomes aware of new safety information that it believes should be included in the labeling of a drug. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">The Hatch</font><font style="display: inline;font-weight:bold;font-style:italic;">&#8209;Waxman Amendments</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;text-decoration:underline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;text-decoration:underline;">Orange Book Listing</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In seeking approval for our product candidates through an NDA, we will be required to list with FDA each patent whose </font><font style="display: inline;">claims</font><font style="display: inline;"> cover the drug product. Upon receiving regulatory approval, each of the patents listed in the application for this drug is then published in FDA&#x2019;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the &#x201C;Orange Book&#x201D;. Drugs listed in the Orange Book can, in turn, be cited by potential generic competitors in support of approval of an abbreviated NDA, or ANDA. An ANDA provides for marketing of a drug product that has the same active ingredient in the same strengths and dosage form as the listed drug and has been shown through bioequivalence testing to be therapeutically equivalent to the listed drug. Other than the requirement for bioequivalence testing, ANDA applicants are not required to conduct, or submit results of, preclinical or clinical tests to prove the safety or efficacy of their drug product. Drugs approved in this way are commonly referred to as &#x201C;generic equivalents&#x201D; to the listed drug, and can often be substituted by pharmacists under prescriptions written for the original listed drug. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">28</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The ANDA applicant is required to make certain certifications to FDA concerning any patents listed for the approved product in FDA&#x2019;s Orange Book. Specifically, the applicant must certify that: (i)&nbsp;the required patent information has not been filed; (ii)&nbsp;the listed patent has expired; (iii)&nbsp;the listed patent has not expired but will expire on a particular date and approval is sought after patent expiration; or (iv)&nbsp;the listed patent is invalid or will not be infringed by the new product. The ANDA </font><font style="display: inline;">applicant</font><font style="display: inline;"> may also elect to submit a section&nbsp;viii statement certifying that its proposed ANDA label does not contain (or carves out) any language regarding the patented method</font><font style="display: inline;">&#8209;</font><font style="display: inline;">of</font><font style="display: inline;">&#8209;</font><font style="display: inline;">use rather than make certifications concerning a listed method</font><font style="display: inline;">&#8209;</font><font style="display: inline;">of</font><font style="display: inline;">&#8209;</font><font style="display: inline;">use patent. If the applicant does not challenge the listed patents, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">A certification that the new product will not infringe the already approved product&#x2019;s listed patents, or that such patents are invalid, is called a Paragraph&nbsp;IV certification. If the ANDA applicant has provided a Paragraph&nbsp;IV certification to FDA, the </font><font style="display: inline;">applicant</font><font style="display: inline;"> must also send notice of the Paragraph&nbsp;IV certification to the NDA and patent holders once the ANDA has been accepted for filing by FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph&nbsp;IV certification. The filing of a patent infringement lawsuit within 45&nbsp;days of the receipt of a Paragraph&nbsp;IV certification automatically prevents FDA from approving the ANDA until the earlier of 30&nbsp;</font><font style="display: inline;">months</font><font style="display: inline;">, expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the ANDA applicant. The ANDA application also will not be approved until any applicable non</font><font style="display: inline;">&#8209;</font><font style="display: inline;">patent exclusivity listed in the Orange Book for the referenced product has expired. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Disclosure of Clinical Study Information</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Sponsors of clinical studies of FDA</font><font style="display: inline;">&#8209;</font><font style="display: inline;">regulated products, including drugs, are required to register and disclose certain clinical study information. Information related to the product, patient population, phase of investigation, clinical study sites and investigators, and other aspects of the clinical study is then made public as part of the registration. Sponsors are also obligated to post certain information regarding the results of their clinical studies after completion. Disclosure of the results of these studies can be delayed until the new product or new indication being studied has been approved. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Other Regulatory Requirements</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We may be subject to federal, state and local environmental laws and regulations, including the Environmental Protection Act and the Clean Air Act. Although we believe that our safety procedures for handling and disposing of controlled materials comply with the standards prescribed by state and federal regulations, accidental contamination or injury from these materials may occur. In the event of such an occurrence, we could be held liable for any damages that result and any such liability could exceed our resources.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We may also be subject to regulations under other federal, state, and local laws, including the Occupational Safety and Health Act, national restrictions on technology transfer, and import, export, and customs regulations. It is possible that any portion of the regulatory framework under which we operate may change and that such change could have a negative impact on our current and anticipated operations. Failure to comply with these requirements could result, among other things, in suspension of regulatory approval, recalls, injunctions or civil or criminal sanctions.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Third</font><font style="display: inline;font-weight:bold;font-style:italic;">&#8209;Party Payor Coverage and Reimbursement</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The commercial success of our product candidates, if approved, will depend, in part, upon the availability of coverage and adequate reimbursement from third</font><font style="display: inline;">&#8209;party payors at the federal, state and private levels. Third</font><font style="display: inline;">&#8209;party payors include governmental programs such as Medicare or Medicaid, private insurance plans and managed care plans. These third</font><font style="display: inline;">&#8209;party payors may deny coverage or reimbursement for our product candidates in whole or in part if they determine that our product candidates are not medically appropriate or necessary. Also, third-party payors attempt to control costs by limiting coverage through the use of formularies and other cost</font><font style="display: inline;">&#8209;containment mechanisms and the amount of reimbursement for particular procedures or drug treatments. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Some third</font><font style="display: inline;">&#8209;</font><font style="display: inline;">party payors also require pre</font><font style="display: inline;">&#8209;</font><font style="display: inline;">approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. While we cannot predict whether any proposed cost</font><font style="display: inline;">&#8209;</font><font style="display: inline;">containment measures will be adopted or otherwise implemented in the future, these requirements or any announcement </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">29</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;">or adoption of such proposals could have a material adverse effect on our ability to obtain adequate prices for our approved product candidates to operate profitably. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Human Capital</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">As of </font><font style="display: inline;">December&nbsp;</font><font style="display: inline;">31, 2020, we had 11 full-time employees. </font><font style="display: inline;">None of our employees are represented by a labor union or covered under a collective bargaining agreement. </font><font style="display: inline;">We also engage numerous consultants to perform services on retainer, per diem or an hourly basis.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;background-color: #FFFFFF;">We focus on identifying, recruiting, developing and retaining a small team of highly talented and motivated employees. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards in order to increase stockholder value by motivating such individuals to perform to the best of their abilities and achieve our objectives. The success of our business is fundamentally connected to the health</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">,</font><font style="display: inline;color:#000000;background-color: #FFFFFF;"> safety </font><font style="display: inline;color:#000000;background-color: #FFFFFF;">and well-being </font><font style="display: inline;color:#000000;background-color: #FFFFFF;">of our employees. In an effort to protect the health and safety of our employees, we took proactive action from the earliest signs of the COVID-19 outbreak, which included implementing social distancing policies at our office, facilitating remote working arrangements and imposing employee travel restrictions.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Corporate Information</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We were incorporated as a Delaware corporation in </font><font style="display: inline;">May 199</font><font style="display: inline;">8 under the name Pain Therapeutics, Inc. In </font><font style="display: inline;">March 201</font><font style="display: inline;">9, we changed our company name to Cassava Sciences, Inc. Our principal offices are located at 7801 N. Capital of Texas Highway, Suite 260, Austin, TX, 78731. Our telephone number is 512-501-2444. Our website address is </font><font style="display: inline;">www.CassavaSciences.com</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We use Cassava Sciences, the Cassava Sciences logo, artwork and other marks as trademarks in the United States and other countries. Solely for convenience, trademarks and trade names referred to in this Annual Report, including logos, artwork, and other visual displays, may appear without the </font><font style="display: inline;font-size:5pt;vertical-align:super;line-height:100%">&#xAE;</font><font style="display: inline;"> or TM&nbsp;symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights, or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities&#x2019; trade names, trademarks, or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We file electronically with the Securities and Exchange Commission, or SEC, our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. The address of the site is http://www.sec.gov.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">You may obtain a free copy of our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K and amendments to those reports on the day of filing with the SEC on our website at http://www.cassavasciences.com, by contacting our corporate offices by calling 512-501-2450 or by sending an e-mail message to </font><font style="display: inline;">IR@cassavasciences.com</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">30</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Item 1A.</font><font style="display: inline;font-weight:bold;"> &nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;">Risk Factors</font><a name="Risk_Factors"></a>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">RISK</font><font style="display: inline;font-weight:bold;"> FACTORS </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as other information contained in this Annual Report on Form 10-K, including our financial statements and the related notes and the section titled &#x201C;Management&#x2019;s Discussion and Analysis of </font><font style="display: inline;font-style:italic;">Financial</font><font style="display: inline;font-style:italic;"> Condition and Results of Operations,&#x201D; before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations, and growth prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;color:#000000;background-color: #FFFFFF;">Below is a summary of the principal factors that make an investment in our common stock speculative or risky. </font><font style="display: inline;font-style:italic;">Additional</font><font style="display: inline;font-style:italic;"> risks </font><font style="display: inline;font-style:italic;">and</font><font style="display: inline;font-style:italic;"> uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations and the market price of our common stock.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Risks Related to the Discovery, Development, and Commercialization of Our Product Candidates </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">Since 2017, we</font><font style="display: inline;font-style:italic;color:#000000;"> have concentrated a substantial portion of our research and development efforts on the treatment and detection of Alzheimer&#x2019;s disease, an area of research that has seen significant failure rates. Further, our product candidates are based on new scientific approaches and novel technology, which makes it difficult to predict the time and cost of product candidate development and likelihood of success.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">We are heavily dependent on the success of simufilam and&nbsp;SavaDx, our product candidates which are still under clinical development. If these product candidates do not receive regulatory approval, we will be unable to generate product revenue and our business will be harmed.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">We have a limited operating history in our business targeting Alzheimer&#x2019;s disease and no history of product approvals for commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">We cannot give any assurance that any of our product candidates will receive regulatory approval, which is necessary before they can be commercialized. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">There can be no assurance that results of smaller Phase 1 and Phase 2 clinical trials with simufilam will be reproduced in the additional large</font><font style="display: inline;font-style:italic;color:#000000;">,</font><font style="display: inline;font-style:italic;color:#000000;"> well</font><font style="display: inline;font-style:italic;color:#000000;">-</font><font style="display: inline;font-style:italic;color:#000000;">controlled studies that are required </font><font style="display: inline;font-style:italic;color:#000000;">to </font><font style="display: inline;font-style:italic;color:#000000;">demonstrate safety and </font><font style="display: inline;font-style:italic;color:#000000;">efficacy </font><font style="display: inline;font-style:italic;color:#000000;">in order to potentially </font><font style="display: inline;font-style:italic;color:#000000;">receive regulatory</font><font style="display: inline;font-style:italic;color:#000000;"> approval.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">We may encounter substantial delays in our clinical studies or may not be able to conduct or complete our clinical studies on the timelines we expect, if at all.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">If physicians and patients do not accept and use our drugs, we will not achieve sufficient product revenues and our business will suffer.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 23.05pt;background-color: #FFFFFF;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;color:#000000;">Risks Related to Government Regulation and Other Legal Compliance Matters</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">If we are ultimately unable to obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business will be substantially harmed.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">Our ability to market and promote our product candidates will be determined and limited by FDA-approved labeling.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">Our employees, independent contractors, consultants, commercial partners, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">If we fail to comply with the complex federal, state, local and foreign laws and regulations that apply to our business, we could suffer severe consequences that could materially and adversely affect our operating results and financial condition.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">Government agencies may establish and promulgate usage guidelines that could limit the use of our product candidates.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 23.05pt;background-color: #FFFFFF;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">Risks Related to Our Intellectual Property </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">If we are unable to obtain and maintain </font><font style="display: inline;font-style:italic;color:#000000;">sufficient </font><font style="display: inline;font-style:italic;color:#000000;">patent protection for any product candidates we develop, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize any product candidates we may develop may be adversely affected.</font></p></td></tr></table></div>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">31</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">U.S. intellectual property rights around diagnostic methods is a complex, evolving area of law and effective patent claims may not be available to us for our investigational diagnostic product candidate,&nbsp;SavaDx</font><font style="display: inline;font-style:italic;color:#000000;">, in the U</font><font style="display: inline;font-style:italic;color:#000000;">nited States</font><font style="display: inline;font-style:italic;color:#000000;">.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">Issued patents covering our product candidates and other technologies could be found invalid or unenforceable if challenged in court or before administrative bodies in the U.S. or abroad.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</font></p></td></tr></table></div>
		<p style="margin:0pt;background-color: #FFFFFF;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">Risks Related to Our Business and Operations </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">The worldwide&nbsp;outbreak of an infectious disease, called COVID-19, may materially and adversely affect our business operations and our ability to conduct clinical studies.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">Our reliance on third parties for both the supply and manufacture of materials for our product candidates carries the risk that we will not have sufficient </font><font style="display: inline;font-style:italic;color:#000000;">quality or </font><font style="display: inline;font-style:italic;color:#000000;">quantities of such materials or product candidates, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">We </font><font style="display: inline;font-style:italic;color:#000000;">expect</font><font style="display: inline;font-style:italic;color:#000000;"> to grow the size and capabilities of our organization</font><font style="display: inline;font-style:italic;color:#000000;">, including accessing new physical facilities</font><font style="display: inline;font-style:italic;color:#000000;">, and we may experience difficulties in effectively managing this growth.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">Our internal computer systems, or those used by third-</font><font style="display: inline;font-style:italic;color:#000000;">parties</font><font style="display: inline;font-style:italic;color:#000000;"> on whom we rely</font><font style="display: inline;font-style:italic;color:#000000;">, may fail or suffer other breakdowns, cyberattacks, or information security breaches that could compromise the confidentiality, integrity, and availability of such systems and data, result in material disruptions of our development programs and business operations, risk disclosure of confidential, financial, or proprietary information, and affect our reputation.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">Our business involves environmental risks that may result in liability for us.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">Business disruptions and lack of appropriate levels of commercial insurance could seriously harm our future revenue and financial condition and increase our costs and expenses.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">Social media platforms present risks and challenges.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 23.05pt;background-color: #FFFFFF;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">Risks </font><font style="display: inline;font-weight:bold;color:#000000;">Related</font><font style="display: inline;font-weight:bold;color:#000000;"> to Financial Condition and Capital Requirements </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">We </font><font style="display: inline;font-style:italic;color:#000000;">have incurred significant net losses in each period since our inception and anticipate that we will continue to incur net losses for the foreseeable future.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">We have broad discretion in the use of the net proceeds from&nbsp;any of our financing transactions&nbsp;and may not use them effective</font><font style="display: inline;font-style:italic;color:#000000;">ly.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">Risks Related to the Ownership of Our Common Stock </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">We d</font><font style="display: inline;font-style:italic;color:#000000;">o not know whether a </font><font style="display: inline;font-style:italic;color:#000000;">sufficient </font><font style="display: inline;font-style:italic;color:#000000;">market will continue to develop for our common stock or what the market price of our common stock will be, and, as a result, it may be difficult </font><font style="display: inline;font-style:italic;color:#000000;">for investors </font><font style="display: inline;font-style:italic;color:#000000;">to </font><font style="display: inline;font-style:italic;color:#000000;">sell</font><font style="display: inline;font-style:italic;color:#000000;"> shares of our common stock.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">The market price of our common stock </font><font style="display: inline;font-style:italic;color:#000000;">has historically been highly volatile and we expect it to continue to</font><font style="display: inline;font-style:italic;color:#000000;"> be volatile, which could result in substantial losses for investors who purchase our shares.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">If we are unable to maintain effective internal controls, our business, financial position, and results of operations could be adversely affected.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">Anti-takeover provisions in our charter documents and Delaware law may prevent or delay removal of incumbent management or a change of control.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">Changes </font><font style="display: inline;font-style:italic;color:#000000;">in our ownership could limit our ability to utilize net operating loss carryforwards.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">Risks Related to the Discovery, Development, and Commercialization of Our Product Candidates </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Since 2017, we have concentrated a substantial portion of our research and development efforts on the treatment and detection of Alzheimer&#x2019;s disease, an area of research that has seen significant failure rates. Further, our product candidates are based on new scientific approaches and novel technology, which makes it difficult to predict the time and cost of product candidate development and likelihood of success.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<a name="_Hlk67332082"></a>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">32</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;">Since 2017, we have concentrated a substantial portion of our research and development efforts </font><font style="display: inline;">on experimental methods for the treatment and detection of Alzheimer&#x2019;s disease. Prior efforts by biopharmaceutical companies to develop new treatments for Alzheimer&#x2019;s disease have seen very limited clinical success. No new treatments have been approved for Alzheimer&#x2019;s disease since 2003, and since that time, while many large clinical studies have been completed, no drug candidate has shown clear evidence of clinical efficacy in large, Phase 3 clinical studies. FDA-approved drugs for Alzheimer&#x2019;s disease only address symptoms, and there are no FDA-approved disease modifying therapeutics available for patients with Alzheimer&#x2019;s disease. Notwithstanding these substantial challenges to date, we seek to improve brain health by addressing the neurodegeneration and neuroinflammation components of Alzheimer&#x2019;s disease. Our lead drug candidate for Alzheimer&#x2019;s disease is based on a new approach of stabilizing &#x2013; but not removing &#x2013; a critical protein in the brain. We cannot be certain that our novel technologies will lead to an approvable or marketable product. In addition, because FDA has limited comparators to evaluate our lead drug candidate, we could experience a longer than expected regulatory review process and increased development costs.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">We are heavily dependent on the success of simufilam and SavaDx, our product candidates which are still under clinical development. If these product candidates do not receive regulatory approval, we will be unable to generate product revenue and our business may be harmed. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Since inception, we have not succeeded in getting regulatory approval for our product candidates and we may never do so. In recent years we have invested a significant portion of our efforts and financial resources in the development of </font><font style="display: inline;">simufilam and SavaDx</font><font style="display: inline;"> for the treatment and detection of Alzheimer&#x2019;s disease, respectively. Our future success is substantially dependent on our ability to successfully complete clinical development and obtain regulatory approval for our product candidates, which may never occur. We expect that a substantial portion of our efforts and expenditures over the next few years will be devoted to </font><font style="display: inline;">simufilam and SavaDx</font><font style="display: inline;">. This will require additional clinical development, management of clinical and manufacturing activities, regulatory approval in one or more national jurisdictions and obtaining commercial-scale manufacturing supply. Substantial investment and significant efforts will be required before we can generate any revenues from any commercial sales. We cannot be certain that we will be able to successfully complete any of these activities. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">We </font><font style="display: inline;font-weight:bold;font-style:italic;">have</font><font style="display: inline;font-weight:bold;font-style:italic;"> a limited</font><font style="display: inline;font-weight:bold;font-style:italic;"> operating history in our business targeting Alzheimer&#x2019;s disease and no history of product approvals for commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We are an early clinical-stage biopharmaceutical company with a limited operating history </font><font style="display: inline;">in </font><font style="display: inline;">our business targeting </font><font style="display: inline;">Alzheimer&#x2019;s disease</font><font style="display: inline;">. Since we commenced operations in 1998, we have had no product candidates approved for commercial sale and have not generated any revenue from product sales. Drug development is a highly uncertain undertaking and involves a substantial degree of risk. To date, we have not initiated or completed a pivotal clinical study involving Alzheimer&#x2019;s disease, obtained marketing approval for any </font><font style="display: inline;">product</font><font style="display: inline;"> candidates, or conducted sales and marketing activities necessary for successful product commercialization. Our long operating history as a company without product revenue makes any assessment of our future success and viability subject to significant uncertainty.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We will continue to encounter risks and difficulties frequently experienced by early-stage biopharmaceutical companies in rapidly </font><font style="display: inline;">evolving</font><font style="display: inline;"> fields. We have not yet demonstrated an ability to successfully overcome such risks and difficulties. If we do not successfully address these risks and difficulties, our business, results of operations and financial condition will suffer materially. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">We cannot give any assurance that any of our product candidates will receive regulatory approval, which is necessary before they can be commercialized. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We are at the early stages of development of our product candidates. To date, we have invested substantial effort and financial resources to identify, procure intellectual property for, and develop our programs in neurodegeneration, including conducting preclinical studies and early-stage clinical studies for our product candidates, simufilam and SavaDx, and providing general and administrative support for these operations. Our future success is dependent on our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize our product candidates, and we may fail to do so for many reasons, including the following: </font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">our product candidates may not successfully complete preclinical studies or clinical studies;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">33</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">a product candidate may, on further study, be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">our competitors may develop products that render our product candidates obsolete or less attractive;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the product candidates that we develop may not be sufficiently covered by intellectual property;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the product candidates that we develop may be challenged by third parties&#x2019; patents or other intellectual property or exclusive rights;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the market for our product candidates may change so that the continued development of a product candidate is no longer reasonable or commercially attractive;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">our product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">if a product candidate obtains regulatory approval, we may be unable to establish sales and marketing capabilities, or successfully market such approved product candidate, to gain market acceptance; and</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">&nbsp;a product candidate may not be accepted as safe, effective or useful by patients, the medical community or third-party payors, if applicable.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which would have a material adverse effect on our business and could potentially cause us to cease operations. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">We may not be successful in our efforts to further develop our current product candidates. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. Each of our product candidates is in the early stages of development and will require significant additional clinical development, management of preclinical, clinical, and manufacturing activities, regulatory approval, adequate manufacturing supply, a commercial organization, and significant marketing efforts before we generate any revenue from product sales, if at all. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">We have never completed a product development program in neurodegeneration. None of our product candidates in neurodegeneration have advanced into late-stage development and we may not be able to initiate such program on anticipated timelines, if at all. Further, we cannot be certain that any of our product candidates will be successful in clinical studies. We may in the future advance product candidates into clinical studies and terminate such studies prior to their completion. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">If any of our product candidates successfully complete clinical studies, we may seek regulatory approval to market our product candidates in the U.S., the European Union, and in additional foreign countries where we believe there is a viable commercial opportunity. We may never receive regulatory approval to market any product candidates even if such product candidates successfully complete clinical studies, which would adversely affect our viability. To obtain regulatory approval in countries outside the U.S., we would need to comply with numerous and varying regulatory requirements of such other countries regarding safety, efficacy, manufacturing and controls, clinical studies, commercial sales, pricing, and distribution of our product candidates. Even if we are successful in obtaining approval in one jurisdiction, we cannot ensure that we will obtain approval in any other jurisdictions. If we are unable to obtain approval for our product candidates in multiple jurisdictions, our business, financial condition, results of operations, and our growth prospects could be negatively affected. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Even if we receive regulatory approval to market any of our product candidates, whether for the treatment or diagnosis of neurodegenerative diseases or other diseases, we cannot provide assurance that any such product candidate will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Investment in biopharmaceutical product development involves significant risk that any product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval, and become commercially viable. We </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">34</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;">cannot provide any assurance that we will be able to successfully advance any of our product candidates through the development process or, if approved, successfully commercialize any of our product candidates. </font>
		</p>
		<p style="margin:5pt 0pt;background-color: #FFFFFF;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">There can be no assurance that results of smaller Phase 1 and Phase 2 clinical trials with simufilam will be reproduced in the additional large, well-controlled studies that are required to demonstrate safety and efficacy in order to potentially receive regulatory approval.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Results of our Phase 1, Phase 2 and open-label safety studies with simufilam may not be predictive of the results of later-stage clinical trials. Simufilam may fail to show the desired safety and efficacy in later clinical trials despite having progressed through preclinical studies and initial clinical trials. Many companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. In addition, conclusions based on data from analyses of Phase 1 and Phase 2 clinical studies and open-label results may not be reproduced when implemented in large, well-controlled, randomized clinical trials. Even if our clinical trials for simufilam are completed as planned, we cannot be certain that their results will support the safety and efficacy sufficient to obtain regulatory approval.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">We may encounter substantial delays in our clinical studies or may not be able to conduct or complete our clinical studies on the timelines we expect, if at all. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Clinical testing is expensive, time consuming, and subject to uncertainty. We cannot guarantee that any clinical studies will be conducted as planned or completed on schedule, if at all. We cannot be sure that submission of an IND or a clinical study application (CTA) will result in FDA or European Medicines Agency (EMA), as applicable, allowing clinical studies to begin in a timely manner, if at all. Moreover, even if these studies begin, safety or other issues may arise that could suspend or terminate such clinical studies. A failure of one or more clinical studies can occur at any stage of testing, and our future clinical studies may not be successful. Events that may prevent successful or timely initiation or completion of clinical studies include: </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">inability to generate sufficient preclinical, toxicology, or other in vivo or in vitro data to support the initiation or continuation of clinical studies;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">delays in confirming target engagement, patient selection, or other relevant biomarkers to be utilized in preclinical and clinical product candidate development;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">delays in reaching a consensus with regulatory agencies on study design;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">delays in reaching an agreement on acceptable terms with prospective contract research organizations (CROs) and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical study sites;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">delays in identifying, recruiting, and training suitable clinical investigators;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">delays in obtaining required IRB approval for each clinical study site;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">&nbsp;imposition of a temporary or permanent clinical hold by regulatory agencies for a number of reasons, including:</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">&nbsp;after review of an IND or amendment, CTA or amendment, or equivalent application or amendment;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">&nbsp;as a result of a new safety finding that presents unreasonable risk to clinical study participants;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">&nbsp;a negative finding from an inspection of our clinical study operations or study sites; or</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the finding that the investigational protocol or plan is clearly deficient to meet its stated objectives;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">delays in identifying, recruiting, and enrolling suitable patients to participate in our clinical studies, and delays caused by patients withdrawing from clinical studies, or failing to return for post-treatment follow-up;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">35</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">delays caused by disease epidemics or pandemics, such as COVID-19;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">difficulty collaborating with patient groups and investigators;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">failure by our CROs, other third parties, or us to adhere to clinical study requirements;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">failure to perform in accordance with FDA&#x2019;s or any other regulatory authority&#x2019;s Code of Good Clinical Practice (GCPs) requirements, or applicable EMA or other regulatory guidelines in other countries;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">changes in the standard of care on which a clinical development plan was based, which may require new or additional studies;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the cost of clinical studies of our product candidates being greater than we anticipate;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">clinical studies of our product candidates producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical studies or abandon product development programs; and</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates for use in clinical studies or the inability to do any of the foregoing.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Any inability to successfully initiate or complete clinical studies could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required to, or we may elect, to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical study delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">We may in the future advance product candidates into clinical studies and terminate such studies prior to their completion, which could adversely affect our business. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Delays in the completion of any clinical study of our product candidates will increase our costs, slow down our product candidate development and approval process and delay, or potentially jeopardize our ability to commence product sales and generate revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical studies may also ultimately lead to the denial of regulatory approval of our product candidates. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">If physicians and patients do not accept and use our drugs, we will not achieve sufficient product revenues and our business will suffer.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Even if FDA approves our drugs, physicians and patients may not accept and use them. Acceptance and use of our drugs will depend on a number of factors including: </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">when the drug is launched into the market and related competition;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">approved label claims;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">perceptions by members of the healthcare community, including physicians, about the safety and effectiveness of our drugs; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">36</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">perceptions by physicians regarding the cost-benefit of our product candidates; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">published studies demonstrating the cost effectiveness of our drugs relative to competing products; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">availability of reimbursement for our products from government or healthcare payers; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">effectiveness of marketing and distribution efforts by us and other licensees and distributors. </font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Because we expect to rely on sales generated by our current lead product candidates for substantially all of our revenues for the foreseeable future, the failure of any of these drugs to find market acceptance would harm our business and could require us to seek additional financing. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">We may not be successful in developing our product candidates in neurodegeneration. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Our product candidates in neurodegeneration are still in the early stages of development and will take several more years to develop and must undergo extensive clinical and scientific validations.</font><font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Even</font><font style="display: inline;color:#000000;"> if we are successful in developing any of our product candidates through clinical and scientific validation, we may not be able to develop a drug or a diagnostic that:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">meets applicable regulatory standards, in a timely manner or at all;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">successfully competes with other technologies and tests; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">avoids infringing the proprietary rights of others; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">are adequately reimbursed by third-party payors; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">can be performed at commercial levels or at reasonable cost; or</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">can be successfully marketed.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">To the extent we are not successful in developing our new product candidates in neurodegeneration, our results of operations and business will be materially adversely affected.</font><font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">We currently have no in-house capabilities to manufacture or commercialize our </font><font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">product candidates</font><font style="display: inline;font-weight:bold;font-style:italic;color:#000000;"> and we rely on third-party commercial drug manufacturers for clinical drug supplies</font><font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">. If we are unable to develop our own manufacturing, sales, marketing and distribution capabilities, or if we are not successful in contracting with third parties for these services on favorable terms, or at all, our product revenues could be adversely impacted. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">We rely on various third parties to manufacture, fill, label, store, test and ship our product candidates. We plan to continue to outsource formulation, manufacturing and related activities. These suppliers must comply with cGMP regulations enforced by FDA and other government agencies, and are subject to ongoing periodic unannounced inspection, including preapproval inspections by FDA and corresponding state and foreign government agencies to ensure strict compliance with cGMP and other standards. These manufacturers may subsequently be stopped from producing, manufacturing, filling, labeling, storing, testing and shipping our product candidates due to their non-compliance with federal, state or local regulations. We do not have control over our suppliers&#x2019; compliance with these regulations and standards and we cannot control decisions by our suppliers that affect their ability or willingness to continue to supply us on acceptable terms, or at all.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Disputes in the past have arisen with some of these third parties with respect to fulfilling certain conditions and obligations. There can be no guarantee that such disputes will not arise again in the future, which may lead to termination of an agreement. If an agreement is terminated, we would not be able to commercialize our product candidates until another manufacturer is identified and we have entered into a manufacturing agreement with such manufacturer. We may not be able to replace a commercial supplier on commercially reasonable terms, or at all. Replacing any of our commercial suppliers would be expensive and time consuming. Failure by any of our suppliers to perform as expected could delay or prevent the commercialization or potential regulatory approval of our product candidates for an extended period of time, result in shortages, cost overruns or other problems and would materially harm our business.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">We currently have no sales, marketing or distribution capabilities. We have not established commercial strategies regarding any of our product candidates. In order to commercialize our products, if any are approved by FDA, we will either have to develop such capabilities internally or collaborate with third parties who can perform these services for us. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">37</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;">If we decide to commercialize any of our drugs ourselves, we may not be able to </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">hire and retain the necessary experienced personnel; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">build sales, marketing and distribution operations in a cost-effective manner which are capable of successfully launching new drugs;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">obtain access to adequate numbers of physicians to prescribe our products; or</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">generate sufficient product revenues. </font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">In addition, establishing such operations on our own will take time and involve significant expense. If our commercial operations lack complementary products, we may not be able to compete in a cost-effective manner with competitors with more products to sell. If we engage third-party collaborators to perform any commercial operations, our future revenues may depend significantly upon the performance of those collaborators.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">If we decide to enter into new co-promotion or other licensing arrangements with third parties, we may be unable to locate acceptable collaborators because the number of potential collaborators is limited and because of competition from others for similar alliances. Even if we are able to identify one or more acceptable new collaborators, we may not be able to enter into any collaborative arrangements on favorable terms, or at all.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">In addition, due to the nature of the market for our product candidates, it may be necessary for us to license all or substantially all of our product candidates to a single collaborator, thereby eliminating our opportunity to commercialize these other products independently. If we enter into any such new collaborative arrangements, our revenues are likely to be lower than if we marketed and sold our products ourselves. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">In addition, any revenues we receive would depend upon our collaborators&#x2019; efforts which may not be adequate due to lack of attention or resource commitments, management turnover, change of strategic focus, business combinations or other factors outside of our control. Depending upon the terms of our collaboration, the remedies we have against an under-performing collaborator may be limited. If we were to terminate the relationship, it may be difficult or impossible to find a replacement collaborator on acceptable terms, or at all. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Alzheimer&#x2019;s disease has failed every attempt at drug approval.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Despite</font><font style="display: inline;color:#000000;"> billions</font><font style="display: inline;color:#000000;"> of dollars invested by the biopharmaceutical industry in research programs to develop novel therapeutics for Alzheimer&#x2019;s disease, no FDA approved treatments have been developed in the past 15 years. In that span of time, many new types and classes of drugs have been developed and tested in Alzheimer&#x2019;s disease, including monoclonal antibodies, g-secretase modulators and inhibitors, &#x3B2;-site amyloid precursor protein cleaving enzyme (BACE) inhibitors, receptor for advanced glycation end-products (RAGE) inhibitors, nicotinic agonists, serotonin subtype receptor (5HT6) antagonists, and others. Virtually all of these scientific programs have failed in clinical testing.</font><font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">We may not be successful in our efforts to expand our technology or product candidates in other indications. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Our drug development strategy is to clinically test and seek regulatory approval for our product candidates in Alzheimer&#x2019;s disease, our primary indication. We may expand our research efforts outside of this primary indication and into other areas of clinical medicine based on genetic, biological or mechanistic overlap with the primary indication. Conducting clinical studies for additional indications for our product candidates will require substantial technical, financial and human resources and is prone to the inherent risks of failure in drug development. We cannot provide you any assurance that we will be successful in our effort to expand our technology or our product candidates in additional indications, even if we obtain approval for our product candidate in Alzheimer&#x2019;s disease. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">If we fail to successfully identify and develop additional product candidates, our commercial opportunity </font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">will</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;"> be limited</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;"> to Alzheimer&#x2019;s disease or other neurodegenerations</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">.</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Identifying, developing, obtaining regulatory approval, and commercializing additional product candidates requires substantial expertise and funding and is prone to the risks of failure inherent in drug development. We cannot provide any assurance that we will be able to successfully identify or acquire additional product candidates, advance any additional product candidates through the development process, or assemble sufficient resources to identify, acquire, or develop additional </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">38</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;">product candidates. If we are unable to successfully identify, acquire, develop, and commercialize additional product candidates, our commercial opportunity may be limited.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Early indications of safety, tolerability or biomarker results from our small clinical studies with simufilam may not predict the results of later studies</font><font style="display: inline;font-weight:bold;font-style:italic;">.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Results of a Phase 1 clinical study with simufilam demonstrated safety, tolerability and pharmacokinetics in 24 healthy subjects exposed to 50-200 mg in a single ascending dose study. However, this was a small, &#x201C;first-in-human&#x201D; Phase 1 study designed to assess the initial safety characteristics of simufilam in healthy subjects and this study was not designed to, and did not, evaluate safety, tolerability and efficacy of simufilam in patients. Additional large, well-controlled, multi-dose studies will be required to evaluate the safety, tolerability and efficacy of simufilam to treat patients with any indication, including Alzheimer&#x2019;s disease. There can be no assurance that such future studies will demonstrate the safety, tolerability or efficacy of simufilam. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Results of Phase 2 clinical studies with simufilam demonstrated a reduction in biomarkers of disease. However, these were small, clinical-proof-of-concept Phase 2 studies designed to assess the initial safety characteristics of simufilam in patients. Our Phase 2 program was not designed to, and did not, evaluate large-scale or long-term safety, tolerability and efficacy of simufilam in patients. Additional large, well-controlled, multi-dose studies will be required to evaluate the safety, tolerability and efficacy of simufilam to treat patients with any indication, including Alzheimer&#x2019;s disease. There can be no assurance that such future studies will demonstrate the safety, tolerability or efficacy of simufilam. The failure of simufilam to show safety, tolerability or efficacy in any future clinical studies would significantly harm our business.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">We have never obtained FDA approval for a diagnostic test and we may not be able to secure such approval in a timely manner or at all. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We are developing a blood-based diagnostic test for Alzheimer&#x2019;s disease, called SavaDx, which will require FDA approval prior to commercialization. </font><font style="display: inline;">Our diagnostic product candidate, marketing, sales and development activities and manufacturing processes are subject to extensive and rigorous regulation by FDA pursuant to the FDCA, by comparable agencies in foreign countries, and by other regulatory agencies and governing bodies. Under the FDCA, a diagnostic must receive FDA clearance or approval before it can be commercially marketed in the U.S. The process of obtaining marketing approval or clearance from FDA or by comparable agencies in foreign countries for new products could:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">take a significant period of time;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">require the expenditure of substantial resources;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;"> involve rigorous pre-clinical testing, as well as increased post-market surveillance; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">require changes to products; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">result in limitations on the indicated uses of products.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">If we do not compete effectively with scientific and commercial competitors, we may not be able to successfully develop our diagnostic test for Alzheimer&#x2019;s disease.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<a name="_AEIOULastRenderedPageBreakAEIOU26"></a><font style="display: inline;color:#000000;">The field of clinical laboratory testing is highly competitive. Diagnostic tests that are developed are characterized by rapid technological change. Our competitors in the U.S. and abroad are numerous and include, among others, major diagnostic companies, reference laboratories, molecular diagnostic firms, universities and other research institutions. Most of our potential competitors have considerably greater financial, technical, marketing and other resources than we do, which may allow these competitors to discover important biological markers and determine their function before we do. We could be adversely affected if we do not discover proteins or biomarkers and characterize their function, develop diagnostic and pharmaceutical and clinical services based on these discoveries, obtain required regulatory and other approvals and launch these tests and their related services before our competitors. We also expect to encounter significant competition with respect to any diagnostic tests that we may develop or commercialize. Those companies that bring to market new diagnostic tests before we do may achieve a significant competitive advantage in marketing and commercializing their tests. We may not be able to develop additional diagnostic tests successfully and we may not obtain or enforce patents, if any, covering these tests that provide protection against our competitors. Moreover, our competitors may succeed in developing diagnostic tests that circumvent our technologies or tests. Furthermore, our competitors may succeed in developing technologies or tests that are more effective or less costly than those developed by us or that would render our technologies or tests less competitive or obsolete. We expect competition to intensify in the fields in which we are involved as technical advances in these fields occur </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">39</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;">and become more widely known and changes in intellectual property laws generate challenges to our intellectual property position.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">We will need to develop our own proprietary antibodies to advance our SavaDx and our diagnostic program.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">SavaDx currently relies on the use of commercially available antibodies, which are complex molecules that can recognize and bind to an intended protein. Commercially available antibodies present certain technical flaws, such as improper validation, significant batch-to-batch variations or inconsistent storage, any of which can jeopardize our studies and experiments. Because antibody underperformance can be a significant drain on time and resources, we are developing and validating our own, fit-for-purpose antibody for use with SavaDx and such technical activities </font><font style="display: inline;">are</font><font style="display: inline;"> on-going. The </font><font style="display: inline;">complexity of developing our own antibody gives rise to many technical issues that are challenging to solve, and we cannot be certain that we will be able to successfully complete any of these activities, in which case our program may be harmed. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">We have concentrated a substantial portion of our research and development efforts on the treatment and detection of Alzheimer&#x2019;s disease, an area of research that has seen significant failure rates. Further, our product candidates are based on new scientific approaches and novel technology, which makes it difficult to predict the time and cost of product candidate development. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We focus substantially all of our research and development efforts on addressing neurodegenerations, such as Alzheimer&#x2019;s disease. Collectively, efforts by biopharmaceutical companies in the field of neurodegenerative diseases have seen many failures and limited success in drug development. For example, there are no therapeutic options available to reverse Alzheimer&#x2019;s disease, or even to halt its progress. Our future success is highly dependent on the successful development of our product candidates for treating Alzheimer&#x2019;s disease. Developing and, if approved, commercializing our product candidates for treatment of Alzheimer&#x2019;s disease subjects us to many challenges, including obtaining regulatory approval from FDA and other regulatory authorities who have only a limited set of precedents to rely on. We cannot be sure that our approach will yield satisfactory therapeutic products that are safe and effective, scalable, or profitable.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Our Phase 2 clinical studies with simufilam in patients with Alzheimer&#x2019;s disease are not designed to show a statistically meaningful difference between those patients who receive placebo and those who receive drug.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Clinical research data is often analyzed with statistical probability (p-value) to address the question of whether a clinical observation is related to a treatment effect, a random effect or something else. This, in turn, requires a clinical study to incorporate a sufficiently large sample patient population to infer the appropriate statistical analysis. By design, our Phase 2 clinical program with simufilam does not include a sufficiently large patient population to generate statistical probability on clinical observations. This feature may make it difficult for investors to properly interpret whether clinical observations in our Phase 2 studies with simufilam are important or meaningful. Conversely, our clinical studies may generate statistically meaningful data (i.e., p&lt;0.05) with regard to biomarkers, or other endpoints, that h</font><font style="display: inline;">ave unknown</font><font style="display: inline;"> or no clinical importance. In general, the distinction between statistical significance and clinical significance is a complex area of research that continues to evolve and may be subject to differences of opinion among scientists, clinicians and other professionals. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">We may encounter difficulties enrolling patients in our clinical studies, and our clinical development activities could thereby be delayed or otherwise adversely affected. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The timely completion of clinical studies in accordance with their protocols depends, among other things, on our ability to enroll enough patients who remain in the study until its conclusion. We may experience difficulties in patient enrollment in our clinical studies for a variety of reasons, including: </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the size and </font><font style="display: inline;color:#000000;">severity of disease</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">in</font><font style="display: inline;color:#000000;"> the patient population;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the patient eligibility criteria defined in the protocol, including biomarker-driven identification and/or certain highly-specific criteria related to stage of disease progression, which may limit the patient populations eligible for our clinical studies to a greater extent than competing clinical studies for the same indication that do not have biomarker-driven patient eligibility criteria;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the size of the study population required for analysis of the trial&#x2019;s primary endpoints;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the design of </font><font style="display: inline;color:#000000;">our </font><font style="display: inline;color:#000000;">study</font><font style="display: inline;color:#000000;"> protocol</font><font style="display: inline;color:#000000;">;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">our ability to recruit clinical study investigators with the appropriate competencies and experience;</font></p></td></tr></table></div>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">40</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">competing clinical studies for similar therapies or targeting patient populations meeting our patient eligibility criteria;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">clinicians&#x2019; and patients&#x2019; perceptions as to the potential advantages and side effects of the product candidate being studied in relation to other available therapies and product candidates;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">our ability to obtain and maintain patient consents;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">physicians&#x2019; </font><font style="display: inline;color:#000000;">patient referral practices that are out of our control;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">our ability to adequately monitor patients and their caregivers during and after treatment; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the risk that patients enrolled in clinical studies will not complete such studies, for any reason.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Our clinical studies may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Before obtaining regulatory approvals for any of our product candidates, we must demonstrate through lengthy, complex, and expensive preclinical experiments and clinical studies that our product candidates are both safe and effective for use in an intended population. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical study process. The results of preclinical studies of our product candidates may not be predictive of the results of early-stage or later-stage clinical studies, and results of early clinical studies of our product candidates may not be predictive of the results of later-stage clinical studies. The results of clinical studies in one set of patients or disease indications may not be predictive of those obtained in another. In some instances, there can be significant variability in safety or efficacy results between different clinical studies of the same product candidate due to numerous factors, including changes in study procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen, and other clinical study protocols and the rate of dropout among clinical study participants. Open-label extension studies may also extend the timing and cost of a clinical study substantially. Product candidates in later stages of clinical studies may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical studies. Many companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical studies due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier studies. This is particularly true in neurodegenerative diseases, where failure rates historically have been higher than in many other disease areas. Most product candidates that begin clinical studies are never approved by regulatory authorities for commercialization. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">We have limited experience in designing clinical studies in neurodegeneration and may be unable to design and execute a clinical study to support marketing approval. We cannot be certain that our current clinical studies or any other future clinical studies will be successful. Additionally, any safety concerns observed in any one of our clinical studies in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition, and results of operations. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">In addition, even if such clinical studies are successfully completed, we cannot guarantee that FDA or foreign regulatory authorities will interpret the results as we do, and more studies could be required before we submit our product candidates for approval. To the extent that the results of the studies are not satisfactory to FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional studies in support of potential approval of our product candidates. Even if regulatory approval is secured for any of our product candidates, the terms of such approval may limit the scope and use of our product candidates, which may also limit its commercial potential.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">If our drug candidate causes or contribute to a death or a serious injury before or after approval, we will be subject to medical reporting regulations, which can result in voluntary corrective actions or agency enforcement actions.</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Our drug candidate in Alzheimer&#x2019;s disease is aimed at a frail, elderly patient population that is in a state of perpetual cognitive decline. Under FDA medical reporting regulations, we are required to report to the FDA information that our drug candidate has or may have caused or contributed to a death or serious injury. Any such serious adverse event involving our drug could result in future FDA action, such as an inspection, enforcement action or warning, or in more serious cases, a complete shutdown of our clinical program. In the context of our ongoing clinical trial, we report adverse events to the FDA in accordance with applicable national and local regulations. Any corrective action, whether voluntary or involuntary, and </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">41</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;">either pre- or post-market, needed to address any serious adverse events will require the dedication of our time and capital, distract management from operating our business, and may harm our reputation and financial results.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">The market opportunities for simufilam and SavaDx, if approved, may be smaller than we anticipate.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">If our clinical development programs succeed, we expect to seek regulatory approval of </font><font style="display: inline;">simufilam and SavaDx </font><font style="display: inline;">for patients with Alzheimer&#x2019;s disease. Our projections of the number of patients with Alzheimer&#x2019;s disease is based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, patient foundations and market research, and may prove to be incorrect. The actual number of patients may turn out to be lower than expected. Additionally, the potential patient population for our current programs or future product candidates may be limited. Even if we obtain significant market share for any product candidate, if approved, if the potential target populations are smaller than anticipated, we may never achieve profitability without obtaining marketing approval for additional indications. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer, more advanced, or more effective than ours, any of which may harm our business operations. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The development and commercialization of new product candidates is highly competitive. Moreover, the neurodegenerative field is characterized by intense and increasing competition, and a strong emphasis on intellectual property. We may face competition with respect to any of our product candidates that we seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Several large pharmaceutical and biotechnology companies are currently pursuing the development of products for the treatment of neurodegenerative diseases, including Alzheimer&#x2019;s disease. Many of these current or potential competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical studies, obtaining regulatory approvals, and marketing approved products than we do. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Furthermore, currently approved products could be discovered to have application for treatment of neurodegenerative disease indications, which could give such products significant advantages over any of our product candidates. Our competitors also may obtain FDA, EMA, or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, products or technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing any product candidates we may develop against competitors. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In addition, we could face litigation or other proceedings with respect to the scope, ownership, validity, and/or enforceability of our patents relating to our competitors&#x2019; products and our competitors may allege that our products infringe, misappropriate, or otherwise violate their intellectual property. The availability of our competitors&#x2019; products could limit the demand, and the price we are able to charge, for any products that we may develop and commercialize. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Risks Related to </font><font style="display: inline;font-weight:bold;font-size:10pt;">Government Regulation</font><font style="display: inline;font-weight:bold;font-size:10pt;"> and Other Legal Compliance Matters</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">If we are ultimately unable to obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business will be substantially harmed.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The time required to obtain approval by FDA, EMA, and comparable foreign regulatory authorities is unpredictable, typically takes many years following the commencement of clinical studies, and depends upon numerous factors, including the type, complexity, and novelty of the product candidates involved. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#x2019;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">42</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;">application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical, or other studies. The FDA has not approved a new drug for Alzheimer&#x2019;s disease since 2003. We have not obtained regulatory approval for any product candidate, including our product candidates aimed at Alzheimer&#x2019;s disease, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Applications for our product candidates could fail to receive regulatory approval in an initial or subsequent indication for many reasons, including but not limited to the following: </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">FDA, EMA, or comparable foreign regulatory authorities may disagree with the design, implementation, or results of our clinical studies;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">FDA, EMA, or comparable foreign regulatory authorities may determine that our product candidates are not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities, or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the population studied in the clinical program may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">we may be unable to demonstrate to FDA, EMA or comparable foreign regulatory authorities that a product candidate&#x2019;s risk-benefit ratio when compared to the standard of care is acceptable;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">FDA, EMA, or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical studies;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the data collected from clinical studies of our product candidates may not be sufficient to support the submission of a new drug application (NDA), or other submission or to obtain regulatory approval in the United States or elsewhere;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">FDA, EMA, or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures, and specifications, or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the approval policies or regulations of FDA, EMA, or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">This lengthy approval process, as well as the unpredictability of the results of clinical studies, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations, and growth prospects. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Our ability to market and promote our product candidates will be determined and limited by FDA-approved labeling. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The commercial success of our product candidates will depend upon our ability to obtain FDA-approved labeling describing their features. Our failure to achieve FDA approval of product labeling containing such information will prevent us from advertising and promoting the key features of our product candidates in order to differentiate them from other similar products. This would make our products less competitive in the market.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Our employees, independent contractors, consultants, commercial partners, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">We are exposed to the risk of fraud, misconduct, or other illegal activity by our employees, independent contractors, consultants, commercial partners, and vendors. Misconduct by these parties could include intentional, reckless, and negligent conduct that fails to: </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">comply with the laws of FDA, EMA, and other comparable foreign regulatory authorities; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">provide true, complete, and accurate information to FDA, EMA, and other comparable foreign regulatory authorities;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">comply with manufacturing standards we have established;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">comply with healthcare fraud and abuse laws in the U.S. and similar foreign fraudulent misconduct laws; or</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">report financial information or data accurately or to disclose unauthorized activities to us.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Activities subject to laws also involve the improper use of information obtained in the course of patient recruitment for clinical studies, which could result in regulatory sanctions and cause serious harm to our reputation. Further, it is not always possible to identify and deter misconduct by employees and third parties, and the precautions we take to detect and prevent </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">43</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;">this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">If we fail to comply with the complex federal, state, local and foreign laws and regulations that apply to our business, we could suffer severe consequences that could materially and adversely affect our operating results and financial condition. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Our operations are subject to extensive federal, state, local and foreign laws and regulations, all of which are subject to change. These laws and regulations currently include, among other things:</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">The Clinical Laboratory Improvement Amendments (CLIA) of 1988, which are United States federal regulatory standards that apply to all </font><font style="display: inline;color:#000000;">clinical</font><font style="display: inline;color:#000000;"> laboratory testing performed on humans in the United States,</font><font style="display: inline;color:#000000;"> requires that laboratories obtain certification from the federal government, and state licensure laws;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">FDA laws and regulations;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">The Health Insurance Portability and Accountability Act</font><font style="display: inline;color:#000000;"> (HIPAA), which imposes comprehensive federal standards with respect to the privacy and security of protected health information and requirements for the use of certain standardized electronic transactions, including penalties for violators, enforcement authority to state attorneys general and requirements for breach notification;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">state laws regulating testing and protecting the privacy of test results, as well as state laws protecting the privacy and security of health information and personal data and mandating reporting of breaches to affected individuals and state regulators;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the federal anti-kickback law, or the Anti-Kickback Statute, which prohibits knowingly and willfully offering, paying, soliciting, receiving, or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing, arranging for, or recommending of an item or service that is reimbursable, in whole or in part, by a federal health care program;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the federal False Claims Act (FCA), which imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment to the federal government;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the federal Civil Monetary Penalties Law, which prohibits, among other things, the offering or transfer of remuneration to a Medicare or state health care program beneficiary if the person knows or should know it is likely to influence the beneficiary&#x2019;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state health care program, unless an exception applies;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">other federal and state fraud and abuse laws, such as anti-kickback laws, prohibitions on self-referral, and false claims acts, which may extend to services reimbursable by any third-party payor, including private insurers;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the federal Physician Payments Sunshine Act, which requires manufacturers to track and report to the federal government certain payments and other transfers of value made to physicians and teaching hospitals and ownership or investment interests held by physicians and their immediate family members; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Section 216 of the federal Protecting Access to Medicare Act of 2014 (PAMA), which requires applicable laboratories to report private payer data in a timely and accurate manner every three years (and in some cases annually);</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">state laws that impose reporting and other compliance-related requirements; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">similar foreign laws and regulations that will apply to us in foreign countries in which we may choose to operate in the future.</font><font style="display: inline;color:#000000;">&nbsp;</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Government agencies may establish and promulgate usage guidelines that could limit the use of our product candidates. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Government agencies, professional and medical societies, and other groups may establish usage guidelines that apply to our product candidates. These guidelines could address such matters as usage and dose, among other factors. Application of such guidelines could limit the clinical use or commercial appeal of our product candidates. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">44</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-weight:bold;font-style:italic;">Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We have not yet completed long</font><font style="display: inline;">-</font><font style="display: inline;">term safety studies with simufilam to determine if this product candidate is safe for humans. Adverse events or other undesirable side effects caused by simufilam could cause us or regulatory authorities to interrupt, delay, or halt clinical studies and could result in a more restrictive label or the delay or denial of regulatory approval by FDA, EMA, or other comparable foreign regulatory authorities. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Drug-related side effects could affect patient recruitment, the ability of enrolled patients to complete the study, and/or result in potential product liability claims. We are required to maintain product liability insurance pursuant to certain of our development and commercialization agreements. We may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. A successful product liability claim or series of claims brought against us could adversely affect our results of operations, business, and reputation. In addition, regardless of merit or eventual outcome, product liability claims may result in impairment of our business reputation, withdrawal of clinical study participants, costs due to related litigation, distraction of management&#x2019;s attention from our primary business, initiation of investigations by regulators, substantial monetary awards to patients or other claimants, the inability to commercialize our product candidates, and decreased demand for our product candidates, if approved for commercial sale.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">If our product candidates receive regulatory approval, we and our collaborators will be subject to ongoing FDA obligations and continued regulatory review, such as continued safety reporting requirements, and we and our collaborators may also be </font><font style="display: inline;font-weight:bold;font-style:italic;">subject</font><font style="display: inline;font-weight:bold;font-style:italic;"> to additional FDA post-marketing obligations or new regulations, all of which may result in significant expense and limit our and our collaborators&#x2019; ability to commercialize our potential drugs. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Any regulatory approvals that our product candidates receive may also be subject to limitations on the indicated uses for which the drug may be marketed or contain requirements for potentially costly post-marketing follow-up studies. In addition, if FDA approves any of our product candidates, the labeling, packaging, adverse event reporting, storage, advertising, promotion and record keeping for the drug will be subject to extensive regulatory requirements. The subsequent discovery of previously unknown problems with the drug, including but not limited to adverse events of unanticipated severity or frequency, or the discovery that adverse events previously observed in preclinical research or clinical studies that were believed to be minor actually constitute much more serious problems, may result in restrictions on the marketing of the drug, and could include withdrawal of the drug from the market. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The FDA&#x2019;s policies may change, and additional government regulations may be enacted that could prevent or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of adverse government regulation that may arise from future legislation or administrative action, either in the U.S. or abroad. If we are not able to maintain regulatory compliance, we may be subject to fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. Any of these events could prevent us from marketing our products and our business could suffer. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Enacted and future legislation may increase the difficulty and cost for us to commercialize our product candidates and may reduce the prices we are able to obtain for our product candidates. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Legislative and regulatory changes and future changes regarding the healthcare system could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities or affect our ability to profitably sell any product candidates for which we obtain marketing approval. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In the U.S., the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (the Medicare Modernization Act) established the Medicare Part&nbsp;D program and provided authority for limiting the number of drugs that will be covered in any therapeutic class thereunder. The Medicare Modernization Act, including its cost reduction initiatives, could limit the coverage and reimbursement rate that we receive for any of our approved products. Private payors may follow Medicare coverage policies and payment limitations in setting their own reimbursement rates resulting in similar limits in payments from private payors. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the Affordable Care Act, among other things, imposes a significant annual fee on companies that manufacture or </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">45</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;">import branded prescription product candidates. It also contains substantial provisions intended to, among other things, broaden access to health insurance, reduce or constrain the growth of health care spending, enhance remedies against healthcare fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, and impose additional health policy reforms, any of which could have a material adverse effect on our business. A significant number of provisions are not yet, or have only recently become, effective, but the Affordable Care Act may result in downward pressure on pharmaceutical pricing, especially under the Medicare program, and may also increase our regulatory burdens and operating costs. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Affordable Care Act, as well as other healthcare reform measures that have been and may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product, and could seriously harm our future revenues. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may compromise our ability to generate revenue, attain profitability or commercialize our products. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Affordable Care Act is a highly complex piece of legislation that continues to evolve. We do not and cannot understand or anticipate the full impact and potential implications of the Affordable Care Act on our business or on our drugs.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Our relationships with customers and payors will be subject to applicable anti-kickback, fraud and abuse, transparency, and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual damages, reputational harm, administrative burdens, and diminished profits and future earnings. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Healthcare providers, physicians and payors play a primary role in the recommendation and prescription of any product candidates for which we may obtain marketing approval. Our future arrangements with payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any product candidates for which we may obtain marketing approval. Even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and patients' rights are and will be applicable to our business. Restrictions under applicable federal, state and foreign healthcare laws and regulations may affect our ability to operate and expose us to areas of risk, including: </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the FCA, which imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">HIPAA, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute to defraud any healthcare benefit program or specific intent to violate it in order to have committed a violation; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 and its implementing regulations, which also imposes obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">federal laws requiring drug manufacturers to report information related to payments and other transfers of value made to physicians and other healthcare providers, as well as ownership or investment interests held by physicians and their immediate family members, including under the federal Open Payments program, commonly known as the Sunshine Act, as well as other state and foreign laws regulating marketing activities; and </font></p></td></tr></table></div>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">46</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">state and foreign equivalents of each of the above laws, including state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental payors, including private insurers; state laws which require pharmaceutical companies to comply with the pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restricting payments that may be made to healthcare providers; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Nonetheless, it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Any future litigation against us could be costly and time-consuming to defend. </font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Innovative drug development is highly litigious, and we may become subject, from time to time, to legal proceedings, claims and allegations that arise in the ordinary course of business or pursuant to governmental or regulatory enforcement activity. Regardless of merit, any lawsuits against us, individually or in the aggregate, may have a material adverse effect on our business, financial condition, results of operations or cash flows. In addition, any litigation to which we subsequently become a party might result in substantial costs and divert management's attention, time and resources, which might seriously harm our business, financial condition, results of operations and cash flows. Our insurance policies might not cover such claims, might not provide sufficient payments to cover all of the costs to resolve one or more such claims, and might not continue to be available on terms acceptable to us. In particular, any claim could result in potential liability for us if the claim is outside the scope of the indemnification agreement we have with our third-party partners, or our third-party partners do not abide by the indemnification agreement as required, or the liability exceeds the amount of any applicable indemnification limits or available insurance coverage. A claim brought against us that is uninsured or underinsured could result in unanticipated costs and could have a material adverse effect on our financial condition, results of operations, cash flows or reputation.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">A recent federal court ruling may mandate significant new disclosure requirements for clinical data dating back over a decade</font><font style="display: inline;font-weight:bold;font-style:italic;color:#000000;"> which may lead to costly or burdensome disclosures</font><font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">.</font>
		</p>
		<p style="margin:0pt;line-height:150%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">A recent federal court ruling may require all clinical study sponsors to report a decade&#x2019;s worth of previously exempted clinical study data to the federal government for publication on ClinicalTrials.gov. In </font><font style="display: inline;color:#000000;">February 202</font><font style="display: inline;color:#000000;">0, the U.S. District Court for the Southern District of New York invalidated a prior interpretation of NIH regulations that had exempted many clinical studies conducted between 2007 and 2017 from reporting requirements mandated by the Food and Drug Administration Amendments Act. If this court ruling takes effect without appeal, or if it is upheld on appeal, it could require us to submit an onerous amount of old clinical data to the federal government. In many cases, we were the responsible party for generating such clinical data, but such prior data may be difficult or not feasible for us to access as a result of our strategic shift away from analgesic drug development in 2019.&nbsp;&nbsp;We may no longer have control over, or access to, prior clinical data that we may legally be required to report to NIH in the future.&nbsp;&nbsp;Furthermore, it is unclear whether such new disclosure requirements apply to inactive, failed or abandoned drug development programs. As a result of these uncertainties, the government&#x2019;s recent ruling may leave us in a conflicted position or out of compliance with new disclosure requirements.&nbsp;&nbsp;We currently do not and cannot understand or anticipate the full impact and potential implications of this court ruling on our business.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">Risks Related to Our Intellectual Property </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">If we are unable to obtain and maintain </font><font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">sufficient </font><font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">patent protection for any product candidates we develop, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize any product candidates we may develop may be adversely affected. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">47</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;">Our success depends in large part on our ability to obtain and maintain patent protection in the U.S. and other countries with respect to our proprietary product candidates and other technologies we may develop. We seek to protect our proprietary position by filing patent applications in the U.S. and abroad relating to our core programs and product candidates, as well as other technologies that are important to our business. Given that the development of our product candidates is at an early stage, our intellectual property portfolio with respect to certain aspects of our product candidates is also at an early stage. For example, we have filed or intend to file patent applications on aspects of our technology and core product candidates; however, there can be no assurance that any such patent applications will issue as granted patents. Furthermore, in some cases, we have only filed provisional patent applications on certain aspects of our technology and product candidates and each of these provisional patent applications is not eligible to become an issued patent until, among other things, we file a non-provisional patent application within 12 months of the filing date of the applicable provisional patent application. Any failure to file a non-provisional patent application within this timeline could cause us to lose the ability to obtain patent protection for the inventions disclosed in the associated provisional patent applications. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Furthermore, in some cases, we may not be able to obtain issued claims covering compositions relating to our core programs and product candidates, as well as other technologies that are important to our business, and instead may need to rely on filing patent applications with claims covering a method of use and/or method of manufacture for protection of such core programs, product candidates, and other technologies. There can be no assurance that any such patent applications will issue as granted patents, and even if they do issue, such patent claims may be insufficient to prevent third parties, such as our competitors, from utilizing our technology. Any failure to obtain or maintain patent protection with respect to our core programs and product candidates could have a material adverse effect on our business, financial condition, results of operations, and growth prospects. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">U.S. intellectual property rights around diagnostic methods is a complex, evolving area of law and effective patent claims may not be available to us for our investigational diagnostic product candidate, SavaDx, in the United States.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The legal system for intellectual property around diagnostic methods is highly complex, remains uncertain and continues to evolve. In the U.S., patent courts have struggled to define a clear means of patent eligibility for modern age diagnostics. Case law interpretations from the U.S. Supreme Court has left certain important scientific advances in the area of </font><font style="display: inline;">diagnostics</font><font style="display: inline;"> without effective patent claims. In 2012, the Supreme Court held that a simple process involving correlations between blood test results and patient health is not eligible for patent claims because such processes incorporate &#x201C;laws of nature&#x201D;. Since then, different outcomes from different courts, including Federal Circuit, district court and Patent Trial and Appeal Board decisions, have continued to create a sometimes vague or conflicting legal framework for determining the eligibility of patent claims for diagnostic methods. As a result, we cannot be certain how SavaDx fits into the current U.S. legal framework for obtaining effective patent claims. </font><font style="display: inline;color:#000000;">We currently have no U.S. patents or patent applications with respect to SavaDx, and it is only protected in the United States by trade secrets, know-how and other proprietary rights technology. </font><font style="display: inline;">Furthermore, </font><font style="display: inline;">claims for diagnostic methods can be complicated to enforce. For patent infringement to occur with a protected diagnostic, the patented method must generally either be performed by one person in its entirety or performed by multiple parties all under the control or direction of a single party. Accordingly, even if effective patent claims are issued for SavaDx, it may be impractical, impossible or even undesirable to enforce potential infringement claims.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">48</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-weight:bold;font-style:italic;">Issued patents covering our product candidates and other technologies could be found invalid or unenforceable if challenged in court or before administrative bodies in the U.S. or abroad. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">If we initiated legal proceedings against a third party to enforce a patent covering our product candidates or other technologies, the defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may raise claims challenging the validity or enforceability of our patents before administrative bodies in the U.S. or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, </font><font style="display: inline;">inter partes</font><font style="display: inline;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;">review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in the revocation of, cancellation of, or amendment to our patents in such a way that they no longer cover our product candidates or other technologies. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we or our licensing partners and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates or other technologies. Such a loss of patent protection would have a material adverse impact on our business, financial condition, results of operations, and growth prospects. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Depending upon the timing, duration, and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act). The Hatch-Waxman Act permits a patent term extension of up to five years as compensation for patent term lost during FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar extensions as compensation for patent term lost during regulatory review processes are also available in certain foreign countries and territories, such as in Europe under a Supplementary Patent Certificate. However, we may not be granted an extension in the U.S. and/or foreign countries and territories because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain a patent term extension or the term of any such extension is shorter than what we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations, and growth prospects could be materially harmed. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In addition to seeking patents for our product candidates and other technologies, we also rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology, and other proprietary information and to maintain our competitive position. We consider trade secrets and know-how to be one of our primary sources of intellectual property. Trade secrets and know-how can be difficult to protect. We expect our trade secrets and know-how to over time be disseminated within the industry through independent development, the publication of journal articles describing the methodology, and the movement of personnel from academic to industry scientific positions. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We seek to protect these trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, CDMOs, consultants, advisors, and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants as well as train our employees not to bring or use proprietary information or technology from former employers to us or in their work, and remind former employees when they leave their employment of their confidentiality obligations. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. Despite our efforts, any of these parties may breach the agreements and disclose our proprietary information, including our </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">49</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;">trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the U.S. are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">If any of our patent applications do not issue as patents in any jurisdiction, we may not be able to compete effectively. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Changes in either the patent laws or their interpretation in the U.S. and other countries may diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our patents with respect to our product candidates. With respect to our intellectual property related to our product candidates, we cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors or other third parties. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, maintain, or enforce all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection. Although we enter into nondisclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, outside scientific collaborators, CROs, CDMOs, consultants, advisors, and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in any of our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical technology and product candidates would be adversely affected. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our product candidates or other technologies or which effectively prevent others from commercializing competitive technologies and product candidates. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we own currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents to which we have rights may be challenged, narrowed, circumvented, or invalidated by third parties. Consequently, we do not know whether product candidates or other technologies will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner which could materially adversely affect our business, financial condition, results of operations and growth prospects. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability, and our patents may be challenged in the courts or patent offices in the U.S. and abroad. We may be subject to a third-party pre-issuance submission of prior art to the United States Patent and Trademark Office (USPTO) or become involved in opposition, derivation, revocation, reexamination, post-grant and </font><font style="display: inline;font-style:italic;">inter partes</font><font style="display: inline;font-style:italic;">&nbsp;</font><font style="display: inline;">review, or interference proceedings or other similar proceedings challenging our patent rights. An adverse determination in any such submission, proceeding, or litigation could reduce the scope of, or invalidate or render unenforceable, such patent rights, allow third parties to commercialize our product candidates </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">50</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;">or other technologies and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge our priority of invention or other features of patentability with respect to our patents and patent applications. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our product candidates and other technologies. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. If we are unsuccessful in any such proceeding or other priority or inventorship dispute, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms or at all or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of the product candidates we may develop. The loss of exclusivity or the narrowing of our owned and licensed patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In addition, given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">We may not be able to protect our intellectual property and proprietary rights throughout the world. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Filing, prosecuting, and defending patents on our product candidates and other technologies in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the U.S. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products, and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the U.S. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Periodic maintenance fees, renewal fees, annuity fees, and various other government fees on patents and applications will be due to be paid to the USPTO and various government patent agencies outside of the U.S. over the lifetime of our owned or licensed patents and applications. The USPTO and various non-U.S. government agencies require compliance with several procedural, documentary, fee payment, and other similar provisions during the patent application process. In some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">51</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;">in a partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products or technology, which could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Changes in either the patent laws or interpretation of the patent laws in the U.S. could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other requirements for patentability are met, prior to </font><font style="display: inline;">March 201</font><font style="display: inline;">3, in the U.S., the first to invent the claimed invention was entitled to the patent, while outside the U.S., the first to file a patent application was entitled to the patent. After </font><font style="display: inline;">March 201</font><font style="display: inline;">3, under the Leahy-Smith America Invents Act (the America Invents Act) enacted in </font><font style="display: inline;">September 201</font><font style="display: inline;">1, the U.S. transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO after </font><font style="display: inline;">March 201</font><font style="display: inline;">3, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Since patent applications in the U.S. and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we were the first to either (i)&nbsp;file any patent application related to our product candidates or other technologies or (ii)&nbsp;invent any of the inventions claimed in our patents or patent applications. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, </font><font style="display: inline;font-style:italic;">inter partes</font><font style="display: inline;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;">review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings as compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and growth prospects. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In addition, the patent positions of companies in the development and commercialization of pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">We may be subject to claims challenging the inventorship of our patents and other intellectual property. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We may be subject to claims that former employees, scientific collaborators or other third parties have an interest in our patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of employees, consultants, or others who are involved in developing our product candidates or other technologies. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership of our patents, trade secrets, or other intellectual property. If the defense of any such claims fails, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates and other technologies. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and growth prospects. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">We may not be successful in obtaining necessary rights to our product candidates or other technologies. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">52</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Many pharmaceutical companies, biotechnology companies, and academic institutions that compete with us in the field of neurodegeneration therapy may have patents filed and are likely filing patent applications potentially relevant to our business. In order to avoid infringing these third-party patents, we may find it necessary or prudent to obtain licenses to such patents from such third-party intellectual property holders. We may also require licenses from third parties for certain technologies for use with future product candidates. In addition, with respect to any patents we co-own with third parties, we may wish to obtain licenses to such co-owner&#x2019;s interest to such patents. However, we may be unable to secure such licenses or otherwise acquire any compositions, methods of use, processes, or other intellectual property rights from third parties that we identify as necessary for our future product candidates. The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources, and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations, and growth prospects. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">We may be subject to claims that our employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property</font><font style="display: inline;font-weight:bold;font-style:italic;"> which may prevent or delay the development of our product candidates</font><font style="display: inline;font-weight:bold;font-style:italic;">. &nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The field of developing innovations for neurodegenerative diseases is highly competitive and dynamic. Due to the focused research and development that is taking place by several companies, including us and our competitors, the intellectual property landscape </font><font style="display: inline;">in this field </font><font style="display: inline;">is in flux, and it may remain uncertain in the future. Additionally, no products utilizing </font><font style="display: inline;">our underlying science and</font><font style="display: inline;"> technology have yet reached the market. As such, there may be significant intellectual property related litigation and proceedings relating to our, and other third party, intellectual property and proprietary rights in the future. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Many of our employees, consultants, and advisors are currently or were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors and potential competitors. Although we try to ensure that our employees, consultants, and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#x2019;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and growth prospects. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Our commercial success depends in part on our ability to develop, manufacture, market, and sell any product candidates that we develop and to use our proprietary technologies without infringing, misappropriating, and otherwise violating the patents and other intellectual property rights of third parties. There is a substantial amount of complex litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We may become party to, or threatened with, such actions in the future, regardless of their merit. As discussed above, recently, due to changes in U.S. law referred to as patent reform, new procedures including inter partes review and post-grant review have been implemented. As stated above, this reform adds uncertainty to the possibility of challenge to our patents in the future. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">53</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;">Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates and other technologies may give rise to claims of infringement of the patent rights of others. Although we believe that we do not infringe on any third parties&#x2019; patents or other intellectual property, we cannot assure you that our product candidates and other technologies that we have developed, are developing or may develop in the future will not infringe existing or future patents owned by third parties. </font><font style="display: inline;">We may not be aware of patents that have already been issued </font><font style="display: inline;">to</font><font style="display: inline;"> a third party, </font><font style="display: inline;">such as</font><font style="display: inline;"> a competitor in the fields in which we are developing product candidates, </font><font style="display: inline;">who</font><font style="display: inline;"> might assert </font><font style="display: inline;">infringement of patents it may hold</font><font style="display: inline;"> by our current or future product candidates or other technologies, including claims to compositions, formulations, methods of manufacture or methods of use or treatment that cover our product candidates or other technologies.</font><font style="display: inline;"> It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our product candidates or other technologies, could be found to be infringed by our product candidates or other technologies. In addition, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates or other technologies may infringe. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Engaging in litigation to defend against third parties alleging that we have infringed, misappropriated, or otherwise violated their patents or other intellectual property rights is very expensive, particularly for a company of our size, and time-consuming. Some of our competitors may be able to sustain the costs of litigation or administrative proceedings more effectively than we can because of greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings against us could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and growth prospects. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming, and unsuccessful. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Competitors may infringe on our patents or the patents of our licensing partners, or we may be required to defend against claims of infringement. In addition, our patents or the patents of our licensing partners also may become involved in inventorship, priority, or validity disputes. To counter or defend against such claims can be expensive and time consuming. In an infringement proceeding, a court may decide that a patent in which we have an interest is invalid or unenforceable, the other party&#x2019;s use of our patented technology falls under the safe harbor to patent infringement, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Intellectual property rights do not necessarily address all potential threats. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">others may be able to make products that are similar to our product candidates or utilize similar technology but that are not covered by the claims of the patents that we may own;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">we might not have been the first to make the inventions covered by the issued patent or pending patent application that we own now or in the future;</font></p></td></tr></table></div>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">54</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">we might not have been the first to file patent applications covering certain of our inventions;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned intellectual property rights;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">it is possible that our current or future pending patent applications will not lead to issued patents;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">we may not develop additional proprietary technologies that are patentable;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the patents of others may harm our business; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations, and growth prospects. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">Risks Related to Our </font><font style="display: inline;font-weight:bold;color:#000000;">Business and </font><font style="display: inline;font-weight:bold;color:#000000;">Operations </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">The worldwide outbreak of an infectious disease, called COVID-19, may materially and adversely affect our business operations and our ability to conduct clinical studies.</font>
		</p>
		<p style="margin:5pt 0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">A widespread outbreak of a novel infectious disease called Coronavirus Disease 2019, or COVID-19, has been declared by the World Health Organization to be a &#x201C;public health emergency of international concern&#x201D;; a national emergency by the President of the U.S; and a major disaster by several states in which we operate. This unprecedented spread of disease may affect our operations by causing a period of business disruption, including the potential interruption or halt of our clinical study activities and delays or disruptions in the supply of our products and product candidates, or the inability of our employees to continue their normal course of work due to disease, quarantine or leave requirements, or the possibility of legal claims and actions against us for claims of loss arising out of COVID-19. As a small company that operates with a limited number of employees, the impact of disease may disproportionately hurt our operations. Further, our business insurance may not provide coverage against economic loss or claims specifically tied to COVID-19 or any other disease. </font>
		</p>
		<p style="margin:5pt 0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">COVID-19 presents many challenges that are without precedent. As such, we cannot presently assess or predict all current and potential uncertainties around the scope and severity of COVID-19 on our business operations with any meaningful precision. There is no assurance that COVID-19 will not have a material adverse impact on our future results. For example, the continued spread of COVID-19 could adversely impact our clinical study operations, including our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 if an outbreak occurs in their geography. COVID-19 could also negatively affect our manufacturing operations, which could result in delays or disruptions in the supply of our product candidates.&nbsp;A greater number of our employees working remotely during this outbreak of disease may expose us to greater risks related to cybersecurity and cyber-liability. Our study participants, vendors, employees, suppliers or others may allege they became sick due to our negligence. In addition, there could be a potential effect of a slowdown at FDA, which could result in delays of regulatory correspondence that are necessary for us to maintain or advance our product candidates in clinical studies. Further, the COVID-19 outbreak may adversely impact our ability to file on a routine and timely basis our obligations under federal securities laws, present new data at annual scientific meetings and professional conferences, reach out to institutional investors through in-person meetings, advance simufilam in a Phase 3 efficacy program, add an international component to our clinical studies, obtain additional financing as needed, engage in partnering discussions or conduct other activities necessary to the success of our business.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">If we or any of the third parties with whom we engage were to experience shutdowns or other business disruptions related to COVID-19, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively impacted, which could have a material adverse effect on our business, results of operations and financial condition.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Our reliance on third parties for both the supply and manufacture of materials for our product candidates carries the risk that we will not have sufficient quality or quantities of such materials or product candidates, or that such supply will not </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">55</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-weight:bold;font-style:italic;">be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We do not have any manufacturing facilities. We currently rely on CDMOs for all of the manufacture of our materials for preclinical studies and clinical studies and expect to continue to do so for preclinical studies, clinical studies, and for commercial supply of any product candidates that we may develop. We currently have established relationships with several CDMOs for the manufacturing of our product candidates. We may be unable to establish any further agreements with CDMOs or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on CDMOs entails additional risks, including: </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the possible breach of the manufacturing agreement by the third party;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">reliance on the third party for regulatory compliance, quality assurance, safety, and pharmacovigilance and related reporting; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the inability to produce required volume in a timely manner and to quality standards.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside the U.S. Our failure, or the failure of our CDMOs, to comply with applicable regulations could result in clinical holds on our studies, sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures, or recalls of product candidates or product candidates, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates and harm our business, financial condition, results of operations, and growth prospects. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Any product candidates that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Any performance failure on the part of our existing or future third-party manufacturers could delay clinical development or marketing approval. If any one of our current contract manufacturers cannot perform as agreed, we may be required to replace that manufacturer and may incur added costs and delays in identifying and qualifying any such replacement. Furthermore, securing and reserving production capacity with contract manufacturers may result in significant costs. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">We also rely on third-parties for the supply of the raw materials required for the production of our product candidates, and we expect to continue to rely on third party manufacturers for the commercial supply of any of our product candidates for which we obtain marketing approval. Our current and anticipated future dependence upon others for the manufacture of any product candidates we may develop may adversely affect our future profit margins and our ability to commercialize any medicines that receive marketing approval on a timely and competitive basis.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">We expect to grow the size and capabilities of our organization, including accessing new physical facilities,</font><font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">and we may experience difficulties in effectively managing this growth. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">As our development plans and strategies develop, we expect to add a significant number of additional managerial, operational, financial, and other personnel. Future growth will impose significant added responsibilities on members of management, including: </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">identifying, recruiting, integrating, retaining, and motivating additional employees;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">leasing or purchasing additional physical facilities to accommodate our increasing employee headcount;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">managing our internal development efforts effectively, including the clinical and FDA review process for our current and future product candidates, while complying with our contractual obligations to contractors and other third parties;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">expanding our operational, financial and management controls, reporting systems, and procedures; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">managing increasing operational and managerial complexity.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">56</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;">Our future financial performance and our ability to continue to develop and, if approved, commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth. Our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to manage these growth activities. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors, and consultants to provide certain services. There can be no assurance that the services of these independent organizations, advisors, and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical studies may be extended, delayed, or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, if at all. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop our product candidates and, accordingly, may not achieve our research, development, and commercialization goals. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Our internal computer systems, or those used by third parties on whom we rely, may fail or suffer other breakdowns, cyberattacks, or information security breaches that could compromise the confidentiality, integrity, and availability of such systems and data, result in material disruptions of our development programs and business operations, risk disclosure of confidential, financial, or proprietary information, and affect our reputation. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In the ordinary course of our business, we collect and store sensitive data, including legally protected patient health information, personally identifiable information about our employees, intellectual property, and proprietary business information. We manage and maintain our applications and data utilizing on-site systems. These applications and data encompass a wide variety of business-critical information including research and development information, commercial information and business and financial information. Despite the implementation of security measures, our internal computer systems and those of our current or future Clinical Research Organizations (CROs) and other contractors and consultants may be vulnerable to damage from computer viruses and unauthorized access. As the cyber-threat landscape evolves, these attacks are growing in frequency, sophistication, and intensity, and are becoming increasingly difficult to detect. Such attacks could include the use of key loggers or other harmful and virulent malware, including ransomware or other denials of service, and can be deployed through malicious websites, the use of social engineering, and/or other means. If a breakdown, cyberattack, or other information security breach were to occur and cause interruptions in our operations, it could result in a misappropriation of confidential information, including our intellectual property or financial information, and a material disruption of our development programs and our business operations. For example, the loss of clinical study data from completed, ongoing, or future clinical studies could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on our third-party research institution collaborators for research and development of our product candidates and other third parties for the manufacture of our product candidates and to conduct clinical studies, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or systems, or inappropriate disclosure of confidential, financial, or proprietary information, including data related to our personnel, we could incur liability or risk disclosure of confidential, financial, or proprietary information, and the further development and commercialization of our product candidates could be delayed. There can be no assurance that we and our business counterparties will be successful in efforts to detect, prevent, or fully recover systems or data from all breakdowns, service interruptions, attacks, or breaches of systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive data, which could result in financial, legal, business, or reputational harm to us.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Our business involves environmental risks that may result in liability for us.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In connection with our research and development activities, we, and our collaborators and vendors, are subject to federal, state and local laws, rules, regulations and policies governing the use, generation, manufacture, storage, air emission, effluent discharge, handling and disposal of certain materials, biological specimens, chemicals and wastes. Although we believe that we comply with such applicable laws, regulations and policies in all material respects and have not been required to correct any material noncompliance, we may incur significant costs to comply with environmental and health and safety regulations in the future. Although we believe that our safety procedures for handling and disposing of controlled materials comply with the standards prescribed by state and federal regulations, accidental contamination or injury from these materials may occur. </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">57</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;">In the event of such an occurrence, we could be held liable for any damages that result and any such liability could exceed our resources.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Business disruptions and lack of appropriate levels of commercial insurance could seriously harm our future revenue and financial condition and increase our costs and expenses. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Our operations, and those of our third-party research institution collaborators, CROs, CDMOs, suppliers, and other contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, disease epidemics or pandemics, such as COVID-19, a novel coronavirus first detected in 2019, and other natural or man-made disasters or business interruptions, for which we are partly or entirely uninsured. In addition, we rely on our third-party research institution collaborators for conducting research and development of our product candidates, and they may be affected by government shutdowns or withdrawn funding. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on third party manufacturers to produce and process our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Our day-to-day operations are located in a single office facility in Austin, Texas. Damage or extended periods of interruption to our corporate, development, or research facilities could cause us to cease or delay development of some or all our product candidates. Our insurance might not cover losses under such circumstances and our business may be seriously harmed by such delays and interruption. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Social media platforms present risks and challenges.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">As social media continues to expand, it also presents us with new challenges. The inappropriate or unauthorized use of our confidential information on media platforms could cause brand damage or information leakage, which would cause legal or regulatory problems for us. In addition, negative, inappropriate or inaccurate posts or comments about us or our product candidates on social media internet sites could quickly and irreversible damage our reputation, brand image and goodwill. Further, the accidental or intentional disclosure of non-public sensitive information by our workforce or others through media channels could lead to information loss or could lead to legal or regulatory problems for us. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">We expect to rely on third parties to conduct our studies and some aspects of our research, and such third parties may not perform satisfactorily, which could delay or harm our</font><font style="display: inline;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;">studies, research, and testing. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We </font><font style="display: inline;">substantiall</font><font style="display: inline;">y rely and expect to continue to rely on third parties, such as CROs, clinical data management organizations, medical institutions, and clinical investigators, to conduct some aspects of our research and preclinical testing and our clinical studies. Any of these third parties may terminate their engagements with us or be unable to fulfill their contractual obligations. If we need to enter into alternative arrangements, it will delay our product development activities. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Our reliance on these third parties for research and development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we remain responsible for ensuring that all of our clinical studies are conducted in accordance with the general investigational plan and protocols for the trial. Moreover, FDA requires us to comply with the norms of Good Clinical Practice (GCPs) for conducting, recording, and reporting the results of clinical studies to assure that data and reported results are credible, reproducible, and accurate and that the rights, integrity, and confidentiality of study participants are protected. We also are required to register ongoing clinical studies and post the results of completed clinical studies on a government-sponsored database within certain timeframes. Failure to do so can result in fines, adverse publicity, and civil and criminal sanctions. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">If our third</font><font style="display: inline;">-</font><font style="display: inline;">party vendors do not successfully carry out their contractual duties, meet expected deadlines, or conduct studies in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for any product candidates we may develop and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. For example, one of our vendors failed to fully comply with certain Good Laboratory Practice (GLP) norms in its research facility, which required us to repeat a lab study at a different research site.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">58</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;">We also rely on other third parties to </font><font style="display: inline;">label, </font><font style="display: inline;">store and distribute drug supplies for our clinical studies. Any performance failure on the part of our distributors, including with the shipment of any drug supplies, could delay clinical development or marketing approval of any product candidates we may develop or commercialization of our product candidates, producing additional losses and depriving us of potential product revenue. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">We do not own any manufacturing facilities and we rely on third-party commercial drug manufacturers for </font><font style="display: inline;font-weight:bold;font-style:italic;">clinical </font><font style="display: inline;font-weight:bold;font-style:italic;">drug supply. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We do not own any manufacturing facilities. We plan to continue to outsource formulation, manufacturing and related activities. We rely on a limited number of third-party suppliers to formulate, manufacture, fill, label, ship or store all of our product candidates. These suppliers must comply with </font><font style="display: inline;color:#000000;">current cGMP</font><font style="display: inline;"> regulations enforced by FDA and other government agencies, and are subject to ongoing periodic unannounced inspection, including preapproval inspections by FDA and corresponding state and foreign government agencies to ensure strict compliance with c</font><font style="display: inline;color:#000000;">GMP </font><font style="display: inline;">and other government regulations and corresponding foreign standards. These manufacturers may subsequently be stopped from producing, storing, shipping or testing our drug products due to their non-compliance with federal, state or local regulations. We do not have control over our suppliers&#x2019; compliance with these regulations and standards. We cannot control decisions by our suppliers that affect their ability or willingness to continue to supply us on acceptable terms, or at all. We may not be able to replace a commercial supplier on commercially reasonable terms, or at all. Replacing any of our commercial suppliers would be expensive and time consuming. Failure by any of our suppliers to perform as expected could delay or prevent commercialization of our product candidates or result in shortages, cost overruns, or other problems and would materially harm our business.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">We are a small company with a limited number of employees. We are highly dependent on our key personnel, and if we are not successful in attracting, motivating, and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract, motivate, and retain highly qualified managerial, scientific, and medical personnel. We are highly dependent on our management, particularly our Chief Executive Officer, Remi Barbier, and our scientific and technical personnel. The loss of the services provided by any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements, could result in delays in the development of our product candidates and harm our business. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Competition for skilled personnel is intense and the turnover rate can be high, which may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. We expect that we may need to recruit talent from outside of our region in Austin, Texas, and doing so may be costly and difficult. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided equity option grants that vest over time. The value to employees of these equity grants that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Although we have employment agreements with our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. If we are unable to attract and incentivize quality personnel on acceptable terms, or at all, it may cause our business and operating results to suffer. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">We may need to cease our operations if we are unable to attract and retain key personnel.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We are engaged in developing early-stage technologies and will continue to do so for the foreseeable future.&nbsp;&nbsp;Unlike larger organizations, we rely on a very small number of highly skilled, and highly sought after, employees to continue the advancement of our development stage technologies. The </font><font style="display: inline;">knowledge and skills contributed by our key employees may be irreplaceable and the loss of a key employee may cause substantial negative financial, operational and scientific consequences for our business.&nbsp;&nbsp;As an example, our research grant awards from NIH depend in part on the continued participation of certain key employees, known as a Principal Investigator. The loss of a Principal Investigator may result in the loss of one or more research grant awards from NIH, which would have significant adverse effects on our ability to continue to conduct, conclude or fund our research programs in Alzheimer&#x2019;s disease. Likewise, the intellectual property that is intended to protect our </font><font style="display: inline;">development stage technologies</font><font style="display: inline;"> is still evolving and its evolution remains highly dependent on a small number of employees </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">59</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;">with specific expertise. The loss of a key employee may jeopardize our existing or pending intellectual property or may prevent us from accessing the technical information and knowledge necessary to extend our portfolio of intellectual property. Furthermore, we believe the adverse effects that may result from losing a key employee&#x2019;s participation cannot be compensated with any specific insurance policies, such as &#x201C;key person&#x201D; or &#x201C;business life&#x201D; insurance. </font><font style="display: inline;">If we are not successful in retaining key employees, our business and financial condition will suffer, and we may need to cease our operations.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">If our current research collaborators or scientific advisors terminate their relationships with us or develop relationships with a competitor, our ability to continue our business operations could be adversely affected.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We have relationships with research collaborators at academic and other institutions who conduct research at our request. These research collaborators are not our employees. As a result, we have limited control over their activities and, except as otherwise required by our collaboration agreements, can expect only limited amounts of their time to be dedicated to our activities. Our ability to discover drugs and biomarkers involved in human disease and validate and commercialize diagnostic tests will depend in part on the continuation of these collaborations. If any of these collaborations are terminated, we may not be able to enter into other acceptable collaborations. In addition, our existing collaborations may not be successful. Our research collaborators and scientific advisors may have relationships with other commercial entities, some of which could compete with us. Our research collaborators and scientific advisors sign agreements which provide for the confidentiality of our proprietary information and the results of studies conducted at our request. We may not, however, be able to maintain the confidentiality of our technology and other confidential information related to all collaborations. The dissemination of our confidential information could have a material adverse effect on our business.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Risks </font><font style="display: inline;font-weight:bold;">Related</font><font style="display: inline;font-weight:bold;"> to Financial Condition and Capital Requirements </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">We have incurred significant net losses in each period since our inception and anticipate that we will continue to incur net losses for the foreseeable future. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We have incurred net losses in each reporting period since our inception, including a net loss of $6.3</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> for the year ended </font><font style="display: inline;">December&nbsp;</font><font style="display: inline;">31, 2020. As of </font><font style="display: inline;">December&nbsp;</font><font style="display: inline;">31, 2020, we had an accumulated deficit of $174.9</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;">. &nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We have invested significant financial resources in research and development activities for product candidates. We do not expect to generate revenue from product sales for several years, if at all. The amount of our future net losses will depend, in part, on the </font><font style="display: inline;">level</font><font style="display: inline;"> of our future expenditures and revenue. Moreover, our net losses may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indicator of our future performance. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We </font><font style="display: inline;">expect</font><font style="display: inline;"> to continue to incur significant expenses and higher operating losses for the foreseeable future. We anticipate that our expenses will increase substantially as we: </font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">continue our research and discovery activities;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">advance our current and any future product candidates through preclinical and clinical development;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">initiate and conduct additional preclinical, clinical, or other studies for our product candidates;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">work with our CDMO&#x2019;s to scale up the manufacturing processes for our product candidates;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">seek regulatory approvals and marketing authorizations for our product candidates;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">obtain, maintain, protect, defend and enforce our intellectual property portfolio;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">attract, hire, and retain qualified personnel;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">provide additional internal infrastructure to support our continued research and development operations and any planned commercialization efforts in the future;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">experience any delays or encounter other issues related to our operations; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">meet the requirements and demands of being a public company.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Our prior </font><font style="display: inline;color:#000000;">losses</font><font style="display: inline;color:#000000;"> and expected future losses have had and will continue to have an adverse effect on our stockholders&#x2019; equity and working capital. In any quarter, our operating results could be below the expectations of securities analysts or investors, which could cause our stock price to decline.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">60</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">We have broad discretion in the use of the net proceeds from </font><font style="display: inline;font-weight:bold;font-style:italic;">any of our financing transactions</font><font style="display: inline;font-weight:bold;font-style:italic;color:#000000;"> and may not use them effectively. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We have</font><font style="display: inline;"> broad discretion in the application of the net proceeds from our financing transactions, and investors will not have the opportunity to assess whether the net proceeds are being used appropriately. </font><font style="display: inline;">We</font><font style="display: inline;"> could spend the net proceeds from offerings in ways that vary substantially from their intended use, do not improve our results of operations or enhance the value of our common stock. </font><font style="display: inline;">Our</font><font style="display: inline;"> failure to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use, we may invest the net proceeds from our financing transactions in a manner that does not produce income or that loses value.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">We have no product revenues and may never achieve revenues or profitability based on product revenues. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We have no products approved for commercial sale. To obtain revenues from the sales of our product candidates that are significant or large enough to achieve profitability, we must succeed, either alone or with third parties, in developing, obtaining regulatory approval for, manufacturing, and marketing product candidates with significant commercial value. This is a significant endeavor that few early-stage biopharmaceutical companies can successfully achieve. Our ability to generate revenue and achieve profitability depends on many factors, including: </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">completing research and preclinical and clinical development of our product candidates;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">obtaining regulatory approvals and marketing authorizations for product candidates for which we successfully complete clinical development;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">developing a sustainable and scalable manufacturing process for our product candidates, as well as establishing and maintaining commercially viable supply relationships with third parties that can provide adequate products and services to support clinical activities and commercial demand for our product candidates;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">identifying, assessing, acquiring, and/or developing new product candidates;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">addressing any competing technological and market developments;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">maintaining, protecting, expanding, and enforcing our portfolio of intellectual property rights, including patents, trade secrets, and know-how; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">attracting, hiring, and retaining qualified personnel.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Because of the numerous risks and uncertainties associated with drug development, we are unable to predict the timing or amount of our expenses, or when we will be able to generate any meaningful revenue or achieve or maintain profitability, if ever. In addition, our expenses could increase beyond our current expectations if we are required by FDA or foreign regulatory agencies to perform studies in addition to those that we currently anticipate, or if there are any delays in any of our clinical studies or the development of any of our product candidates. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">We may require additional capital to fund our operations and to complete the development of our product candidates. A failure to obtain this necessary capital on acceptable terms, or at all, could force us to delay, limit, reduce, or terminate our commercialization efforts, product development, or other operations. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Our operations have required substantial amounts of cash since inception, and we expect our expenses to increase significantly in the foreseeable future. To date, we have financed our operations primarily through the sale of equity securities, research grants and payments received from prior third-party collaborations. Developing our product candidates and conducting clinical studies for the treatment of neurodegenerative diseases, including Alzheimer&#x2019;s disease, will require substantial amounts of capital. We will also require a significant amount of capital to commercialize any approved products. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">As of </font><font style="display: inline;color:#000000;">December&nbsp;</font><font style="display: inline;color:#000000;">31, 2020, we had cash and cash equivalents of $</font><font style="display: inline;color:#000000;">93.5</font><font style="display: inline;color:#000000;">&nbsp;million</font><font style="display: inline;color:#000000;">. Subsequent</font><font style="display: inline;color:#000000;"> to </font><font style="display: inline;color:#000000;">December&nbsp;</font><font style="display: inline;color:#000000;">31, 2020, we completed a registered direct offering of our </font><font style="display: inline;color:#000000;">common stock for net proceeds of approximately </font><font style="display: inline;color:#000000;">$189.7</font><font style="display: inline;color:#000000;">&nbsp;million</font><font style="display: inline;color:#000000;">.</font><font style="display: inline;color:#000000;"> Based on our current operating plan, we believe that our existing cash and cash equivalents will be sufficient to fund our projected operations for at least the next 12&nbsp;months. Our estimate as to how long we expect our existing cash and cash equivalents to be available to fund our operations is based on assumptions that may prove inaccurate, and we could use our available capital resources sooner than we currently expect. In addition, changing circumstances may cause us to increase our spending significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">61</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;">beyond our control. We may need to raise additional funds sooner than we anticipate if we choose to expand more rapidly than we presently anticipate. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We may require additional capital for the further development of our product candidates. Additional capital may not be available when we need it, or on terms acceptable to us or at all. We have no committed source of additional capital. If adequate capital is not available to us on a timely basis, we may be required to significantly delay, limit, reduce or terminate our research and development programs or the commercialization of product candidates, if approved, or be unable to continue or expand our operations, or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition, results of operations, and growth prospects and cause the price of our common stock to decline. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with pharmaceutical partners, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates, or grant licenses on terms that may not be favorable to us. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Global credit and financial market conditions could negatively impact the value of our portfolio of cash equivalents and our ability to meet our financing objectives.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Our cash and cash equivalents are generally maintained in highly liquid investments with original maturities of 90 days or less at the time of purchase. While, as of the date of this filing, we are not aware of any downgrades, material losses, or other significant deterioration in the fair value of our cash equivalents since </font><font style="display: inline;">December&nbsp;</font><font style="display: inline;">31, 2020, no assurance can be given that deterioration in conditions of the global credit and financial markets would not negatively impact our current portfolio of cash equivalents or our ability to meet our financing objectives.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<a name="_AEIOULastRenderedPageBreakAEIOU29"></a><font style="display: inline;font-weight:bold;">Risks Related to the Ownership of Our Common Stock </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">We do not know whether a </font><font style="display: inline;font-weight:bold;font-style:italic;">sufficient </font><font style="display: inline;font-weight:bold;font-style:italic;">market will continue to develop for our common stock or what the market price of our common stock will be, and, as a result, it may be difficult </font><font style="display: inline;font-weight:bold;font-style:italic;">for investors </font><font style="display: inline;font-weight:bold;font-style:italic;">to sell shares of our common stock. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">If a market for our common stock is not sustained, it may be difficult to sell shares of our common stock at an attractive price or at all. We cannot predict the prices at which our common stock will trade. It is possible that in one or more future periods our results of operations and progression of our product pipeline may not meet the expectations of public market analysts and investors, and, as a result of these and other factors, the price of our common stock may fall. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">The market price of our common stock </font><font style="display: inline;font-weight:bold;font-style:italic;">has historically been highly volatile, and we expect it to continue to</font><font style="display: inline;font-weight:bold;font-style:italic;"> be volatile, which could result in substantial losses for investors who purchase our shares. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">For example, the closing price of our common stock has fluctuated from a low of $2.04 to a high of $87.95 over the 12 months preceding the filing date of this Form 10-K. </font><font style="display: inline;">Some of the factors that may cause the market price of our common stock to fluctuate include: </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the success of existing or new competitive products or technologies;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the timing and results of clinical studies for our current product candidates and any future product candidates that we may develop;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">failure or discontinuation of any of our product development and research programs;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">results of preclinical studies, clinical studies, or regulatory approvals of product candidates of our competitors, or announcements about new research programs or product candidates of our competitors;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">regulatory or legal developments in the United States and other countries;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">developments or disputes concerning patent applications, issued patents, or other proprietary rights;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the recruitment or departure of key personnel;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the level of expenses related to any of our research programs, clinical development programs, or product candidates that we may develop;</font></p></td></tr></table></div>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">62</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the results of our efforts to develop additional product candidates or products;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">actual or anticipated changes in estimates as to financial results or development timelines;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">announcement or expectation of additional financing efforts;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">sales of our common stock by us, our insiders, or other stockholders;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">variations in our financial results or those of companies that are perceived to be similar to us;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">changes in estimates or recommendations by securities analysts, if any, that cover our stock;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">market conditions in the pharmaceutical and biotechnology sectors; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">general economic, industry, and market conditions.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">In recent years, the stock market in general, Nasdaq, and the markets for early stage companies and pharmaceutical and biotechnology companies, has experienced significant price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Broad market and industry factors may seriously affect the market price of our common stock, regardless of our actual operating performance. Following periods of such volatility in the market price of a company&#x2019;s securities, securities class action litigation has often been brought against that company. Because of the potential volatility of our stock price, we may become the target of securities litigation in the future. Securities litigation could result in substantial costs and divert management&#x2019;s attention and resources from our business. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">If we are unable to maintain effective internal controls, our business, financial position, and results of operations could be adversely affected. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">As a public company, we are subject to reporting and other obligations under the Securities Exchange Act of 1934, as amended (Exchange Act), including the requirements of Section&nbsp;404 of SOX, which require annual management assessments of the effectiveness of our internal control over financial reporting. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation to meet the detailed standards under the rules. During testing, our management may identify material weaknesses or deficiencies which may not be remedied in time to meet the deadline imposed by SOX. These reporting and other obligations place significant demands on our management and administrative and operational resources, including accounting resources. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the U.S. Any failure to maintain effective internal controls could have an adverse effect on our business, financial position, and results of operations. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Anti-takeover provisions in our charter documents and Delaware law may prevent or delay removal of incumbent management or a change of control. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Anti-takeover provisions of our amended and restated certificate of incorporation and amended and restated bylaws and Delaware law may have the effect of deterring or delaying attempts by our stockholders to remove or replace management, engage in proxy contests and effect changes in control. The provisions of our charter documents include: </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">a classified board so that only one of the three classes of directors on our Board of Directors (the &#x201C;Board&#x201D;) is elected each year; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">elimination of cumulative voting in the election of directors; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">procedures for advance notification of stockholder nominations and proposals; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the ability of the Board to amend our bylaws without stockholder approval; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">the ability of the Board to issue up to 10,000,000 shares of preferred stock without stockholder approval upon the terms and conditions and with the rights, privileges and preferences as the Board may determine. </font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">In addition, as a Delaware corporation, we are subject to Delaware law, including Section</font><font style="display: inline;color:#000000;"> 203</font><font style="display: inline;color:#000000;"> of the Delaware General Corporation Law. In general, Section</font><font style="display: inline;color:#000000;"> 203</font><font style="display: inline;color:#000000;"> prohibits a Delaware corporation from engaging in any business combination with </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">63</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;">any interested stockholder for a period of three years following the date that the stockholder became an interested stockholder unless certain specific requirements are met as set forth in Section</font><font style="display: inline;"> 203</font><font style="display: inline;">. &nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">These provisions, alone or together, could have the effect of deterring or delaying changes in incumbent management, proxy contests or changes in control. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">Changes in our ownership could limit our ability to utilize net operating loss carryforwards.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">As of December&nbsp;31, 2020, we had aggregate federal net operating loss carryforwards of approximately $87.3&nbsp;million, which begin to expire in 2029. Under Section 382 of the Internal Revenue Code of 1986, as amended, changes in our ownership may limit the amount of our net operating loss carryforwards that could be utilized annually to offset our future taxable income, if any. This limitation would generally apply in the event of a cumulative change in ownership of our company of more than 50% within a rolling three-year period. Any such limitation may significantly reduce our ability to utilize our net operating loss carryforwards and tax credit carryforwards. Any such limitation, whether as the result of past offerings, sales of our common stock by our existing stockholders or additional sales of our common stock by us in the future could have a material adverse effect on our results of operations in future years. We have not completed a study to assess whether an ownership change for purposes of Section 382 has occurred, or whether there have been multiple ownership changes since our inception, nor do we plan to do so due to the significant costs and complexities associated with such study.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">We may sell additional equity or debt securities to fund our operations, and have outstanding securities exercisable for our common stock, which may result in dilution to our stockholders and impose restrictions on our business.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In order to raise additional capital to support our operations, we may sell additional shares of our common stock or other securities convertible into or exchangeable for our common stock which could result in dilution our stockholders. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share that is equal to or greater than the price per share paid by investors in prior offerings, and investors purchasing our shares or other securities in the future could have rights superior to existing shareholders. The price per share at which we sell additional shares of our common stock or securities convertible into or exchangeable for our common stock in future transactions may be higher or lower than the price per share in prior offerings. You may also be diluted upon the exercise of outstanding stock options as of </font><font style="display: inline;">December&nbsp;</font><font style="display: inline;">31</font><font style="display: inline;">, 2020</font><font style="display: inline;"> to purchase 2,817,504 shares of our common stock at a weighted average price of $11.30 per share, and the future issuance of up to 252,188 compensatory equity awards authorized under our 2018 Omnibus Incentive Plan and up to 58,017 shares we may sell under our Employee Stock Purchase Plan.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Item 1B.</font><font style="display: inline;font-weight:bold;"> &nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;">Unresolved Staff Comments</font><a name="Unresolved_Staff_Comments"></a>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">None.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font><a name="_DV_M81"></a><a name="_DV_M83"></a><a name="_DV_M84"></a><a name="_DV_M85"></a><a name="_DV_M86"></a><a name="_DV_M87"></a><a name="_DV_M88"></a><a name="_DV_M90"></a><a name="_DV_M190"></a><a name="_DV_M195"></a><a name="_DV_M198"></a><a name="_DV_M200"></a><a name="_DV_M202"></a><a name="_DV_M204"></a><a name="_DV_M205"></a><a name="_DV_M207"></a><a name="_DV_M208"></a><a name="_DV_M209"></a><a name="_DV_M210"></a><a name="_DV_M211"></a><a name="_DV_M213"></a><a name="_DV_M217"></a><a name="_DV_M225"></a><a name="_DV_M218"></a><a name="_DV_M227"></a><a name="_DV_M228"></a><a name="_DV_M314"></a><a name="_DV_M315"></a><a name="_DV_M316"></a><a name="_DV_M317"></a><a name="_DV_M319"></a><a name="_DV_M320"></a><a name="_DV_M497"></a><a name="_DV_M332"></a><a name="_DV_M353"></a><a name="_DV_M354"></a><a name="_DV_M356"></a><a name="_DV_M447"></a><a name="_DV_M451"></a>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Item&nbsp;2. &nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;">Properties</font><a name="Properties"></a>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We lease approximately 6,000 square feet of office space pursuant to a non-cancelable operating lease in Austin, TX that expires </font><font style="display: inline;">April&nbsp;</font><font style="display: inline;">30, 2024.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Item&nbsp;3. &nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;">Legal Proceedings</font><a name="Legal_Proceedings"></a>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Item 4.</font><font style="display: inline;font-weight:bold;"> &nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;">Mine Safety Disclosures</font><a name="Mine_Safety_Disclosures"></a>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Not applicable.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">64</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-weight:bold;">PART II</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Item 5.</font><font style="display: inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;">Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font><a name="Market_For_Registrants_Common_Equity"></a>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Market Price of Dividends of the Registrants Common Equity and Related Stockholder Matters</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Our common stock is quoted on </font><font style="display: inline;color:#000000;">Nasdaq, </font><font style="display: inline;">under the symbol "SAVA." </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We currently expect to retain future earnings, if any, for use in the operation and expansion of our business and, notwithstanding our special non-dividend distributions in </font><font style="display: inline;">December 201</font><font style="display: inline;">2 (of $0.75 per share of common stock totaling $34.0</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;">) and </font><font style="display: inline;">December 201</font><font style="display: inline;">0 (of $2.00 per share of common stock totaling $85.7</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;">), we have not paid and do not anticipate paying any cash dividends in the foreseeable future. As of </font><font style="display: inline;">January&nbsp;</font><font style="display: inline;">2</font><font style="display: inline;">5</font><font style="display: inline;">, 202</font><font style="display: inline;">1</font><font style="display: inline;">, there were approximately </font><font style="display: inline;">28</font><font style="display: inline;"> &nbsp;r</font><font style="display: inline;">egistered holders of record of our common stock. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Item 6.</font><font style="display: inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;">Selected Financial Data</font><a name="Selected_Financial_Data"></a>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Not applicable.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">65</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Item 7.</font><font style="display: inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font><a name="MDA"></a><font style="display: inline;font-weight:bold;font-style:italic;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">This discussion and analysis should be read in conjunction with our financial statements and accompanying notes included elsewhere in this report. Operating results are not necessarily indicative of results that may occur in future periods.</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Overview </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Cassava Sciences, Inc. is a clinical-stage biotechnology company. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer&#x2019;s disease. Our novel science is based on stabilizing &#x2013; but not removing &#x2013; a critical protein in the brain.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Over the past 10 years, we have combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer&#x2019;s disease and other neurodegenerative diseases. </font><font style="display: inline;">Our strategy is to leverage our unique scientific/clinical platform to develop a first-in-class program for </font><font style="display: inline;">treating neurodegenerative diseases, such as Alzheimer&#x2019;s</font><font style="display: inline;">. &nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We currently have two clinical-stage </font><font style="display: inline;">biopharmaceutical </font><font style="display: inline;">assets under development: </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">our lead therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer&#x2019;s disease; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">our lead investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer&#x2019;s disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Our scientific approach for the treatment of Alzheimer&#x2019;s disease seeks to simultaneously improve </font><font style="display: inline;font-style:italic;color:#000000;">both</font><font style="display: inline;color:#000000;"> neurodegeneration and neuroinflammation. We believe our ability to improve multiple vital functions in the brain represents a new, different and crucial approach to address Alzheimer&#x2019;s disease. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Our lead therapeutic product candidate, simufilam, is a proprietary small molecule (oral) drug. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimer&#x2019;s brain. Published studies have demonstrated that the altered form of FLNA causes neuronal dysfunction, neuronal degeneration and neuroinflammation.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">We believe simufilam improves brain health by reverting altered FLNA back to its native, healthy conformation, thus countering the downstream toxic effects of altered FLNA. We have generated and published experimental and clinical evidence of improved brain health with simufilam. </font><font style="display: inline;color:#000000;">Importantly, </font><font style="display: inline;color:#000000;">simufilam</font><font style="display: inline;color:#000000;"> is not dependent on clearing amyloid from the brain. S</font><font style="display: inline;color:#000000;">ince simufilam has a unique mechanism of action, we believe its potential therapeutic effects may be additive or synergistic with that of other therapeutic candidates aiming to treat neurodegeneration.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Simufilam has demonstrated a multitude of beneficial effects in animal models of disease, including normalizing neurotransmission, decreasing neuroinflammation, suppressing neurodegeneration, and restoring memory and cognition.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">In 2019</font><font style="display: inline;color:#000000;">, we completed a small, first-in-patient, clinical-proof-of-concept, open-label Phase 2a study of simufilam in the U.S., with substantial support from the </font><font style="display: inline;font-style:italic;color:#000000;">National Institute on Aging</font><font style="display: inline;color:#000000;"> (NIA), a division of the NIH. Treatment with simufilam for 28 days significantly improved key biomarkers of Alzheimer&#x2019;s pathology, neurodegeneration and neuroinflammation (</font><font style="display: inline;color:#000000;">p&lt;0.001)</font><font style="display: inline;color:#000000;">. &nbsp;</font><font style="display: inline;color:#000000;">Biomarkers effects were seen in all patients in both cerebrospinal fluid (CSF) and plasma.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">In </font><font style="display: inline;color:#000000;font-size:10pt;">September 202</font><font style="display: inline;color:#000000;font-size:10pt;">0, </font><font style="display: inline;font-size:10pt;color:#000000;">we</font><font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">announced </font><font style="display: inline;font-size:10pt;color:#000000;">final</font><font style="display: inline;color:#000000;font-size:10pt;"> results of a Phase 2b study with </font><font style="display: inline;color:#000000;font-size:10pt;">simufilam</font><font style="display: inline;color:#000000;font-size:10pt;"> in Alzheimer&#x2019;s disease. </font><font style="display: inline;font-size:10pt;color:#000000;">In </font><font style="display: inline;font-size:10pt;color:#000000;">this</font><font style="display: inline;font-size:10pt;color:#000000;"> clinical study funded by the NIH, Alzheimer&#x2019;s </font><font style="font-style:italic;display: inline;font-style:normal;font-size:10pt;color:#000000;">patients</font><font style="font-style:italic;display: inline;font-size:10pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">treated with 50 mg or 100 mg of </font><font style="display: inline;font-size:10pt;color:#000000;">simufilam</font><font style="display: inline;font-size:10pt;color:#000000;"> twice-daily for 28 days showed statistically significant (p&lt;0.05) improvements in </font><font style="display: inline;font-size:10pt;color:#000000;">CSF </font><font style="display: inline;font-size:10pt;color:#000000;">biomarkers of </font><font style="font-style:italic;display: inline;font-style:normal;font-size:10pt;color:#000000;">disease pathology, neurodegeneration and neuroinflammation, versus</font><font style="font-style:italic;display: inline;font-size:10pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">Alzheimer&#x2019;s </font><font style="font-style:italic;display: inline;font-style:normal;font-size:10pt;color:#000000;">patients who took placebo</font><font style="font-style:italic;display: inline;font-size:10pt;color:#000000;">.</font><font style="display: inline;font-size:10pt;color:#000000;"> In addition, Alzheimer&#x2019;s </font><font style="font-style:italic;display: inline;font-style:normal;font-size:10pt;color:#000000;">patients</font><font style="font-style:italic;display: inline;font-size:10pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">treated with </font><font style="display: inline;font-size:10pt;color:#000000;">simufilam</font><font style="display: inline;font-size:10pt;color:#000000;"> showed improvements in validated tests of episodic memory and spatial working memory,</font><font style="font-style:italic;display: inline;font-size:10pt;color:#000000;">&nbsp;</font><font style="font-style:italic;display: inline;font-style:normal;font-size:10pt;color:#000000;">versus patients on placebo</font><font style="font-style:italic;display: inline;font-size:10pt;color:#000000;"> &nbsp;(</font><font style="display: inline;font-size:10pt;color:#000000;">Effect Size 17-46%). Cognitive improvements correlated most strongly (R</font><font style="display: inline;font-size:10pt;color:#000000;font-size:5pt;vertical-align:super;line-height:100%">2</font><font style="display: inline;font-size:10pt;color:#000000;">=0.5) with decreases in levels of P-tau181.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;background-color: #FFFFFF;">In </font><font style="display: inline;color:#000000;font-size:10pt;background-color: #FFFFFF;">March 202</font><font style="display: inline;color:#000000;font-size:10pt;background-color: #FFFFFF;">0, we initiated</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">a long-term</font><font style="display: inline;color:#000000;font-size:10pt;"> open-label extension study to evaluate&nbsp;simufilam&nbsp;in patients with Alzheimer&#x2019;s disease.&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;background-color: #FFFFFF;">This open-label, multi-center, </font><font style="display: inline;color:#000000;font-size:10pt;background-color: #FFFFFF;">extension study&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">is intended to monitor the long-term safety and tolerability of&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">simufilam</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;100 mg twice-daily for 12 </font><font style="display: inline;color:#000000;font-size:10pt;">or more </font><font style="display: inline;color:#000000;font-size:10pt;">months. The study&#x2019;s initial target enrollment was</font><font style="display: inline;color:#000000;font-size:10pt;"> approximately 100&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;background-color: #FFFFFF;">patients with m</font><font style="display: inline;color:#000000;font-size:10pt;">ild-to-moderate Alzheimer&#x2019;s </font><font style="display: inline;color:#000000;font-size:10pt;">disease </font><font style="display: inline;color:#000000;font-size:10pt;">and, in </font><font style="display: inline;color:#000000;font-size:10pt;">February 202</font><font style="display: inline;color:#000000;font-size:10pt;">1, was increased to approximately 150</font><font style="display: inline;color:#000000;font-size:10pt;"> patients. This study</font><font style="display: inline;color:#000000;font-size:10pt;"> uses the</font><font style="display: inline;color:#000000;font-size:10pt;"> Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog-11) to assess</font><font style="display: inline;color:#000000;font-size:10pt;"> cognitive symptoms of </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">66</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;color:#000000;font-size:10pt;">dementia&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">and the Neuropsychiatric Inventory (NPI) to assess the presence and severity of dementia-related behavior. Both scales are widely used clinical tools </font><font style="display: inline;color:#000000;font-size:10pt;">in </font><font style="display: inline;color:#000000;font-size:10pt;">trials of Alzheimer&#x2019;s disease</font><font style="display: inline;color:#000000;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">On </font><font style="display: inline;color:#000000;font-size:10pt;">February&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">2, 2021, we </font><font style="display: inline;color:#000000;font-size:10pt;">announced results </font><font style="display: inline;color:#000000;font-size:10pt;">of </font><font style="display: inline;color:#000000;font-size:10pt;">the first of two</font><font style="display: inline;color:#000000;font-size:10pt;"> preplanned interim analysis </font><font style="display: inline;color:#000000;font-size:10pt;">of our</font><font style="display: inline;color:#000000;font-size:10pt;"> open-label study of simufilam. Th</font><font style="display: inline;color:#000000;font-size:10pt;">e first</font><font style="display: inline;color:#000000;font-size:10pt;"> interim analysis summarizes clinical data at the midway point</font><font style="display: inline;color:#000000;font-size:10pt;"> of enrollment, i.e., the first</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">50 patients who have completed at least 6 months of drug treatment. Patients&#x2019; </font><font style="display: inline;color:#000000;font-size:10pt;">cognition and behavior scores both improved following six months of simufilam treatment, with no safety issues. </font><font style="display: inline;color:#000000;font-size:10pt;">S</font><font style="display: inline;font-size:10pt;">ix months of simufilam</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">treatment </font><font style="display: inline;color:#000000;font-size:10pt;">improved cognition scores by 1.6 points on ADAS-Cog11, a 10% mean improvement from baseline to month 6. In these same patients, simufilam also improved </font><font style="display: inline;font-size:10pt;">dementia-related</font><font style="display: inline;color:#000000;font-size:10pt;"> behavior, such as anxiety, delusions and agitation, by 1.3 points on the Neuropsychiatric Inventory, a 29% mean improvement from baseline to month 6.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">Based on the interim results and inbound</font><font style="display: inline;color:#000000;font-size:10pt;"> demand from Alzheimer&#x2019;s patients and their caregivers, </font><font style="display: inline;color:#000000;font-size:10pt;">we announced significant changes to the open-label program, including an increase in </font><font style="display: inline;color:#000000;font-size:10pt;">the enrollment target by up to 50 additional patients,</font><font style="display: inline;color:#000000;font-size:10pt;"> for</font><font style="display: inline;color:#000000;font-size:10pt;"> a total target of approximately 150 patients.</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">This study&nbsp;ha</font><font style="display: inline;color:#000000;font-size:10pt;">d enrolled</font><font style="display: inline;color:#000000;font-size:10pt;"> approximately</font><font style="display: inline;">&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">80</font><font style="display: inline;color:#000000;font-size:10pt;"> patients</font><font style="display: inline;color:#000000;font-size:10pt;"> as of </font><font style="display: inline;color:#000000;font-size:10pt;">February 202</font><font style="display: inline;color:#000000;font-size:10pt;">1.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">We expect to announce&nbsp;results of&nbsp;a second planned interim analysis on safety and cognition for our open-label study approximately mid-2021. The second interim analysis is intended to summarize clinical data on the first 50 patients who complete at least 12 months of open label drug treatment.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">On </font><font style="display: inline;">February&nbsp;</font><font style="display: inline;">22, 2021, we </font><font style="display: inline;">announced the successful completion of an End-of-Phase 2 (EOP2) meeting with the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">FDA for simufilam. Official EOP2 meeting minutes indicate </font><font style="display: inline;">we and the </font><font style="display: inline;">FDA agree on key elements of a pivotal Phase 3 clinical program in support of a New Drug Application (NDA) filing for simufilam in Alzheimer&#x2019;s disease. </font><font style="display: inline;">We believe agreements</font><font style="display: inline;"> reached during the EOP2 meeting show a clear path forward for advancing simufilam into Phase 3 studies</font><font style="display: inline;">. We expect to initiate a pivotal Phase 3 program with simufilam in Alzheimer&#x2019;s disease</font><font style="display: inline;"> in the second half of 2021.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Tahoma;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Our diagnostic effort, called SavaDx, is an early-stage program focused on detecting the presence of Alzheimer&#x2019;s disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. We</font><font style="display: inline;"> are developing </font><font style="display: inline;">SavaDx</font><font style="display: inline;"> as a fast, accurate and quantitative blood-based investigational biomarker/diagnostic to detect and monitor Alzheimer's disease. T</font><font style="display: inline;">he goal is to make the detection of Alzheimer&#x2019;s disease as simple as getting a blood test. </font><font style="display: inline;color:#000000;">We expect to initiate a validation/disease specificity study&nbsp;of SavaDx&nbsp;in 2021.</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Financial Overview</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We have yet to generate any revenues from product sales. We have an accumulated deficit of $174.9</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> at </font><font style="display: inline;">December&nbsp;</font><font style="display: inline;">31, 2020. These losses have resulted principally from costs incurred in connection with research and development activities, salaries and other personnel-related costs and general corporate expenses. Research and development activities include costs of preclinical and clinical studies as well as clinical supplies associated with our product candidates. Salaries and other personnel-related costs include non-cash stock-based compensation associated with options and other equity awards granted to employees and non-employees. Our operating results may fluctuate substantially from period to period as a result of the timing of preclinical activities, enrollment rates of clinical studies for our product candidates and our need for clinical supplies.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We believe that our cash and cash equivalents at </font><font style="display: inline;">December&nbsp;</font><font style="display: inline;">31, 2020, will enable us to fund our operating expenses for at least the next 12 months. In addition, we may seek in the future to fund our operations through additional public or private equity or debt financings or other sources. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If we are unable to obtain financing or reach profitability, the related lack of liquidity will have a material adverse effect on our operations and future prospects.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We expect to continue to use significant cash resources in our operations for the next several years. Our cash requirements for operating activities and capital expenditures may increase substantially in the future as we:</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">initiate a large-scale </font><font style="display: inline;color:#000000;">manufacturing campaign for simufilam;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">plan to initiate a Phase 3 program with simufilam</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">conduct other preclinical and clinical studies for our product candidates;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">seek regulatory approvals for our product candidates; </font></p></td></tr></table></div>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">67</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">develop, formulate, manufacture and commercialize our product candidates; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">implement additional internal systems and develop new infrastructure;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">acquire or in-license additional products or technologies, or expand the use of our technology; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">maintain, defend and expand the scope of our intellectual property; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">hire additional personnel.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Product revenue will depend on our ability to receive regulatory approvals for, and successfully market, our product candidates. If our development efforts result in regulatory approval and successful commercialization of our product candidates, we will generate revenue from direct sales of our drugs and/or, if we license our drugs to future collaborators, from the receipt of license fees and royalties from sales of licensed products. We conduct our research and development programs through a combination of internal and collaborative programs. We rely on arrangements with universities, our collaborators, CDMOs, CROs and clinical research sites for a significant portion of our product development efforts.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;font-family:Courier;text-align:justify;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The following table summarizes expenses which have been reduced for reimbursements received for NIH grants (in</font><font style="display: inline;color:#000000;"> thousands</font><font style="display: inline;color:#000000;">): </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;font-family:Courier;text-align:justify;text-justify:inter-ideograph;font-size: 1pt">
			<font style="display: inline;font-family:Times New Roman;font-size:1pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:2.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:2.25pt;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:2.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:2.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:2.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:2.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:2.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:2.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:2.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:2.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:2.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:2.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:2.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:2.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:2.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:2.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Year ended</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">December 31,</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:11.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Research and development expenses - gross</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.78%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">7,292&nbsp;
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">6,297&nbsp;
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Less:&nbsp;&nbsp;Reimbursement from NIH grants</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">4,239&nbsp;
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">4,729&nbsp;
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> &nbsp;Research and development expenses - net</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.78%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">3,053&nbsp;
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">1,568&nbsp;
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.78%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.20%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;background-color:yellow;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Research and development expenses include compensation, contractor fees and supplies as well as allocated common costs. Contractor fees and supplies generally include expenses for preclinical studies and clinical studies and costs for formulation and manufacturing activities. Other common costs include the allocation of common costs such as facilities. During the year ended </font><font style="display: inline;color:#000000;">December&nbsp;</font><font style="display: inline;color:#000000;">31, 2020 and 2019, we received $4.2</font><font style="display: inline;color:#000000;">&nbsp;million</font><font style="display: inline;color:#000000;"> and $4.7</font><font style="display: inline;color:#000000;">&nbsp;million</font><font style="display: inline;color:#000000;"> from research grants from the NIH. These reimbursements were recorded as a reduction to our research and development expenses.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Our technology has been applied across certain of our portfolio of product candidates. Data, know-how, personnel, clinical results, research results and other matters related to the research and development of any one of our product candidates also relate to, and further the development of, our other product candidates. As a result, costs allocated to a specific product candidate may not necessarily reflect the actual costs surrounding research and development of such product candidate due to cross application of the foregoing.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Estimating the dates of completion of clinical development, and the costs to complete development, of our product candidates would be highly speculative, subjective and potentially misleading. Pharmaceutical products take a significant amount of time to research, develop and commercialize. The clinical study portion of the development of a new drug alone usually spans several years. We expect to reassess our future research and development plans based on our review of data we receive from our current research and development activities. The cost and pace of our future research and development activities are linked and subject to change</font><font style="color:#0000FF;display: inline;text-decoration:none;color:#000000;">.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">Critical Accounting Policies</font>
		</p>
		<p style="margin:0pt;font-family:Courier;text-align:justify;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The preparation of our financial statements in accordance with U.S. generally accepted accounting principles requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and interest income in our financial statements and accompanying notes. We evaluate our estimates on an ongoing basis, including those estimates related to agreements and research collaborations. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">68</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;">may differ from these estimates under different assumptions or conditions. The following items in our financial statements require significant estimates and judgments:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Research Contract Costs and Accruals. </font><font style="display: inline;color:#000000;">The Company has entered into various research and development contracts with research institutions and other third-party vendors. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical accrual estimates have not been materially different from the actual costs.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;color:#000000;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">2020 Cash Incentive Bonus Plan. I</font><font style="display: inline;color:#000000;">n 2020, </font><font style="display: inline;color:#000000;">we</font><font style="display: inline;color:#000000;"> established the 2020 Cash Incentive Bonus Plan (the &#x201C;Plan&#x201D;) to incentivize Plan participants. Awards under the Plan are accounted for as liability awards under ASC 718 </font><font style="display: inline;color:#000000;">&#x201C;Stock-based Compensation&#x201D;.&nbsp;The fair value of each&nbsp;potential Plan&nbsp;award&nbsp;will be&nbsp;determined&nbsp;once&nbsp;a&nbsp;grant date occurs and&nbsp;will be&nbsp;remeasured each reporting period.&nbsp;Compensation expense associated with the Plan&nbsp;will be&nbsp;recognized over the expected achievement period for each&nbsp;Plan award, when&nbsp;a Performance Condition&nbsp;is considered probable of being met.&nbsp; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The Plan was established to promote the long-term success of the Company by creating an &#x201C;at-risk&#x201D; cash bonus program that rewards&nbsp;Plan&nbsp;participants with additional cash compensation in lockstep with significant increases in </font><font style="display: inline;color:#000000;">our</font><font style="display: inline;color:#000000;"> market capitalization. The Plan is considered &#x201C;at-risk&#x201D; because Plan participants&nbsp;will&nbsp;not receive a cash bonus&nbsp;unless&nbsp;</font><font style="display: inline;color:#000000;">our</font><font style="display: inline;color:#000000;"> market capitalization increases&nbsp;significantly and (1) </font><font style="display: inline;color:#000000;">we</font><font style="display: inline;color:#000000;"> complete a&nbsp;merger or acquisition transaction that constitutes a sale of ownership of the Company or its assets (a Merger Transaction) or (2) the Compensation Committee of the Board&nbsp;(the Compensation Committee) determines the Company has sufficient cash on hand, as defined in the Plan, to render payment (each, a &#x201C;Performance Condition&#x201D;),&nbsp;neither&nbsp;of which may ever occur. Because&nbsp;of the inherent discretion and uncertainty regarding&nbsp;these&nbsp;requirements, </font><font style="display: inline;color:#000000;">we</font><font style="display: inline;color:#000000;"> ha</font><font style="display: inline;color:#000000;">ve</font><font style="display: inline;color:#000000;"> concluded that&nbsp;a&nbsp;Plan&nbsp;grant date has not occurred&nbsp;as of December 31, 2020. No actual cash payments were authorized or made to participants under the Plan during the year ended December 31, 2020.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Stock-based </font><font style="display: inline;color:#000000;">C</font><font style="display: inline;color:#000000;">ompensation</font><font style="display: inline;color:#000000;">. We recognize non-cash expense for the fair value of stock options and other share-based awards. We use the Black-Scholes option valuation model to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. </font><font style="display: inline;color:#000000;">It recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally four years.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">We have granted share-based awards that vest upon achievement of certain performance criteria, or performance awards. We multiply the number of performance awards by the fair market value of our common stock on the date of grant to calculate the fair value of each award. We estimate an implicit service period for achieving performance criteria for each award. We recognize the resulting fair value as expense over the implicit service period when we conclude that achieving the performance criteria is probable. We periodically review and update as appropriate our estimates of implicit service periods and determinations on achievement of the performance criteria. Performance awards vest and common stock is issued upon achievement of the performance criteria.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Income Taxes. </font><font style="display: inline;color:#000000;">The Company accounts for income taxes under the asset and liability method. &nbsp;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. &nbsp;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse. &nbsp;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">69</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;">The Company accounts for uncertain tax positions in accordance with ASC 740, &#x201C;Income Taxes&#x201D;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&#x2019;s financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Recent Accounting Pronouncements</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In </font><font style="display: inline;">December 201</font><font style="display: inline;">9, the FABS issued ASU No. 2019-12, </font><font style="display: inline;font-style:italic;">Income Taxes (Topic 740) Simplifying Accounting for Income Taxes </font><font style="display: inline;">as part of its initiative to reduce complexity in the accounting standards. The guidance amended certain disclosure requirements that had become redundant, outdated or superseded. Additionally, this guidance amends accounting for the interim period effects of changes in tax laws or rates, and simplifies aspects of the accounting for franchise taxes. The guidance is effective for annual periods beginning after </font><font style="display: inline;">December&nbsp;</font><font style="display: inline;">15, 2020, and is applicable for the Company in fiscal 2021. Early adoption is permitted. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">In </font><font style="display: inline;color:#000000;">November 201</font><font style="display: inline;color:#000000;">8, the FASB issued ASU No. 2018-18, </font><font style="display: inline;font-style:italic;color:#000000;">Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606. </font><font style="display: inline;color:#000000;">The amendments in this update provide guidance on how to assess whether certain transactions between collaborative arrangement participants should be accounted for within the revenue recognition standard. The amendments in this update are effective for interim and annual periods for the Company beginning on </font><font style="display: inline;color:#000000;">January&nbsp;</font><font style="display: inline;color:#000000;">1, 2020. </font><font style="display: inline;color:#000000;">The adoption of this guidance did not have a material impact on&nbsp;the Company&#x2019;s&nbsp;financial statements.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;background-color: #FFFFFF;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;background-color: #FFFFFF;">In </font><font style="display: inline;color:#000000;background-color: #FFFFFF;">August 201</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">8, the FASB issued ASU </font><font style="display: inline;color:#000000;">No.</font><font style="display: inline;color:#000000;"> 201</font><font style="display: inline;color:#000000;">8-13,</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">&nbsp;</font><font style="display: inline;font-style:italic;color:#000000;">Fair Value Measurement (Topic 820) - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</font><font style="display: inline;color:#000000;background-color: #FFFFFF;"> (ASU </font><font style="display: inline;color:#000000;">2018-13),</font><font style="display: inline;color:#000000;background-color: #FFFFFF;"> which is designed to improve the effectiveness of disclosures by removing, modifying and adding disclosures related to fair value measurements. ASU </font><font style="display: inline;color:#000000;">2018-13</font><font style="display: inline;color:#000000;background-color: #FFFFFF;"> is effective for fiscal years beginning after </font><font style="display: inline;color:#000000;background-color: #FFFFFF;">December&nbsp;</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">15, 2019, including interim periods within those fiscal years. The adoption of ASU 2018-13 did not have a material impact on&nbsp;the Company&#x2019;s&nbsp;financial statements.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Results of Operations</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Research and Development Expense</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Research and development expense consist primarily of costs of drug development work associated with our product candidates, including:</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">clinical studies,</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">preclinical testing,</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">clinical supplies and related formulation and design costs, and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">compensation and other personnel-related expenses.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Research and development expenses increased to $3.1</font><font style="display: inline;color:#000000;">&nbsp;million</font><font style="display: inline;color:#000000;"> in 2020 from $1.6</font><font style="display: inline;color:#000000;">&nbsp;million</font><font style="display: inline;color:#000000;"> in 2019, representing a 95% increase. This </font><font style="display: inline;color:#000000;">increase was due primarily to </font><font style="display: inline;color:#000000;">costs related to manufacture clinical trial supplies</font><font style="display: inline;color:#000000;"> in anticipation of </font><font style="display: inline;color:#000000;">launching a</font><font style="display: inline;color:#000000;"> Phase 3 clinical prog</font><font style="display: inline;color:#000000;">ram </font><font style="display: inline;color:#000000;">in simufilam </font><font style="display: inline;color:#000000;">as well as lower NIH reimbursement compared to the prior year</font><font style="display: inline;color:#000000;">. &nbsp;</font><font style="display: inline;color:#000000;">We received NIH r</font><font style="display: inline;color:#000000;">eimbursement of $4.</font><font style="display: inline;color:#000000;">2</font><font style="display: inline;color:#000000;">&nbsp;million</font><font style="display: inline;color:#000000;"> from research grants in 20</font><font style="display: inline;color:#000000;">20</font><font style="display: inline;color:#000000;"> recorded as a reduction to research and development expense, as compared to $</font><font style="display: inline;color:#000000;">4.7</font><font style="display: inline;color:#000000;">&nbsp;million</font><font style="display: inline;color:#000000;"> in 2019.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Research and development expenses included non-cash stock-based compensation expenses of $0.5</font><font style="display: inline;color:#000000;">&nbsp;million</font><font style="display: inline;color:#000000;"> in both 2020 and 2019.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">We expect research and development expense to increase</font><font style="display: inline;color:#FF0000;">&nbsp;</font><font style="display: inline;color:#000000;">in future periods as we plan to hire new personnel, manufacture drug supply, continue our development efforts and launch a</font><font style="display: inline;color:#000000;"> Phase 3 clinical program </font><font style="display: inline;color:#000000;">in simufilam.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">70</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-style:italic;">General and Administrative Expense</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">General and administrative expenses consist of personnel costs, allocated expenses and other expenses for outside professional services, including legal, human resources, audit and accounting services. Personnel costs consist of salaries, bonus, benefits and stock-based compensation. Allocated expenses consist primarily of facility costs. We incur expenses associated with operating as a public company, including expenses related to compliance with the rules and regulations of the SEC and Nasdaq, additional insurance expenses, additional audit expenses, investor relations activities, SOX compliance expenses and other administrative expenses and professional services. General and administrative expense increased to $3.7</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> in 2020 from $3.4</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> in 2019, representing a 10% increase. </font><font style="display: inline;">The increase</font><font style="display: inline;"> was due primarily to </font><font style="display: inline;">higher insurance expenses </font><font style="display: inline;">and professional fees </font><font style="display: inline;">compared to the prior year</font><font style="display: inline;">, partially offset by lower non-cash stock-based compensation expense</font><font style="display: inline;">.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">General and administrative expenses included non-cash stock-based compensation expenses of $0.5</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> in 2020 compared to $0.8</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> in 2019. We expect general and administrative expense for 2021 will </font><font style="display: inline;">increase compared to</font><font style="display: inline;"> 2020</font><font style="display: inline;"> due to higher </font><font style="display: inline;color:#000000;">operating costs such as insurance, office space and information technology related expenses</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;color:#000000;">Gain on Sale of Property and Equipment</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">During the&nbsp;year ended&nbsp;</font><font style="display: inline;">December&nbsp;</font><font style="display: inline;">31, 2020,&nbsp;we&nbsp;sold surplus manufacturing equipment to an independent third party and received proceeds totaling $360,000. </font><font style="display: inline;">The original&nbsp;cost of the property and equipment was </font><font style="display: inline;">$892,000</font><font style="display: inline;">&nbsp;and accumulated depreciation was </font><font style="display: inline;">$878,000</font><font style="display: inline;">,&nbsp;resulting </font><font style="display: inline;">in </font><font style="display: inline;">a gain on sale&nbsp;of property and equipment of </font><font style="display: inline;">$346,000</font><font style="display: inline;">&nbsp;during the&nbsp;year ended&nbsp;</font><font style="display: inline;">December&nbsp;</font><font style="display: inline;">31, 2020.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">There were no sales of property and equipment during&nbsp;the year ended </font><font style="display: inline;">December&nbsp;</font><font style="display: inline;">31, 2019.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Tahoma;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">We&nbsp;do not&nbsp;expect any future gains&nbsp;on sales&nbsp;of property and equipment.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Interest Income</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Interest and other income, net, was $112,000 in 2020 compared to $328,000 in 2019. The decrease was due primarily to a significant decrease in interest rates in 2020 compared to the prior year.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:normal;">Liquidity and Capital Resources</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Since inception, we have financed our operations primarily through public and private stock offerings, payments received under collaborative agreements and interest earned on our investments. We intend to continue to use our capital resources to fund research and development activities, capital expenditures, working capital requirements and other general corporate purposes. As of </font><font style="display: inline;">December&nbsp;</font><font style="display: inline;">31, 2020, cash and cash equivalents totaled $93.5</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">2021 Registered Direct Offering</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">On </font><font style="display: inline;">February&nbsp;</font><font style="display: inline;">12, 2021, we completed a common stock offering pursuant to which certain investors purchased 4,081,633 shares of common stock at a price of $49.00 per share. Net proceeds of the offering were approximately $189.7</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> after deducting offering expenses.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">2020 </font><font style="display: inline;font-weight:bold;font-style:italic;">Follow-on Public Offering</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;text-decoration:underline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">On </font><font style="display: inline;">November&nbsp;</font><font style="display: inline;">13, 2020, we completed the sale of&nbsp;9,375,000&nbsp;shares of our common stock in an underwritten public offering at a price of&nbsp;$8.00&nbsp;per share. We received net proceeds from the offering of&nbsp;</font><font style="display: inline;">approximately </font><font style="display: inline;">$70</font><font style="display: inline;">.3 million</font><font style="display: inline;">&nbsp;after deducting underwriting discounts and offering expenses.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Common Stock Warrants</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In </font><font style="display: inline;">August 201</font><font style="display: inline;">8, we </font><font style="display: inline;color:#000000;">issued warrants to&nbsp;purchase up to an aggregate of&nbsp;9.1</font><font style="display: inline;color:#000000;">&nbsp;million</font><font style="display: inline;color:#000000;"> shares of its common stock in conjunction with an offering of our common stock.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">During 2019, we received proceeds of $5.9</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> from the exercise of 4.6</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> shares pursuant to warrants. During 2020, we received proceeds of $4.9</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> from the exercise of 4.0</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> shares pursuant to warrants. During 2021, we </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">71</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;">received proceeds of $0.7</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> from the exercise of an additional 0.6</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> shares pursuant to warrants. There were no warrants outstanding following the 2021 exercises.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">At the Market (ATM) Common Stock Issuance </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">On </font><font style="display: inline;color:#000000;font-size:10pt;">March&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">27, 2020, we established an at-the-market offering program (ATM) to sell, from time to time, shares of our common stock having an aggregate offering price of up to&nbsp;$100</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;million</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;in transactions pursuant to a shelf registration statement that was declared effective by the&nbsp;U.S. Securities and Exchange Commission (the SEC)&nbsp;on </font><font style="display: inline;color:#000000;font-size:10pt;">May&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">5, 2020. We are obligated to pay a commission of&nbsp;3.0%&nbsp;of the gross proceeds from the sale of shares of common stock in the offering. We are not obligated to sell any shares in the offering.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Tahoma;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">There were&nbsp;no&nbsp;common stock sales under the ATM during the year ended </font><font style="display: inline;color:#000000;font-size:10pt;">December&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">31, 2020.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">NIH Research Grant Awards</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Our </font><font style="display: inline;color:#000000;">research</font><font style="display: inline;"> has been supported by NIH under multiple research grant awards. Strong, long-term support from NIH has allowed us to advance our two lead product candidates, simufilam and SavaDx, into clinical development.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">In </font><font style="display: inline;color:#000000;font-size:10pt;">March 202</font><font style="display: inline;color:#000000;font-size:10pt;">0, we were awarded a supplemental research funding grant from NIH of up to $374,000.&nbsp; </font><font style="display: inline;color:#000000;font-size:10pt;">In </font><font style="display: inline;color:#000000;font-size:10pt;">April 202</font><font style="display: inline;color:#000000;font-size:10pt;">0, we were awarded a research grant from NIH of up to $2.5</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;million</font><font style="display: inline;color:#000000;font-size:10pt;">. These new, non-dilutive research grants are intended to strengthen our clinical program of&nbsp;simufilam, our investigational drug to treat Alzheimer&#x2019;s disease. All of our NIH research grant awards are paid out </font><font style="display: inline;color:#000000;font-size:10pt;">on a reimbursement basis and require</font><font style="display: inline;color:#000000;font-size:10pt;"> milestone-based technical progress.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">2020 Cash Incentive Bonus Plan Obligation</font><font style="display: inline;font-weight:bold;font-style:italic;">s</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">On </font><font style="display: inline;color:#000000;font-size:10pt;">August&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">26, 2020, the Board approved the </font><font style="display: inline;font-style:italic;color:#000000;font-size:10pt;">2020 Cash Incentive Bonus Plan</font><font style="display: inline;color:#000000;font-size:10pt;"> (the Plan). The Plan was established to promote the long-term success of the Company by </font><font style="display: inline;color:#000000;font-size:10pt;">creat</font><font style="display: inline;color:#000000;font-size:10pt;">ing an &#x201C;at-risk&#x201D; cash bonus program that rewards&nbsp;Plan&nbsp;participants with additional cash compensation in lockstep with significant increases in the Company&#x2019;s </font><font style="display: inline;color:#000000;font-size:10pt;">market capitalization</font><font style="display: inline;color:#000000;font-size:10pt;">. The Plan is considered &#x201C;at-risk&#x201D; because Plan participants&nbsp;will&nbsp;not receive a cash bonus&nbsp;unless&nbsp;the Company&#x2019;s </font><font style="display: inline;color:#000000;font-size:10pt;">market capitalization</font><font style="display: inline;color:#000000;font-size:10pt;"> increases&nbsp;significantly and&nbsp;certain&nbsp;other&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">condition</font><font style="display: inline;color:#000000;font-size:10pt;">s specified in the Plan&nbsp;are met.&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">Specifically</font><font style="display: inline;color:#000000;font-size:10pt;">, Plan participants&nbsp;will&nbsp;not&nbsp;be paid&nbsp;any </font><font style="display: inline;color:#000000;font-size:10pt;">cash bonuses unless </font><font style="display: inline;color:#000000;font-size:10pt;">(1) the Company completes a&nbsp;merger or acquisition transaction that constitutes a sale of ownership of the Company or its assets (a Merger Transaction) or (2) </font><font style="display: inline;color:#000000;font-size:10pt;">the Compensation Committee</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;determines the Company has sufficient cash on hand, as defined in the Plan. Plan participants will be paid all earned</font><font style="display: inline;color:#000000;font-size:10pt;"> cash bonuses in the event of a Merger Transaction.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">The Company</font><font style="display: inline;color:#000000;font-size:10pt;">&#x2019;s</font><font style="display: inline;color:#000000;font-size:10pt;"> market capitalization, </font><font style="display: inline;color:#000000;font-size:10pt;">including all outstanding stock options</font><font style="display: inline;color:#000000;font-size:10pt;">, &nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">was</font><font style="display: inline;color:#000000;font-size:10pt;"> $89.4</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;million</font><font style="display: inline;color:#000000;font-size:10pt;"> at the inception of the Plan on </font><font style="display: inline;color:#000000;font-size:10pt;">August&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">26, 2020. </font><font style="display: inline;color:#000000;font-size:10pt;">If the Company </font><font style="display: inline;color:#000000;font-size:10pt;">were to </font><font style="display: inline;color:#000000;font-size:10pt;">exceed a $5</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;billion</font><font style="display: inline;color:#000000;font-size:10pt;"> market capitalization&nbsp;for no less than 20 consecutive </font><font style="display: inline;color:#000000;font-size:10pt;">trading days</font><font style="display: inline;color:#000000;font-size:10pt;">, and conditions </font><font style="display: inline;color:#000000;font-size:10pt;">noted above for</font><font style="display: inline;color:#000000;font-size:10pt;"> payment are met</font><font style="display: inline;color:#000000;font-size:10pt;">, all&nbsp;Plan milestones would be deem</font><font style="display: inline;color:#000000;font-size:10pt;">ed achieved, in which case </font><font style="display: inline;color:#000000;font-size:10pt;">total </font><font style="display: inline;color:#000000;font-size:10pt;">cash bonus awards would&nbsp;range from&nbsp;a minimum of&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">$137.4</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;million</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;up to&nbsp;a </font><font style="display: inline;color:#000000;font-size:10pt;">hypothetical </font><font style="display: inline;color:#000000;font-size:10pt;">m</font><font style="display: inline;color:#000000;font-size:10pt;">aximum of&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">$322.3</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;million</font><font style="display: inline;color:#000000;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">The Company&#x2019;s potential financial obligation to plan participants at </font><font style="display: inline;color:#000000;font-size:10pt;">December&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">31, 2020 totaled $7.3</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;million</font><font style="display: inline;color:#000000;font-size:10pt;">, based upon the achievement of one Plan milestone in the Company&#x2019;s market capitalization. No actual cash bonus payments have been made to any Plan participant, as the Company has not yet satisfied all the conditions necessary for amounts to be paid under the Plan. Subsequent to </font><font style="display: inline;color:#000000;font-size:10pt;">December&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">31, 2020, the Company&#x2019;s market capitalization increased substantially. These increases triggered the achievement of </font><font style="display: inline;color:#000000;font-size:10pt;">eight</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">additional Plan milestones. Collectively, the achievement of such milestones could trigger potential Company obligations to Plan participants ranging from a minimum of $59.9</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;million</font><font style="display: inline;color:#000000;font-size:10pt;"> up to a hypothetical maximum of $145.0</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;million</font><font style="display: inline;color:#000000;font-size:10pt;">, with exact amounts to be determined by the Compensation Committee. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">No actual cash payments were made to participants under the Plan during the year ended </font><font style="display: inline;color:#000000;font-size:10pt;">December&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">31, 2020</font><font style="display: inline;color:#000000;font-size:10pt;">, or through the filing date of this Form 10-</font><font style="display: inline;color:#000000;font-size:10pt;">K</font><font style="display: inline;color:#000000;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Use of Cash</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Net cash used in operating activities was $5.4</font><font style="display: inline;color:#000000;">&nbsp;million</font><font style="display: inline;color:#000000;"> for the&nbsp;year ended&nbsp;</font><font style="display: inline;color:#000000;">December&nbsp;</font><font style="display: inline;color:#000000;">31, 2020, resulting primarily from the net loss reported of $6.3</font><font style="display: inline;color:#000000;">&nbsp;million</font><font style="display: inline;color:#000000;"> and&nbsp;a gain on sale of property and equipment of $0.3</font><font style="display: inline;color:#000000;">&nbsp;million</font><font style="display: inline;color:#000000;">,&nbsp;partially offset by non-cash stock-based compensation expense of $1.0</font><font style="display: inline;color:#000000;">&nbsp;million</font><font style="display: inline;color:#000000;"> and changes in operating assets and liabilities of $0.3</font><font style="display: inline;color:#000000;">&nbsp;million</font><font style="display: inline;color:#000000;">.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">72</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Net cash used in operating activities was $2.5</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> for 2019, </font><font style="display: inline;color:#000000;">resulting primarily from a $4.6</font><font style="display: inline;color:#000000;">&nbsp;million</font><font style="display: inline;color:#000000;"> net loss incurred partially offset by $1.3</font><font style="display: inline;color:#000000;">&nbsp;million</font><font style="display: inline;color:#000000;"> of non-cash stock-based compensation expense and $0.8</font><font style="display: inline;color:#000000;">&nbsp;million</font><font style="display: inline;color:#000000;"> from changes in operating assets and liabilities.</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Net cash provided by investing activities during the&nbsp;year ended&nbsp;</font><font style="display: inline;color:#000000;">December&nbsp;</font><font style="display: inline;color:#000000;">31, 2020 was $360,000 for proceeds received from the sale of property and equipment.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Net cash used in investing activities was $18,000 for 2019 from purchases of computer equipment.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Net cash provided by financing activities </font><font style="display: inline;color:#000000;">during the&nbsp;year ended&nbsp;</font><font style="display: inline;color:#000000;">December&nbsp;</font><font style="display: inline;color:#000000;">31, 2020 </font><font style="display: inline;">was $75.4</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> consisting of $70.3</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> proceeds from our follow-on public offering of common stock in </font><font style="display: inline;">November 202</font><font style="display: inline;">0, $4.9</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> proceeds from exercise of common stock warrants and $0.3</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> from exercise of stock options.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Net cash provided by financing activities for 2019 was $5.8</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> consisting of $5.9</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> proceeds from exercise of common stock warrants partially offset by $0.1</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> in offering expenses related the 2018 sale of common stock and warrants.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Realization of our deferred tax assets is dependent on future earnings, if any. We are uncertain about the timing and amount of any future earnings. Accordingly, we offset these net deferred tax assets with a valuation allowance.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We lease approximately 6,000 square feet of office space pursuant to a non-cancelable operating lease in Austin, TX that expires in </font><font style="display: inline;">April 202</font><font style="display: inline;">4. Future lease payments are as follows (in</font><font style="display: inline;"> thousands</font><font style="display: inline;">):</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-size:9pt;">For the year ending December 31,</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">2021</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">66&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">2022</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">102&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">2023</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">107&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">2024</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">36&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">Total future lease payments</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">311&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:6.75pt;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:6.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:6.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:6.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We have an accumulated deficit of $174.9</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> at </font><font style="display: inline;">December&nbsp;</font><font style="display: inline;">31, 2020. We expect our cash requirements to be significant in the future. The amount and timing of our future cash requirements will depend on regulatory and market acceptance of our product candidates and the resources we devote to researching and developing, formulating, manufacturing, commercializing and supporting our products. We believe that our current resources should be sufficient to fund our operations for at least the next 12 months. We may seek additional future funding through public or private financing in the future, if such funding is available and on terms acceptable to us.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font><a name="_DV_C136"></a>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="color:#0000FF;display: inline;font-weight:bold;color:#000000;text-decoration:none;">Off-balance Sheet Arrangements</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<a name="_DV_C137"></a><font style="color:#0000FF;display: inline;color:#000000;text-decoration:none;">As of </font><font style="color:#0000FF;display: inline;color:#000000;text-decoration:none;">December&nbsp;</font><font style="color:#0000FF;display: inline;color:#000000;text-decoration:none;">31, 2020, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we do not engage in trading activities involving non-exchange traded contracts. Therefore, we are not materially exposed to financing, liquidity, market or credit risk that could arise if we had engaged in these relationships. We do not have relationships or transactions with persons or entities that derive benefits from their non-independent relationship with us or our related parties.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Item 7A.</font><font style="display: inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;">Quantitative and Qualitative Disclosures about Market Risk</font><a name="Quantitative_And_Qualitative_Disclosures"></a>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Pursuant to Item 305(e) of Regulation S-K, the information called for by Item 7A is not required.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">73</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-weight:bold;">Item 8.</font><font style="display: inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;">Financial Statements and Supplementary Data</font><a name="Financial_Statements_Supplementary_Data"></a>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">INDEX TO FINANCIAL STATEMENTS</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:93.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.6pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.6pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:93.08%;padding:0pt 6.6pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:06.92%;padding:0pt 6.6pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;text-decoration:underline;">Page</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:93.08%;background-color: #CCEEFF;padding:0pt 6.6pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="#Report_Of_Independent_Firm"><font style="display: inline;">Report of Independent Registered Public Accounting Firm</font></a></p>
				</td>
				<td valign="top" style="width:06.92%;background-color: #CCEEFF;padding:0pt 6.6pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;">74</font><font style="display: inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:93.08%;padding:0pt 6.6pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="#Balance_Sheets"><font style="display: inline;">Balance Sheets</font></a></p>
				</td>
				<td valign="top" style="width:06.92%;padding:0pt 6.6pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;">76</font><font style="display: inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:93.08%;background-color: #CCEEFF;padding:0pt 6.6pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="#Statements_Of_Operations"><font style="display: inline;">Statements of Operations</font></a></p>
				</td>
				<td valign="top" style="width:06.92%;background-color: #CCEEFF;padding:0pt 6.6pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;">77</font><font style="display: inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:93.08%;background-color: #auto;padding:0pt 6.6pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="#Stockholders_Equity"><font style="display: inline;">Statements of Stockholders' Equity</font></a><font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:06.92%;background-color: #auto;padding:0pt 6.6pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;">78</font><font style="display: inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:93.08%;background-color: #CCEEFF;padding:0pt 6.6pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="#Cash_Flows"><font style="display: inline;">Statements of Cash Flows</font></a></p>
				</td>
				<td valign="top" style="width:06.92%;background-color: #CCEEFF;padding:0pt 6.6pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;">79</font><font style="display: inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:93.08%;background-color: #auto;padding:0pt 6.6pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="#Notes_To_Financial_Statements"><font style="display: inline;">Notes to Financial Statements</font></a></p>
				</td>
				<td valign="top" style="width:06.92%;background-color: #auto;padding:0pt 6.6pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;"></font><font style="display: inline;">80</font><font style="display: inline;"></font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">74</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<a name="Report_Of_Independent_Firm"></a><font style="display: inline;font-weight:bold;">Report of Independent Registered Public Accounting Firm</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">To the Stockholders and the Board of Directors of Cassava Sciences, Inc.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Opinion on the Financial Statements </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We have audited the accompanying balance sheets of Cassava Sciences, Inc. (the Company) as of </font><font style="display: inline;">December&nbsp;</font><font style="display: inline;">31, 2020 and 2019, the related statements of operations,&nbsp;stockholders' equity and cash flows for the years then ended, and the related notes</font><font style="display: inline;font-size:5pt;vertical-align:super;line-height:100%">&nbsp;</font><font style="display: inline;">(collectively referred to as the &#x201C;financial statements&#x201D;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at </font><font style="display: inline;">December&nbsp;</font><font style="display: inline;">31, 2020 and 2019, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Basis for Opinion</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion</font><font style="display: inline;color:#000000;"> on the Company&#x2019;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Critical Audit Matter</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<a name="_Hlk53148191"></a><a name="_Hlk53148173"></a>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">75</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-weight:bold;">Accrued Development </font><font style="display: inline;font-weight:bold;">Expenses</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;text-align:justify;text-justify:inter-ideograph;margin-left:0pt;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:12.62%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:87.38%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:12.62%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-style:italic;font-size:9pt;">Description of</font></p>
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-style:italic;font-size:9pt;">the Matter</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:87.38%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">As explained in Note 2 to the financial statements, the Company has various research and development contracts with research institutions and other third-party vendors, the costs under which are recorded as research and development expenses as incurred. The Company records an accrual for estimated ongoing research and development costs incurred but not yet billed at the end of each reporting period. At December 31, 2020, accrued development expense totaled $719,000, resulting primarily from patient clinical trials and ongoing drug manufacturing activities.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:12.62%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-style:italic;font-size:9pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:87.38%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:12.62%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-style:italic;font-size:9pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:87.38%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Auditing the Company&#x2019;s accrued development expense was challenging because the accrual involved a higher degree of management judgment to estimate costs incurred for patient clinical trials and drug manufacturing activities at the end of the reporting period. An estimate of the costs incurred was necessary due to the long duration of the clinical trials, the progress of drug manufacturing activities, and the delayed timing of invoices received from third parties. </font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:12.62%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-style:italic;font-size:9pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:87.38%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:12.62%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-style:italic;font-size:9pt;">How We</font></p>
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-style:italic;font-size:9pt;">Addressed th</font><font style="display: inline;font-style:italic;font-size:9pt;">e</font></p>
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-style:italic;font-size:9pt;"> Matter in Our</font></p>
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-style:italic;font-size:9pt;">Audit</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:87.38%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">To evaluate the adequacy of the Company&#x2019;s accrued development expense, our audit procedures included, among others, testing the accuracy and completeness of the underlying data used in the estimate, evaluating the significant assumptions used by management to estimate the accrual, and recalculating the accrual. To evaluate the significant assumptions (i.e., progress of patient clinical trials, progress of drug manufacturing activities), on a sample basis, we obtained external confirmation of key clinical trial contract terms and conditions directly from third parties, agreed information used in the estimate to the contracts with third parties and any amendments thereto, and corroborated the progress of clinical trials and drug manufacturing activities through inquiry of Company personnel who oversee research and development efforts. We also obtained and reviewed subsequent invoices received from third parties to corroborate the accrual at the end of the reporting period.</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:left;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:hanging;vertical-align:baseline;font-family:Times;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:left;border-top:1pt none #D9D9D9 ;punctuation-wrap:hanging;vertical-align:baseline;font-family:Times;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">/s/ Ernst &amp; Young LLP </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;background-color:yellow;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We have served as the Company&#x2019;s auditor since 2002.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Austin, Texas</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">March 23, 2021</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">76</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-weight:bold;font-size:1pt;">&#xFEFF;</font><a name="Balance_Sheets"></a>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="7" valign="bottom" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:12pt;">CASSAVA SCIENCES, INC.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="7" valign="bottom" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:12pt;">BALANCE SHEETS</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="7" valign="bottom" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">(In thousands, except share and par value data)</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="7" valign="bottom" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:27.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">December 31,</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">2020</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="7" valign="bottom" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">ASSETS</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Current assets:</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Cash and cash equivalents</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">93,506&nbsp;
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">23,081&nbsp;
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Other current assets</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">488&nbsp;
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">268&nbsp;
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Total current assets</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">93,994&nbsp;
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">23,349&nbsp;
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Operating lease right-of-use assets</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">295&nbsp;
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">90&nbsp;
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Property and equipment, net</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">11&nbsp;
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">47&nbsp;
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Total assets</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">94,300&nbsp;
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">23,486&nbsp;
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.36%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.94%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="7" valign="bottom" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">LIABILITIES AND STOCKHOLDERS' EQUITY</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Current liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Accounts payable</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">911&nbsp;
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">453&nbsp;
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Accrued development expense</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">719&nbsp;
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">777&nbsp;
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Accrued compensation and benefits</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">83&nbsp;
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">58&nbsp;
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Operating lease liabilities, current</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">58&nbsp;
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">90&nbsp;
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Other current liabilities</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">94&nbsp;
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">9&nbsp;
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Total current liabilities</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,865&nbsp;
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,387&nbsp;
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Operating lease liabilities, non-current</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">235&nbsp;
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Total liabilities</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,100&nbsp;
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,387&nbsp;
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Commitments and contingencies (Notes 7 and 8)</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Stockholders' equity:</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Preferred stock, </font><font style="display: inline;color:#000000;">$.001</font><font style="display: inline;color:#000000;"> par value; </font><font style="display: inline;color:#000000;">10,000,000</font><font style="display: inline;color:#000000;"> shares authorized, </font><font style="display: inline;color:#000000;">none</font><font style="display: inline;color:#000000;"> issued and outstanding</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Common stock, </font><font style="display: inline;color:#000000;">$.001</font><font style="display: inline;color:#000000;"> par value; </font><font style="display: inline;color:#000000;">120,000,000</font><font style="display: inline;color:#000000;"> shares authorized; </font><font style="display: inline;color:#000000;">35,237,987</font><font style="display: inline;color:#000000;"> and </font><font style="display: inline;color:#000000;">21,841,810</font><font style="display: inline;color:#000000;"> shares issued and outstanding at December 31, 2020 and 2019, respectively</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">35&nbsp;
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">22&nbsp;
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Additional paid-in capital</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">267,086&nbsp;
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">190,664&nbsp;
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Accumulated deficit</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(174,921)
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(168,587)
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Total stockholders' equity </font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">92,200&nbsp;
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">22,099&nbsp;
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Total liabilities and stockholders' equity</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">94,300&nbsp;
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">23,486&nbsp;
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.36%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.94%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">See accompanying notes to financial statements.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">77</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font><a name="Statements_Of_Operations"></a>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="7" valign="bottom" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:12pt;">CASSAVA SCIENCES, INC.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="7" valign="bottom" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:12pt;">STATEMENTS OF OPERATIONS</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="7" valign="bottom" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">(In thousands, except per share data)</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="7" valign="bottom" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:27.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:27.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Year ended December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Operating expenses:</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Research and development, net of grant reimbursement</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,053&nbsp;
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,568&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">General and administrative </font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,739&nbsp;
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,391&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Gain on sale of property and equipment</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(346)
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Total operating expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">6,446&nbsp;
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,959&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Operating loss</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(6,446)
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(4,959)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Interest income</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">112&nbsp;
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">328&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(6,334)
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(4,631)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Net loss per share, basic and diluted</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(0.24)
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(0.27)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Shares used in computing net loss per share, basic and diluted</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">26,105&nbsp;
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">17,412&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">See accompanying notes to financial statements.</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			&nbsp;
		</p></div><div style="margin-left:72pt;margin-right:72pt;">
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">&nbsp;</font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">78</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-weight:bold;font-size:1pt;">&#xFEFF;</font><a name="Stockholders_Equity"></a>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:47.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:08.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:08.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="17" valign="bottom" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:12pt;">CASSAVA SCIENCES, INC.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:08.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="17" valign="bottom" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">STATEMENTS OF STOCKHOLDERS' EQUITY</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="17" valign="bottom" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">(in thousands)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:08.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:08.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:08.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:7pt;">Accumulated</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="4" valign="bottom" style="width:15.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:7pt;">other</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:7pt;">Total</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="4" valign="bottom" style="width:15.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:7pt;">Common stock</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:7pt;">Additional</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:7pt;">comprehensive</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:7pt;">Accumulated</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:7pt;">stockholders'</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:08.72%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:7pt;">Shares</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:05.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:7pt;">Par value</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:7pt;">paid-in capital</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:7pt;">income</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:7pt;">deficit</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:7pt;">equity</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;"> Balance at December 31, 2018</font></p>
				</td>
				<td valign="bottom" style="width:08.72%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">17,219,300&nbsp;
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:04.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">17&nbsp;
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">183,567&nbsp;
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(163,956)
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">19,628&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Non-cash stock-based compensation for:</font></p>
				</td>
				<td valign="bottom" style="width:08.72%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.92%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Stock options for employees</font></p>
				</td>
				<td valign="bottom" style="width:08.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,287&nbsp;
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,287&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Stock options for non-employees</font></p>
				</td>
				<td valign="bottom" style="width:08.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">9&nbsp;
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">9&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Issuance costs from 2018 sale of common stock and warrants</font></p>
				</td>
				<td valign="bottom" style="width:08.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(60)
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(60)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Issuance of common stock pursuant to exercise of warrants</font></p>
				</td>
				<td valign="bottom" style="width:08.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,622,510&nbsp;
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5&nbsp;
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5,861&nbsp;
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5,866&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:08.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(4,631)
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(4,631)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;"> Balance at December 31, 2019</font></p>
				</td>
				<td valign="bottom" style="width:08.72%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">21,841,810&nbsp;
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:04.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">22&nbsp;
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">190,664&nbsp;
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(168,587)
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">22,099&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Non-cash stock-based compensation for:</font></p>
				</td>
				<td valign="bottom" style="width:08.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Stock options for employees</font></p>
				</td>
				<td valign="bottom" style="width:08.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">961&nbsp;
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">961&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Stock options for non-employees</font></p>
				</td>
				<td valign="bottom" style="width:08.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">27&nbsp;
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">27&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Issuance of common stock pursuant to exercise of stock options</font></p>
				</td>
				<td valign="bottom" style="width:08.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">71,105&nbsp;
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">256&nbsp;
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">256&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Issuance of common stock pursuant to exercise of warrants</font></p>
				</td>
				<td valign="bottom" style="width:08.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,950,072&nbsp;
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4&nbsp;
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,936&nbsp;
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,940&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Common stock issued in conjunction with follow-on public offering, net of issuance costs</font></p>
				</td>
				<td valign="bottom" style="width:08.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">9,375,000&nbsp;
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">9&nbsp;
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">70,242&nbsp;
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">70,251&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:08.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(6,334)
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(6,334)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;"> Balance at December 31, 2020</font></p>
				</td>
				<td valign="bottom" style="width:08.72%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">35,237,987&nbsp;
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:04.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">35&nbsp;
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">267,086&nbsp;
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(174,921)
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">92,200&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:08.72%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.92%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.60%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">See accompanying notes to financial statements.</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			&nbsp;
		</p></div><div style="margin-left:72pt;margin-right:58pt;">
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">79</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 1pt"><font style="display: inline;font-weight:bold;font-size:1pt;">&#xFEFF;</font><a name="Cash_Flows"></a>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="6" valign="bottom" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:12pt;">CASSAVA SCIENCES, INC.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="6" valign="bottom" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:12pt;">STATEMENTS OF CASH FLOWS</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="6" valign="bottom" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">(In thousands)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:27.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:27.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Year ended December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Cash flows from operating activities:</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(6,334)
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(4,631)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Adjustments to reconcile net loss to net cash used in operating activities:</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Non-cash stock-based compensation</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">988&nbsp;
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,296&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Depreciation and amortization</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">22&nbsp;
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">58&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Gain on sale of property and equipment</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(346)
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Changes in operating assets and liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Other current assets</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(220)
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(23)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Operating lease right-of-use assets and liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(2)
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Accounts payable</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">458&nbsp;
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">159&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Accrued development expense</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(58)
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">621&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Accrued compensation and benefits</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">25&nbsp;
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(3)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Other current liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">85&nbsp;
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">9&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Net cash used in operating activities</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(5,382)
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(2,514)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Cash flows from investing activities:</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Purchases of property and equipment</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(18)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Proceeds from sale of property and equipment</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">360&nbsp;
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Net cash provided by (used in) investing activities</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">360&nbsp;
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(18)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Cash flows from financing activities:</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Issuance costs from 2018 sale of common stock and warrants</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(60)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Proceeds from exercise of stock options</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">256&nbsp;
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Proceeds from exercise of common stock warrants</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,940&nbsp;
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5,866&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Proceeds from follow-on public offering, net of issuance costs</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">70,251&nbsp;
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Net cash provided by financing activities</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">75,447&nbsp;
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5,806&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Net increase in cash and cash equivalents</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">70,425&nbsp;
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,274&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Cash and cash equivalents at beginning of period</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">23,081&nbsp;
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">19,807&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Cash and cash equivalents at end of period</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">93,506&nbsp;
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">23,081&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.66%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.22%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">See accompanying notes to financial statements. </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">80</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">CASSAVA SCIENCES, INC.</font><a name="Notes_To_Financial_Statements"></a>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">1.&nbsp;&nbsp;General and Liquidity</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Cassava Sciences, Inc. (the Company), formerly known as Pain Therapeutics, Inc., develops proprietary </font><font style="display: inline;">products </font><font style="display: inline;">that offer significant improvements to patients and healthcare professionals. The Company generally focuses its </font><font style="display: inline;">product</font><font style="display: inline;"> development efforts on disorders of the nervous system. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">Coronavirus Disease 2019 (COVID-19)</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The</font><font style="display: inline;"> recent, widespread outbreak of a novel infectious disease called Coronavirus Disease 2019, or COVID-19, has not significantly impacted the Company&#x2019;s operations or financial condition as of </font><font style="display: inline;">March&nbsp;</font><font style="display: inline;">23</font><font style="display: inline;">, 2021. </font><font style="display: inline;">However, this pandemic has created a dynamic and uncertain situation in the national economy. The Company continues to closely monitor the latest information to make timely, informed business decisions and public disclosures regarding the potential impact of pandemic on its operations and financial condition. The scope of pandemic is unprecedented and its long-term impact on the Company&#x2019;s operations and financial condition cannot be reasonably estimated at this time.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Liquidity&nbsp; </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company has incurred significant net losses and negative cash flows since inception, and as a result has an accumulated deficit of </font><font style="display: inline;">$174.9</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> at </font><font style="display: inline;">December&nbsp;</font><font style="display: inline;">31, 20</font><font style="display: inline;">20</font><font style="display: inline;">. The Company expects its cash requirements to be significant in the future. The amount and timing of its future cash requirements will depend on regulatory and market acceptance of the Company&#x2019;s product candidates and the resources it devotes to researching and developing, formulating, manufacturing, commercializing and supporting its products. The Company may seek additional future funding through public or private financing in the future, if such funding is available and on terms acceptable to the Company.</font><font style="display: inline;"> There are no assurances that additional financing will be available on favorable terms, or at all. However, management believes that the current working capital position will be sufficient to meet the Company&#x2019;s working capital needs for at least the next 12 months.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">2.&nbsp;&nbsp;Summary of Significant Accounting Policies</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Use of Estimates</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. Actual results could differ from those estimates.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Proceeds from Grants</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In 20</font><font style="display: inline;">20</font><font style="display: inline;">, the Company received $4.</font><font style="display: inline;">2</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> of reimbursement from the National Institutes of Health and National Institute on Drug Abuse and $</font><font style="display: inline;">4.7</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> in 201</font><font style="display: inline;">9</font><font style="display: inline;">. The Company records the proceeds from these grants as reductions to its research and development expenses.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Cash and Cash Equivalents and Concentration of Credit Risk</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company invests in cash and cash equivalents and, in the past, marketable securities. The Company considers highly-liquid financial instruments with original maturities of three months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market </font><font style="display: inline;">accounts, money market </font><font style="display: inline;">funds</font><font style="display: inline;"> and</font><font style="display: inline;"> certificates of deposit. The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company&#x2019;s investment policy allows for investments in marketable securities with active secondary or resale markets, establishes diversification and credit quality requirements and limits investments by maturity and issuer. The Company maintains its investments at one financial institution. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">81</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-weight:bold;font-style:italic;">Fair Value Measurements </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company reports its cash and cash equivalents at fair value as Level 1, Level 2 or Level 3 using the following inputs:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Level 1 includes quoted prices in active markets. The Company bases the fair value of money market funds on Level 1 inputs.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Level 2 includes significant observable inputs, such as quoted prices for identical or similar investments, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from third-party providers. It uses the bid price to establish fair value where a bid price is available. The Company bases the fair value of its certificates of deposit, if any, on Level 2 inputs.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Level 3 includes unobservable inputs that are supported by little or no market activity. The Company does not have any investments where the fair value is based on Level 3 inputs.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. </font><font style="display: inline;color:#000000;">A certificate of deposit totaling $13.0</font><font style="display: inline;color:#000000;">&nbsp;million</font><font style="display: inline;color:#000000;"> at </font><font style="display: inline;color:#000000;">December&nbsp;</font><font style="display: inline;color:#000000;">31, 2019 was included within cash equivalents as a Level 2 input.</font><font style="display: inline;color:#000000;"> The fair value of the remainder of cash and cash equivalents</font><font style="display: inline;color:#000000;">, including money market accounts,</font><font style="display: inline;color:#000000;"> was based on Level 1 inputs at </font><font style="display: inline;color:#000000;">December&nbsp;</font><font style="display: inline;color:#000000;">31, 20</font><font style="display: inline;color:#000000;">20</font><font style="display: inline;color:#000000;"> and 20</font><font style="display: inline;color:#000000;">19</font><font style="display: inline;color:#000000;">.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Business Segments</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&#x2019;s operations are confined to one business segment: the development of novel drugs and diagnostics.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Stock-based Compensation</font><font style="display: inline;font-weight:bold;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each </font><a name="_cp_text_1_372"></a><font style="display: inline;color:#000000;">award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management's judgment.</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">The Company recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally four years. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The Company has granted share-based awards that vest upon achievement of certain performance criteria, or performance awards. The Company multiplies the number of performance awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. The Company periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance awards vest and common stock is issued upon achievement of the performance criteria.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">82</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-weight:bold;font-style:italic;">Net Loss per Share</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Basic net loss per share is computed on the basis of the weighted-average number of common shares outstanding for the reporting period. Diluted net loss per share is computed on the basis of the weighted-average number of common shares outstanding plus dilutive potential common shares outstanding using the treasury-stock method. Potential dilutive common shares consist of outstanding equity awards and warrants. There is no difference between the Company&#x2019;s net loss and comprehensive loss. The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in</font><font style="display: inline;"> thousands</font><font style="display: inline;">, except </font><font style="display: inline;">net loss </font><font style="display: inline;">per share data</font><font style="display: inline;">):</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:24.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:24.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Year ended December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Numerator:</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">(6,334)
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">(4,631)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Denominator:</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Shares used in computing net loss per share, basic and diluted</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">26,105&nbsp;
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">17,412&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Net loss per share, basic and diluted</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">(0.24)
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">(0.27)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> Dilutive common stock options excluded from net loss per share, diluted</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">2,145&nbsp;
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">2,932&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> Common stock warrants excluded from net loss per share, diluted</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">554&nbsp;
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">4,504&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company excluded weighted equity awards and warrants outstanding to purchase common stock from the calculation of diluted net loss per share because the effect of including these shares in this calculation would be anti-dilutive.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-family:Tahoma;font-size:1pt;">&#xFEFF;</font><font style="display: inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Fair Value of Financial Instruments</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Financial instruments include cash and cash equivalents, accounts payable and accrued liabilities. The estimated fair value of financial instruments has been determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies may be material to the estimated fair value amounts. The carrying amounts of cash and cash equivalents, accounts payable and accrued liabilities are at cost, which approximates fair value due to the short maturity of those instruments.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Research Contract Costs and Accruals</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The Company has entered into various research and development contracts with research institutions and other third-party vendors. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical accrual estimates have not been materially different from actual costs.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Incentive Bonus Plan</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">In 2020, the Company established the 2020 Cash Incentive Bonus Plan (the &#x201C;Plan&#x201D;) to incentivize Plan participants.&nbsp;&nbsp;Awards under the Plan are accounted for as liability awards under ASC 718 &#x201C;</font><font style="display: inline;font-style:italic;color:#000000;">Stock-based Compensation</font><font style="display: inline;color:#000000;">&#x201D;.&nbsp;The fair value of each&nbsp;potential Plan&nbsp;award&nbsp;will be&nbsp;determined&nbsp;once&nbsp;a&nbsp;grant date occurs and&nbsp;will be&nbsp;remeasured each reporting period.&nbsp;Compensation expense associated with the Plan&nbsp;will be&nbsp;recognized over the expected achievement period for each&nbsp;Plan award, when&nbsp;a Performance Condition&nbsp;is considered probable of being met.&nbsp;&nbsp;See Note 8 for further discussion of the Plan.</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Leases</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">83</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;">The Company recognizes&nbsp;assets and liabilities that arise from leases.&nbsp;For operating leases, the Company is required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, in the&nbsp;statements&nbsp;of financial position.&nbsp;As the Company`s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the</font><font style="display: inline;"> lease term.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Income Taxes</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company accounts for income taxes under the asset and liability method.&nbsp;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. &nbsp;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&nbsp;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company accounts for uncertain tax positions in accordance with ASC 740, &#x201C;Income Taxes&#x201D;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&#x2019;s financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Recent Accounting Pronouncements</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company reviewed recently issued accounting pronouncements and plan to adopt those that are applicable to it, and does not expect the adoption of these pronouncements to have a material impact on its financial position, results of operations or cash flows. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In </font><font style="display: inline;">December 201</font><font style="display: inline;">9, the FABS issued ASU No. 2019-12, </font><font style="display: inline;font-style:italic;">Income Taxes (Topic 740) Simplifying Accounting for Income Taxes </font><font style="display: inline;">as part of its initiative to reduce complexity in the accounting standards. The guidance amended certain disclosure requirements that had become redundant, outdated or superseded. Additionally, this guidance amends accounting for the interim period effects of changes in tax laws or rates and simplifies aspects of the accounting for franchise taxes. The guidance is effective for annual periods beginning after </font><font style="display: inline;">December&nbsp;</font><font style="display: inline;">15, 2020, and is applicable for the Company in fiscal </font><font style="display: inline;">year </font><font style="display: inline;">2021. Early adoption is permitted. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">In </font><font style="display: inline;color:#000000;">November 201</font><font style="display: inline;color:#000000;">8, the FASB issued ASU No. 2018-18, </font><font style="display: inline;font-style:italic;color:#000000;">Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606. </font><font style="display: inline;color:#000000;">The amendments in this update provide guidance on how to assess whether certain transactions between collaborative arrangement participants should be accounted for within the revenue recognition standard. The amendments in this update are effective for interim and annual periods for the Company beginning on </font><font style="display: inline;color:#000000;">January&nbsp;</font><font style="display: inline;color:#000000;">1, 2020. </font><font style="display: inline;color:#000000;">The adoption of this guidance did not have a material impact on&nbsp;the Company&#x2019;s&nbsp;financial statements.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;background-color: #FFFFFF;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;background-color: #FFFFFF;">In </font><font style="display: inline;color:#000000;background-color: #FFFFFF;">August 201</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">8, the FASB issued ASU </font><font style="display: inline;color:#000000;">No.</font><font style="display: inline;color:#000000;"> 201</font><font style="display: inline;color:#000000;">8-13,</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">&nbsp;</font><font style="display: inline;font-style:italic;color:#000000;">Fair Value Measurement (Topic 820) - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</font><font style="display: inline;color:#000000;background-color: #FFFFFF;"> (ASU </font><font style="display: inline;color:#000000;">2018-13),</font><font style="display: inline;color:#000000;background-color: #FFFFFF;"> which is designed to improve the effectiveness of disclosures by removing, modifying and adding disclosures related to fair value measurements. ASU </font><font style="display: inline;color:#000000;">2018-13</font><font style="display: inline;color:#000000;background-color: #FFFFFF;"> is effective for fiscal years beginning after </font><font style="display: inline;color:#000000;background-color: #FFFFFF;">December</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">&nbsp;</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">15, 2019, including interim periods within those fiscal years. </font><font style="display: inline;color:#000000;background-color: #FFFFFF;">The adoption of ASU 2018-13 did not have a material impact on&nbsp;the Company&#x2019;s&nbsp;financial statements.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">3</font><font style="display: inline;font-weight:bold;">.&nbsp;&nbsp;Property and Equipment</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company&#x2019;s property and equipment</font><font style="display: inline;"> include furniture and equipment</font><font style="display: inline;">. Depreciation is recognized using the straight-line method over the expected life of the property and equipment.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">84</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;color:#000000;font-size:10pt;">During the&nbsp;year ended&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">December&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">31, 2020, the Company sold surplus manufacturing equipment to an independent third party and received proceeds totaling $360,000.&nbsp;The original&nbsp;cost of the property and equipment was</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">$892,000&nbsp;and accumulated depreciation was $878,000,&nbsp;resulting a gain on sale&nbsp;of property and equipment of $346,000&nbsp;during the&nbsp;year ended&nbsp;</font><font style="display: inline;font-size:10pt;">December&nbsp;</font><font style="display: inline;font-size:10pt;">31, 2020. There were no sales of property and equipment during year ended&nbsp;</font><font style="display: inline;font-size:10pt;">December&nbsp;</font><font style="display: inline;font-size:10pt;">3</font><font style="display: inline;font-size:10pt;">1</font><font style="display: inline;font-size:10pt;">, 2019.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">4</font><font style="display: inline;font-weight:bold;">.&nbsp;&nbsp;Stockholders' Equity and Stock-Based Compensation</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Preferred Stock</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company&#x2019;s Board of Directors </font><font style="display: inline;">(the &#x201C;Board&#x201D;) </font><font style="display: inline;">has the authority to issue preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number of shares constituting any series or the designation of the series.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">2021 Registered Direct Offering</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">On </font><font style="display: inline;color:#000000;">February&nbsp;</font><font style="display: inline;color:#000000;">12, 2021, the Company completed a common stock offering pursuant to which certain investors purchased </font><font style="display: inline;color:#000000;">4,081,633</font><font style="display: inline;color:#000000;"> shares of common stock at a price of </font><font style="display: inline;color:#000000;">$49.00</font><font style="display: inline;color:#000000;"> per share. Net proceeds of the offering were approximately </font><font style="display: inline;color:#000000;">$189.7</font><font style="display: inline;color:#000000;">&nbsp;million</font><font style="display: inline;color:#000000;"> after deducting offering expenses.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">2020 </font><font style="display: inline;font-weight:bold;font-style:italic;">Follow-on Public Offering</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;text-decoration:underline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">On </font><font style="display: inline;color:#000000;">November&nbsp;</font><font style="display: inline;color:#000000;">1</font><font style="display: inline;color:#000000;">3</font><font style="display: inline;color:#000000;">, 20</font><font style="display: inline;color:#000000;">20</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;"> the Company completed the sale of&nbsp;</font><font style="display: inline;color:#000000;">9,</font><font style="display: inline;color:#000000;">375</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;">0</font><font style="display: inline;color:#000000;">00</font><font style="display: inline;color:#000000;">&nbsp;shares of </font><font style="display: inline;color:#000000;">Cassava</font><font style="display: inline;color:#000000;"> common stock in an underwritten public offering at a price of&nbsp;</font><font style="display: inline;color:#000000;">$</font><font style="display: inline;color:#000000;">8</font><font style="display: inline;color:#000000;">.</font><font style="display: inline;color:#000000;">00</font><font style="display: inline;color:#000000;">&nbsp;per share. The Company received net proceeds from the offering of&nbsp;</font><font style="display: inline;color:#000000;">$</font><font style="display: inline;color:#000000;">70</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;">251</font><font style="display: inline;color:#000000;">,000</font><font style="display: inline;color:#000000;">&nbsp;after deducting underwriting discounts and offering expenses.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 10pt;line-height:106.67%;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">Common Stock Warrants</font><font style="display: inline;font-style:italic;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">In </font><font style="display: inline;color:#000000;">August 201</font><font style="display: inline;color:#000000;">8, the Company issued warrants to&nbsp;purchase up to an aggregate of&nbsp;</font><font style="display: inline;color:#000000;">9.1</font><font style="display: inline;color:#000000;">&nbsp;million</font><font style="display: inline;color:#000000;"> shares of its common stock in conjunction with an offering of its common stock.&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">During 2020, the Company received proc</font><font style="display: inline;">eeds of </font><font style="display: inline;">$4.9</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> from the exercise of </font><font style="display: inline;">4.0</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> shares pursuant to warrants. </font><font style="display: inline;">During 2019, the Company received proceeds of </font><font style="display: inline;">$5.9</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> from the exercise of </font><font style="display: inline;">4.6</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> shares pursuant to warrants. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Subsequent to </font><font style="display: inline;">December&nbsp;</font><font style="display: inline;">31, 20</font><font style="display: inline;">20</font><font style="display: inline;">, the Company received proceeds of </font><font style="display: inline;">$</font><font style="display: inline;">0.7</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> from the exercise of an additional </font><font style="display: inline;">0.6</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> shares pursuant to warrants.</font><font style="display: inline;"> There were no warrants outstanding following the 2021 exercise</font><font style="display: inline;">s</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Warrants outstanding as of </font><font style="display: inline;">December&nbsp;</font><font style="display: inline;">31, 20</font><font style="display: inline;">20</font><font style="display: inline;"> and 201</font><font style="display: inline;">9</font><font style="display: inline;"> were as follows:</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:41.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">Number of Shares Outstanding under Warrant</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:41.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">Issuance Date</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">Expiration Date</font></p>
				</td>
				<td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">Exercise Price Per Share</font></p>
				</td>
				<td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:17.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">August 17, 2018</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">February 17, 2021</font></p>
				</td>
				<td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.25&nbsp;
				</td>
				<td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">554,019&nbsp;
				</td>
				<td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,496,116&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">August 17, 2018</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">February 17, 2021</font></p>
				</td>
				<td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.59&nbsp;
				</td>
				<td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">7,975&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">554,019&nbsp;
				</td>
				<td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,504,091&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.26%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.80%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">At the Market (ATM) Common Stock Issuance </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">On </font><font style="display: inline;color:#000000;font-size:10pt;">March&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">27, 2020, the Company established an at-the-market offering program (ATM) to sell, from time to time, shares of Company common stock having an aggregate offering price of up to&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">$100</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;million</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;in transactions pursuant to a shelf registration statement that was declared effective by the&nbsp;U.S. Securities and Exchange Commission (the SEC)&nbsp;on </font><font style="display: inline;color:#000000;font-size:10pt;">May&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">5, 2020. The Company is obligated to pay a commission of&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">3.0%</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;of the gross proceeds from the sale of shares of common stock in the offering. The Company is not obligated to sell any shares in the offering.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">85</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">There were&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">no</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;common stock sales under the ATM during the </font><font style="display: inline;color:#000000;font-size:10pt;">year</font><font style="display: inline;color:#000000;font-size:10pt;"> ended </font><font style="display: inline;color:#000000;font-size:10pt;">December&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">3</font><font style="display: inline;color:#000000;font-size:10pt;">1</font><font style="display: inline;color:#000000;font-size:10pt;">, 2020.</font>
		</p>
		<p style="margin:0pt 2.5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 2.5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">2008 Equity Incentive Plan </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Under the Company&#x2019;s </font><font style="display: inline;">2008 Equity Incentive Plan, or 2008 Equity Plan,</font><font style="display: inline;"> its employees, directors and consultants received share-based awards, including grants of stock options and performance awards. The </font><font style="display: inline;">2008 Equity Plan</font><font style="display: inline;"> expired in </font><font style="display: inline;">December 201</font><font style="display: inline;">7. Share-based awards generally expire </font><font style="display: inline;">ten</font><font style="display: inline;"> years from the date of grant.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 2.5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">2018 Equity Incentive Plan </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">I</font><font style="display: inline;">n &nbsp;</font><font style="display: inline;">January 201</font><font style="display: inline;">8, the Company&#x2019;s Board approved the Company&#x2019;s 2018 Omnibus Incentive Plan (the 2018 Plan). The Company&#x2019;s Board or a designated Committee of the Board is responsible for administration of the 2018 Plan and determined the terms and conditions of each option granted, consistent with the terms of the 2018 Plan. The Company&#x2019;s employees, directors, and consultants are eligible to receive awards under the 2018 Plan, including grants of stock options and performance awards. Share-based awards generally expire </font><font style="display: inline;">ten</font><font style="display: inline;"> years from the date of grant. The 2018 Plan provides for issuance of up to </font><font style="display: inline;">1,000,000</font><font style="display: inline;"> shares of common stock, par value </font><font style="display: inline;">$0.001</font><font style="display: inline;"> per share under the 2018 Plan, subject to adjustment as provided in the 2018 Plan. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">When stock options or performance awards are exercised net of the exercise price and taxes, the number of shares of stock issued is reduced by the number of shares equal to the amount of taxes owed by the award recipient and that number of shares are cancelled. The Company then uses its cash to pay tax authorities the amount of statutory taxes owed by and on behalf of the award recipient.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Stock Options</font>
		</p>
		<p style="margin:0pt 2.5pt 0pt 0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 2.5pt 0pt 0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The following summarizes information about stock option activity during 20</font><font style="display: inline;">20</font><font style="display: inline;">:</font>
		</p>
		<p style="margin:0pt 2.5pt 0pt 0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Number of Options</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Weighted Average Exercise Price</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Weighted Average Remaining Contractual Term</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Aggregate Intrinsic Value</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;text-decoration:underline;">In years</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;text-decoration:underline;">In millions</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Outstanding as of December 31, 2019</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">3,210,965&nbsp;
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> 12.27&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">6.05</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">4.2</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Options granted</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">60,000&nbsp;
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> 7.25&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Options exercised</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">(71,105)
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> 3.60&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Options forfeited/canceled</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">(382,356)
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> 20.31&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Outstanding as of December 31, 2020</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">2,817,504&nbsp;
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> 11.30&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">5.60</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">6.4</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#FF0000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Vested and expected to vest at December 31, 2020</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">2,817,504&nbsp;
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> 11.30&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">5.60</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">6.4</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#FF0000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Exercisable at December 31, 2020</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">2,167,633&nbsp;
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> 13.86&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">4.85</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">3.7</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The following summarizes information about stock options at </font><font style="display: inline;">December&nbsp;</font><font style="display: inline;">31, 20</font><font style="display: inline;">20</font><font style="display: inline;"> by a range of exercise prices:</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 14.4pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="6" valign="bottom" style="width:37.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Options outstanding</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="4" valign="bottom" style="width:24.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Options exercisable</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Weighted</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">average</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Weighted</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Weighted</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Number of</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">remaining</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">average</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Number of</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">average</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:23.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Range of exercise prices</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">outstanding</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">contractual</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">exercise</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"> vested</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">exercise</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">From</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">To</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">options</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">life (in years)</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">price</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">options</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">price</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">0.95</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">1.88</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">659,688&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">8.4</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">1.47</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">251,613&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">1.31</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">3.24</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">4.09</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">812,094&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">6.7</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">3.51</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">643,377&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">3.48</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">4.10</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">13.09</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">598,462&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">5.0</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10.89</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">525,383&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">11.42</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">14.21</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">35.00</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">619,599&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">2.8</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">24.02</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">619,599&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">24.02</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">36.40</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">53.55</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">127,661&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">0.7</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">51.72</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">127,661&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">51.72</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,817,504&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">5.6</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">11.30</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,167,633&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">13.86</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">86</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company uses Black-Scholes to estimate the fair value of options granted. Black-Scholes considers a number of factors, including the market price of the Company&#x2019;s common stock. </font><font style="display: inline;">I</font><font style="display: inline;">t used certain factors to value each stock option granted, which resulted in a weighted average fair value of options granted during 20</font><font style="display: inline;">20</font><font style="display: inline;"> and 201</font><font style="display: inline;">9</font><font style="display: inline;">, as follows:</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">2020</font></p>
				</td>
				<td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Volatility</font></p>
				</td>
				<td valign="middle" style="width:15.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">123%</font><font style="display: inline;color:#000000;"> to </font><font style="display: inline;color:#000000;">139%</font></p>
				</td>
				<td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.74%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">118%</font><font style="display: inline;color:#000000;"> to </font><font style="display: inline;color:#000000;">119%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Risk-free interest rates</font></p>
				</td>
				<td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">0.46%</font><font style="display: inline;color:#000000;"> to </font><font style="display: inline;color:#000000;">0.78%</font></p>
				</td>
				<td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">1.7%</font><font style="display: inline;color:#000000;"> to </font><font style="display: inline;color:#000000;">2.5%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Expected life of option</font></p>
				</td>
				<td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">7</font><font style="display: inline;color:#000000;"> years</font></p>
				</td>
				<td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">7</font><font style="display: inline;color:#000000;"> years</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Dividend yield</font></p>
				</td>
				<td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">zero</font></p>
				</td>
				<td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">zero</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Forfeiture rate</font></p>
				</td>
				<td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">zero</font></p>
				</td>
				<td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">zero</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Weighted average fair value of stock options granted</font></p>
				</td>
				<td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$6.69</font></p>
				</td>
				<td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$1.60</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Volatility</font><font style="display: inline;"> is based on reviews of the historical volatility of the Company&#x2019;s common stock. Risk-free interest rates are based on yields of U.S. treasury notes in effect at the date of grant. Expected life of option is based on actual historical option exercises. Dividend yield is </font><font style="display: inline;">zero</font><font style="display: inline;"> because the Company does not anticipate paying cash dividends in the foreseeable future. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">As of </font><font style="display: inline;">December&nbsp;</font><font style="display: inline;">31, 20</font><font style="display: inline;">20</font><font style="display: inline;">, the Company expects to recognize compensation expense of </font><font style="display: inline;">$</font><font style="display: inline;">1.5</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> related to non-vested options held by </font><font style="display: inline;">equity plan participants</font><font style="display: inline;"> over the weighted average remaining recognition period of </font><font style="display: inline;">2.</font><font style="display: inline;">1</font><font style="display: inline;"> years.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Subsequent to </font><font style="display: inline;color:#000000;">December&nbsp;</font><font style="display: inline;color:#000000;">31, 2020, there </font><font style="display: inline;color:#000000;">were&nbsp;</font><font style="display: inline;color:#000000;">20,</font><font style="display: inline;color:#000000;">385</font><font style="display: inline;">&nbsp;</font><font style="display: inline;color:#000000;">stock options exercised resulting in proceeds to the Company </font><font style="display: inline;color:#000000;">totaling&nbsp;</font><font style="display: inline;color:#000000;">$</font><font style="display: inline;color:#000000;">169</font><font style="display: inline;color:#000000;">,000</font><font style="display: inline;color:#000000;">.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Performance Awards</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The following summarizes information about performance award activity during 20</font><font style="display: inline;">20</font><font style="display: inline;">:</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Number of Performance Awards</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Outstanding as of December 31, 2019</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">138,055&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Granted</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Vested performance awards</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Forfeited/Canceled</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Outstanding as of December 31, 2020</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">138,055&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.58%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;"> If and when outstanding performance awards vest, the Company would recognize </font><font style="display: inline;">$2.3</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> in non-cash stock-based compensation expense. These performance awards expire between </font><font style="display: inline;">2022</font><font style="display: inline;"> and </font><font style="display: inline;">2026</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Stock-Based Compensation Expense</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The following summarizes information about non-cash stock-based compensation expense, in</font><font style="display: inline;"> thousands</font><font style="display: inline;">:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Year ended</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">December 31,</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Research and development</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.78%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">453&nbsp;
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">542&nbsp;
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">General and administrative</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">535&nbsp;
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">754&nbsp;
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Total non-cash stock-based compensation expense</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.78%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">988&nbsp;
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">1,296&nbsp;
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.78%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.20%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">87</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-weight:bold;">5</font><font style="display: inline;font-weight:bold;">.&nbsp;&nbsp;Employee 401(k) Benefit Plan</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers substantially all employees. Employees are eligible to participate in the plan the first day of the month after hire and may contribute up to the current statutory limits under Internal Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf of all employees. Through </font><font style="display: inline;">December&nbsp;</font><font style="display: inline;">31, 20</font><font style="display: inline;">20</font><font style="display: inline;">, the Company has not made any matching contributions to the 401(k) plan.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">6</font><font style="display: inline;font-weight:bold;">.&nbsp;&nbsp;Income Taxes</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company did not provide for income taxes in 20</font><font style="display: inline;">20</font><font style="display: inline;"> and 201</font><font style="display: inline;">9</font><font style="display: inline;"> because it had </font><font style="display: inline;">book and federal</font><font style="display: inline;"> tax</font><font style="display: inline;">able losses</font><font style="display: inline;"> in those years and the tax benefit that would have resulted from the </font><font style="display: inline;">pre-tax losses</font><font style="display: inline;"> was fully offset by </font><font style="display: inline;">a change in </font><font style="display: inline;">the valuation allowance. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The reconciliation of the statutory federal income tax rate to the Company&#x2019;s effective tax rate for the years ended </font><font style="display: inline;">December&nbsp;</font><font style="display: inline;">31, 20</font><font style="display: inline;">20</font><font style="display: inline;"> and 201</font><font style="display: inline;">9</font><font style="display: inline;"> was as follows:</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="4" valign="bottom" style="width:30.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Year ended December 31,</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Tax at federal statutory rate</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">21.0&nbsp;
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">%</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">21.0&nbsp;
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">%</font></p>
				</td>
				<td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">State tax, net of federal benefit</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Share-based compensation</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(42.8)
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(2.4)
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Research and development credits</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.6&nbsp;
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">0.6&nbsp;
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Change in valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">20.2&nbsp;
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(19.2)
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Effective income tax rate</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">%</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">%</font></p>
				</td>
				<td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Deferred tax assets and valuation allowance</font>
		</p>
		<p style="margin:0pt;text-indent:15.15pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Deferred tax assets reflect the tax effects of net operating loss and tax credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company&#x2019;s deferred taxes assets at </font><font style="display: inline;">December&nbsp;</font><font style="display: inline;">31, 20</font><font style="display: inline;">20</font><font style="display: inline;"> and 201</font><font style="display: inline;">9</font><font style="display: inline;"> were valued at the corporate tax rate of 21%. The Company offsets its deferred tax assets by a valuation allowance because it is uncertain about the timing and amount of any future profits. Significant components of its deferred tax assets are as follows (in</font><font style="display: inline;"> thousands</font><font style="display: inline;">):</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">December 31, </font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Deferred tax assets:</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Net operating loss carryforwards</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">18,333&nbsp;
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">17,110&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Share-based compensation</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,230&nbsp;
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5,817&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Research and development credit carryforwards</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">6,687&nbsp;
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">6,587&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Other</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">264&nbsp;
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">237&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Total deferred tax assets:</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">28,514&nbsp;
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">29,751&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(28,447)
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(29,725)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Net deferred tax assets:</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">67&nbsp;
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">26&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Deferred tax liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Property and equipment</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(5)
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(7)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Operating lease right-of-use assets</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(62)
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(19)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Total deferred tax liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(67)
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(26)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Net deferred tax asset / (liability):</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">88</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;">The valuation allowance decreased by </font><font style="display: inline;">$1.3</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> in 2020. The valuation allowance decreased by </font><font style="display: inline;">$2.4</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> due to </font><font style="display: inline;">a write down of</font><font style="display: inline;"> the share-bas</font><font style="display: inline;">ed com</font><font style="display: inline;">pensation deferred tax asset and is offset</font><font style="display: inline;"> in part by</font><font style="display: inline;"> a </font><font style="display: inline;">$1.1</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> increase due to additional book losses during the year. The valuation allowance increased by </font><font style="display: inline;">$0.9</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> in 2019 due to additional book losses during the year. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company&#x2019;s pre-tax net operating loss carryforwards of </font><font style="display: inline;">$8</font><font style="display: inline;">7.</font><font style="display: inline;">3</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> are federal, of which </font><font style="display: inline;">$7</font><font style="display: inline;">4.1</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> expires between </font><font style="display: inline;">2029</font><font style="display: inline;"> and </font><font style="display: inline;">203</font><font style="display: inline;">9</font><font style="display: inline;"> and </font><font style="display: inline;">$</font><font style="display: inline;">13.2</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> carries forward indefinitely. As of </font><font style="display: inline;">December&nbsp;</font><font style="display: inline;">31, 20</font><font style="display: inline;">20</font><font style="display: inline;">, the Company had federal research and development tax credits of approximately </font><font style="display: inline;">$11.</font><font style="display: inline;">1</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;">, which expire in the years </font><font style="display: inline;">2023</font><font style="display: inline;"> through </font><font style="display: inline;">20</font><font style="display: inline;">40</font><font style="display: inline;">. &nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Unrecognized tax benefits</font>
		</p>
		<p style="margin:0pt;text-indent:14.4pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">As of </font><font style="display: inline;">December&nbsp;</font><font style="display: inline;">31, 2020 and 2019, the Company has unrecognized tax benefits related to tax credits of </font><font style="display: inline;">$4.5</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> and </font><font style="display: inline;">$4.4</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;">, respectively. None of the unrecognized tax benefits as of </font><font style="display: inline;">December&nbsp;</font><font style="display: inline;">31, 2020, if recognized, would impact the effective tax rate due to the valuation allowance and no interest or penalties have been recognized. A reconciliation of the beginning and ending balance of unrecognized tax benefits is as follows (in</font><font style="display: inline;"> thousands</font><font style="display: inline;">): </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="4" valign="bottom" style="width:31.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Year ended December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:15.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:15.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Beginning balance</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,400&nbsp;
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,400&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Additions based on tax positions related to the current year</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">100&nbsp;
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Ending balance</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,500&nbsp;
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,400&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">As of </font><font style="display: inline;">December&nbsp;</font><font style="display: inline;">31, 20</font><font style="display: inline;">20</font><font style="display: inline;">, there were no unrecognized tax benefits that we expect would change significantly over the next 12 months.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company files U.S. and Texas income tax returns. In the United States, the statute of limitations with respect to the federal income tax returns for tax years after 201</font><font style="display: inline;">6</font><font style="display: inline;">&nbsp;are open to audit; however, since the Company has net operating losses, the taxing authority has the ability to review tax returns prior to the 201</font><font style="display: inline;">7</font><font style="display: inline;"> tax year and make adjustments to these net operating loss carryforwards.&nbsp;We are not under audit in any taxing jurisdiction at this time.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">7</font><font style="display: inline;font-weight:bold;">.&nbsp;&nbsp;Leases and Commitments</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Right-of-use Asset and Liability</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The Company has a single non-cancelable operating lease for approximately </font><font style="display: inline;font-size:10pt;">6,000</font><font style="display: inline;font-size:10pt;"> square feet of office space in Austin, Texas, which is used for the development of novel products. </font><font style="display: inline;color:#000000;font-size:10pt;">On </font><font style="display: inline;color:#000000;font-size:10pt;">September&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">4, 2020, the Company entered into a lease amendment that extended&nbsp;the&nbsp;lease termination date to </font><font style="display: inline;color:#000000;font-size:10pt;">April&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">30, 2024</font><font style="display: inline;color:#000000;font-size:10pt;"> and set&nbsp;new rental rates effective as of </font><font style="display: inline;color:#000000;font-size:10pt;">January&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">1, 2021.&nbsp;</font><font style="display: inline;font-size:10pt;">Future lease payments are (in</font><font style="display: inline;font-size:10pt;"> thousands</font><font style="display: inline;font-size:10pt;">).</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-size:9pt;">For the year ending December 31,</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">2021</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">66&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">2022</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">102&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">2023</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">107&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">2024</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">36&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">Total future lease payments</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">311&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">Less: imputed interest</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">(18)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">293&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Rent expense was </font><font style="display: inline;">$0.1</font><font style="display: inline;">&nbsp;million</font><font style="display: inline;"> for the year ended </font><font style="display: inline;">December&nbsp;</font><font style="display: inline;">31, 2020 and 2019.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">89</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;color:#000000;font-size:10pt;">The Company recorded a&nbsp;right-of-use asset and lease liability&nbsp;of </font><font style="display: inline;color:#000000;font-size:10pt;">$316,000</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;as a result of the lease&nbsp;modification in </font><font style="display: inline;color:#000000;font-size:10pt;">September 202</font><font style="display: inline;color:#000000;font-size:10pt;">0. The Company utilized a discount rate of&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">3.25%</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;for the modified lease&nbsp;to determine the present value of the future lease payments, which&nbsp;approximated the Company&#x2019;s incremental borrowing rate&nbsp;in </font><font style="display: inline;color:#000000;font-size:10pt;">September 202</font><font style="display: inline;color:#000000;font-size:10pt;">0. </font><font style="display: inline;font-size:10pt;">There were </font><font style="display: inline;font-size:10pt;">no</font><font style="display: inline;font-size:10pt;"> right-of-use assets exchanged for operating lease liabilities during the year ended </font><font style="display: inline;font-size:10pt;">December&nbsp;</font><font style="display: inline;font-size:10pt;">31, 2019.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">Cash paid for operating lease liabilities totaled </font><font style="display: inline;color:#000000;font-size:10pt;">$99,000</font><font style="display: inline;color:#000000;font-size:10pt;"> and </font><font style="display: inline;color:#000000;font-size:10pt;">$95,000</font><font style="display: inline;color:#000000;font-size:10pt;"> during the years ended </font><font style="display: inline;color:#000000;font-size:10pt;">December&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">31, 2020 and 2019, respectively.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;color:#000000;font-size:10pt;">Other Commitments</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company conducts its product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. It has contractual arrangements with these organizations, however these contracts are cancelable on thirty days&#x2019; notice and the Company&#x2019;s obligations under these contracts are largely based on services performed.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company is dependent on contract development and manufacturing organizations for the manufacture of all our materials for clinical studies.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;font-size:10pt;">Note&nbsp;</font><font style="display: inline;font-weight:bold;color:#000000;font-size:10pt;">8</font><font style="display: inline;font-weight:bold;color:#000000;font-size:10pt;">.&nbsp;</font><font style="display: inline;font-weight:bold;color:#000000;font-size:10pt;"> 202</font><font style="display: inline;font-weight:bold;color:#000000;font-size:10pt;">0 Cash Incentive Bonus Plan</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">On </font><font style="display: inline;color:#000000;font-size:10pt;">August&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">26, 2020, the Board approved the Plan. The Plan was established to promote the long-term success of the Company by </font><font style="display: inline;color:#000000;font-size:10pt;">creat</font><font style="display: inline;color:#000000;font-size:10pt;">ing an &#x201C;at-risk&#x201D; cash bonus program that rewards&nbsp;Plan&nbsp;participants with additional cash compensation in lockstep with significant increases in the Company&#x2019;s </font><font style="display: inline;color:#000000;font-size:10pt;">market capitalization</font><font style="display: inline;color:#000000;font-size:10pt;">. The Plan is considered &#x201C;at-risk&#x201D; because Plan participants&nbsp;will&nbsp;not receive a cash bonus&nbsp;unless&nbsp;the Company&#x2019;s </font><font style="display: inline;color:#000000;font-size:10pt;">market capitalization </font><font style="display: inline;color:#000000;font-size:10pt;">increases&nbsp;significantly and&nbsp;certain&nbsp;other&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">condition</font><font style="display: inline;color:#000000;font-size:10pt;">s specified in the Plan&nbsp;are met.&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">Specifically</font><font style="display: inline;color:#000000;font-size:10pt;">, Plan participants&nbsp;will&nbsp;not&nbsp;be paid&nbsp;any cash bonuses unless </font><font style="display: inline;color:#000000;font-size:10pt;">(1) the Company completes a&nbsp;merger or acquisition transaction that constitutes a sale of ownership of the Company or its assets (a Merger Transaction) or (2) </font><font style="display: inline;color:#000000;font-size:10pt;">the </font><font style="display: inline;color:#000000;font-size:10pt;">Compensation Committee of the </font><font style="display: inline;color:#000000;font-size:10pt;">Board&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">(the Compensation Committee) </font><font style="display: inline;color:#000000;font-size:10pt;">determines the Company has sufficient cash on hand, as defined in the Plan. Because&nbsp;of the inherent discretion and uncertainty regarding&nbsp;these&nbsp;requirements, the Company has concluded that&nbsp;a&nbsp;Plan&nbsp;grant date has not occurred&nbsp;as of </font><font style="display: inline;color:#000000;font-size:10pt;">December&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">31, 2020.&nbsp;Plan participants will be paid all earned cash bonuses in the event of a Merger Transaction.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">The Company&#x2019;s </font><font style="display: inline;color:#000000;font-size:10pt;">market capitalization for purposes of the Plan</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;is&nbsp;determined based on either (1) the Company&#x2019;s closing price&nbsp;of one share&nbsp;on the Nasdaq Capital&nbsp;Market&nbsp;multiplied by the total issued and outstanding shares and options to purchase shares of the Company or (2) the aggregate consideration payable to security holders of the Company in a&nbsp;Merger Transaction.&nbsp;This constitutes a market condition under applicable accounting guidance.&nbsp; &nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">The Plan&nbsp;triggers a </font><font style="display: inline;color:#000000;font-size:10pt;">potential </font><font style="display: inline;color:#000000;font-size:10pt;">cash bonus each time&nbsp;the&nbsp;Company&#x2019;s </font><font style="display: inline;color:#000000;font-size:10pt;">market capitalization</font><font style="display: inline;color:#000000;font-size:10pt;"> increases significantly, up to a maximum&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">$5</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;billion</font><font style="display: inline;color:#000000;font-size:10pt;"> in market capitalization. The Plan specifies 14&nbsp;incremental&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">amounts</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;between&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">$200</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;million</font><font style="display: inline;color:#000000;font-size:10pt;"> and&nbsp;$5</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;billion</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;&nbsp;(each increment,&nbsp;a &#x201C;Valuation Milestone&#x201D;). Each&nbsp;Valuation Milestone&nbsp;triggers&nbsp;a </font><font style="display: inline;color:#000000;font-size:10pt;">potential </font><font style="display: inline;color:#000000;font-size:10pt;">cash bonus award in a pre-set amount defined in the Plan. Each&nbsp;Valuation&nbsp;Milestone&nbsp;must be achieved and maintained for no less than 20 consecutive trading days for&nbsp;Plan&nbsp;participants to be eligible for a </font><font style="display: inline;color:#000000;font-size:10pt;">potential </font><font style="display: inline;color:#000000;font-size:10pt;">cash bonus award.&nbsp;Approximately </font><font style="display: inline;color:#000000;font-size:10pt;">59%</font><font style="display: inline;color:#000000;font-size:10pt;"> of each&nbsp;cash bonus award&nbsp;associated with a Valuation Milestone&nbsp;is subject to&nbsp;adjustment and&nbsp;approval&nbsp;by the Compensation Committee.&nbsp;Any amounts&nbsp;not awarded by the Compensation Committee&nbsp;are&nbsp;no longer available for distribution.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">If the Company </font><font style="display: inline;color:#000000;font-size:10pt;">were to </font><font style="display: inline;color:#000000;font-size:10pt;">exceed a $5</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;billion</font><font style="display: inline;color:#000000;font-size:10pt;"> market capitalization&nbsp;for no less than 20 consecutive trading days, all&nbsp;Valuation&nbsp;Milestones would be deemed achieved, in which case cash bonus awards would&nbsp;range from&nbsp;a minimum of&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">$137.4</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;million</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;up to&nbsp;a </font><font style="display: inline;color:#000000;font-size:10pt;">hypothetical </font><font style="display: inline;color:#000000;font-size:10pt;">maximum of&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">$322.3</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;million</font><font style="display: inline;color:#000000;font-size:10pt;">.&nbsp;Payment of cash bonuses is deferred until such time as&nbsp;(1)&nbsp;the Company completes a Merger Transaction, or&nbsp;(2)&nbsp;the&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">Compensation Committee</font><font style="display: inline;color:#000000;font-size:10pt;"> determines the&nbsp;Company has sufficient cash&nbsp;on hand&nbsp;to render payment&nbsp;(each, a &#x201C;Performance Condition&#x201D;),&nbsp;neither&nbsp;of which may ever occur. Accordingly, there can be no assurance that&nbsp;Plan&nbsp;participants will&nbsp;ever&nbsp;be&nbsp;paid a cash bonus that is awarded under the Plan, even if the Company&#x2019;s market capitalization increases&nbsp;significantly.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">The Plan is accounted for as a liability award.&nbsp;The fair value of each&nbsp;Valuation&nbsp;Milestone&nbsp;award&nbsp;will be&nbsp;determined&nbsp;once&nbsp;a&nbsp;grant date occurs and&nbsp;will be&nbsp;remeasured each reporting period.&nbsp;Compensation expense associated </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">90</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;color:#000000;font-size:10pt;">with the Plan&nbsp;will be&nbsp;recognized over the expected achievement period for each&nbsp;of the 14&nbsp;Valuation&nbsp;Milestones, when&nbsp;a Performance Condition&nbsp;is considered probable of being met. &nbsp;&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">On </font><font style="display: inline;color:#000000;font-size:10pt;">October&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">13, 2020, the Company&nbsp;achieved&nbsp;the first&nbsp;Valuation&nbsp;Milestone.&nbsp;Subsequently, the Compensation Committee&nbsp;approved&nbsp;a </font><font style="display: inline;color:#000000;font-size:10pt;">potential </font><font style="display: inline;color:#000000;font-size:10pt;">cash bonus&nbsp;award&nbsp;of&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">$7.3</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;million</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;in total&nbsp;for&nbsp;all Plan participants</font><font style="display: inline;color:#000000;font-size:10pt;">, subject to future satisfaction of a Performance Condition</font><font style="display: inline;color:#000000;font-size:10pt;">.&nbsp;However,&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">no</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;compensation expense has been recorded&nbsp;since no&nbsp;grant date has occurred and no&nbsp;Performance Conditions are considered probable of being met.&nbsp;There is no continuing service requirement for Plan participants once&nbsp;the Compensation Committee approves a cash&nbsp;bonus award.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">Subsequent to </font><font style="display: inline;color:#000000;font-size:10pt;">December&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">31, 2020, the Company achieved </font><font style="display: inline;color:#000000;font-size:10pt;">eight</font><font style="display: inline;color:#000000;font-size:10pt;"> additional Valuation Milestones triggering </font><font style="display: inline;color:#000000;font-size:10pt;">potential </font><font style="display: inline;color:#000000;font-size:10pt;">Company obligations to all Plan participants from a minimum of </font><font style="display: inline;color:#000000;font-size:10pt;">$</font><font style="display: inline;color:#000000;font-size:10pt;">59.9</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;million</font><font style="display: inline;color:#000000;font-size:10pt;"> up to a </font><font style="display: inline;color:#000000;font-size:10pt;">hypothetical </font><font style="display: inline;color:#000000;font-size:10pt;">maximum of </font><font style="display: inline;color:#000000;font-size:10pt;">$</font><font style="display: inline;color:#000000;font-size:10pt;">145</font><font style="display: inline;color:#000000;font-size:10pt;">.0</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;million</font><font style="display: inline;color:#000000;font-size:10pt;">, to be determined by the Compensation Committee</font><font style="display: inline;color:#000000;font-size:10pt;"> and </font><font style="display: inline;color:#000000;font-size:10pt;">contingent upon future satisfaction of a Performance Condition</font><font style="display: inline;color:#000000;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">N</font><font style="display: inline;color:#000000;font-size:10pt;">o</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">actual cash </font><font style="display: inline;color:#000000;font-size:10pt;">payments </font><font style="display: inline;color:#000000;font-size:10pt;">were authorized or </font><font style="display: inline;color:#000000;font-size:10pt;">made to participants under the Plan during the year ended </font><font style="display: inline;color:#000000;font-size:10pt;">December&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">31, 2020.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">91</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Item 9.</font><font style="display: inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</font><a name="Changes_And_Disagreements"></a>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">None. </font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-indent:14.4pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Item 9A.</font><font style="display: inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;">Controls and Procedures</font><a name="Controls_And_Procedures"></a>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Evaluation of disclosure controls and procedures.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Annual Report on Form 10-K. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures are effective to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission, or SEC, rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosures.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Management&#x2019;s annual report on internal control over financial reporting.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Our management has assessed the effectiveness of internal control over financial reporting as of </font><font style="display: inline;">December&nbsp;</font><font style="display: inline;">31, 20</font><font style="display: inline;">20</font><font style="display: inline;">. Our assessment was based on criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO, in Internal Control-Integrated Framework (2013 Framework). </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that:</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> (1)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and dispositions of our assets; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> (2)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and board of directors; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> (3)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Based on the COSO </font><font style="display: inline;color:#000000;">criteria, </font><font style="display: inline;color:#000000;">we believe our internal control over financial reporting as of </font><font style="display: inline;color:#000000;">December&nbsp;</font><font style="display: inline;color:#000000;">31, 20</font><font style="display: inline;color:#000000;">20</font><font style="display: inline;color:#000000;"> was effective.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. &nbsp;Management&#x2019;s assessment of the effectiveness of our internal control over financial reporting as of </font><font style="display: inline;color:#000000;">December&nbsp;</font><font style="display: inline;color:#000000;">31, 20</font><font style="display: inline;color:#000000;">20</font><font style="display: inline;color:#000000;">, was not subject to attestation by our independent registered public accounting firm pursuant to rules of the SEC that permit a smaller reporting company to provide only management&#x2019;s report in the Company&#x2019;s Annual Report on Form 10-K.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;color:#000000;">Changes in internal control over financial reporting.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">There was no change in our internal control over financial reporting that occurred during the quarter ended </font><font style="display: inline;color:#000000;">December&nbsp;</font><font style="display: inline;color:#000000;">31, 20</font><font style="display: inline;color:#000000;">20</font><font style="display: inline;color:#000000;">&nbsp;that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</font><font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<a name="_DV_C126"></a>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">92</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="color:#0000FF;display: inline;font-weight:bold;color:#000000;text-decoration:none;">Item 9B.</font><font style="display: inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="color:#0000FF;display: inline;font-weight:bold;font-style:italic;color:#000000;text-decoration:none;">Other Information</font><a name="Other_Information"></a>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">None</font><font style="display: inline;font-weight:bold;">.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">PART III</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Item 10.</font><font style="display: inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Directors and Executive Officers and Corporate Governance </font><a name="_DV_M860"></a><a name="Directors_And_Executive_Officers"></a>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The information regarding our directors, executive officers, director nomination process and the audit committee of the Board is incorporated by reference from "Directors and Executive Officers" in our Proxy Statement for our 202</font><font style="display: inline;">1</font><font style="display: inline;"> Annual Meeting of Stockholders.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Section 16(a) Beneficial Ownership Reporting Compliance</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Section 16(a) of the Exchange Act requires our executive officers and directors and persons who own more than ten percent (10%) of a registered class of our equity securities to file reports of ownership and changes in ownership with the SEC. Executive officers, directors and greater than ten percent (10%) stockholders are required to furnish us with copies of all Section 16(a) forms they file. We believe all of our executive officers and directors complied with all applicable filing requirements during 20</font><font style="display: inline;">20</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Code of Ethics </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We have adopted a Code of Ethics that applies to all of our directors, officers and employees, including our principal executive officer and principal financial officer. We publicize the Code of Ethics through posting the policy on our website, http://www.cassavasciences.com. We will disclose on our website any waivers of, or amendments to, our Code of Ethics.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Item 11.</font><font style="display: inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;">Executive Compensation</font><a name="Executive_Compensation"></a>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The information required by this Item is incorporated by reference from our definitive Proxy Statement referred to in Item 10 above where it appears under the heading "Executive Compensation and Other Matters."</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:18.55pt;"><font style="display: inline;font-weight:bold;">Item 12.</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;font-weight:bold;"></font><font style="display: inline;font-weight:bold;font-style:italic;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></font><a name="Security_Ownership"></a>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The information required by this Item regarding security ownership of certain beneficial owners and management is incorporated by reference from our definitive Proxy Statement referred to in Item 10 above where it appears under the heading "Security Ownership of Certain Beneficial Owners and Management."</font><a name="_DV_M872"></a>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The following table summarizes the securities authorized for issuance under our equity compensation plans as of </font><font style="display: inline;">December&nbsp;</font><font style="display: inline;">31, 20</font><font style="display: inline;">20</font><font style="display: inline;">:</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-weight:bold;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:46.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:46.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Number of</font><br /><font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Securities to be</font><br /><font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Issued Upon</font><br /><font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Exercise of</font><br /><font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Outstanding</font><br /><font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Options, Warrants</font><br /><font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">and Rights</font></p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Weighted Average</font><br /><font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Exercise Price of</font><br /><font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Outstanding</font><br /><font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Options,</font><br /><font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Warrants</font><br /><font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">and Rights</font></p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Number of Securities</font><br /><font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Remaining Available</font><br /><font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">for Future Issuance</font><br /><font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Under Equity</font><br /><font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Compensation</font><br /><font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Plans</font></p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:46.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Equity compensation plans approved by stockholders</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,955,559&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:5pt;vertical-align:super;line-height:100%">(1)</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10.77&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:5pt;vertical-align:super;line-height:100%">(2)</font></p>
				</td>
				<td valign="bottom" style="width:16.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">310,205&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:5pt;vertical-align:super;line-height:100%">(3)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:46.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Equity compensation plans not approved by stockholders</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:46.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,955,559&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10.77&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">310,205&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:46.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.16%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.56%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.66%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> (1)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Includes outstanding stock options and awards for 2,</font><font style="display: inline;color:#000000;">220,871</font><font style="display: inline;color:#000000;"> shares of our common stock under the 2008 Plan and 7</font><font style="display: inline;color:#000000;">34</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;">688</font><font style="display: inline;color:#000000;"> shares of our common stock under the 2018 Plan.</font></p></td></tr></table></div>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">93</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;border-top:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> (2)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Includes the weighted average stock price for outstanding stock options of $1</font><font style="display: inline;color:#000000;">4.54</font><font style="display: inline;color:#000000;"> under the 2008 Plan and $</font><font style="display: inline;color:#000000;">2.11</font><font style="display: inline;color:#000000;"> for the 2018 Plan.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> (3)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Represents 2</font><font style="display: inline;color:#000000;">52,188</font><font style="display: inline;color:#000000;"> shares of our common stock for the 2018 Plan and 58,017 for the Employee Stock Purchase Plan. No future awards shall occur under the 2008 Plan.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">Item 13.</font><font style="display: inline;font-weight:bold;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Certain Relationships and Related Transactions</font><font style="color:#0000FF;display: inline;font-weight:bold;font-style:italic;color:#000000;text-decoration:none;"> and Director Independence</font><a name="Certain_Relationships"></a>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The information required by this Item is incorporated by reference from our definitive Proxy Statement referred to in Item 10 above where it appears under the heading "Certain Relationships and Related Transactions."</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">Item 14.</font><font style="display: inline;font-weight:bold;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Principal Accountant Fees and Services</font><a name="Principal_Accountant_Fees"></a>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The information required by this Item is incorporated by reference from our definitive Proxy Statement referred to in Item 10 above where it appears under the heading </font><font style="display: inline;font-weight:bold;color:#000000;">&#x201C;</font><font style="display: inline;color:#000000;">Principal Accountant Fees and Services.&#x201D;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">94</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<a name="_Hlk505686828"></a><font style="display: inline;font-weight:bold;">PART IV</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Item 15.</font><font style="display: inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;">Exhibits and Financial Statement Schedules</font><a name="Exhibits"></a>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 15.3pt;text-indent: -15.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">(a)</font><font style="display: inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 6pt 0pt 0pt;"></font><font style="display: inline;">The following documents are filed as part of this Form 10-K:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 9pt;text-indent:9pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:16pt;"><font style="display: inline;">(1)</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;"></font><font style="display: inline;font-style:italic;">Financial Statements (included in Part II of this report):</font></font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent:9pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Report of Independent Registered Public Accounting Firm</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent:9pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Balance Sheets</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent:9pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Statements of Operations</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent:9pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Statements of Stockholders' Equity</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent:9pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Statements of Cash Flows</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent:9pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Notes to Financial Statements</font>
		</p>
		<p style="margin:0pt 0pt 0pt 9pt;text-indent:9pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:16pt;"><font style="display: inline;">(2)</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;"></font><font style="display: inline;font-style:italic;">Financial Statement Schedules:</font></font>
		</p>
		<p style="margin:0pt 0pt 0pt 45pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">All financial statement schedules are omitted because the information is inapplicable or presented in the notes to the financial statements.</font>
		</p>
		<p style="margin:0pt 72pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:16pt;"><font style="display: inline;">(3)</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;"></font><font style="display: inline;font-style:italic;">Management Contracts, Compensatory Plans and Arrangements</font><font style="display: inline;">. &nbsp;</font></font>
		</p>
		<p style="margin:0pt 72pt 0pt 45pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Management contracts, compensatory plans and arrangements are indicated by the symbol &#x201C;*&#x201D; in the applicable exhibits listed in Item 15(b), below.</font>
		</p>
		<p style="margin:0pt 72pt 0pt 45pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 72pt 0pt 15.3pt;text-indent: -15.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">(b)</font><font style="display: inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 6pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;font-style:italic;">Exhibits </font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0.2pt 0pt 0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The exhibits listed below are filed as part of this Form 10-K other than Exhibit 32.1, which shall be deemed furnished.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:26.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;">Incorporated by Reference</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;">Exhibit</font><br /><font style="display: inline;font-weight:bold;">No.</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;"> Description</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;">Form</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;">Filing</font><br /><font style="display: inline;font-weight:bold;">Date</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;">Exhibit</font><br /><font style="display: inline;font-weight:bold;">No.</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;">Filed</font><br /><font style="display: inline;font-weight:bold;">Herewith</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312505152582/dex31.htm" style="-sec-extract:exhibit"><font style="display: inline;">3.1</font></a></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312505152582/dex31.htm" style="-sec-extract:exhibit"><font style="display: inline;">Amended and Restated Certificate of Incorporation.</font></a></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10-Q</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">7/29/2005</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">3.1</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:08.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953017000028/ptie-20170508xex3_1.htm" style="-sec-extract:exhibit"><font style="display: inline;">3.2</font></a></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953017000028/ptie-20170508xex3_1.htm" style="-sec-extract:exhibit"><font style="display: inline;">Certificate of Amendment of Restated Certificate of Incorporation</font></a><font style="display: inline;">.</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">8-K</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">5/8/2017</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">3.1</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953019000019/sava-20181231xex3_3.htm" style="-sec-extract:exhibit"><font style="display: inline;">3.3</font></a></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953019000019/sava-20181231xex3_3.htm" style="-sec-extract:exhibit"><font style="display: inline;">Certificate of Amendment of Restated Certificate of Incorporation.</font></a></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10-K</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">3/29/2019</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">3.3</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953020000071/sava-20201211xex3_1.htm" style="-sec-extract:exhibit"><font style="display: inline;">3.4</font></a></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953020000071/sava-20201211xex3_1.htm" style="-sec-extract:exhibit"><font style="display: inline;">Amended and Restated Bylaws of Cassava Sciences, Inc.</font></a></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">8-K</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">12/11/2020</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">3.1</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953019000032/sava-20190630xex4_1.htm" style="-sec-extract:exhibit"><font style="display: inline;">4.1</font></a></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953019000032/sava-20190630xex4_1.htm" style="-sec-extract:exhibit"><font style="display: inline;">Specimen Common Stock Certificate.</font></a></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10-Q</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">8/12/2019</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">4.1</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953020000009/sava-20191231xex4_2.htm" style="-sec-extract:exhibit"><font style="display: inline;">4.2</font></a></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953020000009/sava-20191231xex4_2.htm" style="-sec-extract:exhibit"><font style="display: inline;">Description of Registrant&#x2019;s Securities.</font></a></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10-K</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">3/26/2020</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">4.2</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953018000045/ptie-20180817xex4_1.htm" style="-sec-extract:exhibit"><font style="display: inline;">4.3</font></a></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953018000045/ptie-20180817xex4_1.htm" style="-sec-extract:exhibit"><font style="display: inline;">Form of Common Stock Purchase Warrant</font></a><font style="display: inline;">.</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">8-K</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">8/20/2018</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">4.1</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953018000045/ptie-20180817xex4_2.htm" style="-sec-extract:exhibit"><font style="display: inline;">4.4</font></a></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953018000045/ptie-20180817xex4_2.htm" style="-sec-extract:exhibit"><font style="display: inline;">Form of Wainwright Warrant</font></a><font style="display: inline;">.</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">8-K</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">8/20/2018</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">4.2</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/1069530/000089161800001419/0000891618-00-001419.txt" style="-sec-extract:exhibit"><font style="display: inline;">10.1</font></a></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:5pt;vertical-align:super;line-height:100%">*</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/1069530/000089161800001419/0000891618-00-001419.txt" style="-sec-extract:exhibit"><font style="display: inline;">Form of Indemnification Agreement between Registrant and each of its directors and officers.</font></a></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">S-1</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">3/14/2000</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10.1</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/1069530/000089161802001349/f79726ex10-5.txt" style="-sec-extract:exhibit"><font style="display: inline;">10.2</font></a></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:5pt;vertical-align:super;line-height:100%">*</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/1069530/000089161802001349/f79726ex10-5.txt" style="-sec-extract:exhibit"><font style="display: inline;">Employment Agreement, dated </font><font style="display: inline;">October&nbsp;</font><font style="display: inline;">23, 2001, between Registrant and Nadav Friedmann, PhD. M.D.</font></a><font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10-K</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">3/22/2002</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10.5</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312509027574/dex1012.htm" style="-sec-extract:exhibit"><font style="display: inline;">10.5</font></a></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:5pt;vertical-align:super;line-height:100%">*</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312509027574/dex1012.htm" style="-sec-extract:exhibit"><font style="display: inline;">Employment Agreement, dated </font><font style="display: inline;">July&nbsp;</font><font style="display: inline;">1, 1998 and amended </font><font style="display: inline;">December&nbsp;</font><font style="display: inline;">17, 2008, between Registrant and Remi Barbier.</font></a></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10-K</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">2/13/2009</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10.12</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312510170701/dex101.htm" style="-sec-extract:exhibit"><font style="display: inline;">10.6</font></a></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:5pt;vertical-align:super;line-height:100%">*</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312510170701/dex101.htm" style="-sec-extract:exhibit"><font style="display: inline;">2000 Employee Stock Purchase Plan, as amended and restated.</font></a></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10-Q</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">7/29/2010</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10.1</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312513315094/d547249dex101.htm" style="-sec-extract:exhibit"><font style="display: inline;">10.7</font></a></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:5pt;vertical-align:super;line-height:100%">*</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312513315094/d547249dex101.htm" style="-sec-extract:exhibit"><font style="display: inline;">Amendment Number 1 to the 2008 Equity Incentive Plan.</font></a></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10-Q</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">8/1/2013</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10.1</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312513315094/d547249dex102.htm" style="-sec-extract:exhibit"><font style="display: inline;">10.8</font></a></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:5pt;vertical-align:super;line-height:100%">*</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312513315094/d547249dex102.htm" style="-sec-extract:exhibit"><font style="display: inline;">Amendment No. 2 to Employment Agreement between Registrant and Remi Barbier.</font></a></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10-Q</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">8/1/2013</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10.2</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312511110829/dex101.htm" style="-sec-extract:exhibit"><font style="display: inline;">10.9</font></a></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312511110829/dex101.htm" style="-sec-extract:exhibit"><font style="display: inline;">Lease Agreement, dated as of </font><font style="display: inline;">February&nbsp;</font><font style="display: inline;">14, 2011 between Registrant and StoneCliff Office, L.P.</font></a></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10-Q</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">4/27/2011</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10.1</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312512049361/d268570dex1020.htm" style="-sec-extract:exhibit"><font style="display: inline;">10.10</font></a></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:5pt;vertical-align:super;line-height:100%">*</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312512049361/d268570dex1020.htm" style="-sec-extract:exhibit"><font style="display: inline;">First Amendment to Lease Agreement, dated </font><font style="display: inline;">September&nbsp;</font><font style="display: inline;">21, 2011.</font></a></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10-K</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">2/9/2012</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10.20</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953014000025/ptie-20140630ex101b345fc.htm" style="-sec-extract:exhibit"><font style="display: inline;">10.11</font></a></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953014000025/ptie-20140630ex101b345fc.htm" style="-sec-extract:exhibit"><font style="display: inline;">Second Amendment to Lease Agreement, dated as of </font><font style="display: inline;">April&nbsp;</font><font style="display: inline;">3, 2014 between Registrant and StoneCliff Office, L.P.</font></a><font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10-Q</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">8/6/2014</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10.1</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953018000004/ptie-20171231xex10_17.htm" style="-sec-extract:exhibit"><font style="display: inline;">10.12</font></a></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953018000004/ptie-20171231xex10_17.htm" style="-sec-extract:exhibit"><font style="display: inline;">Third Amendment to Lease Agreement, dated as of </font><font style="display: inline;">November&nbsp;</font><font style="display: inline;">3, 2017 between Registrant US REIF Eurus Austin, LLC dba StoneCliff Building as successor in interest to StoneCliff Office, L.P.</font></a></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10-K</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">2/6/2018</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10.17</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953020000050/sava-20200910xex10_1.htm" style="-sec-extract:exhibit"><font style="display: inline;">10.13</font></a></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953020000050/sava-20200910xex10_1.htm" style="-sec-extract:exhibit"><font style="display: inline;">Fourth</font><font style="display: inline;"> Amendment to Lease Agreement, dated </font><font style="display: inline;">September&nbsp;</font><font style="display: inline;">4, 2020 between Registrant US REIF Eurus Austin, LLC dba StoneCliff Building as successor in interest to StoneCliff Office, L.P.</font></a></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">8-K</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">9/10/2020</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10.1</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953018000025/ptie-20180511xex10_1.htm" style="-sec-extract:exhibit"><font style="display: inline;">10.14</font></a></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:5pt;vertical-align:super;line-height:100%">*</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953018000025/ptie-20180511xex10_1.htm" style="-sec-extract:exhibit"><font style="display: inline;">2018 Omnibus Incentive Plan.</font></a></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">8-K</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">5/11/2018</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10.1</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr></table>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">95</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div>
		<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953018000045/ptie-20180817xex10_1.htm" style="-sec-extract:exhibit"><font style="display: inline;">10.15</font></a></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953018000045/ptie-20180817xex10_1.htm" style="-sec-extract:exhibit"><font style="display: inline;">Form of Securities Purchase Agreement, dated </font><font style="display: inline;">August&nbsp;</font><font style="display: inline;">15, 2018, by and between Registrant and the purchasers named therein.</font></a></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">8-K</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">8/20/2018</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10.1</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953018000045/ptie-20180817xex10_2.htm" style="-sec-extract:exhibit"><font style="display: inline;">10.16</font></a></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953018000045/ptie-20180817xex10_2.htm" style="-sec-extract:exhibit"><font style="display: inline;">Agreement between Registrant and H.C. Wainwright &amp; Co., dated </font><font style="display: inline;">August&nbsp;</font><font style="display: inline;">15, 2018.</font></a></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">8-K</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">8/20/2018</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10.2</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953020000015/sava-20200327xex1_1.htm" style="-sec-extract:exhibit"><font style="display: inline;">10.17</font></a></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953020000015/sava-20200327xex1_1.htm" style="-sec-extract:exhibit"><font style="display: inline;">Sales Agreement, Dated </font><font style="display: inline;">March&nbsp;</font><font style="display: inline;">27, 2020, between Registrant and SVB Leerink LLC.</font></a></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">S-3</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">3/27/2020</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">1.1</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953020000048/sava-20200901xex10_1.htm" style="-sec-extract:exhibit"><font style="display: inline;">10.18</font></a></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:5pt;vertical-align:super;line-height:100%">*</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953020000048/sava-20200901xex10_1.htm" style="-sec-extract:exhibit"><font style="display: inline;">Cassava Sciences, Inc. 2020 Cash Incentive Bonus Plan</font></a></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">8-K</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">9/1/2020</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10.1</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953020000069/sava-20201113xex1_1.htm" style="-sec-extract:exhibit"><font style="display: inline;">10.19</font></a></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953020000069/sava-20201113xex1_1.htm" style="-sec-extract:exhibit"><font style="display: inline;">Underwriting Agreement, dated </font><font style="display: inline;">November&nbsp;</font><font style="display: inline;">13, 2020</font></a></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">8-K</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">11/13/2020</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">1.1</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953018000058/ptie-20181011xex10_1.htm" style="-sec-extract:exhibit"><font style="display: inline;">10.20</font></a></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:5pt;vertical-align:super;line-height:100%">*</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953018000058/ptie-20181011xex10_1.htm" style="-sec-extract:exhibit"><font style="display: inline;">Employment Agreement, executed on </font><font style="display: inline;">October&nbsp;</font><font style="display: inline;">9, 2018, by and between Registrant and Eric Schoen.</font></a></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">8-K</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10/11/2018</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10.1</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953021000002/sava-20210106xex10_1.htm" style="-sec-extract:exhibit"><font style="display: inline;">10.21</font></a></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:5pt;vertical-align:super;line-height:100%">*</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953021000002/sava-20210106xex10_1.htm" style="-sec-extract:exhibit"><font style="display: inline;">Employment Agreement, executed on </font><font style="display: inline;">January&nbsp;</font><font style="display: inline;">1, 2020, by and between Registrant and Dr. James Kupiec.</font></a></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">8-K</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">1/6/2021</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10.1</font></p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="sava-20201231xex23_1.htm" style="-sec-extract:exhibit"><font style="display: inline;">23.1</font></a></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="sava-20201231xex23_1.htm" style="-sec-extract:exhibit"><font style="display: inline;">Consent of Independent Registered Public Accounting Firm.</font></a></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">X</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="#Power_of_Attorney"><font style="display: inline;">24.1</font></a></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="#Power_of_Attorney"><font style="display: inline;">Power of Attorney (included in the signature page to this report).</font></a></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">X</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="sava-20201231xex31_1.htm" style="-sec-extract:exhibit"><font style="display: inline;">31.1</font></a></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="sava-20201231xex31_1.htm" style="-sec-extract:exhibit"><font style="display: inline;">Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a><font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">X</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="sava-20201231xex31_2.htm" style="-sec-extract:exhibit"><font style="display: inline;">31.2</font></a></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="sava-20201231xex31_2.htm" style="-sec-extract:exhibit"><font style="display: inline;">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a><font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">X</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><a href="sava-20201231xex32_1.htm" style="-sec-extract:exhibit"><font style="display: inline;">32.1</font></a></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<a href="sava-20201231xex32_1.htm" style="-sec-extract:exhibit"><font style="display: inline;">Certifications of the Chief Executive Officer and the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></a></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">X</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">101.INS</font></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">XBRL Instance Document.</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">X</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">101.SCH</font></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">XBRL Taxonomy Extension Schema Document.</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">X</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">101.CAL</font></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">XBRL Taxonomy Extension Calculation Linkbase Document.</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">X</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">101.DEF</font></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">XBRL Taxonomy Extension Definition Linkbase Document.</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">X</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">101.LAB</font></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">XBRL Taxonomy Extension Labels Linkbase Document.</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">X</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">101.PRE</font></p>
				</td>
				<td valign="top" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:56.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">XBRL Taxonomy Extension Presentation Linkbase Document.</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">X</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="4" valign="top" style="width:65.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">* Management contract, compensatory plan or arrangement.</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="4" valign="top" style="width:65.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 72pt 0pt 15.95pt;text-indent: -15.95pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">(c)</font><font style="display: inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 6pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;font-style:italic;">Financial Statement Schedules </font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">All financial statement schedules are omitted because the information is inapplicable or presented in the notes to the financial statements.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Item 16.</font><font style="display: inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font><a name="Form10KSummary"></a><font style="display: inline;font-weight:bold;font-style:italic;">Form 10-K Summary</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company has elected not to include summary information.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">96</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;"></font>
		</p>
		<p style="margin:0pt 4.7pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">SIGNATURES</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:212.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 10pt">
						<font style="display: inline;">(Principal Executive</font></p>
				</td>
				<td valign="top" style="width:166.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:90.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:212.75pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:166.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Cassava Sciences, Inc.</font></p>
				</td>
				<td valign="top" style="width:90.30pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:212.75pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:256.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">(Registrant)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:212.75pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:256.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:212.75pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:166.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">/s/ REMI BARBIER</font></p>
				</td>
				<td valign="top" style="width:90.30pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:212.75pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:256.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Remi Barbier,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:212.75pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:256.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Chairman of the Board of Directors,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:212.75pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:256.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">President and Chief Executive Officer</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:212.75pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:256.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:93.75%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Dated: </font><font style="display: inline;">March&nbsp;</font><font style="display: inline;">23</font><font style="display: inline;">, 2021</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 4.7pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">POWER</font><a name="Power_of_Attorney"></a><font style="display: inline;font-weight:bold;"> OF ATTORNEY</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Remi Barbier his true and lawful attorneys-in-fact, with full power of substitution, for him in any and all capacities, to sign any amendments to this Annual Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact or their substitute or substitutes may do or cause to be done by virtue hereof.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:37.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:40.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:37.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:40.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Signature</font><font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:40.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Title </font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:16.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Date</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:40.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:16.86%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">/s/&nbsp;&nbsp;REMI BARBIER</font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:40.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">President, Chief Executive Officer and </font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">March </font><font style="display: inline;">23</font><font style="display: inline;">, 2021</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Remi Barbier</font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:40.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Chairman of the Board of Directors</font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:40.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">(Principal Executive Officer)</font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:40.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">/s/&nbsp;&nbsp;ERIC </font><font style="display: inline;">J. </font><font style="display: inline;">SCHOEN</font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:40.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Chief Financial Officer</font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">March </font><font style="display: inline;">23</font><font style="display: inline;">, 2021</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Eric </font><font style="display: inline;">J. </font><font style="display: inline;">Schoen</font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:40.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">(Principal Financial Officer)</font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:40.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">/s/&nbsp;&nbsp;NADAV FRIEDMANN, PH.D., M.D.</font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:40.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Chief Medical Officer</font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">March </font><font style="display: inline;">23</font><font style="display: inline;">, 2021</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Nadav Friedmann, Ph.D., M.D.</font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:40.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;"> and Director</font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:40.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">/s/&nbsp;&nbsp;ROBERT Z. GUSSIN, PH.D. </font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:40.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Director</font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">March </font><font style="display: inline;">23</font><font style="display: inline;">, 2021</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Robert Z. Gussin, Ph.D.</font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:40.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:40.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">/s/&nbsp;&nbsp;MICHAEL J. O'DONNELL, ESQ. </font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:40.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Director</font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">March </font><font style="display: inline;">23</font><font style="display: inline;">, 2021</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Michael J. O'Donnell, Esq.</font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:40.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:40.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">/s/&nbsp;&nbsp;SANFORD R. ROBERTSON</font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:40.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Director</font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">March </font><font style="display: inline;">23</font><font style="display: inline;">, 2021</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Sanford R. Robertson</font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:40.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:40.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">/s/&nbsp;&nbsp;PATRICK SCANNON, M.D., PH.D. </font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:40.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Director</font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">March </font><font style="display: inline;">23</font><font style="display: inline;">, 2021</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Patrick Scannon, M.D., Ph.D.</font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:40.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:40.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">97</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>sava-20201231xex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--HTML document created with Certent Disclosure Management 6.39.2.1-->
<!--Created on: 3/23/2021 3:59:36 PM-->
<html>
	<head>
		<title>
			Exhibit 231
		</title>
	</head>
	<body><div style="margin-left:72pt;margin-right:72pt;">
		<p style="margin:0pt 0pt 0pt 54pt;text-indent: -18pt;text-align:right;text-decoration:none;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="color:#0000FF;display: inline;color:#000000;text-decoration:none;">EXHIBIT 23.1</font>
		</p>
		<p style="margin:0pt;text-align:center;text-decoration:none;line-height:93.75%;font-weight:bold;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:normal;font-size:10pt;text-decoration:none;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:5pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Consent of Independent</font><font style="display: inline;font-weight:bold;"> Registered Public Accounting Firm</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We consent to the incorporation by reference in the following Registration Statements:</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size: 10pt;margin:5pt 0pt 0pt;">
				<font style="margin:5pt 0pt;border-bottom:1pt none #D9D9D9;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size:10pt;;"> 1)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size: 10pt;margin:5pt 0pt 0pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">Registration Statement (Form S-3 No. 333-252931) and related Prospectus of Cassava Sciences, Inc.,</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size: 10pt;margin:5pt 0pt 0pt;">
				<font style="margin:5pt 0pt;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size:10pt;;"> 2)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size: 10pt;margin:5pt 0pt 0pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">Registration Statement (Form S-3 No. 333-237452) and related Prospectus of Cassava Sciences, Inc.,</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size: 10pt;margin:5pt 0pt 0pt;">
				<font style="margin:5pt 0pt;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size:10pt;;"> 3)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size: 10pt;margin:5pt 0pt 0pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">Registration Statement (Form S-8 No. 333-168390) pertaining to the 2000 Employee Stock Purchase Plan of Registrant,</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size: 10pt;margin:5pt 0pt 0pt;">
				<font style="margin:5pt 0pt;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size:10pt;;"> 4)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size: 10pt;margin:5pt 0pt 0pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">Registration Statement (Form S-1 No. 333-228883) and related Prospectus of Registrant, </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size: 10pt;margin:5pt 0pt 0pt;">
				<font style="margin:5pt 0pt;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size:10pt;;"> 5)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size: 10pt;margin:5pt 0pt 0pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">Registration Statement (Form S-8 No. 333-225708) pertaining to the 2018 Omnibus Incentive Plan of Registrant, and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size: 10pt;margin:5pt 0pt 0pt;">
				<font style="margin:5pt 0pt;border-top:1pt none #D9D9D9;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size:10pt;;"> 6)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size: 10pt;margin:5pt 0pt 0pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">Registration Statement (Form S-8 No. 333-147336) pertaining to the 2000 Employee Stock Purchase Plan of Registrant;</font></p></td></tr></table></div>
		<p style="margin:5pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">of our report dated March 23, 2021, with respect to the financial statements of Cassava Sciences, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2020.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;background-color:yellow;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">/s/Ernst &amp;Young LLP</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Austin, Texas</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">March 23, 2021</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>sava-20201231xex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--HTML document created with Certent Disclosure Management 6.39.2.1-->
<!--Created on: 3/23/2021 3:59:44 PM-->
<html>
	<head>
		<title>
			Exhibit 311
		</title>
	</head>
	<body><div style="margin-left:72pt;margin-right:72pt;">
		<p style="margin:5pt 0pt;text-align:right;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="color:#0000FF;display: inline;color:#000000;text-decoration:none;">EXHIBIT </font><font style="display: inline;">31.1</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">PRINCIPAL EXECUTIVE OFFICER CERTIFICATION PURSUANT TO</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">I, Remi Barbier, certify that: </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 1.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">I have reviewed this </font><font style="display: inline;color:#000000;">Annual </font><font style="display: inline;color:#000000;">Report on Form 10-K of </font><font style="display: inline;color:#000000;">Cassava Sciences</font><font style="display: inline;color:#000000;">, Inc.;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 2.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 3.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;border-bottom:1pt none #D9D9D9;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 4.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">The registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e</font><font style="display: inline;color:#000000;">))</font><a name="_DV_C218"></a><font style="color:#0000FF;display: inline;color:#000000;text-decoration:none;"> and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))</font><font style="display: inline;color:#000000;"> for the registrant and have: </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> a.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 72pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;font-size:6pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;text-decoration:none;color:#000000;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;border-top:1pt none #D9D9D9;text-decoration:none;color:#000000;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> b.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;text-decoration:none;color:#000000;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="color:#0000FF;display: inline;color:#000000;text-decoration:none;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;color:#000000;font-size:6pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> c.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Evaluated the effectiveness of the registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;font-size:6pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> d.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Disclosed in this report any change in the registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s internal control over financial reporting that occurred during the registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s most recent fiscal quarter (the registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 5.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">The registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s auditors and the audit committee of the registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> a.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s ability to record, process, summarize and report financial information; and</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 54pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> b.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s internal control over financial reporting.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-indent:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 270pt;border-bottom:1pt none #D9D9D9 ;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:2.5pt;"><font style="display: inline;text-decoration:underline;color:#000000;">/s/ REMI BARBIER</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:20.5pt;text-align:left"><font style="display: inline;text-decoration:underline;color:#000000;"></font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;text-decoration:underline;color:#000000;"></font></font><font style="display: inline;text-decoration:underline;color:#000000;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;text-decoration:underline;color:#000000;"></font><font style="display: inline;text-decoration:underline;color:#000000;"></font>
		</p>
		<p style="margin:0pt 0pt 0pt 270pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Remi Barbier,</font>
		</p>
		<p style="margin:0pt 0pt 0pt 270pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Chairman of the Board of Directors,</font>
		</p>
		<p style="margin:0pt 0pt 0pt 270pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">President and Chief Executive Officer</font>
		</p>
		<p style="margin:0pt 0pt 3pt 270pt;border-top:1pt none #D9D9D9 ;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">(Principal Executive Officer)</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Date: </font><font style="display: inline;color:#000000;">March </font><font style="display: inline;color:#000000;">23</font><font style="display: inline;color:#000000;">, 20</font><font style="display: inline;color:#000000;">2</font><font style="display: inline;color:#000000;">1</font>
		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>sava-20201231xex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--HTML document created with Certent Disclosure Management 6.39.2.1-->
<!--Created on: 3/23/2021 3:59:52 PM-->
<html>
	<head>
		<title>
			Exhibit 312
		</title>
	</head>
	<body><div style="margin-left:72pt;margin-right:72pt;">
		<p style="margin:0pt;text-align:right;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="color:#0000FF;display: inline;color:#000000;text-decoration:none;">EXHIBIT </font><font style="display: inline;">31.2</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">PRINCIPAL FINANCIAL OFFICER CERTIFICATION PURSUANT TO</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">I, </font><font style="display: inline;">Eric J. Schoen</font><font style="display: inline;">, certify that: </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 1.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">I have reviewed this </font><font style="display: inline;color:#000000;">Annual </font><font style="display: inline;color:#000000;">Report on Form 10-K of </font><font style="display: inline;color:#000000;">Cassava Sciences</font><font style="display: inline;color:#000000;">, Inc.;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 2.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 3.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 4.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">The registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)</font><font style="display: inline;color:#000000;">)</font><font style="color:#0000FF;display: inline;color:#000000;text-decoration:none;"> and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) </font><font style="display: inline;color:#000000;">for the registrant and have: </font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> a.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;font-size:6pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="text-decoration:none;color:#000000;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;text-decoration:none;color:#000000;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> b.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-decoration:none;color:#000000;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="color:#0000FF;display: inline;color:#000000;text-decoration:none;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;color:#000000;font-size:6pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> c.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Evaluated the effectiveness of the registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;font-size:6pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> d.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Disclosed in this report any change in the registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s internal control over financial reporting that occurred during the registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s most recent fiscal quarter (the registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s internal control over financial reporting; and </font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 5.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">The registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s auditors and the audit committee of the registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s board of directors (or persons performing the equivalent functions): </font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;border-bottom:1pt none #D9D9D9;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> a.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s ability to record, process, summarize and report financial information; and </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;border-top:1pt none #D9D9D9;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> b.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s internal control over financial reporting. </font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 270pt;border-bottom:1pt none #D9D9D9 ;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:55.5pt;"><font style="display: inline;text-decoration:underline;color:#000000;">/s/ </font><font style="display: inline;text-decoration:underline;color:#000000;">ERIC J. SCHOEN</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:65.5pt;text-align:left"><font style="display: inline;text-decoration:underline;color:#000000;"></font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:center"><font style="display: inline;text-decoration:underline;color:#000000;"></font></font>
		</p>
		<p style="margin:0pt 0pt 0pt 270pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Eric J. Schoen</font><font style="display: inline;color:#000000;">,</font>
		</p>
		<p style="margin:0pt 0pt 0pt 270pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Chief Financial Officer</font>
		</p>
		<p style="margin:0pt 0pt 0pt 270pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">(Principal Financial Officer)</font>
		</p>
		<p style="margin:0pt 0pt 0pt 270pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 270pt;text-align:center;border-top:1pt none #D9D9D9 ;line-height:normal;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;">Date: </font><font style="display: inline;">March </font><font style="display: inline;">23</font><font style="display: inline;">, 20</font><font style="display: inline;">2</font><font style="display: inline;">1</font>
		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>sava-20201231xex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--HTML document created with Certent Disclosure Management 6.39.2.1-->
<!--Created on: 3/23/2021 4:00:01 PM-->
<html>
	<head>
		<title>
			Exhibit 321
		</title>
	</head>
	<body><div style="margin-left:72pt;margin-right:72pt;">
		<p style="margin:0pt 4.5pt 0pt 396pt;text-align:right;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="color:#0000FF;display: inline;color:#000000;text-decoration:none;">EXHIBIT </font><font style="display: inline;color:#000000;">32.1</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">CERTIFICATIONS OF THE CHIEF EXECUTIVE OFFICER AND THE </font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 0pt;text-align:center;text-decoration:none;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">CHIEF FINANCIAL OFFICER PURSUANT TO </font><font style="color:#0000FF;display: inline;color:#000000;text-decoration:none;">18 U.S.C. SECTION 1350, </font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="color:#0000FF;display: inline;color:#000000;text-decoration:none;">AS ADOPTED PURSUANT TO </font><font style="display: inline;color:#000000;">SECTION 906 OF THE SARBANES-OXLEY ACT OF </font><font style="color:#0000FF;display: inline;color:#000000;text-decoration:none;">2002</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, </font><font style="display: inline;">each of the undersigned officers</font><font style="display: inline;"> of </font><font style="display: inline;">Cassava Sciences</font><font style="display: inline;">, Inc. (the &#x201C;Company&#x201D;), hereby certif</font><font style="display: inline;">ies</font><font style="display: inline;"> that to the best of </font><font style="display: inline;">such officer&#x2019;s </font><font style="display: inline;"> knowledge:</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 4.5pt 0pt 0pt;">
				<font style="margin:0pt 4.5pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 1.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 4.5pt 0pt 0pt;">
			<font style="display: inline;color:#000000;">The Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, </font><font style="display: inline;color:#000000;">20</font><font style="display: inline;color:#000000;">20</font><font style="display: inline;color:#000000;">, and to which this certification is attached as Exhibit 32.1 (the &#x201C;Periodic Report&#x201D;), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and</font></p></td></tr></table></div>
		<p style="margin:0pt 4.5pt 0pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 4.5pt 0pt 0pt;">
				<font style="margin:0pt 4.5pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 2.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 4.5pt 0pt 0pt;">
			<font style="display: inline;color:#000000;">The information contained in this Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table></div>
		<p style="margin:0pt 4.5pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 288pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Date: </font><font style="display: inline;color:#000000;">March</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">23</font><font style="display: inline;color:#000000;">, &nbsp;</font><font style="display: inline;color:#000000;">20</font><font style="display: inline;color:#000000;">2</font><font style="display: inline;color:#000000;">1</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 288pt;text-align:left;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 288pt;text-align:left;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;text-decoration:underline;color:#000000;">/s/ REMI BARBIER</font><font style="display: inline;text-decoration:underline;color:#000000;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;text-decoration:underline;color:#000000;"></font><font style="display: inline;text-decoration:underline;color:#000000;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;text-decoration:underline;color:#000000;"></font><font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 288pt;text-align:left;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Remi Barbier,</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 288pt;text-align:left;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Chairman of the Board of Directors,</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 288pt;text-align:left;border-top:1pt none #D9D9D9 ;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">President and Chief Executive Officer</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 288pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 288pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 288pt;text-align:left;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;text-decoration:underline;color:#000000;">/s/ </font><font style="display: inline;text-decoration:underline;color:#000000;">ERIC J. SCHOEN</font><font style="display: inline;text-decoration:underline;color:#000000;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;text-decoration:underline;color:#000000;"></font><font style="display: inline;text-decoration:underline;color:#000000;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;text-decoration:underline;color:#000000;"></font><font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 288pt;text-align:left;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Eric J. Schoen</font><font style="display: inline;color:#000000;">,</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 288pt;text-align:left;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Chief </font><font style="display: inline;color:#000000;">Financial</font><font style="display: inline;color:#000000;"> Officer</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 288pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 288pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>sava-20201231x10kg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sava-20201231x10kg001.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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MJS10!6_L^U_YY?\ CQ_QH_L^U_YY?^/'_&K-% %;^S[7_GE_X\?\:/[/M?\
MGE_X\?\ &K-% %;^S[7_ )Y?^/'_ !H_L^U_YY?^/'_&K-% %;^S[7_GE_X\
M?\:/[/M?^>7_ (\?\:LT4 5O[/M?^>7_ (\?\:/[/M?^>7_CQ_QJS10!6_L^
MU_YY?^/'_&C^S[7_ )Y?^/'_ !JS10!6_L^U_P">7_CQ_P :/[/M?^>7_CQ_
MQJS10!6_L^U_YY?^/'_&C^S[7_GE_P"/'_&K-% %;^S[7_GE_P"/'_&C^S[7
M_GE_X\?\:LT4 5O[/M?^>7_CQ_QH_L^U_P">7_CQ_P :LT4 5O[/M?\ GE_X
M\?\ &C^S[7_GE_X\?\:LT4 5O[/M?^>7_CQ_QH_L^U_YY?\ CQ_QJS10!6_L
M^U_YY?\ CQ_QH_L^U_YY?^/'_&K-% %;^S[7_GE_X\?\:/[/M?\ GE_X\?\
M&K-% %;^S[7_ )Y?^/'_ !H_L^U_YY?^/'_&K-% %;^S[7_GE_X\?\:/[/M?
M^>7_ (\?\:LT4 5O[/M?^>7_ (\?\:/[/M?^>7_CQ_QJS10!6_L^U_YY?^/'
M_&C^S[7_ )Y?^/'_ !JS10!6_L^U_P">7_CQ_P :/[/M?^>7_CQ_QJS10!6_
ML^U_YY?^/'_&C^S[7_GE_P"/'_&K-% %;^S[7_GE_P"/'_&C^S[7_GE_X\?\
M:LT4 5O[/M?^>7_CQ_QH_L^U_P">7_CQ_P :LT4 5O[/M?\ GE_X\?\ &C^S
M[7_GE_X\?\:LT4 5O[/M?^>7_CQ_QH_L^U_YY?\ CQ_QJS10!6_L^U_YY?\
MCQ_QH_L^U_YY?^/'_&K-% %;^S[7_GE_X\?\:/[/M?\ GE_X\?\ &K-% %;^
MS[7_ )Y?^/'_ !H_L^U_YY?^/'_&K-% %;^S[7_GE_X\?\:/[/M?^>7_ (\?
M\:LT4 5O[/M?^>7_ (\?\:/[/M?^>7_CQ_QJS10!6_L^U_YY?^/'_&C^S[7_
M )Y?^/'_ !JS10!6_L^U_P">7_CQ_P :/[/M?^>7_CQ_QJS10!6_L^U_YY?^
M/'_&C^S[7_GE_P"/'_&K-% %;^S[7_GE_P"/'_&C^S[7_GE_X\?\:LT4 5O[
M/M?^>7_CQ_QH_L^U_P">7_CQ_P :LT4 5O[/M?\ GE_X\?\ &C^S[7_GE_X\
M?\:LT4 5O[/M?^>7_CQ_QH_L^U_YY?\ CQ_QJS10!6_L^U_YY?\ CQ_QH_L^
MU_YY?^/'_&K-% %;^S[7_GE_X\?\:/[/M?\ GE_X\?\ &K-% %;^S[7_ )Y?
M^/'_ !H_L^U_YY?^/'_&K-% %;^S[7_GE_X\?\:/[/M?^>7_ (\?\:LT4 5O
M[/M?^>7_ (\?\:/[/M?^>7_CQ_QJS10!6_L^U_YY?^/'_&C^S[7_ )Y?^/'_
M !JS10!6_L^U_P">7_CQ_P :/[/M?^>7_CQ_QJS10!6_L^U_YY?^/'_&C^S[
M7_GE_P"/'_&K-% %;^S[7_GE_P"/'_&C^S[7_GE_X\?\:LT4 5O[/M?^>7_C
MQ_QH_L^U_P">7_CQ_P :LT4 5O[/M?\ GE_X\?\ &C^S[7_GE_X\?\:LT4 9
M>H6L,$"M&FUBV,Y/H:*FU7_CU7_?'\C10!+I_P#QXQ_C_,U9JKI__'C'^/\
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M/_[]O_\ %UQ-%>C]4H_RG)[>IW.V_P"%HZW_ ,^NG_\ ?M__ (NC_A:.M_\
M/KI__?M__BZXFBCZI1_E#V]3N=M_PM'6_P#GUT__ +]O_P#%T?\ "T=;_P"?
M73_^_;__ !=<311]4H_RA[>IW.V_X6CK?_/KI_\ W[?_ .+H_P"%HZW_ ,^N
MG_\ ?M__ (NN)HH^J4?Y0]O4[G;?\+1UO_GUT_\ []O_ /%T?\+1UO\ Y]=/
M_P"_;_\ Q=<311]4H_RA[>IW.V_X6CK?_/KI_P#W[?\ ^+H_X6CK?_/KI_\
MW[?_ .+KB:*/JE'^4/;U.YVW_"T=;_Y]=/\ ^_;_ /Q='_"T=;_Y]=/_ ._;
M_P#Q=<311]4H_P H>WJ=SMO^%HZW_P ^NG_]^W_^+H_X6CK?_/KI_P#W[?\
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M )]=/_[]O_\ %T?\+1UO_GUT_P#[]O\ _%UQ-%'U2C_*'MZG<[;_ (6CK?\
MSZZ?_P!^W_\ BZ/^%HZW_P ^NG_]^W_^+KB:*/JE'^4/;U.YVW_"T=;_ .?7
M3_\ OV__ ,71_P +1UO_ )]=/_[]O_\ %UQ-%'U2C_*'MZG<]O\ !NO77B+1
MYKN[CA21+@Q 0J0,!5/<GGDUT5<1\+O^19N?^OQO_0$KMLUX>)BHU9);'I4F
MW!-BT4F:,U@:"T4F:,T +7)>-_%%]X:^P_8XK>3[1YF_SE8XV[<8P1_>-=9F
MO-_BO_S"/^VW_LE=.$A&=91DM/\ @&5>3C3;1F_\+1UO_GUT_P#[]O\ _%T?
M\+1UO_GUT_\ []O_ /%UQ-%>U]4H_P IYWMZG<[;_A:.M_\ /KI__?M__BZ/
M^%HZW_SZZ?\ ]^W_ /BZXFBCZI1_E#V]3N=M_P +1UO_ )]=/_[]O_\ %T?\
M+1UO_GUT_P#[]O\ _%UQ-%'U2C_*'MZG<[;_ (6CK?\ SZZ?_P!^W_\ BZ/^
M%HZW_P ^NG_]^W_^+KB:*/JE'^4/;U.YVW_"T=;_ .?73_\ OV__ ,71_P +
M1UO_ )]=/_[]O_\ %UQ-%'U2C_*'MZG<[;_A:.M_\^NG_P#?M_\ XNC_ (6C
MK?\ SZZ?_P!^W_\ BZXFBCZI1_E#V]3N=M_PM'6_^?73_P#OV_\ \71_PM'6
M_P#GUT__ +]O_P#%UQ-%'U2C_*'MZG<[;_A:.M_\^NG_ /?M_P#XNC_A:.M_
M\^NG_P#?M_\ XNN)HH^J4?Y0]O4[GK'@WQGJ/B+6)K2[AM4C2W,H,*,#D,H[
ML>.37<UY)\+O^1FN?^O-O_0TKUK->/C81A5M%61WX>3E"[%HI,T9KD-Q:*3-
M&: %KG?&6O77AW1X;NTCA>1[@1$3*2,%6/8CG@5T.:XGXHG_ (IFV_Z_%_\
M0'K?#14JL4]C.JVH-HYO_A:.M_\ /KI__?M__BZ/^%HZW_SZZ?\ ]^W_ /BZ
MXBBO<^J4/Y3S?;5.YV__  M'6_\ GUT__OV__P 71_PM'6_^?73_ /OV_P#\
M77$44?5*'\H>VJ=SM_\ A:.M_P#/KI__ '[?_P"+H_X6CK?_ #ZZ?_W[?_XN
MN(HH^J4/Y0]M4[G;_P#"T=;_ .?73_\ OV__ ,71_P +1UO_ )]=/_[]O_\
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M /OV_P#\77$T57U2A_*3[>IW.V_X6CK?_/KI_P#W[?\ ^+H_X6CK?_/KI_\
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M\C-<_P#7FW_H:5CB<-2C2DU'4TI59N:39ZY129HS7A'HBT4F:,T +129HS0
MM%)FC- "T4F:,T +129HS0!2U7_CU7_?'\C12:K_ ,>J_P"^/Y&B@"73_P#C
MQC_'^9JS5;3_ /CQC_'^9JS0 4444 %%%% !1110 4444 %%%% !1110 444
M4 <WX]_Y$K4/^V?_ *,6O$Z]L\>_\B5J'_;/_P!&+7B=>WEO\)^OZ(\[%_&O
M0****]$Y0HHHH **** "BBB@ HHHH **** "BBB@ K2\/?\ (S:5_P!?D/\
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MXT3*M_#9Y)1245]&>4+1244 +1244 +1244 +1244 +1244 +1244 +1244
M:?AW_D9M)_Z_(?\ T,5] U\_>'?^1GTG_K\A_P#0Q7T#7CYG\<3OPGPL****
M\PZPHHHH *S?$7_(LZK_ -><W_H!K2K,\1?\BSJW_7G-_P"@&KI_&B9?"SP"
MBBBOJ#QPHHHH **** "BBB@ HHHH **** "BBB@ HHHH *^@/#O_ "+.E?\
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M579F9HS4>:,UJ029HS4>:,T 29KN/A6?^*HN?^O)O_0TK@\UW7PI/_%47/\
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M_P"VW_LE=>!_WB/S_(QQ'\)GF]%%%?0GEA1110 4444 %%%% !1110 4444
M%%%% !1110!VWPO_ .1FN?\ KS;_ -#2O6J\E^%__(S7/_7FW_H:5ZU7@YA_
M'/2PO\,****X3H"BBB@ KB/BG_R+%M_U^+_Z ]=O7#_%/_D6+;_K]7_T!ZZ,
M+_&B95OX;/(\T9IN:,U]$>4.S1FFYHS0 [-&:;FC- #LT9IN:,T .S1FFYHS
M0 [-&:;FC- #LT9IN:,T .S1FFYHS0!J>'?^1GTG_K\A_P#0Q7T%7SYX</\
MQ4^D_P#7[#_Z&*^@Z\?,OCB=^$^%A1117FG6%%%% !6;XB_Y%G5O^O.;_P!
M-:59OB+_ )%G5O\ KSF_] -73^-$R^%GS_1117U!XX4444 %%%% !1110 44
M44 %%%% !1110 4444 %?0'AW_D6=)_Z\X?_ $ 5\_U] >'?^19TG_KSA_\
M0!7F9G\$3KPGQ,TJ***\<[PHHHH **** /G[Q%_R,VK?]?DW_H9K-K2\1?\
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M;7B7C[_D=M0_[9_^BUKT,M_BOT_5'+B_@7J<W1117MGGA1110 4444 %%%%
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M!7CG>,2/:*EHHH **** "BBB@ HHHH **** *6J?\>R_[X_D:*-3_P"/9?\
M?'\C10!)8?\ 'E'^/\S5G-5;'_CRC_'^9JS0 N:,TE% "YHS244 +FC-)10
MN:,TE% "YHS244 +FC-)10 N:,TE% '.>/?^1*U#_MG_ .C%KQ.O:_'O_(E:
MA_VS_P#1BUXI7MY;_"?K^B//Q?QKT"BBBO0.4**** "BBB@ HHHH **** "B
MBB@ HHHH *TO#W_(RZ5_U^0_^ABLVM+P]_R,NE?]?D/_ *&*FI\#*C\2/?LT
M9I**^6/8%S1FDHH 7-&:2B@!<U\W5](5\W5ZN6?;^7ZG%C/LBT4E%>L<0M%)
M10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10!] >'O^19TK_KSA_\ 0!6E
MFLSP]_R+.E?]></_ * *TJ^7J?&SV(_"A<T9I**@H7-&:2B@!<UXEX^_Y';4
M/^V?_HM:]LKQ+Q]_R.VH?]L__1:UZ&6_Q7Z?JCEQ?P+U.<HI**]L\\6BDHH
M6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH ];^%Q_XIFY_Z_&_] 2NWS7$?
M"[_D6;G_ *_&_P#0$KMJ^<Q?\:1ZM'^&A<T9I**YS47-&:2B@!<UYO\ %?\
MYA'_ &V_]DKT>O./BM_S"/\ MM_[)77@?X\?G^1AB/X3/-Z***^@/,"BBB@
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MTZS/#W_(LZ5_UYP_^@"M*OEZGQL]B/PH6BDHJ"A:*2B@!:\2\?'_ (K;4/\
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M/_7FW_H:5ZS7DOPO_P"1EN?^O-O_ $-*]9KP<P_C'I87^&+1245Q'0+1244
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MQ_(T4 /L?^/./\?YFK%5[+_CSC_'^9JQ0 4444 %%%% !1110 4444 %%%%
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MZHY<7\"]3FZ*2BO:. 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH
M]<^%W_(LW/\ U^-_Z E=M7$?"[_D6;G_ *_&_P#0$KMZ^=Q7\:1ZE'^&@HHH
MKG-0HHHH *\X^*W_ #"/^VW_ +)7H]><?%;_ )A/_;;_ -DKKP/\>/S_ ",,
M3_"9YQ1117T!Y84444 %%%% !1110 4444 %%%% !1110 4444 =K\,/^1EN
M?^O-O_0TKUFO)OAA_P C+<_]>;?^AI7K->#F'\8]/"_PPHHHKB.@**** "N$
M^*__ "*UK_U^I_Z ]=W7"?%?_D5K7_K]3_T!ZWPO\:)E6_AL\=HHHKZ \P**
M** "NRTOXE:SI.F6]A!;6#10)L4R1N6(]\,*XVBHG3A-6DKE1DXZH]"\+V=M
MXXUS4-0O;Z>QU4%9(ULVV<;=N1G)XP,\]ZZS1--NO!]GJ.K^(]7^U2% BLTK
M/A1D@ MSDD]!7BD,TMO*LL,CQR(<JZ,00?8BK-QJU_>NC7MY/=[/NBXE:0#\
MS7-5P\I:)^[V-854M6M2"XG:YNI9W W2N7;'J3FNW?\ XI3X>*@^74M<Y8]T
M@ Z?B#_X\?2N1N)A&(PL$/SQAB=G0FC5-9U#6KA)]0N/.DC01I\BJ%4=@% %
M:*]5+2R)T@WW/8%FFM/$7A.RL))$TZ2TD+1Q_<<!,@GU[<^_O7DOB1(8O$VI
MQVP A6ZD"@=!\QX%6++QAX@T_3OL%KJ<L=L 0J[5)4'T8C(_ UB$EF+,223D
MD]Z5"A*G)M_UJ.I44E9"4445TF(4444 7M&/_$\T_P#Z^8__ $(5Z]FO(-&_
MY#FG_P#7S'_Z$*]@"YKR<Q^*)VX3X6)S4BH34D4!8]*T(+7VKSCK*\-N36A#
M;8[58C@"U. !0 U$P*H>(O\ D6-6_P"O*;_T UIUF>(_^18U;_KRF_\ 0#5T
M_C1,OA9\^YHS3:*^F/('9HS3:* '9HS3:* '9HS3:* '9HS3:* '9HS3:* '
M9HS3:* '9HS3:* '9KZ"\._\BQI/_7G#_P"@"OGNOH3PY_R+&D_]>4/_ * *
M\W,O@B=>$^)FG1117D'<%%%% !1110!\\>)/^1HU?_K]F_\ 0S696EXD_P"1
MIU?_ *_9O_0S697TM/X$>1+XF+12458A:*2B@!:*U?#OA^\\1ZHEG:J53(,L
MVW*Q+ZG^@[T[Q/H7_"-ZT^G?:?M&U%?S/+V=1Z9-1[2//R7U'ROEYNAD45U/
MA/P/>>)UEG:4V=H@PLS1;M[>@&1GW.:P[;2Y[S6UTNVP\SS&)2>!UQD^@[TE
M5@VU?;<?)*R=MRE178:KX#%EIU]<V6K1WLNGL!=PB$H8^,\')SC^A],5EZ%X
M<_M?3]1U"XN_LEG8Q[FE\O?N;LH&1S_B/6DJT''F3T&Z<D[6,.BDHK4@6BDH
MH 6O7_A4<>%[G_K];_T!*\?KU/X:W B\.7"YZW;'_P <2N/'_P $WPW\0]'W
M"C<*ROMH]:/MH]:\,]$U=PHW"LK[:/6C[:/6@#5W"C<*RQ>9[U*EP6H OYI:
MB1LBI* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** *>I?\ 'NO^_P#T-%&I?\>Z_P"__0T4 /LO^/2/
M\?YFK%5[+_CT3\?YU/0 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)1
M0!SOCS_D2]0_[9_^C%KQ6O:?'G_(EZA_VS_]&+7BM>WEO\)^OZ(\_%_&O06B
MDHKT#E%HI** %HI** %HI** %HI** %HI** %HI** %K1\/?\C+I7_7Y#_Z&
M*S:TO#W_ ",NE?\ 7Y#_ .ABHJ? QQ^)'OE%)17RY[(M%)10 M%)10 M?-^:
M^CZ^;Z]7+/M?+]3BQGV1<T9I**]4XQ<T9I** %S1FDHH 7-&:2B@!<T9I**
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MH 6BDHH 6BDHH 6BDHH 6BDHH 6OH3PY_P BQI/_ %Y0_P#H KYZKZ$\.?\
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M_P"V?_HM:[\N_BOT_P CFQ7P+U.<HI**]H\\6BDHH 6BDHH 6BDHH 6BDHH
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MTC2XI%DCTVT1U(966!001T(.*NT %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5-0_P"/=?\
M>_H:*-0_U"_[W]#10 ^S_P"/5/Q_G4]5[3_CU3\?YU/0 M%)10 M%)10 M%)
M10 M%)10 M%)10 M%)10 M%)10!SOCS_ )$O4/\ MG_Z,6O%J]H\=_\ (F:A
M_P!L_P#T8M>+U[>6_P )^OZ(\_%_&O0****[SE"BBB@ HHHH **** "BBB@
MHHHH **** "M'P__ ,C+I?\ U^1?^ABLZM'P_P#\C)I?_7Y%_P"ABIJ? RH_
M$CWNBDHKY<]@6BDHH 6BDHH 6OFZOI"OF_->IEGVOE^IQXOH%%&:,UZIQ!11
MFC- !11FC- !11FC- !11FC- !11FC- !11FC- !11FC- 'O_A[_ )%G2O\
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MI** %HI** %HI** %HI** %HI** %HI** .U^&7_ ",EQ_UYM_Z&E>KUY/\
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M%)10 M%)10 M?-]?1]?-]>IEOVOE^IQXOH+1245ZIQ"T4E% "T4E% "T4E%
M"T4E% "T4E% "T4E% "T4E% 'O\ X>_Y%G2O^O.'_P! %:59GA[_ )%G2O\
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M_P"AI7JU>4?#+_D9+C_KS;_T-*]6KPLP_C'I87^&+1245Q'0+1244 +1244
M+1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244
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M[^*7_,)_[;?^R5UX+^/'Y_D8XC^$SSNBBBO?/+"BBB@ HHHH **** "BBB@
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M:,TE% "YHS244 +FC-)10 N:,TE% "YHS244 +FC-)10 N:,TE% "YHS244
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M?^AI7JM>5?#3_D8[C_KT;_T-*]4KPL?_ !CT<-_#%HI**XCH%HI** %HI**
M%HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI**
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ME% "T4E% "T4E% "T4E% "T4E% '/>.O^1-O_P#MG_Z,6O&:]E\=?\B;?_\
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M9D9#AU*GT(Q3:<SLYR[%CZDYIM6KVU)=KZ!1113 **** "BBB@#O_ [E=%F
M/_+PW_H*UTWFMZURW@G_ ) TW_7PW_H*UTE?/8K^-(].C_#1+YK>M'FMZU%1
M6!J2^:WK1YK>M144 2^:WK7(^-V+?8,_]-/_ &6NIKE/&O\ RX_]M/\ V6NK
M!?QX_/\ (QQ'\-G)T445] >8%%%% !1110 4444 %%%% !1110 4444 %%%%
M '9_#3_D8[C_ *]&_P#0TKU2O*OAI_R,=Q_UZ-_Z&E>J5X6/_C'HX;^&+124
M5Q'0+1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1
M244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +3)ED>"1(I/*D9
M2$DV[MIQP<=\4ZB@#GO[ U;[=]M_M_\ TCRO*W_8T^YG.,9QUK?A61((TED\
MV15 >3;MW'')QVS3J* %HI** %HI** %HI** %HI** %HI** %HI** %HI**
M %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI**
M %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI**
M %HI** %HI** %HI** %HI** %HI** %HI** %HI** (;O\ U0_WJ*2[_P!4
M/]ZB@!;?_4+^/\ZEJ*#_ %*U)0 M%)10 M%)10 M%)10 M%)10 M%)10 M%)
M10 M%)10!SWCK_D3;_\ [9_^C%KQJO9/'/\ R)M__P!L_P#T8M>-U[67?PGZ
M_P"1Y^*^->@4445WG,%%%% !1110 4444 %%%% !1110 4444 %:.@?\C'I?
M_7W%_P"ABLZM'0/^1CTO_K[B_P#0Q45/@94?B1[M1245\R>N+1244 +1244
M+7SC7T;7SE7J9;]KY?J<>+Z!1117J'&%%%% !1110 4444 %%%% !1110 44
M44 %%%% 'KFCW!&B6 STMHQ_XZ*N_:3ZUD:3_P @:Q_Z]X__ $$5<S7S,_B9
MZT?A1;^TGUH^TGUJIFC-246_M)]:/M)]:J9HS0!;^TGUKS#Q:Q?Q/>-Z[/\
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M* (KG_5CZT4EQ_JQ]:* %A_U2U)4<7^J%/H 6BDHH 6BDHH 6BDHH 6BDHH
M6BDHH 6BDHH 6BDHH Y_QS_R)U__ -L__1BUXW7L?CC_ )$Z_P#^V?\ Z,6O
M'*]G+OX3]?\ (\_%?&O0****] Y@HHHH **** "BBB@ HHHH **** "BBB@
MK1T#_D8]+_Z^XO\ T,5G5H:#_P C'IG_ %]Q?^ABHG\#*C\2/=:*2BOF3UQ:
M*2B@!:*2B@!:^=*^BJ^=:]3+?M?+]3CQ?0****],XPHHK;\.>%[WQ1<3PV4M
MO&T*!V,S, 03CC -*4E%7EL-)MV10TK3I=6U6VL("!)/($!/0>I_ <UZD_A?
MP%HUQ;Z5J4F^_E PTDL@))X&=N%7GIFN)USPAK'A"""_FO+<%I-B-:ROO4X)
MSDJ,=*N>%/#E[XCOQK6KW,@T^V(>2YN9"3)M_A!;L,<GH*Y*S4X\ZG:/EW-J
M:<7RN.HGB/P*VG>*K'3+&5GAOS^Z:3JG/S9]<#FNM;PGX$TB6'3=1?S+UPOS
MR2R DL<#.TA5R>F:X[QQXL_MGQ#'-ITLD<%FI2&9"59B?O,.XST^@JWX0T&\
M\032ZMJ]S(+")E:2YN),[]ASC+=ACD]!653VOLHRE*WY[_Y%PY.=J*N&K> 8
M[+QIIVE0SR&ROCN5VQO0#[P]"<=#[U?U/PUX?O--U]-+LI+2ZT9O]:9V<3 #
M)R#TZ-T]OI5#Q+XX%SXTL]1L%\RVTX[8L\>;G[Q]@>@_.K5QXJTV_CU"QT"Q
MO%U#7)528W&W8F>#MVDGN>OJ3[57[^T6^WZ]?D+]W=I?U_3,C0-&T^/PMJ?B
M#5[?SHD_<VD1=EW2>ORD''(_6N2KTSQ!H]QJ3P>&-)>&+3]&A#W5S.^R,2$9
M)8\\]3^)KB==\/7WAZXBBO/*=)DWQ30ON20>H-;T:BDW=ZOIY?UJ9U(-+1;&
M3111709!1110!ZCI7_('L?\ KWC_ /015RJ6E?\ ('L?^O>/_P!!%7*^:G\3
M/6C\*%HI*4#-24%/5":DCA+5?AM?:@"M%;DUYCXR79XKO5]/+_\ 0%KV5(0H
MKRKQEI&I7/BN]FM].NY8FV;7CA9E/R*."!7=@&E5=^W^1SXE-PT.2HJ__8>K
M_P#0+OO_  '?_"C^Q-6_Z!=[_P" [_X5Z_/'N</++L4**O\ ]B:M_P! N]_\
M!W_PH_L35O\ H%WO_@._^%'/'N'++L4**O\ ]B:M_P! N]_\!W_PH_L35O\
MH%WO_@._^%'/'N'++L4*LV?_ "\?]<6J;^Q-6_Z!=[_X#O\ X5+!I>H0>9YM
MA=1[XRB;X6&YCT XY/M65:<>1ZE4XOFV,NBK_P#8FK?] N]_\!W_ ,*/[$U;
M_H%WO_@._P#A6O/'N3RR[%"BK_\ 8FK?] N]_P# =_\ "C^Q-6_Z!=[_ . [
M_P"%'/'N'++L4**O_P!B:M_T"[W_ ,!W_P */[$U;_H%WO\ X#O_ (4<\>X<
MLNQ0HJ__ &)JW_0+O?\ P'?_  H_L35O^@7>_P#@._\ A1SQ[ARR['6^"1G1
MIO\ KX;_ -!6NICA+5C>"-.N(-(F6YMY87-P2%E0J2-J\X-=A#; 5X.)=ZLK
M'I4?@16AM?45?C@"BI50"G\5@: % IU)10 M>>_$_P#YA7_;;_V2O0:\]^)_
M_,*_[;?^R5U8+^/'Y_D8XC^&SSZBBBO?/,"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#L?AM_P C%<?]>C?^AI7J=>6?#;_D8KC_ *]&_P#0TKU*O#Q_
M\8]'#?PQ:*2BN(Z!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*
M2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*
M2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*
M2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*
M2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*
M2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@".X_P!6/K123_<'UHH 6+_5BGU'
M%_JQ3Z %HI** %HI** %HI** %HI** %HI** %HI** %HI** .?\<?\ (G7_
M /VS_P#1BUXY7L7CC_D3K_\ [9_^C%KQVO9R[^$_7_(\_%?&O0****[SF"BB
MB@ HHHH **** "BBB@ HHHH **** "M'0?\ D8M,_P"ON+_T,5G5H:#_ ,C%
MIG_7W%_Z&*F?PLJ/Q(]THI**^9/7%HI** %HI** %KYVKZ(KYVKU,M^U\OU.
M/%]!:*2BO3.,6K-GJ-[I[L]E>7%LSC#&&5D)'O@U5HH:3T8'0:5=3^(-9L[+
M7-9G-CYF^1KJZ.U0 3U8X!/3\:]2UF+PIK6G0:>_B2WM+.$8$%K>PHK8Z9SG
M.*\-HKFJX?GDFG:QK"KRIIJ]SNM0\,^%[?Q%I-K9ZW'+93%VNI9+N-@@7! W
M+@#/(YKN]7C\*ZSI4>GMX@MK:QA 'E6MY$J\=,YSZ5X55F'_ (\KK_@'\ZSK
M4&U%N3TM^++IU4FU;?\ R-[QAHVA:/+:+HFI?;5D5C*?/23:1C'W0,=3UK1\
M"V\6F66I>*KM 8[&,I;!NCRD?_7 _P"!>U</170Z3=/D;,E-*7,D>B^#[MM9
M\.^)-,\U7U:]W3(KL%,I(YQGW_G4/Q"ECMM'\/:.[HU[9VX$ZHP/EG:HP?R/
MY5P%%0J"53GO_5K%>U]WE%HI**Z#(6BDHH ]0TK_ ) ]E_U[Q_\ H(JX*JZ0
MI.CV/_7O'_Z"*U(K<GM7S4_B9ZT?A1$D9-6X;;/:K,-K[5=2$+VJ2B&*W [5
M:5 *<!BEH .*:5!IU% $1B!I/)7TJ:B@"'R5]*/)7TJ:B@"'R5]*/)7TJ:B@
M"'R5]*Q]?C _LOWU"(?SK>K&\0_\PK_L(P_UH T_)7TH\E?2IJ* (?)7TH\E
M?2IJ* (?)7TH\E?2IJ* (?)7TH\E?2IJ* (Q&!4@ %%% "T4E% "T4E% "UY
M]\3_ /F%?]MO_9*] KS[XG?\PK_MM_[)75@OX\?G^1CB/X;//J***]\\P***
M* "BBB@ HHHH **** "BBB@ HHHH **** .Q^&W_ ",5Q_UZ-_Z&E>I5Y;\-
M_P#D8KC_ *]&_P#0TKU&O#Q_\8]'#?PQ:*2BN(Z!:*2B@!:*2B@!:*2B@!:*
M2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*
M2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*
M2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*
M2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*
M2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@".;
M[@^M%$WW!]:* %C_ -6*=3(_N"G4 +1244 +1244 +1244 +1244 +1244 +
M1244 +1244 <_P"./^1.O_\ MG_Z,6O':]B\<?\ (GW_ /VS_P#1BUXY7LY=
M_"?K_D<&*^->@M%)17><HM%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M:&
M@_\ (Q:9_P!?<7_H8K.K1T'_ )&+3/\ K[B_]#%3/X65'XD>YT4E%?,GKBT4
ME% "T4E%  37A']A:P.NE7W_ (#O_A7NYIA7-=.'Q+HWLKW,JM)5+7/"O[$U
M;_H%WO\ X#O_ (4?V)JW_0+O?_ =_P#"O<O*%'DCTKH_M&7\IE]57<\-_L35
MO^@7>_\ @._^%']B:M_T"[W_ ,!W_P *]R\D>E'DCTH_M&7\H?55W/#?[$U;
M_H%WO_@._P#A1_8FK?\ 0+O?_ =_\*]R\D>E'DCTH_M&7\H?55W/#?[$U;_H
M%WO_ (#O_A4L>EZ@EO-$]A=+))MV(86!;!YP,<XKVWR1Z5CZA&!XBT8>OG_^
M@"IGCY25K=OP''#)/<\E_L35O^@7>_\ @._^%']B:M_T"[W_ ,!W_P *]R\D
M>E'DCTJO[1E_*+ZJNYX;_8FK?] N]_\  =_\*/[$U;_H%WO_ (#O_A7N7DCT
MH\D>E']HR_E#ZJNYX;_8FK?] N]_\!W_ ,*/[$U;_H%WO_@._P#A7N7DCTH\
MD>E']HR_E#ZJNYX;_8FK?] N]_\  =_\*/[$U;_H%WO_ (#O_A7N7DCTH\D>
ME']HR_E#ZJNY@Z+9NFD6*R(R.MO&&5A@@[1P:VHK<+VJ8(!4@&*\]N[N=*5E
M815Q3J2BD,6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6L;Q#_S"O^PC#_6MBL?Q
M!_S"O^PC%_6@#9HI** %HI** %HI** %HI** %HI** %HI** %HI** %KS[X
MG?\ ,*_[;?\ LE>@5Y_\3O\ F%_]M?\ V2NK!?QX_/\ (QQ'\-GGU%%%>\>8
M%%%% !1110 4444 %%%% !1110 4444 %%%% '8_#?\ Y&*X_P"O1O\ T-*]
M1KR[X;_\C%<?]>C?^AI7J%>)C_XQZ.&_ABT4E%<1T"T4E% "T4E% "T4E% "
MT4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "
MT4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "
MT4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "
MT4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "
MT4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% #
M)ON#ZT42_='UHH $^X*=34^X*=0 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** &2_=_&BB3[OXT4 "?<%.IJ?=%+0
M M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10!@>-_^1/O_ /MG_P"C
M%KQVO8?&_P#R)]]_VS_]&+7CU>SEW\)^O^1P8KXUZ!1117><P4444 %%%% !
M1110 4444 %%%% !1110 5H:#_R,6F?]?<7_ *&*SZT-!_Y&+3/^ON+_ -#%
M3/X6./Q(]RHI**^9/7%HI*3=0 ZBF[J-U #J*;NHW4 .HINZC=0 ZBF[J-U
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MBN/^O1O_ $-*]1KR[X<?\C#<?]>C?^AI7J%>'C_XQZ.&_ABT4E%<9T"T4E%
M"T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E%
M"T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E%
M"T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E%
M"T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E%
M"T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E%
M"T4E% "T4E% #9/N_C10_P!W\:* !?NBES2+]VEH ,T9HHH ,T9HHH ,T9HH
MH ,T9HHH ,T9HHH ,T9HHH ,T9HHH Y_QN?^*/OO^V?_ *,6O'Z]@\;_ /(G
MWW_;/_T8M>/5[.7?PGZ_Y'!BOC7H+1245WG,+1244 +1244 +1244 +1244
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MT44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44
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M_P"87_VU_P#9*ZL%_'C\_P C'$?PV>?T445[QYH4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M30 P+FIXX2QZ5/%;$]JOQ6P':@"M#:^U7HX O:I50"I,4 -"XIU%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7G_Q-_P"87_VU_P#9*] KS_XF_P#,
M+_[:_P#LE=6"_CQ^?Y&.(_ALX"BBBO>/-"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#L/AQ_R,-Q_P!>C?\ H:5Z?7E_PY_Y&&X_Z]&_]#2O36<"O#Q_
M\8]##?PQQ.*B>4+4$MP!WJA-<Y[UQG069KKWJC)<$GK4+R$U'F@"0RGUH\T^
MM144 2^:?6CS3ZU%10!+YI]:/-/K45% $OFGUH\T^M144 2^:?6CS3ZU%10!
M+YI]:/-/K45% $OFGUH\QJ8JDU9BMR3TH 1-QJW#&QJ6&UQVJXD044 -B3 J
M<4 4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C=**
M&Z44  Z44@Z4M !1110 4444 %%%% !1110 4444 %%%% !1110!S_C;_D4+
M[_MG_P"C%KR"O7_&W_(H7W_;/_T8M>05[.7_ ,)^O^1P8KXUZ!1117<<P444
M4 %%%% !1110 4444 %%%% !1110 5:TS_D+6?\ UW3_ -"%5:M:9_R%K/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 AZ44'I10 #I2TE% "T4E%
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M3DC>3.Q&;'7 S2;2U86N-HI[12(,O&RCU(Q3*$T]@::W"BBBF 4444 %%%%
M&_X1_P"0M+_UP/\ Z$M=IFN+\(_\A67_ *X'_P!"6NSKP\?_ !CT,-_#%HI*
M*XSH%HI** %HI** %HI** %HI*4#- !2@9IZ1DU;BMB>U $$<);M5Z&V]JL1
M6X':K2H!0!%'"%'2IP *6B@ I:2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!
M:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!
M:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!
M:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!
M:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@
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M8;BI%C)J6.$GM5Z&U]J *T5N3VJ_%; =JGCA"CI4P7% #5C J3%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<!
M\3/^87_VU_\ 9*[^N ^)G_,+_P"VO_LE=6"_CQ^?Y&.(_ALX"BBBO=/-"BBB
M@ HHHH *FM79;B,*Q 9QD ]>:AJ2W_X^8O\ ?'\ZBHKP=RH_$A]S([3R*SL5
M#G )X'-05)<?\?,O^^?YU'1324%8)/WF%%%%62%%%% !1110!O\ A'_D*R_]
M<#_Z$M=G7&>$?^0K+_UP/_H2UV=>)COXQZ&&_AA1117&= 4444 %%%% !12@
M9J5(B: (U4FK$<!/:K$-MGM5^*W [4 5X;7VJZD07M4BJ!3J $ Q2T44 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M** &A0*=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7 ?$S_F%_]M?_ &2N_K@/B9_S"_\
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MTWW\= W'(H UZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O/
M_B9_S"_^VO\ [)7H%<-\0[&[O?[.^RVL\^SS=WE1EMN=F,X^E=.#:5:+?]:&
M-=7IL\YHJ]_8NJC_ )AE[_WX;_"D_L;5/^@;>?\ ?AO\*]SGCW//Y9=BE15W
M^QM4_P"@;>?]^&_PH_L;5/\ H&WG_?AO\*.>/<.678I45=_L;5/^@;>?]^&_
MPH_L;5/^@;>?]^&_PHYX]PY9=BE4MO\ \?,7^^/YU8_L;5/^@;>?]^&_PI\6
MDZC',COI]TJ*P+,T+  #N>*B<X\KU'&+NM"I<?\ 'S+_ +Y_G45:$NDZC),[
MII]TR,Q*LL+$$'N.*9_8VJ?] V\_[\-_A1"<>5:A*+N]"E15W^QM4_Z!MY_W
MX;_"C^QM4_Z!MY_WX;_"KYX]Q<LNQ2HJ[_8VJ?\ 0-O/^_#?X4?V-JG_ $#;
MS_OPW^%'/'N'++L4J*N_V-JG_0-O/^_#?X4?V-JG_0-O/^_#?X4<\>X<LNQI
M^$!G5I?^N!_]"6NX2(GM7*^#],O8=7E:XL[B%# 0&DB*C.Y>.17?Q6N.U>+C
MFG5T._#IJ&I6AM<]JOQ6X Z5,D0 J4"N0W&J@%/Q110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%%  .E+0.E+0 E%+10 E%+10 E%+10 E%+10
ME%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10
ME%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10
ME%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10
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MH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 8W2BE?I10
MY/NBEH3[@IU #:*=10 VBG44 -HIU% #:*=10 VBG44 -HIU% #:*=10 VBG
M44 -HIU% #:*=10 VBG44 -HIU% #:*=10 VBG44 -HIU% #:*=10 VBG44
M-HIU% #:*=10 VBG44 -HIU% #:*=10 VBG44 -HIU% #:*=10 VBG44 -HI
MU% #:*=10 VBG44 -HIU% #:*=10 VBG44 -HIU% #:*=10 VBG44 -HIU%
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M* &XHQ3L48H ;BC%.Q1B@!N*,4[%&* &XHQ3L48H ;BC%.Q1B@!N*,4[%&*
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MY_U8^M% #[?_ %"_C_.I:9;#]POX_P ZEQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0
MVBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8
MHQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0
MVBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8
MHQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0
MVBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8
MHQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0
MVBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8
MHQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0
MVBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8
MHQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0
MVBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8
MHQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0
MVBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8
MHQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0!6NO]4/\
M>HIUV/W0_P!ZB@"2V'^CK^/\ZEQ4=K_Q[)^/\ZFH ;BC%.HH ;BC%.HH ;BC
M%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH
M ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC
M%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH
M ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC
M%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH
M ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC
M%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH
M ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC
M%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH
M ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC
M%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH
M ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC
M%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH
M ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH JW@
M_<C_ 'J*6^_U*_[W^-% $MI_QZI^/\ZFJ*S_ ./5/Q_G4^* &T4[%&* &T4[
M%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&*
M&T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[
M%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&*
M&T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[
M%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&*
M&T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[
M%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&*
M&T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[
M%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&*
M&T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[
M%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&*
M&T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[
M%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&*
M&T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[
M%&* *=__ *A?][^AHIVH?ZA?][^AHH ELO\ CT3\?YU/4-E_QYQ_C_,U/B@!
M**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H
M 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&
M* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ
M1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI
M<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!*
M*7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H
M2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&*
M $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1
MB@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<
M48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**
M7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2
MBEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&*
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MBC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M%
M"8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+1
M0 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2
MT4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,
M4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )B
MC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "
M8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10
M F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T
M4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4
MM% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC
M%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8
MHQ2T4 )BC%+10 F*,4M% %+4O^/9?]\?R-%&I_\ 'LO^^/Y&B@"6P_X\H_Q_
MF:LU7L/^/*/\?YFK- "44M% "44M% "44M% "44M% "44M% "44M% "44M%
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MFXOQ!,_FBW$_[J)R<EE7&,]>N>M;EMID-KJ-Y?(TAENP@<,1M&P8&./>KM%
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MZ5<TCP_9Z+/=36SSL]SL\TS2;RQ4'YLGDDY).3^5:U% !1110 4444 %%%%
M!1110 4444 %%%% !1110 52&F0C6FU3=)YYMQ;[<C;M#;L],YR?6KM% %*]
MTR&^N+*>5I UG-YT84C!.TKSQTP346J:+;:K):S2/+#<6LOF0SPD!U/<9(/!
M[CO6E10!RI\#0B69X->UVV665I3%!>!$!8Y. %]370VUF+?3TLS//,%CV&69
M]TC>Y/<U9HH RAX>L#X>CT.57EM$C$8WM\W'0Y&.1ZBH=(\+VFD7;7?VJ]O;
MHIY:S7LWF,B?W5X&!6W10 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!2U73(=7TZ2RN&D6.0J28R ?E8,.H/<5FZIX4AU/5#J U35+*9H
MEB;['<",, 21GC)ZFM^B@#-TC2/[(@DB_M"_O=[;M][-YC+QT!P,"H]8\/6F
MLM%+)-<VMU#D1W-I+Y<B@]1GT-:U% &9HVA6>AV\D=L99))6WS3SOODE;U8U
MIT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5AW'A:SN-,N[
M W%U&EU=&[:2-P'5RP;Y3C@9'UK<HH YZP\*?8;Z*Z_M_7;CRSGRKB\WQM]1
MCFM2]TR&^N+*>5I UG-YT84C!.TKSQTP35VB@# U#PE9ZAJ$]_\ ;-0M;J94
M4RVL_ELJKG@8'0YYSGH.E$G@_2FTJ&QC$\'D.9([B*4K,KGJV_U/?/\ 05OT
M4 8NF>&;/3?M#-/=WL]Q'Y4D]Y,9'*?W<]ASVJC_ ,(-8BQMK=-1U2-[5F,%
MPESB6-6 !0''W>!QBNHHH QM$\,V>@SW4UK-=2/<A?-,\N_<PS\V<9R<\ULT
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% %.YTV&ZU&RO7:026A<QA
M2,'<,'/%#Z9#)J\.IEI/.BA:%5!&TJQ!.>,YX'>KE% &5)X?L9/$<.N_O%O(
MHS%\I&UP1CYACJ,U8L],ALKN]N(VD+WDHED#$8!"A>..F!5VB@#(UKP];:VU
MO+)<7=K<6^?+N+27RY%!ZC//!P*KZ=X1L-,CU!(9[Q_M\82=I9=Y)P1NR1]X
M[C[>U;]% ''7OAE+GQ%I]KF]BMK;3#'%=PN4>-PR@?.!C=C/'UXK3M_".G6U
MO%&LER\BW27;SR2;Y)I%Z;V(Y'L,5O44 4FTN!M7_M)BYF^SFWVY&TJ6W=,9
MS^-<])\.]*EA:W:^U7[+G,5M]JS'"<]47';WS7744 (JX4#).!C)I:** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@"CJG_'JO\ OC^1HHU7_CU7_?'\
MC10!+I__ !XQ_C_,U:K+M=0B@MDC97)&<X ]?K4W]JP?W)/R'^- %ZBJ/]JP
M?W)/R'^-']JP?W)/R'^- %ZBJ/\ :L']R3\A_C1_:L']R3\A_C0!>HJC_:L'
M]R3\A_C1_:L']R3\A_C0!>HJC_:L']R3\A_C1_:L']R3\A_C0!>HJC_:L']R
M3\A_C1_:L']R3\A_C0!>HJC_ &K!_<D_(?XT?VK!_<D_(?XT 7J*H_VK!_<D
M_(?XT?VK!_<D_(?XT 7J*H_VK!_<D_(?XT?VK!_<D_(?XT 7J*H_VK!_<D_(
M?XT?VK!_<D_(?XT 7J*H_P!JP?W)/R'^-']JP?W)/R'^- %ZBJ/]JP?W)/R'
M^-']JP?W)/R'^- %ZBJ/]JP?W)/R'^-']JP?W)/R'^- %ZBJ/]JP?W)/R'^-
M']JP?W)/R'^- %ZBJ/\ :L']R3\A_C1_:L']R3\A_C0!>HJC_:L']R3\A_C1
M_:L']R3\A_C0!>HJC_:L']R3\A_C1_:L']R3\A_C0!>HJC_:L']R3\A_C1_:
ML']R3\A_C0!>HJC_ &K!_<D_(?XT?VK!_<D_(?XT 7J*H_VK!_<D_(?XT?VK
M!_<D_(?XT 7J*H_VK!_<D_(?XT?VK!_<D_(?XT 7J*H_VK!_<D_(?XT?VK!_
M<D_(?XT 7J*H_P!JP?W)/R'^-']JP?W)/R'^- %ZBJ/]JP?W)/R'^-']JP?W
M)/R'^- %ZBJ/]JP?W)/R'^-']JP?W)/R'^- %ZBJ/]JP?W)/R'^-']JP?W)/
MR'^- %ZBJ/\ :L']R3\A_C1_:L']R3\A_C0!>HJC_:L']R3\A_C1_:L']R3\
MA_C0!>HJC_:L']R3\A_C1_:L']R3\A_C0!>HJC_:L']R3\A_C1_:L']R3\A_
MC0!>HJC_ &K!_<D_(?XT?VK!_<D_(?XT 7J*H_VK!_<D_(?XT?VK!_<D_(?X
MT 7J*H_VK!_<D_(?XT?VK!_<D_(?XT 7J*H_VK!_<D_(?XT?VK!_<D_(?XT
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FJP?W)/R'^- !JO\ QZK_ +X_D:*K7M['<PJB*X(;/('O10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>sava-20201231x10kg002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sava-20201231x10kg002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
M"BBB@ HHHH **** "BBLOQ&TJ^';\P,ZR^2=ICSN!]L4 :E%>?MJ6M:9+=1*
ML\\UG8@(S@LK@NN']V )!^E6H/$FJ0V]M+>.C12"=1)%$6W, "F<#KG/08H
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MJ1VQOY#Y,?V>5;GY8Y,_.9,GG\B*;_8.H02W!@BFQ->S.X,I(9#$0#@G^\:
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MSD_*CS?^F4GY4ADE%1^;_P!,I/RH\W_IE)^5 $E%1^;_ -,I/RH\W_IE)^5
M$E%1^;_TRD_*CS?^F4GY4 245'YO_3*3\J/-_P"F4GY4 245'YO_ $RD_*CS
M?^F4GY4 245'YO\ TRD_*CS?^F4GY4 245'YO_3*3\J/-_Z92?E0!)14?F_]
M,I/RH\W_ *92?E0!)135?=GY67ZBG4 %0?8[7:5^S0X)R1Y8YJ>B@!%544*H
M 4<  <"EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P!9!$^?[R T)SB[QE^7^5_Q$XQ>Z/$CXBOM./\ HUC>:>W]V"Z;9_WRX/\
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M !H\E/5_^^S_ (U)10 U4"=,\^K$TZBB@ I" 1@@$>]+10 4444 %%%% !7
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MX62DI347;JXV?R:*4X6M%M?.Z.RVR_\ /4?]\T;9?^>H_P"^:DHK<DCVR_\
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M< ;1@=..E ',>'=5O[Z_"W$I?? [S1%0/L\@? 7\O6NE9G'W4#?CBG!0"2
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MD;GX?M%'G1M<OH%Q\L,[B>/\-PKFKWPIK&\QWEMI5PW9RK6SGZ,N4_,5W_\
MPC\ML=VF7DMF?[GF%X_^^2*)+C6K:,I>:=!?Q=V@;!_[Y/\ 2L:E&<GS49J_
M9K^G]S^0XRBOXD?FOZ_0K> ]*N=(\/M;W=J;:0SLP0R*^0<8.5X-=16;I4RR
MV>ZVMFA3<<I*6!!_$5>S-_<C_P"^S_A1%22]Y6?9%KE^SL245'F;^Y'_ -]G
M_"C,W]R/_OL_X4P)**1=V/F !]CFB@!:**;O7:&W#!Z'- #J*3<"2 1D=12T
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV?XGMO\ 4:U;W2CHMS;X_5:#J/B>U_U^BV]THZM;7&/T:NBHI>PM\,FOG?\
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M&!,^]@5SWX'K72$,>C8_"@!:*9M?_GH?R% 5O[^?PH ?13<-_?\ THPW]_\
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L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>sava-20201231x10kg003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sava-20201231x10kg003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
M"BBB@ HHHH **** "BBB@ JG/JVG6L_D7%_;13<?NWE56Y]B:N5A:WH]QJ%_
M9SVQC0PK(#(W525P"/7F@#;>2.--SNJJ>,L<"FS31V\+S3.$C0;F8]A7$2>$
M]3N+"6.18UPL6(3=.XD=3EGR?NY%27'AW7)]4N)@T26\D;H$$[$$%<*"".Q[
MT =FMQ"T4<@D79)C82<;L],5)7.:IH4UYI6E0B..2:SDB=D:0J"%&#@BLO\
MX1W7VO;^7[1&BS1L$"SM@G(*\=N.,T =O161HMKJ$,]]/?A$,[JR1I*7"@+@
M\D"M>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** (&O+9+M+1[B-;B12R1%AN8#J0*KPZUIUQ?M9172M<*2"NTX)'4 XP2/
M8UA7OAW5KG6GU5+JV66.=&AC*G_5KU!;MG)XQ5'2M)U6"];41:E/L\]P1&7.
MZ8,> %(  [[L\T =U17.Z;K.H7-Y8PW$(B:2-S.K1,NT@G&#TY]*Z*@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHJKJ5FM_IT]L^X;U."IP0>Q%<5-HNNMIVG2123?VE),\ES*W&/E( QV&/YT
M=_17'6(O[34BT&G74:RV*11"0%DCE!.=Q_K6?%I.MP_:EN[266!KF*2<13ES
M,N#NVYQQ[<4 >@T5C^&K>YM=($=TLB$RNT<<C99$)^4'\*V* "BBB@ HHHH
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M]FCRA_>?_OLT 245'Y0_O/\ ]]FCRA_>?_OLT 245'Y0_O/_ -]FCRA_>?\
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M\H?WG_[Z- #Z*9Y0_O/_ -]&CRA_>?\ [Z- #Z*9Y0_O/_WT:/*']Y_^^C0
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M_P Q2*,^DRM'_P"A 5I6^L:;=_\ 'OJ%K+_N2J?ZU"J0>S+=.<=T6?.7T?\
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M_P!X?G7SMI DFU&UVRVY'FKG-PJ=_1J^B/+3^XOY40E)WYE;^O1&NG07<O\
M>'YT;E_O#\Z3RT_N+^5'EI_<7\JT$+N7^\/SI:;Y: Y"+^5.H **;)_JVZ]#
M]WK7&;]9S*I^W?9?/;:R,Q;&P[0"?FQNQGM0!VM%<CH3:ZU[:?;_ +0)<O\
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M5@\ZPNXKB/UC;./J.U7*S=*W5K^O,M5;[I/^O(A228HI: *Q R-^<&G;Y?\
MGE_X]4E%:&9'OE_YY?\ CU&^7_GE_P"/5)10!'ODS_JO_'JDHHH *KWUS]BL
M)[G87\I"^T=\58I" 001D'J#0!R'_"6W+0 +]G%P$:23?&0J@+N"CYN2?7/X
M5U%O<^=:03-&RF6-7V@$XR,XI/[.LO*$?V2#8K;@OEC /K5GI0!'YP_NR?\
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M;+_ST7_OC_Z]244 ,VRYYD7_ +Y_^O3Z** "H;L.;.8(YC<H<.!DJ?7%344
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MF_,4;V_YY-^8I]% #-S?\\V_,4;F_P">;?F*?10 S>?[A_,4QT208>W##_:
M-4KG0;&[N&GD$HD;J4E9?Y&H?^$:LA]V>]7Z7+_XUHE#O^'_  2&Y]OQ_P"
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M('0;E/1E8$&G;F_YYM^8JOIJPI81+;VK6L0'RPLFTK^%6ZYVK.QJG=#-S?\
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M^Y_Y#2OM^:/9/*7U;_OHTAC0=68?5C7C;:U=3G,DNMM_O7BI_P"RBHFOK=F
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M:>6+!D.P!!DG.,Y- '245S6C^*9-5FLS]E6."Z9T3YR74J,G(QTKI&8+US^
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MV4D /R-).58_48J#[5XI_P"@9IW_ ($M_A7'.S;^+[F;*4K=/P. _P"$LO\
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MDB(6Z!F S4G% ";E_O#\Z-R_WA^=([I&I9V55'4L<"F^;$75!(FYAD#<,D4
M/W+_ 'A^=&Y?[P_.EP/2C ]* $!!Z$&EHHH **** $+JI + $] 3UI:YO6]%
MO+_43+"J,K1HJ2,V# 0V2P^H]*Z,@D8!(/K0 M%1>7)G_7MC_=%+L?\ Y[-^
M0H DHJ/8_P#SV;\A1L?_ )[-^0H DHJ/8_\ SV;\A1L?_GLWY"@"2BH]C_\
M/9OR%&Q_^>S?D* )**CV/_SV;\A1L?\ Y[-^0H DHJ/8_P#SV;\A1L?_ )[-
M^0H DHJ/8_\ SV;\A1L?_GLWY"@"2BH]C_\ /9OR%&Q_^>S?D* )**CV/_SV
M;\A1L?\ Y[-^0H DHJ/8_P#SV;\A1L?_ )[-^0H DHJ/8_\ SV;\A1L?_GLW
MY"@"2BH]CY_UK?D*DH *0@$8(R#U!I:* (A;0*NU88PN<X"#&?6I:YSQ)'J,
MD\7V1;AD,3!/))XER-I;VZ]>*WD$XAC#%"X4;R?7O0!+14?[[_IG^M'[[_IG
M^M $E%1_OO\ IG^M'[[_ *9_K0!)14?[[_IG^M'[[_IG^M $E%1_OO\ IG^M
M'[[_ *9_K0!)14?[[_IG^M'[[_IG^M $E%1_OO\ IG^M'[[_ *9_K0!)14?[
M[_IG^M'[[_IG^M $E%1_OO\ IG^M'[[_ *9_K0!)14?[[_IG^M'[[_IG^M $
ME%1_OO\ IG^M'[[_ *9_K0!)14?[[_IG^M'[[_IG^M $E%1CS<C.S'?&:DH
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M-P-TBSGY4+=@#Z#M6=9>&+VVU:RG0*D$ 0;6DW' !SGC[W/&#BNRHH ****
M"BBB@ HHHH **** "N:G\326-]=17L: *?\ 1TC&=XR!DONP/<$#%=+4/V2V
MS(?L\69.'.P?-]: ,.X\5BV%P9+%RL!1&99%(+MT'T]ZC/C. 2Q1_8;C<T>]
MP<?+U_/I70"TMA&T8@BV, &78,'%!M+8E";>+Y!A?D' ]J .?_X2KS(XW^SO
M"=Z%D)#;E921SGCI4<WC:&&!&>RD65RH5&D7!W+D<^OM72?9;?\ YX1]OX!V
MJK>:)IU_L\^W'R< HQ3C&,?*1D4 7HV+Q(Y7:64$KZ4ZFHBQQK&@VJH"J!V
MIU !1110 4444 %%%% !1110!S5[X@N[74+M!]F:&WEB00[3YDF_J0=W;Z4W
M_A-+,-<%H6,-O($>56!4 Y /YC%=#]EMS<>>8(_._P">FT;OSJ&?2K&X@>&2
MVC\N0AG"C;N(.1G'6@#.U36KBVTJUN8%BCN;@J([:926<GL"",<=^:KZ1XCN
M;_79+*5(%B ?84SR5(!P<\_D/QK?FM+>XV^?!')L^[O4''TI8[:"*1I(X8T=
MNK*H!- $M%%% !1110 4444 %%%% !5+5-0&F6#W1A>4*0-J#U[GT%7:BN+=
M+F$Q2&0*>\<C(?S!!H SO^$BL!"TCN2$C$DK1 NJ ],L.*;_ ,)/I(G$+W.Q
MRNXAU*XXS@YZ'%2+X=TM$9$MV1'7:ZK*P#CW /)]SS4C:)I[W$D[09>1=KC>
MVUAC'(S@G'>@"HGBW1Y%REPS>H6,G ]3Z"G-XEL8II8YF(V.5!12W  Y/''6
MI5\/:8L>SR&*A"@W2N<*>HY-..@Z:S2,;?F0$-\[<YQGO["@!;/6[&_O9;6V
M=GDC&6.P[?SK1K&TGP]%I%W//#<2L)224/3DYY]3^5;- !1110 4444 %%%%
M !1110 5AKXC7[4R2VKI +DVPF# Y<#/(ZXK<K,_L#33-)*T#,9'+LK2L5W$
M8)"DX!]Q0!$OBC2F5C]H*[-V[*GJ.H^M2:EK(TW[*QMGECN'5!M8;LGT4\GW
MJO)X4TQHX(HXV2.*=9R"Q8L0, 9)/%7KK2+.]NX[J993-&I5&69UP#UX!Q0!
M5T7Q!%K4UQ''"T?DGDE@>Y'Y\5L52L=(LM.=GM8BK,NTEG9L#T&2<#V%7: "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBJFIWPTS3IKQHS((@#M!QGG% %NBJ6FZBNHP32B,QB.
M9X2"<YVG&:@T;6#K"S2I;B.!6Q$_FABXYY*C[OX^M &I1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !116,/$"'6?[.
M^SMN^T>1OW<?ZO?G'Z4 ;-%9VI:I_9\EFHMWE6YN%A+J0 FXXR?\*S]/\137
MOB.;3C%"(5$FTJY\P;" 2PZ8.>,>E '0T444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 445B>([W4K""WFL&M@'F6)Q,
MA/+, ",$=* -NBN17Q1?1WUQ:7$4&^.[C@C=00'&0'[]1D?G3=,\8/+9>?<^
M7=322F..ULT/F)C.=V3CH,T =A1532]0BU738;Z!76*8$H'&#C)&?TJW0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5'6
M;%]2TFXM(W5'D  9N@Y!J]10!SUEH-TIN;>]EC-F;EKB$P.Z298DX;L1STIO
MAOPY-HMQ/)*]O@QK$@@4C> S'<_^USC\*Z.B@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG+KP[>-J3W]G>Q13&
MY\]1)"6 'E[".H^M='10!@:AX?EDAMH],F@M1'<BYDWQL^]P<_WN*JZ-H5VN
MLR:A=R*B17$[0QB+#-OXR6SR/05U-% !1110 4444 %%%% !1110 4444 %%
M%% !1110 45 ]Y:QJS27,**K;6+2 8/I]:F!#*&4@@C(([T +1110 4444 %
M%%% !1110 54U"PCU&".*5F54E24%?53D5;HH Q9_#-E<3+*[RAUO/M@((^]
M@ CZ<"D?PQ:G3;6SCGN(3;.SQS1L XW9R,X[@D5MT4 4]+T]-*T^*RBEDDCB
M&$,AR0.P_"KE%% !1110 4444 %%%% !1110 4444 %%%% '-^)+D+J&FVL%
MV\%Y)*K ^<418P1N+#.&ST ]Z-!F=-7N[1Y?M1VF4W"3NZKESA"IX4@>GI71
M-&CD%D4D="12A57.U0,]<#K0 '..!FFEI.R _P# J?10 S=)W0?G1N?^X/SI
M]% #-S_W!^=&Y_[@_.GT4 ,W/_<'YT;G_N#\Z?10 S<_]P?G1N?^X/SI]% #
M-S_W!^=&Y_[@_.GT4 ,W/_<'YT;G_N#\Z?10 S<_]P?G1N?^X/SI]% #-S_W
M!^=&Y_[@_.GT4 ,W/_<'YT;G_N#\Z?10 S<_]P?G1N?^X/SI]% #,O\ W!^=
M/HHH *HZR]S'HE\]GN^TK YBVCG=@XQ[U>HH \XEGF>Q\HI,MO'%-Y$L)D_?
M3[%*'GG.21SQG->@VOF_8X//_P!=Y:[_ />QS^M38'I10 P^9GC;CWH_>?[-
M/HH ;^\_V:/WG^S3J* &_O/]FC]Y_LTZB@!O[S_9H_>?[-.HH ;^\_V:/WG^
MS3J* &_O/]FC]Y_LTZB@!O[S_9H_>?[-.HH ;^\_V:/WG^S3J* &_O/]FC]Y
M_LTZB@!O[S_9H_>?[-.HH ;^\_V:/WG^S3J* &_O/]FE&[^+'X4M% !4<_FB
MWD, 4R[3L#=-V.,U)10!P4&D7MO:WGVBSN$N%N!-"\2K+YDGE@$D$8P3G\Z[
M:R\_[!;_ &I56X\M?,5.@;'./QJN^MZ9''-(][$%AD\J0YZ/Z?6KJ.LD:R(P
M9&&58'((H 1A)GY64#W%)B7^^O\ WS4E% #,2_WE_*C$O]Y?RI]% #,2_P!Y
M?RHQ+_>7\J=D9QD9]*6@!F)?[R_E1B7^\OY4^B@!F)?[R_E1B7^\OY4^B@!F
M)?[R_E1B7^\OY4^B@!F)?[R_E1B7^\OY4^B@!F)?[R_E1B7^\OY4^B@!F)?[
MR_E1B7^\OY4^B@!F)?[R_E1B7^\OY4^B@!F)?[R_E1B7^\OY4^B@!F)?[R_E
M1B7^\OY4^B@!@$F>67'TI]%% !167K&J2Z4+>06ZRPR3)$W[S#Y8X&T8Y]>M
M0Z7KYU&^\@V_EQR1O+ ^_)95?:<C'!Z&@#:HH) &2<4W>G]X?G0 ZBDWK_>'
MYT;E_O#\Z %HI-R_WA^=&Y?[P_.@!:*3<O\ >'YT;E_O#\Z %HI-R_WA^=&Y
M?[P_.@!:*3<O]X?G1N7^\/SH 6BDW+_>'YT;E_O#\Z %HI-R_P!X?G1N7^\/
MSH 6BDW+_>'YT;E_O#\Z %HI-R_WA^=&Y?[P_.@!:*3<O]X?G1N7^\/SH 6B
MDW+_ 'A^=+0 4UW2*-I)&5$4$LS'  '<TZJ]_"MSIUS Z.Z2Q,C*A 8@C! S
MWH :-3L#"LPO;?RF;8K^:,%O0'UJU7#7&E:Q/ PDM)9XC%/;VZ2%/,C#JH5G
MP<=0>G.*[.UB:"S@B=MSI&JL?4@8H FHIA63/#@#Z4N'_O#\J '4ASM.#@XX
MI,/_ 'A^5&'_ +P_*@#CF_X6#9N2!H^H1CH/FB8_TII\7^(K(?\ $R\&WF!U
M>TD$H_(<UV>'_O#\J,/_ 'A^5:<ZZI$\KZ,XZ/XG: '"7J7U@_<7-LPQ^6:V
MK/Q;X>U# MM9LG)Z*90I_(X-:DD"S+ME5'4]F0$5CWG@[P_?Y^T:19,3W6((
M?S7%%Z;Z-![QMI(D@RCJP/=3FG5Q3_#'14??87%_I[=OLURRC\J/^$2\26>/
M[.\87)4?P7<(D'Y]:.6#V87EV.UHKB2WQ%LNB:/J*CT+1,?Z4W_A,O$-EQJ?
M@^_4#J]HPF'Z4>S?34.==3N**XN'XF: 6V7<EW8OW%S:L,?EFMNS\4:'J&!:
MZU92$_PB4 _D3FDZ<EN@4HOJ;-%1HWF#*2JP]1S3L/\ WA^504.HIN'_ +P_
M*C#_ -X?E0 ZBFX?^\/RHP_]X?E0 ZBFX?\ O#\J,/\ WA^5 #J*;A_[P_*E
M (ZG/X4 +4<ZR/;R+"X20J0C$9P<<&I*1F"J6)P ,F@#BH/#NK64AD$5O,(Y
MMRHKE=X,.PL<]\\_G75:3:/8:19V<C!GAA5&(Z$@8JO_ ,)%IFTD32%A)Y1C
M$#E]Q&0-N,].>E::L'16&<$9&1@_E0 UD=CD2%?8 4WRW_Y[-^0J6B@"/RW_
M .>K?D*/+?\ YZM^0J2B@#GM3\':;JUZUY<27*W#  O%*5Z=*J?\(.(O^/77
MM6@QT_?Y _"NLHH Y0^&]?A&+;Q5<\=/.A5J/[/\:0_<UBQG_P"ND&W^5=71
M0!R/F^.83\UMIMP/]F4J?U%']M^*8?\ CX\-R,!WAN$:NNHH X__ (3"YB_X
M^M UF+U*PAA^@I1X^TA3B<ZA;G_IK;$?RKKZ0JK##*#]10!S<7C7P]-TUI%/
MHZ%?YBK\.N:3<8\K6K1\]A,F:MRZ9I\W^ML;9_\ >B4_TJC-X3T"?_6:3:_\
M!3;_ "H T$DCD&8[M7'JI!J3RW_Y[-^0KG9/ 'AUSE+1X3ZQ2LO]:C/@2U3_
M (]M5U6W_P!VY- '3^6__/5OR%'EO_SU;\A7,?\ "*ZM",6WBJ_7_KJJO2C2
MO%\'^KU^UG]IK;'\J .F\M_^>K?D*/+?_GJWY"N9#>.(.L>DW('HS(36_ILE
M]+8H^HP1P7))W)&^Y1Z<T 3^6_\ SV;\A1Y;_P#/5OR%244 1^6__/5OR%'E
MO_SU;\A4E% $81P03*Q]L"I*** ,V_T@7VHVEX;J6-K;.Q%"E<GJ<$'G'&:;
MIVA6VFW+3122OA62-7((C4MN('X^M:E% "$ C!&:3RT_N+^5.HH ;Y:?W%_*
MCRT_N+^5.HH Y+QMX@N?#L5E):6ZR"5F#_)D8&/\:Y^U^*D&0+O3E'J4X_QK
M9^(.M2:/!8E+"&[$KN&$A(V@8Z8^M<$WBG3+C_C[\.NOJ8Y ?T*_UKBJXF,*
MCB_P:_)V7XC]E)^\K_<_^#^1Z#:?$/PY<X#NT)/]],_RK9C\1:#(@==0M,'U
M8 _K7CKWGA.X^];7ENQ]8QQ^1J$VOAV3FVU=XC_MJP_F*J&*@]VUZJ__ *3S
M&;YEU7]>MCVL:YHA./[0LL_]=%IXU?1VZ7UF?^VBUX?_ &<K?\>VM6LOLSBK
M%O%JEIRMII]VH]45\UUPJX>6\OQ7Y.S);J=OS/:QJ6ED\7EH<_\ 31:>+S3S
MTN;8_P# UKR*+7;> 8U#P=;-ZM%N7_&M&#Q#X&E(%UHDUL>Y*DC]#71R4[7U
M^[_@B4Y/:WWGIPN+(])K?_OI:<)K0])(3_P(5PMLWP[O!\C6Z9[2,Z?SK6A\
M*>$KH V\<+Y_YYW!_H:FU'N_N_X)5ZG9??\ \ Z4/;'HT1_$4[]SV\O]*Y__
M (030.UM*/I._P#C0? NA]H[@?2X?_&CEH_S/[O^"%Y]E]__  #H=L1[)^0I
M?+3^XOY5SG_""Z1_"UXH]!<M2?\ "#Z;_#=:@ON+DT<M+^9_=_P0O/M^)TGE
MI_<7\J/+3^XOY52TK28=(MF@AEGD5FW$S2%S5^LI63T+5[:C?+3^XOY4>6G]
MQ?RIU%(8WRT_N+^5.HHH **** "BLD^)=)%L+C[6IB+LFX*3ROWCTZ#UZ5J@
MAE#*001D$=Z %HHHH *;(=L;'T!-.IKG:C'&<#./6@#Q1/'>HI*V-5O% / =
M4D_PK0A^(FIC'_$RA;_KM:X_]!S5:X\<Z5+(XO/"=FW/)!&?Y52D\0>#[G_6
M>&S$3WCN&7^E9?7:R^)1?RM^@<N'>TFOZ]3J(/B+?G )TJ7_ (&\?_H5:4'C
M^XDQG2H9?^N%ZC?I7GLDWA&;F./4;<^BSJP_5:JR6^DMS;ZC<#T$L*M^H/\
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MY$AV.D6,E3CJ<X_"NHMYEN+:*=00LB!QGT(S0!)13#(@."X!'O2^8G]\?G0
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M^]^AH^T1?WOT- $FQ?[H_*C8O]T?E4?GQ_WOT-'GQ_WOT- $FQ?[H_*C8O\
M='Y5']HC_O?H://C_O?H: )-B_W1^5&Q?[H_*F>?'_>_0T>?'_>_0T /V+_=
M'Y4;%_NC\JC\^/\ O?H://C_ +WZ&@"38O\ ='Y4;%_NC\JC\^/^]^AH^T1?
MWOT- $FQ?[H_*C8O]T?E3//C_O?H:3SX_P"]^AH DV+_ '1^5&Q?[H_*H_/C
M_O?H:/M$7][]#0!)L7^Z/RHV+_='Y5'Y\?\ >_0TOGQ_WOT- #]J_P!T?E2U
M&)HR0 W)]JDH ***J6.I6NHHSVKLZ+_$8V4'Z$CG\* +=%%% !1110 4444
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M_P#/)OS%+O;_ )YM^8H ?13-[?\ /-OS%&]O^>;?F* 'T4S>W_/-OS%&]O\
MGFWYB@!]%,WM_P \V_,4;V_YYM^8H ?13-[?\\V_,4;V_P">;?F* 'T4S>W_
M #S;\Q1O;_GFWYB@!]%,WM_SS;\Q1O;_ )YM^8H ?13-[?\ /-OS%&]O^>;?
MF* 'T4S>W_/-OS%&]O\ GFWYB@!]%,WM_P \V_,4;V_YYM^8H ?13-[?\\V_
M,4^@ HHHH **Y7Q3J-W:712"Y>#R[1IX]I \V0, %/K]/>NI4DHI(P2.10 M
M%1EY Q B)'KN%&^3_GD?^^A0!)14>^3_ )Y'_OH4;Y/^>1_[Z% $E%1[Y/\
MGD?^^A1OD_YY'_OH4 245'OD_P">1_[Z%&^3_GD?^^A0!)14>^3_ )Y'_OH4
M;Y/^>1_[Z% $E%1[Y/\ GD?^^A1OD_YY'_OH4 245'OD_P">1_[Z%&^3_GD?
M^^A0!)14>^3_ )Y'_OH4;Y/^>1_[Z% $E%1[Y/\ GD?^^A1OD_YY'_OH4 24
M5'OD_P">1_[Z%&^3_GD?^^A0!)14>^3_ )Y'_OH4;Y/^>1_[Z% $E%1[Y/\
MGD?^^A3E9CG<A7\: '4444 07-G;7@47,$<P4Y4.H.#4_08%<UXKN)(6MD,\
MD$#1S,7C8KF0)E!D>_;O6YI[3/IUJ]QGSFB4R9_O8&: +-%,9G!X3/XT;G_Y
MY_\ CU #Z*9N?_GG^M&Y_P#GG^M #Z*9N?\ YY_K1N?_ )Y_K0 ^BF;G_P">
M?ZT;G_YY_K0 ^BF;G_YY_K1N?_GG^M #Z*9N?_GG^M&Y_P#GG^M #Z*9N?\
MYY_K1N?_ )Y_K0 ^BF;G_P">?ZT;G_YY_K0 ^BF;G_YY_K1N?_GG^M #Z*9N
M?_GG^M&Y_P#GG^M #Z*9N?\ YY_K1N?_ )Y_K0 ^BF;G_P">?ZT;G_YY_K0
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ML(3/FLG!.!ZDC\JS= L;FVU^RRLTD4=OL,C1LO\ #UR1]W/ 7KWH [NBBB@
MHHHH **** (Y((9F0RQ(Y0Y4LH.T^U2444 %%%17""2UF1M^&0@[/O=.WO0
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M **** "F22QPIOED2-?[S-@4^L?Q%$9+>S/V=YXX[M'D1$W': <\=Z -<$$
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MKHLB%'4,K#!5AD&BB@ 1%C0(BA5 P%48 IU%% !1110 4444 %%%% !1110
M4444 -"*'9PH#-U..33J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M!B0Q1NSI&BL_+,% +?6GT44 %%%% !1110 4444 %%%% !1110 =1@TBJJ*%
810J@8  P!110 M%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>sava-20201231x10kg004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sava-20201231x10kg004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF6WB^33O$EQ976EZA;O^\*?(+C _/;[^F1SUKMZ $551%1%"JHP !@ 4M%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11534M2
MM-(L);V]F$4$0RS'] !W- %NBN7T'QYI6OZD;"&.YM[@KOC6X0+Y@QGC!/;G
MZ5U% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%4KW5].TUXTOKZWMVE.$$L@4M^= %VBCJ,BB@ HHHH **** "BBB@
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M** "BBB@ HHHH ***C,\0F$)E3S2,A-PW8]<4 24444 %%%% !1110 4444
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M^BZ;IDLD]GI]O;33?ZQHD SWQGTS570/"VE>'1(UA;;)90-[LY<X] 3VK:H
M**** "BBB@ HHHH ***K:A=FPT^XNQ!+/Y*%_*B&6;'84 6:HZRVHII%RVDQ
MQ/?!/W2RG@G_ !QG';-8L7BR+6/!M]JND_\ 'U!;NS0MRT3@$\^O3(]:X'2K
M?[<8=9TZ_P!26>TB-SJNH-(.N"3$BMPQX/4XYYZT ;SWVD^/?#TT&J,FG:U8
M*S,7.TQL.K#/53CD=OR-6O#=A<>+_#4,7BFP,BP%'M;HO\\JD9Y(YZ8!/?OR
M,U=B\/:!XVM+37[O3GBEG7+*LA4N 2!NQC/3K_\ 6KKXXTBC6.-0B( JJHP
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ME;GA(ZXVGW%AXAM0S6S^4EPS!A<+CKCOCCGO]0:Z-$2*-8XT5$4855& ![4
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M9R5' R 2.F:?6Q-]+G6T4BLKJ&4AE(R"#P12T#"BBB@ HHHH **** $P-P;
MR!@&EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P">$7_? H^RV_\ SPB_[X%2T4 1?9;?_GA%_P!\"C[+;_\ /"+_ +X%2T4
M1?9;?_GA%_WP*/LMO_SPB_[X%2T4 1?9;?\ YX1?]\"C[+;_ //"+_O@5+10
M!%]EM_\ GA%_WP*/LMO_ ,\(O^^!4M% $7V6W_YX1?\ ? H^RV__ #PB_P"^
M!4M% $7V6W_YX1?]\"C[+;_\\(O^^!4M% $7V6W_ .>$7_? H^RV_P#SPB_[
MX%2T4 1?9;?_ )X1?]\"C[+;_P#/"+_O@5+10!%]EM_^>$7_ 'P*/LMO_P \
M(O\ O@5+10!%]EM_^>$7_? H^RV__/"+_O@5+10!%]EM_P#GA%_WP*/LMO\
M\\(O^^!4M% $7V6W_P">$7_? H^RV_\ SPB_[X%2T4 1?9;?_GA%_P!\"C[+
M;_\ /"+_ +X%2T4 1?9;?_GA%_WP*/LMO_SPB_[X%2T4 1?9;?\ YX1?]\"C
M[+;_ //"+_O@5+10!%]EM_\ GA%_WP*/LMO_ ,\(O^^!4M% $7V6W_YX1?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%8$6O7'VW5Q=6?V:WLK9)XPY!D<'?DG!(
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !16;JFK-I>QCIUW<1NR)YD)BP&=@BK\SJ<
MDD=L<]:NV\KS0+))!) S=8I"I9?KM)'Y&@"6BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ K)GTR>34-2N%^S,MS:1P(DREUW*7)W+QE3O'?UK6HH R].L[L:A/?7L
M<$,CPQP+#;RF10JECG)5><N1C'&.O/%#4]!N=0>2YDCM+B4S@BWF8^4\*JP5
M&.T]VW]#S@=@:Z.BAZ@5=,M9++2[2UEF,TD,*QM(?XB!@FK#QI(,.BL,YPPS
M3J*;=W<$1?9;?_GA%_WP*/LMO_SPB_[X%2T4@(OLMO\ \\(O^^!1]EM_^>$7
M_? J6B@"AJ5M NEW9$$8(@?!"#CY:\QU/_D$WG_7!_\ T$UZGJ?_ "";S_K@
M_P#Z":\IU5\:=<1!)'>6)U4)&S9./8<?C7@YJKXBG_74]K+7^XJ?UT+M>CW)
MTZRC$ET;6",G:&EVJ,^F3]/TKS2&99TW(' SCYXV0_D0*Z?XD?\ (NV__7VO
M_H#UCEM1T*5:=M5;]3?'4E7JTH7T=_T+&IZCH9U#1BEYIQ5;QBY65,!?L\HY
MYZ9('Y5KPWFBW4RPP7.GS2MG")(C,>YX'XUX5+_K(/\ ?_\ 9372^"/^1PL?
M^VG_ *+:MZ>;3G.$.5>];\[$U<GA"G.?,_=O^5SUS[+;_P#/"+_O@4?9;?\
MYX1?]\"I:*]T\ B^RV__ #PB_P"^!1]EM_\ GA%_WP*EHH B^RV__/"+_O@4
M?9;?_GA%_P!\"I:* (OLMO\ \\(O^^!1]EM_^>$7_? J6B@"+[+;_P#/"+_O
M@4?9;?\ YX1?]\"I:* (OLMO_P \(O\ O@4?9;?_ )X1?]\"I:* (OLMO_SP
MB_[X%'V6W_YX1?\ ? J6B@"+[+;_ //"+_O@4?9;?_GA%_WP*EHH B^RV_\
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M;_\ /"+_ +X%'V6W_P">$7_? J6B@"+[+;_\\(O^^!1]EM_^>$7_ 'P*EHH
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M:* (OLMO_P \(O\ O@4?9;?_ )X1?]\"I:* (OLMO_SPB_[X%'V6W_YX1?\
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M122QE)RTD@7./E* #(&?O'J*2TU^6XQ UFBWGVH0-$D^Y -JNSAMHX"L.W7
M[YH6H/0W**** "BBB@ HHHH JZG_ ,@F\_ZX/_Z":\VKTC4_^03>?]<'_P#0
M37F]?.YU_$CZ'O91\$O4*Z/XD?\ (NV__7VO_H#USE='\2/^1=M_^OM?_0'K
MGP?^[5_1?J=-?_>J/J_T/+JZ#P1_R.%C_P!M/_1;5S]=!X(_Y'"Q_P"VG_HM
MJXL)_O$/5?F>KC/]WJ?X7^1[#1117VY\&%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 450N=<TFRG:"
MZU2R@F7&8Y;A%89Z<$YJ['(DL:R1NKQN RLIR&!Z$'TH =1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9D_O2_\ ?UO\:/LR?WI?^_K?XU+10!%]F3^]+_W];_&C[,G]Z7_OZW^-2T4
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MV9/[TO\ W];_ !J6B@"+[,G]Z7_OZW^-'V9/[TO_ '];_&I:* (OLR?WI?\
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M^D\U:M<=?W4XO=+'F/\ -=,"2<D?N9>GH?<=N.F:TH9I7GC5II<,P!'F'O\
MY/\ GH ;]%<EXCO;JQU".*VN)8T:(,1O)YRWK61_;>I?\_DOYUYM;-:-*;A)
M.Z]/\ST*66U:D%--6?K_ )'HE%<EX=O;J_U"2*YN)701%@-Y'.1Z?4USWBGQ
M#JVG>)+NTM+Z6."/9M7@XR@)Y//4FJEF5)456L[-VZ?YA#+:LZSHIJZ5^O\
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MGZL 2/R-9NAV^IVD4D%[!:)&TTTP>&X9SF25GVX*+P-V,Y[=.:UZ* "BBB@
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M-6K0!Q?B[_D+1?\ 7 ?^A-6!6_XN_P"0M%_UP'_H35@5\=C_ />9^I]7@O\
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M,^)'_(Q6_P#UZ+_Z&]:?AS_D/VW_  +_ -!-9GQ(_P"1BM_^O1?_ $-ZN/\
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M^5PO\>'JOS/I,3_!GZ/\C,^)'_(Q6_\ UZ+_ .AO7'UV'Q(_Y&*W_P"O1?\
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M?R7_  H\E_\ GYE_)?\ "I:* (O)?_GYE_)?\*/)?_GYE_)?\*EHH B\E_\
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M_/R+R7_Y^9?R7_"CR7_Y^9?R7_"I:* (O)?_ )^9?R7_  H\E_\ GYE_)?\
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MWB'J<76IX>!;7;8!BOWN1C^Z:RZU?#G_ "'[;_@7_H)KY7"_QX>J_,^DQ/\
M!GZ/\C*^(JE?$%N"[/\ Z*O+8_O/Z"N1KL/B1_R,5O\ ]>B_^AO7'U68?[S/
MU.K+O]UAZ'7?#I2_B"X"NR'[*W*X_OIZBO3O*?/_ !\2_DO^%>9_#?\ Y&*X
M_P"O1O\ T-*]1KW\H_W9>K/G,Y_WI^B(O)?_ )^9?R7_  H\E_\ GYE_)?\
M"I:*]0\HA\E_^?F7\E_PI?*?_GXEZ^B_X5+10!C6\3_\)5J \^3BRM><+S\\
M_M6IY+_\_,OY+_A6?;_\C7J'_7C:_P#H<]:M 'FVI C5+L$DD3/R>_S&JM6M
M3_Y"MY_UW?\ ]"-5:^&J_P 27JS[&E\"]#H;!&/@K5R)&4".;Y0!@_NQ[5YA
M7J6G?\B1K'_7.;_T6*\MKJQO\*CZ?J++OXE7U_0*]LT*)SX?TPB>0?Z+%P O
M]T>U>)U[CH/_ "+NF?\ 7I%_Z *[,C_B3]#ES[^'#U+?DO\ \_,OY+_A3D1D
MSND9\_W@./R I]%?1GS(4444 %%%% !1110 56U"=[:R>5&*LI'(MWG.,C/R
M)\Q_#IU[59HH Y>76[\S.8;ITB+'8K^'+QB!V!(89/O@5NZ9/+<6$<LS[Y&S
MEOLKV^>3_ Y+#\>O6N.O-6^R>)(3J^IR6G^E3HT+3M%']G\MO+8*" V3_%R=
MW&> !TWAJ2\ET"V>^,IF.X!IEP[)N.PL/[Q7!/O56]VY-];&M1114E!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q?B[_D+1?\
M7 ?^A-7:5Q?B[_D+1?\ 7 ?^A-7F9M_NS]4>AEG^\?)F!75>#?\ E]_[9_\
MLU<K75>#?^7W_MG_ .S5XN6?[W#Y_DSU\Q_W:7R_-'F^O?\ (Q:G_P!?<O\
MZ&:SZT->_P"1BU/_ *^Y?_0S6?7#5_B2]6>S1_AQ]$>H_#?_ )%VX_Z^V_\
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MM6_Y"6A?]?S?^D\U:M4+K0](O9VGN]+LIYFQNDEMT9CCW(J['&D4:QQHJ1H
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M7_7I<?\ L]>?E?\ $G_A?Z'=F'PP_P 2_4\CHHHKRCWSZ!HHHK[\_.PHHHH
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M ,B[IG_7I%_Z *Z\D_B3]#ES[^'#U-"BBBOI#YD**** "BBB@ HHHH ****
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MS+^2_P"%2T4 1>2__/S+^2_X4>2__/S+^2_X5+10!GZG;2R:3>HLLTC- ZA
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MHQZ>]2:M_P A+0O^OYO_ $GFK5K!8.@FFHK0V>*K--.6YY9\15*^(+<%V?\
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M]GKS^O0/AC_S%/\ ME_[/665_P"]P^?Y,ZLV_P!SG\OS1Z#1117UY\8%%%%
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M'_/6+_OV?_BJ-MQ_SUB_[]G_ .*J6B@"+;<?\]8O^_9_^*HVW'_/6+_OV?\
MXJI:* .)\5AQJD7F,K'R!RJX[M[FL*M_Q=_R%HO^N _]":L"OCL?_O,_4^KP
M7^[P]#=\*!SJDOELJGR#RRY[K[BN3\:[AXNOMY!;]WR!C_EFM==X1_Y"TO\
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M^+]$5#_D8Q_P_P"9Q]=]\-1(?[4\ME7_ %7WES_?]Q7 UZ!\,?\ F*?]LO\
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MG_XJEVW'_/6+_OV?_BJEHK[\_.R+;<?\]8O^_9_^*HVW'_/6+_OV?_BJEHH
MBVW'_/6+_OV?_BJ-MQ_SUB_[]G_XJI:* (MMQ_SUB_[]G_XJC;<?\]8O^_9_
M^*J6B@"+;<?\]8O^_9_^*HVW':6+_OV?_BJEHH \L^(N\>(+?>5)^RKRHQ_&
M]<2L,0NGQ$@PJD?*.#DUW'Q(_P"1BM_^O1?_ $-ZXI?^/J3_ '%_FU?(XN4E
MB*MG_5T?98.,98>C=?U9G9_#H.?$%QL95/V5OO+G^)/<5Z;MN,?ZV+_OV?\
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M45]V?GX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC67I_P#Q[/\ ]=YO_1C5UUYX7OI[V>9)(-LDC.-S'.">_%9>D^%[Z>SD99(
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M=I)7MY$C 0X;#E0IQ@]">E+!K5A<6XGCF?:9A!M:)U<.<8!4C<."#TZ<].:
M-"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P!?<7_H8KY&F](>O^1]G46L_3_,]QHHHK[8^$"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .5
M\9=;+_@?_LM<M74^,NME_P #_P#9:Y:ODLS_ -[G\OR1]/EW^[1^?YLU/#G_
M "'K;_@7_H)K-^)'_(Q6_P#UZ+_Z&]:7AS_D/6W_  +_ -!-9OQ(_P"1BM_^
MO1?_ $-ZN/\ R+I?XOT14/\ D8Q_P_YG'UZ!\,?^8I_VR_\ 9Z\_KT#X8_\
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M\8?_ $ 5JT %%%% !1110 4444 %%%% !7,>,9M1BBM?LK:DEHQ;SWTV$23
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MC_GE%_W\/_Q-&ZX_YY1?]_#_ /$U+10!%NN/^>47_?P__$T;KC_GE%_W\/\
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MVRLK?3K*&SM8_+MX5"1IN)P/J>:L54Y<SN3%65C%\0-/_9T.8XP/MUITD/\
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MN/\ GE%_W\/_ ,34M% $6ZX_YY1?]_#_ /$UE>'VG_LZ7$<?_']=_P#+0_\
M/Q)GM6K<3I;0--()"J]1'&TC?@J@D_@*R/#=VKVTUN8+N*3[3<S?OK26(%6G
M=E.64#)# XZT :VZXQ_JHO\ OX?_ (FH+N&\N8=D4[6K;L^9"ZEB/3YXV'Z=
MJNT4 96DZ=<Z39QVBW$ES#&BQQ+.Z?NU48 !6-<\>N>E:&ZX_P">47_?P_\
MQ-2T4 1;KC_GE%_W\/\ \33D,ASYB*OIM;/]!3Z* "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *RKC_D:]/_Z\;K_T."M6LJX_Y&O3_P#KQNO_ $."@#5K
MQ[QQG_A+K_& ?W>,C_IFM>PUX]XW_P"1POO^V?\ Z+6O(SK_ '>/K^C/9R/_
M 'B7^%_FCF8C*TCAF0JIQPI&> ?7WKU?X;_\B[<?]?;?^@)7E,7^LG_W_P#V
M45ZM\-_^1=N/^OMO_0$KS\M_WM>GZ'HYI_N;]?U9V%%%%?3GRH4444 %%%%
M!1110 4444 9&H>(;73[[3+4Q3SMJ$IBB> *R*1C.XDC'7/&>AK521) 2CJV
M#@[3G!]*\LUKP->S:K>R:1:7%G:V8\]$:X9OMDI^]M^;Y3C(SUZ>M=_X;TRW
MTG0X+>VLI+)6'F/;R2^848]1G)_2J:26A*;N:U%%%24%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 <KXRZV7_ _P#V6N,N_P#CYL?^NY_]%O79^,O^7+_@?_LM<9=_\?-C_P!=
MS_Z+>OE<?_OD_3_VT^DP7^ZP]?\ VXWO#G_(>MO^!?\ H)K-^)'_ ",5O_UZ
M+_Z&]:7AS_D/6W_ O_036;\2/^1BM_\ KT7_ -#>B/\ R+I?XOT1K#_D8Q_P
M_P"9Q]>@?#'_ )BG_;+_ -GKS^O0/AC_ ,Q3_ME_[/665_[W#Y_DSJS;_<Y_
M+\T>@T445]>?&!1110 4444 %>;_ !**OJ>EVI.N-YS!GBLCF-XU)9BJ]Y!P
M?85Z15.[TNROKF&XN8=\L*.D;;B-H<8;H>X[TT[.X/56..^%ZYTZ^N"-5+7$
MWFF2]'R29+89#_$V -Q]<5WM0VEI!8V<-I;1^7!"@2-,DX4< 9/-34Y.[NB8
MJRU"BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HJKJ5_%I>F7-_.KM%;QF1P@!8@#/&<4FEZC#JVEVVH0*ZQ7"!T$@ 8 ^N
M": +1(523T')KSG5?B38#Q'I(T_5O^)9E_MW^C-_P'JN[_OFO1B 1@C(-<;J
MO@2TNO$6DWEG8:9#8VQ<W4/DA?-ST^4+AL>]5"W,KBE?E=CI]+U6RUFP2]T^
M;SK=R0K[2N<'!X(!ZU<J&UM+:Q@6"TMXK>%22(XD"J,]>!Q4U)VOH"OU"BBB
MD,**** "BBB@ HHHH **** "BBB@ HHI@FB:9H1(AE10S(&&X YP2/0X/Y&@
M!]%4XM6TV>>6"'4+62:$$RQI,I9 #@Y .1@^M/BU&QGMEN8;VWDMV8(LJ2J5
M+$X R#C.3C% %FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*+_OX?\ XFC=<?\ /*+_ +^'_P")J6B@"+=<?\\HO^_A_P#B:-UQ_P \HO\
MOX?_ (FI:* (MUQ_SRB_[^'_ .)HW7'_ #RB_P"_A_\ B:EHH BW7'_/*+_O
MX?\ XFC=<?\ /*+_ +^'_P")J6B@"+=<?\\HO^_A_P#B:-UQ_P \HO\ OX?_
M (FI:* (MUQ_SRB_[^'_ .)HW7'_ #RB_P"_A_\ B:EHH BW7'_/*+_OX?\
MXFC=<?\ /*+_ +^'_P")J6B@"+=<?\\HO^_A_P#B:-UQ_P \HO\ OX?_ (FI
M:* (MUQ_SRB_[^'_ .)HW7'_ #RB_P"_A_\ B:EHH BW7'_/*+_OX?\ XFC=
M<?\ /*+_ +^'_P")J6B@"+=<?\\HO^_A_P#B:-UQ_P \HO\ OX?_ (FI:* (
MMUQ_SRB_[^'_ .)HW7'_ #RB_P"_A_\ B:EHH BW7'_/*+_OX?\ XFC=<?\
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M/_Q-2T4 1;KC_GE%_P!_#_\ $T;KC_GE%_W\/_Q-2T4 1;KC_GE%_P!_#_\
M$T;KC_GE%_W\/_Q-2T4 1;KC_GE%_P!_#_\ $T;KC_GE%_W\/_Q-2T4 1;KC
M_GE%_P!_#_\ $T;KC_GE%_W\/_Q-2T4 1;KC_GE%_P!_#_\ $T;KC_GE%_W\
M/_Q-2T4 1;KC_GE%_P!_#_\ $T;KC_GE%_W\/_Q-2T4 1;KC_GE%_P!_#_\
M$T;KC_GE%_W\/_Q-2T4 1;KC_GE%_P!_#_\ $T;KC_GE%_W\/_Q-2T4 1;KC
M_GE%_P!_#_\ $T;KC_GE%_W\/_Q-2T4 1;KC_GE%_P!_#_\ $T;KC_GE%_W\
M/_Q-2T4 1;KC_GE%_P!_#_\ $T;KC_GE%_W\/_Q-2T4 1;KC_GE%_P!_#_\
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M>ZD%O?B.:VMX4=["=5+*\Q.24P -Z\GCFNAHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBJD&J:
M?=74EK;WUM-<1YWQ1S*SK@X.0#D8/% %NBJ<6K:;//+!#J%K)-""98TF4L@!
MP<@'(P?6GQ:C8SVRW,-[;R6[,$65)5*EB< 9!QG)QB@"S1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8FN0
M>'+4"_UFQLF,CK%YLMJ)&9CPH^Z3VK;KS_XE6>IM:07":MLLVN846U^S*=KY
M.'W]?PZ4XJ\DA-V39WT<:11K'&BI&@"JJC 4#H /2G52TJVOK2Q6+4-0^WW
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M\U_QH\Y_^?:7\U_QJ6JUQ>QVT@1U<L1GY1]?\* )/.?_ )]I?S7_ !H\Y_\
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M#=\Y_P#GVE_-?\:/.?\ Y]I?S7_&J&E^(]'UFVFN+"^CEB@_UI(*;!UR0P!
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MY_\ GVE_-?\ &I:* (O.?_GVE_-?\:/.?_GVE_-?\:EHH B\Y_\ GVE_-?\
M&CSG_P"?:7\U_P :EHH B\Y_^?:7\U_QH\Y_^?:7\U_QJ6B@"+SG_P"?:7\U
M_P :/.?_ )]I?S7_ !J6B@"+SG_Y]I?S7_&CSG_Y]I?S7_&I:* (O.?_ )]I
M?S7_ !H\Y_\ GVE_-?\ &I:* (O.?_GVE_-?\:/.?_GVE_-?\:EHH B\Y_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
)110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>sava-20201231x10kg005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sava-20201231x10kg005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
M   !    2@,#  $    !     %$0  $    ! 0   %$1  0    !   .Q%$2
M  0    !   .Q        8:@  "QC__; $, " 8&!P8%" <'!PD)" H,% T,
M"PL,&1(3#Q0=&A\>'1H<'" D+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T
M,O_; $,!"0D)# L,& T-&#(A'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,O_  !$( AX$90,!(@ "$0$#$0'_
MQ  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#
M!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*"
M"0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS
M='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$!
M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
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M*\^\7^+KN#Q/8Z'IFK6E@C\W-VX1_*.3\K;N!@#H<'D5VVF"4:9;^??+?2%
M3<J@42YY# +QC'I1ROEYA7][E+=%>4Z?J?CGQ%K>L6VEZU;0Q65PR;9X4'RE
MF  Q&<_=[UI^&O$WB"V\8MX9\1O#/,ZEHYHU YV[NP ((![9JE!L3E8]#HKG
M]1\;^'-*O6L[S4T2X0X9%C=]I]"5! -0^)O&5EHGAQ=2M9H;A[@8M ,E)#D9
MY'H,GG'3%39VN5=7L=-17"1>,#J?P_N+ZTU6&VU*W2/[1.\#;(79AQC8V>,C
M@&NBL-8AMO"MGJ>J:C"RF!&DNL;5<D=0" >>PP#[4W%J]^@E).UC9HK&TCQ7
MH>O3-#INH1S2J,F,JR-CU 8 G\*;=>+M!L;VZL[K48X;BU4-*KJPP#C&#C!/
M(X&32::T"Z-NBL?3/%6B:Q!<36%^DRVZEY1M9651WVD X_"N8T#XC6^K>*KJ
MRFFCBM'816 6-R9CN(R3CC(QUQBFHMNP.22N=_17.WOCKPSIUZ]I<ZK&LZ':
MZK&[A3Z$J",UO6]Q#=6\<]O*DL,@W(Z-D,/4&E9VN.^MB2BN&\<>(-5\/:WH
MDUO=;--GDV7,9C4YPPSR1D<$]/2JOQ'\6:IHUW8V.BW'E3O&\TV(U<[!T^\#
MZ,?PH46TGW%?5H]#HKAM4\7W$7PQAURVF5+Z=$17"@@29PW!&.S5G:IXDU_3
M(/" DO\ $M^0UX6BC^8%DX^[Q@,1QBJY'>WG87,K7\KGI5%85GXR\/:AJ7]G
M6NJ0R762H7# ,?16(P?P-7=6UO3=#MQ/J5Y';QL<+NR2WT Y/X"ILRKFA163
MH_B;1M?+C3+^.=T&63!5@/7:P!Q[UJGI2=UN"=Q:*\D\.ZC\0/%$-S/8:[:1
MQP2^61/"@.>O&(S6YX4\3:Z/%MUX:\0/#<7$:%EGB4#D ''  ((.>@-7R/8E
MRL=_16#J7C/P[I-]]CO=3CCN!]Y K/M^I4$#\:TI=5L(-,_M*2\A6RVA_/WC
M:0>F#WJ;.URKZV+E%8&F>-?#NL7BVECJ<<EPWW49'3=]-P&3["I[_P 4Z)I>
MH_8+Z_2WN/+\W:ZL!MYYW8QV/&<T6:%=&Q16-I'BO0]>F:'3=0CFE49,95D;
M'J P!(^E2:QXET?0 G]IW\<#/RJ8+,1Z[5!./?%%FM NC5HK/TG7=,UV!IM,
MO([A%.&"Y#+]5/(_$5GS>-_#<!NA-JD:-:R>5*K(X(;)& ,9;H>F:+/8+HZ"
MBL_2=;TW7;9KC3+M+B-3M;:""I]P<$50G\:^'+?4CI\NK0+<AMI&&*@^A?&T
M?B:+.]@NK7-^BN)^'OB'4=:M]5DU2[$HMY]J,45 JX/H!^M:L'CGPS<WXL8M
M7A:<MM&58*3[,1M/YT^5WL',K7.AHJEJFKZ?HMH;K4;J.WAS@%NI/H .2?I7
M"^*/'H<:1)X;U5&CFN3'< 1@MC*X!#KD=^>*48N3L@;25V>CT4R:5((9)I6V
MQQJ68XS@#DUP>@?$:WU;Q5=64TT<5H["*P"QN3,=Q&2<<9&.N,413D[(&TE=
MG?T5BZMXNT'0[@0:CJ,<4Q&?+"L[#ZA0<?C5_3M3L=7M%NM/NH[B$G&Y#T/H
M1V/L:+.UQWZ%NBJ6L:@-)T:\U QF3[/"TFP'&[ Z5YUINH?$'Q%IK:QIVI:=
M'!EBMHJJ6X_AY4XS[M0E<3=CU*BN6TK7-5U#P;>WFH6CZ5J$$4@+30LJ@A<B
M0*03CVP>AIFB>)H;7P;!JVN:O%<*TC(UU%"X5CN( VA >V/NTW%JX7T3.LHK
M!C\:^')=233X]5A:Y<A54!MI)[;L;<^V>O%/MO&'A^[U;^S+?4X9+O)4( <,
M?0-C:3]#2Y7V"Z-NBLZ;7=-@UN#1Y+G;?SIOCBV,=PYYSC'\)[]J2YU[3+36
M+?29[G9?7*[HHO+8[ASW P.AZFBS'<TJ*\VU;Q?>WWC9M'T[Q!8Z780QY:[9
M8Y [8!(RQQG)Q@$=#6YI^I:@?'USI<VM6\]O%:JWV00E9 VU,N3LQ@DDX#GK
M346U<ERUL=;17&>$M=U+4_%7B.RO+GS+>SGV0)L4;!N8=0,G@#K6A-X]\+V]
MZUI)J\0E5MIPCE0?]X#;^M+E>@[K7R.CHK,U'Q!I6DQVLE[>+''=L%@<*65R
M>G*@C'(Y/%5;3QGX=OKY[.WU:!YD#$YRJD#DD,1M/'/!HLPNC=HK&TOQ9H6M
M7KV>GZC'-<("2@5ER!UQD -^&:V:&FMQW"BL#4?&WAS2KQK2\U2))U.&149]
MI]"5! /L:T_[5L3I3:FMU&]DL9D,T9WC:.IXZXQ19VN'6Q<HKFI/'_A:*&&5
M]7CVS#* 1N6QG'("Y7\<5T%M<P7EM'<VTJ2PR+N1T.0PHLT*Z):*Y/QKXME\
M/1VMG86XN-4O6VP(W1><9([DDX _PYPYO^%G:9"E_)<6=^H(W6<<:EAGZ*#Q
M[,::C=7!NVAZ117&^+/%M_H/A6TO5L5AU"[98_*E.Y86().<=>G'Z],5BRW'
MQ(TNUBU1KFSU:!B";:VB#M@]_E0$_4$T*+8N8],HKB/'/B34]-\'66IZ>9+&
MYGEC#I+$"R HQ*D,.H(].U4H=-^)DT$<J^(M-"NH89C7."/^N5"B]1N6WF>B
M45!9+<I86Z7DBR72QJ)G7HSXY(X'&?85P?C+6O$<7C33M%T/4([7[5 "!)&K
M+NW-R25)Z"DE>7*@OI<]#HKR[5M5\>>#TM]0U;4+&_LVF$;Q1H >A/78I' /
M/-=)XHUB\M;W0/LFJPV$=W-B2*:(LTP)3Y1A&P>2.HZ]:KDVL+F[G6T5GZMK
M>FZ';B?4KR.WC8X7=DEOH!R?P%0Z/XFT;7RXTR_CG=!EDP58#UVL <>]39LJ
MYK45@W/C3P]9SW<-SJ:12VC!9E9'R">PX^8_3-(WC7PXNEKJ1U6'[*SE V&W
M%AU&S&[N.W>BSM<5U>QOT52L-6L-3TX:A9W4<MJ03Y@. ,=<YZ8]ZR(?'WA>
M>\6UCU>+S6;:-R.JY_WB-OZT6=[!=6N=)165JGB/2-&N8+?4;Q;>2=2T896P
M0.O(&!^-<?XN\='^QK*^\-:E\CW9@E?R.ORYQAU]QTIQBY; VEN>BT5E77B/
M2K'5+?3+B[Q?7 'EPI&SL<^NT''XU'J_BS0]!F6'4M0CAE89$85G8#U(4$C\
M:5F%T;-%9XUS3&T9]72\C>P12[3)E@ .O YS[8S5&R\9^'M0OH+*TU));B==
MT:"-^1@GDXP.!G!Q19A=&]17--\0/"RW?V8ZQ#YF[;D(Y3/^_C;CWSBND5E=
M0RD,I&00>"*+/<=^@M%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2?EP >_<FL6Y^%OANYU)KPI<QJS;FMXI (R>_&,@>P(H4E:S[)#:UOYW//\
M1GDA^&WBC[(S;3/$I(Z["<']*M)X:NM0\%V<A;PG9VCA2M[([QS[NZLY&">H
M(Z>G2O2]$\':7H5E?6< EFM[TYECG(88QC P!QS6/!\*?#<-\+DB[D0-N%O)
M*#'].!NQ^-5SJ[^7Y$\KM]_XG.>)X1+XC\'V6M7$4UE]F02R++F.1LX8[N.#
MA>?0T?$73-&T[6M"&GVUM;7#R_O(X%"Y7<N"5'OGGO\ A7H?B#PQIGB6Q2UO
MXFQ&<Q21G:\?T/\ 3IP*YZ+X4^'H1"4DOA)%()/,,J[FQT!^7&/H!2C-73?1
MW"479I=K'<.BR(R.H9&&&5AD$>AKR_P-IUB?'WB1396Y%K.3;@Q+^ZQ(V-O'
MR_A7J-<K+\/]&E\2KKH:ZCN1,)S&CCRRX.<D$9Y/O40=GJ5-7C8Y/X?6&F:Q
MK&N3:U!!=:H)S^ZN0'P,G)"GKSQG'''K5GP((K7X@^(;/2VSI:KD!3E0P88Q
M^;#Z"N@UWX=:#KU\UY,L]M<.<R-;.%WGU(((S],5L:%X>TWPY9&UTZ'8K'+N
MQR[GU)_R*KF5K^5K"<7^-R37;ZVTW0[R[O;>2XM4C_>Q1J&+*>#P2!CGGGI7
MG=GX&T75[%=<\-:U=Z8#EB'8'R<=5)!!7\2:]3DC2:)XI$#QNI5E89!!Z@UP
MUS\)O#D]RTJ/?0*3GRHI5VC_ +Z4G]:F+L5)71F^&=>U#5_!'B2UU"?[4UE;
MR(ESU\P%&[]^G7KS6)<?\D/M?^OL_P#H;5ZC:^&M,L-!GT:SA,%K.CI(4;+'
M<,$Y.><>M9[^!=,?PK'X=,]Y]C23S X=?,SDGKMQCGTJG)7=O+\"4G9?/\3@
M?'&B:;I_@;P_<6EG%#.^P22(H#/NCR=QZGD=ZN^-M&T_1-4\)G3;6*V;SPK-
M&H!?:R8+'N>3R:[C6?"&GZYH]EI=U-<I!:;?+:)E#':NT9RI'3VJ77/"UCK\
M^GS74MPC6+[XA$R@$Y!^;(/]T=,52FN9/SN+D?+;RL<GKDJP_&C0V<@ VVW)
M..2) /YU%K]Q#-\9=#2*17:&()(%.=K?.<'WP1^==7XE\&:3XI:&2^$T<T0V
MK+ P5MOH<@@C\*I:=\.-#TO4K*_M&NDFM.1F0$2'GEN/?MBIA)*U^@YIN]NI
MS5MI>G2?&>^M'L+5K86^\0M"I0-L0YVXQG))S[U?T_\ Y+=JG_7F/_08ZZF+
MPO91>*YO$2RW'VR6/RV0LOEXP!P,9[#O3H?#-E!XIN/$*RW!NYXO*9"P\L#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOYTZB@!OF)_?7\Z/,3^^OYTZHHO]9/\ [_\ [** '^8G]]?SH\Q/[Z_G3J*
M&^8G]]?SH\Q/[Z_G3J* &^8G]]?SH\Q/[Z_G3J* &^8G]]?SH\Q/[Z_G3J*
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M WS$_OK^=.J*Y_X]9O\ </\ *I: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@"*?_5C_ 'T_]"%2U%/_ *L?[Z?^A"I: "BB
MB@ HHHH **** "BBB@")?^/J3_<7^;5+42_\?4G^XO\ -JEH **** "BBB@
MHHHH **** (K;_CUA_W!_*I:BMO^/6'_ '!_*I: "BBB@ HHHH **** "HI?
M]9!_O_\ LIJ6HI?]9!_O_P#LIH EHHHH **** "BBB@ HHHH *BB_P!9/_O_
M /LHJ6HHO]9/_O\ _LHH EHHHH **** "BBB@ HHHH BN?\ CUF_W#_*I:BN
M?^/6;_</\JEH **** "BBB@ HHHH **** (E_P"/J3_<7^;5+42_\?4G^XO\
MVJ6@ HHHH **** "BBB@ HHHH BMO^/6'_<'\JEJ*V_X]8?]P?RJ6@ HHHH
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MS_\ 84?\)G>_] 3_ ,F?_L*.5A='845Q_P#PF=[_ - 3_P F?_L*/^$SO?\
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M,[W_ * G_DS_ /84<K"Z.PHKC_\ A,[W_H"?^3/_ -A1_P )G>_] 3_R9_\
ML*.5A='845Q__"9WO_0$_P#)G_["C_A,[W_H"?\ DS_]A1RL+H["BN/_ .$S
MO?\ H"?^3/\ ]A1_PF=[_P! 3_R9_P#L*.5A='5VW_'K#_N#^52UQL?C"]CB
M1/[%SM4#/VG_ .PIW_"9WO\ T!/_ "9_^PHY6%T=A17'_P#"9WO_ $!/_)G_
M .PH_P"$SO?^@)_Y,_\ V%'*PNCL**X__A,[W_H"?^3/_P!A1_PF=[_T!/\
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M"3Z#-:*>)O%&H^(M8TG2;+3"MBX"S7&\ #G@X/+'MT P:.1_U\O\QM_U]_\
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M2/\ NBK-% %;[)'_ '11]DC_ +HJS10!6^R1_P!T4?9(_P"Z*LT4 5OLD?\
M=%'V2/\ NBK-% %;[)'_ '11]DC_ +HJS10!6^R1_P!T4?9(_P"Z*LT4 5OL
MD?\ =%'V2/\ NBK-% %;[)'_ '11]DC_ +HJS10!6^R1_P!T4?9(_P"Z*LT4
M 5OLD?\ =%'V2/\ NBK-% %;[)'_ '11]DC_ +HJS10!6^R1_P!T4?9(_P"Z
M*LT4 5OLD?\ =%'V2/\ NBK-% %;[)'_ '11]DC_ +HJS10!6^R1_P!T4?9(
M_P"Z*LT4 5OLD?\ =%'V2/\ NBK-% %;[)'_ '11]DC_ +HJS10!6^R1_P!T
M4?9(_P"Z*LT4 5OLD?\ =%'V2/\ NBK-% %;[)'_ '11]DC_ +HJS10!6^R1
M_P!T4?9(_P"Z*LT4 5OLD?\ =%'V2/\ NBK-% %;[)'_ '11]DC_ +HJS10!
M6^R1_P!T4?9(_P"Z*LT4 5OLD?\ =%'V2/\ NBK-% %;[)'_ '11]DC_ +HJ
MS10!6^R1_P!T4?9(_P"Z*LT4 5OLD?\ =%'V2/\ NBK-% %;[)'_ '11]DC_
M +HJS10!6^R1_P!T4?9(_P"Z*LT4 5OLD?\ =%'V2/\ NBK-% %;[)'_ '11
M]DC_ +HJS10!6^R1_P!T4?9(_P"Z*LT4 5OLD?\ =%'V2/\ NBK-% %;[)'_
M '11]DC_ +HJS10!6^R1_P!T4?9(_P"Z*LT4 5OLD?\ =%'V2/\ NBK-% %;
M[)'_ '11]DC_ +HJS10!6^R1_P!T4?9(_P"Z*LT4 5OLD?\ =%'V2/\ NBK-
M% %;[)'_ '11]DC_ +HJS10!6^R1_P!T4?9(_P"Z*LT4 5OLD?\ =%(;2/'W
M15JD/2@#C/%-J@M'PHZ5Z77GGBO_ (]'^E;7B_6[^QN=*TG2W2&\U.8QBX=-
MPB48R0#P3SW]#6<E=I(N+LFSI+G_ (]9O]P_RJ6N&TWQ#JMMJ&NZ%J\B7MS8
MVK7$-Q'&(S*NW."HXSR.GOUK$A\6>)(=+TSQ#-J=K<6][=^0=-2!1M&2.&'S
M9X[^HZT*#>W]7&Y)+4]4HK@M;\2ZM::SJA@GV1:?+:QQVOEJ1.)#\Q)(W=^-
MI'3O6_;ZA=ZCXLN(+:;;IVGQ[)P%!\V=N<9QGY1UP>II<KM?^OZU&W9V-ZBB
MBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !VKSNT\):P_PZU31Y(Q;
MWL]TTL:M(I#+E2!D$XS@UZ)10G8#S./0O$5SJ/AR:3P]:6%KILR^9%#.A8YQ
MNDX(&..F2?K6A_97B/1O%>LW.F:=;WEMJNTB5[@1B%@#RP/)ZG@>U=Y15.;?
MX_B2HV_#\#S;P?X6UJQO=(&IV?DP6/VB8MYJ,#(^% ^4D],GTJ'2;G6K3QOX
MKFTC3X;\><JR0-.(FR=VU@3Q@<Y'N*]/JC9Z/8:??7E[:P>7<7C!IWWL=Y&<
M<$X'4],4^>[N^WZARZ67<YG0O T+>'I;;Q%"EQ<75VUY*B2,H1R, 94@G@G\
M_P :ZG3M-M-)T^.QL8O*MX@0B;BV,G/4DGJ:MT5+;8TK'G=IX2UA_AUJFCR1
MBWO9[II8U:12&7*D#()QG!JO'H7B*YU'PY-)X>M+"UTV9?,BAG0L<XW2<$#'
M'3)/UKTRBJ4VG<3C?\?Q.#_LKQ'HWBO6;G3-.M[RVU7:1*]P(Q"P!Y8'D]3P
M/:M/X?Z1?Z)X8%GJ,/DW F=BN]6X.,'()%=312YM+#:N[GF\UGXTT?Q7K5]H
MNCVUS;WTBD//*O11Q@>8I'4]:DTOP[XBO;_6=;UFVM[:\N;%[6*V@9?G)'!)
MR1V'4_EBO1**.;2WE8+:W^9YU'X0U=?!^@^5%'%K.DS-,D,C@J^7)*[@<<\=
MZ=J&A>(/%%])J.I:;%8"ULIHK6T%PLK22NA&2PX Y]N@KT.BFYMW?]:B44CS
MB^\+ZS-\.M$TJ.SS>VURLDT7FI\J@OSG.#U'0UMW6BZA+\2+?54A(L5L&A:8
M.ORN=W&,Y[CM7644G-O\?QT!125O3\'<\D'A+Q-!X;U#08M$LF>20N=1\]-\
MZA@P4#KG([X'\ZZ31M"U.V\9VNHSV?E6J:3';LWF*=L@"Y7 )/;KT]Z[>BGS
MO^O2P<J_KUN<'J7@QM;\=WUUJ%GNTV6Q\N*;>,K+@#(&<Y SU&*S9?"NOW&C
MZ6+FPM[F\T6=HXXIW1H[R XQU)P> ,-C\Z].HI*30W%,\_;0=4O=&UD?\(SI
M&E/-;&*V@ME0SL3C.Z087''3_#G?L]/U.V\#6MA##:?VA':I&T-V-\1(&"K;
M3]:Z&BARNK E9W/,;+PEJ-SXETV^7P[!H MI1+/-#=B038_A5%.%!Y_ UZ=1
M10Y-JP*-C*\2_P#(M:C_ -<&_E7.^'?^/1/I71>)>/#.I'_IW;^5<SX>G46B
M<CI3@3,Z0=**A$Z8ZBE\]/45H02T5%YZ>HH\]/44 2T5%YZ>HH\]/44 2T5%
MYZ>HH\]/44 2T5%YZ>HH\]/44 2T5%YZ>HH\]/44 2T5%YZ>HH\]/44 2T5%
MYZ>HH\]/44 2T5%YZ>HH\]/44 2T5%YZ>HH\]/44 2T5%YZ>HH\]/44 2T5%
MYZ>HH\]/44 2T5%YZ>HH\]/44 2T5%YZ>HH\]/44 2T5%YZ>HH\]/44 2T5%
MYZ>HH\]/44 2T5%YZ>HH\]/44 2T5%YZ>HH\]/44 2T5%YZ>HH\]/44 2T5%
MYZ>HH\]/44 2T5%YZ>HH\]/44 2T5%YZ>HH\]/44 2T5%YZ>HH\]/44 2T5%
MYZ>HH\]/44 2T5%YZ>HH\]/44 2T5%YZ>HH\]/44 2T5%YZ>HH\]/44 2T5%
MYZ>HH\]/44 2T5%YZ>HH\]/44 2T5%YZ>HH\]/44 2T5%YZ>HH\]/44 2T5%
MYZ>HH\]/44 2T5%YZ>HH\]/44 2T5%YZ>HH\]/44 2T5%YZ>HH\]/44 2T5%
MYZ>HH\]/44 2T5%YZ>HH\]/44 2T5%YZ>HH\]/44 2T5%YZ>HH\]/44 2T5%
MYZ>HH\]/44 2T5%YZ>HH\]/44 2T5%YZ>HH\]/44 2T5%YZ>HH\]/44 2T5%
MYZ>HH\]/44 2T5%YZ>HH\]/44 2TAZ5'YZ>HI#.F.HH YGQ7_P >C_2M'XA1
MV:V6GWEQ)>VTMM<AH;VVA$HMSZNI(^7CMZ#Z')\53*;1^1TKTBLY.S3+CL>4
M^';34+K5/$.OV=U/? V#Q07DT/E_:)2 <JA'"C;C'TK!MTT]+'3?[(AO/^$S
M2ZS,K1MD')SN!^4#I[^M>WW/_'K-_N'^52TU4LPY=##\12Z?I>GR:U<V-O->
M6Z8@9H@SESPJJ<9&2>U<A--J?AJ)]/AO1;S0Z;)JEQ)Y:L;FX+\@E@?E'3C!
M]Z]&GM;>Z$8N((IO+<2)YB!MK#HPST(]:CN].L;\QF\LK>Y,9S'YT2OM/MD<
M5"=OZ_K^K%-?U_7]:AI]P]WIUK<R1^7)+$DC)_=) )%%6:*'JP6B"BBBD,**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** ,[7[66^T"^LX&19IXC%&7
M)"AFX&<=LFN+L/!OB6SB"&YTXX])7_\ B*] G_U8_P!]/_0A4M-.PFKG$_\
M".>(_P#GXL/^_K__ !%'_".>(_\ GXL/^_K_ /Q%=M13YF'*CB?^$<\1_P#/
MQ8?]_7_^(H_X1SQ'_P _%A_W]?\ ^(KMJ*.9ARHXG_A'/$?_ #\6'_?U_P#X
MBC_A'/$?_/Q8?]_7_P#B*[:BCF8<J.)_X1SQ'_S\6'_?U_\ XBC_ (1SQ'_S
M\6'_ ']?_P"(KMJ*.9ARHX<>'_$1D*?:+'( /^L?OG_8]J=_PCGB/_GXL/\
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M_P"$<\1_\_%A_P!_7_\ B*/^$<\1_P#/Q8?]_7_^(KMJ*.9ARHXG_A'/$?\
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MV*_\?4G^XO\ -JEHYF'*CB?^$<\1_P#/Q8?]_7_^(H_X1SQ'_P _%A_W]?\
M^(KMJ*.9ARHXG_A'/$?_ #\6'_?U_P#XBC_A'/$?_/Q8?]_7_P#B*[:BCF8<
MJ.)_X1SQ'_S\6'_?U_\ XBC_ (1SQ'_S\6'_ ']?_P"(KMJ*.9ARHXG_ (1S
MQ'_S\6'_ ']?_P"(H_X1SQ'_ ,_%A_W]?_XBNVHHYF'*CAT\/^(I(U<7%CA@
M",R/_P#$4[_A'/$?_/Q8?]_7_P#B*[&V_P"/6'_<'\JEHYF'*CB?^$<\1_\
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M #\6'_?U_P#XBC_A'/$?_/Q8?]_7_P#B*[:BCF8<J.)_X1SQ'_S\6'_?U_\
MXBD/ASQ'C_CXL/\ OZ__ ,17;T4<S#E1YIJ?@?Q+?Q,BW6G#/K*__P 17I=%
M%)NX)6(KG_CUF_W#_*I:BN?^/6;_ '#_ "J6D,**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** (I_\ 5C_?3_T(5+44_P#JQ_OI
M_P"A"I: "BBB@ HHHH **** "BBB@")?^/J3_<7^;5+42_\ 'U)_N+_-JEH
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M **** "BBB@ HHHH *BB_P!9/_O_ /LHJ6HHO]9/_O\ _LHH EHHHH ****
M"BBB@ HHHH BN?\ CUF_W#_*I:BN?^/6;_</\JEH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** (I_P#5C_?3_P!"%2U7FB55
M5@7SO7JY(^\/>K% !1110 4444 %%%% !1110!$O_'U)_N+_ #:I:B7_ (^I
M/]Q?YM4M !1110 4444 %%%% !1110!%;?\ 'K#_ +@_E4M16W_'K#_N#^52
MT %%%% !1110 4444 %12_ZR#_?_ /934M12_P"L@_W_ /V4T 2T444 %%%%
M !1110 4444 %11?ZR?_ '__ &45+447^LG_ -__ -E% $M%%% !1110 444
M4 %%%% $5S_QZS?[A_E4M17/_'K-_N'^52T %%%% !1110 4444 %%%% $2_
M\?4G^XO\VJ6HE_X^I/\ <7^;5+0 4444 %%%% !1110 4444 16W_'K#_N#^
M52U%;?\ 'K#_ +@_E4M !1110 4444 %%%% !44O^L@_W_\ V4U+44O^L@_W
M_P#V4T 2T444 %%%% !1110 4444 %11?ZR?_?\ _914M11?ZR?_ '__ &44
M 2T444 %%%% !1110 4444 17/\ QZS?[A_E4M17/_'K-_N'^52T %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $4_P#JQ_OI
M_P"A"I:BG_U8_P!]/_0A4M !1110 4444 %%%% !1110!$O_ !]2?[B_S:I:
MB7_CZD_W%_FU2T %%%% !1110 4444 %%%% $5M_QZP_[@_E4M16W_'K#_N#
M^52T %%%% !1110 4444 %12_P"L@_W_ /V4U+44O^L@_P!__P!E- $M%%%
M!1110 4444 %%%% !447^LG_ -__ -E%2U%%_K)_]_\ ]E% $M%%% !1110
M4444 %%%% $5S_QZS?[A_E4M17/_ !ZS?[A_E4M !1110 4444 %%%% !111
M0!$O_'U)_N+_ #:I:B7_ (^I/]Q?YM4M !1110 4444 %%%% !1110!%;?\
M'K#_ +@_E4M16W_'K#_N#^52T %%%% !1110 4444 %12_ZR#_?_ /934M12
M_P"L@_W_ /V4T 2T444 %%%% !1110 4444 %11?ZR?_ '__ &45+447^LG_
M -__ -E% $M%%% !1110 4444 %%%% $5S_QZS?[A_E4M17/_'K-_N'^52T
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MK3O_  *3_&C_ (2/0_\ H-:=_P"!2?XT6871IU%+_K(/]_\ ]E-4?^$CT/\
MZ#6G?^!2?XU')XBT0R0D:SI_#Y/^E)Q\I]Z+,+HUZ*S/^$CT/_H-:=_X%)_C
M1_PD>A_]!K3O_ I/\:+,+HTZ*S/^$CT/_H-:=_X%)_C1_P )'H?_ $&M._\
M I/\:+,+HTZ*S/\ A(]#_P"@UIW_ (%)_C1_PD>A_P#0:T[_ ,"D_P :+,+H
MTZ*S/^$CT/\ Z#6G?^!2?XT?\)'H?_0:T[_P*3_&BS"Z-.HHO]9/_O\ _LHJ
MC_PD>A_]!K3O_ I/\:CC\1:())B=9T_E\C_2DY^4>]%F%T:]%9G_  D>A_\
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M_0:T[_P*3_&C_A(]#_Z#6G?^!2?XT6871IU%%_K)_P#?_P#915'_ (2/0_\
MH-:=_P"!2?XU''XBT023$ZSI_+Y'^E)S\H]Z+,+HUZ*S/^$CT/\ Z#6G?^!2
M?XT?\)'H?_0:T[_P*3_&BS"Z-.BLS_A(]#_Z#6G?^!2?XT?\)'H?_0:T[_P*
M3_&BS"Z-.BLS_A(]#_Z#6G?^!2?XT?\ "1Z'_P!!K3O_  *3_&BS"Z-.BLIO
M%'A]!E]=TQ?K=QC^M:M(9%<_\>LW^X?Y5+45S_QZS?[A_E4M !1110 4444
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MO]B0_P!P4?V)#_<%;6*,4<J#F9B_V)#_ '!1_8D/]P5M8HQ1RH.9F+_8D/\
M<%']B0_W!6UBC%'*@YF8O]B0_P!P4?V)#_<%;6*,4<J#F9B_V)#_ '!1_8D/
M]P5M8HQ1RH.9F+_8D/\ <%']B0_W!6UBC%'*@YF8O]B0_P!P4?V)#_<%;6*,
M4<J#F9B_V)#_ '!1_8D/]P5M8HQ1RH.9F+_8D/\ <%']B0_W!6UBC%'*@YF8
MO]B0_P!P4?V)#_<%;6*,4<J#F9B_V)#_ '!1_8D/]P5M8HQ1RH.9F+_8D/\
M<%']B0_W!6UBC%'*@YF8O]B0_P!P4?V)#_<%;6*,4<J#F9B_V)#_ '!1_8D/
M]P5M8HQ1RH.9F+_8D/\ <%']B0_W!6UBC%'*@YF8O]B0_P!P4?V)#_<%;6*,
M4<J#F9B_V)#_ '!1_8D/]P5M8HQ1RH.9F+_8D/\ <%']B0_W!6UBC%'*@YF8
MO]B0_P!P4?V)#_<%;6*,4<J#F9B_V)#_ '!1_8D/]P5M8HQ1RH.9F+_8D/\
M<%']B0_W!6UBC%'*@YF8O]B0_P!P4?V)#_<%;6*,4<J#F9B_V)#_ '!1_8D/
M]P5M8HQ1RH.9F+_8D/\ <%']B0_W!6UBC%'*@YF8O]B0_P!P4?V)#_<%;6*,
M4<J#F9B_V)#_ '!1_8D/]P5M8HQ1RH.9F+_8D/\ <%']B0_W!6UBC%'*@YF8
MO]B0_P!P4?V)#_<%;6*,4<J#F9B_V)#_ '!1_8D/]P5M8HQ1RH.9F+_8D/\
M<%']B0_W!6UBC%'*@YF8O]B0_P!P4?V)#_<%;6*,4<J#F9B_V)#_ '!1_8D/
M]P5M8HQ1RH.9F+_8D/\ <%']B0_W!6UBC%'*@YF8O]B0_P!P4?V)#_<%;6*,
M4<J#F9B_V)#_ '!1_8D/]P5M8HQ1RH.9F+_8D/\ <%']B0_W!6UBC%'*@YF8
MO]B0_P!P4?V)#_<%;6*,4<J#F9B_V)#_ '!1_8D/]P5M8HQ1RH.9F+_8D/\
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MOS#YC@$@CGW%>HRZ?9362V4MG;R6B@ 0/$I0 =!MQCBB?3K&ZM5M;BSMYK=
M L4D2L@QTP",5?M/S_S_ ,R5#\O\O\CS-+"'_A%O%]Q::Z-6:9 9VCLS#&'4
MDDC'RMD?W?KWJOK>MZ?=>"?"MA;W<,MRDUOYD2,"R;5VG<.W)[UZQ;VMO:6Z
MP6T$4,*C CC0*H_ <5370=&1"BZ38*I<2$"V3&X=&Z=?>DIJ_P!WX XZ??\
MB<IX7AC?XC>+)&12ZF-58CD CG^0K)\-ZAI.EZ%XDLM>E@CU W$OVB.?&^8$
M?+C/+<YQC/7/>O2XK*T@N)KB&UACGFQYLB1@-)CIN(Y/XU%<:3IMY<+<76GV
MD\Z?=DEA5F'T)&:F^EGVL5;6_G<\JMH;J#2? *W88,;YF0-U"%U*_I^E=)X:
M@BE^(?BUI(U9AL4$CH"#D?C@5VT]E:74D,EQ:PS20MNB:2,,8SZJ3T/THBLK
M2"XFN(;6&.>;'FR)& TF.FXCD_C3E.]_._XV)4;)+T_"YXKIW_(L>'AV&OX
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MC<* %HI-PHW"@!:*3<*-PH 6BDW"C<* %HI-PHW"@!:*3<*-PH 6BDW"C<*
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M9[BR\':+JMS?Q7FDB]\Q-)'&WYFX#]6(YX/3->LV>AZ9HFEW%MIMG'!$RL6
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M>0;M:_Z NI?^ DG^%&[6O^@+J7_@))_A7K]%:?6)&?L(GD&[6O\ H"ZE_P"
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M^L2#V$3R7=K7_0%U+_P$D_PHW:U_T!=2_P# 23_"O7Z*/K$@]A$\@W:U_P!
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M%>OT4?6)![")Y!NUK_H"ZE_X"2?X4;M:_P"@+J7_ ("2?X5Z_11]8D'L(GD
M?62 1HVI$'D$6LG^%&[6O^@+J7_@))_A7K5M_P >L/\ N#^52T?6)![")Y!N
MUK_H"ZE_X"2?X4;M:_Z NI?^ DG^%>OT4?6)![")Y!NUK_H"ZE_X"2?X4;M:
M_P"@+J7_ ("2?X5Z_11]8D'L(GD&[6O^@+J7_@))_A1NUK_H"ZE_X"2?X5Z_
M11]8D'L(GD&[6O\ H"ZE_P" DG^%!?600#HVI<\#_19.?TKU^HI?]9!_O_\
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MBB@ HHHH **** "BBB@"*V_X]8?]P?RJ6HK;_CUA_P!P?RJ6@ HHHH ****
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M[B_S:I: "BBB@ HHHH **** "BBB@"*V_P"/6'_<'\JEJ*V_X]8?]P?RJ6@
MHHHH **** "BBB@ J*7_ %D'^_\ ^RFI:BE_UD'^_P#^RF@"6BBB@ HHHH *
M*** "BBB@ J*+_63_P"__P"RBI:BB_UD_P#O_P#LHH EHHHH **** "BBB@
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M_P#LHH EHHHH **** "BBB@ HHHH BN?^/6;_</\JEJ*Y_X]9O\ </\ *I:
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MPZO_ .!LO_Q5']L^(_\ H8=7_P# V7_XJC%&*/80[![>?<!K'B,  >(=6 '
M O9/_BJ/[9\1_P#0PZO_ .!LO_Q5&*,4>PAV#V\^X?VSXC_Z&'5__ V7_P"*
MH_MGQ'_T,.K_ /@;+_\ %48HQ1["'8/;S[A_;/B/_H8=7_\  V7_ .*H_MGQ
M'_T,.K_^!LO_ ,51BC%'L(=@]O/N']L^(_\ H8=7_P# V7_XJC^V?$?_ $,.
MK_\ @;+_ /%48HQ1["'8/;S[A_;/B/\ Z&'5_P#P-E_^*H.L>(R03XAU;CD?
MZ;)Q_P"/48HQ1["'8/;S[A_;/B/_ *&'5_\ P-E_^*H_MGQ'_P!##J__ (&R
M_P#Q5&*,4>PAV#V\^X?VSXC_ .AAU?\ \#9?_BJ/[9\1_P#0PZO_ .!LO_Q5
M&*,4>PAV#V\^X?VSXC_Z&'5__ V7_P"*H_MGQ'_T,.K_ /@;+_\ %48HQ1["
M'8/;S[A_;/B/_H8=7_\  V7_ .*H_MGQ'_T,.K_^!LO_ ,51BC%'L(=@]O/N
M']L^(_\ H8=7_P# V7_XJ@:QXC!)'B'5N>3_ *;)S_X]1BC%'L(=@]O/N']L
M^(_^AAU?_P #9?\ XJC^V?$?_0PZO_X&R_\ Q5&*,4>PAV#V\^X?VSXC_P"A
MAU?_ ,#9?_BJ/[9\1_\ 0PZO_P"!LO\ \51BC%'L(=@]O/N']L^(_P#H8=7_
M / V7_XJC^V?$?\ T,.K_P#@;+_\51BC%'L(=@]O/N']L^(_^AAU?_P-E_\
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M##J__@;+_P#%4?VSXC_Z&'5__ V7_P"*HQ1BCV$.P>WGW :QXC  'B'5@!P
M+V3_ .*H_MGQ'_T,.K_^!LO_ ,51BC%'L(=@]O/N']L^(_\ H8=7_P# V7_X
MJC^V?$?_ $,.K_\ @;+_ /%48HQ1["'8/;S[A_;/B/\ Z&'5_P#P-E_^*H_M
MGQ'_ -##J_\ X&R__%48HQ1["'8/;S[A_;/B/_H8=7_\#9?_ (JC^V?$?_0P
MZO\ ^!LO_P 51BC%'L(=@]O/N']L^(_^AAU?_P #9?\ XJ@ZQXC)!/B'5N.1
M_ILG'_CU&*,4>PAV#V\^X?VSXC_Z&'5__ V7_P"*H_MGQ'_T,.K_ /@;+_\
M%48HQ1["'8/;S[A_;/B/_H8=7_\  V7_ .*H_MGQ'_T,.K_^!LO_ ,51BC%'
ML(=@]O/N']L^(_\ H8=7_P# V7_XJC^V?$?_ $,.K_\ @;+_ /%48HQ1["'8
M/;S[A_;/B/\ Z&'5_P#P-E_^*H_MGQ'_ -##J_\ X&R__%48HQ1["'8/;S[A
M_;/B/_H8=7_\#9?_ (J@:QXC!)'B'5N>3_ILG/\ X]1BC%'L(=@]O/N']L^(
M_P#H8=7_ / V7_XJC^V?$?\ T,.K_P#@;+_\51BC%'L(=@]O/N']L^(_^AAU
M?_P-E_\ BJ/[9\1_]##J_P#X&R__ !5&*,4>PAV#V\^X?VSXC_Z&'5__  -E
M_P#BJ/[9\2?]##J__@;+_P#%48H(XH]A#L'MY]RE>^(/$T2$KXCU@?2^E_\
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M3W-_>W)A,*37D_F-$A&,+P .M)R33\_\BE%Z7Z?Y[G$>&?"7]I?#[^T; O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M71_:$>P?4)=SPW[6GJ*/M:>HKVZ#X7^#G@C9M())4$G[5-Z?[]2?\*M\&_\
M0'/_ (%S?_%T?VA'L'U"7<\-^UIZBC[6GJ*]R_X5;X-_Z Y_\"YO_BZ/^%6^
M#?\ H#G_ ,"YO_BZ/[0CV#ZA+N>&_:T]11]K3U%>Y?\ "K?!O_0'/_@7-_\
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MM\&_] <_^!<W_P 71_:$>P?4)=SPW[6GJ*/M:>HKW+_A5O@W_H#G_P "YO\
MXNC_ (5;X-_Z Y_\"YO_ (NC^T(]@^H2[GAOVM/44?:T]17N7_"K?!O_ $!S
M_P"!<W_Q='_"K?!O_0'/_@7-_P#%T?VA'L'U"7<\-^UIZBC[6GJ*]R_X5;X-
M_P"@.?\ P+F_^+H_X5;X-_Z Y_\  N;_ .+H_M"/8/J$NYX;]K3U%'VM/45[
M=/\ "_P<D$C+I!!"D@_:IO3_ 'ZD_P"%6^#?^@.?_ N;_P"+H_M"/8/J$NYX
M;]K3U%'VM/45[E_PJWP;_P! <_\ @7-_\71_PJWP;_T!S_X%S?\ Q=']H1[!
M]0EW/#?M:>HH^UIZBO<O^%6^#?\ H#G_ ,"YO_BZ/^%6^#?^@.?_  +F_P#B
MZ/[0CV#ZA+N>&_:T]11]K3U%>Y?\*M\&_P#0'/\ X%S?_%T?\*M\&_\ 0'/_
M (%S?_%T?VA'L'U"7<\-^UIZBC[6GJ*]R_X5;X-_Z Y_\"YO_BZ/^%6^#?\
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M!]0EW/$?M:>HH^UIZBO<O^%6^#?^@.?_  +F_P#BZ/\ A5O@W_H#G_P+F_\
MBZ/[0CV#ZA+N>&_:T]11]K3U%>Y?\*M\&_\ 0'/_ (%S?_%T?\*M\&_] <_^
M!<W_ ,71_:$>P?4)=SPW[6GJ*/M:>HKW+_A5O@W_ * Y_P# N;_XNC_A5O@S
M_H#G_P "YO\ XNC^T(]@^H2[GSWJ-RIC/-?6E<8_PH\$R##:*3_V]S__ !==
MG7%B*RJM-'7AZ+I)ID5S_P >LW^X?Y5+45S_ ,>LW^X?Y5+7.= 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 13_ZL?[Z?^A"
MI:BG_P!6/]]/_0A4M !1110 4444 %%%% !1110!$O\ Q]2?[B_S:I:B7_CZ
MD_W%_FU2T %%%% !1110 4444 %%%% $5M_QZP_[@_E4M16W_'K#_N#^52T
M%%%% !1110 4444 %12_ZR#_ '__ &4U+44O^L@_W_\ V4T 2T444 %%%% !
M1110 4444 %11?ZR?_?_ /914M11?ZR?_?\ _910!+1110 4444 %%%% !11
M10!%<_\ 'K-_N'^52U%<_P#'K-_N'^52T %%%% !1110 4444 %%%% $2_\
M'U)_N+_-JEJ)?^/J3_<7^;5+0 4444 %%%% !1110 4444 16W_'K#_N#^52
MU%;?\>L/^X/Y5+0 4444 %%%% !1110 5%+_ *R#_?\ _934M12_ZR#_ '__
M &4T 2T444 %%%% !1110 4444 %11?ZR?\ W_\ V45+447^LG_W_P#V44 2
MT444 %%%% !1110 4444 17/_'K-_N'^52U%<_\ 'K-_N'^52T %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $4_^K'^^G_H0
MJ6J\TJLJJ ^=Z]4('WA[58H **** "BBB@ HHHH **** (E_X^I/]Q?YM4M1
M+_Q]2?[B_P VJ6@ HHHH **** "BBB@ HHHH BMO^/6'_<'\JEJ*V_X]8?\
M<'\JEH **** "BBB@ HHHH *BE_UD'^__P"RFI:BE_UD'^__ .RF@"6BBB@
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (I_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (I
M_P#5C_?3_P!"%2U%/_JQ_OI_Z$*EH **** "BBB@ HHHH **** (E_X^I/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** ,SQ%J/]C^'=0U/RO.^QPM<>7NV[]GS8S@XSCK@UY.G[0#N,_P#"+?\
ME0_^U5Z7XZ_Y$+7_ /KPF_\ 0#7RS:H-@KHH4U/<PK5'#8]>_P"%^2?]"M_Y
M/_\ VNC_ (7Y)_T*W_D__P#:Z\J\L>E'ECTKI^K0.;ZQ,]5_X7Y)_P!"M_Y/
M_P#VNC_A?DG_ $*W_D__ /:Z\J\L>E'ECTH^K0#ZS,]5_P"%^2?]"M_Y/_\
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M_P#:Z\J\L>E'ECTH^K0#ZS,]5_X7Y)_T*W_D_P#_ &NC_A?DG_0K?^3_ /\
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M%;_R?_\ M='_  OR3_H5O_)__P"UUY5Y8]*/+'I1]6@'UF9ZK_POR3_H5O\
MR?\ _M='_"_)/^A6_P#)_P#^UUY5Y8]*/+'I1]6@'UF9ZK_POR3_ *%;_P G
M_P#[735^/,BLY_X1?.YL_P#'_P!. /\ GG[5Y9Y8]*/+'I1]6@'UF9ZK_P +
M\D_Z%;_R?_\ M='_  OR3_H5O_)__P"UUY5Y8]*/+'I1]6@'UF9ZK_POR3_H
M5O\ R?\ _M=,?]H!T&?^$6_\J'_VJO+?+'I5:Z0;#2>&@D4L1-L^N-%U'^V-
M!T[4_*\G[9:QW'E[MVS>H;&<#.,]<"KU8G@W_D1O#_\ V#;;_P!%+6W7 ]SM
M6P4444AD5S_QZS?[A_E4M17/_'K-_N'^52T %%%% !1110 4444 %%%% !11
M10 5@^-O^1*U?_KV:MZLCQ197&H^%]1L[2/S+B:$I&FX#)^IXI/8:W/"0WA)
M=*#(==&J"($',0A$N/\ OK;G\:]#TBY?_A)_"<5VEM=W3Z<Q-X)'9AP_ (;:
M>."2#SGFHH?^%C1Z&FCCP_IWV9;<6^YY$+;=NW)_>8)Q[?A5K0_!NJ:-XA\.
MR,@FM[.UE6XF5QA78N< $Y(^8<XKI<E?^NS,+.W]=T:ESXCUS4M>OM-\.6EB
MZ:> +B:]9@&<_P *A>_!Y/'';C.5)\1=1GCTA;#3H#>7-U):7-M*Q^61=OW6
M!X!W=2#^E7CIFO\ AOQ'JE[HVFQ:E::FPD:-KA8FADYY.>HY/3GZ=\FV\$:O
M9W^@W;QI/.-0DO+]XW 6+<4P!D@GH>F>]9Q4=+EROK;S+\'BCQ;-K&H:$-/T
MDZE:H)O.#R"$)@'&.I)R,=*O6/B^^U'P-_;5O8P?;%<QNDLZQPH0<%RS$?+[
M9SV]ZDLM%U"'XA:UJDEOBRN;5(XI=Z_,P"9&,Y'0]17-)X,UT_#ZWT\VL8O+
M>_-R;6252LR^F0<=^Y%"LUKY?GJ#NGI_6G^9HZ+X\O;G7)M*O&TJZ?[.\L<^
MGF0QAE!.T[NO ZBLN\U_Q-XC\ 7M_/;:9#IS1LLA7?YCD'@J,X S@<D]ZOPZ
M)K]SXKMM4GT.WL;5;*6V2""=&\G*MC., Y+=@:LV/AS5H?A3/HLEIC465PL/
MF)SE\CYLXZ>]$K6?I^K"-[KU_1$?A3Q->:F=)T?1HX#;V=G%]ON9U)P=H^5
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MY?74XGCTY3I]JX.5P&).#Z8Q_P!]5ZA2FDM%_7;\ BV]_P"NYS_CK_D0M?\
M^O";_P! -?+=K]P5]2>.O^1"U_\ Z\)O_0#7RW:_<%=.$ZG-BNA:HHHKN.(*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M73H_MMWZ&3!\I#^K?@*R/"NIZC<:[I\<EY<SW$L=R=4@ED)$#!_D^0\1]@
M,BE\7]>O]?</X?Z_K^FST6BBBLRPHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#G;OP)X9OKU[NXTF-IG;<Q61T!/J54@?I6]!!%;01P01K'%&H5$08"@=@
M*DHIW=K!;6X55U+3;35["6QOHO-MI<;TW%<X((Y!!Z@5:HI 5--TRRT>Q2ST
M^W6"W3HBY//J2>2?<U;HHH;ON"5CG_'7_(A:_P#]>$W_ * :^6;5QL'-?6?B
M+3O[8\.ZAIGF^3]LA:W\S;NV;_ESC(SC/3(KR=/V?W08_P"$I_\ *?\ _;:Z
M*%10W,*U-SV/+?,'K1Y@]:]5_P"%!R?]#3_Y(?\ VRC_ (4')_T-/_DA_P#;
M*Z?K,#F^KS/*O,'K1Y@]:]5_X4')_P!#3_Y(?_;*/^%!R?\ 0T_^2'_VRCZS
M /JTSRKS!ZT>8/6O5?\ A0<G_0T_^2'_ -LH_P"%!R?]#3_Y(?\ VRCZS /J
MTSRKS!ZT>8/6O5?^%!R?]#3_ .2'_P!LH_X4')_T-/\ Y(?_ &RCZS /JTSR
MKS!ZT>8/6O4Q\!I#*R?\)1T4'/V#US_TT]J=_P *#D_Z&G_R0_\ ME'UF ?5
MIGE7F#UH\P>M>J_\*#D_Z&G_ ,D/_ME'_"@Y/^AI_P#)#_[91]9@'U:9Y5Y@
M]:/,'K7JO_"@Y/\ H:?_ "0_^V4?\*#D_P"AI_\ )#_[91]9@'U:9Y5Y@]:/
M,'K7JO\ PH.3_H:?_)#_ .V4?\*#D_Z&G_R0_P#ME'UF ?5IGE7F#UH\P>M>
MJ_\ "@Y/^AI_\D/_ +91_P *#D_Z&G_R0_\ ME'UF ?5IGE7F#UH\P>M>IQ_
M :22)'_X2C&Y0<?8/_ME._X4')_T-/\ Y(?_ &RCZS /JTSRKS!ZT>8/6O5?
M^%!R?]#3_P"2'_VRC_A0<G_0T_\ DA_]LH^LP#ZM,\J\P>M'F#UKU7_A0<G_
M $-/_DA_]LH_X4')_P!#3_Y(?_;*/K, ^K3/*O,'K1Y@]:]5_P"%!R?]#3_Y
M(?\ VRC_ (4')_T-/_DA_P#;*/K, ^K3/*O,'K1Y@]:]5_X4')_T-/\ Y(?_
M &RFM\!I%9!_PE&=S8_X\.G!/_/3VH^LP#ZM,\L\P>M'F#UKU7_A0<G_ $-/
M_DA_]LH_X4')_P!#3_Y(?_;*/K, ^K3/*O,'K1Y@]:]5_P"%!R?]#3_Y(?\
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M*/K, ^K3/*O,'K1Y@]:]3D^ TD<3O_PE&=JDX^P?_;*=_P *#D_Z&G_R0_\
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M:?\ R0_^V4?\*#D_Z&G_ ,D/_ME'UF ?5IGE7F#UH\P>M>J_\*#D_P"AI_\
M)#_[91_PH.3_ *&G_P D/_ME'UF ?5IGE7F#UH\P>M>J_P#"@Y/^AI_\D/\
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MB@ HHHH **** "BBB@")?^/J3_<7^;5+42_\?4G^XO\ -JEH **** "BBB@
MHHHH **** (K;_CUA_W!_*I:BMO^/6'_ '!_*I: "BBB@ HHHH **** "HI?
M]9!_O_\ LIJ6HI?]9!_O_P#LIH EHHHH **** "BBB@ HHHH *BB_P!9/_O_
M /LHJ6HHO]9/_O\ _LHH EHHHH **** "BBB@ HHHH BN?\ CUF_W#_*I:BN
M?^/6;_</\JEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MEH **** "BBB@ HHHH **** (E_X^I/]Q?YM4M1+_P ?4G^XO\VJ6@ HHHH
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M>S4/%O\ )4(2P"2GA@YRHZ]*N:1XKE:\L[?5;F6 I%Y4FZV(\Z9F4*7PI$>
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M@7VK&"\G,,CJL4, A.QI &WMY@! )*N%4MDB,L 0<UU=1*+B[,:=QNP>K?\
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/5MT44G)O<$D@HHHI#/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>sava-20201231x10kg006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sava-20201231x10kg006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
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M4 %%%% !1110 456U"Z^PZ;=7FS?Y$+R[,XW;03C/;I61X/\3_\ "6:1+?\
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M]J[BFTT).X45SN@7GBFXU&[37--M;6T4?Z/)"P)<Y[_.W;V%=%0U8:"BBBD
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MJ@#) R=I(';;CBMCXH^'+O6](M;JQB:::R9B8D&69& R0.Y&T<5BW_Q,?5-
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M!*XY'7H2<UO_ !$\*W^L-9:KI*A[ZSZQY +*#N&,]P<\=\UB:MK'C+Q3I?\
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M#^J7WA^_LKHV8=F@NO);RLCKAL8PPP1[_6G-IK0F.^IF?"S_ )&W7/\ =/\
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MVD(MA)+%"Q1-LQSE@,# QU[4>-/#6HVWB]/$EAI<>K02!1/:O&).0NW[O<8
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M1E#WUEC,>1DA6W*1GJ0<\>]8VLZIXQ\7Z<-%3PU-8B5E^T32!E5L'/!8# R
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MIG_?Q?\ X]1_:_Q._P"A=TS_ +^+_P#'J]!HHYO(.7S//O[7^)W_ $+NF?\
M?Q?_ (]7.Z!HGCWPYJ-W?6>AVSRW0PXFF0@<YXQ(*]CHI\_D'+YGGW]K_$[_
M *%W3/\ OXO_ ,>H_M?XG?\ 0NZ9_P!_%_\ CU>@T4N;R#E\SS[^U_B=_P!"
M[IG_ '\7_P"/4?VO\3O^A=TS_OXO_P >KT&BCF\@Y?,\^_M?XG?]"[IG_?Q?
M_CU']K_$[_H7=,_[^+_\>KT&BCF\@Y?,\^_M?XG?]"[IG_?Q?_CU']K_ !._
MZ%W3/^_B_P#QZO0:*.;R#E\SS[^U_B=_T+NF?]_%_P#CU']K_$[_ *%W3/\
MOXO_ ,>KT&BCF\@Y?,Y;PW?>,;G49$\0Z59VEH(B4D@<$E\C _UC<8W=NU=3
M112;N-!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[_H8M,_[]K_\9KT&BCF\@Y3S[^R/B=_T,6F?]^U_^,T?V1\3O^ABTS_OVO\
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ME9F.W'3"^7C]*U_[(^)W_0Q:9_W[7_XS7H-%'.PY4>??V1\3O^ABTS_OVO\
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MX:PTOXB1ZC:O?:]ITMHLJ&>-(QEDR-P'[H<D9[BNYHHI-W&E8****0PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK7O#MOK=G;QB5[2>UD$EK/"!F)AZ#T]J$TM LWJ8WQ _>'P[;Q\7#ZO"8V]
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M;9_^>D?_ '[/^-&V?_GI'_W[/^- $M%1;9_^>D?_ '[/^-&V?_GI'_W[/^-
M$M%1;9_^>D?_ '[/^-1W$D\$#2[XVVXXV$=_K0!9HK'_ +5G_N1_D?\ &C^U
M9_[D?Y'_ !H V**Q_P"U9_[D?Y'_ !H_M6?^Y'^1_P : -BBL?\ M6?^Y'^1
M_P :/[5G_N1_D?\ &@#8HJC:74]UOYC7;C^$G.?QJSMG_P">D?\ W[/^- $M
M%1;9_P#GI'_W[/\ C1MG_P">D?\ W[/^- $M%1;9_P#GI'_W[/\ C1MG_P">
MD?\ W[/^- $M%1;9_P#GI'_W[/\ C1MG_P">D?\ W[/^- $M%1;9_P#GI'_W
M[/\ C1MG_P">D?\ W[/^- $M%1;9_P#GI'_W[/\ C1MG_P">D?\ W[/^- $M
M%1;9_P#GI'_W[/\ C1MG_P">D?\ W[/^- $M%1;9_P#GI'_W[/\ C6%K6N7F
MEWB01K X:,/ED/J1Z^U8UZ\*$.>>QK1HRK2Y(;G145Q?_"7:A_SQMO\ OEO_
M (JC_A+M0_YXVW_?+?\ Q5<7]K8;N_N.O^S,1Y?>=I17%_\ "7:A_P \;;_O
MEO\ XJC_ (2[4/\ GC;?]\M_\51_:V&[O[@_LS$>7WG:45Q?_"7:A_SQMO\
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M- $M%1;9_P#GI'_W[/\ C1MG_P">D?\ W[/^- $M%4=1GN;+2[NZ1XF:"%Y
M#&<$A2?[WM7GG_"R-8_Y]K'_ +]O_P#%5R8G&TL.TJG4[,-@:V)3=/H>HT5Y
M=_PLC6/^?:Q_[]O_ /%4?\+(UC_GVL?^_;__ !5<W]KX;N_N.G^QL5V7WGJ-
M%>7?\+(UC_GVL?\ OV__ ,51_P +(UC_ )]K'_OV_P#\51_:^&[O[@_L;%=E
M]YZC17EW_"R-8_Y]K'_OV_\ \56[X5\6:EK^J2VL\=I&J0F0%(VSD,H[M[UI
M2S/#U9J$;W?D9U<JQ%*#G)*R\SM*J7FEZ?J.W[=86MUM^[Y\*OCZ9%3;9_\
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M&3\/YB@#"HHHH **** "BBB@#3TC_EM_P'^M:=9FD?\ +;_@/]:TZ "BBB@
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M3_\ /Q)^2_X4>4__ #\2?DO^%2T4 1>4_P#S\2?DO^%'E/\ \_$GY+_A4M%
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MQ=_R%HO^N _]":NTKB_%W_(6B_ZX#_T)J\S-O]V?JCT,L_WCY,P****^6/I
MHHHH **** /2=,_Y!-G_ -<$_P#015JJNF?\@FS_ .N"?^@BK5?<4OX<?1'Q
MU3XWZA1116A 4444 %%%% !1110 4444 %%%% &?KW_(NZG_ ->DO_H!KPZO
M<=>_Y%W4_P#KTE_] ->'5\YGG\2'H?3Y#_#GZA1117AGNA1110 5V'PW_P"1
MBN/^O1O_ $-*X^NP^&__ ",5Q_UZ-_Z&E=F7_P"\P]3CS'_=9^AZC1117V9\
M.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5CZK_P ?2_[@
M_F:V*Q]5_P"/I?\ <'\S0!1HHHH **** "NAMO\ CUA_W!_*N>KH;;_CUA_W
M!_*@"6BBB@ HHHH **** "BBB@ HHHH *RO$?_( N?\ @/\ Z$*U:RO$?_(
MN?\ @/\ Z$*Y\5_ GZ/\C?#?QH>J_,X&BBBOBSZT**** "M_PC_R%I?^N!_]
M"6L"M_PC_P A:7_K@?\ T):Z\!_O,/4YL;_N\_0[2BBBOL3Y0**** "BBB@
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M)^2_X4 2T5%Y3_\ /Q)^2_X4>4__ #\2?DO^% $M%1>4_P#S\2?DO^%'E/\
M\_$GY+_A0!+147E/_P _$GY+_A1Y3_\ /Q)^2_X4 2UQ?B[_ )"T7_7 ?^A-
M77^4_P#S\2?DO^%<=XL4KJD0+LW[@<G']YO2O,S;_=GZH]#+/]X^3,*BBBOE
MCZ0**** "BBB@#TG3/\ D$V?_7!/_015JJ&FQN=+LR)Y!^X3@!>/E'M5KRG_
M .?B3\E_PK[BE_#CZ(^.J?&_4EHJ+RG_ .?B3\E_PH\I_P#GXD_)?\*T():*
MB\I_^?B3\E_PH\I_^?B3\E_PH EHJ+RG_P"?B3\E_P */*?_ )^)/R7_  H
MEHJ+RG_Y^)/R7_"CRG_Y^)/R7_"@"6BHO*?_ )^)/R7_  H\I_\ GXD_)?\
M"@"6BHO*?_GXD_)?\*/*?_GXD_)?\* *FO?\B[J?_7I+_P"@&O#J]MUV-QX?
MU(F>0_Z++P0O/R'VKQ*OG,\_B0]#Z?(?X<_4****\,]T**** "NP^&__ ",5
MQ_UZ-_Z&E<?77_#I2WB"X =E_P!%;D8_OIZUV9?_ +S#U./,?]UGZ'J5%1>4
M_P#S\2?DO^%'E/\ \_$GY+_A7V9\.2T5%Y3_ //Q)^2_X4>4_P#S\2?DO^%
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M* ,*BBB@ HHHH **** -/2/^6W_ ?ZUIUF:1_P MO^ _UK3H **** "BBB@
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MYC_NL_0]1HHHK[,^'"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** ,'5/"EIJ6I?VE%>7VGWIC\J2:QF$;2+V#9!!QZ]:GM?#MG8:!)I
M%E)<VT4@;=/%+B;<W5]Y_B]ZUZ* (;2W^R6<%MYTLWDQK'YLS;G? QN8]R>I
M-4[+1+:QUK5-5B>4SZCY7G*Q&U?+7:NWC(X/.2:TJ* ,S7-#MO$%C':7;S)&
MDR3 Q$ [E.1U!XK3HHH **** "BBB@ HHHH **** "BBB@ K*\1_\@"Y_P"
M_P#H0K5K*\1_\@"Y_P" _P#H0KGQ7\"?H_R-\-_&AZK\S@:***^+/K0HHHH
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M_P"?B3\E_P */*?_ )^)/R7_  K0@EHJ+RG_ .?B3\E_PH\I_P#GXD_)?\*
M):*B\I_^?B3\E_PH\I_^?B3\E_PH EHJ+RG_ .?B3\E_PH\I_P#GXD_)?\*
M):*B\I_^?B3\E_PH\I_^?B3\E_PH EHJ+RG_ .?B3\E_PH\I_P#GXD_)?\*
M*FO?\B[J?_7I+_Z :\.KVW78W'A_4B9Y#_HLO!"\_(?:O$J^<SS^)#T/I\A_
MAS]0HHHKPSW0HHHH *[#X;_\C%<?]>C?^AI7'UU_PZ4MX@N '9?]%;D8_OIZ
MUV9?_O,/4X\Q_P!UGZ'J5%1>4_\ S\2?DO\ A1Y3_P#/Q)^2_P"%?9GPY+14
M7E/_ ,_$GY+_ (4>4_\ S\2?DO\ A0!+147E/_S\2?DO^%'E/_S\2?DO^% $
MM%1>4_\ S\2?DO\ A4O;UH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KA]6\7WY\1Z=8:?;2PV1U$6MQ=2H,2L#AD0'MP
M<L/_ ->O9?\ "9?VC']O_L'[#N/F>1YWF;>V,\9Z51\:?\A3PM_V%4JDE<E[
M'7US&J:CJ5_XH30=*O%LO*M_M-U<^4)&&3A4 ;C)ZYKIZY&VQ;?%2^$I"F[T
MY&AR?O[6P0/?CIZ41&RUX?U2_P#[7U'0M5F2XNK,))'<H@3S8V'&5' (/'%=
M)7(Z;_I7Q-UBXB.Z*VLHK=V'(WD[L?45UU*6X(***BVSYXDC_P"_9_QI#):*
MBVS_ //2/_OV?\:-L_\ STC_ ._9_P : ):*BVS_ //2/_OV?\:-L_\ STC_
M ._9_P : ):*BVS_ //2/_OV?\:-L_\ STC_ ._9_P : ):*BVS_ //2/_OV
M?\:-L_\ STC_ ._9_P : ):*BVS_ //2/_OV?\:-L_\ STC_ ._9_P : ):*
MBVS_ //2/_OV?\:-L_\ STC_ ._9_P : ):*BVS_ //2/_OV?\:-L_\ STC_
M ._9_P : ):*BVS_ //2/_OV?\:-L_\ STC_ ._9_P : ):*BVS_ //2/_OV
M?\:-L_\ STC_ ._9_P : ):*BVS_ //2/_OV?\:-L_\ STC_ ._9_P : ):*
MBVS_ //2/_OV?\:-L_\ STC_ ._9_P : ):RO$?_ " +G_@/_H0K0VS_ //2
M/_OV?\:S/$(E_L*YW.A'RY 0C^(>]<^*_@3]'^1OAOXT/5?F<)1117Q9]:%%
M%% !6_X1_P"0M+_UP/\ Z$M8%;OA,.=4EV,H/D'J,_Q+[UUX#_>8>IS8W_=Y
M^AVU%1;9_P#GI'_W[/\ C1MG_P">D?\ W[/^-?8GRA+146V?_GI'_P!^S_C1
MMG_YZ1_]^S_C0!+146V?_GI'_P!^S_C1MG_YZ1_]^S_C0!+146V?_GI'_P!^
MS_C1MG_YZ1_]^S_C0!+146V?_GI'_P!^S_C1MG_YZ1_]^S_C0!+146V?_GI'
M_P!^S_C1MG_YZ1_]^S_C0!Y'XW_Y'"^_[9_^BUKGZW_&N[_A+K[<03^[R0,?
M\LUK KXC%_[Q/U?YGWF#_P!WI_X5^04445SG0%%%% 'T#146V?\ YZ1_]^S_
M (T;9_\ GI'_ -^S_C7WY^=DM%1;9_\ GI'_ -^S_C1MG_YZ1_\ ?L_XT 2T
M5%MG_P">D?\ W[/^-&V?_GI'_P!^S_C0!+6%XML)[_10+4QFY@N(KB&.4@+*
MR,"$.?7I]<5NUS?C>&:?0HA;& 7*7<+PF>4(N\-\N<\'GC'>FMQ/8I3>+]1N
M+9K:W\):P+YU* 3P 0 GCE\X(_#FM[P]ICZ/X?L=/D</)!$%9AT)[X]LUC)J
M/C8*/,T#3F;N5O,#^M=)8R74MC$]["D%R1^\C1]P4^Q[TWL)%BN/\5P^$XKK
M[7JEZ;+4@HV36LS+< =L!<G\Q785Q'B364TK6KR?3O#T-]>VMNL]W=R,%,2<
M[0.,YP">*([CEL5-'U;Q:9_] M+G4], R)-3C6VD(]%;/S9]2M=CH>L0ZYIB
MWD4;Q$,T<D4GWHW4X93ZUSECXH\0S:UI]C?:+;6L-X-Z3?:-X=0,G;C^+'.#
M780P0VZ%((DB4L6(10H)/4\=Z)"1)1114E'/7/@CP]>7DUW/8,T\[EY'%Q*N
MXGV#8J[I_A[2]+M;BVL[9HX;@8E4RN^[C'5B2.#VK4HH SH]"TR/1AHXM$-@
M%*B%R6&"<]2<]?>H]+\.:3HTSS6-F(YG7:9&=G;;Z L20/85JT4 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %<7XN_Y"T7_7 ?\ H35VE<7XN_Y"T7_7 ?\ H35YF;?[L_5'
MH99_O'R9@4445\L?2!1110 4444 >DZ9_P @FS_ZX)_Z"*M55TS_ )!-G_UP
M3_T$5:K[BE_#CZ(^.J?&_4****T("BBB@ HHHH **** "BBB@ HHHH S]>_Y
M%W4_^O27_P! ->'5[CKW_(NZG_UZ2_\ H!KPZOG,\_B0]#Z?(?X<_4****\,
M]T**** "NP^&_P#R,5Q_UZ-_Z&E<?78?#?\ Y&*X_P"O1O\ T-*[,O\ ]YAZ
MG'F/^ZS]#U&BBBOLSX<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ JG>Z79ZC+:RW4/F/:2B:$[B-KC
MH>#S^-7** *6J:38ZS:"UU"#SH0X<+O9?F'0Y!!J/5=#TW6TC74+43>4=T;!
MF1E/LRD$?G6C13NP*6F:38Z-:?9M/MD@AW%B%R2Q/<D\D^YJ[112 **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *RO
M$?\ R +G_@/_ *$*U:RO$?\ R +G_@/_ *$*Y\5_ GZ/\C?#?QH>J_,X&BBB
MOBSZT**** "M_P (_P#(6E_ZX'_T):P*W_"/_(6E_P"N!_\ 0EKKP'^\P]3F
MQO\ N\_0[2BBBOL3Y0**** "BBB@ HHHH **** "BBB@#Q[QO_R.%]_VS_\
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M2_\ 7 _^A+77@/\ >8>IS8W_ '>?H=I1117V)\H%%%% !1110 4444 %%%%
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M!R#SBL..R\>Q1)&NH:)M10H_=2=!^%=C6/K?B;3= ,27DCM/-_JX(4+R,/7
M[?6A-[#:6YA_V%XJO]6TRXU:]TM[>RN!/M@1U8\$=Q[UVE86C>+M+UN[:SA,
M\%VJ[OL]S$8W(]1GK6[2=^H*W0***P=3TKQ!=7SRV'B7[#;D#;!]@CEV\<_,
M3DY/-(9%>Z+?W^J75S?:S<6FGHJBVBLIS$5X^9G..3G\*/!6HW6I:+,UU/\
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M15JJNF?\@FS_ .N"?^@BK5?<4OX<?1'QU3XWZA1116A 4444 %%%% !1110
M4444 %%%% &?KW_(NZG_ ->DO_H!KPZO<=>_Y%W4_P#KTE_] ->'5\YGG\2'
MH?3Y#_#GZA1117AGNA1110 5V'PW_P"1BN/^O1O_ $-*X^NP^&__ ",5Q_UZ
M-_Z&E=F7_P"\P]3CS'_=9^AZC1117V9\.%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 52U:TDO],FMHBH=]N"QXX8'^E7:*F<%.+@]F5"3A)26Z.+_X1'4/
M^>UM_P!]-_\ $T?\(CJ'_/:V_P"^F_\ B:[2BO._LG#=G]YW?VGB/+[CB_\
MA$=0_P">UM_WTW_Q-'_"(ZA_SVMO^^F_^)KM**/[)PW9_>']IXCR^XXO_A$=
M0_Y[6W_?3?\ Q-:FA:%=:9?/--)"RM&4 0DG.0>X]JZ"BM*66T*4U.-[KS(J
M9A6J1<);,****[SB"BBB@ HHHH **** "BBB@ HHHH \>\;_ /(X7W_;/_T6
MM<_70>-_^1POO^V?_HM:Y^OB,7_O$_5_F?>8/_=Z?^%?D%%%%<YT!1110!]
MT445]^?G84444 %%%% !5'5]5M]%TR6^N0S(F J(,L[$X"@=R2:O5D>)=*GU
M;2/*M)5BO(94N+=W^Z)$;(S[4UN#,>V\5:RUQ?0W7A_R9H+,7D-N+@,\BEB,
M$@8!X/'6NETV_AU73;:_MR3#<1B1<]1GL?>N&$OC277YKM?#T4%U)8K:><;I
M3$A#LWF>I^]]WKQ7::)IBZ-HEGIROO\ L\00M_>/<_GFG)(E-E^L[5]>TO0H
M%FU.\CMU<X4')9OHHR3^5:-<3JE_9:#XZ?4-<B86L]M''9W9C+K"REMR\ X)
MR#FDE<;=CI;/7M+U!K9;:[1VNHC-"I!4N@."0"!6C7EWAJ\M]6M_"=A8(TMY
MISF:ZF53M@CPP*$^K$CCVKU&G)68)W"BBBI&%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5Q?B[_D+1?]<!_P"A-7:5Q?B[_D+1?]<!_P"A-7F9M_NS]4>AEG^\
M?)F!1117RQ](%%%% !1110!Z3IG_ "";/_K@G_H(JU573/\ D$V?_7!/_015
MJON*7\./HCXZI\;]0HHHK0@**** "BBB@ HHHH **** "BBB@#/U[_D7=3_Z
M])?_ $ UX=7N.O?\B[J?_7I+_P"@&O#J^<SS^)#T/I\A_AS]0HHHKPSW0HHH
MH *[#X;_ /(Q7'_7HW_H:5Q]=A\-_P#D8KC_ *]&_P#0TKLR_P#WF'J<>8_[
MK/T/4:***^S/APHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BFR2+%$\CG:B*68^@%<;#X@\3ZAI$FN
M65EIR:> SQV\Y?SI(USD[@=JDX/&*:5Q-G:452TC4HM8TBUU&%66.XC#A6ZK
MZC\ZRM6UK4/[>AT/18K5KPPFXFEN=QCBCS@<+R2318+G145@Z#K=U>7M]I6J
M0PPZE9%2_D$F.1&&59<\CZ5O4-6&%%%%( HHHH **** "BBB@ HHHH ****
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M7/U\1B_]XGZO\S[S!_[O3_PK\@HHHKG.@**** /H&BBBOOS\["BBB@ HHHH
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M.9Y_$AZ'T^0_PY^H4445X9[H4444 %=A\-_^1BN/^O1O_0TKCZZ_X=*6\07
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M;/\ \](_^_9_QHVS_P#/2/\ []G_ !J6B@"+;/\ \](_^_9_QHVS_P#/2/\
M[]G_ !J6B@"+;/\ \](_^_9_QHVS_P#/2/\ []G_ !J6B@"+;/\ \](_^_9_
MQHVS_P#/2/\ []G_ !J6B@"+;/\ \](_^_9_QHVS_P#/2/\ []G_ !J6B@"+
M;/\ \](_^_9_QHVS_P#/2/\ []G_ !J6B@"+;/\ \](_^_9_QHVS_P#/2/\
M[]G_ !J6B@"+;/\ \](_^_9_QHVS_P#/2/\ []G_ !J6B@"+;/\ \](_^_9_
MQHVS_P#/2/\ []G_ !J6B@"+;/\ \](_^_9_QJ&.R6&YFN8H[5)Y]OG2K!AI
M-HPNXYR<#@9Z5;HH IQV*17<UW'%:I<S "698,/)@8&YLY.!ZU!)HEE->B]E
ML=/>Z!R)VM%+C_@6<UIT4 5;FS%Y T%TEM/"WWHY8-RGZ@FF6>G1:=#Y-C!9
MVL1.=D%N$7/T!J[10!%MG_YZ1_\ ?L_XT;9_^>D?_?L_XU+10!%MG_YZ1_\
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M$8O_ 'B?J_S/O,'_ +O3_P *_(****YSH"BBB@#Z!HHHK[\_.PHHHH ****
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M))]Z[&B6K%$****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI6I6'ED#%]"(R^<_=P3G&*U*J.&HQ=XP2?HB98JO)<LIMKU84445L8!1110
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M^>,?_? H^S0?\\8_^^!4M% $7V:#_GC'_P!\"C[-!_SQC_[X%2T4 1?9H/\
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MY/\ XU6[XM\71>%8;3-H]W<73E8HE?:#C&<G!]1V[UC0ZK\2FGC$WA_35B+
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M$8O_ 'B?J_S/O,'_ +O3_P *_(****YSH"BBB@#Z!HHHK[\_.PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KB
M_%W_ "%HO^N _P#0FKM*I7>DV-_*);F#>X7:#O8<?@?>N/'8>6(H\D-SJP=>
M-"KSRV/.:*[[_A'-)_Y]/_(C_P"-'_".:3_SZ?\ D1_\:\7^QJ_=?C_D>O\
MVM1[/\/\S@:*[[_A'-)_Y]/_ "(_^-'_  CFD_\ /I_Y$?\ QH_L:OW7X_Y!
M_:U'L_P_S.!HKOO^$<TG_GT_\B/_ (T?\(YI/_/I_P"1'_QH_L:OW7X_Y!_:
MU'L_P_S+>F?\@FS_ .N"?^@BK5,BC2&)(HQA$4*HST Z4^OI(1<8I/H>!-\T
MFT%%%%42%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#GG'_W\/\ A1NG_P"><?\ W\/^% $M%1;I_P#GG'_W\/\ A1NG_P"><?\
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MXP, $@#OG.:S+7P_XJT+QW?W^FVEO/8W]P6DE>1?EC9]QXR#D<CH:]&W3_\
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MSC_[^'_"I;N-*Q+146Z?_GG'_P!_#_A1NG_YYQ_]_#_A2&2T5%NG_P"><?\
MW\/^%&Z?_GG'_P!_#_A0!+146Z?_ )YQ_P#?P_X4;I_^><?_ '\/^% $M%1;
MI_\ GG'_ -_#_A1NG_YYQ_\ ?P_X4 2T5%NG_P"><?\ W\/^%&Z?_GG'_P!_
M#_A0!+146Z?_ )YQ_P#?P_X4;I_^><?_ '\/^% 'D?C?_D<+[_MG_P"BUKGZ
MW_&N[_A+K[< #^[R <_\LUK KXC%_P"\3]7^9]Y@_P#=Z?\ A7Y!1117.= 4
M444 ?0-%1;I_^><?_?P_X4;I_P#GG'_W\/\ A7WY^=DM%1;I_P#GG'_W\/\
MA1NG_P"><?\ W\/^% $M%1;I_P#GG'_W\/\ A1NG_P"><?\ W\/^% $M%%%
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M147D)_>D_P"_C?XT>0G]Z3_OXW^- $M%1>0G]Z3_ +^-_C1Y"?WI/^_C?XT
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M,.A!Y!I]9F@?+HT$)^] 6@8>Z,5_I56]VXKZV-.BBBI&%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 4;W1=*U.59;_ $RRNY%7:KSVZR$#
MT!(Z5B:KIVKZ;K%AJ6@0B>S@@-M+I2RB%-N<AD!^4,/PX %=310!RFCZ7JE[
MXJE\1ZQ;)9,MM]EM;-9!(RKNW%G8<9)["MO3;O4+G3WFOM,^Q7(9@MO]H63<
M!T.X<<_I6A10!S?@71[O1O"\4.H1>7?S2R3W*[@WSLQ[@D=-O>NB,B"58BZB
M1E+!,\D#&3CTY'YBG5F#][XF;'_+O9X/UD?_ .U_RJHJXF[&G1114C"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.?\ ^,T>?K?_ $#]/_\  Y__ (S6E11S+M^?^86?<S?/UO\ Z!^G_P#@<_\
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MC?XT 2T5%Y"?WI/^_C?XT>0G]Z3_ +^-_C0!+147D)_>D_[^-_C1Y"?WI/\
MOXW^- $M%1>0G]Z3_OXW^-'D)_>D_P"_C?XT 2T5%Y"?WI/^_C?XT>0G]Z3_
M +^-_C0!+147D)_>D_[^-_C1Y"?WI/\ OXW^- $M%1>0G]Z3_OXW^-'D)_>D
M_P"_C?XT 2T5%Y"?WI/^_C?XT>0G]Z3_ +^-_C0!+147D)_>D_[^-_C1Y"?W
MI/\ OXW^- $M%1>0G]Z3_OXW^-'D)_>D_P"_C?XT 2T5%Y"?WI/^_C?XT>0G
M]Z3_ +^-_C0!+147D)_>D_[^-_C1Y"?WI/\ OXW^- $M%1>0G]Z3_OXW^-'D
M)_>D_P"_C?XT 2U@77C;PY97LEI/J:++$VR0B-V2,^C.!M4_4U8@UK0;JY6V
MM]:LYKACA8H[X,Q/H &S7/\ B:*U\->&;RPTO0;NYBN8Y6?RBS11ENK2$DD]
M<\ \#M0!VRLKHKHP96&00<@BLS5O$6DZ&8EU&\$4DO\ JXU1G=OHJ@G'X54\
M(6UNOA#2U@O3>1K;JHGC=@K8X. <$ '(Y /%37VG6-E<2ZZNGW-U?I#Y(\AV
M:1DS]U06 Z\T 7--UC3]7LC>6%W'/ "0S#C:1U!!Y!^M9D'C?PW<WB6L6J1M
M([^6C%'$;MZ!R-I/T-<[X+CM]7U/Q2UW&UM)>2JLVF,[J\2;2NYNF2^<D@GZ
MU!X]%O8^'4\/VVEW%OIX,2&_<,UO;*&!SP2Q/;..IZT >DT56@BB>VB=)I)4
M9 5D$K'<,=>O>I/(3^])_P!_&_QH EHJ+R$_O2?]_&_QH\A/[TG_ '\;_&@"
M6BHO(3^])_W\;_&CR$_O2?\ ?QO\: ):*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** ,_3[=X;W579"JS72NA_O#R8QG\PU:%%%-N[N)*P4444AA111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9L'AW
M1+6Y6YM]'T^&X4Y66.U16!]00,UA0WGC6P@FLYM*AU2<.WD7ZW$<2%2?EWIP
M1CV'/ZUU]% '+:-I>H>$?"=C86=FNJ72R_OPLRQ*NXDLP+#H,XQWJQJDOB6Q
MUI;K3[=-3TQXMC68=(I(WS]X,W!!]":Z&B@#CM-T76[G5M7UZZ\K3;^[MA;6
MD2L)?) Y#.>C'..!VJO>_P#"8ZKX?ET*YT:W2XGB^SS:BURAB*GAG"#YLD=L
M#!KN:* *NFV2:;I=I81L62VA2%6/4A5 S^E6J** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M$) !)( '))KSNZ^*\23SM8Z)<W=A ^V2[#[5'O\ =(Y[9(KT0@$$$ @\$&N#
M\?VVIVF@267A_2H4L94>2_:&-5( VXP,C)(!SP3@"JC:]F3*]M#<N_%!/A>#
M6]'TVXU-9B-L$>0^,D'. W0C!KE[SXH:IIT2R7W@Z\M8V.T-/*R GTR8ZZ'X
M?2::W@VS33'D>.,LLAD7#"3.6SCZ\>V*Y>X'_"<?$TVDAWZ5I&=R9^5V!P?S
M;CZ+5)*[NA-NQT=WXV:#3]&:#29)]2U50\-F)0N!C/+D>X[5?\/^*K77-&N-
M0>-K0VK,ES'(<^45&3SW&/ZU5\3^'+[4M1TO5=)GMXK[3V.Q+D'RW4]0=O(_
M^OVKDKS1KO2]/@\*)=+-JFNW9GO'B!VQQ#[V.^..OL10E%H+M,[SPSKDOB+2
M?[1:R-I$\C"$-)N+H#C<>!C)SQSTK9KG=)\3^&6N(=#TW4(3)"OE1Q*& (48
MP&(P>G8UT50]RD<-KOQ!N=)\32Z)::!+J$R*K#RICN;*AC\H0GBF6OCO7I[N
M&&3P/J4222*K2,7P@)QD_N^U<YKLVK6_QBEDT2VBN;\1+Y<4IPI'E#/\0[9[
MUU&FZG\0I=2MDU#0M/BLVD432(X+*F>2/WIYQ[&M&DD3=W+_ (G\9#P_J-EI
MMOITE]?7>/+B$@C')P.2#U-5]:\<3:%9:=]KT:3^T[UF460G!V8;'+@8.<C&
M!7(^--*S\3=(A^WWW^F,C;_.^:#+D8C./E ZCWJ'Q]HOV+Q+H4/]IZE<>>53
M?//N:/!5<J<<$]2?7FA1CH)MZGJVE75[>6(EU#3S87&X@P&82X'KN'%7J\A\
M=WIL]2TOPO+K%ZFFH@>[NIF,DK[F/WB!EL <#'?VJGH.IV'A_P <:?:^'=7G
MO=*O76*:.967#,=HX( )!((('J*7)=7'S:V/:J*\F>RE^('C[5;"_O9X=/TX
MLB10D#[K;>^1DG)S@^E;^B^ [VQL]4TF^U9YM(NUVQQ(?WB<C#9(P#C@@#%)
MQ2W8[MF[X;\56?B@WCV,<@@MG5 \G!?(SG'85MNZQQM([!44$LQZ "O(/A)H
M5K=WDNLR23"XLI-L:J1L(9&!R,9[]B*]<NK>.\M)K:7/ES1M&^#S@C!I323L
M@BVT<"_Q0DN9YAH_AN^U&VB)#3(2/QP%; ^N*Z+PKXNLO%5M*UO&\%Q 0)8)
M.JYZ$'N.*X.WT;QQX%FE328UU#3V<OL5=X;W*_>!P!TKIO WB33-:O;N%=&A
MTW5U4O<".(*9!GDDX!SDC(/K52BK:"3=]3I-)OM4O);I=1T?^STC8"%OM*R^
M<.<G"_=Q@=?7VK3KR?X=Z?%JW_"7Z?.SK%</'&YC(# $R],@US.N^&=-_P"$
MFBT#PTUW=W6[;,\TBE5/<<*.G<T<BO8.9VN>_45Y#XVN9-&30?"3:C);6*6Z
M&[N$4Y9=Q7.!R0-I.*S])U/3?#?C+34\.:S<7>F73K%<QS(RX+'&2"H!ZY!
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MQZ#UJ#^V/^H=J'_?C_Z])0DU<?,C2HK-_MC_ *AVH?\ ?C_Z]']L?]0[4/\
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M.SQ64SHWT94((]P:7^W+3_GCJ'_@NN/_ (BE[.?8?-'N:5%9O]N6G_/'4/\
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M^0KHZRM#M7M?[2WAAYM]+*N5QP<?G]:U:TJN\VT1!6B%%%%9EA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7-Z\KQ:C'%%E1J:"VD*G'(=>?KL:3GV%=)65JT8?4=%)[7C?\ HF0_T%:4
MG:5R)JZ-155$5$4*JC  & !2T45F6%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D*JQ4E02IR"1T/3^M
M+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYI60$^F3'6[_ ,)W9P>#+;Q#?6SP?:"RQVJON9F#,  <#C"YSC\^_ /J-O\
M$#Q=YVJZA;V&BVA_=Q3W"QEEST )^\V.3V''I6I\43:W&D:'<Z9/#)IL$KPE
M[8JZ(<+M''' 4\4^572L',[-FUIWQ-2;4K:UU71;G3$NL>1-(Q*MGH>5''N,
MUWM>1:Q;6>OBSAU+XBVMQD[X NGHI4GCDJPVGV;%>MH&6-0[;F  +8QD^M1)
M);%1;'4445!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 <H?AMX2)R=)R3_T\R__ !5:NC>&M(\/"<:7
M9^1]HV^;^\=]VW./O$^IK6HI\S8K(YQO ?A=KW[6='@\TMNQN;9G_<SM_2NB
M "J%4  #  [4M%#;8[&3H_AZTT6YO[F&6>:XOI?-FEG8%B>< 8 X&3^=9/\
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MG)-0?\(KHHO;^\^Q?Z1?Q/#<OYK_ +Q'QN&,X&<#IBMFBB[%9'*?\*U\(_\
M0)_\F9?_ (JM:U\-Z/9Z.^DPV*?8')9H79G!)_WB3VK5HHYFPLCGK#P/X:TR
M\6[M=*C69#E6=W?:?4!B0#70T44-M[CM8****0!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
*4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>sava-20201231x10kg007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sava-20201231x10kg007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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MFZ^O_P!>D/>@]Z %#L?XC^?_ ->C>QZ,WY__ %Z0]Z#WH 4.Q_B;KZ__ %Z
M['^(_G_]>D/>@]Z %WL>C-^?_P!>@.Q_B;KZ_P#UZ0]Z#W_*@!0['^(_G_\
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MJGB2STK5[#39XKAIKYML31J"HY YR00,GL*$K@;(=C_$W7U_^O0'8_Q'\_\
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M'O0>] "[V/1F_/\ ^O0'8_Q-U]?_ *](>]![T *'8_Q'\_\ Z]&]CT9OS_\
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M\8Q7;6N@:AHOC>>YL+;S-&U%?])19%'E.<\[2<GG/3LQ]JR+;0_&/A2>]L]
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MZ,2?WE_[Y_\ KT .HIN)/[R_]\__ %Z,2?WE_P"^?_KT .HIN)/[R_\ ?/\
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M**[UF@>)@&&Y3M=02I'(;&#@X)Q4DVKZ?;ZK#I<ERBWLT3S1PD9/EH1N8X&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *2EI* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH_SD#]:.I]SS1WS[YSZ?C0 #KGW]:3_"EY'6B@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !24M)0 M%%% !1110 4444 %%%% !1110 4444
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M5^]SCI\IK)K7\,?\C%:?\"Z_[AK?#?QH>J_,PQ7\"?H_R/0!$P_Y;2>XPO\
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M5_\ GT_\BI_C7AYG2J3JIQBWIV\V>]E=:G"BU.26O5^2,FBM;_A&=7_Y]/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M )^YOR3_ .)H\B7_ )^YOR3_ .)H GHJ#R)?^?N;\D_^)H\B7_G[F_)/_B:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7_7Q'_Z$*]1KR[2O^0Q9?]?$?_H0KU&O=RGX)>IX&<?''T"BBBO6/'"BBB@
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M:N\4,CLX:%T\W+, F<[E^\,J.]G2HK?38)U.OV3SW<TMQ=S(%4M(X !C!<A
MH  #;\X&3ZTX+'=>7-_?^)[">^>P:P@EAA6)8U)W%V7S&W-G:>"HX. ,FCVL
M.Z#V4^S-+PGJ.J:II]Q=ZC+:2PM<.EG);V[0^;$OR[RK.^-S!L<_=P>^!OUD
MZ=<:5IFEVEA#?VGE6L"0IB51\JJ%'&?:K7]JZ=_S_P!K_P!_E_QH]I#N@]E/
M^5ERBJ?]JZ=_S_VO_?Y?\:F@N[:ZW?9[B*7;][RW#8^N*:G%NR8.G-*[1-5/
M5?\ D#WW_7N__H)JY5;4(GGTVZAC7=))"ZJ,]200*517@PINTTWW/+**UO\
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MLW_/_<?]\Q__ !-6J* *OV6;_G_N/^^8_P#XFC[+-_S_ -Q_WS'_ /$U:HH
MJ_99O^?^X_[YC_\ B:/LLW_/_<?]\Q__ !-6J* *OV6;_G_N/^^8_P#XFC[+
M-_S_ -Q_WS'_ /$U:HH J_99O^?^X_[YC_\ B:/LLW_/_<?]\Q__ !-6J* *
MOV6;_G_N/^^8_P#XFC[+-_S_ -Q_WS'_ /$U:HH J_99O^?^X_[YC_\ B:/L
MLW_/_<?]\Q__ !-6J* *OV6;_G_N/^^8_P#XFC[+-_S_ -Q_WS'_ /$U:HH
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M ,35JB@"K]EF_P"?^X_[YC_^)H^RS?\ /_<?]\Q__$U:HH J_99O^?\ N/\
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M"ESW_P _YZT<Y'7MZ^E "<=.*6CTYQQQ_*C]* "BBB@ HHHH **** "BBB@
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M3O\ GM=>_P R_P#Q-=%],>V<>M'TQ[9QZT?4L/\ RH/KV(_G9SO_  AFG?\
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M3^Q3_P#03N_^^8O_ (BC[%<?]!.[_P"^8O\ XB@"Y15/[%/_ -!.[_[YB_\
MB*/L4_\ T$[O_OF+_P"(H N453^Q7'_03N_^^8O_ (BC[%/_ -!.[_[YB_\
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M $$[O_OF+_XBC[%/_P!!.[_[YB_^(H N=\>OZT=>O7O5/[%<?]!.[Y_V8O\
MXBD^Q3X_Y"=W@=ML7_Q% %SOD8R:7O@#].35/['<9_Y"EYU(Y6+_ .(I/L4_
M_03N_P#OF+_XW0!<Q_+KBEJE]BG[:G=<'/W8O_C=+]BG_P"@G=_]\Q?_ !%
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MQ^!QCFG-_K&^I[>])SVSGC% !R#P?UQ^-'TH]QTY[44 %%%% !1110 4444
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MCJ?YTWC!^GI3G_UC9.?F]?RI.V>O?\Z #]?3BBC]>U% !1110 4444 %%%%
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M>N/\^E+Z=/\ "@ ]NU%'X44 %% HH **** "BBB@ HHHH .W?\/Y44GK2]Z
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MU_*E[T@H 7]:2E[=S10 4444 %%%% !1110 4444 ':@]31].HZ4?AQ]?K0
M=Z***  44"B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *#R.?YT&COZY/YT !&?Q-)
MU'UY]:.XSWYY_6E//4_7_&@"X#D _P J*!R :* *C_?)QW)_6N6NO!GVF[FN
M/^$E\1P^;(S^5#?;43)SA1C@#M74O]]CQP32>U ')?\ ""_]37XG_P#!C_\
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M8)P/H.:P4\?^&'=474\LQP!Y$O7_ +YH K_\(+_U-7B?_P &'_V-'_""\?\
M(U>)_P#P8?\ V-='>ZC::<L37<ZQ"618HP>KL>  !R?Z5:YS[C_/]* .3_X0
M7G_D:O%'_@P_^QI/^$%_ZFKQ/_X,/_L:ZREH Y+_ (07_J:O$_\ X,/_ +&C
M_A!?^IJ\3_\ @P_^QKK:* .2_P"$%_ZFKQ/_ .##_P"QH_X07_J:O$__ (,/
M_L:ZVB@#DO\ A!?^IJ\3_P#@P_\ L:/^$%_ZFKQ/_P"##_[&NIGGBM;>6XF<
M)%$A=V/90,DU5TK6=/UNV:XTZX$\2OL8[2N#UZ$ ]Z ,#_A!?^IJ\3_^##_[
M&C_A!?\ J:O$_P#X,/\ [&M:'Q/H]Q%:217FY+N8P0'RG&]QVZ<?C6O0!R7_
M  @O_4U>)_\ P8?_ &-'_""_]35XG_\ !A_]C76T4 <E_P (+_U-7B?_ ,&'
M_P!C1_P@O_4U>)__  8?_8UTM_?VVF64MY>2>7;Q %WVDXR<=!SWJ6*5)H4E
MC.Y'4,IQU!Z4 <K_ ,(+_P!35XG_ /!A_P#8T?\ ""_]35XG_P#!A_\ 8UUM
M% ')?\(+_P!35XG_ /!A_P#8T?\ ""_]35XG_P#!A_\ 8UUM% ')?\(+_P!3
M5XG_ /!A_P#8T?\ ""_]35XG_P#!A_\ 8UUM% ')?\(+_P!35XG_ /!A_P#8
MT?\ ""_]35XG_P#!A_\ 8UT5WJ=G8W%K!<S;);I_+A7:3N;TX''7O1I^IV>J
MQ22V4WFI%*T+G:5PXQD<@>HH YW_ (07_J:O$_\ X,/_ +&C_A!?^IJ\3_\
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M 'V<_P![]*/LY_O_ *444 'V<_W_ -*/LY_O_I110 ?9S_>_2C[.?[_Z444
M'V<_W_TH^SG^_P#I110 ?9S_ '_TH^SG^_\ I110 ?9S_?\ TH^SG^]^E%%
M!]G/][]*/LY_O?I110 ?9S_>_2C[.?[WZ444 'V<_P![]*/LY_O?I110 ?9S
M_>_2C[.?[WZ444 'V<_WOTH^SG^]^E%% !]G/]_]*/LY_O\ Z444 'V<_P!_
M]*/LY_O_ *444 'V<_WOTH^SG^]^E%% !]G/][]*/LY_O?I110 ?9S_>_2C[
M.?[WZ444 'V<_P![]*/LY_O?I110 ?9S_>_2C[.?[WZ444 'V<_WOTH^SG^]
M^E%% !]G/][]*/LY_O?I110 ?9S_ 'OTH^SG^]^E%% !]G/][]*/LY_O?I11
M0 ?9S_>_2C[.?[WZ444 'V<_WOTH^SG^]^E%% !]G/\ >_2C[.?[WZ444 'V
M<_WOTH^SG^]^E%% !]G/][]*/LY_O?I110 ?9S_>_2C[.?[WZ444 'V<_P![
M]*/LY_O?I110 ?9S_>_2C[.?[WZ444 'V<_WOTH^SG^]^E%% !]G/][]*/LY
M_O?I110 ?9S_ 'OTH^SG^]^E%% !]G/][]*/LY_O?I110 ?9S_>_2C[.?[WZ
M444 'V<_WOTH^SG^]^E%% !]G/\ >_2C[.?[WZ444 'V<_WOTH^SG^]^E%%
G!]G.?O?I1]G;^\/R_P ^U%% !]G/]['X4&W/]ZBB@"?M1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>sava-20201231x10kg008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sava-20201231x10kg008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
M   !    2@,#  $    !     %$0  $    ! 0   %$1  0    !   .Q%$2
M  0    !   .Q        8:@  "QC__; $, " 8&!P8%" <'!PD)" H,% T,
M"PL,&1(3#Q0=&A\>'1H<'" D+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T
M,O_; $,!"0D)# L,& T-&#(A'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,O_  !$( 4(#W ,!(@ "$0$#$0'_
MQ  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#
M!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*"
M"0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS
M='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$!
M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
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MZ%CGGU^E:]<WHO\ R.WB?_MT_P#19K2"3C)OHOU1$FTU_71G24445F6%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%8Q\265OJC:;J#?8[GK&93A)5/0JW3VP<<UL]1D54HRCNA*2>P4445(PHHHH
M **** "BBB@ HHHH **** "N2\4V%KJGBCPY9WD7FV\GVG>FXKG"*1R,'J!7
M6UEWVE/=Z[I.HB556Q\[<A'+[U"\?2M:,^25[VT?Y,BI'F5O3\S/_P"$!\,_
M] W_ ,CR?_%4?\(#X9_Z!O\ Y'D_^*KI**/K%7^9_>P]E#LCF_\ A ?#/_0-
M/_?^3_XJC_A O#7_ $#C_P!_Y/\ XJNDHH^L5?YG]X>RAV1S?_"!>&O^@<?_
M  (D_P#BJ/\ A O#7_0//_@1)_\ %5TE%'MZO\S^\/90[(YO_A O#?\ T#V_
M\")/_BJ/^$"\-_\ 0/;_ ,")/_BJZ2BCV]7^9_>'LH=D<W_P@7AO_GP;_P "
M)/\ XJC_ (0+PW_SX-_X$2?_ !5=)11[>K_,_O#V4.R.;_X0+PY_SXO_ .!$
MG_Q5'_"!>'/^?%__  (D_P#BJZ2BCV]7^9_>'LH=D<W_ ,(%X<_Y\7_\")/_
M (JC_A _#O\ SY/_ .!$G_Q5=)11[>K_ #/[P]E#LCF_^$#\._\ /D__ ($2
M?_%4?\('X=_Y\I/_  (D_P#BJZ2BCV]7^9_>'LH=D<W_ ,('X=_Y\Y/_  (D
M_P#BJQ/%WA+1M,\+WEY:6SI/'LVL9G;&74'@G'0FN_K+\1:4^MZ%<Z<DJQ--
MMP[#(&&#?TK2EB*BG%RD[7[DSI1Y79:E&/P+X;BE21-.PZ,&4^?)P1_P*M75
M-)L=9M1;:A!YT*N'"[V7D C.01ZFKM%9.K4;3<G=%J$4K)&5I7AO2=$FDETZ
MT\EY%VL?,=LCK_$346H^$]#U6\:[O;+S9W #/YKKG P. 0*VJ*/:U.;FYG<.
M2-K6T*D&FVEKI@TZ&';:!#&(]Q/RG.1DG/<]ZR[7P5X>L[J*YM]/V31.'1O.
MD.".G!:M^BDJDU>S>H.$7NC/U70].UN../4;?SEC)9!O9<$_[I%-TG0=,T,3
M#3K;R/.QO_>,V<9Q]XGU-:5%'M)\O+?3L'+&][:F%>>#= O[N6ZN;#S)Y6W.
MWG2#)^@;%:3Z;:/I?]F-#FS$0A\O<?N 8 SG/3WJW10ZDW:[>@*$5LC#L?"&
MA:9>QWEG8^7<1YV/YSG&1CH6QT-6=5\/:7K;1-J-KYQB!"?O&7&>OW2/2M.B
MG[6HY<W,[AR1M:VA0TO1K#1;=X-/@\F-VWLN]FR<8[D^E9L_@?P[<W$D\NG;
MI)&+NWGR#))R?XJZ&BA5:B=U)W8.$6K-%2]TVTU'3VL+J'S+9@ 4W$="".0<
M]A6;:^&-)T21[W2].Q=A"J#SGYSV^8D8K=HI*I-*R>@.,6[V./L/ T3ZF^K:
MS/\ :;V1_,*0Y2-#[=SC\*H>$?".A:IX7L[R\L?-N)-^]_-=<X=@. P'0"N_
MK"\'65SI_A2RM;N)HIX]^Y&ZC+L1^A%;_6*CIM\VMU]VIG[**DM._P"A!_P@
M/AG_ *!G_D>3_P"*H_X0'PS_ - S_P CR?\ Q5=)167UBK_,_O9?LH=D<W_P
M@/AG_H&?^1Y/_BJ/^$!\,_\ 0,_\CR?_ !5=)11]8J_S/[V'LH=D<W_P@/AG
M_H&?^1Y/_BJ/^$!\,_\ 0,_\CR?_ !5=)11]8J_S/[V'LH=D<W_P@/AG_H&?
M^1Y/_BJ/^$!\,_\ 0,_\CR?_ !5=)11]8J_S/[V'LH=D<W_P@/AG_H&?^1Y/
M_BJ/^$!\,_\ 0,_\CR?_ !5=)11]8J_S/[V'LH=D<W_P@/AG_H&?^1Y/_BJ/
M^$!\,_\ 0,_\CR?_ !5=)11]8J_S/[V'LH=D<W_P@/AG_H&?^1Y/_BJ/^$!\
M,_\ 0,_\CR?_ !5=)11]8J_S/[V'LH=D<W_P@/AG_H&?^1Y/_BJ/^$!\,_\
M0,_\CR?_ !5=)11]8J_S/[V'LH=D<W_P@/AG_H&?^1Y/_BJ/^$!\,_\ 0,_\
MCR?_ !5=)11]8J_S/[V'LH=D<W_P@/AG_H&?^1Y/_BJ/^$!\,_\ 0,_\CR?_
M !5=)11]8J_S/[V'LH=D<+XD\*^&](T*XN8M-_T@@1P#SI#F1N!QNY]?PKH]
M/MX/#7A>..0@1VD!>0^K=6/XG-6;_2K?4KBRFN#)_HDOG1HI&TMCC/':H]<T
MHZUIIL3<-#&[J9"JY+*#DKUXSZU;J\\8QG)[ZDJ'*VXHYS1/".FZOIB:IK-H
M9KV]9KAB977 8Y48!';%:/\ P@/AG_H&?^1Y/_BJZ-55$5%4*JC  ' %+2EB
M*K=U)KYC5*"6J.;_ .$!\,_] S_R/)_\51_P@/AG_H&?^1Y/_BJZ2BI^L5?Y
MG]['[*'9'-_\(#X9_P"@9_Y'D_\ BJ/^$!\,_P#0,_\ (\G_ ,57244?6*O\
MS^]A[*'9'-_\(#X9_P"@9_Y'D_\ BJ/^$!\,_P#0,_\ (\G_ ,57244?6*O\
MS^]A[*'9'-_\(#X9_P"@9_Y'D_\ BJ/^$!\,_P#0,_\ (\G_ ,57244?6*O\
MS^]A[*'9'-_\(#X9_P"@9_Y'D_\ BJ/^$!\,_P#0,_\ (\G_ ,57244?6*O\
MS^]A[*'9'-_\(#X9_P"@9_Y'D_\ BJ/^$!\,_P#0,_\ (\G_ ,57244?6*O\
MS^]A[*'9'-_\(#X9_P"@9_Y'D_\ BJ/^$!\,_P#0,_\ (\G_ ,57244?6*O\
MS^]A[*'9'-_\(#X9_P"@9_Y'D_\ BJ/^$!\,_P#0,_\ (\G_ ,57244?6*O\
MS^]A[*'9'-_\(#X9_P"@9_Y'D_\ BJ/^$!\,_P#0,_\ (\G_ ,57244?6*O\
MS^]A[*'9'-_\(#X9_P"@9_Y'D_\ BJ/^$!\,_P#0,_\ (\G_ ,57244?6*O\
MS^]A[*'9'-_\(#X9_P"@9_Y'D_\ BJQ-,\(Z%<>*->LY;'=;VOV?R4\UQMW(
M2W.[)R?6N_JI;Z=;VVH7E]$K">[V>:2V0=@P,#MQ5QQ-1)WD]N_FB72C=62(
MM*T33M$BDCTZW\E)&W.-[-D_\")JA<^"O#UY=2W,^G[YI7+NWG2#))R3@-6_
M16:JU$^92=RW"+5K%2XTVTN]-.G3P[[0H$,>XC@8P,@Y["J&G>$]$TF\6[LK
M+RIU! ;S7;&>#P216U1252:32>C!QBW=HRM5\-Z3K<Z3:A:>=(B[5/F.N!G/
M\)%6-,TFRT:U-M80>3"7+E=[-R<=R3Z"KM%#J3<>5O0.6-[VU.=?P+X;DE:1
MM.R[,6)\^3K_ -]5KZEIEGJ]H;6^A\V L&*[BO(Z<@@U;HH=6;:;;T!0BMD9
M&E^&-'T6Y:YT^S\F9D,9;S7;*D@XY)[@4FI>%=%UB[^U7]EYTVT+N\UUX'L"
M!6Q13]K4YN;F=PY(VM;0J6.FVFFV"V-I#Y=LN<)N)ZG)Y)SWK)@\#^';:XCG
MBT[;)&P=&\^0X(.1_%70T4E5FKV;U!PB]T4-4T:PUJW2#4(/.C1MZKO9<'&.
MQ'K4>E>'M*T1Y7TZU\EI0 Y\QFR!T^\36G11[2?+RWT#EC>]M3$O_"&A:G>R
M7EY8^;<28WOYSC.  . V.@%:":99QZ5_9BPXLS$8?+W'[A&",YSW]:MT4.I-
MI)MZ HQ3ND85GX-T"PNXKJVL/+GB;<C>=(<'Z%L5<U;0=,UP1#4;;SA#G9^\
M9<9QG[I'H*T:*;JS;YG)W#DC:UC/TK0].T2.1-.M_)64@N-[-DC_ 'B:H77@
MOP_>W4MU<:?OFE8N[>=(,D]> V*WZ*%5J)\RD[AR1:M8J3Z;:76F'3IH=UH4
M$9CW$?*,8&0<]AWJAI_A+0]*O4O+*Q\J= 0K^:[8R,'@DBMJBDJDTFD]&#C%
MN[1E:KX<TG6Y8Y=1M/.>-=JGS'7 _P" D58TO2+'1K5K;3X/)A9RY7>S?,0!
MG))]!5VBAU)N/+?0.6-[VU.=E\"^&YI7EDT[+NQ9CY\G)/7^*M?4=-M-6LVM
M+Z'S8&()7<5Y'3D$&K=%#JS;3;>@*$5LC@6^'%I>:HTIC%A8)PD,4C/))_M,
MS$A?H,\5VMA8V^FV<=I:H4AC&%4L6Q^)JS155*]2HDI,4:<8ZI!111618444
M4 %%%% !1110 4444 %%%% '/^./^1)U?_KW/]*\WC:^%_I,6QF&BWJ6L"-_
MRU,GF2+_ ..I&/QKVBBJ4K*Q+C=GE]QXLUF+29)[75/M4QL%GN3Y,8^PS&15
MV8"^[+M;)^7-2ZIJ&H'4#:7FL3+;V.MVZ&<K''A&C+?-\NW"L.,COSG QZ71
M3YEV#E9YQX/N[VTN-'MENW:TOI[X/ R)M38Q((.-V<DYR2/:G7.[_A.'SC^T
M_P"UH/*Z>9]D\D[L?['WL]L]>:]%HHYM;ARA1114%!1110 4444 %%%% !11
M10 5XLWB#6DT:_L1J-X9[EWNH9_-8M''&9=ZALY7F-.!_>->TU2_L?2]NW^S
M;/;M9<>0N,-RPZ=#W]:J+2):N<E9>+-1$$$S+;R6L=Y#8/"0QN)"R#]X&W8Z
MG.-IR >:S;GQGKTVA"7=9Q/=Z?/<1M#$P:$QO@\ECG(SV&">^.?05TK3EO$O
M%L+474:[4F$*[U&,8#8R!CCZ4@TG351473[0(B-&JB%<*C?>4<=#W'>GS+L%
MF<''KVMZ7>ZC<O=17,,(T]9(I5?GS  =GSX0\DD_-DXK<\<S:I;65I-97GV:
MW%S$LPCR))"74 9[+C.?7@=,UO)HNE1Q-%'IEFD;[2R+ H#;?NY&.W;TJS<6
MT%U&([F".9 P8+(@89'(.#W%+F5[A9V.3EEFG\>16^F7E].T+^;J)>8_9X8R
MF%B"?=W$\],]>>N.QJC_ &+I0O?MHTRR^U[M_G_9UW[O7=C.?>KU)L:"BBBD
M,**** "BBB@ HHHH **** "O)&\<Z\FC7\1O%.H/*9+60PIE85,F_C&#CRL<
MC^.O6ZP_^$0T$H%-@,".2(?O7SMD)+C.>Y)^F>,546EN2TWL9EIXRD,$,TUE
MNLEN(K.:Z\W#^:R@DB,+C;N8#.0>>!5&7Q]>R:0;B+3(H))[&:YMF:X+X\MM
MIW#:/<C!.> <9XZ>/PSI$5W'=):8DC975?-?9O5=JL4SM+ ?Q$9]Z:GA;1DA
MBA6R_=Q026Z*9'.(Y/OKUYSGZT[Q"S.8M?&&KVEU=R7]O%<6L2V0<)*%,1E
MR5^0;R2<D$@#& :T_%&K:C;7TMO8W9M1;:7/J#$1J_F,A4!#N!PO)SCFM-?"
MFC+!-#]E=DF,1DWSR,6\O[G);/%6-3T+3=8:-KZW\QD!4$2,A*G&5.TC*G X
M.11=7"SL6K*<W5C;W!4*98E<@=LC-3T@      X %+4%!1110 4444 %%%%
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M]'T&XGOM BO]+G:V6ZU$SK- VT!@-N[(Z''&>M'*@YCU&D=UC1G=@J*,LS'
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MW>F7 \5VVA"+_0=4>WOYU/\ #Y2GS%(_VBJUZ=4M6&G<****0PHHHH ****
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MV-Q%*HAD:.6)@ZY4'H>AP1^E<)#KNJS:9IOVG4OMJZKIEV\\9B1?)9$)##:
M>3P<YYSCV2C<;=CT:&>*YA2:"5)8G&4>-@RL/4$=:DKR5/$>IV/ABUCTN\:+
M[!ID4TJ%(P@+-@9+!F<G(&T!?][M72V>MW^IWNHS3:O%I,5B]NHBDC0QN&4,
M2Y;#?-G PR\8ZGJW!B4CM:BMKJWO(1-:SQ3Q$D!XG#*2.#R*X73O$>N7FKQR
M%BL+ZG):/;RM;I&L:\87)$ID'!(Q@YZ5E>&M4O\ 2='T-[6[-Q'=WL\,EAL7
M@98Y! W;N_7'(XHY YCU2BN"TSQ%JKQ^'K^2\^U#5I9$FLUB7;$HR<Q[1O\
MEVX.XMWZ&M+4->FO-=TG3+*:[L8+LRF2X>T,<A*+D(HF3'.<DX/3 I<K'='5
MT5Q:ZI?WFKV^E1^((5A33FN3J-O%%BX<.4/WMR@+C)QCG/05E0>)]<U06K"\
M:R,FBRWC+'"AS(CD!OF!X( X]#^-'*Q<QZ317FEMJ6I7NL6^I-J$Z2?\(V]T
M$54V!]P! 4J>"0">_ YQQ5ZPU?6+B#PS#+JTRMJZ/+-<>5$"A100B#;CG/\
M$#TXHY0YCMYKNVMY8HIKB*.27/EH[@%\#)P#UP*6WN8+RW2>VFCGA?[LD3AE
M;Z$<5YNVI76I:OH)NY%F:VO[ZV2X50HG5$P'P..?;CBJ6B:UJL&A:9IUA++
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M>V50T?&,#=N R.>*.30.8[NBBBH*"BBB@ HHHH **** "BBB@ HHHH ****
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MW\QA*JE@2&P""?3\*TM!N]4N/&/B*"ZNU>UMGB2.+RB-H92PP=V!P>3@YXZ
M8HY78=SJ:***D84444 %%%% !1161XGW?\([=[)'C?Y=KH<,IWCD'L::5W83
M=E<UZ*R]+OYWDDT_4 JW\ R2HPLZ=I%]O4=CQZ$ZE#5F"=PHHHI#"LG6_$VD
M>'?(_M6[^S^?N\O]V[[MN,_=!QU'6M:N1\1_\C]X0_[??_10JZ<5*5GY_D3)
MM+0=_P +,\(?]!?_ ,EI?_B:Q[;Q)\.+.^6\@NRLJR-*@\NY*([?>94(VJ3[
M"N[W4;JOW.S^_P#X!/O?TO\ @G.?\+,\(?\ 07_\EI?_ (FC_A9GA#_H+_\
MDM+_ /$UT>ZC=2_=]G]__ #WN_\ 7WG%ZCXP\ :K-!-=ZBYFM]WE2QI<1.FX
M8(#( <$5:L_'_@C3[.&TM-16*WA4*B+;38 _[Y_6NJW4;J?N=G]__ #WOZ7_
M  3G/^%F>$/^@O\ ^2TO_P 352T\<^!;">ZGMM1V27<GFS'R)SN;IGE>/PKK
MMU&ZC]WV?W_\ />[_A_P3G/^%F>$/^@O_P"2TO\ \31_PLSPA_T%_P#R6E_^
M)KH]U&ZE^[[/[_\ @![W?^OO.<_X69X0_P"@O_Y+2_\ Q-'_  LSPA_T%_\
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M&GN]*L;B9L9DEMT=CCIR1FIKO3;#4(TCO;*VN8T.46:)7"_0$<5X4OB+7/\
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MMJ98W$FF7D>D7DC.K _8[ASDR*.J,?[ZC_OH<]0:I1NKBOK8V:***D84444
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M7#"Q5U+5WL<D\7)V<=%:YS\.DS36MQ<I)$8[<D-\QYQZ<54 KIK-0NCZPJ@
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MEA4AC&25/)/&0/6M3-38=R3=69XD;_BE]7_Z\IO_ $ U?S69XC/_ !3&K?\
M7E-_Z :<5[R$WH2>&].U!_"^D.FN7,:-90E4$$1"C8.,E<\>]:G]F:G_ -!^
MZ_\  >'_ .(K'MM2O--\%^'7MHP(GM(1/<&W><0*(<Y,:$,02 ,YP,\U VI7
M^I:CX9E@U*PD26XF#M;*[QOB)B,C<"#M_A.=I/4XQ6<F^9FJM8W_ .S-3_Z#
M]U_X#P__ !%']F:G_P!!^Z_\!X?_ (BLV'Q)>2:!I=^8X/-N]06UD 4[0AE9
M,CGK@#\:RM<U'4=6\/Q:@OV5=-EU&)(XMC>:%68*&+[L9)7[NW@'J<<K4-#I
M_P"S-3_Z#]U_X#P__$5/IFG-I_VII+J2YEN9O.DDD55.=BH!A0!T05C0>)+R
M6>WT\QV_]I'4GM9E"MM\I 7,@&<C*;<9)Y;\*ZBI;>PTD%5KZQ@U&SDM;E2T
M;^AP5(Y# ]B#R#5FBI3L496G7LT5Q_9>H.#>(NZ*7&!<QC^(>C#C</QZ$5JU
M2U/38]2MU1F:*:)O,@G3[T3CHP_D1W!(J/3-1:Y:2TNE6+4+?'G1CHP/1U]5
M/Z<@\BJ>JNA+30T:^6;&:"WNXI;FU6ZA4_/"SLH<>F5Y%?4U?*0Z"M:.S_KN
M9U-T>JSZ-8E6O(M T&WN&1BD4U]([(PC#$&)05)"D' ^M>55ZB(->MM16TCN
M[*ZMY $:]%J&DMI1$?F9<_*Y7"[B2",5Y=50)D%%%%62>A?#O_D5_&?_ %XC
M_P! FKBEKM?AW_R*_C/_ *\1_P"@35Q2UX.;_P 5>A[V4_PWZDJU,M0K4JUY
M)ZZ)5J9:A6IEJ2B5:D6HEJ5:D9,M2K42U*M(I&MI.I06'FI<Z?;WD4@P1( &
M7_=;&15^^\0+<:4NF6=BMI:[MS+YAD)YSU/O7/K4JU:K34>5/3^NIFZ,'+G:
MU_KIL=/+XI\[4K"\^Q[?LBLNSS?OY&.N.*++Q']EU6]O?LF[[2/N>9C;^..:
MYU:E6J^LU;WOUOT[6%]5HVM;I;KWO^9L6>K_ &;1;G3O(W>>V?,WXV].V/:K
MD>OHVG06MS81SM /W;LY &.F1W_.L%:E6G"O46B?D3.A3;NUUN;=SKGVK6+?
M4/LVWR5 V;\YP2>N/>I(=;\O6I=1^SY\Q<>7OZ< =<>U8JU*M:JO4O>_6_S,
MG0IVM;I;Y&O#JWEVEY!Y&?M+,V[?]W/X<U:77598&ELDDGA&%D+_ -*PUJ51
M6L:U1=3*5"F^AL1ZR$U22]%MS(FPIYGTYSCVJ*UO_L]A/:^5N\W^+=C''IBJ
M*BI *M59[W[_ (F;I06ENWX;%M[S?ID5GY>/+?=OW=>O;\:JXIP%/Q0VY;@D
MH[$TEYOTR*S\O'EMNW[NO7M^-20:BJ6JV]Q;K.B-N3+8Q57%-*U7/).Y/)%J
MWS)Y-2G;41><!EX"]L>E.N-5#P31V]JL!G.9&#9W?X53(J-A4NI/77<I4H.V
MFQ'&_E3QR8SL8-CUQ5Z36=VLQZA]GQL7;Y>_KP1UQ[U085$U9*<HJR-G3C)W
M?H:%KK/V2ZO9OL^[[22<;\;<DGTYZU:T99Y]'F@\B"[AW?ZAI2C@_ET[]?6L
M!JB:E&O*+UU6OXA+#QDM-'I^'S.C\32JFCV=HZQQSAMQB0Y"  C'ZU@Z1J?]
MDWWVGR?-^0KMW;>OO@U5:HFK*K7E*I[1:6-J6'C&G[-ZIG1?\)59)+YR:#;K
M+G(<,,Y]<[:SK7Q++;Z[-JDT E>5"FP/M"CC&.#Z5DM4+5$L55;3OMKLBUA*
M*35M]-V;NF^)HK"RN+6;34NHYYC*5=QCG'&"ISTINH>+3+ITEE8:?#8QR@A_
M+(.0>N,  9K :H6IK%5>7EOI\@>%H\W-;7YD35$U2M435B;$35$U2M434Q$3
M5$U2M4351)$U1-4C5&U,ED35UOPRM/MGBVXC^T3P8L&;= ^UC^\3C/IS7(M7
M;?"7_D<[G_L'/_Z,2NK"/]]$Y<9_!D>I_P!A?]175/\ P(_^M1_87_45U3_P
M(_\ K5F+XBO%\0BRNI+.S1[EHHK>Z@D1IXQ@;XYB=C,200@&><9[U1TG5-3L
MV83SPW'VK7Y+1B8V!50')QES_<4 =AQSV^CO(^;T.A_L+_J*ZI_X$?\ UJ/[
M"_ZBNJ?^!'_UJS+KQ)>+K5UI4"6XF-[%;6[NK$*K0B5V8 _-CD  CJ*S(=1U
M'2-?UBYNOLLBB\M(KMXXV"B)DVAP-QVX)7(.>]%Y!H=%<>&XKJVEMY]2U.2&
M5"CH;CAE(P1T]*VJR]&U&;5/MTY6,6J73PVQ4'+JGRLQ.<'+!L8'0=ZU*EMO
M1C270*R]3L)C/'J5A@7T*[2A.%N(^IC;^8/8^Q-:E%).S!JY6L;Z#4;1;FW)
M*MD%6&&1AP58=B#P15FL6^A?2;J35[2-GC?!O;=!DN!QYBC^^!U'\0'J!6M!
M-%<P1SPR+)%(H9'4Y# ]"*;75 GT9A2G'BZ^_P"O"V_]&3U;W52N#CQ=>_\
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MNNN?]N__ +4KU>N;$4X2G[RN=%&I.$?=;1S/_"OO"P_YA8_[_P G_P 52_\
M" >&/^@8/^_\G_Q5=+16'L*7\J^XU^L5?YG][.<_X0+PR/\ F&#_ +_R?_%4
MO_""^&_^@:/^_P!)_P#%5T5%'L*7\J^X?UBM_,_O9SW_  @WAS_H&C_O])_\
M52_\(3X='_,.'_?Z3_XJN@HH]A2_E7W(/K%;^=_>S _X0OP^/^8?_P"1I/\
MXJG?\(;H'_/A_P"1G_\ BJW:*7U>E_*ON0?6*W\[^]F'_P (?H(_Y</_ "*_
M_P 52_\ "(Z'_P ^/_D5_P#&MNBCZO1_D7W(/K-;^=_>S&_X1/1/^?+_ ,BO
M_C2_\(MHH_Y<O_(K_P"-;%%'U>C_ "+[D'UFM_._O9D?\(QHX_Y<_P#R(_\
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M,JN/F_/''-8F@:=J,&EZ]'%#J$>F/:NEK;W@_>E]ISA1TY)Z=<CKBN]W4;J
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MBM"%8$@$J<'(.#R.G-6;C3];N+RRU1AI_P!LM7E5;8.XC,3A009-N=WR@YV
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MNVH?]^T_^+II^*NA#_EUU#_OVG_Q=>2-434_K]8G^SZ'F>O'XL:"/^774?\
MOVG_ ,75?P]XBM/$OQ.DO;*.=(TT8Q$3* <B8'L3Q\PKR1J[7X2_\CG=?]@]
M_P#T8E:T<54J5%&1E7PE.E3E*)Z3:Z=K&F37<-C]A>VN;MKD33N^^/>VYQL
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M4]&GH+5,UJK7U]!IUG)=7+%8T]!DL3P% [DG@"I9YXK:WDGGD6.*-2SNQP%
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M&GV$>G6BP1LSL26DE?EI'/5F/J?_ *U"T5V#UT);:VAL[:.WMXUCAC7:B+T
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M.W#^3_Q,F^4L<D_<YYKDZZO_ (5MXN_Z!'_DS#_\71_PK;Q=_P! C_R9A_\
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M'@?Q%_T#Q_W_ (__ (JI^KU?Y7]P_K%'^=?>C$6I5K;'@GQ"/^7#_P C1_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!"0 22
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M&():SPVR0D$8)0.&&!TQE:32&FS9HHHJ1A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &/<
MZO=OJ4]CI=A'=26R!KAYK@PJK,,J@(5B6(YZ #(YYJ==:LDLK:XOI5T\W ^6
M*\81/N[K@GD_2J#1:AI.N:A=V^GRW]O?A),0R1JT4B*$P=[#*D '()Q@\=,Y
M]YI^M/.]W<V,=[-=:6]G)' ZJL3EB>=Y&5((!(R?EZ55D3=G2W>JZ=82K%>7
M]K;R,I<)-,J$J.IP3TX--_MC3#>BR&HVGVHDJ(//7>2.HVYSV/Y5P&MV5QI>
MA:[:211WS26-I$\J3)^Z9%V@.K'<,GYEP#DMVZUMG0K\"4BU 9O$"WN0ZY,(
M*_-U] >.OM3Y4%V6?^$TMO*>(QVXU 6SW @^VQ>60K$;?,S@' STX&?2MW^T
M[);J*TDO+9+R50RVYF7>P]AG)'!_*N#;PSK*:0UN+!GEETN>UP)8_D<S%USE
MNA'IGWQ6E-H>I%KNR%F7^UW\%VFH>8F(%3R\@C.[<NP@8&/F'(YH:079U$.L
M:9<77V6#4;26XY_=).K/QUX!SQ@_E5VN+L= U&"+2-UJ%>#5I[F8AUR(V\S#
M=><@KQUKM*EI+8:"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JI;:7I]E/)/:V-M!-+_K
M)(H55GYSR0.>:**I;,3W+=%%%2,**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH JSZ987-W%=W%C;2W,6/+FDB5G3!R,,1D<\U:HHIO9"04444AA1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
*1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>sava-20201231x10kg009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sava-20201231x10kg009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 5"'C0# 2(  A$! Q$!_\0
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M_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\
MA!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T
M*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+
M_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH**
M .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$
M\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?
M_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B
M:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!
M_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_
M^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")
MKH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_
M .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]
M"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB
M_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\
MA!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T
M*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+
M_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH**
M .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$
M\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?
M_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B
M:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!
M_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_
M^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")
MKH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_
M .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]
M"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB
M_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\
MA!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T
M*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+
M_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH**
M .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$
M\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?
M_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B
M:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!
M_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_
M^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")
MKH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_
M .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]
M"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB
M_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\
MA!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T
M*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+
M_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH**
M .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$
M\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?
M_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B
M:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!
M_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_
M^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")
MKH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_
M .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]
M"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB
M_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\
MA!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T
M*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+
M_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH**
M .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$
M\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?
M_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B
M:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!
M_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_
M^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")
MKH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_
M .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]
M"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB
M_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\
MA!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T
M*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+
M_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH**
M .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$
M\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?
M_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B
M:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!
M_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_
M^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")
MKH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_
M .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]
M"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB
M_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\
MA!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T
M*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+
M_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH**
M .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$
M\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?
M_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B
M:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!
M_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_
M^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")
MKH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_
M .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]
M"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB
M_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\
MA!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T
M*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+
M_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH**
M .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$
M\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?
M_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B
M:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!
M_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_
M^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")
MKH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_
M .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]
M"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB
M_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\
MA!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T
M*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+
M_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH**
M .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$
M\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?
M_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B
M:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!
M_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_
M^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")
MKH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_
M .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]
M"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB
M_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\
MA!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T
M*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+
M_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH**
M .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$
M\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?
M_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B
M:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!
M_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_
M^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")
MKH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_
M .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]
M"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB
M_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\
MA!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T
M*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+
M_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH**
M .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$
M\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?
M_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B
M:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!
M_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_
M^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")
MKH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_
M .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]
M"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB
M_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\
MA!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T
M*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+
M_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH**
M .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$
M\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?
M_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B
M:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!
M_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_
M^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")
MKH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_
M .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]
M"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB
M_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\
MA!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T
M*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+
M_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH**
M .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$
M\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?
M_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B
M:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!
M_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_
M^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")
MKH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_
M .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]
M"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB
M_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\
MA!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T
M*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+
M_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH**
M .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$
M\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?
M_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B
M:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!
M_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_
M^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")
MKH** .?_ .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_
M .$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]
M"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB
M_P#B:/\ A!/!_P#T*FA_^"Z+_P")KH** .?_ .$$\'_]"IH?_@NB_P#B:/\
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MBC_A,/$/_05N/S%']F5.Z#ZW'L>K?\()X/\ ^A4T/_P71?\ Q-'_  @G@_\
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M?^@K<?F*/^$P\0_]!6X_,4?V94[H/K<>QZM_P@G@_P#Z%30__!=%_P#$T?\
M"">#_P#H5-#_ /!=%_\ $UY3_P )AXA_Z"MQ^8H_X3#Q#_T%;C\Q1_9E3N@^
MMQ['JW_"">#_ /H5-#_\%T7_ ,31_P ()X/_ .A4T/\ \%T7_P 37E/_  F'
MB'_H*W'YBC_A,/$/_05N/S%']F5.Z#ZW'L>K?\()X/\ ^A4T/_P71?\ Q-'_
M  @G@_\ Z%30_P#P71?_ !->4_\ "8>(?^@K<?F*/^$P\0_]!6X_,4?V94[H
M/K<>QZM_P@G@_P#Z%30__!=%_P#$T?\ "">#_P#H5-#_ /!=%_\ $UY3_P )
MAXA_Z"MQ^8H_X3#Q#_T%;C\Q1_9E3N@^MQ['JW_"">#_ /H5-#_\%T7_ ,31
M_P ()X/_ .A4T/\ \%T7_P 37E/_  F'B'_H*W'YBC_A,/$/_05N/S%']F5.
MZ#ZW'L>K?\()X/\ ^A4T/_P71?\ Q-'_  @G@_\ Z%30_P#P71?_ !->4_\
M"8>(?^@K<?F*/^$P\0_]!6X_,4?V94[H/K<>QZM_P@G@_P#Z%30__!=%_P#$
MT?\ "">#_P#H5-#_ /!=%_\ $UY3_P )AXA_Z"MQ^8H_X3#Q#_T%;C\Q1_9E
M3N@^MQ['JW_"">#_ /H5-#_\%T7_ ,31_P ()X/_ .A4T/\ \%T7_P 37E/_
M  F'B'_H*W'YBC_A,/$/_05N/S%']F5.Z#ZW'L>K?\()X/\ ^A4T/_P71?\
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M,4?V94[H/K<>QZM_P@G@_P#Z%30__!=%_P#$T?\ "">#_P#H5-#_ /!=%_\
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M#_T%;C\Q1_9E3N@^MQ['JW_"">#_ /H5-#_\%T7_ ,31_P ()X/_ .A4T/\
M\%T7_P 37E/_  F'B'_H*W'YBC_A,/$/_05N/S%']F5.Z#ZW'L>K?\()X/\
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MBC_A,/$/_05N/S%']F5.Z#ZW'L>K?\()X/\ ^A4T/_P71?\ Q-'_  @G@_\
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M?^@K<?F*/^$P\0_]!6X_,4?V94[H/K<>QZM_P@G@_P#Z%30__!=%_P#$T?\
M"">#_P#H5-#_ /!=%_\ $UY3_P )AXA_Z"MQ^8KTCX>ZG>ZIHES-?7#SR+<E
M0S]0-JG'ZUC6P4Z,.=M&E/$1G+E2+W_"">#_ /H5-#_\%T7_ ,31_P ()X/_
M .A4T/\ \%T7_P 37-_$37-3TK4[..QO)8$>$LP0]3N-<;_PF'B'_H*W'YBJ
MI8"=2"FFM29XF,)<K1ZM_P ()X/_ .A4T/\ \%T7_P 31_P@G@__ *%30_\
MP71?_$UY3_PF'B'_ *"MQ^8H_P"$P\0_]!6X_,5I_9E3NB?K<>QZM_P@G@__
M *%30_\ P71?_$T?\()X/_Z%30__  71?_$UY3_PF'B'_H*W'YBC_A,/$/\
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M *%30_\ P71?_$T?\()X/_Z%30__  71?_$UY3_PF'B'_H*W'YBC_A,/$/\
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M *%30_\ P71?_$T?\()X/_Z%30__  71?_$UY3_PF'B'_H*W'YBC_A,/$/\
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M *%30_\ P71?_$T?\()X/_Z%30__  71?_$UY3_PF'B'_H*W'YBC_A,/$/\
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M *%30_\ P71?_$T?\()X/_Z%30__  71?_$UY3_PF'B'_H*W'YBC_A,/$/\
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M *%30_\ P71?_$T?\()X/_Z%30__  71?_$UY3_PF'B'_H*W'YBC_A,/$/\
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M?_@NB_\ B:/^$$\'_P#0J:'_ ."Z+_XFN@HH Y__ (03P?\ ]"IH?_@NB_\
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M$/\ T%;C\Q1_9E3N@^MQ['JW_"">#_\ H5-#_P#!=%_\31_P@G@__H5-#_\
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M$/\ T%;C\Q1_9E3N@^MQ['JW_"">#_\ H5-#_P#!=%_\31_P@G@__H5-#_\
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M$/\ T%;C\Q1_9E3N@^MQ['JW_"">#_\ H5-#_P#!=%_\31_P@G@__H5-#_\
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M$/\ T%;C\Q1_9E3N@^MQ['JW_"">#_\ H5-#_P#!=%_\31_P@G@__H5-#_\
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M$/\ T%;C\Q1_9E3N@^MQ['JW_"">#_\ H5-#_P#!=%_\31_P@G@__H5-#_\
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M$/\ T%;C\Q1_9E3N@^MQ['JW_"">#_\ H5-#_P#!=%_\31_P@G@__H5-#_\
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MQ#_T%;C\Q1_PF'B'_H*W'YBC^S*G=!];CV/5O^$$\'_]"IH?_@NB_P#B:/\
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MQ#_T%;C\Q1_PF'B'_H*W'YBC^S*G=!];CV/5O^$$\'_]"IH?_@NB_P#B:/\
MA!/!_P#T*FA_^"Z+_P")KRG_ (3#Q#_T%;C\Q1_PF'B'_H*W'YBC^S*G=!];
MCV/5O^$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KRG_ (3#Q#_T
M%;C\Q1_PF'B'_H*W'YBC^S*G=!];CV/5O^$$\'_]"IH?_@NB_P#B:/\ A!/!
M_P#T*FA_^"Z+_P")KRG_ (3#Q#_T%;C\Q1_PF'B'_H*W'YBC^S*G=!];CV/5
MO^$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KRG_ (3#Q#_T%;C\
MQ1_PF'B'_H*W'YBC^S*G=!];CV/5O^$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T
M*FA_^"Z+_P")KRG_ (3#Q#_T%;C\Q1_PF'B'_H*W'YBC^S*G=!];CV/5O^$$
M\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KRG_ (3#Q#_T%;C\Q1_P
MF'B'_H*W'YBC^S*G=!];CV/5O^$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_
M^"Z+_P")KRG_ (3#Q#_T%;C\Q1_PF'B'_H*W'YBC^S*G=!];CV/5O^$$\'_]
M"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KRG_ (3#Q#_T%;C\Q1_PF'B'
M_H*W'YBC^S*G=!];CV/5O^$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+
M_P")KRG_ (3#Q#_T%;C\Q1_PF'B'_H*W'YBC^S*G=!];CV/5O^$$\'_]"IH?
M_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KRG_ (3#Q#_T%;C\Q1_PF'B'_H*W
M'YBC^S*G=!];CV/5O^$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")
MKRG_ (3#Q#_T%;C\Q1_PF'B'_H*W'YBC^S*G=!];CV/5O^$$\'_]"IH?_@NB
M_P#B:/\ A!/!_P#T*FA_^"Z+_P")KRG_ (3#Q#_T%;C\Q1_PF'B'_H*W'YBC
M^S*G=!];CV/5O^$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KRG_
M (3#Q#_T%;C\Q1_PF'B'_H*W'YBC^S*G=!];CV/5O^$$\'_]"IH?_@NB_P#B
M:/\ A!/!_P#T*FA_^"Z+_P")KRG_ (3#Q#_T%;C\Q1_PF'B'_H*W'YBC^S*G
M=!];CV/5O^$$\'_]"IH?_@NB_P#B:/\ A!/!_P#T*FA_^"Z+_P")KRG_ (3#
MQ#_T%;C\Q1_PF'B'_H*W'YBC^S*G=!];CV/5O^$$\'_]"IH?_@NB_P#B:/\
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MQ#_T%;C\Q1_PF'B'_H*W'YBC^S*G=!];CV/5O^$$\'_]"IH?_@NB_P#B:/\
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MQ#_T%;C\Q1_PF'B'_H*W'YBC^S*G=!];CV/5O^$$\'_]"IH?_@NB_P#B:/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?/FL_\ (<U#
M_KYD_P#0C5&KVL_\AS4/^OF3_P!"-4:^IA\*/&ENPHHHJR0HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KUCX6_P#(O7?_ %]G_P! 6O)Z]8^%O_(O7?\ U]G_ - 6N',/X#.G
M"_Q#$^*?_(8L?^O<_P#H1K@J[WXI_P#(8L?^O<_^A&N"K3!_P(D5_P"(PHHH
MKJ,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]J^'_\ R)=E_O2?^AM7
M3US'P_\ ^1+LO]Z3_P!#:NGKYG$?QI>K/8I? O0****Q+"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#R?XI?\C#:?]>@_P#0VKAJ[GXI?\C#:?\ 7H/_
M $-JX:OH\)_ B>57_B,****Z3$**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ KU+X5_\@S4/^NR_^@UY;7J7PK_Y!FH?]=E_
M]!KBQ_\  ?R.C#?Q$4_BO_K=*_W9?_9*\YKT;XK_ .MTK_=E_P#9*\YJL#_
MC_746(_BL****ZS **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ K;\'_ /(W:9_UV'\C6)6WX/\ ^1NTS_KL/Y&LJW\.7HRZ?QH]6\=_
M\D\\3?\ 8*NO_135\05]O^._^2>>)O\ L%77_HIJ^(*^8/8"BBB@#[?\"?\
M)//#/_8*M?\ T4M=!7/^!/\ DGGAG_L%6O\ Z*6N@H **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^?-9_
MY#FH?]?,G_H1JC5[6?\ D.:A_P!?,G_H1JC7U,/A1XTMV%%%%62%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %>L?"W_D7KO\ Z^S_ .@+7D]>L?"W_D7KO_K[/_H"UPYA_ 9T
MX7^(8GQ3_P"0Q8_]>Y_]"-<%7>_%/_D,6/\ U[G_ -"-<%6F#_@1(K_Q&%%%
M%=1B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'M7P_\ ^1+LO]Z3_P!#
M:NGKF/A__P B79?[TG_H;5T]?,XC^-+U9[%+X%Z!1116)84444 %%%% !111
M0 4444 %%%% !1110 4444 >3_%+_D8;3_KT'_H;5PU=S\4O^1AM/^O0?^AM
M7#5]'A/X$3RJ_P#$84445TF(4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7J7PK_P"09J'_ %V7_P!!KRVO4OA7_P @S4/^
MNR_^@UQ8_P#@/Y'1AOXB*?Q7_P!;I7^[+_[)7G->C?%?_6Z5_NR_^R5YS58'
M^!'^NHL1_%84445UF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !6WX/_Y&[3/^NP_D:Q*V_!__ "-VF?\ 78?R-95OX<O1ET_C1ZMX
M[_Y)YXF_[!5U_P"BFKX@K[?\=_\ )//$W_8*NO\ T4U?$%?,'L!1110!]O\
M@3_DGGAG_L%6O_HI:Z"N?\"?\D\\,_\ 8*M?_12UT% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'SYK/
M_(<U#_KYD_\ 0C5&KVL_\AS4/^OF3_T(U1KZF'PH\:6["BBBK)"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "O6/A;_P B]=_]?9_] 6O)Z]8^%O\ R+UW_P!?9_\ 0%KAS#^
MSIPO\0Q/BG_R&+'_ *]S_P"A&N"KO?BG_P ABQ_Z]S_Z$:X*M,'_  (D5_XC
M"BBBNHQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#VKX?_\ (EV7^])_
MZ&U=/7,?#_\ Y$NR_P!Z3_T-JZ>OF<1_&EZL]BE\"] HHHK$L**** "BBB@
MHHHH **** "BBB@ HHHH **** /)_BE_R,-I_P!>@_\ 0VKAJ[GXI?\ (PVG
M_7H/_0VKAJ^CPG\")Y5?^(PHHHKI,0HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "O4OA7_R#-0_Z[+_ .@UY;7J7PK_ .09
MJ'_79?\ T&N+'_P'\CHPW\1%/XK_ .MTK_=E_P#9*\YKT;XK_P"MTK_=E_\
M9*\YJL#_  (_UU%B/XK"BBBNLP"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *V_!_\ R-VF?]=A_(UB5M^#_P#D;M,_Z[#^1K*M_#EZ
M,NG\:/5O'?\ R3SQ-_V"KK_T4U?$%?;_ ([_ .2>>)O^P5=?^BFKX@KY@]@*
M*** /M_P)_R3SPS_ -@JU_\ 12UT%<_X$_Y)YX9_[!5K_P"BEKH* "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M HHHH **** "BBB@ KU+X5_\@S4/^NR_^@UY;7J7PK_Y!FH?]=E_]!KBQ_\
M ?R.C#?Q$4_BO_K=*_W9?_9*\YKT;XK_ .MTK_=E_P#9*\YJL#_ C_746(_B
ML****ZS **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
M;\'_ /(W:9_UV'\C6)6WX/\ ^1NTS_KL/Y&LJW\.7HRZ?QH]6\=_\D\\3?\
M8*NO_135\05]O^._^2>>)O\ L%77_HIJ^(*^8/8"BBB@#[?\"?\ )//#/_8*
MM?\ T4M=!7/^!/\ DGGAG_L%6O\ Z*6N@H **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7K'PM_Y%Z[_ .OL_P#H"UY/7K'PM_Y%Z[_Z^S_Z M<.8?P&=.%_B&)\4_\
MD,6/_7N?_0C7!5WOQ3_Y#%C_ ->Y_P#0C7!5I@_X$2*_\1A111748A1110 4
M444 ;O@ZWANO%=E#<0QS1-OW)(H93\C'D&O5_P"P=&_Z!-A_X#)_A7EG@?\
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M /R)=E_O2?\ H;5T]?,XC^-+U9[%+X%Z!1116)84444 %%%% !1110 4444
M%%%% !1110 4444 >3_%+_D8;3_KT'_H;5PU=S\4O^1AM/\ KT'_ *&U<-7T
M>$_@1/*K_P 1A111728A1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %.CC>:58HD9Y'(5549))["FUZ;X \/);6:ZO<Q@W$P
M/DY'W$]?J?Y?4UR8S%+#4N=[]#:A1=6?*5M"^'2;$GUER6//V:-L ?[S?X?G
M7;6>F6.GKML[2&#W1 "?J>IJU17R=?%5:[O-_P"1[-.C"FK1045!<7MI:?\
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MQ!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %>I?"O\ Y!FH?]=E_P#0:\MKU+X5_P#(,U#_ *[+_P"@
MUQ8_^ _D=&&_B(I_%?\ UNE?[LO_ +)7G->C?%?_ %NE?[LO_LE><U6!_@1_
MKJ+$?Q6%%%%=9@%%%% !1110!N^#K>&Z\5V4-Q#'-$V_<DBAE/R,>0:]7_L'
M1O\ H$V'_@,G^%>6>!_^1QL/^VG_ *+:O8Z^:SB<HUTD[:?JSU<#%.F[KJ9_
M]@Z-_P! FP_\!D_PH_L'1O\ H$V'_@,G^%:%%>3[6I_,_O.WDCV,_P#L'1O^
M@38?^ R?X4?V#HW_ $";#_P&3_"M"BCVM3^9_>')'L9_]@Z-_P! FP_\!D_P
MH_L'1O\ H$V'_@,G^%:%%'M:G\S^\.2/8S_[!T;_ *!-A_X#)_A7"_$:PL['
M^S?LEI!;[_-W>5&$W8V8SCKU->E5Y[\4/^85_P!MO_9*[\LJ3>*BFWU_)G-B
MXQ5%V7]7//:***^L/&"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KNOA
MS86=]_:7VNT@N-GE;?-C#[<[\XSTZ"N%KT+X7_\ ,5_[8_\ L]<&9MK"R:\O
MS1TX1)UE?^M#LO[!T;_H$V'_ (#)_A6%XQTC3;7PI>S6^G6D,J[-KQP*K#YU
M'! KK:Y[QQ_R)U__ -L__1BU\WA:LW7@FWNOS/5K0C[.6G1GCE%%%?9G@A11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!ZOX.TC3;K
MPI937&G6DTK;]SR0*S'YV')(K=_L'1O^@38?^ R?X5G>!_\ D3K#_MI_Z,:N
MAKXS%59JO-)O=_F>]1A'V<=.B/-?B-86=C_9OV2T@M]_F[O*C";L;,9QUZFN
M%KT+XH?\PK_MM_[)7GM?298V\+%OS_-GE8M)5G;^M HHHKO.8**** "BBB@
MHHHH **** "BBNO\+^"7UB"*_NYA'9L3M1.7?!(/^Z,CW_K6%?$0H0YZCT-*
M=.527+$YO3],O-5N1!96[S2=\#A?<GH!]:U/$7AE_#MM8F:X$L]QO+A1\J[=
MO ]>IYKURQT^TTRV%O9P)#$.RCJ?4GJ3[FN&^*'_ #"O^VW_ +)7DT,RGB,5
M&$5:.OY,[:F%C2HN3U9Y[1117NGG!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6WX
M/_Y&[3/^NP_D:Q*V_!__ "-VF?\ 78?R-95OX<O1ET_C1ZMX[_Y)YXF_[!5U
M_P"BFKX@K[?\=_\ )//$W_8*NO\ T4U?$%?,'L!1110!]O\ @3_DGGAG_L%6
MO_HI:Z"N?\"?\D\\,_\ 8*M?_12UT% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'SYK/_(<U#_KYD_\
M0C5&KVL_\AS4/^OF3_T(U1KZF'PH\:6["BBBK)"BBB@ HHHH **** "BBB@
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MU_\ ^!+_ .-']O:S_P!!:_\ _ E_\:SZ*/94_P"5?<'/+N:']O:S_P!!:_\
M_ E_\:KW5_>7VS[7=SW&S.WS9"^W/7&?H*KT4U3@G=)"<I/=A116KX<TV'6-
M>MK"X:18I=VXQD!N%)XR#Z43FH1<WLM0C%R:2ZF517J7_"M=&_Y^;_\ [^)_
M\31_PK71O^?F_P#^_B?_ !->=_:^&[O[CI^I53RVBK6G:==:K>):V<1DE;GV
M4>I/85Z)I/PYL((U?4Y&N9B/FC1BL8_$<GZ\?2NC%8ZCAM)O7LC.EAYU?AV/
M,:*]QC\.:+$NU=*LR/\ :A5C^9%5[OPAH-XN'TZ*,]FAS&1^7%<"SNE?6+.A
MX"?<\6HKLO$'@&XTV)[K3Y&N;=>61A^\0>O'#?ACZ5QM>I0Q%.O'FILY*E*5
M-VD%%%%;F845-;6L][<QV]M$TLTAPJ*.37H.C_#B%4675YB[]?(A.%'L6ZG\
M,5R8G&4L.O?>O;J;4J$ZOPGG%%>W0>&-#MT"II=J0/\ GI&'/YMFDN/"^AW*
M%7TNV4'O&GEG\UQ7G_VW3O\ "SJ^H3[GB5>A?"__ )BO_;'_ -GIFM_#IHT:
M?1Y6DQDFWE//_ 3_ $/YU+\,T>.35XY%9'4Q!E88((W\&JQ>*I8C!S=-]OS1
M-"C.E7BI>?Y'H%<]XX_Y$Z__ .V?_HQ:Z&N>\<?\B=?_ /;/_P!&+7@X3_>(
M>J_,]&M_#EZ,\<HHHK[<\ **]2_X5KHW_/S?_P#?Q/\ XFC_ (5KHW_/S?\
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MK%XJEB,'-TWV_-$T*,Z5>*EY_D>@5SWCC_D3K_\ [9_^C%KH:Y[QQ_R)U_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\^
M:S_R'-0_Z^9/_0C5&KVL_P#(<U#_ *^9/_0C5&OJ8?"CQI;L****LD**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** /=-!M_LN@:?#C#+;IN'OC)_7-:%-10D:H.B@"G5\#)N3NSZ-*RL>>?$ZY
M.[3[4'C#R,/7H!_6O/J[+XE$_P#"0VRYX%HI_P#'WKC:^ORR/+A8_P!=3Q<6
M[UF%%%%=YS!1110 4444 %%%% %W2M,N-8U&*RMER[GENR+W8^PKV?1]&L]$
MLEMK1,=WD/WG/J:Y_P"'VCK9Z0=0D7]_=_=)'*QCH/Q//Y5V%?*YGC'6J.G%
M^ZOQ9[&$H*$.9[L*CFGBMX_,FE2-!U9V 'ZUD>)O$$?A_3?-PKW,AVPQD]3W
M)]A_@.]>0:AJ5YJER;B]G>:0]-QX7V Z ?2L\'ET\2N:]H]RJ^*C2TW9[=!J
MVFW,GEV^H6DKG^&.96/Z&KE?/==EX3\97%C<QV6HS&6S<[5D<Y,1['/]W^5=
M.)R>5.+G3=_+J94L:I.TE8]2KA/&G@];A)-5TV,"91NGA4??'=A[^H[_ %Z]
MW17ET*\Z%13@=E2G&I'ED?/=%='XTT5='UUC"@6VN!YD8 X4_P 2_G^A%<Y7
MVE&K&M352.S/!J0<).+Z!1116I 4444 %%%% 'NF@_\ (NZ9_P!>D7_H K0K
M/T'_ )%W3/\ KTB_] %:%?"5?XDO5GT4/A1Y[\4/^85_VV_]DKSVO8_%'A?_
M (23[+_IGV?[/O\ ^66_=NV^XQ]VN>_X5?\ ]1C_ ,EO_LZ]_ 8_#TL/&$Y6
M:OT?=^1YN)PU6=5RBM#SVBO0U^&"Y^;5R1[6^/\ V:K]K\-]*B=6N+BYGP>5
MR%5OK@9_6NF6;86.S;^7^9DL%5>ZL<MX%T:74-=CNV0_9K0[V8C@O_"![YY_
M#WKUNH;6UM[*W2WM84BA0?*B# %35\]C,4\35Y[66R/3H452ARA7BGBRX%UX
MJU&13D"7R_\ OD!?Z5ZUKFJQ:+I$]Y(1N48C4_QN>@_SVS7ATDC2R-([%G<E
MF)[DUZ624GS2J]-CDQ\U90^8VO=-!_Y%W3/^O2+_ - %>%U[IH/_ "+NF?\
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M:_?EI@RV,)S*PXW'LH]_7T'X5Z];V\-K;I!;QK'$@PJ*, "J6AZ5'HVD062
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M/_0VKIZYCX?_ /(EV7^])_Z&U=/7S.(_C2]6>Q2^!>@4445B6%%%% !1110
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M]D1%.321V/@7PJDRKJ]_'E<YMXV'!Q_&1_+\_2O1:9%%'!"D,2!(XU"JJC@
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M>O5PWQ,A#:98S_Q),4'_  (9_P#9:>5U7#$Q2V>@L7!2I-]CS2E +,%4$DG
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K;\'_P#(
MW:9_UV'\C6)6WX/_ .1NTS_KL/Y&LJW\.7HRZ?QH]6\=_P#)//$W_8*NO_13
M5\05]O\ CO\ Y)YXF_[!5U_Z*:OB"OF#V HHHH ^W_ G_)//#/\ V"K7_P!%
M+705S_@3_DGGAG_L%6O_ **6N@H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MNBE@,15@IPC=/S7^9E/$TH2Y9/4]"HKSW_A:'_4'_P#)G_["HG^)UP1\FF1
M^K2D_P!!6G]EXO\ D_%?YD_6Z/?\ST>J>I:I9:3:FXO9UB3MGJQ] .YKS.Y^
M(>MSH5B^S6^?XHX\G_QXD?I7,W5Y<WTYGNIY)I3QND8DX]/I730R:K)_O79?
MB95,=!+W-36\3>))_$-Z&P8[6+(ABS^I]S^G\\.BBOHJ5*%*"A!62/+G-S?-
M(*]TT'_D7=,_Z](O_0!7A=>Z:#_R+NF?]>D7_H KQ\[_ (</4[L!\3-"N-^(
MVHM;:+#9HV&NI/F]U7!(_,K795YK\39<ZA81?W8F;\SC^E>3ET%/%03_ *MJ
M=F*DXTI-'"T445]D>&%=E\-?^1BN/^O1O_0TKC:[+X:_\C%<?]>C?^AI7'C_
M /=I^AOAOXL3U*L_7O\ D7=3_P"O27_T UH5GZ]_R+NI_P#7I+_Z :^0I?Q(
M^J/;G\+/"Z***^[/G3W30?\ D7=,_P"O2+_T 5H5GZ#_ ,B[IG_7I%_Z *T*
M^$J_Q)>K/HH?"CS?XFSDWNGV^>$C9\?4@?\ LM<'79?$K_D8K?\ Z]%_]#>N
M-KZW+8\N%A_74\7%.]:05[)X)8MX/L"?1Q^3M7C=>Q^!_P#D3K#_ +:?^C&K
MDSI+V$7Y_HS; /\ >->1T-<3\2[C9I%G;@D>9/N/N%!_^*%=M7GOQ/)QI0SQ
M^]_]DKQLNCS8J"_K34[L4[49'GM%%%?9'AGJGPW<MX;F!Z+=,!_WRI_K785Q
MOPU_Y%VX_P"OMO\ T!*[*OB\<DL3.W<][#N]*)QOQ*_Y%VW_ .OM?_0'KRVO
M4OB5_P B[;_]?:_^@/7EM?091_NR]6>9C?XH445VF@?#^XOXEN=3D:VA896-
M?]8P]\\+^OX5V8C$T\/'FJ,PITI5':)Q=6K;3KZ]YM;.XG&<9CC+#]*]CL/#
M&BZ<!Y&GPEQSOD&]L_4]/PK7Z# KR*F=_P#/N'W_ -?J=T<O_F9Y#:> ]>NC
M\]O';+_>FD'\AD_I7;>%_!Z^'KF2[>[,\SQF/:J;5 )!^IZ>U=117G5\RQ%:
M+C)V3['33PM.F[K<*S]>_P"1=U/_ *])?_0#6A6?KW_(NZG_ ->DO_H!KDI?
MQ(^J-Y_"SPNBBBONSYT]C\#_ /(G6'_;3_T8U=#7/>!_^1.L/^VG_HQJZ&OB
M,7_O$_5_F>_1_AQ]$<[XVU%M.\,SF-MLDY$"GZ]?T!KQVO2_B9+C3;&+^],6
M_(8_K7FE?0Y/!+#\W=GFXZ3=2W8****]8XC?\&ZC_9OB:V9CB.?]P_T;I_X\
M%KV6OGNO<M U+^UM#M+PD%W0"3 Q\XX;]0:^=SJA:4:JZZ/^OZV/4P%2Z<&7
M+NVCO+.:UE'[N:-HVQZ$8KP6X@DM;F6WE&)(G*./0@X-?0%>2>/]/^Q^)'G4
M8CND$@]-W0_RS^-9Y+6Y:KIOK^A6/A>"EV,71+#^U-;L[+&5ED ?!Q\HY;]
M:]UZ# KS7X:Z?YE_=:@P^6%!&F?[S<G\@/UKTJHS>MSU^1?916"ART[]PS@9
M->&:[J1U;6[N]R2DCGR\_P!P<+^@%>J>,M2_LWPU<LK8EG'DI]6Z_IDUXU75
MDM#XJS]/\S''U-H?,****]\\T**** "BBB@ KUCX6_\ (O7?_7V?_0%KR>O6
M/A;_ ,B]=_\ 7V?_ $!:X<P_@,Z<+_$,3XI_\ABQ_P"O<_\ H1K@J[WXI_\
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M_1BUXY7L?CC_ )$Z_P#^V?\ Z,6O'*]C)?\ =WZ_HCAQ_P#$7I_F%>Q^!_\
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M17<<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110![5\/_\
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M[N_7]$<./_B+T_S"O8_ _P#R)UA_VT_]&-7CE>Q^!_\ D3K#_MI_Z,:C.O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "MOP?\ \C=IG_78?R-8E;?@_P#Y&[3/^NP_
MD:RK?PY>C+I_&CU;QW_R3SQ-_P!@JZ_]%-7Q!7V_X[_Y)YXF_P"P5=?^BFKX
M@KY@]@**** /M_P)_P D\\,_]@JU_P#12UT%<_X$_P"2>>&?^P5:_P#HI:Z"
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^=YJ/8Z'P/\ \CC8?]M/_1;5['7CG@?_ )'&P_[:?^BVKV.N+.O]X7I^K.C
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MKI,@HHHH **** "O4OA7_P @S4/^NR_^@UY;7J7PK_Y!FH?]=E_]!KBQ_P#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.BBBOB#WSY[HHHK[\^;"O4OAK_R+MQ_U]M_Z E>6UZE\-?\ D7;C_K[;_P!
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M -#:NGKYG$?QI>K/8I? O0****Q+"BBB@ HHHH **** "BBB@ HHHH ****
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M21Y9&DD=G=CEF8Y)/J37J9?ELI256LK)=.YQXG%I+DAN-HHHKZ0\L]C\#_\
M(G6'_;3_ -&-70USW@?_ )$ZP_[:?^C&KH:^(Q?^\3]7^9[]'^''T1Y[\4/^
M85_VV_\ 9*\]KT+XH?\ ,*_[;?\ LE>>U]/E?^Z0^?YL\G%_QG_70T-!_P"1
MBTS_ *^XO_0Q7NE>%Z#_ ,C%IG_7W%_Z&*]TKS,[_B0]#KP'PL*\+U[_ )&+
M4_\ K[E_]#->Z5X7KW_(Q:G_ -?<O_H9HR3^)/T#'_"C/HHHKZ,\L]"^%_\
MS%?^V/\ [/7H5>>_"_\ YBO_ &Q_]GKT*OD,T_WN?R_)'MX3^"OZZG/>./\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *V_
M!_\ R-VF?]=A_(UB5M^#_P#D;M,_Z[#^1K*M_#EZ,NG\:/5O'?\ R3SQ-_V"
MKK_T4U?$%?;_ ([_ .2>>)O^P5=?^BFKX@KY@]@**** /M_P)_R3SPS_ -@J
MU_\ 12UT%<_X$_Y)YX9_[!5K_P"BEKH* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS*>=C.=OY=*HT5$<-1B[Q@E\D4ZM1Z.3"BBBMS,**** "BBB@ HHHH ****
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M8I?(4JDY:-L****V("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#VKX?_ /(EV7^])_Z&U=/7,?#_ /Y$NR_WI/\ T-JZ>OF<1_&E
MZL]BE\"] HHHK$L**** "BBB@ HHHH **** "BBB@ HHHH **** /)_BE_R,
M-I_UZ#_T-JX:NY^*7_(PVG_7H/\ T-JX:OH\)_ B>57_ (C"BBBNDQ"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "I
M[:]N[,DVMU- 3U,4A7/Y5!14RBI*S5QIM:HW(O&'B"$ +J<IQ_?56_F#4O\
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MBO\ ZW2O]V7_ -DKSFJP/\"/]=18C^*PHHHKK, HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *?%+)!*LL,CQ
MR*<JZ,01]#3**32:LQIV-R#QCX@MXPB:E(0!C]XJN?S8$U!>^)=9U!"ESJ,S
M(>"JG8#]0N,UE45BL-03NH+[D6ZM1_:?WA1116YF%%%% !1110!]"4445\ ?
M2'CGCC_D<;__ +9_^BUK#M[F>UE\VVGDAD QOC<J?S%;GCC_ )'&_P#^V?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5M^#_^1NTS_KL/Y&L2MOP?_P C=IG_ %V'
M\C65;^'+T9=/XT>K>._^2>>)O^P5=?\ HIJ^(*^W_'?_ "3SQ-_V"KK_ -%-
M7Q!7S![ 4444 ?;_ ($_Y)YX9_[!5K_Z*6N@KG_ G_)//#/_ &"K7_T4M=!0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!\^:S_R'-0_Z^9/_ $(U1J]K/_(<U#_KYD_]"-4:^IA\*/&E
MNPHHHJR0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "MOP?_R-
MVF?]=A_(UB5M^#_^1NTS_KL/Y&LJW\.7HRZ?QH]6\=_\D\\3?]@JZ_\ 135\
M05]O^._^2>>)O^P5=?\ HIJ^(*^8/8"BBB@#[?\  G_)//#/_8*M?_12UT%<
M_P"!/^2>>&?^P5:_^BEKH* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** /GS6?^0YJ'_7S)_Z$:HU>UG_D
M.:A_U\R?^A&J-?4P^%'C2W844459(4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5ZQ\+?^1>N_
M^OL_^@+7D]>L?"W_ )%Z[_Z^S_Z M<.8?P&=.%_B&)\4_P#D,6/_ %[G_P!"
M-<%7>_%/_D,6/_7N?_0C7!5I@_X$2*_\1A111748A1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110![5\/\ _D2[+_>D_P#0VKIZYCX?_P#(EV7^])_Z&U=/
M7S.(_C2]6>Q2^!>@4445B6%%%% !1110 4444 %%%% !1110 4444 %%%% '
MD_Q2_P"1AM/^O0?^AM7#5W/Q2_Y&&T_Z]!_Z&U<-7T>$_@1/*K_Q&%%%%=)B
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MZE\*_P#D&:A_UV7_ -!KRVO4OA7_ ,@S4/\ KLO_ *#7%C_X#^1T8;^(BG\5
M_P#6Z5_NR_\ LE><UZ-\5_\ 6Z5_NR_^R5YS58'^!'^NHL1_%84445UF 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6WX/_P"1NTS_
M *[#^1K$K;\'_P#(W:9_UV'\C65;^'+T9=/XT>K>._\ DGGB;_L%77_HIJ^(
M*^W_ !W_ ,D\\3?]@JZ_]%-7Q!7S![ 4444 ?;_@3_DGGAG_ +!5K_Z*6N@K
MG_ G_)//#/\ V"K7_P!%+704 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 ?/FL_\ (<U#_KYD_P#0C5&O
MH%]!T>21I)-)L&=B2S-;(22>YXIO_"/:)_T!]/\ _ 5/\*]>.9022Y3A>$DW
MN> 45[__ ,(]HG_0'T__ ,!4_P */^$>T3_H#Z?_ . J?X57]IP_E%]3EW/
M**]__P"$>T3_ * ^G_\ @*G^%'_"/:)_T!]/_P# 5/\ "C^TX?RA]3EW/ **
M]_\ ^$>T3_H#Z?\ ^ J?X4?\(]HG_0'T_P#\!4_PH_M.'\H?4Y=SP"BO?_\
MA'M$_P"@/I__ ("I_A1_PCVB?] ?3_\ P%3_  H_M.'\H?4Y=SP"BO?_ /A'
MM$_Z ^G_ /@*G^%'_"/:)_T!]/\ _ 5/\*/[3A_*'U.7<\ HKW__ (1[1/\
MH#Z?_P" J?X4?\(]HG_0'T__ ,!4_P */[3A_*'U.7<\ HKW_P#X1[1/^@/I
M_P#X"I_A1_PCVB?] ?3_ /P%3_"C^TX?RA]3EW/ **]__P"$>T3_ * ^G_\
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M /P%3_"C^TX?RA]3EW/ **]__P"$>T3_ * ^G_\ @*G^%'_"/:)_T!]/_P#
M5/\ "C^TX?RA]3EW/ **]_\ ^$>T3_H#Z?\ ^ J?X4?\(]HG_0'T_P#\!4_P
MH_M.'\H?4Y=SP"BO?_\ A'M$_P"@/I__ ("I_A1_PCVB?] ?3_\ P%3_  H_
MM.'\H?4Y=SP"BO?_ /A'M$_Z ^G_ /@*G^%'_"/:)_T!]/\ _ 5/\*/[3A_*
M'U.7<\ HKW__ (1[1/\ H#Z?_P" J?X4?\(]HG_0'T__ ,!4_P */[3A_*'U
M.7<\ HKW_P#X1[1/^@/I_P#X"I_A1_PCVB?] ?3_ /P%3_"C^TX?RA]3EW/
M**]__P"$>T3_ * ^G_\ @*G^%'_"/:)_T!]/_P# 5/\ "C^TX?RA]3EW/ **
M]_\ ^$>T3_H#Z?\ ^ J?X4?\(]HG_0'T_P#\!4_PH_M.'\H?4Y=SP"BO?_\
MA'M$_P"@/I__ ("I_A1_PCVB?] ?3_\ P%3_  H_M.'\H?4Y=SP"BO?_ /A'
MM$_Z ^G_ /@*G^%'_"/:)_T!]/\ _ 5/\*/[3A_*'U.7<\ HKW__ (1[1/\
MH#Z?_P" J?X4?\(]HG_0'T__ ,!4_P */[3A_*'U.7<\ HKW_P#X1[1/^@/I
M_P#X"I_A1_PCVB?] ?3_ /P%3_"C^TX?RA]3EW/ **]__P"$>T3_ * ^G_\
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M /P%3_"C^TX?RA]3EW/ **]__P"$>T3_ * ^G_\ @*G^%'_"/:)_T!]/_P#
M5/\ "C^TX?RA]3EW/ **]_\ ^$>T3_H#Z?\ ^ J?X4?\(]HG_0'T_P#\!4_P
MH_M.'\H?4Y=SP"BO?_\ A'M$_P"@/I__ ("I_A1_PCVB?] ?3_\ P%3_  H_
MM.'\H?4Y=SP"BO?_ /A'M$_Z ^G_ /@*G^%'_"/:)_T!]/\ _ 5/\*/[3A_*
M'U.7<\ HKW__ (1[1/\ H#Z?_P" J?X4?\(]HG_0'T__ ,!4_P */[3A_*'U
M.7<\ HKW_P#X1[1/^@/I_P#X"I_A1_PCVB?] ?3_ /P%3_"C^TX?RA]3EW/
M**]__P"$>T3_ * ^G_\ @*G^%'_"/:)_T!]/_P# 5/\ "C^TX?RA]3EW/ **
M]_\ ^$>T3_H#Z?\ ^ J?X4?\(]HG_0'T_P#\!4_PH_M.'\H?4Y=SP"BO?_\
MA'M$_P"@/I__ ("I_A1_PCVB?] ?3_\ P%3_  H_M.'\H?4Y=SP"BO?_ /A'
MM$_Z ^G_ /@*G^%'_"/:)_T!]/\ _ 5/\*/[3A_*'U.7<\ HKW__ (1[1/\
MH#Z?_P" J?X4?\(]HG_0'T__ ,!4_P */[3A_*'U.7<\ HKW_P#X1[1/^@/I
M_P#X"I_A1_PCVB?] ?3_ /P%3_"C^TX?RA]3EW/ **]__P"$>T3_ * ^G_\
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M /P%3_"C^TX?RA]3EW/ **]__P"$>T3_ * ^G_\ @*G^%'_"/:)_T!]/_P#
M5/\ "C^TX?RA]3EW/ **]_\ ^$>T3_H#Z?\ ^ J?X4?\(]HG_0'T_P#\!4_P
MH_M.'\H?4Y=SP"BO?_\ A'M$_P"@/I__ ("I_A1_PCVB?] ?3_\ P%3_  H_
MM.'\H?4Y=SP"BO?_ /A'M$_Z ^G_ /@*G^%'_"/:)_T!]/\ _ 5/\*/[3A_*
M'U.7<\ HKW__ (1[1/\ H#Z?_P" J?X4?\(]HG_0'T__ ,!4_P */[3A_*'U
M.7<\ HKW_P#X1[1/^@/I_P#X"I_A1_PCVB?] ?3_ /P%3_"C^TX?RA]3EW/
M**]__P"$>T3_ * ^G_\ @*G^%'_"/:)_T!]/_P# 5/\ "C^TX?RA]3EW/ **
M]_\ ^$>T3_H#Z?\ ^ J?X4?\(]HG_0'T_P#\!4_PH_M.'\H?4Y=SP"BO?_\
MA'M$_P"@/I__ ("I_A1_PCVB?] ?3_\ P%3_  H_M.'\H?4Y=SP"BO?_ /A'
MM$_Z ^G_ /@*G^%'_"/:)_T!]/\ _ 5/\*/[3A_*'U.7<\ HKW__ (1[1/\
MH#Z?_P" J?X4?\(]HG_0'T__ ,!4_P */[3A_*'U.7<\ HKW_P#X1[1/^@/I
M_P#X"I_A1_PCVB?] ?3_ /P%3_"C^TX?RA]3EW/ *]8^%O\ R+UW_P!?9_\
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MY=SP"BO?_P#A'M$_Z ^G_P#@*G^%'_"/:)_T!]/_ / 5/\*/[3A_*'U.7<\
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M:)_T!]/_ / 5/\*/[3A_*'U.7<\ HKW_ /X1[1/^@/I__@*G^%'_  CVB?\
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MY=SP"BO?_P#A'M$_Z ^G_P#@*G^%'_"/:)_T!]/_ / 5/\*/[3A_*'U.7<\
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M:)_T!]/_ / 5/\*/[3A_*'U.7<\ HKW_ /X1[1/^@/I__@*G^%'_  CVB?\
M0'T__P !4_PH_M.'\H?4Y=SP"BO?_P#A'M$_Z ^G_P#@*G^%'_"/:)_T!]/_
M / 5/\*/[3A_*'U.7<\ HKW_ /X1[1/^@/I__@*G^%'_  CVB?\ 0'T__P !
M4_PH_M.'\H?4Y=SP"BO?_P#A'M$_Z ^G_P#@*G^%'_"/:)_T!]/_ / 5/\*/
M[3A_*'U.7<\ HKW_ /X1[1/^@/I__@*G^%'_  CVB?\ 0'T__P !4_PH_M.'
M\H?4Y=SP"BO?_P#A'M$_Z ^G_P#@*G^%'_"/:)_T!]/_ / 5/\*/[3A_*'U.
M7<ROA_\ \B79?[TG_H;5T]16]M!:0K#;0QPQ+T2- JC\!4M>34GSS<N[.V"Y
M8I!1114%!1110 4444 %%%% !1110 4444 %%%% !1110!Y/\4O^1AM/^O0?
M^AM7#5]#76EZ??2"2[L+6X=1M#30JY ],D5!_P (]HG_ $!]/_\  5/\*]2C
MCXTZ:@UL<=3#.4G*YX!17O\ _P (]HG_ $!]/_\  5/\*/\ A'M$_P"@/I__
M ("I_A6O]IP_E(^IR[G@%%>__P#"/:)_T!]/_P# 5/\ "C_A'M$_Z ^G_P#@
M*G^%']IP_E#ZG+N> 45[_P#\(]HG_0'T_P#\!4_PH_X1[1/^@/I__@*G^%']
MIP_E#ZG+N> 45[__ ,(]HG_0'T__ ,!4_P */^$>T3_H#Z?_ . J?X4?VG#^
M4/J<NYX!17O_ /PCVB?] ?3_ /P%3_"C_A'M$_Z ^G_^ J?X4?VG#^4/J<NY
MX!17O_\ PCVB?] ?3_\ P%3_  H_X1[1/^@/I_\ X"I_A1_:</Y0^IR[G@%%
M>_\ _"/:)_T!]/\ _ 5/\*/^$>T3_H#Z?_X"I_A1_:</Y0^IR[G@%%>__P#"
M/:)_T!]/_P# 5/\ "C_A'M$_Z ^G_P#@*G^%']IP_E#ZG+N> 45[_P#\(]HG
M_0'T_P#\!4_PH_X1[1/^@/I__@*G^%']IP_E#ZG+N> 45[__ ,(]HG_0'T__
M ,!4_P */^$>T3_H#Z?_ . J?X4?VG#^4/J<NYX!17O_ /PCVB?] ?3_ /P%
M3_"C_A'M$_Z ^G_^ J?X4?VG#^4/J<NYX!17O_\ PCVB?] ?3_\ P%3_  H_
MX1[1/^@/I_\ X"I_A1_:</Y0^IR[G@%%>_\ _"/:)_T!]/\ _ 5/\*/^$>T3
M_H#Z?_X"I_A1_:</Y0^IR[G@%%>__P#"/:)_T!]/_P# 5/\ "C_A'M$_Z ^G
M_P#@*G^%']IP_E#ZG+N> 45[_P#\(]HG_0'T_P#\!4_PH_X1[1/^@/I__@*G
M^%']IP_E#ZG+N> 45[__ ,(]HG_0'T__ ,!4_P */^$>T3_H#Z?_ . J?X4?
MVG#^4/J<NYX!17O_ /PCVB?] ?3_ /P%3_"C_A'M$_Z ^G_^ J?X4?VG#^4/
MJ<NYX!17O_\ PCVB?] ?3_\ P%3_  H_X1[1/^@/I_\ X"I_A1_:</Y0^IR[
MG@%%>_\ _"/:)_T!]/\ _ 5/\*/^$>T3_H#Z?_X"I_A1_:</Y0^IR[G@%%>_
M_P#"/:)_T!]/_P# 5/\ "C_A'M$_Z ^G_P#@*G^%']IP_E#ZG+N> 45[_P#\
M(]HG_0'T_P#\!4_PH_X1[1/^@/I__@*G^%']IP_E#ZG+N> 45[__ ,(]HG_0
M'T__ ,!4_P */^$>T3_H#Z?_ . J?X4?VG#^4/J<NYX!17O_ /PCVB?] ?3_
M /P%3_"C_A'M$_Z ^G_^ J?X4?VG#^4/J<NYX!17O_\ PCVB?] ?3_\ P%3_
M  H_X1[1/^@/I_\ X"I_A1_:</Y0^IR[G@%%>_\ _"/:)_T!]/\ _ 5/\*/^
M$>T3_H#Z?_X"I_A1_:</Y0^IR[G@%%>__P#"/:)_T!]/_P# 5/\ "C_A'M$_
MZ ^G_P#@*G^%']IP_E#ZG+N> 45[_P#\(]HG_0'T_P#\!4_PH_X1[1/^@/I_
M_@*G^%']IP_E#ZG+N> 45[__ ,(]HG_0'T__ ,!4_P */^$>T3_H#Z?_ . J
M?X4?VG#^4/J<NYX!17O_ /PCVB?] ?3_ /P%3_"C_A'M$_Z ^G_^ J?X4?VG
M#^4/J<NYX!17O_\ PCVB?] ?3_\ P%3_  H_X1[1/^@/I_\ X"I_A1_:</Y0
M^IR[G@%%>_\ _"/:)_T!]/\ _ 5/\*/^$>T3_H#Z?_X"I_A1_:</Y0^IR[G@
M%%>__P#"/:)_T!]/_P# 5/\ "C_A'M$_Z ^G_P#@*G^%']IP_E#ZG+N> 45[
M_P#\(]HG_0'T_P#\!4_PH_X1[1/^@/I__@*G^%']IP_E#ZG+N> 45[__ ,(]
MHG_0'T__ ,!4_P */^$>T3_H#Z?_ . J?X4?VG#^4/J<NYX!17O_ /PCVB?]
M ?3_ /P%3_"C_A'M$_Z ^G_^ J?X4?VG#^4/J<NYX!17O_\ PCVB?] ?3_\
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M3_\ P%3_  H_X1[1/^@/I_\ X"I_A1_:</Y0^IR[G@%%>_\ _"/:)_T!]/\
M_ 5/\*/^$>T3_H#Z?_X"I_A1_:</Y0^IR[G@%%>__P#"/:)_T!]/_P# 5/\
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M] ?3_P#P%3_"C_A'M$_Z ^G_ /@*G^%']IP_E#ZG+N> 45[_ /\ "/:)_P!
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M ^G_ /@*G^%']IP_E#ZG+N> 45[_ /\ "/:)_P! ?3__  %3_"C_ (1[1/\
MH#Z?_P" J?X4?VG#^4/J<NYX!17O_P#PCVB?] ?3_P#P%3_"C_A'M$_Z ^G_
M /@*G^%']IP_E#ZG+N> 45[_ /\ "/:)_P! ?3__  %3_"C_ (1[1/\ H#Z?
M_P" J?X4?VG#^4/J<NYX!17O_P#PCVB?] ?3_P#P%3_"C_A'M$_Z ^G_ /@*
MG^%']IP_E#ZG+N> 45[_ /\ "/:)_P! ?3__  %3_"C_ (1[1/\ H#Z?_P"
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M<NYX!17O_P#PCVB?] ?3_P#P%3_"C_A'M$_Z ^G_ /@*G^%']IP_E#ZG+N>
M45[_ /\ "/:)_P! ?3__  %3_"C_ (1[1/\ H#Z?_P" J?X4?VG#^4/J<NYX
M!17O_P#PCVB?] ?3_P#P%3_"C_A'M$_Z ^G_ /@*G^%']IP_E#ZG+N> 45[_
M /\ "/:)_P! ?3__  %3_"C_ (1[1/\ H#Z?_P" J?X4?VG#^4/J<NYX!17O
M_P#PCVB?] ?3_P#P%3_"C_A'M$_Z ^G_ /@*G^%']IP_E#ZG+N> 45[_ /\
M"/:)_P! ?3__  %3_"C_ (1[1/\ H#Z?_P" J?X4?VG#^4/J<NYX!17O_P#P
MCVB?] ?3_P#P%3_"C_A'M$_Z ^G_ /@*G^%']IP_E#ZG+N> 45[_ /\ "/:)
M_P! ?3__  %3_"C_ (1[1/\ H#Z?_P" J?X4?VG#^4/J<NYX!17O_P#PCVB?
M] ?3_P#P%3_"C_A'M$_Z ^G_ /@*G^%']IP_E#ZG+N> 45[_ /\ "/:)_P!
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M ^G_ /@*G^%']IP_E#ZG+N> 45[_ /\ "/:)_P! ?3__  %3_"C_ (1[1/\
MH#Z?_P" J?X4?VG#^4/J<NYX!17O_P#PCVB?] ?3_P#P%3_"C_A'M$_Z ^G_
M /@*G^%']IP_E#ZG+N> 45[_ /\ "/:)_P! ?3__  %3_"C_ (1[1/\ H#Z?
M_P" J?X4?VG#^4/J<NYX!17O_P#PCVB?] ?3_P#P%3_"C_A'M$_Z ^G_ /@*
MG^%']IP_E#ZG+N> 45[_ /\ "/:)_P! ?3__  %3_"C_ (1[1/\ H#Z?_P"
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M<NYX!17O_P#PCVB?] ?3_P#P%3_"C_A'M$_Z ^G_ /@*G^%']IP_E#ZG+N>
M45[_ /\ "/:)_P! ?3__  %3_"C_ (1[1/\ H#Z?_P" J?X4?VG#^4/J<NYX
M!17O_P#PCVB?] ?3_P#P%3_"C_A'M$_Z ^G_ /@*G^%']IP_E#ZG+N> 45[_
M /\ "/:)_P! ?3__  %3_"C_ (1[1/\ H#Z?_P" J?X4?VG#^4/J<NYX!17O
M_P#PCVB?] ?3_P#P%3_"C_A'M$_Z ^G_ /@*G^%']IP_E#ZG+N> 45[_ /\
M"/:)_P! ?3__  %3_"C_ (1[1/\ H#Z?_P" J?X4?VG#^4/J<NYX!17O_P#P
MCVB?] ?3_P#P%3_"C_A'M$_Z ^G_ /@*G^%']IP_E#ZG+N> 45[_ /\ "/:)
M_P! ?3__  %3_"C_ (1[1/\ H#Z?_P" J?X4?VG#^4/J<NYX!17O_P#PCVB?
M] ?3_P#P%3_"C_A'M$_Z ^G_ /@*G^%']IP_E#ZG+N> 45[_ /\ "/:)_P!
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M ^G_ /@*G^%']IP_E#ZG+N> 45[_ /\ "/:)_P! ?3__  %3_"C_ (1[1/\
MH#Z?_P" J?X4?VG#^4/J<NYX!17O_P#PCVB?] ?3_P#P%3_"C_A'M$_Z ^G_
M /@*G^%']IP_E#ZG+N> 45[_ /\ "/:)_P! ?3__  %3_"C_ (1[1/\ H#Z?
M_P" J?X4?VG#^4/J<NYX!17O_P#PCVB?] ?3_P#P%3_"C_A'M$_Z ^G_ /@*
MG^%']IP_E#ZG+N> 45[_ /\ "/:)_P! ?3__  %3_"C_ (1[1/\ H#Z?_P"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** .?\=_\D\\3?]@JZ_\ 135\05]O^._^2>>)O^P5=?\ HIJ^(* "BBB@
M#[?\"?\ )//#/_8*M?\ T4M=!7/^!/\ DGGAG_L%6O\ Z*6N@H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_03_ /($?_Q-'_"?>)O^@G_Y C_^)KFZ*/J]+^5?<@]K/NSI/^$^\3?]!/\
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MX3[Q-_T$_P#R!'_\373>!O%.LZQK[6M_>>="(&?;Y2+R".X />O-:[+X9_\
M(U/_ ->S_P UK'$T::I2:BMNQI2J3<TFSO\ QIJ5WI/AN6[L9O*G5T ;:&X)
MYX((KS+_ (3[Q-_T$_\ R!'_ /$UZ%\1?^1/G_ZZQ_SKQFL,!2A*E>44]33$
MSE&=DSI/^$^\3?\ 03_\@1__ !-'_"?>)O\ H)_^0(__ (FN;HKM^KTOY5]R
M.?VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(_P#XFN;HH^KTOY5]
MR#VL^[.D_P"$^\3?]!/_ ,@1_P#Q->C>!-6OM9T&2YU"?SIEN&0-L5> JG&
M!ZFO%:]=^&/_ "*\W_7V_P#Z"M<>.I4XT;QBE\C?#3DYV;*7C[Q+J^BZK;0:
M?=^3&\&]AY:-D[B.X/I7)_\ "?>)O^@G_P"0(_\ XFM?XI?\ARS_ .O;_P!F
M:N$K3"T:<J,6XK[B*U2:J-)G2?\ "?>)O^@G_P"0(_\ XFC_ (3[Q-_T$_\
MR!'_ /$US=%='U>E_*ON1G[6?=G2?\)]XF_Z"?\ Y C_ /B:/^$^\3?]!/\
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M_P#D"/\ ^)H_X3[Q-_T$_P#R!'_\37-T4?5Z7\J^Y![6?=G2?\)]XF_Z"?\
MY C_ /B:/^$^\3?]!/\ \@1__$US=%'U>E_*ON0>UGW9TG_"?>)O^@G_ .0(
M_P#XFC_A/O$W_03_ /($?_Q-<W11]7I?RK[D'M9]V=)_PGWB;_H)_P#D"/\
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M_P#R!'_\37-T4?5Z7\J^Y![6?=G2?\)]XF_Z"?\ Y C_ /B:/^$^\3?]!/\
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M3?\ 03_\@1__ !-<W11]7I?RK[D'M9]V=)_PGWB;_H)_^0(__B:/^$^\3?\
M03_\@1__ !-<W11]7I?RK[D'M9]V=)_PGWB;_H)_^0(__B:/^$^\3?\ 03_\
M@1__ !-<W11]7I?RK[D'M9]V=)_PGWB;_H)_^0(__B:/^$^\3?\ 03_\@1__
M !-<W11]7I?RK[D'M9]V=)_PGWB;_H)_^0(__B:/^$^\3?\ 03_\@1__ !-<
MW11]7I?RK[D'M9]V=)_PGWB;_H)_^0(__B:/^$^\3?\ 03_\@1__ !-<W11]
M7I?RK[D'M9]V=)_PGWB;_H)_^0(__B:/^$^\3?\ 03_\@1__ !-<W11]7I?R
MK[D'M9]V=)_PGWB;_H)_^0(__B:/^$^\3?\ 03_\@1__ !-<W11]7I?RK[D'
MM9]V=)_PGWB;_H)_^0(__B:/^$^\3?\ 03_\@1__ !-<W11]7I?RK[D'M9]V
M=)_PGWB;_H)_^0(__B:/^$^\3?\ 03_\@1__ !-<W11]7I?RK[D'M9]V=)_P
MGWB;_H)_^0(__B:/^$^\3?\ 03_\@1__ !-<W11]7I?RK[D'M9]V=)_PGWB;
M_H)_^0(__B:/^$^\3?\ 03_\@1__ !-<W11]7I?RK[D'M9]V=)_PGWB;_H)_
M^0(__B:/^$^\3?\ 03_\@1__ !-<W11]7I?RK[D'M9]V=)_PGWB;_H)_^0(_
M_B:/^$^\3?\ 03_\@1__ !-<W11]7I?RK[D'M9]V=)_PGWB;_H)_^0(__B:/
M^$^\3?\ 03_\@1__ !-<W11]7I?RK[D'M9]V=)_PGWB;_H)_^0(__B:/^$^\
M3?\ 03_\@1__ !-<W11]7I?RK[D'M9]V=)_PGWB;_H)_^0(__B:/^$^\3?\
M03_\@1__ !-<W11]7I?RK[D'M9]V=)_PGWB;_H)_^0(__B:/^$^\3?\ 03_\
M@1__ !-<W11]7I?RK[D'M9]V=)_PGWB;_H)_^0(__B:/^$^\3?\ 03_\@1__
M !-<W11]7I?RK[D'M9]V=)_PGWB;_H)_^0(__B:/^$^\3?\ 03_\@1__ !-<
MW11]7I?RK[D'M9]V=)_PGWB;_H)_^0(__B:/^$^\3?\ 03_\@1__ !-<W11]
M7I?RK[D'M9]V=)_PGWB;_H)_^0(__B:/^$^\3?\ 03_\@1__ !-<W11]7I?R
MK[D'M9]V=)_PGWB;_H)_^0(__B:/^$^\3?\ 03_\@1__ !-<W11]7I?RK[D'
MM9]V=)_PGWB;_H)_^0(__B:/^$^\3?\ 03_\@1__ !-<W11]7I?RK[D'M9]V
M=)_PGWB;_H)_^0(__B:/^$^\3?\ 03_\@1__ !-<W11]7I?RK[D'M9]V=)_P
MGWB;_H)_^0(__B:/^$^\3?\ 03_\@1__ !-<W11]7I?RK[D'M9]V=)_PGWB;
M_H)_^0(__B:/^$^\3?\ 03_\@1__ !-<W11]7I?RK[D'M9]V=)_PGWB;_H)_
M^0(__B:/^$^\3?\ 03_\@1__ !-<W11]7I?RK[D'M9]V=)_PGWB;_H)_^0(_
M_B:/^$^\3?\ 03_\@1__ !-<W11]7I?RK[D'M9]V=)_PGWB;_H)_^0(__B:/
M^$^\3?\ 03_\@1__ !-<W11]7I?RK[D'M9]V=)_PGWB;_H)_^0(__B:/^$^\
M3?\ 03_\@1__ !-<W11]7I?RK[D'M9]V=)_PGWB;_H)_^0(__B:/^$^\3?\
M03_\@1__ !-<W11]7I?RK[D'M9]V=)_PGWB;_H)_^0(__B:/^$^\3?\ 03_\
M@1__ !-<W11]7I?RK[D'M9]V=)_PGWB;_H)_^0(__B:/^$^\3?\ 03_\@1__
M !-<W11]7I?RK[D'M9]V=)_PGWB;_H)_^0(__B:/^$^\3?\ 03_\@1__ !-<
MW11]7I?RK[D'M9]V=)_PGWB;_H)_^0(__B:/^$^\3?\ 03_\@1__ !-<W11]
M7I?RK[D'M9]V=)_PGWB;_H)_^0(__B:/^$^\3?\ 03_\@1__ !-<W11]7I?R
MK[D'M9]V=)_PGWB;_H)_^0(__B:/^$^\3?\ 03_\@1__ !-<W11]7I?RK[D'
MM9]V=)_PGWB;_H)_^0(__B:/^$^\3?\ 03_\@1__ !-<W11]7I?RK[D'M9]V
M=)_PGWB;_H)_^0(__B:/^$^\3?\ 03_\@1__ !-<W11]7I?RK[D'M9]V=)_P
MGWB;_H)_^0(__B:/^$^\3?\ 03_\@1__ !-<W11]7I?RK[D'M9]V=)_PGWB;
M_H)_^0(__B:/^$^\3?\ 03_\@1__ !-<W11]7I?RK[D'M9]V=)_PGWB;_H)_
M^0(__B:/^$^\3?\ 03_\@1__ !-<W11]7I?RK[D'M9]V=)_PGWB;_H)_^0(_
M_B:/^$^\3?\ 03_\@1__ !-<W11]7I?RK[D'M9]V=)_PGWB;_H)_^0(__B:/
M^$^\3?\ 03_\@1__ !-<W11]7I?RK[D'M9]V=)_PGWB;_H)_^0(__B:/^$^\
M3?\ 03_\@1__ !-<W11]7I?RK[D'M9]V=)_PGWB;_H)_^0(__B:/^$^\3?\
M03_\@1__ !-<W11]7I?RK[D'M9]V=)_PGWB;_H)_^0(__B:/^$^\3?\ 03_\
M@1__ !-<W11]7I?RK[D'M9]V=)_PGWB;_H)_^0(__B:/^$^\3?\ 03_\@1__
M !-<W11]7I?RK[D'M9]V=)_PGWB;_H)_^0(__B:/^$^\3?\ 03_\@1__ !-<
MW11]7I?RK[D'M9]V=)_PGWB;_H)_^0(__B:/^$^\3?\ 03_\@1__ !-<W11]
M7I?RK[D'M9]V=)_PGWB;_H)_^0(__B:/^$^\3?\ 03_\@1__ !-<W11]7I?R
MK[D'M9]V=)_PGWB;_H)_^0(__B:/^$^\3?\ 03_\@1__ !-<W11]7I?RK[D'
MM9]V=)_PGWB;_H)_^0(__B:/^$^\3?\ 03_\@1__ !-<W11]7I?RK[D'M9]V
M=)_PGWB;_H)_^0(__B:/^$^\3?\ 03_\@1__ !-<W11]7I?RK[D'M9]V=)_P
MGWB;_H)_^0(__B:/^$^\3?\ 03_\@1__ !-<W11]7I?RK[D'M9]V=)_PGWB;
M_H)_^0(__B:/^$^\3?\ 03_\@1__ !-<W11]7I?RK[D'M9]V=)_PGWB;_H)_
M^0(__B:/^$^\3?\ 03_\@1__ !-<W11]7I?RK[D'M9]V=)_PGWB;_H)_^0(_
M_B:]"\!:Q?ZUHUQ<:A/YTJ7!16V*N!M4XX ]37C->L?"W_D7KO\ Z^S_ .@+
M7)CJ5.-%N,4OD;X:<G4LV0^/O$FK:)J5I%IUWY*20EF'EHV3DC^(&N1_X3[Q
M-_T$_P#R!'_\36S\4_\ D,6/_7N?_0C7!5>%HTY48MQ7W$UJDU4:3.D_X3[Q
M-_T$_P#R!'_\31_PGWB;_H)_^0(__B:YNBNCZO2_E7W(R]K/NSI/^$^\3?\
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M !-'_"?>)O\ H)_^0(__ (FN;HH^KTOY5]R#VL^[.D_X3[Q-_P!!/_R!'_\
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M *"?_D"/_P")KFZ*/J]+^5?<@]K/NSI/^$^\3?\ 03_\@1__ !-'_"?>)O\
MH)_^0(__ (FN;HH^KTOY5]R#VL^[.D_X3[Q-_P!!/_R!'_\ $T?\)]XF_P"@
MG_Y C_\ B:YNBCZO2_E7W(/:S[LZ3_A/O$W_ $$__($?_P 31_PGWB;_ *"?
M_D"/_P")KFZ*/J]+^5?<@]K/NSI/^$^\3?\ 03_\@1__ !-'_"?>)O\ H)_^
M0(__ (FN;HH^KTOY5]R#VL^[.D_X3[Q-_P!!/_R!'_\ $T?\)]XF_P"@G_Y
MC_\ B:YNBCZO2_E7W(/:S[LZ3_A/O$W_ $$__($?_P 31_PGWB;_ *"?_D"/
M_P")KFZ*/J]+^5?<@]K/NSI/^$^\3?\ 03_\@1__ !-'_"?>)O\ H)_^0(__
M (FN;HH^KTOY5]R#VL^[.D_X3[Q-_P!!/_R!'_\ $T?\)]XF_P"@G_Y C_\
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M $$__($?_P 31_PGWB;_ *"?_D"/_P")KFZ*/J]+^5?<@]K/NSI/^$^\3?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O$/'7_(Z:C_ +R?
M^@+7M]>(>.O^1TU'_>3_ - 6O1RW^*_3_(Y<7\"]3G:***]L\X**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *[+X9_\C4_
M_7L_\UKC:[+X9_\ (U/_ ->S_P UKGQ7\&7H:T?XB.T^(O\ R)\__76/^=>,
MU[-\1?\ D3Y_^NL?\Z\9KGR[^#\S7%_Q HHHKT#E"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KUWX8_\BO-_P!?
M;_\ H*UY%7KOPQ_Y%>;_ *^W_P#05KAS#^#\SIPO\0YWXI?\ARS_ .O;_P!F
M:N$KN_BE_P ARS_Z]O\ V9JX2M<)_ B17_B,****Z3$**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7K'PM_P"1>N_^OL_^@+7D]>L?"W_D7KO_ *^S_P"@+7#F'\!G3A?X
MAB?%/_D,6/\ U[G_ -"-<%7>_%/_ )#%C_U[G_T(UP5:8/\ @1(K_P 1A111
M748A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110![5\/_\ D2[+_>D_]#:N
MGKF/A_\ \B79?[TG_H;5T]?,XC^-+U9[%+X%Z!1116)84444 %%%% !1110
M4444 %%%% !1110 4444 >3_ !2_Y&&T_P"O0?\ H;5PU=S\4O\ D8;3_KT'
M_H;5PU?1X3^!$\JO_$84445TF(4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !7J7PK_Y!FH?]=E_]!KRVO4OA7_R#-0_Z[+_
M .@UQ8_^ _D=&&_B(I_%?_6Z5_NR_P#LE><UZ-\5_P#6Z5_NR_\ LE><U6!_
M@1_KJ+$?Q6%%%%=9@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5M^#_P#D;M,_Z[#^1K$K;\'_ /(W:9_UV'\C65;^'+T9=/XT>K>.
M_P#DGGB;_L%77_HIJ^(*^W_'?_)//$W_ &"KK_T4U?$%?,'L!1110!]O^!/^
M2>>&?^P5:_\ HI:Z"N?\"?\ )//#/_8*M?\ T4M=!0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5XAXZ_P"1TU'_ 'D_] 6O;Z\0\=?\
MCIJ/^\G_ * M>CEO\5^G^1RXOX%ZG.T445[9YP4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5V7PS_ .1J?_KV?^:UQM=E
M\,_^1J?_ *]G_FM<^*_@R]#6C_$1VGQ%_P"1/G_ZZQ_SKQFO9OB+_P B?/\
M]=8_YUXS7/EW\'YFN+_B!1117H'*%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7KOPQ_Y%>;_K[?_P!!6O(J]=^&
M/_(KS?\ 7V__ *"M<.8?P?F=.%_B'._%+_D.6?\ U[?^S-7"5W?Q2_Y#EG_U
M[?\ LS5PE:X3^!$BO_$84445TF(4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !4EO_Q\Q?[X_G4=26__ !\Q?[X_G2>PT?1M%%%?*'M!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 ?/FL_\AS4/^OF3_P!"-4:O:S_R
M'-0_Z^9/_0C5&OJ8?"CQI;L****LD**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]8^%O_ "+U
MW_U]G_T!:\GKUCX6_P#(O7?_ %]G_P! 6N',/X#.G"_Q#$^*?_(8L?\ KW/_
M *$:X*N]^*?_ "&+'_KW/_H1K@JTP?\  B17_B,****ZC$**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** /:OA__P B79?[TG_H;5T]<Q\/_P#D2[+_ 'I/
M_0VKIZ^9Q'\:7JSV*7P+T"BBBL2PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH \G^*7_(PVG_ %Z#_P!#:N&KN?BE_P C#:?]>@_]#:N&KZ/"?P(GE5_X
MC"BBBNDQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K;\'
M_P#(W:9_UV'\C6)6WX/_ .1NTS_KL/Y&LJW\.7HRZ?QH]6\=_P#)//$W_8*N
MO_135\05]O\ CO\ Y)YXF_[!5U_Z*:OB"OF#V HHHH ^W_ G_)//#/\ V"K7
M_P!%+705S_@3_DGGAG_L%6O_ **6N@H **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1171:!X-U37BLBQ_9[0];B4<$?[(ZM_+WK.I4C37-)V*C&4G:)SM%>
M@>,O"VF^'?"MN;5&>X:[57GD.68;'./0#V'I7G]31K1JQYH[#J0<'9A1116Q
M 4444 %%%% !79?#/_D:G_Z]G_FM<;79?#/_ )&I_P#KV?\ FM<^*_@R]#6C
M_$1VGQ%_Y$^?_KK'_.O&:]F^(O\ R)\__76/^=>,USY=_!^9KB_X@4445Z!R
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9/\ T(U1J]K/_(<U#_KYD_\ 0C5&OJ8?"CQI;L****LD**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *]8^%O\ R+UW_P!?9_\ 0%KR>O6/A;_R+UW_ -?9_P#0%KAS#^ SIPO\
M0Q/BG_R&+'_KW/\ Z$:X*N]^*?\ R&+'_KW/_H1K@JTP?\")%?\ B,****ZC
M$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** /:OA__ ,B79?[TG_H;5T]<
MQ\/_ /D2[+_>D_\ 0VKIZ^9Q'\:7JSV*7P+T"BBBL2PHHHH **** "BBB@ H
MHHH **** "BBB@ HHHH \G^*7_(PVG_7H/\ T-JX:NY^*7_(PVG_ %Z#_P!#
M:N&KZ/"?P(GE5_XC"BBBNDQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *]2^%?_(,U#_KLO_H->6UZE\*_^09J'_79?_0:
MXL?_  '\CHPW\1%/XK_ZW2O]V7_V2O.:]&^*_P#K=*_W9?\ V2O.:K _P(_U
MU%B/XK"BBBNLP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *V_!_P#R-VF?]=A_(UB5M^#_ /D;M,_Z[#^1K*M_#EZ,NG\:/5O'?_)/
M/$W_ &"KK_T4U?$%?;_CO_DGGB;_ +!5U_Z*:OB"OF#V HHHH ^W_ G_ "3S
MPS_V"K7_ -%+705S_@3_ ))YX9_[!5K_ .BEKH* "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?]?B_P#H#UY)6V7_ ,$C%?Q HHHKN.8**** "BBB@ KLOAG_ ,C4_P#U[/\
MS6N-KLOAG_R-3_\ 7L_\UKGQ7\&7H:T?XB.T^(O_ ")\_P#UUC_G7C->S?$7
M_D3Y_P#KK'_.O&:Y\N_@_,UQ?\0****] Y0HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]=^&/\ R*\W_7V__H*U
MY%7KOPQ_Y%>;_K[?_P!!6N',/X/S.G"_Q#G?BE_R'+/_ *]O_9FKA*[OXI?\
MARS_ .O;_P!F:N$K7"?P(D5_XC"BBBNDQ"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** -+P]_R,VE?]?D/_ *&*]_KP#P]_R,VE?]?D/_H8
MKW^O&S/XXG?@_A9YM\6/^81_VV_]DKS>O2/BQ_S"/^VW_LE>;UW8'_=X_/\
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M0 4444 %%%% !1110 4444 %%%% 'SYK/_(<U#_KYD_]"-4:O:S_ ,AS4/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ KHM!\&ZCXBL7N[2:U2-)3$1,S
MY ![*>.17.UZW\+O^19N?^OQO_0$KEQ=65*GS1W-J$%.=F<U_P *NUO_ )^M
M/_[^/_\ $4?\*NUO_GZT_P#[^/\ _$5ZM<7$%I T]S-'#"N-TDC!5&3CDGWJ
ME_PD.B?]!C3_ /P*3_&O,6.Q#V_(['AZ2W/-O^%7:W_S]:?_ -_'_P#B*/\
MA5VM_P#/UI__ '\?_P"(KTG_ (2'1/\ H,:?_P"!2?XT?\)#HG_08T__ ,"D
M_P :?US$]OP%]7H_TSS;_A5VM_\ /UI__?Q__B*/^%7:W_S]:?\ ]_'_ /B*
M])_X2'1/^@QI_P#X%)_C1_PD.B?]!C3_ /P*3_&CZYB>WX!]7H_TSQ37M!NO
M#M\EI=R0O(\0E!A8D8)([@<\&LNNP^(][:WWB&WEM+F&XC%HJEX9 X!WOQD=
M^17'UZU"4I4U*6YPU$HS:04445L0%%%% !1110 4444 %%%% !1110 4444
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M -#:N&KZ/"?P(GE5_P"(PHHHKI,0HHHH **** "BBB@ HHHH **** "BBB@
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M=*_W9?\ V2O.:K _P(_UU%B/XK"BBBNLP"BBB@ HHHH **** "BBB@ HHHH
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MU1QEV.S$48PC>)S=%%%>F<84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %;?@_P#Y&[3/^NP_D:Q*V_!__(W:9_UV'\C65;^'+T9=
M/XT>K>._^2>>)O\ L%77_HIJ^(*^W_'?_)//$W_8*NO_ $4U?$%?,'L!1110
M!]O^!/\ DGGAG_L%6O\ Z*6N@KG_  )_R3SPS_V"K7_T4M=!0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4/\ P%?_  H]I#N'++L9M%27%O/:3M!<PR0S+C='(I5AD9Y!]JCJKW$%>_\
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MMJ]MKQ+P#_R.VG_]M/\ T6U>VUYV9?Q5Z?JSJPGP/U/$O'W_ ".VH?\ ;/\
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M:)I,:B*R264=9IP'8GUYX'X8K<"J%VA0%],<5YQJ?Q2VR,FEV 91TEN">?\
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MHHKT#E"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKQN8]3Z =2?85XN)QLYRY:6B_,]"EAXQ5YD=IHVF6"@6MA;1>ZQC)^IZFKI
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MX2MR!1117><H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4EO\
M\?,7^^/YU'4EO_Q\Q?[X_G2>PT?1M%%%?*'M!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 ?/FL_\AS4/^OF3_T(U1J]K/\ R'-0_P"OF3_T(U1K
MZF'PH\:6["BBBK)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "O6/A;_R+UW_U]G_T!:\GKUCX
M6_\ (O7?_7V?_0%KAS#^ SIPO\0Q/BG_ ,ABQ_Z]S_Z$:X*N]^*?_(8L?^O<
M_P#H1K@JTP?\")%?^(PHHHKJ,0HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "O6_A=_R+-S_ -?C?^@)7DE>M_"[_D6;G_K\
M;_T!*X<P_@'3A?XAI>/O^1)U#_MG_P"C%KQ*O;?'W_(DZA_VS_\ 1BUXE49;
M_"?K^B'B_C7H%%%%>B<H4444 %%%% !17H&G?#+[?IEI>?VOY?VB%)=GV;.W
M< <9W\]:YKQ1X>_X1K4X[/[5]IWPB7?Y>S&2PQC)_NUA#$TIRY(O4UE2G%<S
M6AB4445N9!117I'_  J?_J-?^2O_ -G6-6O3I6YW:YI"G*?PH\WHK2U_2?[#
MUNXT[S_/\G;^\V;<Y4-TR?7UK-K2,E)*2V9#33LPHKMM ^'O]N:);ZC_ &IY
M'G;OW?V?=C#%>NX>GI6;XL\)_P#"+_8_]-^T_:-__++9MV[?<Y^]^E91Q-*4
M_9IZFCI34>9K0YNBNLT+P!JFL1+<3D65NWW6E4EV'J%XX^I%=7%\+=*" 37M
MZ[=RA51^14UG/&T8.U[E1P]22O8\HHKU"\^%=HR_Z%J4\;>DR!P?RQBN&UOP
MUJ?A^0"]A'E,<)-&=R,?KV/L<=*JEBZ55VB]13H3@KM&1111728A116CI.AZ
MCK<_E6%LTF/O/T5?J3Q_6IE)15Y.PTFW9&=17I%C\*_E5M0U+!QRD"=/^!'_
M  K2_P"%7:+M_P"/N_SZ[T_^)KD>/H)VN;K#5#R6BO1M0^%DBHSZ=J(<]HYT
MQ_X\/\*X/4--O-*NFMKZW>"8<[6[CU!Z$>XK:EB:572+(G2G#=%6M+P]_P C
M-I7_ %^0_P#H8JMIUI]OU.TL]_E_:)DBWXSMW$#.._6O2=.^&7V#4[2\_M?S
M/L\R2[/LV-VT@XSOXZ5.(KTZ:Y9/5A2IRD[I'?UX!XA_Y&;5?^OR;_T,U[_7
M :C\,OM^IW=Y_:_E_:)GEV?9L[=Q)QG?SUKRL#6A2DW-V.W$TY32Y3RVBND\
M6>$_^$7^Q_Z;]I^T;_\ EELV[=ON<_>_2L33K3[?J=I9[_+^T3)%OQG;N(&<
M=^M>U"I&<.>+T//E!QERO<K45Z1_PJ?_ *C7_DK_ /9UP&HVGV#4[NSW^9]G
MF>+?C&[:2,X[=*BEB*=5V@[E3I3A\2*U%%%;F845OZ'X/U;7@LL$(AMC_P M
MYN%/T[G\./>NRM?A79*H^UZC<2-W\E50?KFN6IBZ--V;U-H4)R5TCRZBO6'^
M%NCE?W=Y?*WJS(?_ &45SVK?#/4K-#+83I>J.J8V/^ )P?SJ88ZA)VO8<L-4
M2O8XBBGRQ20RM%+&T<B'#(XP0?0BF5UWN8A117;:!\/?[<T2WU'^U/(\[=^[
M^S[L88KUW#T]*SJU84ES3=D5"$INT3B:*Z3Q9X3_ .$7^Q_Z;]I^T;_^66S;
MMV^YS][]*L:%X U36(EN)R+*W;[K2J2[#U"\<?4BI>)I*"FWHQ^RGS<MM3DZ
M*]7B^%NE! )KV]=NY0JH_(J:@O/A7:,O^A:E/&WI,@<'\L8K#^T*'<T^JU#R
M^BM?6_#6I^'Y +V$>4QPDT9W(Q^O8^QQTK(KKA.,US1=T8RBXNS"BBBK)"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M /:OA_\ \B79?[TG_H;5T]<Q\/\ _D2[+_>D_P#0VKIZ^9Q'\:7JSV*7P+T"
MBBBL2PHHHH **** "BBB@ HHHH **** "BBB@ HHHH \G^*7_(PVG_7H/_0V
MKAJ[GXI?\C#:?]>@_P#0VKAJ^CPG\")Y5?\ B,****Z3$**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *]$^''AI)V_MN[C#*C8ME/3<.K_
M (=![Y]!7 6MO)>7<-M$ 9)I%C0'U)P*^A+&SBT^Q@LX!B*% B_A7G9C6<(*
M"Z_D=>%I\TN9]!]S<PV=K)<W$@CAB4L['H *\A\2>.[_ %B1X+)WM+') 53A
MY!ZL1_(?K6Q\3]:8RP:-"Q" ":?!ZG^%3_/\17G-9X'"QY?:SU[%8FL[\D0H
MHHKU3B'1R20R+)$[)(IRK*<$'V->H>!_&TM_*FE:H^ZX(_<3GJ_^RWOZ'O\
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M7!F%>G.')%ZI_P"9U86G*,N9K2QQ'Q8_YA'_ &V_]DKS>O;?%GA/_A*/L?\
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MAO7$UT8>;G2C*6YE5BHS:04445N9A1110 4444 %%%% !1110 4444 %%%%
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MK<.S/;:*\2_X3[Q-_P!!/_R!'_\ $T?\)]XF_P"@G_Y C_\ B:/[-J]U^/\
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M7TC5YI]CY_H+!_:^1YM\6/\ F$?]MO\ V2O-Z](^+'_,(_[;?^R5YO77@?\
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M_(=O/^O;_P!F6L,<OW$OE^9IAOXJ/5J\B^)&LR7FN?V:C$6]F!E0>&<C)/X
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M *_%_P#0'KR2MLO_ ()&*_B!1117<<P4444 %%%% !79?#/_ )&I_P#KV?\
MFM<;79?#/_D:G_Z]G_FM<^*_@R]#6C_$1VGQ%_Y$^?\ ZZQ_SKQFO9OB+_R)
M\_\ UUC_ )UXS7/EW\'YFN+_ (@4445Z!RA1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5Z[\,?\ D5YO^OM__05K
MR*O7?AC_ ,BO-_U]O_Z"M<.8?P?F=.%_B'._%+_D.6?_ %[?^S-7"5W?Q2_Y
M#EG_ ->W_LS5PE:X3^!$BO\ Q&%%%%=)B%%%% !1110 4444 %%%% !1110
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MO91["J-%%?11BHJRV/*;;=V%=S\,=1D@UR:P+'R;B(L%_P!M>_Y9_2N&KI/
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M#?\ D;]-_P"NO]#7NXC^%+T?Y'G4OC7J>ZUXY\2?^1M;_K@G]:]CKQSXD_\
M(VM_UP3^M>/E_P#&._%?PSD:***]X\P**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *DM_^/F+_ 'Q_.HZDM_\ CYB_WQ_.D]AH^C:***^4
M/:"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^?-9_Y#FH?]?,G_
M *$:HU>UG_D.:A_U\R?^A&J-?4P^%'C2W844459(4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&%%%%=)B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 =-X
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MI+FZE:6:0Y9V/)_SZ5Y6&PLL0W.3T.VM65)<J1ZNWQ/T,2;1!?,,XWB-<?\
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M#_R).G_]M/\ T8U>)5[;X!_Y$G3_ /MI_P"C&K;,OX2]?T9GA/C?H<U\6/\
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M:*4#IP]&5-MR/*_BC_R,UM_UYK_Z&]<37M^O>#=.\17R7=W-=)(D0B A90,
MD]U//)K+_P"%7:)_S]:A_P!_$_\ B*WH8VE"FHO=&57#SE-M'DE%>M_\*NT3
M_GZU#_OXG_Q%>=^)]+@T7Q#=:?;/(\,.S:9""QR@;G '<UUT<53K2Y8F,Z,X
M*\C(HHHKI,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MU+X5_P#(,U#_ *[+_P"@UY;7J7PK_P"09J'_ %V7_P!!KBQ_\!_(Z,-_$13^
M*_\ K=*_W9?_ &2O.:]&^*_^MTK_ '9?_9*\YJL#_ C_ %U%B/XK"BBBNLP"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KTCX3_\
MQ?\ [8_^SUYO7I'PG_YB_P#VQ_\ 9ZY,=_N\OE^9OAOXJ.W\0_\ (LZK_P!>
M<W_H!KP"O?\ Q#_R+.J_]><W_H!KP"N?+/@D:XSXD%%%%>F<84444 =)X$NC
M:^,++G"R[HF'KD''ZXKVVO ?#C%?$^E$''^EQ#\W%>_5XF91M53[H]'"/W&C
MP/Q-;?9/$^I0X  N'8 #H"<C]#65U.!71^/%"^-=1 ]8S_Y#6I_A_I"ZGXD2
M65<PVB^<?0MGY1^?/X5Z2J\F'4WV1R.'-5<5W.U\%^#8M'MX[^^C#ZBXR >1
M"#V'^UZG\!WSU-[?VFG0&>\N(X(Q_%(V,^P]34.LZI#HVDW%_,,K$N0H_B8\
M ?B2*\+U75KW6;Y[N]F+NQX7^%!Z*.PKRJ-&>+FYR>G];';.I&A%12/4[CXE
M:! V(_M5P/[T46!_X\12VWQ)\/SMB1KJW'K+%D?^.DUX[17=_9M&UKLYOK<[
MGT5:WEM?0+/:3QSQ-T>-@17$^.O!T=U;RZMIT06Z0%YHD'$H[MC^]W]_K7G^
M@Z]>>']06ZM6RIP)8B?ED7T/OZ'M7N]I=17UG#=0G=%,@=#[$9K@JTJF$J*4
M7I_6ATPG&O%IGSI4EO\ \?,7^^/YUL>+M)71O$MU;1KM@8^;$.P5N<#V!R/P
MK'M_^/F+_?'\Z]GG4Z7,NJ.#E<9V9]&UB67AVWM_$-]K4P#W,[ 19'^K4* <
M>YP>?3\:VZX#XD^();2"+2+61D>=?,G93@[,X"Y]R#GZ>]?/482G/DCU/4J2
MC&/,^AMZGXZT+2Y&B:Y:XE7ADMUW8_'@?K5:R^(V@7DPC=Y[4L<!IXP!^:DX
M_&O&Z*]99;2M:[N<7UN=]CZ0!# $$$$9!'>N'U7P%#J'BZ.\"[-/E4R7*J<9
M<'H/][.?P/M5CX;ZA)>>&F@E8LUK*8U)_N$ C^9'T KJ+^\CT[3[B\ESY<$;
M2,!U.!TKR[U*%1QB]=CLM&I%-E>^U/2_#]E']JFBM85&V.,#L.RJ.?RKG&^)
MVA+(5$-\RYQO$:X/ORV?TKR[5-4NM8U"2]NY"\CG@=E'91Z 53KTJ>6PM>H]
M3DGBY7]U:'T!I.N:=K<+26%RLNW[R=&7Z@\T[6-*@UK2Y[&X'RR+\K=T;L1]
M*\4\,:A+IGB.QGB<J#*L<@[,C'!!_P ]0*]ZK@Q5#ZO47*SIHU/:QU/G*>&2
MWN)()5VR1L4<>A!P:CK<\8PK!XOU-%  ,N_CU8!C_.L[2[%]3U2UL8\[IY F
M1V!/)_ 9->["HG34WVN>;*/O\J.Q\">#H]2 U74H]UJ#^YA/24CJ3_L@]N_T
MZ^I.\<$1=V6.-!DEC@**;;P0V5I'!$H2&% BCT4"O%_%OBFX\0:@Z1R,NGQM
MB&,9 ;_:8=R?T_//BJ-3&56]E^1Z#<:$#T6]^(/A^S=D6YDN67J($R/S. ?P
M-5(OB=H4D@5HKV('^)XEP/R8FO(:*[UEM*UFV<WUN=SZ!TS7--UF,OI]Y'-C
M[RCAE^JGD51\3^%[7Q%9$,%CO$'[F?'(]CZK7B5K=3V5U'<VTK131G<CJ>0:
M]O\ "FO?\)#HB73A5N$8QS*O3<.X]B"#^G:N+$866&:J0>AT4JT:JY9(\/N;
M::SNI;:XC,<T3%70]B*BKT#XH:2L-[;:I&N//'E2D#^(=#]2./\ @->?UZ^'
MJ^UIJ9PU8<DG$]M\ _\ (DZ?_P!M/_1C5HZCH=KJFI6-W=J)%LPY2)AD,S;<
M$_3;T]ZSO /_ ").G_\ ;3_T8U6_%.M?V#H,]XN/..(X0>[GI^0R?PKP:BDZ
M\E'=MGI0M[--]B;5O$&EZ(H^WW:1NPRL8RSG\!S^-<\?B=H0DV^3?%<_?\M<
M?^A9_2O)KBXFN[AY[B1I9I#N9V.234=>E#+8)>^[LY)8N5_=1] :3KVFZW$S
MV%TLI7[R=&7Z@\_C5F^L;?4K*6SNXQ)#*NUE/\Q[CUKP+3-2N-)U&&]MG*R1
M-G&>&'<'V-?04,J3P1S1G*2*&4^H(R*X,5AWAY+E>CV.FC5]JG<^?=6TZ32=
M6NK"7EH)"H./O#L?Q&#^-=5\/=?TS0_[1_M&Y\CSO*\O]VS9QOS]T'U%0_$N
M!8O%8=5P9K='8^IR5_DHKCZ]>,5B*"4^IPM^RJMQZ'O^DZ_IFN>=_9USY_D[
M?,_=LN,YQ]X#T-6;^_M=+LI+R\E\JWCQO?:6QD@#@9/4BO/_ (3_ /,7_P"V
M/_L]=+X^_P"1)U#_ +9_^C%KQZE",<1[);77XG?&HW2Y^NH?\)]X9_Z"?_D"
M3_XFO(-9N(KO7-0N8&WPS7,DB-@C*EB0>?:J-%>Q0PL*#;BWJ<%2M*HK,](^
M$_\ S%_^V/\ [/72^/O^1)U#_MG_ .C%KFOA/_S%_P#MC_[/72^/O^1)U#_M
MG_Z,6O-K?[ZO5?H==/\ W?Y,\2JUINGSZKJ5O8VX!EF?:,]!ZD^P&3^%5:ZW
MP!?Z5I>K3W>I72PL(MD.Y2023R>!Q@#]:]:O-PIN4=SAIQ4II,]3T71;/0M/
M2TM$P!R[G[TC>IJ+5O$FDZ(0M]=JDA&1$H+.?P'3ZFJFH^,='MM*N;JVU"VG
MFC0F.)9!N9N@&.O7]*\4N+B:[N9+BXD,DTC%G=NI)KR,-A)5Y.530[ZM94TE
M$]7;XGZ&K$"WOV [B-,'\VJ]8^/_  _?.J&Z>V=N@N$VC\2,@?B:\5HKM>6T
MFM&SG6+G?4^D P90RD%2,@CO7 ?$K08I+ :U"@6:)E2<CC>IX!/N#@?0^PJ7
MX8:E-=:5=V,K,RVKJ8R3T5L\?FI_.NF\3QB7PMJBD XM9&Y]E)_I7F14J%=+
MLSK;56E?N>!T445]&>4%%%% !1110!TG@'_D=M/_ .VG_HMJ]DU&T^WZ9=V>
M_9]HA>+=C.-RD9_6O&_ /_([:?\ ]M/_ $6U>VUXF9.U9-=OU9Z.$_AOU,R2
M;2_"^CQ++(EM:0@(F>I/L.I)Y/YFL&/XF:"\_ELMXBY_UC1#;^A)_2N&\>ZM
M)J7B:>'?F"T)AC7T(^\?KNS^0KF*UH8",X*51N[,ZF)<96CT.[^(?B.UU5+&
MTT^X6:W"^>[+TW'( /<$#/!]17':;I]QJNH0V5JFZ:5L+GH/4GV YJK7I_PO
MTA4M+G5I%^>1O)B)[*,%C^)P/^ UTS:PE#W3*-Z]34ZOP_X=LO#MB(+9=TS
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MLC_QTFNHM+RVOK=;BTGCFA;H\;9%?.M=E\-]2FMO$BV(9C#=HP*9X#*"P/Y
MC\:G$8",(.<'L.EB7*2C(]$\4Z#%K^C2PE ;F-2]N_=6],^AZ'_ZU>$U](U\
M^ZW&(=?U&(  )=2J /9C3RR;]Z'0,9%:2/4-&\;>'K30]/MI]0V30VT<;KY,
MAPP4 CA?6NMM[B*[MHKF!M\,R"1&P1E2,@\^U?.=>_\ A[_D6=*_Z\X?_0!6
M.-PT*24H]2\/6E/1]"+5/$^CZ+<K;:A>>3,R"0+Y3ME22,\ ]P:Y?Q=XNT+5
M/"]Y9V=]YMQ)LV)Y+KG#J3R5 Z UA_%'_D9K;_KS7_T-ZXFNC"X*FXQJW=]S
M*MB))N 5Z;X$\&1I!%K&I1!Y'P]M$W11V<CN?3TZ]>G%^%M)&M>(K6T=28=V
M^7_<7D_GT_&O<KJYAL;.:YF.R&%"[$#H ,T9A7:M2CUW#"TT_?8MQ<P6D#3W
M,T<,2_>>1@H'XFN7N_B-X?MF*I)/<XX_<Q<?^/8KS+Q!XAO/$-^T]PY6$']S
M #\L8_Q]3_\ 6%9%*CEJM>HQSQ;O:"/8(/B7H,TFUUO(!_>DB!'_ (Z2:Z;3
M]4L=5M_/L;J.>/N4/(]B.H/L:^>:N:9J=WI%]'>64ICE3\F'<$=Q3J9;&UZ;
MU%#%N_O(]9\8^$(=<M7N[6-4U*-<@C \['\)]_0_TKQME9&*LI5E."",$&OH
M#1-5CUK1K;4(QM\U?F7/W6'!'Y@UY9\1-)73O$9N(EVQ7B^;P.-_1OZ'\:C
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MYX9_[!5K_P"BEKH* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_L]>DUYM\)_^8O\ ]L?_ &>O2:^>QW^\2^7Y'J8;^$CYNHHHKZ$\L]M\ _\
M(DZ?_P!M/_1C4>/O^1)U#_MG_P"C%H\ _P#(DZ?_ -M/_1C4>/O^1)U#_MG_
M .C%KY[_ )B_^WOU/4_Y<?+]#Q*BBBOH3RPKVSP#_P B5I__ &T_]&-7B=>P
M_#6Y$WA7RN\$[I^>&_\ 9OTKS\R_@KU_S.K"?'\BYX]!/@K4,#/^K_\ 1BUX
ME7OWB*R;4/#NH6J+N=X&V+ZL!D?J!7@-1EDO<E'S*QB]Y,****],XPKI? ()
M\:Z?@=/,S_W[:N:KMOAC9--XAFNBOR6\!Y]&8X'Z;JY\5+EHR?D:T5>HCUNO
M$O'I!\:ZA@Y_U?\ Z+6O;:\&\5W/VKQ7J<HZ"=D'_ ?E_I7F9;_%?I_D=F+^
M!>ICU](U\W5](UKFGV/G^A&#^U\CS;XL?\PC_MM_[)7F]>D?%C_F$?\ ;;_V
M2O-ZZ\#_ +O'Y_F88G^*SI/ /_([:?\ ]M/_ $6U>VUXEX!_Y';3_P#MI_Z+
M:O;:\[,OXJ]/U9U83X'ZGB7C[_D=M0_[9_\ HM:YNND\??\ ([:A_P!L_P#T
M6M<W7K8?^%'T7Y'%5^-^IZ;\*?\ CVU3_?C_ )-7H$__ ![R?[I_E7G_ ,*?
M^/;5/]^/^35Z!/\ \>\G^Z?Y5X.+_CR/2H?PT?.5%%%?2'DA7=_"W_D.WG_7
MM_[,M<)7=_"W_D.WG_7M_P"S+7)CO]WE\OS-\-_%1ZM7SYK?_(>U'_KZE_\
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M_P#(GS_]=8_YUXS7LWQ%_P"1/G_ZZQ_SKQFN?+OX/S-<7_$"BBBO0.4****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"WOU/4_P"7'R_0\2HHHKZ$\L*Z3P#_ ,CMI_\ VT_]%M7-UTG@'_D=M/\
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M-^F_]=?Z&L.MSP;_ ,C?IO\ UU_H:]W$?PI>C_(\ZE\:]3W6O'/B3_R-K?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "O6/A;_ ,B]=_\ 7V?_ $!:\GKUCX6_\B]=_P#7V?\
MT!:X<P_@,Z<+_$,3XI_\ABQ_Z]S_ .A&N"KO?BG_ ,ABQ_Z]S_Z$:X*M,'_
MB17_ (C"BBBNHQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *];^%W_ "+-S_U^-_Z E>25ZW\+O^19N?\ K\;_ - 2N',/
MX!TX7^(;_B?5)]%\/76H6R1O-#LVB0$J<N%YP1V->=_\+1UO_GUT_P#[]O\
M_%UV_C[_ )$G4/\ MG_Z,6O$JY\!0IU*;<E?7_(TQ-2<9VBSMO\ A:.M_P#/
MKI__ '[?_P"+H_X6CK?_ #ZZ?_W[?_XNN)HKM^J4?Y3G]O4[G;?\+1UO_GUT
M_P#[]O\ _%UB>(?%%]XE^S?;(K>/[/NV>2K#.[&<Y)_NBL2BJAAZ4'S1CJ*5
M6<E9L****W,SW_P]_P BSI7_ %YP_P#H KS;XH_\C-;?]>:_^AO7I/A[_D6=
M*_Z\X?\ T 5YM\4?^1FMO^O-?_0WKP\'_O+^9Z.(_@_<<31117N'G!7TC7S=
M7TC7DYI]CY_H=V#^T>)>/O\ D=M0_P"V?_HM:YNND\??\CMJ'_;/_P!%K7-U
MZ&'_ (4?1?D<M7XWZGMO@'_D2=/_ .VG_HQJP/BK.5L],M_X7DD<_P# 0!_[
M-6_X!_Y$G3_^VG_HQJYKXL?\PC_MM_[)7D4E?&_-_J=TW;#_ "1YO1117NGF
MA7O_ (?)/AK2B3DFSBR3_N"O *]_\/?\BSI7_7G#_P"@"O+S/X8G9@_B9YM\
M4?\ D9K;_KS7_P!#>N)KMOBC_P C-;?]>:_^AO7$UUX3^#$PK_Q&?1-A;BTT
MZUME&!#"D8'T %>2_$FZ,_BMH<\6\*)C/K\W_LU>P@A@"#D'D5XIX_4CQK?D
MC[PC(_[]K7EY<DZUWV.W%:4SFJ***]T\T**** "M+P]_R,VE?]?D/_H8K-K2
M\/?\C-I7_7Y#_P"ABHJ? RH_$CW^O /$/_(S:K_U^3?^AFO?Z\ \0_\ (S:K
M_P!?DW_H9KR<L^.1VXSX49M:7A[_ )&;2O\ K\A_]#%9M:7A[_D9M*_Z_(?_
M $,5ZU3X&<4?B1[_ %X!XA_Y&;5?^OR;_P!#->_UX!XA_P"1FU7_ *_)O_0S
M7DY9\<CMQGPHM^#8!<>+]-1AD"7?^*@L/Y5[I7B7@(A?&NGD^L@_\AM7MM3F
M7\5>GZLK"? _4^>M5NS?:O>79)/G3.XR<\$G'Z53I64HQ5A@@X-)7LP244D>
M?)MN["BBBJ$>S?#JZ-SX1A0DDP2O%R??</\ T*LWXIP*VCV-P1\T=P4!] RD
MG_T$58^&"E?#$Y(P&NV(]_E0?TIOQ1(_X1NU7N;Q3_XX]>#!)8RR[GI2UH:]
MCR6O;? /_(DZ?_VT_P#1C5XE7MO@'_D2=/\ ^VG_ *,:NW,OX2]?T9SX3XWZ
M&!\59RMGIEO_  O)(Y_X" /_ &:O,:](^+'_ #"/^VW_ +)7F]:X!6H+Y_F3
MB7^\84445V'.>_\ A\D^&M*).2;.+)/^X*\V^*/_ ",UM_UYK_Z&]>D^'O\
MD6=*_P"O.'_T 5YM\4?^1FMO^O-?_0WKP\%_O+^9Z.(_@G$T445[AYP4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110![
M5\/_ /D2[+_>D_\ 0VKIZYCX?_\ (EV7^])_Z&U=/7S.(_C2]6>Q2^!>@444
M5B6%%%% !1110 4444 %%%% !1110 4444 %%%% 'D_Q2_Y&&T_Z]!_Z&U<-
M7<_%+_D8;3_KT'_H;5PU?1X3^!$\JO\ Q&%%%%=)B%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 =E\,Y1'XJ92<>9;.H]^5/\ 2O7Z\(\)
MWHT_Q5IT['"^:(V/H&&W/ZU[O7A9C%JM?NCTL([PL?.EU";:\G@(P8Y&0CZ'
M%0UO^-+ Z?XLODP0DK^>A/<-R?UR/PK KV:4N:FI>1P35I-!1116A 4444 %
M%==X4\%CQ)IMS=/=/;[)!'&0FX$XR<C(]1WHUCX>ZII5K-=K/;3V\*EV(8JV
M!UX/'ZUS?6J2GR-ZFOL9\O-8Y&O>/"4 M_">F(HP# K_ (M\Q_G7@]>_>'"&
M\,:41_SYQ#_QP5RYG\$?4WP?Q,X/XJ79:^T^S!.$C:4C/7<<#_T$_G7GM=Q\
M45/_  DEJV.#:*!_WV_^-</73@DE0C8QQ#;J,****ZC$[#X;71@\5B')Q<0N
MF,]Q\W_LIKUJ\@6ZL;BW<;EEC9"/4$8KQOP I;QI8D#(42$^W[MA_6O:F(52
MQX &37@Y@DJUUV/2PMW3U/F^O>?"ENMMX4TN-  #;K)QZL-Q_4UX-7T#H+A_
M#NF.!@-:1''I\@KJS-OEBC'![L\[^*=RS:S8VO\ #';F0?5F(/\ Z"*X*NU^
M)Z%?$T#<X:T4_P#CS5Q5=6#25"-C&O\ Q&%%%%=1B>K?"ZZ:31+NV9B?)GW*
M#V##_$'\ZT_B%_R)MW_O1_\ H8K$^%2D6>IOCY3(@!^@/^-;?Q"_Y$V[_P!Z
M/_T,5X$_]\_[>1Z<?X'R/%JZ3P#_ ,CMI_\ VT_]%M7-UTG@'_D=M/\ ^VG_
M *+:O9Q'\*7H_P C@I?&O4]MKYTNIS=7DUPWWI9&<_B<U]%U\W5YV6+63]#J
MQCT2"BBBO7.$[?X7$_\ "2W(SP;-N/\ @:5Z1XA_Y%G5?^O.;_T UYM\+O\
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M<?@I->8_"[_D9KG_ *\V_P#0TKTGQ#_R+.J_]><W_H!K#&J^(L_(TP[M2N>
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M/^NR_P#H->6UZE\*_P#D&:A_UV7_ -!KBQ_\!_(Z,-_$13^*_P#K=*_W9?\
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M .@+5SX<6PG\71R$?ZB%Y!^6W_V:J?CC_D<M1_WE_P#0%K5^%Y \37 )ZV;
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MD]W8\ K7TOPQK&M6S7.GV?G0JYC+>:BX8 '')'8BLBO6_A=_R+-S_P!?C?\
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M+/)$7+@S,"1G' P!QQ^M<I\5( VDV%QCYHYR@./[RY_]EJQ_PM'1/^?74/\
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M_'?_ "3SQ-_V"KK_ -%-7Q!7S![ 4444 ?;_ ($_Y)YX9_[!5K_Z*6N@KG_
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M^1ZF&_A(^;J***^A/+/;? /_ ").G_\ ;3_T8U'C[_D2=0_[9_\ HQ:/ /\
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M1Q5?C?J>F_"G_CVU3_?C_DU>@3_\>\G^Z?Y5Y_\ "G_CVU3_ 'X_Y-7H$_\
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MN^IQ[G@'_"/:W_T!]0_\!7_PH_X1[6_^@/J'_@*_^%>_T4?VG/\ E#ZG'N>
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M+.E?]></_H IYG\$18/XF<W\4?\ D6;;_K\7_P! >O)*];^*/_(LVW_7XO\
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M %P3^M>/E_\ &._%?PSD:***]X\P**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *DM_^/F+_?'\ZCJ2W_X^8O\ ?'\Z3V&CZ-HHHKY0]H**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y\UG_D.:A_U\R?^A&J-
M7M9_Y#FH?]?,G_H1JC7U,/A1XTMV%%%%62%%%% !1110 4444 %%%% !1110
M 459L;"[U*Y6VLK=YYFYVH,\>I]![FNXTSX774H634[U(!WBA&]OQ/0'\ZPJ
MXBG2^)FD*4Y[(\^HKV6W^'/AZ%0)(9[@^LDQ'_H.*G;P!X9(P-.*^XGD_P#B
MJY?[2I=G_7S-OJD^Z/$Z*]7OOA?IDRDV5W<6[]@^)%_+@_K7#:[X1U70,R7$
M0EMLX$\7*_CW'XUO2QE*H[)V?F9SH3AJT8-%%%=1B%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%=%X-T&U\1:Q-
M:7<DR1I;F4&%@#D,H[@\<FHG-0BY/9%1BY.R.=HKT_5?AQH]CH][=Q7-\9(+
M>250SI@E5)&?EZ<5YA44:\*R;@54IRINT@HHJ>SLKG4+E;:T@>:9NB(,G_ZP
M]ZU;25V0E?8@HJYJFFW&D:A)8W043QA2X4Y RH;&?QJG0FI*Z!IIV8445ZW_
M ,*NT3_GZU#_ +^)_P#$5C6Q$*-N?J:4Z4JGPGDE%:_B?2X-%\0W6GVSR/##
MLVF0@L<H&YP!W-9%:QDI14EU,VFG9A1115""BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBM31O#VI:],4L;<LBG#RL<(OU/]!S4RG&"O
M)V0U%R=D9=%>GZ?\++94#:C?RR/W2W 4#VR<Y_(5MQ_#[PV@PUD\GNT[_P!"
M*XI9C13TNSH6%J,\5HKVI_A]X:<86Q9/=9W_ *DUC7WPLLW4FPOYHFZ[9E#C
MZ<8(_6B.8T6];H;PM1'EU%;.M>%]5T%LWEOF'.!/$=R'\>WXXK&KLA.,US1=
MT<\HN+LPHHHJR0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***ZWP1X7
ML?$OV[[9+<1_9_+V>2RC.[=G.0?[HK.I4C3BYRV*A%S?*CDJ*]$\3^ M+T7P
M]=:A;7%X\T.S:)'4J<N%YPH[&O.ZFC6C6CS1'.G*#M(****V("BBB@ HHHH
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M /1BUXE49;_"?K^B'B_C7H%%%%>B<H4444 %%%% 'OWAT@^&=*P<_P"AQ?\
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M+_>D_P#0VKIZ^9Q'\:7JSV*7P+T"BBBL2PHHHH **** "BBB@ HHHH ****
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M-"C.3LD=%\/M-?3_  M$\@(>Z<SX/92 %_, '\:=\0O^1-N_]Z/_ -#%=.
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M:;C3<GU%BY7DH]CMOA=_R,US_P!>;?\ H:5Z3XA_Y%G5?^O.;_T UYM\+O\
MD9KG_KS;_P!#2O2?$/\ R+.J_P#7G-_Z :Y,9_O*^1MA_P"#]YX!1117N'G!
M7I'PG_YB_P#VQ_\ 9Z\WKTCX3_\ ,7_[8_\ L]<F._W>7R_,WPW\5'2^/O\
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MILCPRJ'1@R\@]#C.:Z#PQ\/;NZGCNM9C,%JI#" GYY/8_P!T?K].M>J@+&F
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MQ,*_\1GI'PG_ .8O_P!L?_9ZZ7Q]_P B3J'_ &S_ /1BUS/PH8;]67N1"?\
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MA'9$SFYRYF;?A&_M=+\46=Y>2^5;Q[][[2V,HP' R>I%>I?\)]X9_P"@G_Y
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M95Z%)4I-16SZ%TZDW-)M[GMM>=^/?$^L:+KD%MI]YY,+6RR%?*1LL689Y![
M5Z)7DGQ1_P"1FMO^O-?_ $-Z\K QC*M:2N=N);4+HS?^$^\3?]!/_P @1_\
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M->)44?V;2[O\/\@^MS[(]M_X3[PS_P!!/_R!)_\ $T?\)]X9_P"@G_Y D_\
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M32UL$:LZM1)GKU>,_$60/XPG4?\ +.*-3S_LY_K7LU>#^++L7OBO4IAR/.*
M^H7Y?Z5QY=&]:_9'1BW:%C&HHHKW#S3T3PG\08K2TBT_6 ^R(;8[E5SA1T#
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M^9;,I4445Z)R!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\JIECO\ NW]YVQQ:M[R/=J@N[VUL+=I[NXC@B7J\C8%>+R>.O$LJ[6U1@/\
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MY,K)NQTS@\]36&(I.K3<%U-*4^2:D>R>/O\ D2=0_P"V?_HQ:\2J]<:SJEW
MT%SJ5Y-"V-T<D[,IP<\@GUJC486@Z$'%N^I5:HJDKH****ZC$**** "BBB@
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M?,MY,":$G&X>H]Q6'16DX1G'EEL3&3B[H]_T?7=/URV$UC<*Y R\9X=/J/\
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M_)//#/\ V"K7_P!%+705S_@3_DGGAG_L%6O_ **6N@H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *\0\=?\ (Z:C_O)_Z M>WUXAXZ_Y
M'34?]Y/_ $!:]'+?XK]/\CEQ?P+U.=HHHKVSS@HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU>U;5[S6[][R]DWR-P .%0>@'851KV,)AO8PUW9PUZOM):;!111768!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5);_ /'S%_OC^=1U);_\?,7^^/YTGL-'T;1117RA[04444 %%%%
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MI14R2DK,:;3NCTR\^*D0)%CICMZ//(%_09_G7"ZWK5QKVH?;;J.%)=@0B)2
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M_7N?_0C7!5WOQ3_Y#%C_ ->Y_P#0C7!5I@_X$2*_\1A111748A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110![5\/_ /D2[+_>D_\ 0VKIZYCX?_\ (EV7
M^])_Z&U=/7S.(_C2]6>Q2^!>@4445B6%%%% !1110 4444 %%%% !1110 44
M44 %%%% 'D_Q2_Y&&T_Z]!_Z&U<-7<_%+_D8;3_KT'_H;5PU?1X3^!$\JO\
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MP(_UU%B/XK"BBBNLP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *V_!_P#R-VF?]=A_(UB5M^#_ /D;M,_Z[#^1K*M_#EZ,NG\:/5O'
M?_)//$W_ &"KK_T4U?$%?;_CO_DGGB;_ +!5U_Z*:OB"OF#V HHHH ^W_ G_
M "3SPS_V"K7_ -%+705S_@3_ ))YX9_[!5K_ .BEKH* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=HG_ #]:A_W\3_XBO56/H)61Q/#5&>245ZW_ ,*NT3_GZU#_ +^)_P#$4?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "I+?_CYB_P!\?SJ.I+?_ (^8O]\?SI/8:/HVBBBOE#V@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /GS6?^0YJ'_7S)_P"A
M&J-7M9_Y#FH?]?,G_H1JC7U,/A1XTMV%%%%62%%%% !1110 4444 %%%% 'K
M7PN_Y%FY_P"OQO\ T!*T_'O'@K4,?],__1BUB?"N<-IFH6_\4<RN?^!#'_LM
M=+XN@^T^$M33T@+_ /?/S?TKY^L[8J_FCU(:T?D>$4445] >6%%%% !1110
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MG^%3+,:<E9Q&L)).Z9?AE2X@CFC.8Y%#*?4$9%>$>)].72O$E]:(H6-9-T8
MX"M\P'X X_"O>(XTAB2*)%2-%"JBC 4#H .PKR/XFQA/%,; #]Y:HQ_[Z8?T
MK#+I-5;=T:8I7A<XRBBBO</."BBB@ HHHH **** "BBB@ KUCX6_\B]=_P#7
MV?\ T!:\GKUCX6_\B]=_]?9_] 6N',/X#.G"_P 0Q/BG_P ABQ_Z]S_Z$:X*
MN]^*?_(8L?\ KW/_ *$:X*M,'_ B17_B,****ZC$**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /:OA_\ \B79?[TG_H;5T]<Q\/\ _D2[+_>D_P#0VKIZ
M^9Q'\:7JSV*7P+T"BBBL2PHHHH **** "BBB@ HHHH **** "BBB@ HHHH \
MG^*7_(PVG_7H/_0VKAJ[GXI?\C#:?]>@_P#0VKAJ^CPG\")Y5?\ B,****Z3
M$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "K5OJ5]9KMMKVY@4<X
MBE9?Y&JM%)I/<:;6QHMK^LL,-J]^1Z&Y?_&J$DLDSEY79W/5F.2:;124(K5(
M')O<****H04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %>I?"O_D&:A_UV7_T&O+:]2^%?_(,U#_KLO\ Z#7%C_X#^1T8
M;^(BG\5_];I7^[+_ .R5YS7HWQ7_ -;I7^[+_P"R5YS58'^!'^NHL1_%8444
M5UF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6WX/_
M .1NTS_KL/Y&L2MOP?\ \C=IG_78?R-95OX<O1ET_C1ZMX[_ .2>>)O^P5=?
M^BFKX@K[?\=_\D\\3?\ 8*NO_135\05\P>P%%%% 'V_X$_Y)YX9_[!5K_P"B
MEKH*Y_P)_P D\\,_]@JU_P#12UT% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7B'CK_ )'34?\ >3_T!:]OKQ#QU_R.FH_[R?\ H"UZ
M.6_Q7Z?Y'+B_@7J<[1117MGG!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNB.6+[4C*6,[(^A=+U.WUC3HKZUW^3*6V[Q@G#%>GX5#XA_Y%G5?^O.;_P!
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M * :\ KW_P 0_P#(LZK_ -><W_H!KP"LLL^"1>,^)!7K?PN_Y%FY_P"OQO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5);_\?,7^^/YU'4EO_P ?,7^^
M/YTGL-'T;1117RA[04444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
MSYK/_(<U#_KYD_\ 0C5&KVL_\AS4/^OF3_T(U1KZF'PH\:6["BBBK)"BBB@
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MA_VS_P#1BUXE6.6_PGZ_HB\7\:] HHHKT3E/6_A=_P BS<_]?C?^@)1\4?\
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M+!8>"O);=S#ZQ5D[(]ZT>>6ZT2PN)SNFEMHW<XQEBH)X^M<'\6/^81_VV_\
M9*]%@A2VMHH(_N1H$7Z 8KSOXK@XT@XX'G<_]\5YF"?^T1?K^1V8C^$SS:O2
M/A/_ ,Q?_MC_ .SUYO7I'PG_ .8O_P!L?_9Z];'?[O+Y?F<6&_BHZ7Q]_P B
M3J'_ &S_ /1BUXE7MOC[_D2=0_[9_P#HQ:\2K'+?X3]?T1>+^->A[7\/W#>"
M[(#^ R _]]L?ZU'XU\1ZAX<@LYK*&WD25F60S*QP0 1C!'^U67\+;\2:7>6#
M'YX91(N?[K#''XJ?SKH/%^BMKOAZ:WB7-Q&1+"/5AV_$$C\:\^:C'%/GVO\
MF=4;RHKEWL<%_P +1UO_ )]=/_[]O_\ %T?\+1UO_GUT_P#[]O\ _%UQ3*R.
MR.I5E."",$&DKV/JE#^5'![:IW.V_P"%HZW_ ,^NG_\ ?M__ (NC_A:.M_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5ZE\*_\ D&:A_P!=E_\
M0:\MKU+X5_\ (,U#_KLO_H-<6/\ X#^1T8;^(BG\5_\ 6Z5_NR_^R5YS7HWQ
M7_UNE?[LO_LE><U6!_@1_KJ+$?Q6%%%%=9@%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5M^#_^1NTS_KL/Y&L2MOP?_P C=IG_ %V'
M\C65;^'+T9=/XT>K>._^2>>)O^P5=?\ HIJ^(*^W_'?_ "3SQ-_V"KK_ -%-
M7Q!7S![ 4444 ?;_ ($_Y)YX9_[!5K_Z*6N@KG_ G_)//#/_ &"K7_T4M=!0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5XAXZ_Y'34?
M]Y/_ $!:]OKQ#QU_R.FH_P"\G_H"UZ.6_P 5^G^1RXOX%ZG.T445[9YP4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %.CC>:5(HD9
MY'8*J*,EB>@ [FFUI>'O^1FTK_K\A_\ 0Q4R=HMC2N[!_P (]K?_ $!]0_\
M 5_\*/\ A'M;_P"@/J'_ ("O_A7O]%>1_:<_Y3N^IQ[G@'_"/:W_ - ?4/\
MP%?_  H_X1[6_P#H#ZA_X"O_ (5[_11_:<_Y0^IQ[G@'_"/:W_T!]0_\!7_P
MH_X1[6_^@/J'_@*_^%>_T4?VG/\ E#ZG'N> ?\(]K?\ T!]0_P# 5_\ "C_A
M'M;_ .@/J'_@*_\ A7O]%']IS_E#ZG'N> ?\(]K?_0'U#_P%?_"J-Q;SVD[0
M7,,D,RXW1R*589&>0?:OHVO$O'W_ ".VH?\ ;/\ ]%K73A<9*M-Q:MH95J"I
MQNF<W1117H'*%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%:6D:%J.N7'E6-LS@'#2'A$^I_I
MUKOAX!L-&\.:C=7;?:[U+.5@Q&$C8(>5'<^Y].U<U7%4Z;Y6]36%&4U=;'E]
M%%%=)D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5V7PS_Y&I_^O9_YK7&UV7PS_P"1J?\ Z]G_ )K7/BOX,O0UH_Q$=I\1
M?^1/G_ZZQ_SKQFO9OB+_ ,B?/_UUC_G7C-<^7?P?F:XO^(%%%%>@<H4444 %
M%%% !1110 4444 %%%% !72> ?\ D=M/_P"VG_HMJYNND\ _\CMI_P#VT_\
M1;5CB/X4O1_D:4OC7J>VUY)\4?\ D9K;_KS7_P!#>O6Z\D^*/_(S6W_7FO\
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M>MUY)\4?^1FMO^O-?_0WKQ,O_C'HXK^&<31117O'F!7K?PN_Y%FY_P"OQO\
MT!*\DKUOX7?\BS<_]?C?^@)7#F'\ Z<+_$.D\0_\BSJO_7G-_P"@&O *]_\
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M&]<37J4:CJ4U-]3CJ1Y9.(4445J0%%%% !1110 4444 %%%% !1110 4444
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !4EO_ ,?,7^^/YU'4EO\
M\?,7^^/YTGL-'T;1117RA[04444 %%%% !1110 4444 %%%% !1110 4444
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M50PU2O/GJ["J5H4X\L"@2222<D]2:^@-"U%-6T.SO5.3)&-_/1APP_/-?/\
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M 'AZ^X_6N$N?AUXB@;$<$-P/6*8 ?^/8KT33/&^@ZD@Q>K;2=X[GY"/Q/!_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3[:WLWAAV;3(C%CE W.&'<U\]1C5K2Y8O\3U)N$%>2.R_P"$>T3_ * ^G_\
M@*G^%'_"/:)_T!]/_P# 5/\ "O-O^%HZW_SZZ?\ ]^W_ /BZ/^%HZW_SZZ?_
M -^W_P#BZZ/J>)[_ (F7UBC_ $CTG_A'M$_Z ^G_ /@*G^%'_"/:)_T!]/\
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ML^G^9Z&%2<'?N?-U%%%>T>>%%%% !1110 4444 %%%% !1110 4444 %%%%
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MEPO.".QKY_$.<L0XQ>[/4I**I)M$O_"/:)_T!]/_ / 5/\*/^$>T3_H#Z?\
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M7FWQ1_Y&:V_Z\U_]#>O%P<I/$M-]ST*Z2I'$T445[1YX4444 %%%% !1110
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M_P "?\D\\,_]@JU_]%+704 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8E_?W6J7LEY>2^;<28WOM"YP !P,#H!5:BJC2A!WBDB7.4M&PHHHK0D****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ];^%W_(LW/_7XW_H"5TGB'_D6=5_Z\YO_ $ US?PN_P"1
M9N?^OQO_ $!*Z3Q#_P BSJO_ %YS?^@&OGJ_^\OU/4I_P5Z'@%%%%?0GEA11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=E\
M,_\ D:G_ .O9_P":UQM=E\,_^1J?_KV?^:USXK^#+T-:/\1':?$7_D3Y_P#K
MK'_.O&:]F^(O_(GS_P#76/\ G7C-<^7?P?F:XO\ B!1117H'*%%%% !1110
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M@ HHHH *Z3_A/O$W_03_ /($?_Q-<W142IPG\2N5&4H[,Z3_ (3[Q-_T$_\
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M% !1110 4444 %%%% !1110 5Z1\)_\ F+_]L?\ V>O-Z](^$_\ S%_^V/\
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MI:A<7LY_>3.7;'09[#V'2N3+Z;E4=1]/S-\5)*'*BM1117M'GA1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 >U?#_ /Y$NR_WI/\ T-JZ>N8^'_\ R)=E
M_O2?^AM73U\SB/XTO5GL4O@7H%%%%8EA1110 4444 %%%% !1110 4444 %%
M%% !1110!Y/\4O\ D8;3_KT'_H;5PU=S\4O^1AM/^O0?^AM7#5]'A/X$3RJ_
M\1A111728A1110 4444 %%%% !6EX>_Y&;2O^OR'_P!#%9M:7A[_ )&;2O\
MK\A_]#%14^!E1^)'O]>)>/O^1VU#_MG_ .BUKVVO$O'W_([:A_VS_P#1:UXV
M6_Q7Z?JCOQ?P+U.;HHHKW#S@HHHH **** "BNV^%W_(S7/\ UYM_Z&E>D^(?
M^19U7_KSF_\ 0#7#6QGLJOL^6_S.FGA^>'-<\ HHHKN.8***](^$_P#S%_\
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MW4@EB=[3=^[N%&5([9]#[5P9;."DXO=G3BXR:36QAT445[)P!76?#W5I-/\
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MYS7HWQ7_ -;I7^[+_P"R5YS58'^!'^NHL1_%84445UF 4444 %%%% !1110
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M;HHHKN.<]_\ #W_(LZ5_UYP_^@"O-OBC_P C-;?]>:_^AO7I/A[_ )%G2O\
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MUW/G"2-XG*2(R..JL,$4VOHB]T^SU&'RKVUBG3L)%!Q]/2O-?%?P^:PBDO\
M1]\ENH+26Y.60>JGN/U^O;>AF$)OEFK&53"RBKQU.!HHHKT3E"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *V_!_P#R-VF?]=A_(UB5M^#_ /D;M,_Z[#^1K*M_#EZ,NG\:/5O'?_)/
M/$W_ &"KK_T4U?$%?;_CO_DGGB;_ +!5U_Z*:OB"OF#V HHHH ^W_ G_ "3S
MPS_V"K7_ -%+705S_@3_ ))YX9_[!5K_ .BEKH* "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "O7?AC_ ,BO-_U]O_Z"M>15Z[\,?^17F_Z^W_\ 05KAS#^#\SIPO\0Y
MWXI?\ARS_P"O;_V9JX2N[^*7_(<L_P#KV_\ 9FKA*UPG\")%?^(PHHHKI,0H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#2\/?\C-I7_7Y#
M_P"ABO?Z\ \/?\C-I7_7Y#_Z&*]_KQLS^.)WX/X6>;?%C_F$?]MO_9*\WKTC
MXL?\PC_MM_[)7F]=V!_W>/S_ #.?$_Q6%%%%=9@%>O\ @G1M+N_"%C/<Z;9S
M3-YFZ22!68XD8<DCTKR"O;? /_(DZ?\ ]M/_ $8U>?F+:I*W?_,ZL*DYN_8Y
MCX@Z'#]KT:UTG3H(YKAI5VP1*F\_)C./3)Z].:Z7P]X*TS18%:6&.ZO",O-(
MN0I]%!Z#WZUT#VL,EW#=.@,T*,D;'^$-C/\ Z"*YOQ1XWM/#\GV2*/[5>XR4
M#86/TW'U]OY<5YRJU:L%1A_PYU.$(2<Y'4-&CIL9%9>FTC(KBO'&@Z%;Z!<W
MYLDAN5P(F@PF7)[@<'U/&<9K A^*>J+-F>PLWB_NIN5OS)/\JJ^-/%T'B*VL
M8+198XDS)*D@'W^@'X#/_?5:T<)7A5C?1>1$Z].4'U..JYIFF7>KWR6=E"9)
M6Y]E'<D]A4-K;37EU%;6Z%YI6"(H[DU[GX;\/6WAW3%MX</,^&FFQR[?X#L/
M_KUZ&+Q2H1LMV<M&C[1Z['/Z+\-=.M(UDU1C>3X!**2L:G^9_'\JZVUTRPLE
MVVME;PC_ *9Q!?Y5%JVMZ?HEMY]_<+&#]Q>K.?8=ZX2^^*DA9ET_35"_PO</
MDGZJ.GYUY*CB,3KJSNO2I:;'I3*KC#*&'H161?\ A70]25A<:; &;K)&NQL_
M48_6O/X_BEK <&2SL67N%5P?SW&NCT?XDZ;?2+#?Q-8R-P'+;H_Q/4?B,>].
M6$KTO>2^X2K4IZ7.9\2?#VZTN-[O37>[M5Y9"/WB#UX^\/I^7>N)KZ0!# $$
M$$9!'>O+?B%X62QD_MBRC"V\K8G11PCGHP]C_/ZUV8/&N3]G4^3,*^'27-$X
M&BBE52S!5!+$X  Y->H<1<TK2;S6;Y;2RB,DC<D] H]2>PKTS2/AIIELBOJ4
MCWDV.45BD8/MCD_G^%;GA7P_%X?T>.#:OVJ0![AQU+>F?0=!^?>M._O[;3+*
M2[O)1%#&,LQ_D/4UX>(QM2I+EIZ+\STJ6'C%7EN16NC:99 ?9M/M8B.Z1*#^
M?6KH  P!@#L*\VOOBHV\K8::-@Z/</R?^ CI^=9X^*.M9^:TL".^$<?^S5"P
M5>6K17UBDM+GJ<]E:72E;BUAF4]1)&&!_.N;U?X?Z+J2,UO%]AG[/!]W\5Z8
M^F/K67I7Q0M)Y5BU*S:U!X\V-MZCZC&0/IFN]CD26-9(W5XW 964Y!!Z$&LI
M1K4):W1:<*J[G@NO:!>^'K_[-=KE6YBE7[L@]O?U';\JRJ]R\9Z2FK>&;I-N
M9H%,T1QD@J,D#ZC(_&O#:]K!XAUH:[H\^O2]G+38]/\ AQI6G7WAZXEN["UN
M)!=LH>:%7(&Q.,D=.37<VFG6-AO^QV=O;;\;_)B5-V.F<#GJ:\D\+^-_^$:T
MR2S_ +/^T[YC+O\ .V8R%&,;3_=KT#PGXL_X2C[9_H7V;[/L_P"6N_=NW>PQ
M]W]:\[&4:RE*;^'U.JA4IV4>ITE9O_"/:)_T!]/_ / 5/\*TJ\V_X6Q_U!?_
M ":_^PKFHTJM2_LS:I.$?C,?XCV=K8^(;>*TMH;>,VBL4AC" G>_.!WX%8?A
MR*.?Q)IL4T:R1O<(&1UR&&>A%3^*/$/_  DNIQWGV7[-LA$6SS-^<%CG.!_>
MJ+PO_P C5I?_ %\I_.O:M*&&:ENDSS[J5:ZVN>T_\(]HG_0'T_\ \!4_PKS+
MQSI*GQ=;V&E6,:-+ FV&",*"V6YP..W7VKU^J:Z;;KJTNIE<W#Q+$&/\*@DX
M'U)Y^@KQZ&)E2ES/4[ZE)35CEM ^'6GV$:S:H%O+KKL/^K3VQ_%^/Y5V$%M;
MVL8CMX(H4 P%C0*!^ KCM<^)%AI\S6^GP_;95.&D#[8Q]#SN_#CWKG5^*6L>
M9EK.Q*9Y 5P<?7=_2M'0Q-?WVB/:4J?NH]/N].LK]-EW:03KZ21AOYUYSXM^
M'\=G:R:AH^_RXQNDMF.[:O<J>O'H?_K5U7A?QC:>(PT/EFWO$&XQ%LAAZJ>]
M=+64*E7#S[>1<HPJQ/G2TM)[ZZCM;6)I9Y6VHB]2:]4T#X<V%C&LVJ8O+G&2
MG_+-/P_B_'\JV=!\*V6A7E[=0@-)<2$H<8\J,\[!^/\ 3TK.\0?$#3]'G>UM
MHS>72':X5MJ(?0MW/L/TKKK8JIB)<E'8QIT84ES5#JK>UM[6,1VT$4*#HL:!
M1^E-N;*TO$*7-M#,IZB2,,/UKRYOBEK'F96SL0F> 5<G'UW?TKJ_#7CNSUV<
M6<\7V6\;[BEMRR?0^OL:Y:F$K4US21K&O3D[)E#Q'\.;6Y@>XT51!<CGR"WR
M2>PS]T_I].M>6.CQ2-'(K(ZDJRL,$$=017T?7DGQ+TM+/7(;V-0JWB$L!_?7
M )_(K79@,3)R]G-W[&&)HI+GB<3114UK;37EU%;6Z%YI6"(H[DUZS:2NSB2O
MH3:9IEWJ]\EG90F25N?91W)/85Z;HOPUTZTC635&-Y/@$HI*QJ?YG\?RKH/#
M?AZV\.Z8MO#AYGPTTV.7;_ =A_\ 7JQJVMZ?HEMY]_<+&#]Q>K.?8=Z\3$8R
MI5ERT]%^+/0I8>,%>>Y+:Z9862[;6RMX1_TSB"_RJTRJXPRAAZ$5YK??%20L
MRZ?IJA?X7N'R3]5'3\ZI1_%+6 X,EG8LO<*K@_GN-9K UY*]B_K%):7/0+_P
MKH>I*PN--@#-UDC78V?J,?K7GGB3X>W6EQO=Z:[W=JO+(1^\0>O'WA]/R[UT
MVC_$G3;Z18;^)K&1N Y;='^)ZC\1CWKM 0P!!!!&01WI1J5\-*ST\N@.%.LK
MH^;Z*[[XA>%DL9/[8LHPMO*V)T4<(YZ,/8_S^M<#7MT:T:T.>)Y]2#A+E85[
M_P#\(]HG_0'T_P#\!4_PKP"OI&N#,I-<MGW_ $.G").]SS+XBZ/;Q7&CP:9I
M\,<L[2KLMX0I<_)CH.>IJ_X?^&UK;QI/K)\^<\^0K81?J1RQ_3ZUV\EI!+>0
MW;QAIH%=8V/\(;&<?]\C]?6N?\0>.-,T*1K<9NKQ>L,9P%_WF[?3D^U<D<16
MG!4J9LZ5.,G.1O6NGV5B@2TM((%':.,+_*II88ITV31)(I[.H(KRN;XI:L9"
M8;*R1.P<.Q_,,/Y5JZ1\3X)IEBU6T%N#QYT1+*/JO7'TS2E@JZ7,T-8BFW9,
MV=8\ Z+J<;&" 65P1\KP#"_BG3\L?6O*M<T.\T#4#:7:CD;HY%^ZZ^H_PKWR
M.1)8UDC=7C<!E93D$'H0:YKQYI":GX:GE"CS[,&=&]A]X?E^H%7A<7.G-1D[
MIBK4(RC=;GBM>G_#C2M.OO#UQ+=V%K<2"[90\T*N0-B<9(Z<FO,*ZWPOXW_X
M1K3)+/\ L_[3OF,N_P [9C(48QM/]VO4Q<)SIVAN<5"48SO+8];M-.L;#?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ KUCX6_\ (O7?_7V?_0%KR>O6/A;_ ,B]=_\
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M5RT<#-U.:ML;5,3%0M3+]QXLU^Z;=)JUTI_Z9/Y8_)<4V#Q3KUN^]-7O"?\
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M HHHH **** "BBB@ HHHH **** "BBB@#VKX?_\ (EV7^])_Z&U=/7,?#_\
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M',_87OK8XC_A/O$W_03_ /($?_Q-<W117MQIPA\*L>?*4I;L];^%W_(LW/\
MU^-_Z E'Q1_Y%FV_Z_%_] >CX7?\BS<_]?C?^@)1\4?^19MO^OQ?_0'KQO\
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M *+:N>FB>WGDAD&'C8HP]P<&NA\ _P#([:?_ -M/_1;5[==WHR:[/\CSZ?\
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M111768!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(TZ;L?H/H?3!\P;Q3KSS^<=7O-V<X$I"_P#?(X_2KOCN\:[\7WGS92';$@]
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MM_P)_P D\\,_]@JU_P#12UT%<_X$_P"2>>&?^P5:_P#HI:Z"@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGO\ X>_Y%G2O^O.'_P! %-\1ZB=*\/7UZIQ)'$0A]&/"_J13O#W_ "+.E?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5<\(O91[#_Z]>[ZKIL6KZ9-83R21Q3 !FB(#8!!XR#Z5RO\ PJ[1/^?K4/\
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MWB7R_(]3#?PD?-U%%%?0GEA1110 4444 %%%% !1110 4444 %%%% !1110
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M[-7HX[_=Y?+\SEPW\5'IM%8_BH7!\+Z@UI-+#,D7F*\3%6&TAC@CV!%>,?\
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MEBVF:K=63$DP2L@)[@'@_B.:[SX4(#)JS]P(@/QW_P"%<WX\"CQIJ.WIF/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KUWX8_\ (KS?]?;_ /H*UY%7KOPQ_P"17F_Z^W_]
M!6N',/X/S.G"_P 0YWXI?\ARS_Z]O_9FKA*[OXI?\ARS_P"O;_V9JX2M<)_
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M?^$^\,_]!/\ \@2?_$T?\)]X9_Z"?_D"3_XFO$J*/[-I=W^'^0?6Y]D>V_\
M"?>&?^@G_P"0)/\ XFO+?%U_:ZIXHO+RSE\VWDV;'VE<X10>#@]0:Q**VH82
M%&7-%LBI7E45F%?2-?-U?2-<F:?8^?Z&^#^U\CS;XL?\PC_MM_[)7F]>D?%C
M_F$?]MO_ &2O-ZZ\#_N\?G^9AB?XK"BBBNLP/2/A/_S%_P#MC_[/7I->;?"?
M_F+_ /;'_P!GKTFOGL=_O$OE^1ZF&_A(^;J***^A/+/2/A/_ ,Q?_MC_ .SU
MZ37FWPG_ .8O_P!L?_9Z])KY['?[Q+Y?D>IAOX2/FZBBBOH3RPHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "I+?_CYB_P!\?SJ.I+?_ (^8O]\?
MSI/8:/HVBBBOE#V@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /G
MS6?^0YJ'_7S)_P"A&J-7M9_Y#FH?]?,G_H1JC7U,/A1XTMV%%%%62%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM#IHX?D?-+<S/$VI+I/AV]NBP5Q&4C]W/ _7G\*\$KJO&GBO_A(;Q8+;<MA
M3LSP9&_O$=O8?XXKE:[L#0=*%Y;LYL144Y:;([?X9:DMKKL]DYP+N/Y?=UR0
M/R+5ZAJ5C'J>FW-C+PD\90D=L]#^'6OGRWN);2YCN('*2Q,'1AV(Z5[GX:\1
M6WB+35FC95N$ $\.>4;_  /8UR9A1E&?M5L=&%J)QY&>)ZEIUSI-_+97<>R:
M,X/H1V(]0:J5[]K/A_3M>@$5]!N9?N2*<.GT/]#Q7'3_  I@:3-OJTD:>DD
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 >U?#_\ Y$NR_P!Z3_T-JZ>N8^'_ /R)=E_O2?\
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MXH_\BS;?]?B_^@/1\+O^19N?^OQO_0$H^*/_ "+-M_U^+_Z ]>5_S&_,[?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUBSMT:/G*BG.C1NR."&4D$'L:;7U5[GC'O\ X>_Y%G2O^O.'_P! %<W\4?\
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M.(SE,_[IZ?0$"KPV8*,5&ITZDU<*V^:!X_17I2_"A=^6UDE?06V#^>ZM_2/
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M9@%%%% !1110 4444 %%%% !1110 4444 %%%% !4EO_ ,?,7^^/YU'4EO\
M\?,7^^/YTGL-'T;1117RA[04444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'SYK/\ R'-0_P"OF3_T(U1J]K/_ "'-0_Z^9/\ T(U1KZF'PH\:6["B
MBBK)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"^6'A52"H^[U8<XX_"O-Z*WJ8:G4BHM:(SA5G%W3.N\:^)=+\2+:26<-U'/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&I'EDKHJ,G%W1[#9_$G0KA!]H,]JW</&6'X%<_RJ>?XA^'(8RR7<DY'\,<+
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M(BA?0@X8]C^@KA:**JE2C2CRQV)G-S=V%%%%:D'HWASXAV.F:%;65_#=R30
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MW_8*NO\ T4U?$%?,'L!1110!]O\ @3_DGGAG_L%6O_HI:Z"N?\"?\D\\,_\
M8*M?_12UT% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M7B'CK_D=-1_WD_\ 0%KV^O$/'7_(Z:C_ +R?^@+7HY;_ !7Z?Y'+B_@7J<[1
M117MGG!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9T#78;P@F%AY<P'4H>OY8!_"L:BNM8>FH."6C,'5FY<S9[;_ ,)]X9_Z"?\
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MOI<V$_G0B!4+;&7D%NQ />N9HK.C@J=&7-%LJIB)3CRL****[# ?"P2>-F.
M&!/YU[5_PGWAG_H)_P#D"3_XFO$J*Y:^%A7:<F]#:G6E35D=I\0==TW7)K!M
M.N?.$2N'_=LN,[<?> ]#7%T45K2I*E!0CLB)S<Y<S"BBBM2#V+3/''ARWTFS
M@EU';)' B./(D."% /\ #7/>/O$ND:UI%M!I]WYTB3[V7RW7 VD=P/6O/J*X
M:> ITY*2;T_KL=$L3.4>5A1117<<Y-:7=Q8W4=S:S/%-&<JZ'!%>AZ/\4 (U
MBUBU8L.//@ Y]RI_H?PKS:BL*V'IUE[R-:=64-CW2V\9>'KM<IJD">TN8_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7K'PM_Y%Z[_P"OL_\
MH"UY/7K'PM_Y%Z[_ .OL_P#H"UPYA_ 9TX7^(8GQ3_Y#%C_U[G_T(UP5=[\4
M_P#D,6/_ %[G_P!"-<%6F#_@1(K_ ,1A111748A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110![5\/_P#D2[+_ 'I/_0VKIZYCX?\ _(EV7^])_P"AM73U
M\SB/XTO5GL4O@7H%%%%8EA1110 4444 %%%% !1110 4444 %%%% !1110!Y
M/\4O^1AM/^O0?^AM7#5W/Q2_Y&&T_P"O0?\ H;5PU?1X3^!$\JO_ !&%%%%=
M)B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5ZE\*_^09J'_79?_0:\MKU+X5_\@S4/^NR_^@UQ8_\ @/Y'1AOXB*?Q7_UN
ME?[LO_LE><UZ-\5_];I7^[+_ .R5YS58'^!'^NHL1_%84445UF 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6WX/\ ^1NTS_KL/Y&L
M2MOP?_R-VF?]=A_(UE6_AR]&73^-'JWCO_DGGB;_ +!5U_Z*:OB"OM_QW_R3
MSQ-_V"KK_P!%-7Q!7S![ 4444 ?;_@3_ ))YX9_[!5K_ .BEKH*Y_P "?\D\
M\,_]@JU_]%+704 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7KOPQ_Y%>;_K[?
M_P!!6O(J]=^&/_(KS?\ 7V__ *"M<.8?P?F=.%_B'._%+_D.6?\ U[?^S-7"
M5W?Q2_Y#EG_U[?\ LS5PE:X3^!$BO_$84445TF(4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !4EO_Q\Q?[X_G4=26__ !\Q?[X_G2>PT?1M%%%?
M*'M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?/FL_\AS4/^OF3
M_P!"-4:O:S_R'-0_Z^9/_0C5&OJ8?"CQI;L****LD**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *]8^%O_ "+UW_U]G_T!:\GKUCX6_P#(O7?_ %]G_P! 6N',/X#.G"_Q#$^*
M?_(8L?\ KW/_ *$:X*N]^*?_ "&+'_KW/_H1K@JTP?\  B17_B,****ZC$**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** /:OA__P B79?[TG_H;5T]<Q\/
M_P#D2[+_ 'I/_0VKIZ^9Q'\:7JSV*7P+T"BBBL2PHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH \G^*7_(PVG_ %Z#_P!#:N&KN?BE_P C#:?]>@_]#:N&
MKZ/"?P(GE5_XC"BBBNDQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *]2^%?_(,U#_KLO\ Z#7EM>I?"O\ Y!FH?]=E_P#0
M:XL?_ ?R.C#?Q$4_BO\ ZW2O]V7_ -DKSFO1OBO_ *W2O]V7_P!DKSFJP/\
M C_746(_BL****ZS **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ K;\'_P#(W:9_UV'\C6)6WX/_ .1NTS_KL/Y&LJW\.7HRZ?QH]6\=
M_P#)//$W_8*NO_135\05]O\ CO\ Y)YXF_[!5U_Z*:OB"OF#V HHHH ^W_ G
M_)//#/\ V"K7_P!%+705S_@3_DGGAG_L%6O_ **6N@H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *\0\=?\ (Z:C_O)_Z M>WUXAXZ_Y
M'34?]Y/_ $!:]'+?XK]/\CEQ?P+U.=HHHKVSS@HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "GQ32P.'AD>-QT9&(-,H
MI-)Z,9HKX@UI1A=7OP/07+_XU!<:G?W:E;F^N9E/422LP_4U5HJ?9P[#YI=P
MHHHJR0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *[+X9_P#(U/\
M]>S_ ,UKC:[+X9_\C4__ %[/_-:Y\5_!EZ&M'^(CM/B+_P B?/\ ]=8_YUXS
M7LWQ%_Y$^?\ ZZQ_SKQFN?+OX/S-<7_$"BBBO0.4**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O7?AC_ ,BO-_U]
MO_Z"M>15Z[\,?^17F_Z^W_\ 05KAS#^#\SIPO\0YWXI?\ARS_P"O;_V9JX2N
M[^*7_(<L_P#KV_\ 9FKA*UPG\")%?^(PHHHKI,0HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "I+?_CYB_WQ_.HZDM_^/F+_ 'Q_.D]AH^C:***^
M4/:"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^?-9_Y#FH?]?,G
M_H1JC5[6?^0YJ'_7S)_Z$:HU]3#X4>-+=A1115DA1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M7K'PM_Y%Z[_Z^S_Z M>3UZQ\+?\ D7KO_K[/_H"UPYA_ 9TX7^(8GQ3_ .0Q
M8_\ 7N?_ $(UP5=[\4_^0Q8_]>Y_]"-<%6F#_@1(K_Q&%%%%=1B%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% 'M7P_P#^1+LO]Z3_ -#:NGKF/A__ ,B7
M9?[TG_H;5T]?,XC^-+U9[%+X%Z!1116)84444 %%%% !1110 4444 %%%% !
M1110 4444 >3_%+_ )&&T_Z]!_Z&U<-7<_%+_D8;3_KT'_H;5PU?1X3^!$\J
MO_$84445TF(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^P5=?^BFKX@K[?\ '?\ R3SQ-_V"KK_T4U?$%?,'L!1110!]O^!/^2>>&?\
ML%6O_HI:Z"N?\"?\D\\,_P#8*M?_ $4M=!0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKW]^S_[^G_"C_A6>O?W[/_OZ?\*/K5'^9![&IV.-HKLO^%9Z]_?L_P#OZ?\
M"C_A6>O?W[/_ +^G_"CZU1_F0>QJ=CC:*[+_ (5GKW]^S_[^G_"C_A6>O?W[
M/_OZ?\*/K5'^9![&IV.-HKLO^%9Z]_?L_P#OZ?\ "C_A6>O?W[/_ +^G_"CZ
MU1_F0>QJ=CC:*[+_ (5GKW]^S_[^G_"C_A6>O?W[/_OZ?\*/K5'^9![&IV.-
MHKLO^%9Z]_?L_P#OZ?\ "C_A6>O?W[/_ +^G_"CZU1_F0>QJ=CC:*[+_ (5G
MKW]^S_[^G_"C_A6>O?W[/_OZ?\*/K5'^9![&IV.-HKLO^%9Z]_?L_P#OZ?\
M"C_A6>O?W[/_ +^G_"CZU1_F0>QJ=CC:*[+_ (5GKW]^S_[^G_"C_A6>O?W[
M/_OZ?\*/K5'^9![&IV.-HKLO^%9Z]_?L_P#OZ?\ "C_A6>O?W[/_ +^G_"CZ
MU1_F0>QJ=CC:*[+_ (5GKW]^S_[^G_"C_A6>O?W[/_OZ?\*/K5'^9![&IV.-
MHKLO^%9Z]_?L_P#OZ?\ "C_A6>O?W[/_ +^G_"CZU1_F0>QJ=CC:*[+_ (5G
MKW]^S_[^G_"C_A6>O?W[/_OZ?\*/K5'^9![&IV.-HKLO^%9Z]_?L_P#OZ?\
M"C_A6>O?W[/_ +^G_"CZU1_F0>QJ=CC:*[+_ (5GKW]^S_[^G_"C_A6>O?W[
M/_OZ?\*/K5'^9![&IV.-HKLO^%9Z]_?L_P#OZ?\ "C_A6>O?W[/_ +^G_"CZ
MU1_F0>QJ=CC:*[+_ (5GKW]^S_[^G_"C_A6>O?W[/_OZ?\*/K5'^9![&IV.-
MHKLO^%9Z]_?L_P#OZ?\ "C_A6>O?W[/_ +^G_"CZU1_F0>QJ=CC:*[+_ (5G
MKW]^S_[^G_"C_A6>O?W[/_OZ?\*/K5'^9![&IV.-HKLO^%9Z]_?L_P#OZ?\
M"C_A6>O?W[/_ +^G_"CZU1_F0>QJ=CC:*[+_ (5GKW]^S_[^G_"C_A6>O?W[
M/_OZ?\*/K5'^9![&IV.-HKLO^%9Z]_?L_P#OZ?\ "C_A6>O?W[/_ +^G_"CZ
MU1_F0>QJ=CC:*[+_ (5GKW]^S_[^G_"C_A6>O?W[/_OZ?\*/K5'^9![&IV.-
MHKLO^%9Z]_?L_P#OZ?\ "C_A6>O?W[/_ +^G_"CZU1_F0>QJ=CC:*[+_ (5G
MKW]^S_[^G_"C_A6>O?W[/_OZ?\*/K5'^9![&IV.-HKLO^%9Z]_?L_P#OZ?\
M"C_A6>O?W[/_ +^G_"CZU1_F0>QJ=CC:*[+_ (5GKW]^S_[^G_"C_A6>O?W[
M/_OZ?\*/K5'^9![&IV.-HKLO^%9Z]_?L_P#OZ?\ "C_A6>O?W[/_ +^G_"CZ
MU1_F0>QJ=CC:*[+_ (5GKW]^S_[^G_"C_A6>O?W[/_OZ?\*/K5'^9![&IV.-
MHKLO^%9Z]_?L_P#OZ?\ "C_A6>O?W[/_ +^G_"CZU1_F0>QJ=CC:*[+_ (5G
MKW]^S_[^G_"C_A6>O?W[/_OZ?\*/K5'^9![&IV.-HKLO^%9Z]_?L_P#OZ?\
M"C_A6>O?W[/_ +^G_"CZU1_F0>QJ=CC:*[+_ (5GKW]^S_[^G_"C_A6>O?W[
M/_OZ?\*/K5'^9![&IV.-HKLO^%9Z]_?L_P#OZ?\ "C_A6>O?W[/_ +^G_"CZ
MU1_F0>QJ=CC:*[+_ (5GKW]^S_[^G_"C_A6>O?W[/_OZ?\*/K5'^9![&IV.-
MHKLO^%9Z]_?L_P#OZ?\ "C_A6>O?W[/_ +^G_"CZU1_F0>QJ=CC:*[+_ (5G
MKW]^S_[^G_"C_A6>O?W[/_OZ?\*/K5'^9![&IV.-HKLO^%9Z]_?L_P#OZ?\
M"C_A6>O?W[/_ +^G_"CZU1_F0>QJ=CC:*[+_ (5GKW]^S_[^G_"C_A6>O?W[
M/_OZ?\*/K5'^9![&IV.-HKLO^%9Z]_?L_P#OZ?\ "C_A6>O?W[/_ +^G_"CZ
MU1_F0>QJ=CC:*[+_ (5GKW]^S_[^G_"C_A6>O?W[/_OZ?\*/K5'^9![&IV.-
MKLOAG_R-3_\ 7L_\UH_X5GKW]^S_ ._I_P *Z'P;X-U30=;:\O&MS$863]VY
M)R2/;VK'$8BE*E)*1I2I34TVC3^(O_(GS_\ 76/^=>,U[KXMTBYUO0)+*T,8
ME9U8>8<#@UYY_P *SU[^_9_]_3_A6&!K4X4K2=M33$TY2G=(XVBNR_X5GKW]
M^S_[^G_"C_A6>O?W[/\ [^G_  KM^M4?YD<_L:G8XVBNR_X5GKW]^S_[^G_"
MC_A6>O?W[/\ [^G_  H^M4?YD'L:G8XVBNR_X5GKW]^S_P"_I_PH_P"%9Z]_
M?L_^_I_PH^M4?YD'L:G8XVBNR_X5GKW]^S_[^G_"C_A6>O?W[/\ [^G_  H^
MM4?YD'L:G8XVBNR_X5GKW]^S_P"_I_PH_P"%9Z]_?L_^_I_PH^M4?YD'L:G8
MXVBNR_X5GKW]^S_[^G_"C_A6>O?W[/\ [^G_  H^M4?YD'L:G8XVBNR_X5GK
MW]^S_P"_I_PH_P"%9Z]_?L_^_I_PH^M4?YD'L:G8XVBNR_X5GKW]^S_[^G_"
MC_A6>O?W[/\ [^G_  H^M4?YD'L:G8XVBNR_X5GKW]^S_P"_I_PH_P"%9Z]_
M?L_^_I_PH^M4?YD'L:G8XVBNR_X5GKW]^S_[^G_"C_A6>O?W[/\ [^G_  H^
MM4?YD'L:G8XVBNR_X5GKW]^S_P"_I_PH_P"%9Z]_?L_^_I_PH^M4?YD'L:G8
MXVBNR_X5GKW]^S_[^G_"C_A6>O?W[/\ [^G_  H^M4?YD'L:G8XVBNR_X5GK
MW]^S_P"_I_PH_P"%9Z]_?L_^_I_PH^M4?YD'L:G8XVBNR_X5GKW]^S_[^G_"
MC_A6>O?W[/\ [^G_  H^M4?YD'L:G8XVBNR_X5GKW]^S_P"_I_PH_P"%9Z]_
M?L_^_I_PH^M4?YD'L:G8XVBNR_X5GKW]^S_[^G_"C_A6>O?W[/\ [^G_  H^
MM4?YD'L:G8XVBNR_X5GKW]^S_P"_I_PH_P"%9Z]_?L_^_I_PH^M4?YD'L:G8
MXVBNR_X5GKW]^S_[^G_"C_A6>O?W[/\ [^G_  H^M4?YD'L:G8XVBNR_X5GK
MW]^S_P"_I_PH_P"%9Z]_?L_^_I_PH^M4?YD'L:G8XVBNR_X5GKW]^S_[^G_"
MC_A6>O?W[/\ [^G_  H^M4?YD'L:G8XVBNR_X5GKW]^S_P"_I_PH_P"%9Z]_
M?L_^_I_PH^M4?YD'L:G8XVBNR_X5GKW]^S_[^G_"C_A6>O?W[/\ [^G_  H^
MM4?YD'L:G8XVBNR_X5GKW]^S_P"_I_PH_P"%9Z]_?L_^_I_PH^M4?YD'L:G8
MXVBNR_X5GKW]^S_[^G_"C_A6>O?W[/\ [^G_  H^M4?YD'L:G8XVBNR_X5GK
MW]^S_P"_I_PH_P"%9Z]_?L_^_I_PH^M4?YD'L:G8XVBNR_X5GKW]^S_[^G_"
MC_A6>O?W[/\ [^G_  H^M4?YD'L:G8XVBNR_X5GKW]^S_P"_I_PH_P"%9Z]_
M?L_^_I_PH^M4?YD'L:G8XVBNR_X5GKW]^S_[^G_"C_A6>O?W[/\ [^G_  H^
MM4?YD'L:G8XVBNR_X5GKW]^S_P"_I_PH_P"%9Z]_?L_^_I_PH^M4?YD'L:G8
MXVBNR_X5GKW]^S_[^G_"C_A6>O?W[/\ [^G_  H^M4?YD'L:G8XVBNR_X5GK
MW]^S_P"_I_PH_P"%9Z]_?L_^_I_PH^M4?YD'L:G8XVBNR_X5GKW]^S_[^G_"
MC_A6>O?W[/\ [^G_  H^M4?YD'L:G8XVBNR_X5GKW]^S_P"_I_PH_P"%9Z]_
M?L_^_I_PH^M4?YD'L:G8XVBNR_X5GKW]^S_[^G_"C_A6>O?W[/\ [^G_  H^
MM4?YD'L:G8XVBNR_X5GKW]^S_P"_I_PH_P"%9Z]_?L_^_I_PH^M4?YD'L:G8
MXVBNR_X5GKW]^S_[^G_"C_A6>O?W[/\ [^G_  H^M4?YD'L:G8XVBNR_X5GK
MW]^S_P"_I_PH_P"%9Z]_?L_^_I_PH^M4?YD'L:G8XVBNR_X5GKW]^S_[^G_"
MC_A6>O?W[/\ [^G_  H^M4?YD'L:G8XVBNR_X5GKW]^S_P"_I_PH_P"%9Z]_
M?L_^_I_PH^M4?YD'L:G8XVBNR_X5GKW]^S_[^G_"C_A6>O?W[/\ [^G_  H^
MM4?YD'L:G8XVBNR_X5GKW]^S_P"_I_PH_P"%9Z]_?L_^_I_PH^M4?YD'L:G8
MXVBNR_X5GKW]^S_[^G_"C_A6>O?W[/\ [^G_  H^M4?YD'L:G8XVBNR_X5GK
MW]^S_P"_I_PH_P"%9Z]_?L_^_I_PH^M4?YD'L:G8XVBNR_X5GKW]^S_[^G_"
MC_A6>O?W[/\ [^G_  H^M4?YD'L:G8XVBNR_X5GKW]^S_P"_I_PH_P"%9Z]_
M?L_^_I_PH^M4?YD'L:G8XVBNR_X5GKW]^S_[^G_"C_A6>O?W[/\ [^G_  H^
MM4?YD'L:G8XVBNR_X5GKW]^S_P"_I_PH_P"%9Z]_?L_^_I_PH^M4?YD'L:G8
MXVO7?AC_ ,BO-_U]O_Z"M<I_PK/7O[]G_P!_3_A7>^#-$N] T62TO#&9&G:0
M>6V1@A1Z>U<>.KTYTK1=S?#TYQG=HXOXI?\ (<L_^O;_ -F:N$KUCQMX2U+Q
M!J=O<630!(X=C>8Y!SDGT]ZYG_A6>O?W[/\ [^G_  K7"XBE&C%.6I%:E-S;
M2.-HKLO^%9Z]_?L_^_I_PH_X5GKW]^S_ ._I_P *W^M4?YD9^QJ=CC:*[+_A
M6>O?W[/_ +^G_"C_ (5GKW]^S_[^G_"CZU1_F0>QJ=CC:*[+_A6>O?W[/_OZ
M?\*/^%9Z]_?L_P#OZ?\ "CZU1_F0>QJ=CC:*[+_A6>O?W[/_ +^G_"C_ (5G
MKW]^S_[^G_"CZU1_F0>QJ=CC:*[+_A6>O?W[/_OZ?\*/^%9Z]_?L_P#OZ?\
M"CZU1_F0>QJ=CC:*[+_A6>O?W[/_ +^G_"C_ (5GKW]^S_[^G_"CZU1_F0>Q
MJ=CC:*[+_A6>O?W[/_OZ?\*/^%9Z]_?L_P#OZ?\ "CZU1_F0>QJ=CC:*[+_A
M6>O?W[/_ +^G_"C_ (5GKW]^S_[^G_"CZU1_F0>QJ=CC:*[+_A6>O?W[/_OZ
M?\*/^%9Z]_?L_P#OZ?\ "CZU1_F0>QJ=CC:*[+_A6>O?W[/_ +^G_"C_ (5G
MKW]^S_[^G_"CZU1_F0>QJ=CC:*[+_A6>O?W[/_OZ?\*/^%9Z]_?L_P#OZ?\
M"CZU1_F0>QJ=CC:*[+_A6>O?W[/_ +^G_"C_ (5GKW]^S_[^G_"CZU1_F0>Q
MJ=CC:*[+_A6>O?W[/_OZ?\*/^%9Z]_?L_P#OZ?\ "CZU1_F0>QJ=CC:*[+_A
M6>O?W[/_ +^G_"C_ (5GKW]^S_[^G_"CZU1_F0>QJ=CC:*[+_A6>O?W[/_OZ
M?\*/^%9Z]_?L_P#OZ?\ "CZU1_F0>QJ=CC:*[+_A6>O?W[/_ +^G_"C_ (5G
MKW]^S_[^G_"CZU1_F0>QJ=CC:*[+_A6>O?W[/_OZ?\*/^%9Z]_?L_P#OZ?\
M"CZU1_F0>QJ=CC:*[+_A6>O?W[/_ +^G_"C_ (5GKW]^S_[^G_"CZU1_F0>Q
MJ=CC:*[+_A6>O?W[/_OZ?\*/^%9Z]_?L_P#OZ?\ "CZU1_F0>QJ=CC:*[+_A
M6>O?W[/_ +^G_"C_ (5GKW]^S_[^G_"CZU1_F0>QJ=CC:*[+_A6>O?W[/_OZ
M?\*/^%9Z]_?L_P#OZ?\ "CZU1_F0>QJ=CC:*[+_A6>O?W[/_ +^G_"C_ (5G
MKW]^S_[^G_"CZU1_F0>QJ=CC:*[+_A6>O?W[/_OZ?\*/^%9Z]_?L_P#OZ?\
M"CZU1_F0>QJ=CC:*[+_A6>O?W[/_ +^G_"C_ (5GKW]^S_[^G_"CZU1_F0>Q
MJ=CC:*[+_A6>O?W[/_OZ?\*/^%9Z]_?L_P#OZ?\ "CZU1_F0>QJ=CC:*[+_A
M6>O?W[/_ +^G_"C_ (5GKW]^S_[^G_"CZU1_F0>QJ=CC:*[+_A6>O?W[/_OZ
M?\*/^%9Z]_?L_P#OZ?\ "CZU1_F0>QJ=CC:*[+_A6>O?W[/_ +^G_"C_ (5G
MKW]^S_[^G_"CZU1_F0>QJ=CC:*[+_A6>O?W[/_OZ?\*/^%9Z]_?L_P#OZ?\
M"CZU1_F0>QJ=CC:*[+_A6>O?W[/_ +^G_"C_ (5GKW]^S_[^G_"CZU1_F0>Q
MJ=CC:*[+_A6>O?W[/_OZ?\*/^%9Z]_?L_P#OZ?\ "CZU1_F0>QJ=CC:*[+_A
M6>O?W[/_ +^G_"C_ (5GKW]^S_[^G_"CZU1_F0>QJ=CC:*[+_A6>O?W[/_OZ
M?\*/^%9Z]_?L_P#OZ?\ "CZU1_F0>QJ=CC:*[+_A6>O?W[/_ +^G_"C_ (5G
MKW]^S_[^G_"CZU1_F0>QJ=CC:*[+_A6>O?W[/_OZ?\*/^%9Z]_?L_P#OZ?\
M"CZU1_F0>QJ=CC:*[+_A6>O?W[/_ +^G_"C_ (5GKW]^S_[^G_"CZU1_F0>Q
MJ=CC:*[+_A6>O?W[/_OZ?\*/^%9Z]_?L_P#OZ?\ "CZU1_F0>QJ=CC:*[+_A
M6>O?W[/_ +^G_"C_ (5GKW]^S_[^G_"CZU1_F0>QJ=CC:*[+_A6>O?W[/_OZ
M?\*/^%9Z]_?L_P#OZ?\ "CZU1_F0>QJ=CC:*[+_A6>O?W[/_ +^G_"C_ (5G
MKW]^S_[^G_"CZU1_F0>QJ=CC:*[+_A6>O?W[/_OZ?\*/^%9Z]_?L_P#OZ?\
M"CZU1_F0>QJ=CC:*[+_A6>O?W[/_ +^G_"C_ (5GKW]^S_[^G_"CZU1_F0>Q
MJ=CC:*[+_A6>O?W[/_OZ?\*/^%9Z]_?L_P#OZ?\ "CZU1_F0>QJ=CC:*[+_A
M6>O?W[/_ +^G_"C_ (5GKW]^S_[^G_"CZU1_F0>QJ=CC:*[+_A6>O?W[/_OZ
M?\*/^%9Z]_?L_P#OZ?\ "CZU1_F0>QJ=CC:*[+_A6>O?W[/_ +^G_"C_ (5G
MKW]^S_[^G_"CZU1_F0>QJ=CC:*[+_A6>O?W[/_OZ?\*/^%9Z]_?L_P#OZ?\
M"CZU1_F0>QJ=CC:*[+_A6>O?W[/_ +^G_"C_ (5GKW]^S_[^G_"CZU1_F0>Q
MJ=CC:*[+_A6>O?W[/_OZ?\*/^%9Z]_?L_P#OZ?\ "CZU1_F0>QJ=CC:*[+_A
M6>O?W[/_ +^G_"C_ (5GKW]^S_[^G_"CZU1_F0>QJ=CC:*[+_A6>O?W[/_OZ
M?\*/^%9Z]_?L_P#OZ?\ "CZU1_F0>QJ=CC:*[+_A6>O?W[/_ +^G_"C_ (5G
MKW]^S_[^G_"CZU1_F0>QJ=CC:*[+_A6>O?W[/_OZ?\*/^%9Z]_?L_P#OZ?\
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M]_3_ (4?\*SU[^_9_P#?T_X4?6J/\R#V-3L<;179?\*SU[^_9_\ ?T_X4?\
M"L]>_OV?_?T_X4?6J/\ ,@]C4['&T5V7_"L]>_OV?_?T_P"%'_"L]>_OV?\
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M*SU[^_9_]_3_ (4?\*SU[^_9_P#?T_X4?6J/\R#V-3L<;179?\*SU[^_9_\
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MO[]G_P!_3_A1]:H_S(/8U.QQM%=E_P *SU[^_9_]_3_A1_PK/7O[]G_W]/\
MA1]:H_S(/8U.QQM%=E_PK/7O[]G_ -_3_A1_PK/7O[]G_P!_3_A1]:H_S(/8
MU.QQM%=E_P *SU[^_9_]_3_A1_PK/7O[]G_W]/\ A1]:H_S(/8U.QQM%=E_P
MK/7O[]G_ -_3_A1_PK/7O[]G_P!_3_A1]:H_S(/8U.QQM%=E_P *SU[^_9_]
M_3_A1_PK/7O[]G_W]/\ A1]:H_S(/8U.QQM%=E_PK/7O[]G_ -_3_A1_PK/7
MO[]G_P!_3_A1]:H_S(/8U.QQM%=E_P *SU[^_9_]_3_A1_PK/7O[]G_W]/\
MA1]:H_S(/8U.QQM%=E_PK/7O[]G_ -_3_A1_PK/7O[]G_P!_3_A1]:H_S(/8
MU.QQM%=E_P *SU[^_9_]_3_A1_PK/7O[]G_W]/\ A1]:H_S(/8U.QQM%=E_P
MK/7O[]G_ -_3_A1_PK/7O[]G_P!_3_A1]:H_S(/8U.QQM%=E_P *SU[^_9_]
M_3_A1_PK/7O[]G_W]/\ A1]:H_S(/8U.QQM%=E_PK/7O[]G_ -_3_A1_PK/7
MO[]G_P!_3_A1]:H_S(/8U.QQM%=E_P *SU[^_9_]_3_A1_PK/7O[]G_W]/\
MA1]:H_S(/8U.QQM%=E_PK/7O[]G_ -_3_A1_PK/7O[]G_P!_3_A1]:H_S(/8
MU.QQM%=E_P *SU[^_9_]_3_A1_PK/7O[]G_W]/\ A1]:H_S(/8U.QQM%=E_P
MK/7O[]G_ -_3_A1_PK/7O[]G_P!_3_A1]:H_S(/8U.QQM%=E_P *SU[^_9_]
M_3_A1_PK/7O[]G_W]/\ A1]:H_S(/8U.QQM%=E_PK/7O[]G_ -_3_A1_PK/7
MO[]G_P!_3_A1]:H_S(/8U.QQM%=E_P *SU[^_9_]_3_A1_PK/7O[]G_W]/\
MA1]:H_S(/8U.QQM%=E_PK/7O[]G_ -_3_A1_PK/7O[]G_P!_3_A1]:H_S(/8
MU.QQM%=E_P *SU[^_9_]_3_A1_PK/7O[]G_W]/\ A1]:H_S(/8U.QQM%=E_P
MK/7O[]G_ -_3_A1_PK/7O[]G_P!_3_A1]:H_S(/8U.QQM%=E_P *SU[^_9_]
M_3_A1_PK/7O[]G_W]/\ A1]:H_S(/8U.QQM%=E_PK/7O[]G_ -_3_A1_PK/7
MO[]G_P!_3_A1]:H_S(/8U.QQM%=E_P *SU[^_9_]_3_A1_PK/7O[]G_W]/\
MA1]:H_S(/8U.QQM%=E_PK/7O[]G_ -_3_A1_PK/7O[]G_P!_3_A1]:H_S(/8
MU.QQM%=E_P *SU[^_9_]_3_A1_PK/7O[]G_W]/\ A1]:H_S(/8U.QQM%=E_P
MK/7O[]G_ -_3_A1_PK/7O[]G_P!_3_A1]:H_S(/8U.QQM%=E_P *SU[^_9_]
M_3_A1_PK/7O[]G_W]/\ A1]:H_S(/8U.QQM%=E_PK/7O[]G_ -_3_A1_PK/7
MO[]G_P!_3_A1]:H_S(/8U.QQM%=E_P *SU[^_9_]_3_A1_PK/7O[]G_W]/\
MA1]:H_S(/8U.QQM%=E_PK/7O[]G_ -_3_A1_PK/7O[]G_P!_3_A1]:H_S(/8
MU.QQM%=E_P *SU[^_9_]_3_A1_PK/7O[]G_W]/\ A1]:H_S(/8U.QQM%=E_P
MK/7O[]G_ -_3_A1_PK/7O[]G_P!_3_A1]:H_S(/8U.QQM%=E_P *SU[^_9_]
M_3_A1_PK/7O[]G_W]/\ A1]:H_S(/8U.QQM%=E_PK/7O[]G_ -_3_A1_PK/7
MO[]G_P!_3_A1]:H_S(/8U.QQM%=E_P *SU[^_9_]_3_A1_PK/7O[]G_W]/\
MA1]:H_S(/8U.QQM%=E_PK/7O[]G_ -_3_A1_PK/7O[]G_P!_3_A1]:H_S(/8
MU.QQM%=E_P *SU[^_9_]_3_A1_PK/7O[]G_W]/\ A1]:H_S(/8U.QQM%=E_P
MK/7O[]G_ -_3_A1_PK/7O[]G_P!_3_A1]:H_S(/8U.QQM%=E_P *SU[^_9_]
M_3_A1_PK/7O[]G_W]/\ A1]:H_S(/8U.QQM%=E_PK/7O[]G_ -_3_A1_PK/7
MO[]G_P!_3_A1]:H_S(/8U.QQM%=E_P *SU[^_9_]_3_A1_PK/7O[]G_W]/\
MA1]:H_S(/8U.QQM%=E_PK/7O[]G_ -_3_A1_PK/7O[]G_P!_3_A1]:H_S(/8
MU.QQM%=E_P *SU[^_9_]_3_A1_PK/7O[]G_W]/\ A1]:H_S(/8U.QQM%=E_P
MK/7O[]G_ -_3_A1_PK/7O[]G_P!_3_A1]:H_S(/8U.QQM%=E_P *SU[^_9_]
M_3_A1_PK/7O[]G_W]/\ A1]:H_S(/8U.QQM%=E_PK/7O[]G_ -_3_A1_PK/7
MO[]G_P!_3_A1]:H_S(/8U.QQM%=E_P *SU[^_9_]_3_A1_PK/7O[]G_W]/\
MA1]:H_S(/8U.QQM%=E_PK/7O[]G_ -_3_A1_PK/7O[]G_P!_3_A1]:H_S(/8
MU.QQM%=E_P *SU[^_9_]_3_A1_PK/7O[]G_W]/\ A1]:H_S(/8U.QQM%=E_P
MK/7O[]G_ -_3_A1_PK/7O[]G_P!_3_A1]:H_S(/8U.QQM%=E_P *SU[^_9_]
M_3_A1_PK/7O[]G_W]/\ A1]:H_S(/8U.QQM%=E_PK/7O[]G_ -_3_A1_PK/7
MO[]G_P!_3_A1]:H_S(/8U.QQM%=E_P *SU[^_9_]_3_A1_PK/7O[]G_W]/\
MA1]:H_S(/8U.QQM%=E_PK/7O[]G_ -_3_A1_PK/7O[]G_P!_3_A1]:H_S(/8
MU.QQM%=E_P *SU[^_9_]_3_A1_PK/7O[]G_W]/\ A1]:H_S(/8U.QQM%=E_P
MK/7O[]G_ -_3_A1_PK/7O[]G_P!_3_A1]:H_S(/8U.QQM%=E_P *SU[^_9_]
M_3_A1_PK/7O[]G_W]/\ A1]:H_S(/8U.QQM%=E_PK/7O[]G_ -_3_A1_PK/7
MO[]G_P!_3_A1]:H_S(/8U.QQM%=E_P *SU[^_9_]_3_A1_PK/7O[]G_W]/\
MA1]:H_S(/8U.QQM%=E_PK/7O[]G_ -_3_A1_PK/7O[]G_P!_3_A1]:H_S(/8
MU.QQM%=E_P *SU[^_9_]_3_A1_PK/7O[]G_W]/\ A1]:H_S(/8U.QQM%=E_P
MK/7O[]G_ -_3_A1_PK/7O[]G_P!_3_A1]:H_S(/8U.QQM%=E_P *SU[^_9_]
M_3_A1_PK/7O[]G_W]/\ A1]:H_S(/8U.QQM%=E_PK/7O[]G_ -_3_A1_PK/7
MO[]G_P!_3_A1]:H_S(/8U.QQM%=E_P *SU[^_9_]_3_A1_PK/7O[]G_W]/\
MA1]:H_S(/8U.QQM%=E_PK/7O[]G_ -_3_A1_PK/7O[]G_P!_3_A1]:H_S(/8
MU.QQM%=E_P *SU[^_9_]_3_A1_PK/7O[]G_W]/\ A1]:H_S(/8U.QQM%=E_P
MK/7O[]G_ -_3_A1_PK/7O[]G_P!_3_A1]:H_S(/8U.QQM%=E_P *SU[^_9_]
M_3_A1_PK/7O[]G_W]/\ A1]:H_S(/8U.QQM%=E_PK/7O[]G_ -_3_A1_PK/7
MO[]G_P!_3_A1]:H_S(/8U.QQM%=E_P *SU[^_9_]_3_A1_PK/7O[]G_W]/\
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MY^E4*FM?]=^%)I!<MNX1=S=*C^TQ^_Y47/\ J3]:I4)7 N_:8_?\J/M,?O\
ME5*BGRH+EW[3'[_E1]IC]_RJE11RH+EW[3'[_E1]IC]_RJE11RH+EW[3'[_E
M1]IC]_RJE11RH+EW[3'[_E1]IC]_RJE11RH+EW[3'[_E1]IC]_RJE11RH+EW
M[3'[_E1]IC]_RJE11RH+EW[3'[_E1]IC]_RJE11RH+EW[3'[_E1]IC]_RJE1
M1RH+EW[3'[_E1]IC]_RJE11RH+EW[3'[_E1]IC]_RJE11RH+EW[3'[_E1]IC
M]_RJE11RH+EW[3'[_E1]IC]_RJE11RH+EW[3'[_E1]IC]_RJE11RH+EW[3'[
M_E1]IC]_RJE11RH+EW[3'[_E1]IC]_RJE11RH+EW[3'[_E1]IC]_RJE11RH+
MEW[3'[_E1]IC]_RJE11RH+EW[3'[_E1]IC]_RJE11RH+EW[3'[_E1]IC]_RJ
ME11RH+EW[3'[_E1]IC]_RJE11RH+EW[3'[_E1]IC]_RJE11RH+EW[3'[_E1]
MIC]_RJE11RH+EW[3'[_E1]IC]_RJE11RH+EW[3'[_E1]IC]_RJE11RH+EW[3
M'[_E1]IC]_RJE11RH+EW[3'[_E1]IC]_RJE11RH+EW[3'[_E1]IC]_RJE11R
MH+EW[3'[_E1]IC]_RJE11RH+EW[3'[_E1]IC]_RJE11RH+EW[3'[_E1]IC]_
MRJE11RH+EW[3'[_E1]IC]_RJE11RH+EW[3'[_E1]IC]_RJE11RH+EW[3'[_E
M1]IC]_RJE11RH+EW[3'[_E1]IC]_RJE11RH+EW[3'[_E1]IC]_RJE11RH+EW
M[3'[_E1]IC]_RJE11RH+EW[3'[_E1]IC]_RJE11RH+EW[3'[_E1]IC]_RJE1
M1RH+EW[3'[_E1]IC]_RJE11RH+EW[3'[_E1]IC]_RJE11RH+EW[3'[_E1]IC
M]_RJE11RH+EW[3'[_E1]IC]_RJE11RH+EW[3'[_E1]IC]_RJE11RH+EW[3'[
M_E1]IC]_RJE11RH+EW[3'[_E1]IC]_RJE11RH+EW[3'[_E1]IC]_RJE11RH+
MEW[3'[_E4B.LBY7I6=5RU_U1^M)JP$CS+&<-GFF?:8_?\JBN_P#6+]*KT)(+
MEW[3'[_E1]IC]_RJE13Y4%R[]IC]_P J/M,?O^54J*.5!<N_:8_?\J/M,?O^
M54J*.5!<N_:8_?\ *C[3'[_E5*BCE07+OVF/W_*C[3'[_E5*BCE07+OVF/W_
M "H^TQ^_Y52HHY4%R[]IC]_RH^TQ^_Y52HHY4%R[]IC]_P J/M,?O^54J*.5
M!<N_:8_?\J/M,?O^54J*.5!<N_:8_?\ *C[3'[_E5*BCE07+OVF/W_*C[3'[
M_E5*BCE07+OVF/W_ "H^TQ^_Y52HHY4%R[]IC]_RH^TQ^_Y52HHY4%R[]IC]
M_P J/M,?O^54J*.5!<N_:8_?\J/M,?O^54J*.5!<N_:8_?\ *C[3'[_E5*BC
ME07+OVF/W_*C[3'[_E5*BCE07+OVF/W_ "H^TQ^_Y52HHY4%R[]IC]_RH^TQ
M^_Y52HHY4%R[]IC]_P J/M,?O^54J*.5!<N_:8_?\J/M,?O^54J*.5!<N_:8
M_?\ *C[3'[_E5*BCE07+OVF/W_*C[3'[_E5*BCE07+OVF/W_ "H^TQ^_Y52H
MHY4%R[]IC]_RH^TQ^_Y52HHY4%R[]IC]_P J/M,?O^54J*.5!<N_:8_?\J/M
M,?O^54J*.5!<N_:8_?\ *C[3'[_E5*BCE07+OVF/W_*C[3'[_E5*BCE07+OV
MF/W_ "H^TQ^_Y52HHY4%R[]IC]_RH^TQ^_Y52HHY4%R[]IC]_P J/M,?O^54
MJ*.5!<N_:8_?\J/M,?O^54J*.5!<N_:8_?\ *C[3'[_E5*BCE07+OVF/W_*C
M[3'[_E5*BCE07+OVF/W_ "H^TQ^_Y52HHY4%R[]IC]_RH^TQ^_Y52HHY4%R[
M]IC]_P J/M,?O^54J*.5!<N_:8_?\J/M,?O^54J*.5!<N_:8_?\ *C[3'[_E
M5*BCE07+OVF/W_*C[3'[_E5*BCE07+OVF/W_ "H^TQ^_Y52HHY4%R[]IC]_R
MH^TQ^_Y52HHY4%R[]IC]_P J/M,?O^54J*.5!<N_:8_?\J/M,?O^54J*.5!<
MN_:8_?\ *C[3'[_E5*BCE07+OVF/W_*C[3'[_E5*BCE07+OVF/W_ "H^TQ^_
MY52HHY4%R[]IC]_RH^TQ^_Y52HHY4%R[]IC]_P J/M,?O^54J*.5!<N_:8_?
M\J/M,?O^54J*.5!<N_:8_?\ *C[3'[_E5*BCE07+OVF/W_*C[3'[_E5*BCE0
M7+OVF/W_ "H^TQ^_Y52HHY4%R[]IC]_RH^TQ^_Y52I1U%'*@N:5%%%0,****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"(W$8)!SQ[4GVF/W_*JC_Z
MQOJ:;5\J%<N_:8_?\J/M,?O^54J*.5!<N_:8_?\ *C[3'[_E5*BCE07+OVF/
MW_*C[3'[_E5*BCE07+OVF/W_ "H^TQ^_Y52HHY4%R[]IC]_RH^TQ^_Y52HHY
M4%R[]IC]_P J/M,?O^54J*.5!<N_:8_?\J/M,?O^54J*.5!<N_:8_?\ *C[3
M'[_E5*BCE07+OVF/W_*C[3'[_E5*BCE07+OVF/W_ "H^TQ^_Y52HHY4%R[]I
MC]_RH^TQ^_Y52HHY4%R[]IC]_P J/M,?O^54J*.5!<N_:8_?\J/M,?O^54J*
M.5!<N_:8_?\ *C[3'[_E5*BCE07+OVF/W_*C[3'[_E5*BCE07+OVF/W_ "H^
MTQ^_Y52HHY4%R[]IC]_RH^TQ^_Y52HHY4%R[]IC]_P J/M,?O^54J*.5!<N_
M:8_?\J/M,?O^54J*.5!<N_:8_?\ *C[3'[_E5*BCE07+OVF/W_*C[3'[_E5*
MBCE07+OVF/W_ "H^TQ^_Y52HHY4%R[]IC]_RH^TQ^_Y52HHY4%R[]IC]_P J
M/M,?O^54J*.5!<N_:8_?\J/M,?O^54J*.5!<N_:8_?\ *C[3'[_E5*BCE07+
MOVF/W_*C[3'[_E5*BCE07+OVF/W_ "H^TQ^_Y52HHY4%R[]IC]_RH^TQ^_Y5
M2HHY4%R[]IC]_P J/M,?O^54J*.5!<N_:8_?\J/M,?O^54J*.5!<N_:8_?\
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M[]IC]_RH^TQ^_P"54J*.5!<N_:8_?\J/M,?O^54J*.5!<N_:8_?\J/M,?O\
ME5*BCE07+OVF/W_*C[3'[_E5*BCE07+OVF/W_*C[3'[_ )52HHY4%R[]IC]_
MRIZ2+("5[5GU;M/NM]:36@$LDJQXW9YIGVF/W_*H[OJGXU6H25@N7?M,?O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J:U_UWX5
M#4UK_KOPH>P$]S_J3]:I5=N?]2?K5*E'8;"BBBF(**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "KEK_JC]:IU<M?]
M4?K2EL-$=W_K%^E5ZL7?^L7Z57IK8&%%%% @HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "E'44E*.HH TJ***S*"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH SG_UC?4TVG/\ ZQOJ:;6A(4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %7+3_5M]:IU<M/]6WUI2V&B.[^^OTJO5B[^^OTJO36P,****!!1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!>M_]0OXU+45O_J%_&I:A[E!1112
M **** "BBB@ HHHH **** "BBB@ HHHH **** *=W_K!]*@J>[_U@^E05HMA
M!1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ JW:?=;ZU4JW:?=;ZTI;#0V[ZI^-5JLW?5/QJM0M@84444Q!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %20_ZY?K4=20_ZY?K0
M!G>._P#DGGB;_L%77_HIJ^(*^W_'?_)//$W_ &"KK_T4U?$%9E!1110!]O\
M@3_DGGAG_L%6O_HI:Z"N?\"?\D\\,_\ 8*M?_12UT% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !5"?_ %[5?JA/_KVJH[B9'1115""B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "I
MK7_7?A4-36O^N_"A[ 3W/^I/UJE5VY_U)^M4J4=AL****8@HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *N6O^J/U
MJG5RU_U1^M*6PT1W?^L7Z57JQ=_ZQ?I5>FM@84444""BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *4=124HZB@#2HHHK,H**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#.?_6-]33:<_P#K&^IIM:$A1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5<M/]6WUJG5RT_U;?6E+8:([O[Z_2J]6+O[Z_2J]-; PHHH
MH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% %ZW_U"_C4M16_^H7\:EJ'
MN4%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH IW?^L'TJ"I[O_6#
MZ5!6BV$%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "K=I]UOK52K=I]UOK2EL-#;OJGXU6JS=]4_&JU"V!A1113$%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5)#_KE^M1U)
M#_KE^M &=X[_ .2>>)O^P5=?^BFKX@K[?\=_\D\\3?\ 8*NO_135\05F4%%%
M% 'V_P"!/^2>>&?^P5:_^BEKH*Y_P)_R3SPS_P!@JU_]%+704 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M116'K'BFQTB1K<[I[L+GRD'"Y!(W-T'0>IY!QBHG4C3CS2=D73ISJ2Y8*[-R
MBLW0+Z?4M$MKNY\OSI V_P I2JY#$< DD=/6M*G"2G%26S%.+A)Q>Z"BBBJ)
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *H3_Z]JOU0G_U[54=Q,CHHHJA!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !15+5M4MM%TN?4+LN((0"VQ=Q))   ]22!Z<\X%8.C?$#2=;U6'3
MK:WO4FFW;6D1 HPI8YPQ[#TIV871U=%%%( HHHH **** "BBB@ HHKE-3^(O
MAW3F*)<O>R!@"MHH< $9SN)"D=!P2<GZX=KA<ZNBN%_X6MH6/^/34?\ OVG_
M ,75K3_B7X>OIC'*]Q9$LJH;F,;6)..JE@ .Y; Y^N'RL7,CL**9%+'/"DT,
MBR12*&1T.58'D$$=13ZD84444 %%%<WK'CK0=&>2*6Z-Q<Q]8+9=[9W;2,\*
M",'()!X^E,#I**X4?%;0\?\ 'IJ0_P"V<?\ \74MK\4?#T\S),M[:H%W>9+"
M&!/'&$+'/X8XI\K%S([6BHK:ZM[RW6XM9XIX6SMDB<,IP<'!''4$5+4C"BBB
M@ HHK#UGQ?HFA.T5Y> W*J3]GB!=\@ @''"DY&-Q .:8&Y17"CXKZ&1S9ZD/
MK''_ /%T^#XIZ!-<)%)%?0(V<S21*57CN%8M[< ]:?*Q<R.WHJIIVIV6K6BW
M5A<QW$)Q\R'[IP#@CJIP1P<$9JW2&%%%%( HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *FM?]=^%0U-:_P"N
M_"A[ 3W/^I/UJE5VY_U)^M4J4=AL****8@HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %7+7_5'ZU3JY:_ZH_6E+8:([O_6+]*KU8N_]8OTJ
MO36P,****!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %*.HI*4
M=10!I4445F4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!G/_K&^
MIIM.?_6-]33:T)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JY:?ZMOK5.KEI_JV^M*6
MPT1W?WU^E5ZL7?WU^E5Z:V!A1110(**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** +UO_J%_&I:BM_]0OXU+4/<H****0!1110 4444 %%%% !1110 4444
M %%%% !1110!3N_]8/I4%3W?^L'TJ"M%L(****!!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %6[3[K?6JE6[3[K?6E+8:&
MW?5/QJM5F[ZI^-5J%L#"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ J2'_ %R_6HZDA_UR_6@#.\=_\D\\3?\ 8*NO_135\05]
MO^._^2>>)O\ L%77_HIJ^(*S*"BBB@#[?\"?\D\\,_\ 8*M?_12UT%<_X$_Y
M)YX9_P"P5:_^BEKH* "BBB@ HHHH **** "BBB@ HHHH **** "BBFR21PQ/
M+*ZI&BEF=C@*!U)/84 0WUY%I]C-=SG]W$I8@$ MZ 9(&2>![FO.3XNUQF+?
M:U7)SM6)<#V&03CZDTOB3Q"=<G6*)-ME"^Z+<OS.V"-YSRO!( ZX//)P,.O
MQV-E*?+2=DNW4^BP&!C&'-5C=OOT-K_A+=<_Y_O_ "$G^%>GUXM7M-=.5U)S
MY^=M[;_,Y<VI0I\G)%+?;Y!1117K'CA169KFM0:)8F:0"29LB&'=@R-]>P'<
MXX]R0#PUUXQUJYD#17$=JJLQ"0Q*<@G@,7!R0.XVYR>.F.6OC*5%VD]3KP^"
MK5U>*T[GIE%>8#Q9KF/^/[/_ &R3_P")IT'B_7(96=KM)P5P$FA7:#QS\H4Y
M_''-<ZS2@WL_Z^9TO*:Z6Z_KY'IM%<]HGBVTU>Y%H\;6UTRED1F!63&<A6[D
M  D$#OC(!(Z&N^G4C4CS0=T>=4ISIRY9JS,?Q3))#X<NI(I9(I%*$/&Y5A\Z
M]QS7EH 4    = *W]1\67^IV$EG-%;+')C)16!X(/<^U8-?.X_$1KU$X;6/I
M<OP\Z%-QGO<]/\)?\BQ9_P# _P#T-JVJ\TT[Q9?Z981V<,5LT<><%U8GDD]C
M[UV7AK5I]8TZ2XN$C5UF* 1@@8P#W)]:];!XNG.,:2W2_(\C&X2K"4JKV;_,
MV:***[SS@HHHH *Y[Q1KMUHOV7[-'"_G;]WF G&-N,8(]:Z&N*\?_P#,._[:
M?^RURXV<H4)2B[/3\SKP,(U,1&,E=:_DRE_PG6J?\\+/_OAO_BJ/^$ZU3_GA
M9_\ ?#?_ !5<Q17@?7<1_,SZ+ZCA_P"1'3_\)UJG_/"S_P"^&_\ BJ/^$ZU3
M_GA9_P#?#?\ Q5<Q11]=Q'\S#ZCA_P"1'3'QUJO:&R'UC;_XJD7QSK'G(6BL
M3$&!=1$X)7N =_!]\'Z5S5%-8W$+[0G@<._L'>6GCRS<XO;66WRQ^>,^:H4#
M.3@!LD\8 /;\.HM[F"[@$UM-'-$Q(#QN&4D'!Y'H01^%>-UJZ%KLVA7+,JF6
MVD.9H0>O;<O;=C\\8/8CMPV9RYN6MMW.#%95'EYJ._8]4HJ*VN(KNUAN86+1
M3()$)4J2I&1P>1QZU+7MGA'/>*-=NM%^R_9HX7\[?N\P$XQMQC!'K7/?\)UJ
MG_/"S_[X;_XJKOC_ /YAW_;3_P!EKBZ\#&XFM"O*,966GY'T6!PM&IAXRE&[
MU_-G<:'XLO\ 4]8@LYHK98Y-V2BL#PI/<^U=C7F'A+_D9[/_ ('_ .@-7I]>
MAEU6=2DW-W=_\CSLSI0I5E&"LK?JPHHHKO/."BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBN$\7>(FFE?2[*9#  5N'C;)9LD&/Z#'.,Y/!Q@@XUZ\:,
M.>1OAZ$J]10B7M5\<6L*/'I:"YEY F8$1*>1GU?! /& 0>&KGY_%^MS2JZW2
M0 * 8XHEVD^OS G/XXXK#HKY^KCZ]1[V]#Z.EE]"FMKOS-H^+-<(XOR/I%'_
M /$U9M?&VK6XB698+I5SO+KL=^N/F7Y1@X_A/ ]>:YRBLXXNO%W4W^9I+!X>
M2LX+\CU;2=>L-93_ $>39-\Q,$I D ! W8!.1R.1ZXZ\5IUXS%++;SQSP2-%
M-&VY)%ZJ?\]NA&0>*].\.:XNM:<'D:%;R+BXBC)^4Y.&P>0& R.O<9.#7M8+
M&JO[LM)?F>%CL"\/[T=8_D;%%%%>@><%%%% !1110 4444 %%%% !1110 50
MG_U[5?JA/_KVJH[B9'1115""BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *;++'#$\LKK'&BEG=S@*!U
M)/85E:UXFTG0(\W]TJRE=RP)\TC]<87L#M(R<#/>O'/%/BV\\47$9E3[/:Q<
MQVRON ;'+$X&X]0#C@<#J2:46Q.21:\<>*O^$CU14M9)1IMN,1HW D?G,F,9
MY!P,]!Z;B*C^'O\ R/.G?]M?_13US-=-\/?^1YT[_MK_ .BGK5JR,T[L]THH
MHK U"BBB@ HHHH *9++';PR332)'%&I=W=@%51R22>@%/KAOB?K4FGZ'#IT.
M]7OV8.XXQ&N-PR".22HZ$$;@::5V#=D<?XV\:OXAD-C9%DTM&SR,&<CHS#LH
M/('XGG 7CJ5$>1U2-'DD8A51%+,Q/0 #DD^E>X^$O!EGX=M4EF2*XU,_,]P5
MSY9P1MCSR!@D9ZG//& -6U%&23DSQ7[#=C3O[1-K/]A_Y^?+/E]=OWNG7CZ\
M57!!&0<BOIJN>\0^#=)\01RR2P+!?,ORW<:X;/ !8#&\84#GMG!'6DIE.!Y-
MX6\5WOAFZQ$P>RFD4W$++NXR-S*,C#[1C.<=,YP,>Y6-]:ZG917EE,LUO*,H
MZ]#V/T(.00>000:^=K^QGTS4+BQN5VS02%&X(!QW&0#@CD''((->C_"C5V>.
M]T>67(CQ<0(=Q(!.'&>@&=IQQRS'GL36ET*+Z'I5%%<SX\UJ31/"\TD&\7%R
MPMHG7C86!);((((4-@COBLT:'&>.O'8U%9=(TB7-F<K<7"'_ %WJJG^YZG^+
M_=^]Y]1P!Z 5[!X&\$6^FV4.IZE"LU_,JR)'+'_Q[#A@,,,A^F3U!&!W)UTB
MC+63/)X;"\N;.6\@M)Y;6'/FS1QED3 R=S#@8'/-5@P894@CU!KZ;K(UOPQI
M/B!/]/M%:8+M2X3Y9$ZXPPZ@;B<'(SVJ><KD/$-"\0:AX<O'NM/=-TB[9(Y0
M3')Z;@".A.000>O8G/NVC:S9:]IR7UA+OC8[64\-&W=6'8C(_,$9!!KP?7M&
MGT#69].N&WF/!20*5$B'D,,_D>N"",G%=7\+=7:VUR;2Y)<0W<9>-#N/[U>>
M.PRN[)(YVKSQ@N235T*+L['KM%%97B35CH7AZ\U%4WO"@$:XR-[$*N1D<9(S
MSG&:S-#C_'7CP6OFZ1H\W^D\I<7*'_5>J*?[WJ?X>G7[OE(      Z 4]W>6
M1I)':21R69W8EF)ZDD]37I?@#P3;3V::UJT*S+,I^SVTL?RA>1O8$?-G^'M@
M@\Y&W72*,M9,\[L]/O=1,@L;.XNC'CS!!$7VYSC.!QG!_*JBNKC*,&'J#FOI
MRL_5=#TS7(5BU*SCN%7[C-PR<@G:PY7.!G!YQS4^T*Y#P+2-6N]$U*._L9-D
MR<$'E74]58=P<?H",$ U[CX5\26WB328YDD3[9&JK=1 ;=CXZ@9/RD@X.3^8
M('C_ (M\-R>&=7^S;VEMI5\R"5E(RN<%2<8+#OCU!XSBK?P^U=M+\5V\;2[;
M>\_T>53N()/W#@=]V!D@X#-TSFG))JZ%%M.Q[C11161H%%%% !1110 4444
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M.1HY$:.1"59'4AE(Z@@]"/2O8?ACJ[7_ (=DL9I=\MC)L4'<2(FY7)/!Y#@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *N6O^J/UJG5RU_U1^M*6PT1W?\ K%^E5ZL7?^L7Z57IK8&%%%%
M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "E'44E*.HH TJ***S
M*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH SG_UC?4TVG/_ *QO
MJ:;6A(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %7+3_ %;?6J=7+3_5M]:4MAHCN_OK
M]*KU8N_OK]*KTUL#"BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 7
MK?\ U"_C4M16_P#J%_&I:A[E!1112 **** "BBB@ HHHH **** "BBB@ HHH
MH **** *=W_K!]*@J>[_ -8/I4%:+804444""BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *MVGW6^M5*MVGW6^M*6PT-N^J
M?C5:K-WU3\:K4+8&%%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD;2!Z;C]#@UL^%& \46(/\1<#_OVU>9A)-5X-=T>KC(J5":?9GJ%%%%?5GR
M4444 %%%% !1110 4444 %%%% !5"?\ U[5?JA/_ *]JJ.XF1T4450@HHHH
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M&UAC@W;L[QC?GV_UA&.>GO7ME?/'B2223Q1J[2R/(PO9E!=LD*'( ^@  'H
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M[=UVUTS^RO(\_=^\^T;MN%+=-H],=:UO$GC72_#JF-V^U7O(%M"XW*=N1O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %6[3[K?6JE6[3[K?6E+8:&W?5/QJM
M5F[ZI^-5J%L#"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ J2'_7+]:CJ2'_7+]: ,[QW_ ,D\\3?]@JZ_]%-7Q!7V_P"._P#D
MGGB;_L%77_HIJ^(*S*"BBB@#[?\  G_)//#/_8*M?_12UT%<_P"!/^2>>&?^
MP5:_^BEKH* "BBB@ HHHH **** "BBB@ HHHH *Q?%O_ "+%Y_P#_P!#6MJJ
M.L:>=5TJ>R680F3&'*;L8(/3(ST]:RK1<J4HK=IFM"2A5C)[)H\DZ#)K9T3P
MU>ZRR38,%EN7=*X(9U(SF,$?-V^;ISQNP17::;X3TO39O.$;W$H;<CW!#;.A
M&  !D$9!QGD\UN5YF'RM)\U5W\CU<3FS:Y:*MYG-:YIEGI7@^]M[* 11EU=A
MDDLQ=<DD\GL.>@ '0"O.Z]/\6_\ (L7G_ /_ $-:\PKGS1)5DEV_5G3E+;HR
M;[_H@KVFO%J]IK?*/M_+]3#.?L?/] HHJ"]NXK"QN+R;/E6\32OCKM49/\J]
MENQX:5W8S=<\-6>ME)79H;J-2J3(!R.<*P_B4$YQP>N",G/$:EX7U;3FD86S
M7,"\B6W&\G+8 V#YL]"< @9Z\&M27Q]=O;,(=.@AG.-K/,95'/.1A2>,]ZT_
M#/B>?5;R:VOVM8Y"BF!8T92Y^;?U)'3;QUZ]>WE5/J>*FHW]Y]3UZ2QN%IN5
MO=70X"16BG>"56CF3&^-QAER,C(/(X(I*]DN+:"\@:"Y@CGA;&Z.5 RG!R,@
M^X!KE?$WAK28--N=0A4V<R%6S&&9&Z*$V=%!R.0!@\GC.>>ME<H1<HRO8Z:.
M;1G)1E&USAXI'@N8KF%S'/"VZ.1>JGV_#(/J"0>*]2\/:Q_;6E"X952=',<R
MKG 88/&?4%3WQG&3BO*Z] \!LIT6Y ZBZ(/UV)4Y74DJO)T96;4HNES]47_%
MO_(L7G_ /_0UKS"O3_%O_(L7G_ /_0UKS"EFO\9>GZL,H_@/U_1'I_A+_D6+
M/_@?_H;5M5S_ (,N89_#L<<3[GMY'CE&"-K$[L>_#*>/6N@KV<-_!AZ+\CQ,
M5_'GZO\ ,****W, HHHH *XKQ_\ \P[_ +:?^RUVM<5X_P#^8=_VT_\ 9:XL
MP_W:7R_-'=EO^]1^?Y,XNKNC_P#(;L/^OF/_ -"%4JM:;,EOJMG-*VV..='8
MXS@!@37SE-VFFSZ:HKP:78]?HK%_X2W0_P#G^_\ (3_X4?\ "6Z'_P _W_D)
M_P#"OJOK-'^=?>CY+ZK7_D?W,VJ*Y)/B!I[G#:?J">[+'_1S6%JOBZ_U6U-N
M(8[2%U D6-R[-UR-V!\IXXQVZX.*QJ8^A"-T[^AO2R^O.5G&R\S*U*[:^U2Z
MNFE\U9)F,;E=O[O/R#&!T7 YYXYYJK117S4Y.4G)]3Z>$5"*BNATO@5P/$$J
M=S:N?R=/\:]$KCO FF[()]3D5"9OW4)V@L%4_-ALYP6P"./N \\5V-?29?!P
MPZOUU/F,QFIXB5NFAQ7C_P#YAW_;3_V6N+KM/'__ ##O^VG_ ++7%UXV8?[S
M+Y?DCV\M_P!UC\_S9>TC4!I6IQ7IB:7RPV$4@9)4@<]AD\^W8]*AOKVXU&]D
MN[I]\S\<# 4=E [ ?XGJ2:KUT_ASPHVHH+R_#Q6IP8D'#2\]3Z*>GJ<Y&!@G
M.C"K67L8;;FM>=&B_;3WV.8HKU*+POHL5K+;K8(4ESN+LS.,C'RL3N7\",=1
MS6+K/@NUCLI)],\U)(DSY!9I X&2<9RVX_4C@#'.:Z:F5U8QYDTSEIYK1G+E
M::.'J]I6KW6C77VBVPP(Q)$QPL@]#Z'T/;W&0:-%<$)RA)2CNCT9PC.+C)73
M/9;>>.ZMHKB%BT4J!T)!&01D<'D5)7->!K@2^'S"(@@MYWCSG._.)"?;ER/P
MKI:^LI3]I34^Y\=6I^SJ2AV9G:UK$.B6'VF9'=F;RXT4?>8@G!/88!.3Z=S@
M'RAWDFFDGGD:6>5MTDK_ 'G/J?Y #@  # %=!XUNS<^(?)R^RTC"!648#-AF
M(/4@C8.>Z]/7GJ\',<0ZE3D6R_,^ARS#*G2]H]W^045L>'M!?6[MUD\Z*T1#
MOGC ^]V4$]^<]#P.<9%=U:^&-&LWD:*P1C)C=YS-*!C/0.3MZ]L9_"IP^ J5
MH\^R+Q.8TJ$N2UV>6T5Z+?>"=*N4D:V$MI.S%]Z.67)!XVL2 N3G"[>F 0*\
M]FB:"XF@<J7BD:-BIR-RD@X_$5EB<)4P]N;9FF%QE/$7Y=&A8)I;:XCG@D:.
M:-MR.O4'_/Y]*]/\.ZQ_;>E"X=52>-S%,J9VAA@\9'=2I[XSC)Q7EE=I\/Y9
M3_:,)?\ <IY;JN!PQW!CGKR%7\JZ<LJRC5]GT9S9K1C*C[3JCM:P?%6M-I.F
M[+>0I>W&1"WE[@H!&YN>,@'C.>2." :WJ\P\6O*_BB\\Q]RH(TCX VIL!Q[_
M #,QY]:]3'5W1HMQW>AY. H*M649;+4QWDDE??++)*Y !>1RS' QR3R>!3:*
MV_"^D6VL:E)'=LIACB+&(2E'<Y &,<[1DY((P=OK7SM*G*M44%NSZ6K4C1IN
M;V1B45Z];:5IUG<-/:V%K!,R[3)%"JL1G.,@9QD"FWFDZ=?LSW5E!+(4\OS&
M0;PO/ ;J.IZ'O7I_V3*WQZ^AY7]L1O\ !IZGD=.222)M\4LD3@$!XW*L,C'!
M'(XK5\0Z&-"O(84EDE@ECW))*5W$CA@<8Z9!S@#YAZ5D5Y=2$J4W&6Z/6IU(
M5H*4=4STOPKK3:MINRXD+WMO@3-Y>T,"3M;CC) YQCD'@ BMZO*/#6HM:^)+
M-;8K+),WDO$&&2AQN/0G"X#<?W>H%>KU]'@:[K4KRW1\SCZ"HUK1V>H5S/B7
MQ0FFA[*R=7OB/G;J( 1GG_:QR![@GC .WJ=Z--TRYO"$8PQEE5WV!V_A7/;)
MP.AZUY')-/<2--<S//.YR\C]6/\ (?0<#H*SS#%.C#ECNS7+L(JT^:>R&]V8
MDEF)9F)R6)Y))[DGO1173^'/"C:B@O+_ ,R*U.#$BG#2\YR?12./4YR,#!/A
M4:,Z\^6.Y[]:O3H0YI[',45ZE#X7T6"UEMTL$*2YW%V9W&1CAB2R_@1CJ*YS
MQ!X.^S0-=Z0DL@4YDM2VXA<#E.Y/!)!))R<= I[*F6581YD[G%2S6C.7*TT<
M>RJZE74,I&"",@UW'ACQ6'\K3M3E_>$A()W/WST"L?[W8'OTZ_>X@'(R* 64
MAE9E8'(9200>Q!'0URX;$2H3YEMU.K$X:&(ARRWZ,]IHK-T+54UC2HKD%?-'
MR3*N/D<=1C)QG@@'G!%:5?4QDI)26S/DY1<9.+W044451(4444 %%%% !116
M!XS:,>&9XY)$5I'C"!FP68.&P/4X4GZ U%2?)!S[(NE#VDU#N[%F[\3:/9K)
MNOX99(W,;10N)'#C.5('W3QCG SUKS2_O)-0U"XO)>&F<MCC@= . ,X  S[5
M7HKYS%8V>(LFK(^GPF!AAKM.[85U_@72UEEDU65,B,F* LO\7\3#([?=R#W<
M&J/AWPQ_;*_:KBX5;5) &CC<,\@VY()4_N^J\'YNO"\&O1HXXX8DBB14C10J
MHHP% Z #L*[,OP<E)59_(X<RQT7%T:?S'4445[1X84444 %%%% !1110 444
M4 %%%% !5"?_ %[5?JA/_KVJH[B9'1115""BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /,OB[_
M ,P?_MO_ .TZYCX>_P#(\Z=_VU_]%/73_%W_ )@__;?_ -IUS'P]_P"1YT[_
M +:_^BGK5?"9OXCW2BBBLC0**** "BBB@ KYX\1_\C1J_P#U^S?^AFOH>OGC
MQ&<^*-7_ .OV;_T,UI#<B9Z/\)[6%-#OKM4Q/+<^4[9/*JH*C'3@NWY_2O0*
M\\^$U[')I.H6 5_-AG69F(&TAUP,>_[LY^HKT.IEN5'8****D9R?Q(M8;CP7
M<RRIN>WDCEB.2-K%@F??Y78<^M>(U[7\2[V.U\'2PNKEKN:.%"H& 0=_/MA#
M^.*\4)P,UK#8SGN?35>%_$'_ )'G4O\ ME_Z*2O=*\+^()_XKG4O;RO_ $4E
M3#<J>QT/PDM87O-4NV3,\4<<2-D\*Q)88Z<E%_+ZUZG7E/PEO8X]3U*P*OYL
MT*S*P V@(<'/O^\&/H:]6I3W".P4445)1C>+;6&\\):K%.F]%MGE R1\R#>I
MX]&4'\*^?J]^\8WL=AX/U2:5796@,(" 9S)\@Z]LL,^U> UK#8SGN?0WAO\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %36O\
MKOPJ&IK7_7?A0]@)[G_4GZU2J[<_ZD_6J5*.PV%%%%,04444 %%%% !1110
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M 1<'/O\ O!CZ&O._#AQXHTC_ *_8?_0Q6L?A,Y?$?0]?/'B/_D:-7_Z_9O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *4=124HZB@#2HHHK,H**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#.?_6-]33:<_P#K&^IIM:$A1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5<M/]6WUJG5RT_U;?6E+8:([O[Z_2J]6+O[Z_2J]-; PHHH
MH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% %ZW_U"_C4M16_^H7\:EJ'
MN4%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH IW?^L'TJ"I[O_6#
MZ5!6BV$%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "K=I]UOK52K=I]UOK2EL-#;OJGXU6JS=]4_&JU"V!A1113$%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5)#_KE^M1U)
M#_KE^M &=X[_ .2>>)O^P5=?^BFKX@K[?\=_\D\\3?\ 8*NO_135\05F4%%%
M% 'V_P"!/^2>>&?^P5:_^BEKH*Y_P)_R3SPS_P!@JU_]%+704 %%%% !1110
M 4444 %%%% !1110 4444 %%%% &+XM_Y%B\_P" ?^AK7F%>G^+?^18O/^ ?
M^AK7F%?/YK_&7I^K/HLH_@/U_1!7M->+5[36^4?;^7ZF.<_8^?Z!1117LGAG
MFGB+PR=#Q/;;FT\D*"Q),1/ 4D]1V!/T/.">?=%D0HZAE88*L,@BO:ZY^^\&
M:1>'=&DEFY8$FV8 $ 8QM(*@=#P!R/KGQ\1EG-+FI.WD>UALU48\E97\SB;7
MQ%J]G&R1:A,P9MQ\T^:<^Q;) XZ=*SY)IY]GVBXGG,8(0SRM(5SC."Q)YP/R
MKOAX$TP#_CXO#]73_P")I8_ FEI.LCSWDJ#.8F=0K<=R%#>_!'2L7@<7)<LI
M:>INL?@X/FC'7T.$LK.?4;V.SM4#SN"0"<!0.K,>RC(Y]P.20*]7TNP33-,M
M[-&W>4N&;!&YCRQP2<9))QGBGV5A:Z=;B"T@2&,8R%'+' &2>I. .3SQ5BO1
MPF#CAU>]VSS,9C98EV2LD9/B:U>\\.7L49?>$$@"1EV;80^T <DG;C\>]>5@
MAE#*001D$=Z]JK$U+PII>I2>88VMI2VYGM\*7ZDY!!!))R3C/O6>.P4J[4H/
M5&N QT<.G":T9YU:ZA>62RI;74T*RHR,J.0.<9('9N!\PY'8UUW@2YNKA]0%
MQ=7$ZHL6WSI6?'W\XR3[?D*M'P)IA&!<WH]PZ?\ Q-:NC:%::'"Z6S2R/)_K
M)96RS8)(X  &,XX ]\UCA,)B*=1.;T72YMC,9AJM-J"]Y];&G1117KGC!111
M0 5Q7C__ )AW_;3_ -EKM:XKQ_\ \P[_ +:?^RUQ9A_NTOE^:.[+?]ZC\_R9
MQ=%%/AB>XGCAB7=)(P11G&23@5\TE?1'U+=M6,HK:_X1+7/^?'_R*G^-'_")
M:Y_SX_\ D5/\:V^K5OY']S,/K5#^=?>C%HK9/A371TT\GZ31_P#Q5.MO".N3
MS-')9BV4+D233(5)]/D+'/X8XIK"UW]A_<)XN@OMK[S$K6T'09M<N" S16L9
MQ+,!R/\ 97_:_EU/8'?T_P !@QAM4NCOW F*V;Y< G(+$9((QT"D<X/0UV$%
MO!:PB&WACAB4DA(U"J,G)X'N2:[\-EDF^:MMV/.Q6:12Y:._<2WMX[2UBMH5
M*Q1((T!8DA0,#D\G\:EHHKW#P3BO'_\ S#O^VG_LM<77:>/_ /F'?]M/_9:X
MNOF<P_WF7R_)'U.6_P"ZQ^?YLD@@-U<PVRR>4T\BQ"3;NVEB%!QQG&>F:]CC
MCCAB2*)%2-%"JBC 4#H .PKRKP_9QWWB"QBE9E591*"I&<I\X_#*C/M7J]>A
ME,?W<I>9YN<2?M(Q\OZ_(****]8\@\2@65+>-9XVCF50'1P05;'((/0YJ2KN
ML?\ (;O_ /KYD_\ 0C5*OCYJTFC[6#O%,]!\"#&B7!];EC_XXE=17,>!/^0)
M-_U\M_Z"M=/7T^#_ ($?0^4QW^\3]2I<Z5IU[.)[K3[6>95VB26%68#.<9(Z
M9-4;GPIHEU,LLEBJLJ[0(I'C7'^ZI S[XS6O))'#$\LKJD:*69V. H'4D]A7
M'ZAX]B!*:7:F8%#B>?**"0-I"8W$9)R#M/''7-.O*A!7JV%0A7F[4KG3:=I=
MGI4,D-E$8XY'\Q@79LM@#/)/8"KE>87?BS6;O</M0@1H]C) @4=\D$Y8'GL>
M,"LFXGFNS&;J>6X,>=AF<N5SC."<XS@?E7%+-*4%:G']#NCE-:;O4E^IZ;+X
MJT*+RO\ B90RB3.UH,RCC'4H"!U[]?PKSO5KJWOM4GNK6 P12L'V,H4AB!N)
M )&2<GWS5*BO.Q6-GB%RM61Z6%P,,.^9.["NT\ ?\Q'_ +9?^SUQ==IX _YB
M/_;/_P!FHR__ 'F/S_)AF7^ZR^7YH[6O+_%F_P#X2B]W1LHRFTLI 8;%Y'J,
MY&1W!':O4*YWQ1X=;5XTN;8JMW"I 4@#S5Z[2>N1SCG')]<CV<?1E5HVCNM3
MQ,OKQHUKRV>AYQ4MM=7%G,)K::2&0$?,C8S@@X/J,@<'@U&RLCLC*592592,
M$$<$$>M)7S2;B[K<^H:4E9ZHZ:V\=:G"0)X+:Y18]O>-V;CYBPR/7@*.O;&*
MWX/'&D2>9YWVFW5,8,D6[?UZ!-QX]\=:\ZHKNIYC7AN[^IP5,LP\]E;T/6?^
M)/K,A_X\+YX!@_<E,8;\\9V_CM]JDM=)TVRG,]II]K;S,NTR10JK$=<9 Z<"
MO(P2KHZDAD8,K#JI'((]ZV+#Q5J]@\8-R;F%>#%<?-D%LGY_O9Z@9) ST.!7
M;2S.FW^\C9]SAJY55BOW<KKL>H45E:+KUKK-M&59(KHJ3);%P67&,D>JY(^;
M'<9P>*U:]6,XS7-%W1Y$X2A+EDK,Y3QW>"+3+>S67:]Q+N9-N=Z)UYQQABA[
M']:X&NS^("_/IK>@E'_H'^%<97SN92;Q#7:Q]+ED4L,GWO\ Y#X8#=7$-LLO
ME-/(L2R;=VPL0H..,XSTS7LD<<<,211(J1HH5448"@= !V%>-(S1RQRH</$Z
MR(?1E((/Y@5L?\);KG_/]_Y"3_"KP.+IX>+YD[LC'X.KB)+D:LNYZ?17F'_"
M6ZY_S_?^0D_PH_X2W7/^?[_R$G^%=W]JT>S_  _S.#^R*_=?C_D4]:M;>PUZ
M^L[8;8H9!M7  3<JOM    &[ 'H!5&K5_J-UJ<ZS7DOF2*NP':!QDGL/<U5K
MPZTHRJ.4=F>]1C*-.,9;I':> ;L#[;8LT2\K.BY^=OX6/7D#"=N,^XKM:\Z\
M#)GQ%(^.EHXS]73_  KT6OHLODY8=7Z'S6914<3*W4****[3A"BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "E'44E*.HH TJ*
M**S*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH SG_UC?4TVG/\
MZQOJ:;6A(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %7+3_5M]:IU<M/]6WUI2V&B.[^
M^OTJO5B[^^OTJO36P,****!!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!>M_]0OXU+45O_J%_&I:A[E!1112 **** "BBB@ HHHH **** "BBB@ HHHH
M **** *=W_K!]*@J>[_U@^E05HMA!1110(**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ JW:?=;ZU4JW:?=;ZTI;#0V[ZI^-
M5JLW?5/QJM0M@84444Q!1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %20_ZY?K4=20_ZY?K0!G>._P#DGGB;_L%77_HIJ^(*^W_'?_)/
M/$W_ &"KK_T4U?$%9E!1110!]O\ @3_DGGAG_L%6O_HI:Z"N?\"?\D\\,_\
M8*M?_12UT% !1110 4444 %%%% !1110 4444 %%%% !1110!B^+?^18O/\
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MT<J)(RI(MU\KJ&(# A#U&#^-30>/K0VRM<V-PDYSN2%E=1SQAB5SQ["N7V.
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MJ4.1M=BR_C@BMFOKJ":I13[+\CX[$-.M-KN_S"BBBM3$**** "BBB@ HHHH
M**** "J$_P#KVJ_5"?\ U[54=Q,CHHHJA!1110 4444 %%%% !1110 4444
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MGN2>]?3%5*-B8RN%8_BG59]$\-W>HVR1O-#LVK("5.753G!'8^M;%<S\0O\
MD1M1_P"V7_HU*E;E/8X7_A:VN_\ /IIW_?M__BZ]@KYEKZ:JYI+8B#;"BBBL
MRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ I1U%)2CJ* -*BBBLR@HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** ,Y_P#6-]33:<_^L;ZFFUH2%%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1110 4444 7K?_4+^-2U%;_ZA?QJ6H>Y04444@"BBB@ HHHH **** "BBB@
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MD5X7\0O^1YU'_ME_Z*2K@KLF3LC4_P"%K:[_ ,^FG?\ ?M__ (NC_A:VN_\
M/IIW_?M__BZYOP_X?N_$E_)9V<D,<B1&4F9B!@$#L#S\PKI/^%4Z[_S]Z=_W
M\?\ ^(JVHHB\F'_"UM=_Y]-._P"_;_\ Q=(?BMKO:UT[_OT__P 72_\ "J==
M_P"?O3O^_C__ !%4[[X:^)+3R_)MX+W?G/V>8#9C'7?MZ^V>E+W1^\:-I\6-
M629FO-/LIXMN D.Z)MV1SN);C&>,?C75:/\ $G0]298KIVTZ;:"3<D"(G!+
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"O-_%/Q U;1/$EWIUM;V3PP[-K2(Y8Y16.<,.Y]*](KPOXA?\CSJ/_;+_P!%
M)5P5V3)V1KP?%;5_M,/VBTLOL_F+YOE1/OV9^;;E\9QG&>,UZO:W,-[9P7=N
MV^&>-9(V*D95AD'!Y'![U\UUZ'\-/%"V<YT*\D1()F+VTCN>)"0/+'8!N2.G
MS9ZEA52CU0HRZ,]7HHHK(L**** /-_%/Q U;1/$EWIUM;V3PP[-K2(Y8Y16.
M<,.Y]*N>"?&VI>)-9FL[R"T2-+=I0848'(91W8\?,:X?XA?\CSJ/_;+_ -%)
M6I\*?^1HN?\ KR;_ -#2M6ERW,[OF/8*Q_%.JSZ)X;N]1MDC>:'9M60$J<NJ
MG.".Q]:V*YGXA?\ (C:C_P!LO_1J5FMS1['"_P#"UM=_Y]-._P"_;_\ Q='_
M  M;7?\ GTT[_OV__P 77"UV5E\--9O["WO(KFP$=Q$LJ!I'R P!&?EZ\UJU
M%&2<F6/^%K:[_P ^FG?]^W_^+H_X6MKO_/IIW_?M_P#XNC_A5.N_\_>G?]_'
M_P#B*/\ A5.N_P#/WIW_ '\?_P"(I>Z/WA#\5M>[6NFCZQ2?_%UI:=\6G B3
M4]+!Z^;-:OCUQM1OP!RWJ?:N?O/AQXFM9UCALX[M2N3)!.@4'GCYRIS^&.:Y
MR]L;O3;MK2]MY;>=>J2+@D9(R/5<@X(R#C@T[187DCWW0O$6F^(K5I]/F+%-
MHEB==KQDC."/S&1D$@X)Q6K7SAINI76DW\5Y9RO')&P)"N5#@$':V",J<#([
MU[UX=UR#Q%HT.H0+Y98E9(BX8QN.H./P(S@D$' S42C8J,KFK6/XIU6?1/#=
MWJ-LD;S0[-JR E3EU4YP1V/K6Q7,_$+_ )$;4?\ ME_Z-2I6Y3V.%_X6MKO_
M #Z:=_W[?_XNO5-)NY+_ $:QO)0HDN+>.5PHX!903CVYKYQKZ'\-_P#(KZ1_
MUY0_^@"KFDB(-LTZ***S+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *DA_UR_6HZDA_P!<OUH SO'?_)//$W_8*NO_ $4U?$%?;_CO
M_DGGB;_L%77_ **:OB"LR@HHHH ^W_ G_)//#/\ V"K7_P!%+705S_@3_DGG
MAG_L%6O_ **6N@H **** "BBB@ HHHH **** "BBB@ HHHH **** ,7Q;_R+
M%Y_P#_T-:\PKT_Q;_P BQ>?\ _\ 0UKS"OG\U_C+T_5GT64?P'Z_H@KVFO%J
M]IK?*/M_+]3'.?L?/] HHHKV3PPHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *XKQ_P#\P[_MI_[+7:UQ7C__ )AW_;3_ -EKBS#_ ':7R_-'=EO^]1^?
MY,XNKNC_ /(;L/\ KYC_ /0A5*KNC_\ (;L/^OF/_P!"%?.T_C7J?35?@?H>
MN4445]>?%A1110 4444 %%%% '%>/_\ F'?]M/\ V6N+KM/'_P#S#O\ MI_[
M+7%U\SF'^\R^7Y(^IRW_ '6/S_-FUX2_Y&>S_P"!_P#H#5Z?7F'A+_D9[/\
MX'_Z U>GUZ>5?P7Z_HCR\W_CKT_5A1117IGE'D>L?\AN_P#^OF3_ -"-4JNZ
MQ_R&[_\ Z^9/_0C5*OCZGQOU/M*7P+T/0O G_($F_P"OEO\ T%:Z>N8\"?\
M($F_Z^6_]!6NGKZ?!_[O'T/E<=_O$_4\6V2Q$Q3ILFC)21<@[6'!&1QP<]**
M[#QIHDRW#ZQ H: H/M"C.Y".-_7[N, XQC&>021Q]?.XFA*C4<7\CZ7"XB->
MFI+YFSX>U]]"FES$9H)BN]-Y&W!Y91TS@^V<+R,5UG_";Z3]A^T;;GS?^?;8
M/,ZXZYV].?O=/?BO.J*UHX^M2CR+5>9C7R^C6GSRT?D='XA\52:O;M9VT;P6
MC_ZPEOGE7 ^4XZ#.<@$Y&.Q(/.4=650"69@JJ!DL3P !W)/:MC4?#=[I.EK>
M7?+/,J".(%A&I4DL[8X.X!>./<[AB)NMB;U'K8T@J&%M36E_Q,>ND\#-+_PD
M4BB1A";1RR \%MZ8)'J 6_,US=7M(U(:3JUO>NSB&-L3!6(RA&"2 "6QG=C'
M)45.%FH5HR?<>+INI0E%=CUNO+?$FE#2=8DCC3;;2_O(0%P #U48  P>PZ#;
MZUZE6=K>CQ:WIYM9)&C96WQ2+_"X! )'\0Y((/KV."/H,9A_;T[+=;'SN"Q/
MU>K=[/<\GJYIFJW>D7JW-J_'26%C\DJ^A]#Z'L?4$@QWVGWFESK!?P^3*X8I
MA@RN <$J>XZ'L0",@9JO7SB]I1GV:/IG[.O3[IGI,'C319O*#S2P22-M"20L
M=O.!EE!4#ODG@=<59N_%&BV31K+?(QDSM\E6EQC'78#CKWQG\*\MHKT%FM6V
MJ1YSRBE?23.L\0>+X]1L9+*QBFC5W*R2N=I90>-N#G#>^..".>.3HIR))*X2
M*-Y)#G:D:EF; R< <G@&N&M6J5Y\TMSOH4*>'ARQV'VUM->745M NZ65@J@@
MXR>YP"<#J3V ->NV5JEC86]G&SND$2Q*SD;B%  )QWXK \,^&%TU4O;U%:^(
M^5>H@!'0?[6."?J!QDGIJ]S+\,Z,'*6[/ S'%*M-1ALBM?V4.I6$UG<+F.5=
MI. 2I[,,@C(."#V(%>1SP2VMS+;3KMFA<HXP0,CN,@'!Z@XY!![U[+7,>+/#
M<FJJ+ZR)-]"FSRBV%F0$G:,\*V2<'H<X/8J8_"NM#FCN@R[%JA/EG\+//:V-
M'\37VBQF*)$N+?);R9&*X.#]UN=N3@G@]#P"2:RIHI+:YEMID*31-MD0]5/_
M .KGW!S3*\&%2=&=XZ,^AJ4Z=:%I:IGHMIXWTFX>02K<VH3&UIHP0^<]-A;I
M[XZUBZOXVEO+8P:=!+:AU&Z:1AY@ZY "Y [?-G/)P <&N4HKJGF5><>78Y(9
M90A+FU?J%(2%4DD  9)-#,%4LQ 4#))/ KK_  OX7NQJ$>H:A%Y$4.&AA< M
M(Q'#,/X0,\#AMP[8^;GP^'G7GRQ.G$8B%"'-+_AS;\(:3_9NCK-+'MNKO$LF
MY<,J_P *'(!& <D'HS-70445]33@H148[(^2J3=2;G+=A1115D!1110!FZ[I
M2:QI,ML0OFCYX&;'RR#H<X. >02!G!->4<]&5D8'!5U(93W!!Z$>E>TUR'BS
MPU<W]PFH:<HDFP(YH/E7>,\."<<C/()Y &.1AO-S#".K'GANCU,MQ:HR]G/9
M_@SA:N:7J=SH]XUU:,H=EV.K E7';<,C."<@]1SV)S3Z,RD$,K%64C!4@X((
M[$'M17@QE*$KQT:/H91C4C:2NF=9+X\O3;Q+%:6ZSC'FN^YE;CG"Y!7GU)Q[
M]:Y6622>>6>:1I)I6WR2,>6/^< #H  !P*;16E7$U:JM-W,J.&I47>G&P5<T
MO3)=8U&.RB8+N^:1MX4K&" S#@\\C'!Y(SQDU'96%UJ5RMO:0M(Y8!F .V/.
M>6/\(X/UQ@9/%>G:+HEMHMIY4/SS/@RS$8+D?R R<#M]22>C!8.5:7-+X5^)
MS8[&QHQY8OWG^!IT445](?,!1110 4444 %%%% !1110 4444 %4)_\ 7M5^
MJ$_^O:JCN)D=%%%4(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQZ1"Y9=I$[-,N./X7)&>.N,UT-%%V*R"BBBD,**** "J6HZ1IVKQ>7J%E!<
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MJ&K%IW"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4HZBDI1U% &E1116904444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^ZM,Q0<]9&'S'@]E.,$8._/5:V7NQ,WK(9\2O#L>F2V%]9Q)'9F%+0J ,JR
M["23EB4&,GH(QD\BN?\ !VL-HGB>TN"R+#*P@G+L%41L1DEB. IPW;[N,\UZ
M_P"+]&;7?#-U9Q(C7( E@W*"=ZG. 21M+#*YSP&/TKP+J*4=58):.Y]-45SW
M@G65UKPM:REG:>W'V><NQ9BZ@<EB.205;O\ >QG(-=#69H%%%%(#Y^\67,EY
MXNU::545Q<O'\@(!"?(I^NU1GWK0\ :'%K?B5?M4/F6=M&9I%:,LCG@*A/09
M)W8.<A",8S65XE22/Q3JRR1O&WVR4@.I!P7)!Y[$$$>H(K:^'WB&#0M<D2^N
M/)LKN,(S%1M60'Y68]0 "PST^;)X&1L_AT,E\6I[91116)J%0W-K;WMNUO=V
M\4\+8W1RH&4X.1D'CJ ?PJ:B@#Y^\4: WAO7);#>\D.T202/C<Z'UQW!!';.
M,X (JSX&U,Z7XOL7R_EW#_99 B@E@^ !ST&_83CG []#ZMXA\%:7XDO(KN[>
MYCGCC\O="X&Y<D@$$$<$GICKSVQG67PTT:QO[>\BN;]I+>594#R)@E2",_+T
MXK7F5K,CE=]#LZ***R+"BBB@ HHHH BNKF*SM)KJX;9##&TDC8)PH&2<#D\"
MOGG6=7N=<U6>_NG8M(QV(S9$29^5!P.!]!GDGDFO3_BKJ'D>'K:Q6;:]U."T
M>S.^-!D\XXPQC/8_AFO(:U@NIG-]#HO"GA&[\3WG!:"PB;]_<8Y_W4SU8_D.
MI[ ^X6-E;:;916=G"L-O$NU$7M_B>Y)Y)YK.\*Z.NA^&[.S,7ESE!)< [2?-
M89;)7@X^Z#SP!R:V:B3NRXJR"BBBI&%>-?$/PLFB7Z:A8PI'I]RVTH'_ -7+
MR2 O92!D8SC##@8%>RUF^(-+&L^'[[3\(7FB(CWL542#E"2.<!@#^'0U479B
M:NCYY1WC=9(W>.1"&5T8JRD="".A'K7T'X;U8ZYX>LM19-DDR8D7&!O4E6P,
MGC(..<XQ7GEI\)M1D\S[;J=K!C'EF%&EW=<YSMQV]?PKOO#'AR#PSI1LH9Y)
MB[^;+(X R^U5. .@^7H2?J:J;3)BFC:HHHK,L**\\\0?%"WM)9+;1H%NI$;:
M;F4_NN,?= .6'WAG(Z C<*X&Z\6>(;R999M9O ZKM_<RF)<<_P *8&>>N,U:
M@V2Y)'T#17SP?$>N$?\ (:U+_P "Y/\ &M?1_B#KVE/&LMR;ZV7@Q7/S,06R
M3O\ O9Z@9) STX%/D8N='N%%<]X8\7Z?XGC=8 \%W$H:2WD(SC RRG^)<G&>
M#TR!D9Z&H+"BBF2RQP0O--(D<4:EG=VPJ@<DDGH*0#Z*\PUWXJ%U>#0K<J#E
M?M5PO/<95/\ OD@M]"M<0_B777F>5M:U#<[%B%N7 R>> #@#V P*M0;)<T?0
MU%?/*>)=>CE25=:U#<C!@&N7(R#GD$X(]CP:[SPS\33-<0V6NI$F[Y1>J=HS
M@ ;UZ#)SEA@#(X R0.#0*29Z517B^K>._$MMKFI6\.I;8H;R:*-?(C.%61@!
MROH!76_#GQ#JNO-J8U*Z\_R!%Y?[M5V[M^?N@>@I.+M<:DKV.[HHHJ1A1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M5RT_U;?6J=7+3_5M]:4MAHCN_OK]*KU8N_OK]*KTUL#"BBB@04444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% '(?$?6&TSPPUO$R":^;R,%AN$>#O(
M4@Y&,*?3>#GI7BT<;RR+'$CR2.0JHBDLQ/0 #J:ZKXAZRNJ^*98HF<P60^S@
M%CM+@G>0I P<_+[[ <XQ3OAWH1U?Q(ES(/\ 1M/*SOSU?/[L<$$<@MGD?)@]
M:VCI&YF]78UO&GA(Z;X0TBXACB$FGQ^3=E.=Q<@EMS$$J)"V%Q_RT/0 UQ&D
M:G-HNKVNHP+NDMWW;<@;QT9<D'&02,XXS7O^L::FKZ->:?(4 N(F16=-X1L?
M*V.Y!P1[BOG>>"6UN9;>=-DT+F.1,@[6!P1D<=12@[JP25G<^DXI8YX4FAD6
M2*10R.ARK \@@CJ*?7%?#/65U#PX;!V<W%@VQM[%B48DH<D< <J!DX"#ID5V
MM9M69HG=!1112 \?^*W_ "-%M_UY+_Z&]9?P]_Y'G3O^VO\ Z*>M3XK?\C1;
M?]>2_P#H;UE_#W_D>=._[:_^BGK9?"9/XCW2BBBL34**** .)\<>"%UV-M1T
MY535$7YESA;A1V)[,.S?@>,%?'9(WBD>.5&21&*LC@@J1U!!Z&OIBO&OB7HD
M>F>($OH=JQ:@&<H,#$BX#G  X.5/4DDM6D)=")KJ:OPKUX(\^A3R<,3-:[F[
M_P :#)_X$ !_?)KU"OG31-3;1M;L]1!<"WE#/L4,Q3HX /&2I(_'M7T72FK,
M<'=$5U<Q6=I-=7#;(88VDD;!.% R3@<G@5\\ZSJ]SKFJSW]T[%I&.Q&;(B3/
MRH.!P/H,\D\DUZ?\5=0\CP];6*S;7NIP6CV9WQH,GG'&&,9['\,UY#5074F;
MZ'1>%/"-WXGO."T%A$W[^XQS_NIGJQ_(=3V!]PL;*VTVRBL[.%8;>)=J(O;_
M !/<D\D\UG>%='70_#=G9F+RYR@DN =I/FL,MDKP<?=!YX Y-;-1)W9<59!1
M114C"O&OB'X631+]-0L84CT^Y;:4#_ZN7DD!>RD#(QG&&' P*]EK-\0:6-9\
M/WVGX0O-$1'O8JHD'*$D<X# '\.AJHNS$U='SRCO&ZR1N\<B$,KHQ5E(Z$$=
M"/6OH/PWJQUSP]9:BR;))DQ(N,#>I*M@9/&0<<YQBO/+3X3:C)YGVW4[6#&/
M+,*-+NZYSG;CMZ_A7?>&/#D'AG2C90SR3%W\V61P!E]JJ< =!\O0D_4U4VF3
M%-&U7B/Q(N9+CQK<I(J 6T4<*%0<E=N_GWR[?ABO;J\-^(:2+XXU O&ZJXB9
M"RD!QY:C(]1D$9]0?2E#<<]C/\*Z0-<\26=BZN8&??.54D!%&2"01M!P%SG@
ML/I7O\44<$2111K'&BA41!@*!P !V%>"^#]<3P_XDM[R>1TM&#1W&Q-Q*$>G
M7 8*3CGCC/0^]12QW$,<T,B212*'1T8%64\@@CJ#3GN*&P^BBBLRQDT,5Q#)
M#-&DD4BE'1U!5E/!!!Z@UXEX\\.#0-<WP?\ 'G>;I8AA0$.?F0 =AD8X'! Y
MP37N%8GB+PKIWB=+<7QG1[<L8WA< @-C(Y!&#@=L\?6JB[,4E='A^BZF=&UN
MSU(%P+>4.^Q0S%.C@ \9*EA^/45]%UPO_"J="_Y^]1_[^)_\17=4Y-/844T%
M%%%04%%%% !1110 4R66."%YII%CBC4L[N<*H')))Z"GUQ7Q,UE=/\."P1G%
MQ?ML78Q4A%(+G('(/"D9&0YZX--*[!NQY/J^IS:UJ]UJ,Z[9+A]VW(.P=%7(
M S@ #..<5VO@'PJ-4T+6+BYC1!>0FTMI9$+;>Y<*<!@&$9!SG*'I7 P02W5S
M%;P)OFF<1QID#<Q. ,GCJ:^AM#TF+0]$M--B;<L"89\$;V)RS8).,L2<9XSB
MM)NRL9Q5W<^>9X);6YEMYTV30N8Y$R#M8'!&1QU%>S_#C6&U/PPMO*R&:Q;R
M,!AN,>!L)4 8&,J/783GK7"?$C1FTWQ,]VBHMO?CS4"*% < !Q@'DYPQ.!DO
MWP34?P\UE=*\4Q12LX@O1]G(#':')&PE0#DY^7VWDYQFAZQN"TE8]NHHHK(T
M"N9^(7_(C:C_ -LO_1J5TU<S\0O^1&U'_ME_Z-2FMQ/8\+KZ'\-_\BOI'_7E
M#_Z *^>*^A_#?_(KZ1_UY0_^@"M*A$#3HHHK(T"L_6=&LM>TR2POHRT;\JR\
M-&W9E/8C_$'()%:%%,#Y[\0>';[PWJ)M;P!D;)AG4865?4>A]5[>X();X>UB
M30==M=13>4C;;*BY^>,\,,9&3CD G&0#VKUOXA:)'JWAB:X&U;BP!N(W.!\H
M'SKG!."O.!C)5<]*\0K6+YEJ925F?2\4L<\*30R))%(H9'1LJP/(((ZBGURG
MP[U-M2\(0*Y<R6;FV9F4 $+@KC'8*RCGG(/U/5UD]#5'A?Q"_P"1YU'_ +9?
M^BDK4^%/_(T7/_7DW_H:5E_$+_D>=1_[9?\ HI*U/A3_ ,C1<_\ 7DW_ *&E
M:OX3)?$>P4445B:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!>M_]0OXU+45O_J%_&I:A[E!1112 **** "BBB@ HHHH **** "B
MBB@ HHHH **** *=W_K!]*@J>[_U@^E05HMA!1110(**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HKQK6_'/B2TU[4;:#4=D,-U+'&OD1G"AB ,E?2NZ^'^LW^M
MZ#/<ZC/YTRW31AMBKA0JG&% [DU3BTKB4DW8ZNBBBI&%>>?%36&M].MM(B9,
MW1\R<;@6"*1M!7&<%N<\?<(YYKT.OGWQ3K*Z]XCN[^)G-NS!(-S$C8HP" 0-
MH."V,<%C5P5V3)V1GV%C<:G?P6-HNZ>=PB9!(&>YP"<#J3C@ FNV^)7AV/3)
M;"^LXDCLS"EH5 &59 =A))RQ*#&3T$8R>13_ (6Z$;G4I=;F'[JTS%!SUD8?
M,>#V4XP1@[\]5KO/%^C-KOAFZLXD1KD 2P;E!.]3G )(VEAE<YX#'Z53E[PE
M'0\@\':PVB>)[2X+(L,K""<NP51&Q&26(X"G#=ONXSS7OE?,O45[SX)UE=:\
M+6LI9VGMQ]GG+L68NH')8CDD%6[_ 'L9R#2FNH0?0Z&BBBLRPKPOXA?\CSJ/
M_;+_ -%)7NE>%_$+_D>=1_[9?^BDJX;DSV-3X4_\C1<_]>3?^AI7L%>/_"G_
M )&BY_Z\F_\ 0TKV"B>X0V"BBBH*"O./'?@1KII=9T:+-P?FN;5!_K?5T'][
MU'\74?-][T>BFG8&KGS+7KWPPUX7ND/I$\F;BRYBW-RT)/'4DG:>.   4%<'
MXVT2/0O$\]O!M%O.!<0HN!L5B?EP   &#  =L4>!M3;2_%]BV7\NX?[-(J*"
M6#\+UZ -M)QS@=^AU>L3):,]XKF?B%_R(VH_]LO_ $:E=-7,_$+_ )$;4?\
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M?EZ<5KS*UF1RN^AV=%%%9%A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %6[3[K?
M6JE6[3[K?6E+8:&W?5/QJM5F[ZI^-5J%L#"BBBF(**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"_Y$;4?^V7_HU*Z:N9^(7_(C:C_VR_\ 1J5DMS1['A=?0_AO_D5](_Z\H?\
MT 5\\5]#^&_^17TC_KRA_P#0!6E0B!IT445D:!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %20_ZY?K4=20_P"N7ZT 9WCO_DGGB;_L
M%77_ **:OB"OM_QW_P D\\3?]@JZ_P#135\05F4%%%% 'V_X$_Y)YX9_[!5K
M_P"BEKH*Y_P)_P D\\,_]@JU_P#12UT% !1110 4444 %%%% !1110 4444
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MG'8UVE%<RP&'3OR_F=+S'$M6YOP7^1G:7HEAI" 6L(\S;AIGY=NF>>P. <#
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MLXR.02JMCW[CK7NGB3_D5]7_ .O*;_T U<WJD1%:7/GBO=/A[_R(VG?]M?\
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MZE_:OG^3M_=_9]N<L%Z[CZ^E>P5S/Q"_Y$;4?^V7_HU*SBVG8N26YX77IO\
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M "BBB@#.?_6-]33:<_\ K&^IIM:$A1110 4444 %%%% !1110 4444 %%%%
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M.AX5>>?E9R1CMGL:J2NKDQ=G8]>KRKXH>(FFNAX?@XBA*2W# L"SXRJ$< @
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MIOPB^]K/T@_]J5<]B([GIU%%%8FH4444 %%%% !1110 4444 %%%% !1110
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MLYX=>W(/L<<9%:506%%%%( HHHH **** "O#_B#J[ZIXKN(EEW6UF?(B4!@
M1]\D'ONR,@#(5>N,UZWXDU8Z%X>O-15-[PH!&N,C>Q"KD9'&2,\YQFOGD *H
M4#  P!6D%U(F^AV/PWT9M2\3)=NJ-;V \U]ZA@7((08)X.<L#@X*=LBO:JX_
MX<:,VE^&5N)E03WS>?D*-PCP @+ G(QEATQO(QG-=A4R=V5%61Q_Q(T9M4\,
MM<PJAGL6\_)4;C'@AP&)&!C#'KG8!C.*\721XI%DB=XY$(971B&4CH01T-?2
MLL4<\+PS1I)%(I5T=<JP/!!!ZBOG75]+FT75KG3;AMTEN^W?@#>.JM@$XR"#
MC/&:N#Z$374][\/ZH-9T"QU#*%YH@9-BE5$@X< 'G 8$?AU-:5>8?"?5<27V
MCF/AO]+1PO?Y48$Y_P!S''9LGI7I]9M69:=T%<S\0O\ D1M1_P"V7_HU*Z:N
M9^(7_(C:C_VR_P#1J4+<'L>%U]#^&_\ D5](_P"O*'_T 5\\5]#^&_\ D5](
M_P"O*'_T 5I4(@:=%%%9&@4444 ,EBCN(9(9HTDBD4HZ.H*LIX((/4&OF:-M
M\:MZ@&OIROGCQ)_R-&K_ /7[-_Z&:TID3.]^$=Q,T&K6S/F"-HI$3 X9@P8Y
MZ\A5_*O2J\R^$7_,8_[8?^U*]-J9;E1V/"_B%_R/.H_]LO\ T4E:GPI_Y&BY
M_P"O)O\ T-*R_B%_R/.H_P#;+_T4E:GPI_Y&BY_Z\F_]#2M'\)FOB/8****Q
M-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH O6_\
MJ%_&I:BM_P#4+^-2U#W*"BBBD 4444 %%%% !1110 4444 %%%% !1110 44
M44 4[O\ U@^E05/=_P"L'TJ"M%L(****!!1110 4444 %%%% !1110 4444
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MIK6[N;&9IK.YFMI6789(9"C%>#C(YQP/RI.'8:F?2E%>/Z-\4-6M)MNJHE_
MS9+*JQR(,CI@!2  >" 23]X"O5M/U*RU6U%S8745Q">"T;9VG .".H.".#SS
M4--%IIEJBBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5;M/NM]:J5;M/NM]
M:4MAH;=]4_&JU6;OJGXU6H6P,****8@HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O"_B%_R/.H_P#;+_T4E>Z5X7\0O^1YU'_ME_Z*
M2KAN3/8U/A3_ ,C1<_\ 7DW_ *&E=YXU\-CQ'H;)$#]MMLRV^T+EVP?W>3C
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "IK7_7?A4-36O^N_"A[ 3W/^I/UJE5VY_U)^M4J4=AL***
M*8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF>29B0=P9 H&/;$C9^@KS_PZ<>*-(_Z_8?\ T-:VC\)G+XCZ(KS+XN_\P?\
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M]-TVUL86=HK:%(49SEB%  SCOQ7S;7TU5U"8!111699POQ6_Y%>V_P"OU?\
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ME@'Z8&.K;<Y&.>*[&OF6O4/AEXFEF+:%>S[MB;K,OC.!]Z/.<G P0,< -S@
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MFMG,L2':/W3=<=SA\DD]-Z\]AY[XA\.7WAJ\BMKWRW\V/S$DBW%#R01D@<C
MR.V1ZU-X/UEM$\3VESN1896$$Y=@JB-B 26(X"G#=ONXR :):H2T9[[116#X
MSU*ZTGPI>WUE+Y5Q&8PC[0V,R*IX((Z$UD:F]17A?_"PO%/_ $%/_)>+_P")
MKU7P9K,VN^&+:\N98I+H%HYO+P,,K$#([$KM;''WL@ $4W%H2DF;]5[RPL]1
MB6*]M(+F-6WJD\8<!N1G![\G\ZL45(SD;_X;^'+W<T<$UG(TAD9[>4\YSE=K
M;E YZ #&!CCBN2UGX6:A:JTNDW"7J[C^Y<".0+D8 ).UB 3DG;TX'.*];HJE
M)H3BF?-,T$UM,T-Q#+#,N-T<J%&7(R,@\C@BMOP?XB/AK7%N'YM)P(KD$M@)
MG[^!G)7DC@\%@,9S7=?%31Q<:5;ZM%$3+;/Y<K#:/W3=">YPVT  \;VX[CR:
MM$^9&;]UGTU7'^*_'7_",:I%9?V;]IWPB7?Y^S&688QM/]W]:WO#SR2^&M*D
MED>21K.%G=V)9B4&22>IKB?B!X6UG6]>@N=.L_.A6U6,MYJ+A@S'&&([$5G%
M*^IHV[:$7_"W?^H'_P"3?_V%'_"W?^H'_P"3?_V%<Q_PKWQ3_P! O_R8B_\
MBJ/^%>^*?^@7_P"3$7_Q57:)%Y'3_P#"W?\ J!_^3?\ ]A78>%/$?_"3Z7+>
M_9/LVR8Q;/,WYPJG.<#^]^E>4?\ "O?%/_0+_P#)B+_XJO2?A_HU_HF@SVVH
MP>3,UTT@7>K94JHSE2>X-*2C;0<6[ZG%?%9)!XGM9#&XB:R55<J=K$.^0#ZC
M(S]1ZURWA]=WB;2!_P!/\!_*137I'Q8L/-T:QOU65FMYS&=HRJJXY9N..44
MYQ\V.XKR5@&4J>A&#51UB3+1GTW16?H>K1:YHMKJ4(VK.F2O/R,#AER0,X8$
M9QSC-:%9&H4444@"BBB@ HKPBY\;ZXVM7=_9:G=Q1S.WE12;2J1D_*-AR@8
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M #Z:=_W[?_XNC_A5.N_\_>G?]_'_ /B*/^%4Z[_S]Z=_W\?_ .(J?='[P?\
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MHHH **** "BBB@ HHHH **** "BBB@"];_ZA?QJ6HK?_ %"_C4M0]R@HHHI
M%%%% !1110 4444 %%%% !1110 4444 %%%% %.[_P!8/I4%3W?^L'TJ"M%L
M(****!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M +^/_P#$5/NE>\5-2^(VJZKIMQ875EIS0SH4;]TQ(]",L1D'!![$"N0KNO\
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M['A==E9?#36;^PM[R*YL!'<1+*@:1\@, 1GY>O-<;7T/X;_Y%?2/^O*'_P!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5)#_ *Y?K4=20_ZY?K0!G>._^2>>)O\ L%77_HIJ
M^(*^W_'?_)//$W_8*NO_ $4U?$%9E!1110!]O^!/^2>>&?\ L%6O_HI:Z"N?
M\"?\D\\,_P#8*M?_ $4M=!0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %36O\
MKOPJ&IK7_7?A0]@)[G_4GZU2J[<_ZD_6J5*.PV%%%%,04444 %%%% !1110
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MUO$.N,,'6M2_"[D']:OD9/.CZ(HKQ_1OBAJMI+MU5%OX&;)956.1!QTP I
M/! ))^\!7JVGZG9:K:BYL+J*XAZ%HVSM. <$=0<$<'D9J6FBDTRU1114C"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M /&5)/)&>RYP016CTC8S6KN=O7F7Q=_Y@_\ VW_]IUZ;7F7Q=_Y@_P#VW_\
M:=9PW+EL<Q\/?^1YT[_MK_Z*>O=*\+^'O_(\Z=_VU_\ 13U[I3GN$-@HHHJ"
MCQ_XK?\ (T6W_7DO_H;T?"G_ )&BY_Z\F_\ 0TH^*W_(T6W_ %Y+_P"AO1\*
M?^1HN?\ KR;_ -#2M?LF?VCV"N9^(7_(C:C_ -LO_1J5TU<O\0SCP+J)]XA_
MY%2LUN6]CPVOIJOF6O7/#?Q&TC^Q[>VU6>>"ZMX4C>256E\X@8W!@"<G )R!
MRW?K6DTV1!V.^KF?B%_R(VH_]LO_ $:E:NDZ]I>NQROIMVDXB(#@ JRYZ9!
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M6LM#UFBBBL34**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*4=124HZB@#2HHHK,H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#.?_ %C?4TVG/_K&^IIM:$A1110 4444 %%%% !1110 4444 %%%% !1110
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M5$E9EIW1\SNCQNT<D;QR(2K(ZD,I'4$'H1Z5WOPP\0)8W\VD74J)#=D/ 6(
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MZBBBL34**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2_['\4W]JJ;(3)YL.(O+78_S *.F%R5R./E/3I6A\/-872?%44<K.(+T?9B
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MK?6E+8:&W?5/QJM5F[ZI^-5J%L#"BBBF(**** "BBB@ HHHH **** "BBB@
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M()P>GK@ BM82Z&<UU,_4]2NM7OY+Z]96N) H=E7:&VJ%SCU('..,] .E=?\
M"G_D:+G_ *\F_P#0TKA:[KX4_P#(T7/_ %Y-_P"AI52V%'<]@KF?B%_R(VH_
M]LO_ $:E=-7,_$+_ )$;4?\ ME_Z-2L5N:/8\+KZ'\-_\BOI'_7E#_Z *^>*
M^A_#?_(KZ1_UY0_^@"M*A$#3HHHK(T"BBB@ HHHH *YGXA?\B-J/_;+_ -&I
M735S/Q"_Y$;4?^V7_HU*:W$]CPNOH?PW_P BOI'_ %Y0_P#H KYXKZ'\-_\
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M!/\ DGGAG_L%6O\ Z*6N@H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *H3_Z]JOU0G_U[54=Q,CHHHJA!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %<C\0?$CZ%HBP6QQ>7VZ-&#,IC0#YG!'\0RH'(Y;/
M."*ZZO(/BL\A\2VL9D<QK9JRH6.T$N^2!ZG S]!Z545=BD[(X, *    .@%=
MEX>^'>HZ[9+>S7"6-M*I,1>,N[],';D?*>><]NF"#6%X<TO^V?$5A8,$,<LH
M,JLQ4-&OS.,CD$J"![XY'6OH:KE*VB(C&YQ%O\+- ANDEDFO[A%SF&250C<=
M]JAO?@CI5B]^&GARZA5(8;BS8-N,D$Q)(]/GW#'X9XZUU]%1S,NR/+M;^%4D
M47FZ)=M,57YH+H@,Q )^5P ,GY0 0!U):O.IX)[69H;B"6"5<;HY4*,N1D9!
MY'!KZ6KS+XK:/:Q16NLQJD=Q++]GFVKS+\I*DG/4!".F2".?E%5&3O9DRBMT
M8GPY\1-I&MC3Y>;34)%0Y+?NY.BD 9'S'"GC^Z<X6O:*^9" RD$9!&#7T=H]
MW+?Z'I][.J+-<6T<KA 0H9E!.,]LFB:UN$'T+M%%%9EA1110 4444 %%%% !
M7A?Q"_Y'G4?^V7_HI*]TKPOXA?\ (\ZC_P!LO_125<-R9['3_"+_ )C'_;#_
M -J5Z;7F7PB_YC'_ &P_]J5Z5++'!"\TTB1Q1J6=W;"J!R22>@I3W".P^BLL
M>)=!(R-;TTC_ *^D_P :LV6J:?J1D%C?VMT8\;Q!,K[<YQG!XS@_E2*+=%%%
M( KDM7^'FDZUJ]SJ5S<7J37!4NL;H%&%"C&5)Z*.]=;133L#5SF_#_@G3?#>
MH/>V<]V\CQ&(B9U(P2#V4<_**Z2BBANX6L%%%%( HJ&ZNK>RMVN+NXBMX$QN
MDE<*JY.!DGCJ0*HCQ)H1&1K>FG_MZ3_&F!J45GV^O:/=W*6UMJUC-.^=D4=P
MC,V!DX .3P"?PK0H ****0!1110 44R66.WADFFD2.*-2[N[ *JCDDD] *SA
MXET%AD:WII^EVG^-,#4HK/M]=TB[N4M[;5;&:=\[8H[A&9L#)P <G@$UH4 %
M%%%(#POX@@#QSJ6!U\K/_?I*Z?X1?\QC_MA_[4KF/B%_R/.H_P#;+_T4E=/\
M(O\ F,?]L/\ VI6K^$S7Q'IM%%%9&@445#=75O96[7%W<16\"8W22N%5<G R
M3QU(% $U%98\2:$>FM::?^WI/\:DM]=TB[N4MK;5;&:=\[8H[A&9L#)P <G@
M$_A3 T****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M4UK_ *[\*AJ:U_UWX4/8">Y_U)^M4JNW/^I/UJE2CL-A1113$%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'D
MWQ9N_,UC3K+RL>1;M*)-WWM[8QC';R^N>_M7(>'])&NZ[:Z89_(\\L!)LW8V
MHS=,C^[ZUH>.KU;[QGJ+QSO+%&XA7=G"%%"LH!Z#>&Z<9)/>MCX5V33^);B[
M:!'BMK8@2-@F.1B N.^2HD&1VR._.VT3+>1I_P#"HO\ J.?^2G_V='_"HO\
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MHJ&VRTK!7GGQ1TV^U#^ROL5E<W.SSM_DQ,^W.S&<#CH?RKT.BA.SN)JZ/&O
MVB:M:>,K">YTR]AA7S-TDENZJ,QL!DD>M>RT44V[@E8****D9Y7\2])U*_\
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MY^7&WG->L6-C;:;916=G"L-O$NU$7M_B2>23R2<FK%%2VV4DD%%%%2,****
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M=V"5CYX_X1S7?^@+J/\ X"O_ (4?\(YKO_0%U'_P%?\ PKZ'HJN=D\A\\?\
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M[Q'/&48KR,X/..#^5?2M%6IM$N"/F4D 9)Q6MH_AK5]=>/[#92-#)R+AQMB
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M444 %7+3_5M]:IU<M/\ 5M]:4MAHCN_OK]*KU8N_OK]*KTUL#"BBB@04444
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M@+J/_@*_^%'_  CFN_\ 0%U'_P !7_PKZ'HHYV'(?.S>'];49.B:G^%G(?\
MV6N@T_X:>(;N8K<Q0V4:LN7EE#DJ3R5"9R0.Q*YR.>N/::*7.Q\B.9\.>!]*
M\.NER@>YOE4C[1*?NY !VKT4<'U.&(R173445-[E!1112 \:\<Z)JUWXROY[
M;3+V:%O+VR1V[LIQ&H."!ZUSO_".:[_T!=1_\!7_ ,*^AZ*T4R7 ^>/^$<UW
M_H"ZC_X"O_A1_P (YKO_ $!=1_\  5_\*^AZ*.=BY#YX_P"$<UW_ * NH_\
M@*_^%'_".:[_ - 74?\ P%?_  KZ'HHYV'(>->!M$U:T\96$]SIE[#"OF;I)
M+=U49C8#)(]:]EHHJ6[E)6"BBBI&%%%% !1110 4444 %%%% !1110 4444
M%%%% %ZW_P!0OXU+45O_ *A?QJ6H>Y04444@"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@"G=_P"L'TJ"I[O_ %@^E05HMA!1110(**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#PG7] UF;Q'JDL6D7[QO=RLCK;.0P+G!!QR*]$^&EE=V'A
MRXBO+6:WD-VS!)HRA(V)S@]N#7945;E=6)4;.YYC\2DUC5-4M[*RL+V>SMX]
M[&*WD*F5NN3C:V%VX(Z;F&>H'&6GA76KF]M[>33+^!)I4C:9K1R(PQ W'@<#
M.>HZ5] T4*5E8'&[N,BBC@A2&&-8XHU"HB+A5 X  '04^BBH*"BBB@ HHHH
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MHH **** "K=I]UOK52K=I]UOK2EL-#;OJGXU6JS=]4_&JU"V!A1113$%%%%
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M@HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "I(
M?]<OUJ.I(?\ 7+]: ,[QW_R3SQ-_V"KK_P!%-7Q!7V_X[_Y)YXF_[!5U_P"B
MFKX@K,H**** /M_P)_R3SPS_ -@JU_\ 12UT%<_X$_Y)YX9_[!5K_P"BEKH*
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J$_P#KVJ_5
M"?\ U[54=Q,CHHHJA!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH *9++';PR332)'%&I=W=@%51R22>@%/K
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M(YQBM2OF='>*1)(W9)$8,CJ<%2#D$'L0:]7\"^.YM5N1I.K,7O'+-!<*@ D
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %*.HI*4=10!I4445F4%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!G/\ ZQOJ:;3G_P!8WU--K0D**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%7+3_5M]:IU<M/\ 5M]:4MAHCN_OK]*KU8N_OK]*KTUL#"BBB@04444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 7K?_ %"_C4M16_\ J%_&I:A[E!1112 *
M*** "BBB@ HHHH **** "BBB@ HHHH **** *=W_ *P?2H*GN_\ 6#Z5!6BV
M$%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "K=I]UOK52K=I]UOK2EL-#;OJGXU6JS=]4_&JU"V!A1113$%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *4=124HZB@#2HHHK,
MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#.?\ UC?4TVG/_K&^
MIIM:$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5<M/]6WUJG5RT_P!6WUI2V&B.[^^O
MTJO5B[^^OTJO36P,****!!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!>
MM_\ 4+^-2U%;_P"H7\:EJ'N4%%%%( HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH IW?\ K!]*@J>[_P!8/I4%:+804444""BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *MVGW6^M5*MVGW6^M*6PT-N^
MJ?C5:K-WU3\:K4+8&%%%%,04444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !4D/^N7ZU'4D/\ KE^M &=X[_Y)YXF_[!5U_P"BFKX@K[?\
M=_\ )//$W_8*NO\ T4U?$%9E!1110!]O^!/^2>>&?^P5:_\ HI:Z"N?\"?\
M)//#/_8*M?\ T4M=!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 50G_U[5?JA/\ Z]JJ.XF1T4450@HHHH **** "BBB@ HHHH ****
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M3G=+E(MV]&"LJ9&\@GH0FX\<^G.*S-#<K-U3P_I.M*?[0L(9V*A?,*XD"@Y
M#C# 9[ ]SZUX0OB#7%Z:UJ?XWDA_]FKVKPCXAM_$&B0NMQYEY!&B7:LH5A)C
MEL#C#$$@CCJ.""!3BT2I)G.W_P )].FW-8:A<VS-(6Q*HE15Y^4#Y3Z<DGIW
MZUS-_P##'Q!:[FMA;WJ&0JHBEVOMYPS!\ =!P">3WZU[/124F'*CYPO]+O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %*.H
MI*4=10!I4445F4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!G/_
M *QOJ:;3G_UC?4TVM"0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *N6G^K;ZU3JY:?ZM
MOK2EL-$=W]]?I5>K%W]]?I5>FM@84444""BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@"];_ZA?QJ6HK?_ %"_C4M0]R@HHHI %%%% !1110 4444 %%%%
M !1110 4444 %%%% %.[_P!8/I4%3W?^L'TJ"M%L(****!!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %6[3[K?6JE6[3[K
M?6E+8:&W?5/QJM5F[ZI^-5J%L#"BBBF(**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ J2'_7+]:CJ2'_ %R_6@#.\=_\D\\3?]@JZ_\
M135\05]O^._^2>>)O^P5=?\ HIJ^(*S*"BBB@#[?\"?\D\\,_P#8*M?_ $4M
M=!7/^!/^2>>&?^P5:_\ HI:Z"@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ JA/\ Z]JOU0G_ ->U5'<3(Z***H04444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !63XC\/VWB326L;AWC(;S(I%_@< @''<<D$
M'U['!&M13 ^<]7TF\T34I+"^CV3)R".5=3T93W!_Q!P0152&::VG2>WFDAF3
M.R2)RC+D8.".1P2/QKZ'U71-,UN%8M2LX[A5^ZS##)R"=K#D9P,X/..:\]U/
MX33JQ;2=21U+ ".[!4JN.3O4')SVVC@^W.BFGN9N#Z&/:_$WQ);0LCR6ETQ;
M<'N(.0..!L*C'X9YZUJ2?%J^-@$BTNW6\VKF5I&://&X[.#@\X&[CCD]\)_A
M[XI2:1%TS>JL5$BW$6UP#U&6!P?< ^U)_P *]\4_] O_ ,F(O_BJ=HA>1-J'
MQ&\1W\(C6>&T4JRO]ECVE@?=BQ!'8J0>?I7*R2/+*\LCL\CL6=V.2Q/))/<F
MNJM?AQXFN9FCDM(K50N1)/.I4GCCY"QS^&.*[+0/AEI]B(Y]6<7UR,-Y0R(5
M/!QCJ^"#UP"#RM%XK8+29R7@KP2_B&07M\'CTM&QP2&G(ZJI[+ZM^ YR1[33
M(HHX(4AAC2.*-0J(BX50.  !T%/K-NY:5@KQKXEZ1=6GB634F5GM+Q4VR;?E
M1U4*4)SUPN[G&<G&=IKV6J][96VHV4MG>0K-;RKM=&[_ .![@CD&B+LP:NCY
MO1WBD22-V21&#*ZG!4CD$$="#WKMM.^*.MVS1)>Q6UY$N[S&*>7(^<X^9?E&
M./X>@]>:N:Q\*KN$M)H]VMQ&%)\JX.V3( P P&UB3GKM X^M8(^'WBDC_D%$
M?]O$7_Q5:7BS.TD:6H_%+6KDRI90VUG&V-C!?,D3&,\GY3GG^'H?7FN=TC3K
M[Q5K\5H;F1YYN9;B;=(551RS'J>  ,D<E1D9K<TOX9Z]>7#+?)'I\*]9'=92
MW!^ZJMSR!G)7KQFO4?#WAO3_  U9O;V*NS2-NDFE(,C^@)  P,X   Z]R24V
MEL-)O<^?*]T^'O\ R(VG?]M?_1KUPO\ PJG7?^?O3O\ OX__ ,17I'A;2I]$
M\-VFG7+QO-#OW-&25.79AC('8^E$VFAQ33-BO"_B%_R/.H_]LO\ T4E>Z5YO
MXI^'^K:WXDN]1MKBR2&;9M61W##"*ISA3W'K4P=F.2NCSB'3KFXTR\U",(;>
MS:-9LM@C>2%('<9&/7D<=<7M!\4ZKX<=OL$RF%VW/!*NY&.,9]0>G0C.!G(%
M>G>"O!]UH$.IPZF;2XBO%1-B$NI4;@P8,HX.[^=86N_"LHKSZ%<%@,M]EN&Y
M[G"O_P!\@!OJ6JN97LR>5VNBO_PMG4?[.V?V;:_;O^>VYO+Z_P#//KTX^]UY
M]JY77O%&J^)'3[?,ODQMOC@B7;&C8QG'4GKR2<9., XJ\/A]XIQ_R"B/;[1%
M_P#%5=TOX9Z[>7#+?)'I\*]9'=9&;@_=53SR!G)'7C-/W4+WF<E:6EQ?W<5I
M:0M-<3-MCC3JQ_IZDG@ $GBO>_"^@Q^'-#BLEYF;]Y<,'+!I2 &QD#C@ <#@
M<\YIF@>$M)\-[GLHG:X==CW$S;G9<YQZ =.@&<#.<5N5$I7+C&P5X/X^_P"1
M\U?_ 'XO_1,=>\5X/X^_Y'S5_P#?B_\ 1,=$-PGL:_PJ_P"1KN/^O%__ $..
MO8:\>^%7_(UW'_7B_P#Z''7L-$]PAL8?BW0/^$DT"6R1T2X5A+ [YVJX]<=B
M"1WQG.#BO![NTN+"[EM+N%H;B%MLD;]5/^>01P001Q7TI6+K_A;2_$<.V]AV
MS#:%N8@!*H!)V[B#D<G@Y'.>N#1&5@E&YX=I6M:EH<TLNF7;VTDRA'*JK!@.
MF0P(R.<''&3ZFNSLOBSJ"&3[=IMK.#C9Y#-%MZYSG=GMZ?C5?4_A9K%HA>PN
M(+\!1E,>3(S9P0 25P!SDL._'KECX?>*2/\ D%$?6XB_^*J_=9'O(OWOQ0U^
MX69+=;.U5FS&\<1:1%SD#+$J3C@G;] *XZ:>:YF::XFEFF;&Z25R[-@8&2>3
MP /PKHT^'GBAYD0Z:$5F ,C7$>U0>YPQ.![ GVKJ-)^%"*\<NL7_ )@'+V]L
M" 2&X&\\D$=0 #SP>.2\4.TF<WX#\,G7]9\^XC?^S[0AY&* I(X((B.>N1R>
M#QP<;@:]OIL44<,211(L<:*%1$& H'0 =A3JS;NRTK%34].M]6TRYT^Z&89T
M*,0 2OHPR",@X(.."!7@_B+P[>^&]1^RW8WQMDPSJ,+*OJ/0CN.WN""?H.J6
MJ:38ZU9FTU"W6>'<'"DD$$="",$'MQV)'0T1E8)1N?/^FZOJ.CSF;3KV6VD/
MWMARK<$#<IRK8R<9!QG-=K9?%G4$,GV[3;6<''E^0S1;>N<YW9[>GXTFJ?"F
M_@#R:9>Q72C>PBF'EO@?=4'D,3TR=HS]>,0?#[Q2?^841];B+_XJM/=9G[R+
M6J?$K7M0BE@A,-E$['#0*?,"'(VEB3SR/F4*<C(Q7(R2/-*\LKL\CL6=V.2Q
M/))/<UU$'PZ\3S7"Q/8I C9S++.A5>.^TEO;@'K7;>'?AI8::4N-59+^XVD&
M%D!@7(&>#]XCYL$X'/W01FB\5L.S>Y1^&7ADQ1_V_=QNLC@I:(Z#&P@?O1WY
MY Z<9/(85Z11163=V:)6/#/B$DB>.-0+QNJN(F0LI 8>6HR/49!'U!K*T/7+
MWP]J7VZQ\KS?+:-EE3<K*<'!Y!Z@'@CIZ9%>Q>+_  A;^)K/>FR'4HEQ#.1P
M1UV/C^']03D=P?,G^'GBA970::'56*AUN(]K@=QE@<'W /L*T4DU9F;3O='3
MK\7HPP,VBNL0/SE+G<P'? *C)]LCZUZ3-#%<0R0S1I)%(I1T=0593P00>H->
M&/\ #[Q3M(_LDMD=KB+_ .+KW:IDET*C?J?/OB3P]=>&]6DM9D;[.S,;:8G/
MF1YXYP/F QN&!@^Q!-+3=3O=(O5O-/N&@N I7>H!R#U!!R".AP1U /85]!:I
MI-CK5F;34+=9X=P<*2001T((P0>W'8D=#7F>J?"F_@#R:9>Q72C>PBE'EO@?
M=4'E6)Z9.T9],\4I)JS)<7T(+'XJ:U \*WEO9W,*+B0A&CDD.,9W E0<\G"X
MZX [2WGQ8U5YU-E86<,.W!2;=*Q;GG<"HQC'&/QK%'P^\4GKI)'UN(O_ (JA
MOA_XI XTDM]+B+_XJG:(7D9FM:]J/B"[%QJ$_F%,B- ,)&"<X4?ER<DX&2<5
M;\(Z!)XAU^&W,3M9QL'NG X5/0G(P6QM&#GDGL:ZG3/A/=-<,=6OXD@'1;0E
MG;@]V4!<''9L\]*]*T_3;+2K46UA:Q6\(P2L:XW' &2>I. .3R<4G))60*+O
M=EJBBBLC0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J:U_UWX5
M#4UK_KOPH>P$]S_J3]:I5=N?]2?K5*E'8;"BBBF(**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *J:GI\&K:9<6%TN8
M9T*-@ E?1AD$9!P0<<$"K=%,#YTUG2KC1-7N-/N48/$QV,RX\Q,G:XY/!QZG
M!R#R#3=-U?4='G,VG7LMM(?O;#\K<$#<IRK8R<9!QG->^ZSHUGKVF26%\A:-
M^59>&C;LRGL1_P#6.02*\SU/X5:G#-*^FW4%S;A2R)*2DI.3A.FTG&/F)4$G
MH!6BDGN9N+6Q)9?%G4$,GV[3;6<''E^0S1;>N<YW9[>GXU2O/BCK]PLR0)9V
MJLV8W2(M(BYR!EB5)QP3M_ 50'P^\4D?\@HCZW$7_P 54EO\.?$\UPL3V*0(
MV<RR3H57COM)/MP#UIVB%Y'+.S22/([,\CL6=V.2S$Y))[DGO7=?#GPJ-4NQ
MK-XDJVMK(K6V/E6:13USG)"D#V)XSPPK;\/?"^&TEBNM;N$N9$;<+:$?NN,_
M>)&7'W3C"\@@[A7HE3*71#C'JPHHHK,L\K^*'AUH;D>((.8I2D5PH#$J^,*Y
M/( ("KVYQU+5YW'(\,J2Q.R2(P9'4X*D<@@]C7TK+%'<0R0S1I)%(I1T=059
M3P00>H->?^(?A?!=RR76C3K;2NVXVTH_=<X^Z0,J/O'&#U &T5I&71D2CU1S
M&E_$G7]/BB@F:"]B1AEKA3YA08&T,".>#\S!CDY.:GU'XHZW=&5+**VLHFV^
M6P3S)4QC/S-\ISS_  ]#Z\U0?X>>*$F=!IH=58@2+<1[7 [C+ X/N :8WP_\
M4@<:26^EQ%_\756B*\CGI[B>ZF::YFEGF;&Z25R[-@8&2>3P!7:?#[PG<:CJ
M5OK%RFRPMI-\>[(,TB]-N".%;!)Z9&,'G&KHWPIVR^9K=XKHK<06I.''!^9R
M 0#\P( ST(85Z7%%'#$D42+'&BA41!@*!T '85,I=$.,>K'4445F6%%%% !6
M1XK_ .1.UO\ [!\__HMJUZHZW92:EH.HV$+(LMS:RPH7)"@LI SCMS3 ^<Z]
MR^'G_(BZ=]9?_1KUP_\ PJG7?^?O3O\ OX__ ,17H_A729]#\-VFG7+QO-"7
MW-$25.YV88R >A]*N;31$4TS9HHHK,L\;^*G_(XP_P#8/C_]&2UG?#[_ )'K
M3/K+_P"BGKMO&O@?4_$>O1W]G/:)$MJD)$SL&R&<]E/'S"JOA?X?:MHGB2SU
M&YN+)X82^Y8W<L<HRC&5 ZD=ZU37+8AI\QZ3111619D>*_\ D3M;_P"P?/\
M^BVKY\KZ,UNRDU+0=1L(619;FUEA0N2%!92!G';FO+?^%4Z[_P _>G?]_'_^
M(K2#2(FFSN/AY_R(NG?67_T:]=16-X5TF?0_#=IIUR\;S0E]S1$E3N=F&,@'
MH?2MFH>Y:V/(_B7X9-C??VW:QN;:Y;_2 J +#)P >.SGN1][O\P%<''(\4J2
MQNR2(P9'4X*D<@@]C7TQ7#:U\,-+U"7SM/F;3G9LNBIYD9ZDX7(VGD=#@ 8
MJXSZ,B4>J.(T_P"(GB.P*A[M+N-8]BQW,8/3'S%AAB>.I)SDYYJCJGC#7]8B
ME@NM1D^S2,Q,,2B-=I!&S*@%EP<88G/?)K='PJU['S76FCZ2R'_V2I[7X3ZH
M\K"[U&SACV_*\0:4[O3:0O'7G/X55XBM(\_ 8@[49BJEB%4DX ))P.P )/H
M:*]GNO".E>'?"&NM8Q.UQ)ITZ/<3-N=EV,<>@'3H!G SG%>,4XRN)JQ[E\//
M^1%T[ZR_^C7KJ*Y;X='=X$TX_P"U,/\ R*]=36+W-%L%%%%(84444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5<M?]4?
MK5.KEK_JC]:4MAHCN_\ 6+]*KU8N_P#6+]*KTUL#"BBB@04444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !2CJ*2E'44 :5%%%9E!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 9S_ .L;ZFFTY_\ 6-]33:T)"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ JY:?ZMOK5.KEI_JV^M*6PT1W?WU^E5ZL7?WU^E5Z:V
M!A1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +UO_ *A?QJ6HK?\
MU"_C4M0]R@HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% %.[_ -8/
MI4%3W?\ K!]*@K1;""BBB@04444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !5NT^ZWUJI5NT^ZWUI2V&AMWU3\:K59N^J?C5:A
M; PHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MDA_UR_6HZDA_UR_6@#.\=_\ )//$W_8*NO\ T4U?$%?;_CO_ ))YXF_[!5U_
MZ*:OB"LR@HHHH ^W_ G_ "3SPS_V"K7_ -%+705S_@3_ ))YX9_[!5K_ .BE
MKH* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J$_^O:K
M]4)_]>U5'<3(Z***H04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSE&FM[:.)RA)4LJ@'&>V15VBBLC4****0!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !5RU_U1^M4ZN6O^J/UI2V&B
M.[_UB_2J]6+O_6+]*KTUL#"BBB@04444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !2CJ*2E'44 :5%%%9E!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 9S_ZQOJ:;3G_UC?4TVM"0HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *N6
MG^K;ZU3JY:?ZMOK2EL-$=W]]?I5>K%W]]?I5>FM@84444""BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@"];_ZA?QJ6HK?_4+^-2U#W*"BBBD 4444 %%%
M% !1110 4444 %%%% !1110 4444 4[O_6#Z5!4]W_K!]*@K1;""BBB@0444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5NT^
MZWUJI5NT^ZWUI2V&AMWU3\:K59N^J?C5:A; PHHHIB"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *DA_P!<OUJ.I(?]<OUH SO'?_)/
M/$W_ &"KK_T4U?$%?;_CO_DGGB;_ +!5U_Z*:OB"LR@HHHH ^W_ G_)//#/_
M &"K7_T4M=!7/^!/^2>>&?\ L%6O_HI:Z"@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*=114%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !2CJ*2E'44 :5%%%9E!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 9S_P"L;ZFFTY_]8WU--K0D****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "KEI_JV^M4ZN6G^K;ZTI;#1'=_?7Z57JQ=_?7Z5
M7IK8&%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH O6_^H7\:EJ*W
M_P!0OXU+4/<H****0!1110 4444 %%%% !1110 4444 %%%% !1110!3N_\
M6#Z5!4]W_K!]*@K1;""BBB@04444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !5NT^ZWUJI5NT^ZWUI2V&AMWU3\:K59N^J?C5:
MA; PHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*DA_UR_6HZDA_P!<OUH SO'?_)//$W_8*NO_ $4U?$%?;_CO_DGGB;_L%77_
M **:OB"LR@HHHH ^W_ G_)//#/\ V"K7_P!%+705S_@3_DGGAG_L%6O_ **6
MN@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *H3_ .O:
MK]4)_P#7M51W$R.BBBJ$%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %36O^N_"H:FM?]=^%#V GN?]2?K5*KMS_J3]:I4H
M[#84444Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5<M?\ 5'ZU3JY:_P"J/UI2V&B.[_UB_2J]6+O_ %B_2J]-
M; PHHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4HZBDI1U%
M &E1116904444 %%%% !1110 4444 %%%% !1110 4444 %%%% &<_\ K&^I
MIM.?_6-]33:T)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JY:?ZMOK5.KEI_JV^M*6P
MT1W?WU^E5ZL7?WU^E5Z:V!A1110(**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** +UO_J%_&I:BM_\ 4+^-2U#W*"BBBD 4444 %%%% !1110 4444 %%%%
M !1110 4444 4[O_ %@^E05/=_ZP?2H*T6P@HHHH$%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5;M/NM]:J5;M/NM]:4MA
MH;=]4_&JU6;OJGXU6H6P,****8@HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M58/VVY_Y[-1]MN?^>S4>S8<R-[RH_P"XOY4>5'_<7\JP?MMS_P ]FH^VW/\
MSV:CV;#F1O>5'_<7\J/*C_N+^58/VVY_Y[-1]MN?^>S4>S8<R-[RH_[B_E3E
M4*,* ![5S_VVY_Y[-6KILKRVQ:1BQW$9/X5,H-*XT[EID5CEE!^M)Y4?]Q?R
MK.U.XEAG01R%05SQ]:I?;;G_ )[-34&U<3:-[RH_[B_E1Y4?]Q?RK!^VW/\
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M5O;G</WS=:/9L.9'04445D4%%%% !1110 4444 %%%% !1110 4444 %%%%
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MV',C>\J/^XOY4>5'_<7\JP?MMS_SV:C[;<_\]FH]FPYD;WE1_P!Q?RH\J/\
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M58/VVY_Y[-1]MN?^>S4>S8<R-[RH_P"XOY4>5'_<7\JP?MMS_P ]FH^VW/\
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MV;#F1O>5'_<7\J/*C_N+^58/VVY_Y[-1]MN?^>S4>S8<R-[RH_[B_E1Y4?\
M<7\JP?MMS_SV:C[;<_\ /9J/9L.9&]Y4?]Q?RH\J/^XOY5@_;;G_ )[-1]MN
M?^>S4>S8<R-[RH_[B_E1Y4?]Q?RK!^VW/_/9J/MMS_SV:CV;#F1O>5'_ '%_
M*CRH_P"XOY5@_;;G_GLU'VVY_P">S4>S8<R-[RH_[B_E1Y4?]Q?RK!^VW/\
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M5'E1_P!Q?RK!^VW/_/9J/MMS_P ]FH]FPYD;WE1_W%_*CRH_[B_E6#]MN?\
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M5'E1_P!Q?RK!^VW/_/9J/MMS_P ]FH]FPYD;WE1_W%_*CRH_[B_E6#]MN?\
MGLU'VVY_Y[-1[-AS(WO*C_N+^5'E1_W%_*L'[;<_\]FH^VW/_/9J/9L.9&]Y
M4?\ <7\J/*C_ +B_E6#]MN?^>S4?;;G_ )[-1[-AS(WO*C_N+^5'E1_W%_*L
M'[;<_P#/9J/MMS_SV:CV;#F1O>5'_<7\J/*C_N+^58/VVY_Y[-1]MN?^>S4>
MS8<R-[RH_P"XOY4>5'_<7\JP?MMS_P ]FH^VW/\ SV:CV;#F1O>5'_<7\J/*
MC_N+^58/VVY_Y[-1]MN?^>S4>S8<R-[RH_[B_E1Y4?\ <7\JP?MMS_SV:C[;
M<_\ /9J/9L.9&]Y4?]Q?RH\J/^XOY5@_;;G_ )[-1]MN?^>S4>S8<R-[RH_[
MB_E1Y4?]Q?RK!^VW/_/9J/MMS_SV:CV;#F1O>5'_ '%_*CRH_P"XOY5@_;;G
M_GLU'VVY_P">S4>S8<R-[RH_[B_E1Y4?]Q?RK!^VW/\ SV:C[;<_\]FH]FPY
MD;WE1_W%_*CRH_[B_E6#]MN?^>S4?;;G_GLU'LV',C>\J/\ N+^5'E1_W%_*
ML'[;<_\ /9J/MMS_ ,]FH]FPYD;WE1_W%_*CRH_[B_E6#]MN?^>S4?;;G_GL
MU'LV',C>\J/^XOY4>5'_ '%_*L'[;<_\]FH^VW/_ #V:CV;#F1O>5'_<7\J/
M*C_N+^58/VVY_P">S4?;;G_GLU'LV',C>\J/^XOY4>5'_<7\JP?MMS_SV:C[
M;<_\]FH]FPYD;WE1_P!Q?RH\J/\ N+^58/VVY_Y[-1]MN?\ GLU'LV',C>\J
M/^XOY4>5'_<7\JP?MMS_ ,]FH^VW/_/9J/9L.9&]Y4?]Q?RH\J/^XOY5@_;;
MG_GLU'VVY_Y[-1[-AS(WO*C_ +B_E1Y4?]Q?RK!^VW/_ #V:C[;<_P#/9J/9
ML.9&]Y4?]Q?RH\J/^XOY5@_;;G_GLU'VVY_Y[-1[-AS(WO*C_N+^5'E1_P!Q
M?RK!^VW/_/9J/MMS_P ]FH]FPYD;WE1_W%_*CRH_[B_E6#]MN?\ GLU'VVY_
MY[-1[-AS(WO*C_N+^5'E1_W%_*L'[;<_\]FH^VW/_/9J/9L.9&]Y4?\ <7\J
M/*C_ +B_E6#]MN?^>S4?;;G_ )[-1[-AS(WO*C_N+^5'E1_W%_*L'[;<_P#/
M9J/MMS_SV:CV;#F1O>5'_<7\J/*C_N+^58/VVY_Y[-1]MN?^>S4>S8<R-[RH
M_P"XOY4>5'_<7\JP?MMS_P ]FH^VW/\ SV:CV;#F1O>5'_<7\J/*C_N+^58/
MVVY_Y[-1]MN?^>S4>S8<R-[RH_[B_E1Y4?\ <7\JP?MMS_SV:C[;<_\ /9J/
M9L.9&]Y4?]Q?RH\J/^XOY5@_;;G_ )[-1]MN?^>S4>S8<R-[RH_[B_E1Y4?]
MQ?RK!^VW/_/9J/MMS_SV:CV;#F1O>5'_ '%_*CRH_P"XOY5@_;;G_GLU'VVY
M_P">S4>S8<R-[RH_[B_E1Y4?]Q?RK!^VW/\ SV:C[;<_\]FH]FPYD;WE1_W%
M_*CRH_[B_E6#]MN?^>S4?;;G_GLU'LV',C>\J/\ N+^5'E1_W%_*L'[;<_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *O:5_Q^'_ '#5&KVE?\?A_P!PU,_A8+<O
MZI_QY-]16%6[JG_'DWU%8533V'+<****T$%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !6UI/_'HW^^?Y"L6MK2?^
M/1O]\_R%9U/A''<K:O\ \?$?^Y_6LZM'5_\ CXC_ -S^M9U.'PB>X44458!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %*OWU^M)2K]]?K2 ZBB
MBBN4T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YJ?_ (^)/]\_
MSJ.I)_\ CXD_WS_.HZZEL9A1113 **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *V=(_P"/9_\
M?_H*QJV=(_X]G_W_ .@K.I\(X[E?5_\ 7Q_[O]:SJT=7_P!?'_N_UK.IP^$'
MN%%%%6(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -[3?^/"/\?YU;JII
MO_'A'^/\ZMURRW9:V"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH ****
M,;5_^/E/]S^IK/K0U?\ X^4_W/ZFL^NF'PF;W"BBBJ **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K7T?\ U4G^\*R*U]'_
M -5)_O"HJ?"..XS6.L/X_P!*RZU-8ZP_C_2LNB'P@]PHHHJQ!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %6++_ (_8O]ZJ]6++_C]B
M_P!ZD]@0OCO_ ))YXF_[!5U_Z*:OB"OM_P =_P#)//$W_8*NO_135\05RF@4
M444 ?;_@3_DGGAG_ +!5K_Z*6N@KG_ G_)//#/\ V"K7_P!%+704 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %8&H?\ '_+^'\A6_6!J
M'_'_ "_A_(5I3W)D5:***W)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "KVE?\?A_W#5&KVE?\?A_W#4S^%@MR_JG_'DW
MU%85;NJ?\>3?45A5-/8<MPHHHK004444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %;6D_\ 'HW^^?Y"L6MK2?\ CT;_
M 'S_ "%9U/A''<K:O_Q\1_[G]:SJT=7_ ./B/_<_K6=3A\(GN%%%%6 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !2K]]?K24J_?7ZT@.HHHHKE
M- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .:G_ ./B3_?/\ZCJ
M2?\ X^)/]\_SJ.NI;&84444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "MG2/^/9_P#?_H*Q
MJV=(_P"/9_\ ?_H*SJ?"..Y7U?\ U\?^[_6LZM'5_P#7Q_[O]:SJ</A![A11
M15B"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#>TW_CPC_'^=6ZJ:;_QX
M1_C_ #JW7++=EK8****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH QM
M7_X^4_W/ZFL^M#5_^/E/]S^IK/KIA\)F]PHHHJ@"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *U]'_U4G^\*R*U]'_U4G^\
M*BI\(X[C-8ZP_C_2LNM36.L/X_TK+HA\(/<****L04444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !5BR_X_8O]ZJ]6++_ (_8O]ZD]@0O
MCO\ Y)YXF_[!5U_Z*:OB"OM_QW_R3SQ-_P!@JZ_]%-7Q!7*:!1110!]O^!/^
M2>>&?^P5:_\ HI:Z"N?\"?\ )//#/_8*M?\ T4M=!0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M61-XGT>WGDAEO-LD;%&'E.<$'![5$ZD(?$[%PISGI!-^AKT5GV&N:=J<[0V=
MQYDBKO(V,.,@=Q[BM"G&<9J\7="G"4':2LPHHHJB0HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P
M-0_X_P"7\/Y"M^L#4/\ C_E_#^0K2GN3(JT445N2%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %7M*_P"/P_[AJC5[2O\
MC\/^X:F?PL%N7]4_X\F^HK"K=U3_ (\F^HK"J:>PY;A1116@@HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *VM)_X
M]&_WS_(5BUM:3_QZ-_OG^0K.I\(X[E;5_P#CXC_W/ZUG5HZO_P ?$?\ N?UK
M.IP^$3W"BBBK **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I5^^
MOUI*5?OK]:0'44445RF@4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% '-3_\ 'Q)_OG^=1U)/_P ?$G^^?YU'74MC,****8!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !6SI'_ ![/_O\ ]!6-6SI'_'L_^_\ T%9U/A''<KZO_KX_]W^M9U:.K_Z^
M/_=_K6=3A\(/<****L04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ;VF_
M\>$?X_SJW533?^/"/\?YU;KEENRUL%%%%(84444 %%%% !1110 4444 %%%%
M !1110 4444 8VK_ /'RG^Y_4UGUH:O_ ,?*?[G]36?73#X3-[A1115 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5KZ/_
M *J3_>%9%:^C_P"JD_WA45/A''<9K'6'\?Z5EUJ:QUA_'^E9=$/A![A1115B
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC(620*2/7FK%>>^._P#D-P_]>R_^A-7-BZ[H4^=*YU82@J]7D;L=K_;&E_\
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *O:5_P ?A_W#5&KVE?\
M'X?]PU,_A8+<OZI_QY-]16%6[JG_ !Y-]16%4T]ARW"BBBM!!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5M:3_Q
MZ-_OG^0K%K:TG_CT;_?/\A6=3X1QW*VK_P#'Q'_N?UK.K1U?_CXC_P!S^M9U
M.'PB>X44458!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %*OWU^
MM)2K]]?K2 ZBBBBN4T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M YJ?_CXD_P!\_P ZCJ2?_CXD_P!\_P ZCKJ6QF%%%%, HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ K9TC_CV?_?\ Z"L:MG2/^/9_]_\ H*SJ?"..Y7U?_7Q_[O\ 6LZM'5_]
M?'_N_P!:SJ</A![A1115B"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#>
MTW_CPC_'^=6ZJ:;_ ,>$?X_SJW7++=EK8****0PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH QM7_ ./E/]S^IK/K0U?_ (^4_P!S^IK/KIA\)F]PHHHJ
M@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*U]'_P!5)_O"LBM?1_\ 52?[PJ*GPCCN,UCK#^/]*RZU-8ZP_C_2LNB'P@]P
MHHHJQ!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[-.DI&W._.4Q[??S^%>2L RE3T(P:9#T9]"T57L;M+_3[:\B5ECN(EE4.,,
MP!&??FK%(L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "KVE?\?A_W#5&KVE?\?A_W#4S
M^%@MR_JG_'DWU%85;NJ?\>3?45A5-/8<MPHHHK004444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %;6D_\ 'HW^^?Y"
ML6MK2?\ CT;_ 'S_ "%9U/A''<K:O_Q\1_[G]:SJT=7_ ./B/_<_K6=3A\(G
MN%%%%6 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2K]]?K24J_
M?7ZT@.HHHHKE- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .:G_
M ./B3_?/\ZCJ2?\ X^)/]\_SJ.NI;&84444P"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "MG2
M/^/9_P#?_H*QJV=(_P"/9_\ ?_H*SJ?"..Y7U?\ U\?^[_6LZM'5_P#7Q_[O
M]:SJ</A![A1115B"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#>TW_CPC
M_'^=6ZJ:;_QX1_C_ #JW7++=EK8****0PHHHH **** "BBB@ HHHH **** "
MBBB@ HHHH QM7_X^4_W/ZFL^M#5_^/E/]S^IK/KIA\)F]PHHHJ@"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *U]'_U4G^\
M*R*U]'_U4G^\*BI\(X[C-8ZP_C_2LNM36.L/X_TK+HA\(/<****L04444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5BR_X_8O]ZJ]6++_
M (_8O]ZD]@0OCO\ Y)YXF_[!5U_Z*:OB"OM_QW_R3SQ-_P!@JZ_]%-7Q!7*:
M!1110!]O^!/^2>>&?^P5:_\ HI:Z"N?\"?\ )//#/_8*M?\ T4M=!0 4444
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M"(03QD=3A>.F[..*]6KTLI@U"4^_Z'F9Q43G&';]?^&,7Q;_ ,BQ>?\  /\
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M'!X..:] \,>)5U*)+.\<"^48#$ "8#N.V['4#ZCC('G=*KO'(DD;;9(V#HV
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M+_T 5I5GZ#_R+NF?]>D7_H K0I%!1110,**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *O:5_Q^
M'_<-4:O:5_Q^'_<-3/X6"W+^J?\ 'DWU%85;NJ?\>3?45A5-/8<MPHHHK004
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %;6D_P#'HW^^?Y"L6MK2?^/1O]\_R%9U/A''<K:O_P ?$?\ N?UK.K1U
M?_CXC_W/ZUG4X?")[A1115@%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4J_?7ZTE*OWU^M(#J****Y30**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#FI_^/B3_?/\ZCJ2?_CXD_WS_.HZZEL9A1113 **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *V=(_X]G_W_P"@K&K9TC_CV?\ W_Z"LZGPCCN5]7_U\?\ N_UK
M.K1U?_7Q_P"[_6LZG#X0>X44458@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH WM-_P"/"/\ '^=6ZJ:;_P >$?X_SJW7++=EK8****0PHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH QM7_P"/E/\ <_J:SZT-7_X^4_W/ZFL^NF'P
MF;W"BBBJ **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ K7T?_52?[PK(K7T?_52?[PJ*GPCCN,UCK#^/]*RZU-8ZP_C_ $K+
MHA\(/<****L04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*5F6.XB:)RA&X!@0<9[\UZDXJ47%]3RJ<G":DNAX]1117QQ]H>E^#4">%;0
M?Q2G\Y&-;U8OA+_D6+/_ ('_ .AM6U7UN'_@P]%^1\?B?XT_5_F<)J7@[5KK
M5[JXCN+62&60NC32OO /.TC:>!T'/0#ITK+F\)ZY%<O$ECYJ+C$J2H%;CME@
M?;D"O3ZBN+F"S@:>YGC@A7&Z25PJC)P,D^Y KFJ9=0DW)W7S.FGF=>"459_(
MQ/">BMI6GO)<1/%>3MB56D# !68+C!QT.?7YN>@ Z"L*\\7Z/:>8JSO<R1X^
M2!,[LXZ,<*< YZ]CWXK'O/'WWEL;#K'\LEP^-K\]47.0./XAGGIUK18C#T(J
M',M/ZZ$/#XG$3<^5Z_+\SLY(TEC:.1%>-P596&0P/4$>E>-RV\MI*]M<%#-"
MQCD*'*EAP<>V:U[KQ9K5T3F[6!&CV,EO&%'?Y@3E@>>S=A6.[M([.[,SL<LS
M'))]2:\G'XJG7LH=#U\OPE7#W<^HVO0/ :XT6Y/]ZZ)_\<05Y_7H7@3_ ) D
MW_7RW_H*U.6?Q_DRLT_W?YHZ>O(M7 &MZAC_ )^9?_0S7KM>6^)M-;3==N 2
M[1W+-<1LW?<26&< <,3P,X!7/6N_-8-TE)=&>?E$TJKB^J,BND\*Z]9Z.9X[
MR/:LQ!\^.++# ;AB.2.F  <%CZUS=%>+1K2HS4XGN5Z,:T'"6Q[!:ZA97KR)
M:7EO<-%CS%BE5BF<XS@\9P?R-6:\6'#HXX=&#(PZJ1R"/0UJ6GB+5[/ COYG
M7S-[+,?,W=.,MD@''0$=\<UZ]/-H/XXV]#QJF3S7P2OZG2^(?"EYJ>L27EFU
MLD<D:[_-D<$N,@G&" -H3I[_ (T+3P'?OYGVR[MH<8\LP[I<^N<A<=O7\*FL
MO'DZMMO[-'4L27MR5*KC@;6)R<]\C@^W/1Z;XDTO5)%A@N=MPR@^3*-K9()P
M,\,0 <[2<8JXT\%B)N2U;Z;$3JX[#P47HEUW,K1O!ATS5X;Z:_6X$(8QHL&P
MAB"N2=QXP3QCOUKJZ**]"E2A2CRP5D>;5K3JRYIN[.5\=WB1Z1%8G86N9 Q5
ME)^5"&R#T!#;.OJ?PX"NG\=RRMKD$+/F%+961<#ABS!CGKR%7\JYBOGLQJ.5
M=KMH?29;34,.GWU'1HTT\4*,BO-(L2%SA=S$*,_B17K>F:9:Z39+:VJ;4!W,
MQY9V[LQ[G_ZP&  *\RT&[CL?$%C<SML@1G\QL$X!C8#@<]2*[_\ X2W0_P#G
M^_\ (3_X5UY8Z4(N<Y)/U./-%6J34(1;2[+J;59'B'0XM;T]DV+]KB5FMI"V
MW:V.A.#\IP,C!]>H!#/^$MT/_G^_\A/_ (4?\);H?_/]_P"0G_PKTI5\/*+C
M*2L_-'F0H8B$E*,'=>3/,,,.'1T8=4=2K*?0@]#[45:U/RFU6\D@N/M$4LSR
MK)L*_>8MC!],X]\9JK7R\THR:1]9"3E%-GJ'A6^DOO#UN\TJ23Q[HI"K$D;3
M\N[))W%=I.>N<]ZV:XOX?W$A74;4J@A0QRJ0#N+-N!SVQA%Q^-=I7U&%J>TH
MQD^Q\EBZ:IUY17<****Z#G"BBB@ HHHH *XOQ_<RJNGV@5/)D,DK$CY@R[0,
M>V';/X5VE8^M^'XM=EMS/<211PJXQ$!N)8K@Y.1@;3QCN.1CGGQ5.52C*$-V
M=&$J1IUHSGLCRZD(R" 2/<5Z)<^"--EL%AMWE@N$7BX)W%CC&67H1GDA=O3@
MBN(U33IM(U*2RG9&=5#JRG[Z$D!L=1T(P>X/4<GY^O@JM!<TMO(^CP^.I5WR
MQW\S>T+Q9:Z7;I:2Z:(H2Q9Y;=BWS%NI5B20%ZG<3\H '0#O4=)8UDC=71P&
M5E.00>A!KQBNE\)Z]-97L.GRMNLYWVKG.8W/3&.Q. 1TYSD<Y[<%CW=4ZFW0
MX<=ERY75I;]4>B4445[9X04444 %%%% !1110 4444 %8&H?\?\ +^'\A6_6
M!J'_ !_R_A_(5I3W)D5:***W)"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G?'1QX-O_
M *Q_^C%KQVO</$EHM]X;U&!H6F)@9TC3.6=1N7&.2=P''>O#Z:(D>R>"M/BT
M_P *V;1MO:Z073MR,EP".,GHNT<=<9QS7056TZ[-_IEI>&/RS<0I*4W9V[E!
MQGOC-6:104444#/,_B79P0:G8W2#;-<QN),  '9MP>F<X;'/8#TKFO#LTL'B
M73'A?:YN8T)P#\K,%8<^JDC\:[CXF7:)IEC9E6\R68RJ0. $7!S[_./R-<)H
M1QXBTO\ Z^X?_0Q3(>Y[I7A6N'/B'5#_ -/DP_\ 'S7NM>,>,;-;+Q7?I'"T
M4<CB5=V<.6 9F!/4;BW3CJ.U)#EL=)\+Y)"VK1EV,2B%E0L< G?D@>IP/R'I
M7H=>8_#2YD36;RU"KY4MOYC$@[MRL ,>WSM^E>G4#6P4444#.-^);R)X=ME1
MV57O%5P&(##8YP?49 /U KRQSA&/H*](^)US(MKIMH%7RI'>5B1R&4 #'MAV
M_2N$TFT6_P!8LK22%IHIIT21%SDH2-W3D#&23V'--$/<]XKQOQN<^,M1'H8Q
M_P"0TKV2O*/B)9K;^)1.D+*+F!7>0YP[C*G!/&0H3@>WK20Y;#_AM)(/$L\8
M=A$UF[,@8X)#I@D>HR?S/K7JE>0^ KF2#Q;;QQJI6X22*0L#D+M+\>^4'X9K
MUZ@([!11104<[XZ>2/P;?M$[(Q,:DJQ!P9%!'T()!]C7CM>K_$6YD@\,")%4
MK<7"1R;AR  7X]\J/PS7E*H\C!(D:21CA409+'L !U--$2W/<?#QSX:TH^MG
M#_Z *TJBM;:*SM(;6W39##&L<:Y)PH& ,GGH*EI%!1110,**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *O:5_Q^'_<-4:O:5_Q^'_<-3/X6"W+^J?\>3?45A5NZI_QY-]16%4T
M]ARW"BBBM!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5M:3_P >C?[Y_D*Q:VM)_P"/1O\ ?/\ (5G4^$<=RMJ_
M_'Q'_N?UK.K1U?\ X^(_]S^M9U.'PB>X44458!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %*OWU^M)2K]]?K2 ZBBBBN4T"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH YJ?\ X^)/]\_SJ.I)_P#CXD_WS_.HZZEL
M9A1113 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF92CXW*0<8(!..Q^A%(I.YH4444#"BJ6JZK::-8/>7DFV-> !]YV[*H[D_\
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M&!Z$&OGVO=-!_P"1=TS_ *](O_0!0).YH4444%!1110 4444 %%%% !1110
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M +O]:SJT=7_U\?\ N_UK.IP^$'N%%%%6(**** "BBB@ HHHH **** "BBB@
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %:^C_P"JD_WA616OH_\
MJI/]X5%3X1QW&:QUA_'^E9=:FL=8?Q_I671#X0>X44458@HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI_C7A=%%@YCW,^(-%'75[ ?6Y3_&KEO<P7D"SVT\<\+9VR1.&4X.#@CCJ*\
MI\,TMO.L\$KQ3)G;)&Q5ER,'!'(X-*P<Q] T5YIX6\=3V\BV6L2//$[(D5P2
MNZ/HOSDXRO<L<GKUSQZ704G<*CGN(;6%IKB:.&)?O/(P51VY)J2N>\<?\B=?
M_P#;/_T8M &C_;VC?]!:P_\  E/\:O1R)+&LD;J\;@,K*<A@>A!KY]KW30?^
M1=TS_KTB_P#0!0).YH4444%!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %6++_C]B_WJKU8LO\ C]B_WJ3V!"^._P#DGGB;_L%77_HI
MJ^(*^W_'?_)//$W_ &"KK_T4U?$%<IH%%%% 'V_X$_Y)YX9_[!5K_P"BEKH*
MY_P)_P D\\,_]@JU_P#12UT% !1110 4444 %%%% !1110 54U._33--GO'&
MX1+D+S\S'@#@'&20,XXJW7"^/;PM=6E@-X6-#.P*C:Q.54@]<@!_;YAU[88F
MM[&DYG1A:/MJR@<G-/-<S--<3--,YR\C=6/\A]!P*9117RC;;NSZY))61);O
M''=0R31^;$CAGCR!O YVG((P>AXZ9Z=1V'_"?_\ 4,_\C_\ V-<716]+$U:*
MM3=ON,*V%I5G>HK_ #9VG_"?_P#4,_\ (_\ ]C1_PG__ %#/_(__ -C7%T5K
M_:&)_F_!?Y&/]FX7^7\7_F=I_P )_P#]0S_R/_\ 8UVM>+5[37IY=B*E;F]H
M[VM^IY>9X:E0Y?9JU[_H%%%%>F>4%%%% !1110 4444 %%%% !1110 4444
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MDCO!;H%P8HHD*D\\_,"<_CCBO8_M2A:^IXG]DU[VT.F\<2VJZ+'%,"T[S P
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M6!J'_'_+^'\A6_6!J'_'_+^'\A6E/<F15HHHK<D**** "BBB@ HHHH ****
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M\_R%9U/A''<K:O\ \?$?^Y_6LZM'5_\ CXC_ -S^M9U.'PB>X44458!1110
M4444 %%%% %74;^#2].GOKEL10H6/(!;T49(&2< #N2*\.O[ZXU._FOKHH9Y
MFW.47 X   'H  /7CO7IWQ%N9(/# B15*W%PD;[AR  7X]\H/UKR<D*I8] ,
MFA$2-O0/#%_XAD8V^R*WC8"2>3.T=,@#^)L<XX]R,BO1;7P'X?MA$7M9+B2-
MMP>65OF.<C*@A2.V,<CKFM/0-*CT;1K>T6*))0@:<QY(>7 W-D\GGIGL .,8
MK2H&D8=UX.\/W<XFETV-6"[0(F:-<?[JD#//7&:\]\5^$9?#[+<VQDGT]L*9
M&P6B;IAL #!/0XZ\'G&?7J;)&DT3Q2HKQNI5D89# ]01W% VCP_0-8ET+6(K
MZ,97[DR[02T9(+ =.> 1R.0,\9KW".2.:))8G62-U#(ZG(8'H0>XKP.[MOL=
M]<VAD\PV\SPE]NW<58KG';ITKU?P#>?:_"L,9:5GMI'A9I#G/.X <] K*!Z8
MQTH9,>QT]%%%!84444 %%%% !1110 4444 %%%% !1110 4444 %%%5-4N9+
M/2+VZB"F2&!Y$#C(R%)&?;B@"S)(D,3RRNJ1HI9F8X"@=23V%>;^)_'DEPZV
MVASM';[?WEQLVL^1T7(RH&>O!STQCGEM5US4M:EWWURSJ&RL0XC3KC"],C)&
M3DXZDU7L;"[U.[%K8P-/.5+!%(' ZDDX '3DGJ0.]%B&^Q6KH? __(XV'_;3
M_P!%M3_$_AR/P[8:8C/YEW-YAG<$[<C9A5]AD\]3GZ ,\#_\CC8?]M/_ $6U
M,74]CHHHI&@5X?XBU=];UNXNV='B!,<!5-O[H$[>O.><G/<GIT'LNJQW$VCW
ML5H6%R]O(L11MI#E3C!['..:\471=7;II&H_C:2#^E")D6= \.W?B*YDBM7B
MC2':9I)#]T,<# '). Q X''45Z1:^ _#]L(BUJ]Q)&VX/-*WS<Y&5!"D=L8Z
M=<U9\(:=)I?AFT@GB2.=P99 JX.6)(W9 .X+M!SZ8[5N4 D8MWX1T"],9ETR
M%?+SCR<Q9SZ[",].]</XM\%'286U#3!)+9KDS1DY:$9SN'J@'![C&3D9(]2H
MH'8^>^HP:]C\%ZM)JWAR%YMYFMV\B1VR=Y4##9)))((R3WS7ENNZ:-(UV\L5
M"B..0^6%8MA#\RC)Y)"D9]_6NP^%X&[5F[D0C_T.F2MST.BBBD6%%%% !7GO
MQ0_YA7_;;_V2O0J\]^*'_,*_[;?^R4(E['GRH\C!(T>1V.%1%)9CV  ZFDK0
MT'_D8M,_Z^XO_0Q2Z]IZZ5KU[8H%$<4A\M58MM0_,HR><[2,_P!:9)ZIX*O/
MMGA.QRT1>%3 RQG[H0X4'G@[=I_'/>M^O.?AGJ#">]TQBQ5E%Q& HVJ1A6R>
MN3E/;Y3T[^C4BUL%%%% SC_B/>>1X<2U5HMUU.H9&/S;%^;*C/9@G//7W%>6
M*KNP2-&D=CA41268]@ .IKK?B)J#77B(68+>79QA=K*,;V 8D'J004'/<'\:
M7@G3UU#Q3;;PICM@;A@6()VXVXQW#%3Z8!^E,AZLYZO4OAK_ ,B[<?\ 7VW_
M * E>6UZE\-?^1=N/^OMO_0$H81W.RHHHI%A117-:CX[T*P8HD[WCA@"MJH8
M $9SN)"D?0GK]:!'2T5QO_"RM'Q_QZW_ /W[3_XNK-C\0-#O)3'(\]H2RJIN
M(QAB?=20 .Y.!S]: NCJ:*;'(DT22Q.KQNH974Y# ]"#W%.H&%%%4]2U6RT>
MV6XOYO)B9P@;8S?-@G' /H:!%RBL*W\8Z#=7,5O#?[I97"(ODR#+$X Y6MBX
MN(+2!I[F:.&)<;I)&"J,G R3[F@"6BN2N/B+H<,JK$+NY4KGS(HL >V'*G/X
M=ZB/Q*T<#BTOS]$3_P"+H"Z.RHK&TGQ5H^LNL5K=A;AE!\B4;'R020,\,0 <
M[2<8K9H *S]>_P"1=U/_ *])?_0#5RXGCM;:6XF;;%$A=VP3A0,D\5RVK^,=
M!NM%OK>&_P!TLMO(B+Y,@RQ4@#E: 9Y17NF@_P#(NZ9_UZ1?^@"O"Z]7TCQC
MH-KHMC;S7^V6*WC1U\F0X8* 1PM-DQ.MK/U[_D7=3_Z])?\ T T:7KFG:SYO
M]GW'G>5C?\C+C.<=0/0T:]_R+NI_]>DO_H!I%'A=>Z:#_P B[IG_ %Z1?^@"
MO"Z]TT'_ )%W3/\ KTB_] %-DQ-"BN:U#QWH5B2J7#WCA@"+5=PP1G.XD*1]
M">OUJE_PLK1\?\>M_P#]^T_^+I%71V5%8.E>,=%U9HXH[DP7#](;@;#G. ,_
M=).1@ D\_6MZ@ HHHH&%%17%S!9P-/<SQP0KC=)*X51DX&2?<@5S=]\0-#LY
M1'&T]V0S*QMXQA2/=B 0>Q&1Q]*!'4T5QO\ PLK1\?\ 'K?_ /?M/_BJGMOB
M)H,XD,S7-J$QCS82V_KTV;NGOCK0%T=714=O<07<"S6TT<T39VO&P93@X."/
M>I*!A1110 4444 %%%% !1110 4J_?7ZTE*OWU^M(#J****Y30**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#FI_^/B3_?/\ZCJ2?_CXD_WS_.HZ
MZEL9A1113 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** . ^)6J,B6FEQ28#@S3*-P) X3GH1G<<<\J#QWX?2=
M/;5=7M+!=^)Y K%& 8)U8C/&0H)_#O3M:U+^V-:N]0\O8)WRJD8(4 *N>3SM
M SSUKK/AKIB375WJ<D>[R,0PL=I 8C+<=00I7GCAR.>SZ$;LXBX@>UNI[:4H
MTD$C1.4.5W*2#CVR#7J/P\U1KW0Y+263?+9OM7.XD1GE<D\'D, !T ''KS?Q
M'L%MM>AO%" 7D7(W$L73 )QT VE!QZ'\<WP9J7]F>)[9C'O6Y_T9L#) <C!'
M(_B"Y]LTN@+1GLM%%%!84444 ?/=>D?#_3+"]T&>2ZL;:>073*&EB5B!M7C)
M'O7F]>I?#7_D7;C_ *^V_P#0$ILSCN=%_8.C?] FP_\  9/\*/[!T;_H$V'_
M (#)_A6A12+,"X\$^';FX:>335#MC(CE=%X&.%5@!^ K'U3X;V,RR2:9<26T
MIY6*0[X^!TS]X9.#DD]^*[>B@+(^?[BWFL[J6VN8FBGB;;)&W53_ )Y!Z$$$
M<5J>&M??P[JANO+:6"1=DT2M@LN<@@9P6'.,^I'&<UZ)XU\.Q:MI4EY#!NU"
MV3=&R [G4<E, $MQG ]?3)SY'3(>C/H**6.:))8G62-U#(Z'(8'H0>XIU<A\
M/-4:]T.2SEDWRV;[5!W$B-N5R3QU#  = !QZ]?2+"BBB@9@^,=4;2O#5Q)%)
MY=Q,1#$?FSENN".A"AB#Z@?2O&>@S78?$74OM>O1V0CPMDF-Q')9PK'!STP%
M[#G/M63X3TQ-6\2VMM+'YD"9FF7Y<;5]0>H+%5(]&_&F0]65M:T>;0[V*UG/
M[R2WCG*%@Q0L,,#@8X=7 QG@#DUT?PYU1K?6)=.>3]S<H613N/[Q>>.PRN[)
M/7:O-;WQ'L%GT&*^ 0/:2C+,Q'R.0I '0DMLZ]@?Q\RMKA[2[@NHU5I()%E0
M.,C<I!&?;(I ]&>_T5!9727UC;W<:LJ3Q+*JN/F 89 /OS4]!84444 >3>/=
M9EO]>DLDFS:6F%"(X*M)CYF..XSMP<XVGIDUSNGV$^J:A!8VP4S3-M7<V!P"
M23[  G\*GUT >(M4Q_S]S?\ H9KIOAHMN=:NV:1Q="WQ'&!\K(6&XGCJ"$QS
MW/7L^AGNSI]+\":+IZQO-";R=>2\YRI)&"-GW<=2,Y(SUX%;MGIMAIYD-E96
MUMYF-_DQ*F['3.!SU/YU:HI%E.ZTG3;Z837>GVEQ*J[0\L*NP'7&2.G)KE=>
M^'MK=AI](9;6X+ F)V/E-DG.."5//&..,8&<UVU% 6/GQE9'9'1D=25974@J
M1U!!Z'VKN?AWKCQ7K://(S13 M;@G(1QDL!QP",GD@97U:F^/-"O9O$"W=EI
M]Q-'/"ID>)2^9!D'(&<?*$] ?SK'T/1]9M]?TZ;^S[^%5N8R\GDNH"[ANR<=
M,9!]LTR=F>R4444BPHHHH **** "O*_'?B1]0OWTNUE865NVV9=NWS)5)SGU
M48&.G.3S\I'<^*]:_L/09KA&Q<2'R8./XR#ST(X +<\'&.]>+  # & *$3)B
MJK.ZHBLSL0JJH)+$\  #J2>U>BZ'\.H5CCN-9D9Y&7)M8VVJO7AF!R3R.F,$
M=2*G\ >'8K>R36+J'-U*3Y&\']W'TR 1P6YYY^4C'4Y[>@$C,@\.Z+;>28M*
MLP\.WRY#"K.I'0[B,YXZYS5F\TVPU QF]L;:Y,>=AFB5]N<9QD<9P/RJU10,
MY36/ .EZD3+:9L)SWB7,9Z=4XQP#]TCDY.:\RU/3+O2+^2SO(]DJ<@CE77LR
MGN#_ /6Z@BO>*Y'Q[H2:AH[:A%$OVNT7<7QRT0SN4G(X&=W?H0/O4"://_#F
MNR^']52Z'FO;M\L\*$?O%YQUXR"<CIZ9 )KVR*6.:))8G62-U#(Z'(8'H0>X
MKY\)"C)( ]37K_@.>XE\*P)<13)Y3%8GE)/F1G#*PS_#AMHQD87CTH8HLZ:B
MBB@L**CGN(+6%IKB:.&)<;GD8*HR<#D^]<M<_$70X952);NY4KGS(H@ #Z8<
MJ<_AWH$=;17&GXE:/C_CUOS_ -LT_P#BZU-*\8Z+JS1Q1W)@N'Z0W V-G=@#
M/W23D8 )//UH"Z-ZBBB@84444 %%5K[4+33;9KB]N(X(A_$YZG!. .I. >!S
M7+M\2=&65T%O?,JL0'$:88>HRV<'W - KG8T5QR_$G1FE1#;WRJS %S&N%'J
M<-G ]@3746.H6FI6PN+*XCGB/\2'H< X(Z@X(X/- 7+-%8,WC/P_;W$L$M_M
MDB=HW7R9#AE."/N^HJ[I>NZ;K1F&GW/G>3MW_(RXSG'4#T- &C1110,****
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MX/4XSR.G0XQ0S*RNC,CJ0RLIP5(Y!![$'O7OE[96VH6<MI=PK+!*,.C=_P#
M@\@CD$9KQ/7-*DT76;FQ<-M1LQ.V?G0\J<X&>.#CC(([4R6K'JWA;Q$GB+36
ME9%BNH6V31A@1G'# 9R%/.,]P1SC)W:\>\$:HVG>)8(VDVP71\B0'<02?N<#
MONP,GH&/3.:]AI%)W"O*_'?B1]0OWTNUE865NVV9=NWS)5)SGU48&.G.3S\I
M'<^*]:_L/09KA&Q<2'R8./XR#ST(X +<\'&.]>+  # & *$*3%56=U1%9G8A
M55026)X  '4D]J]%T/X=0K''<:S(SR,N3:QMM5>O#,#DGD=,8(ZD5/X \.Q6
M]DFL74.;J4GR-X/[N/ID C@MSSS\I&.ISV] )&9!X=T6V\DQ:59AX=OER&%6
M=2.AW$9SQUSFK-YIMAJ!C-[8VUR8\[#-$K[<XSC(XS@?E5JB@9RFL> =+U(F
M6TS83GO$N8STZIQC@'[I')R<UYEJ>F7>D7\EG>1[)4Y!'*NO9E/<'_ZW4$5[
MQ7(^/="34-';4(HE^UVB[B^.6B&=RDY' SN[]"!]Z@31Y_X<UV7P_JJ70\U[
M=OEGA0C]XO..O&03D=/3(!->V12QS1)+$ZR1NH9'0Y# ]"#W%?/A(49) 'J:
M]?\  <]Q+X5@2XBF3RF*Q/*2?,C.&5AG^'#;1C(PO'I0Q19TU>;?$?696O8M
M(AFQ"B"2=4<'<Q/RJPZC  ;&>=P.. :])KQOQP!_PF.H>_EY_P"_:T(<MC"A
MADN+B*")=TLKK&BY RQ. ,GCJ:]2T?X?Z99PQOJ"F[NAM9LL1&K YP ,;AT!
MW9SCH,XKC_ 2V[>+;8SR.DBHY@51P[[2"#QTVECVY ^A]?H8HHIVNDZ;8S&:
MST^TMY67:7AA5&(ZXR!TX'Y4Z[TVPU QF]LK:Y,>=GG1*^W/7&1QT'Y5:HH+
M.1UWP%I^H1R3:>JV=YM^55XB<\8#+CY1QU7'4DAJ\PO;2:POI[.=<2P.4;@@
M''<9 .#U![@@U[[7!?$31;J\GL;RRL9IW"M%,T0+$ $%!M'U?G'U[4(EHP?
MNN/IFMQV<LC?9+QO+*9X60X"MC!Y)PO;KD_=%>MUX8-#UR-@\6F:C'(IRKI
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M%<?]>C?^AI3Z$=3U*BBBD:!1110 4444 %%%% !1110 4444 %%%% !1110
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MTR=F>R4444BPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "M?1_]5)_O"LBM?1_]
M5)_O"HJ?"..XS6.L/X_TK+K4UCK#^/\ 2LNB'P@]PHHHJQ!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %>.>./^1QO_ /MG_P"BUKV.
MO'/''_(XW_\ VS_]%K0B9;'/5IZ!K$NA:Q#>QC*_<F7:"6C)!8#ISP".1R!G
MC(IVA:*^NS7D$3.)X;9IH57'[QP5 4Y]<D9R,'!]CF.CQR-'(C(ZDJRL,%2.
MH([&F2>^VUQ%=VL-S VZ&9!(C8(RI&0<'D<5+7FGP_\ $2VLQT>[D5896+6[
MNYXD./D'8 \D=.<]2U>ETBT[A1110,\<\<?\CC?_ /;/_P!%K6C\-?\ D8KC
M_KT;_P!#2L[QQ_R.-_\ ]L__ $6M:/PU_P"1BN/^O1O_ $-*?0SZGJ5<]XX_
MY$Z__P"V?_HQ:Z&N>\<?\B=?_P#;/_T8M(M['CE>RZ)HFDRZ#ITDFF63R/:Q
M,S-;J2Q*C))QUKQJO=-!_P"1=TS_ *](O_0!39,0_L'1O^@38?\ @,G^%']@
MZ-_T";#_ ,!D_P *T**11A7?@WP_>S"67345@NT"%VB7'/\ "A SSUQFN1\2
M^ ET^TN=1TVX9H(E,DEO+C**,EBK=P!C@\X!Y)XKTNB@+'SW7J7PZU9[W1Y;
M"7<S61 1SSE&SM&2>H(8=  -H%>=ZS8'3-:O;/RO*2*9A$F[=B/.4YR?X2IY
MY]>:Z+X;*/\ A)IV[BS<?^/I_A3)6C/5*Y[QQ_R)U_\ ]L__ $8M=#7/>./^
M1.O_ /MG_P"C%I%/8\<KW30?^1=TS_KTB_\ 0!7A=>Z:#_R+NF?]>D7_ * *
M;)B:%%%%(L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M JQ9?\?L7^]5>K%E_P ?L7^]2>P(7QW_ ,D\\3?]@JZ_]%-7Q!7V_P"._P#D
MGGB;_L%77_HIJ^(*Y30**** /M_P)_R3SPS_ -@JU_\ 12UT%<_X$_Y)YX9_
M[!5K_P"BEKH* "BBB@ HHHH **** "BBB@ KA/$/A_6+_7;FXA@:6!MOEDRK
MA0% ( )X&<G\2>]=W16&(H1KPY),WP^(EAY\\5KYGF'_  B6N?\ /C_Y%3_&
MC_A$M<_Y\?\ R*G^->GT5Q_V51[O\/\ ([O[7K]E^/\ F>8?\(EKG_/C_P"1
M4_QH_P"$2US_ )\?_(J?XUZ?11_95'N_P_R#^UZ_9?C_ )GF'_"):Y_SX_\
MD5/\:/\ A$M<_P"?'_R*G^->GT4?V51[O\/\@_M>OV7X_P"9YA_PB6N?\^/_
M )%3_&O3Z**ZL-A(8>_(WKW.3$XR>)MSI:=@HHHKI.4**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KCO%FAZCJ>JQ36=OYD:P!"=ZCG<Q[GW%=C
M16->A&M#DEL;8>O*A/GCN>8?\(EKG_/C_P"14_QK4\.^'=5L==MKFYM=D*;M
MS>8IQE2!P#ZFN[HKDAEE*$E)-Z>G^1V5,TK3@X-+73K_ )A1117HGFA1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ J]I7_ !^'_<-4:O:5_P ?A_W#4S^%@MR_JG_'DWU%85;NJ?\
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MA;PZWB+46C=F2TA7,\B. ZY!VA<@Y)(],8!]LT9HPT4O)'$@+.[!$11RQ/
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M$^JW"HH8,]K&,EAC[I?/!SP<9X'!YR.]L=/M-,MA;V5O'!$/X4&,G &2>I.
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MD^_K7JU>-^"!GQCI_L9/_1;5[)0PCL%5M0OX-,T^>]N6Q%"A8\@$^@&2!DG
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M6>6"4KM+Q.48CTR.<<#\J+!S'O\ 17CEIXW\06K1?Z;Y\<:[?+FC5@W&!N;
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MD_WA45/A''<9K'6'\?Z5EUJ:QUA_'^E9=$/A![A1115B"BBB@ HHHH ****
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M9!P>1Q4M(L\<\<?\CC?_ /;/_P!%K6C\-?\ D8KC_KT;_P!#2L[QQ_R.-_\
M]L__ $6M:/PU_P"1BN/^O1O_ $-*?0SZGJ5<]XX_Y$Z__P"V?_HQ:Z&N>\<?
M\B=?_P#;/_T8M(M['CE>Z:#_ ,B[IG_7I%_Z *\+KV71-;TF+0=.CDU.R21+
M6)65KA05(49!&>M-DQ-^BL_^WM&_Z"UA_P"!*?XT?V]HW_06L/\ P)3_ !I%
M&A16!/XU\/6]PT#ZDI=<9,<;NO(SPR@@_@:XWQ-XZ.KV36.GP20VTR8F>7B0
M\@[1M; &!@YSD,1QW NCF]:OSJ>MWMYYOFI+,QC?;MS&#A.,#^$#KSZUT?PU
M60^(;EPC&,6C!G"\ ETP"?4X/Y'TKC:];\"Z&^D:.T]S$T=W=D,Z,,%$&=JD
M9Z\D] ?FP>E,E:LZFN>\<?\ (G7_ /VS_P#1BUT-<]XX_P"1.O\ _MG_ .C%
MI%/8\<KW30?^1=TS_KTB_P#0!7A=>Z:#_P B[IG_ %Z1?^@"FR8FA1112+"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *L67_'[%_O5
M7JQ9?\?L7^]2>P(7QW_R3SQ-_P!@JZ_]%-7Q!7V_X[_Y)YXF_P"P5=?^BFKX
M@KE- HHHH ^W_ G_ "3SPS_V"K7_ -%+705S_@3_ ))YX9_[!5K_ .BEKH*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L#4/^/^7\/Y
M"M^L#4/^/^7\/Y"M*>Y,BK1116Y(4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5>TK_C\/^X:HU>TK_C\/^X:F?PL%N7]4
M_P"/)OJ*PJW=4_X\F^HK"J:>PY;A1116@@HHHH **** "BBB@ HHHH ****
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MX&.GW*ZAJWER3IAH(%.Y8SC.YO5@>!C(&,Y)QA[$ZL=X%\+2:<C:GJ,"K<R
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M_P ?$G^^?YU'74MC,****8!1110 4444 %%%% !1110 4444 %%%% !1110
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M/BV&3S-AMHI)MNW._C9CV^_G\*]=H81V"O#_ !%JJZUKUU>QLY@9@L.YB?D
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MP5(Z$'L:]RT/4?[6T.SOB5+RQ@R;%*J''#  \X# C_&DRHLT*Y[QQ_R)U_\
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M7AJXDAD\NXF(AB;#9RW7!'0A0Q!]0/I2*/+O$6JKK6O75[&SF!F"P[F)^0#
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ML**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P-0_X_Y?
MP_D*WZP-0_X_Y?P_D*TI[DR*M%%%;DA1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !139)(X8GEE=8XT4L[L<!0.I)["N8O?B!H5I*(XWGN
MCN96,$?"D>[$ @]BN1Q]*!'4T5YVOQ0;^+1@/I=Y_P#9*<?B@>VC_P#DU_\
M84!='H5%</9?$RQE %]83V[-(%S$PE55X^8GY3Z\ 'IWZ5U6F:SIVLPF73[N
M.<+]Y1D,O) W*<$9P<9'..* N7J***!A1110 4444 %%%% !1110 445S6J^
M-]-T?4IK"X@NVEBQN,:*5Y /&6'K0(Z6BL;0?$MGXA^T?9(IT\C;N\U0,[LX
MQ@GT-;- !1110,**** "BBN8U/QSIFDZI<:?/!=M+ 5#&-%*G*AN,L.S"@1T
M]%8&B>+]/U^^>TM8;E)%C,I,JJ!@$#LQYY%;] !1110,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBHDN8)9Y8(YHWFAQYL:L"R9&1D=LCGF@"6BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ J]I7_'X?\ <-4:O:5_Q^'_ '#4S^%@MR_JG_'DWU%85;NJ?\>3?45A
M5-/8<MPHHHK004444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5\]U]"5\]TT1(]C\#_\B=8?]M/_ $8U=#7/>!_^1.L/
M^VG_ *,:NAI%+8*Y+XBVTD_A@2HRA;>X223<>2""G'OEQ^M=;5/5;!-4TJZL
M7V 3QE SIO"-_"V.Y!P1[B@#P@-(A#Q2-'(IRKH<%3V((Z&O?K:XBN[6&Y@;
M=#,@D1L$94C(.#STKP.:&2WGD@F79+$Y1UR#M8'!&1QU%=UX#\46MC:-I.H3
M+!&K-)!-(0J 'EE)[<Y.2><D<< MDQ9Z/113998X8GEE=8XT4L[N<!0.I)["
MD69OB2Z%EX:U&8S/"WD,B2)G<KL-JX(Y!W$<]J\/KK_'?B2'6+F*QLWWVMLY
M9I!@K))C *\9P 6&<X.X^@)YO3-/EU;4[>PA;;).^W=@':.I;!(S@ G&><4T
M0]6>N^#K:2U\):='(REFC,H*G(VNQ=?QPPS1XQMI+KPEJ,<;*K+&)26.!M1@
M[?CA36U%%'#$D42+'&BA41!@*!T '84DL4<\+Q2QK)&ZE71QD,#P01W%(H^?
MJ]P\-70O?#6G3"9YF\A4>1\[F=1M;)/).X'GO7C.IZ?+I.IW%A,VZ2!]N[ &
MX=0V 3C((.,\9KI? GB2'1[F6QO'V6MRX99#@+')C!+<9P0%&<X&T>I(;)6C
M/5:*;%+'-$DL3K)&ZAD=#D,#T(/<4ZD617-Q%:6LUS.VV&%#([8)PH&2<#GI
M7@):1V+RR-)(QRSN22Q[DD]37>>//%%K?6BZ3I\RSQLRR3S1D,A Y50>_.#D
M'C '/('"PPR7$\<$*[Y97"(N0-S$X R>.IIHB3/5/AU;20>&#*[*5N+AY$VG
MD  )S[Y4_I76U3TJP32]*M;%-A$$80LB; [=VQV).3^-7*104444#"LOQ-_R
M*FL?]>,W_H!K4K+\3?\ (J:Q_P!>,W_H!I >'U[%X%_Y$VQ^LO\ Z,:O':]B
M\"_\B;8_67_T8U4R([G14444BSRGXD?\C7%_UXQ_^AR51\$?\CEI_P!9/_1;
MU>^)'_(UQ?\ 7C'_ .AR51\$?\CEI_UD_P#1;T="'N>R4444%F7XF_Y%36/^
MO&;_ - ->'U[AXF_Y%36/^O&;_T UX?0B)'L7@7_ )$VQ^LO_HQJI?$>&67P
MU&\:;DAN4>4Y VJ59<^_S,HX]:N^!?\ D3;'ZR_^C&K6U6P35-*NK%R@\^,H
M&=-X1L<-CN0<'\*"NAX0'D1@\4C1R*<JZ'!4]B#V->_6]Q%=VL-S VZ&9!(C
M8(RI&0<'GI7@MS:W%E</;74+0SQG#QMU4_U^HX-=AX)\7+II32;\JMDS'R9L
M8\IB<D-_LDDG/8GGC[K9,6>GT4V.2.:))8G62-U#(ZG(8'H0>XJO?ZC9Z7;&
MYOKF."(< N?O'!. .I. >!R<4BS+\97Z6'A6^+A6:=/LZ(S[2Q?Y3CU(!+8]
M%/UKQFNE\8^)AK]Y'%;!EL;<G822/-8_Q$=/IQD GUP.:IHS;/8O O\ R)MC
M]9?_ $8U=%7.^!?^1-L?K+_Z,:NBI%K8****!A1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5M:3_ ,>C?[Y_D*Q:VM)_X]&_WS_(
M5G4^$<=RMJ__ !\1_P"Y_6LZM'5_^/B/_<_K6=3A\(GN%%%%6 4444 %%%%
M!1110!4U/48-)TV>^N=WE0KDA!DDDX 'N20/3FN67XF:0>MGJ"_5(_\ XNM_
MQ)IS:KX=OK- [2/'NC5& +.I#*,GC!( /L>U>( @C(Y!H);L>_VUQ%=VL-S
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MA_X#)_A1_8.C?] FP_\  9/\*T** ,_^P=&_Z!-A_P" R?X4?V#HW_0)L/\
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M;:EXE@D:/=!:?OY"=P (^YR.^[!P>H4]<8I]"'JSV&N-^)7_ "+MO_U]K_Z
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MP/IO]G>&(&,F]KL_:C@Y # ;0.!_"%SUYSSBF2M6:?\ 8.C?] FP_P# 9/\
M"C^P=&_Z!-A_X#)_A6A12*,_^P=&_P"@38?^ R?X4?V#HW_0)L/_  &3_"M"
MB@#QCQ?I*:/XCGAB*^3,/M$:C^!6)XP   &#  =@*7P;J7]F>*+5C'O6Y/V5
ML#) <C!'(_B"Y]L\9KLOB/IOVG1H=1$F#9OAE)X*N57TY.X+W'!/M7EQ (((
MR#P:9+T9]"T5D>&=576/#]K<F7S)P@CG)V@^8HPV0O S]X#CAAP*UZ11\]UZ
ME\-?^1=N/^OMO_0$KRVO4OAK_P B[<?]?;?^@)39,=SLJ***18445@ZKXPT7
M20RR70N)E8J8+8AW!! (/.%(ST8CH<9(H$6O$.KIHFBW%Z=IE VPJW\4AZ#&
M1D=S@YP#7AP 50 , # K5U[7KKQ#?+<W*I&(U*1Q(255<D]S][H"0!G:..*@
MTG3+C6-2ALK96+2,-[!<B-,\N>1P/KSP.I%,ENYW_P -=.E@TVZOY&_=W;JL
M:X'1-P+9SW)(P0/N^]=Q4=O!':VT5O"NV*) B+DG"@8 R>:AU&_@TO3I[VY;
M$4*%CR 6] ,D#). !W)%(H\T^(FI?:]?2R$>%L4QN(Y+.%8X.>F G8<@^U<]
MHVF_VQK-KI_F>6)WPS X(4 LV.#SM!QQUQ5.666>:2>9]\TKEY'P!N8G).!Q
MR37??#/3<R7FJF3A1]E1 >_RLQ(Q_N8Y[MQTI]"=V=I_8.C?] FP_P# 9/\
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M' .".H.".#S0"99IDLL<$+S32+'%&I9W<X"@<DD]A1++'!"\TTBQQ1J6=W.
MH'))/85Y[XR\96UW92:7I<AE60[9[A25  /W5Z;LXY/0@]\\ V['#7ET;V^N
M+PQ^4;B5YC'NSM+$G&>^,UW?PO\ O:M](?\ V>O/J]!^%_WM6^D/_L],A;GH
M=%%%(T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "MG2/^/9_]_P#H*QJV=(_X]G_W_P"@K.I\(X[E?5_]?'_N_P!:
MSJT=7_U\?^[_ %K.IP^$'N%%%%6(**** "BBB@ HHHH **** "BBB@ HHHH
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M  &3_"N+^&>FYDO-5,G"C[*B ]_E9B1C_<QSW;CI7HE ):&?_8.C?] FP_\
M 9/\*/[!T;_H$V'_ (#)_A6A10,S_P"P=&_Z!-A_X#)_A7"_$/0;:Q%IJ-I%
M%!&Y^SO%&H4;N64@ =<;LDGLOO7I59NOZ6=9T*[L%?8\J@H<X&Y2&7/!XR!G
MCIF@&CQ*VG>TNX+F-4:2"194#C*[E((S[9%>\65TE]86]Y&KJD\2RJK@;@&
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M]H\/D'PWI9'3[)%_Z *T:;%%'#$D42+'&BA41!@*!T '84ZD6%%%% PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *U]'_P!5)_O"LBM?1_\ 52?[PJ*GPCCN,UCK#^/]
M*RZU-8ZP_C_2LNB'P@]PHHHJQ!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0?\ D7=,_P"O2+_T 4V3$T****184444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !5BR_X_8O]ZJ]6++_C]B_WJ3V!"^._^2>>)O\ L%77
M_HIJ^(*^W_'?_)//$W_8*NO_ $4U?$%<IH%%%% 'V_X$_P"2>>&?^P5:_P#H
MI:Z"N?\  G_)//#/_8*M?_12UT% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 5\]U]"5QO_"M=&_Y^;_\
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M6_O+$N;2[GMR^-_DR%-V,XSCKU/YU8_M[6?^@M?_ /@2_P#C7H7_  K71O\
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MBY'WCV P!SGIZ**105@^*?#<?B*Q51)Y=U!DP.2=O.,AAZ' YZC'U!WJ* /
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MT= 6YZ!1112+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "MG2/^/9_P#?_H*QJV=(_P"/9_\ ?_H*SJ?"..Y7U?\
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M7[U+JZFN4D2,1@1,H& 2>ZGGFLS_ (5KHW_/S?\ _?Q/_B:8FG<\]_M[6?\
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M0 4444 8VK_\?*?[G]36?6AJ_P#Q\I_N?U-9]=,/A,WN%%%%4 4444 %%%%
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M!^7IQ0)IMFUH&F'1M"M+!GWO$I+G.1N8EFQP.,DXXZ8K2HHH*"BBB@84444
M>->,]-_LSQ/<J)-ZW)^U+DY(#DY!X'\0;'MCG-1^$M472/$=M<2R>7;OF&9O
MEQM;U)Z -M)/H/PKT_7O#-GXB:W-W-<)]G#;1"RC.[&<Y!_N_P ZQ_\ A6NC
M?\_-]_WVG_Q-!%M3LJ\<\<?\CC?_ /;/_P!%K7L,:LD2(TC2,J@%VQEO<X &
M?H!7.:KX(TW6-2FO[B>[667&X1NH7@ <94^E"&U<\FMKNYLI#):W$T$A&TM$
MY4D>F1]*M?V]K/\ T%K_ /\  E_\:]"_X5KHW_/S?_\ ?Q/_ (FC_A6NC?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5XYXX_Y'&__P"V?_HM:]CKFM5\$:;K&I37]Q/=K++C<(W4+P .,J?2
MA$M7.2^&O_(Q7'_7HW_H:5ZE6!H?A&PT"]>ZM9KEY'C,9$K*1@D'LHYXK?H&
ME8****!A7G7Q$\/[&_MRW7Y6(6[W2=#\JHP!_ '!_N\=37HM-DCCFB>*5%>-
MU*NC#(8'J".XH$]3Y]KLOAK_ ,C%<?\ 7HW_ *&E= /AIHX4#[5?G ZF1.?_
M !RM/0_"-AH%Z]U:S7+R/&8R)64C!(/91SQ3N2D[F_7/>./^1.O_ /MG_P"C
M%KH:IZKIL.L:;-87#2+%+C<8R W!!XR#Z4BF>#U[IH/_ "+NF?\ 7I%_Z *Y
MW_A6NC?\_-__ -_$_P#B:ZRTMDLK*"UC+&."-8U+=2 ,#/OQ0Q)6)J***"@H
MHHH **** "N>\<?\B=?_ /;/_P!&+70U3U738=8TV:PN&D6*7&XQD!N"#QD'
MTH$SP>O=-!_Y%W3/^O2+_P! %<[_ ,*UT;_GYO\ _OXG_P 3766ELEE906L9
M8QP1K&I;J0!@9]^*&)*Q-11104%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 58LO^/V+_>JO5BR_P"/V+_>I/8$+X[_ .2>>)O^P5=?
M^BFKX@K[?\=_\D\\3?\ 8*NO_135\05RF@4444 ?;_@3_DGGAG_L%6O_ **6
MN@KG_ G_ "3SPS_V"K7_ -%+704 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !2K]]?K24J_?7ZT@.HHHHKE- H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .:G_P"/B3_?/\ZCJ2?_
M (^)/]\_SJ.NI;&84444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@!LL4<T3Q2HLD;J5='&0P/4$=Q7S\5=&*2(T<BG#(ZD,I[@@]"*
M^@Z\X\:^$+C[9)JVFPM,DS S6\299&/&Y0!R">3W!)/()VB)DA/ 7B6TL8)-
M+OYS$K.989I9/W:\#*<_=Z$CL23T.,^BQ2QSPI-#(LD4BAD=#D,#R"#W%?/P
M((R#D&G02/;7*W-N[13IG;+&=K+D8.".>A-.PE(^@JXSQ1XXMK*T6'1[B&YN
MIER)HV#I$OKD<%O0?B>P;S*ZN)[Z837<TEQ*J[0\S%V ZXR>W)_.HZ5@Y@
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M 4444 %%%% !1110 4444 %%%% !5BR_X_8O]ZJ]6++_ (_8O]ZD]@0OCO\
MY)YXF_[!5U_Z*:OB"OM_QW_R3SQ-_P!@JZ_]%-7Q!7*:!1110!]O^!/^2>>&
M?^P5:_\ HI:Z"N?\"?\ )//#/_8*M?\ T4M=!0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^QI]"-F>YUXQXT_Y'35/]^/_ -%)7L]>,>-/^1TU3_?C_P#124ARV-/X;?\
M(RS_ /7F_P#Z&E>J5Y7\-O\ D99_^O-__0TKU2AA'8\O^(VJ-<:Q%IR29AM4
M#.@W#]XW//8X7;@CIN;FLCPEH8UW6TAF1C:1*9)R"1D=ER!U)[<<!L'BJOB.
M>6X\2ZF\S[G%S(@. /E5BJCCT  _"I]"\2W7AY)Q9V]LS3E=[RAB2!G X8#C
M)[=_I3)ZGL=E96VG6<5I:1+%!$NU$7M_B3U)/)/-3UY;_P +*UG_ )]K#_OV
M_P#\51_PLK6?^?:P_P"_;_\ Q5*Q7,CU*N)\;>%;6?3I]4LH5ANH09)5C4*)
M5SEF;I\PR6SU/(YXQA_\+*UG_GVL/^_;_P#Q50W/Q!U.\M9K:>SL'AF1HY%V
M2#*D8(R'STHL%T<W97D^GWT-Y;-MFA<.N2<''8X(.#T([@FO=;*[2_L+>\C5
MUCN(EE57&& 8 @''?FO J]D\#O(_@^P,CL[#S "QR<"1@!] , >PIL43)^)5
M^8=(M=/4L/M4N]_E!4HF#@D\@[BA&/[I_'S)5=V5(T9W8X5$4EF)Z  =3[5V
M/Q*>0^(K="[F,6BE4).T$N^2!ZG _(5F>"H//\76 ,'FQH7=\IN"81BK'TPV
MW!]<4 ]6>F^&]!@T'2T@5%^TNH:XD!SO?'.#@?*.<# _,FMBBBD4%>1^.M#M
MM%U6&2T5(K>[5G6('[C*1NP,<+\RX&>YZ# KURB@&KGB7A.]GM_%.GBS;=))
M*(WC!)W1G[^0#S@9;T!4'M7MM%% )6/'/''_ ".-_P#]L_\ T6M=#\+_ /F*
M_P#;'_V>N>\<?\CC?_\ ;/\ ]%K70_"__F*_]L?_ &>GT)6YZ%6=X@ /AO5
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *5?OK]:2E7[Z_6D!U%%%%<IH%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!S4__ !\2?[Y_G4=23_\ 'Q)_OG^=1UU+8S"BBBF
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &3J/AG
M1M6N!<7EBCS#JZLR%N /F*D;N ,9SCM6$/AIHXZW>H'ZNG_Q%=G10*QQI^&F
MCGI=Z@/HZ?\ Q%:^F^$M$TP(T5BDDJ[#YL_[QMR]&&>%.>?E _05MT4!8***
M*!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5LZ1_P >S_[_ /05C5LZ1_Q[/_O_ -!6=3X1QW*^K_Z^/_=_
MK6=6CJ_^OC_W?ZUG4X?"#W"BBBK$%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% &]IO_'A'^/\ZMU4TW_CPC_'^=6ZY9;LM;!1112&%%%% !1110 4444
M%%%% !1110 4444 %%%% &-J_P#Q\I_N?U-9]:&K_P#'RG^Y_4UGUTP^$S>X
M44450!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %:^C_P"JD_WA616OH_\ JI/]X5%3X1QW&:QUA_'^E9=:FL=8?Q_I671#
MX0>X44458@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"K%E_P ?L7^]5>K%E_Q^Q?[U)[ A?'?_ "3SQ-_V"KK_ -%-7Q!7V_X[_P"2
M>>)O^P5=?^BFKX@KE- HHHH ^W_ G_)//#/_ &"K7_T4M=!7/^!/^2>>&?\
ML%6O_HI:Z"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MK U#_C_E_#^0K?K U#_C_E_#^0K2GN3(JT445N2%%%% !1110 4444 %%%%
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M%%%%:""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ K:TG_CT;_?/\A6+6UI/_ !Z-_OG^0K.I\(X[E;5_^/B/_<_K
M6=6CJ_\ Q\1_[G]:SJ</A$]PHHHJP"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *5?OK]:2E7[Z_6D!U%%%%<IH%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!S4_\ Q\2?[Y_G4=23_P#'Q)_OG^=1UU+8S"BBBF 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5LZ1_Q[/_ +_]!6-6SI'_ ![/_O\ ]!6=3X1QW*^K
M_P"OC_W?ZUG5HZO_ *^/_=_K6=3A\(/<****L04444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 ;VF_\>$?X_P ZMU4TW_CPC_'^=6ZY9;LM;!1112&%%%%
M!1110 4444 %%%% !1110 4444 %%%% &-J__'RG^Y_4UGUH:O\ \?*?[G]3
M6?73#X3-[A1115 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5KZ/\ ZJ3_ 'A616OH_P#JI/\ >%14^$<=QFL=8?Q_I676
MIK'6'\?Z5ET0^$'N%%%%6(**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ JQ9?\?L7^]5>K%E_P ?L7^]2>P(7QW_ ,D\\3?]@JZ_]%-7
MQ!7V_P"._P#DGGB;_L%77_HIJ^(*Y30**** /M_P)_R3SPS_ -@JU_\ 12UT
M%<_X$_Y)YX9_[!5K_P"BEKH* "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-S]LCU;4H7@2%CY-O+'AG8<;F!' !Y'<D \ #<AW;."KV/P/_P B=8?]M/\
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M-%"HB# 4#@ #L*0)=1]>,>-/^1TU3_?C_P#125[/7C'C3_D=-4_WX_\ T4E
MY;&G\-O^1EG_ .O-_P#T-*]4KROX;?\ (RS_ /7F_P#Z&E>J4,(['!_$C2!)
M:0ZQ&/F@Q#-S_ 3\IY/9CC@9._VKSE'>.19(W9'4AE93@J1T(/8U] 2Q1S1/
M%*BR1NI5T<9# ]01W%>7>)/ EWI\DEUI:-<V18;85R\L>>V,?,HXYZ\\]"U
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !6UI/_ !Z-_OG^0K%K:TG_ (]&_P!\_P A6=3X1QW*VK_\?$?^
MY_6LZM'5_P#CXC_W/ZUG4X?")[A1115@%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4J_?7ZTE*OWU^M(#J****Y30**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#FI_P#CXD_WS_.HZDG_ ./B3_?/\ZCKJ6QF%%%%
M, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %8&H?\?\OX?R%;]8&H?\?\OX?R%:4]R9%6BBBMR0HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ J"ZLK2_C6.\M8;B-6W*LT8<
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4J_?7ZTE*OWU^M(#J***
M*Y30**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#FI_\ CXD_WS_.
MHZDG_P"/B3_?/\ZCKJ6QF%%%%, HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K9TC_ (]G_P!_
M^@K&K9TC_CV?_?\ Z"LZGPCCN5]7_P!?'_N_UK.K1U?_ %\?^[_6LZG#X0>X
M44458@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH WM-_X\(_Q_G5NJFF_
M\>$?X_SJW7++=EK8****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH Q
MM7_X^4_W/ZFL^M#5_P#CY3_<_J:SZZ8?"9O<****H HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "M?1_P#52?[PK(K7T?\
MU4G^\*BI\(X[C-8ZP_C_ $K+K4UCK#^/]*RZ(?"#W"BBBK$%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 58LO\ C]B_WJKU8LO^/V+_
M 'J3V!"^._\ DGGB;_L%77_HIJ^(*^W_ !W_ ,D\\3?]@JZ_]%-7Q!7*:!11
M10!]O^!/^2>>&?\ L%6O_HI:Z"N?\"?\D\\,_P#8*M?_ $4M=!0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ K:TG_ (]&_P!\_P A6+6UI/\
MQZ-_OG^0K.I\(X[E;5_^/B/_ '/ZUG5HZO\ \?$?^Y_6LZG#X1/<****L HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "E7[Z_6DI5^^OUI =111
M17*:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 <U/\ \?$G^^?Y
MU'4D_P#Q\2?[Y_G4==2V,PHHHI@%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %;.D?\>S_ .__
M $%8U;.D?\>S_P"__05G4^$<=ROJ_P#KX_\ =_K6=6CJ_P#KX_\ =_K6=3A\
M(/<****L04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ;VF_\ 'A'^/\ZM
MU4TW_CPC_'^=6ZY9;LM;!1112&%%%% !1110 4444 %%%% !1110 4444 %%
M%% &-J__ !\I_N?U-9]:&K_\?*?[G]36?73#X3-[A1115 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5KZ/_JI/]X5D5KZ
M/_JI/]X5%3X1QW&:QUA_'^E9=:FL=8?Q_I671#X0>X44458@HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "K%E_Q^Q?[U5ZL67_'[%_O
M4GL"%\=_\D\\3?\ 8*NO_135\05]O^._^2>>)O\ L%77_HIJ^(*Y30**** /
MM_P)_P D\\,_]@JU_P#12UT%<_X$_P"2>>&?^P5:_P#HI:Z"@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K U#_C_E_#^0K?K U#_C_E
M_#^0K2GN3(JT445N2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %7M*_X_#_N&J-7M*_X_#_N&IG\+!;E_5/\ CR;ZBL*M
MW5/^/)OJ*PJFGL.6X4445H(**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "MK2?^/1O]\_R%8M;6D_\>C?[Y_D*SJ?
M"..Y6U?_ (^(_P#<_K6=6CJ__'Q'_N?UK.IP^$3W"BBBK **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ I5^^OUI*5?OK]:0'44445RF@4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% '-3_\?$G^^?YU'4D__'Q)_OG^
M=1UU+8S"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5LZ1_Q[/_O_ -!6-6SI'_'L_P#O
M_P!!6=3X1QW*^K_Z^/\ W?ZUG5HZO_KX_P#=_K6=3A\(/<****L04444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 ;VF_P#'A'^/\ZMU4TW_ (\(_P ?YU;K
MEENRUL%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 8VK_P#'RG^Y
M_4UGUH:O_P ?*?[G]36?73#X3-[A1115 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5KZ/_JI/]X5D5KZ/_JI/]X5%3X1Q
MW&:QUA_'^E9=:FL=8?Q_I671#X0>X44458@HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN@#T"BO/_P#A=OP\_P"AA_\ )*X_^-T?\+M^'G_0P_\ DE<?_&Z /0**\_\
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MT?\ "[?AY_T,/_DE<?\ QN@#T"BO/_\ A=OP\_Z&'_R2N/\ XW1_PNWX>?\
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MV_#S_H8?_)*X_P#C='_"[?AY_P!##_Y)7'_QN@#T"BO/_P#A=OP\_P"AA_\
M)*X_^-T?\+M^'G_0P_\ DE<?_&Z /0**\_\ ^%V_#S_H8?\ R2N/_C='_"[?
MAY_T,/\ Y)7'_P ;H ] HKS_ /X7;\//^AA_\DKC_P"-T?\ "[?AY_T,/_DE
M<?\ QN@#T"BO/_\ A=OP\_Z&'_R2N/\ XW1_PNWX>?\ 0P_^25Q_\;H ] HK
MS_\ X7;\//\ H8?_ "2N/_C='_"[?AY_T,/_ ))7'_QN@#T"BO/_ /A=OP\_
MZ&'_ ,DKC_XW1_PNWX>?]##_ .25Q_\ &Z /0**\_P#^%V_#S_H8?_)*X_\
MC='_  NWX>?]##_Y)7'_ ,;H ] HKS__ (7;\//^AA_\DKC_ .-T?\+M^'G_
M $,/_DE<?_&Z /0**\__ .%V_#S_ *&'_P DKC_XW1_PNWX>?]##_P"25Q_\
M;H ] HKS_P#X7;\//^AA_P#)*X_^-T?\+M^'G_0P_P#DE<?_ !N@#T"BO/\
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M_P ;H_X7;\//^AA_\DKC_P"-T>TD'*CI?[*N?5/SH_LJY]4_.N:_X7;\//\
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MRKGU3\ZYK_A=OP\_Z&'_ ,DKC_XW1_PNWX>?]##_ .25Q_\ &Z/:2#E1TO\
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M='_"[?AY_P!##_Y)7'_QNCVD@Y4=+_95SZI^=']E7/JGYUS7_"[?AY_T,/\
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M#S_H8?\ R2N/_C='M)!RHZ7^RKGU3\Z/[*N?5/SKFO\ A=OP\_Z&'_R2N/\
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M\DKC_P"-TE-K8&KG2_V5<^J?G1_95SZI^=<U_P +M^'G_0P_^25Q_P#&Z/\
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M_P ;H_X7;\//^AA_\DKC_P"-T>TD'*CI?[*N?5/SH_LJY]4_.N:_X7;\//\
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MRKGU3\ZYK_A=OP\_Z&'_ ,DKC_XW1_PNWX>?]##_ .25Q_\ &Z/:2#E1TO\
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M='_"[?AY_P!##_Y)7'_QNCVD@Y4=+_95SZI^=']E7/JGYUS7_"[?AY_T,/\
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M#S_H8?\ R2N/_C='M)!RHZ7^RKGU3\Z/[*N?5/SKFO\ A=OP\_Z&'_R2N/\
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M.E_LJY]4_.C^RKGU3\ZYK_A=OP\_Z&'_ ,DKC_XW1_PNWX>?]##_ .25Q_\
M&Z/:2#E1TO\ 95SZI^=']E7/JGYUS7_"[?AY_P!##_Y)7'_QNC_A=OP\_P"A
MA_\ )*X_^-T>TD'*CI?[*N?5/SH_LJY]4_.N:_X7;\//^AA_\DKC_P"-T?\
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M !NCVD@Y4=+_ &5<^J?G1_95SZI^=<U_PNWX>?\ 0P_^25Q_\;H_X7;\//\
MH8?_ "2N/_C='M)!RHZ7^RKGU3\Z/[*N?5/SKFO^%V_#S_H8?_)*X_\ C='_
M  NWX>?]##_Y)7'_ ,;H]I(.5'2_V5<^J?G1_95SZI^=<U_PNWX>?]##_P"2
M5Q_\;H_X7;\//^AA_P#)*X_^-T>TD'*CI?[*N?5/SH_LJY]4_.N:_P"%V_#S
M_H8?_)*X_P#C='_"[?AY_P!##_Y)7'_QNCVD@Y4=+_95SZI^=']E7/JGYUS7
M_"[?AY_T,/\ Y)7'_P ;H_X7;\//^AA_\DKC_P"-T>TD'*CI?[*N?5/SH_LJ
MY]4_.N:_X7;\//\ H8?_ "2N/_C='_"[?AY_T,/_ ))7'_QNCVD@Y4=+_95S
MZI^=']E7/JGYUS7_  NWX>?]##_Y)7'_ ,;H_P"%V_#S_H8?_)*X_P#C='M)
M!RHZ7^RKGU3\Z/[*N?5/SKFO^%V_#S_H8?\ R2N/_C='_"[?AY_T,/\ Y)7'
M_P ;H]I(.5'2_P!E7/JGYT?V5<^J?G7-?\+M^'G_ $,/_DE<?_&Z/^%V_#S_
M *&'_P DKC_XW1[20<J.E_LJY]4_.C^RKGU3\ZYK_A=OP\_Z&'_R2N/_ (W1
M_P +M^'G_0P_^25Q_P#&Z/:2#E1TO]E7/JGYT?V5<^J?G7-?\+M^'G_0P_\
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M//\ H8?_ "2N/_C='M)!RHZ7^RKGU3\Z/[*N?5/SKFO^%V_#S_H8?_)*X_\
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M='M)!RHZ7^RKGU3\Z/[*N?5/SKFO^%V_#S_H8?\ R2N/_C='_"[?AY_T,/\
MY)7'_P ;H]I(.5'2_P!E7/JGYT?V5<^J?G7-?\+M^'G_ $,/_DE<?_&Z/^%V
M_#S_ *&'_P DKC_XW1[20<J.E_LJY]4_.C^RKGU3\ZYK_A=OP\_Z&'_R2N/_
M (W1_P +M^'G_0P_^25Q_P#&Z/:2#E1TO]E7/JGYT?V5<^J?G7-?\+M^'G_0
MP_\ DE<?_&Z/^%V_#S_H8?\ R2N/_C='M)!RHZ7^RKGU3\Z/[*N?5/SKFO\
MA=OP\_Z&'_R2N/\ XW1_PNWX>?\ 0P_^25Q_\;H]I(.5'2_V5<^J?G1_95SZ
MI^=<U_PNWX>?]##_ .25Q_\ &Z/^%V_#S_H8?_)*X_\ C='M)!RHZ7^RKGU3
M\Z/[*N?5/SKFO^%V_#S_ *&'_P DKC_XW1_PNWX>?]##_P"25Q_\;H]I(.5'
M2_V5<^J?G1_95SZI^=<U_P +M^'G_0P_^25Q_P#&Z/\ A=OP\_Z&'_R2N/\
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M[20<J.E_LJY]4_.C^RKGU3\ZYK_A=OP\_P"AA_\ )*X_^-T?\+M^'G_0P_\
MDE<?_&Z/:2#E1TO]E7/JGYT?V5<^J?G7-?\ "[?AY_T,/_DE<?\ QNC_ (7;
M\//^AA_\DKC_ .-T>TD'*CI?[*N?5/SH_LJY]4_.N:_X7;\//^AA_P#)*X_^
M-T?\+M^'G_0P_P#DE<?_ !NCVD@Y4=+_ &5<^J?G1_95SZI^=<U_PNWX>?\
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M'2_V5<^J?G1_95SZI^=<U_PNWX>?]##_ .25Q_\ &Z/^%V_#S_H8?_)*X_\
MC='M)!RHZ7^RKGU3\Z/[*N?5/SKFO^%V_#S_ *&'_P DKC_XW1_PNWX>?]##
M_P"25Q_\;H]I(.5'2_V5<^J?G1_95SZI^=<U_P +M^'G_0P_^25Q_P#&Z/\
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M_P"%V_#S_H8?_)*X_P#C='M)!RHZ7^RKGU3\Z/[*N?5/SKFO^%V_#S_H8?\
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M2#E1TO\ 95SZI^=']E7/JGYUS7_"[?AY_P!##_Y)7'_QNC_A=OP\_P"AA_\
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M.E_LJY]4_.C^RKGU3\ZYK_A=OP\_Z&'_ ,DKC_XW1_PNWX>?]##_ .25Q_\
M&Z/:2#E1TO\ 95SZI^=']E7/JGYUS7_"[?AY_P!##_Y)7'_QNC_A=OP\_P"A
MA_\ )*X_^-T>TD'*CI?[*N?5/SH_LJY]4_.N:_X7;\//^AA_\DKC_P"-T?\
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M !NCVD@Y4=+_ &5<^J?G1_95SZI^=<U_PNWX>?\ 0P_^25Q_\;H_X7;\//\
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M_P +M^'G_0P_^25Q_P#&Z/:2#E1TO]E7/JGYT?V5<^J?G7-?\+M^'G_0P_\
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M'G_0P_\ DE<?_&Z/:2#E1TO]E7/JGYT?V5<^J?G7-?\ "[?AY_T,/_DE<?\
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M_C='M)!RHZ7^RKGU3\Z/[*N?5/SKFO\ A=OP\_Z&'_R2N/\ XW1_PNWX>?\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>15
<FILENAME>sava-20201231.xml
<DESCRIPTION>EX-101.INS
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created by Certent Disclosure Management 6.39.2.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/23/2021 3:59:20 PM-->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:sava="http://www.cassavasciences.com/20201231" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr">
  <link:schemaRef xlink:type="simple" xlink:href="sava-20201231.xsd" />
  <!--Context Section-->
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_sava_WriteDownOfShareBasedCompensationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">sava:WriteDownOfShareBasedCompensationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_sava_BookLossesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">sava:BookLossesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_sava_BookLossesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">sava:BookLossesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_sava_ExpiresBetween2023And2039Member_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:ExpiresBetween2023And2039Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_sava_ExpiresBetween2023And2039Member_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:ExpiresBetween2023And2039Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2020_srt_StatementScenarioAxis_sava_ExpiresBetween2023And2039Member_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:ExpiresBetween2023And2039Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2021_To_1_1_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-01-01</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeThreeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFourMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeFourMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFiveMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeFiveMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeThreeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFourMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeFourMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFiveMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeFiveMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_sava_TwoThousandEightEquityIncentivePlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:TwoThousandEightEquityIncentivePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_2_12_2021_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:RegisteredDirectOffering2021Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-02-12</instant>
    </period>
  </context>
  <context id="As_Of_11_13_2020_us-gaap_PlanNameAxis_sava_PublicOfferingMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:PublicOfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-11-13</instant>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:AtMarketEquityProgramMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_8_1_2018_To_8_31_2018_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_PlanNameAxis_sava_CommonStockWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-08-01</startDate>
      <endDate>2018-08-31</endDate>
    </period>
  </context>
  <context id="Duration_3_27_2020_To_3_27_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:AtMarketEquityProgramMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-03-27</startDate>
      <endDate>2020-03-27</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2021_To_1_1_2021_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_PlanNameAxis_sava_CommonStockWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CommonStockWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-01-01</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2021_To_1_1_2021_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-01-01</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_PlanNameAxis_sava_CommonStockWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_PlanNameAxis_sava_CommonStockWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_2_12_2021_To_2_12_2021_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:RegisteredDirectOffering2021Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-02-12</startDate>
      <endDate>2021-02-12</endDate>
    </period>
  </context>
  <context id="Duration_11_13_2020_To_11_13_2020_us-gaap_PlanNameAxis_sava_PublicOfferingMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:PublicOfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-11-13</startDate>
      <endDate>2020-11-13</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_sava_ExpiresBetween2029And2039Member_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:ExpiresBetween2029And2039Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_sava_ExpiresBetween2029And2039Member_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:ExpiresBetween2029And2039Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2020_srt_StatementScenarioAxis_sava_IndefinitelyMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:IndefinitelyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_srt_StatementScenarioAxis_sava_ExpiresBetween2029And2039Member_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:ExpiresBetween2029And2039Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_srt_StatementGeographicalAxis_sava_AustinMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
    </entity>
    <period>
      <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_sava_AustinMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_PlanNameAxis_sava_TwoThousandEighteenEquityIncentivePlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_1_1_2021_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_PlanNameAxis_sava_CommonStockWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CommonStockWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-01-01</instant>
    </period>
  </context>
  <context id="As_Of_1_1_2021_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-01-01</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_PlanNameAxis_sava_CommonStockWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_PlanNameAxis_sava_CommonStockWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_ClassOfWarrantOrRightAxis_sava_PlacementAgentWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:PlacementAgentWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_sava_PlacementAgentWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:PlacementAgentWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_sava_PlacementAgentWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:PlacementAgentWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_sava_TwoThousandEighteenEquityIncentivePlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_3_27_2020_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:AtMarketEquityProgramMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-27</instant>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_1_1_2021_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_sava_SecondThroughEighthValuationMilestonesMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:SecondThroughEighthValuationMilestonesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-01-01</instant>
    </period>
  </context>
  <context id="As_Of_1_1_2021_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_sava_SecondThroughEighthValuationMilestonesMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:SecondThroughEighthValuationMilestonesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-01-01</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_sava_Exceeds5BillionMarketCapitalizationMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:Exceeds5BillionMarketCapitalizationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_sava_Exceeds5BillionMarketCapitalizationMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:Exceeds5BillionMarketCapitalizationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_10_13_2020_srt_StatementScenarioAxis_sava_FirstValuationMilestoneMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:FirstValuationMilestoneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-10-13</instant>
    </period>
  </context>
  <context id="As_Of_6_30_2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
    </entity>
    <period>
      <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="As_Of_3_18_2021">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
    </entity>
    <period>
      <instant>2021-03-18</instant>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <!--Unit Section-->
  <unit id="Unit16">
    <measure>sava:segment</measure>
  </unit>
  <unit id="Unit15">
    <measure>utr:sqft</measure>
  </unit>
  <unit id="Unit14">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Unit13">
    <measure>xbrli:pure</measure>
  </unit>
  <unit id="Unit12">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="Unit1">
    <measure>xbrli:shares</measure>
  </unit>
  <!--Tuple Section-->
  <!--Element Section-->
  <dei:AmendmentFlag id="Item-497" contextRef="Duration_1_1_2020_To_12_31_2020">false</dei:AmendmentFlag>
  <dei:CityAreaCode id="Item-116" contextRef="Duration_1_1_2020_To_12_31_2020">512</dei:CityAreaCode>
  <dei:CurrentFiscalYearEndDate id="Item-496" contextRef="Duration_1_1_2020_To_12_31_2020">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentAnnualReport id="Item-62" contextRef="Duration_1_1_2020_To_12_31_2020">true</dei:DocumentAnnualReport>
  <dei:DocumentFiscalPeriodFocus id="Item-495" contextRef="Duration_1_1_2020_To_12_31_2020">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus id="Item-494" contextRef="Duration_1_1_2020_To_12_31_2020">2020</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate id="Item-493" contextRef="Duration_1_1_2020_To_12_31_2020">2020-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentsIncorporatedByReferenceTextBlock id="Item-157" contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
			&lt;font style="display: inline;font-size:8pt;"&gt;Portions of the Registrant's Proxy Statement for its 2021 Annual Meeting of Stockholders (the Proxy Statement), to be filed with the U.S. Securities and Exchange Commission, are incorporated by reference to Part III of this Form 10-K Report.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
  <dei:DocumentTransitionReport id="Item-201" contextRef="Duration_1_1_2020_To_12_31_2020">false</dei:DocumentTransitionReport>
  <dei:DocumentType id="Item-492" contextRef="Duration_1_1_2020_To_12_31_2020">10-K</dei:DocumentType>
  <dei:EntityAddressAddressLine1 id="Item-130" contextRef="Duration_1_1_2020_To_12_31_2020">7801 N. Capital of Texas Highway</dei:EntityAddressAddressLine1>
  <dei:EntityAddressAddressLine2 id="Item-122" contextRef="Duration_1_1_2020_To_12_31_2020">Suite 260</dei:EntityAddressAddressLine2>
  <dei:EntityAddressCityOrTown id="Item-23" contextRef="Duration_1_1_2020_To_12_31_2020">Austin</dei:EntityAddressCityOrTown>
  <dei:EntityAddressPostalZipCode id="Item-1" contextRef="Duration_1_1_2020_To_12_31_2020">78731</dei:EntityAddressPostalZipCode>
  <dei:EntityAddressStateOrProvince id="Item-259" contextRef="Duration_1_1_2020_To_12_31_2020">TX</dei:EntityAddressStateOrProvince>
  <dei:EntityCentralIndexKey id="Item-498" contextRef="Duration_1_1_2020_To_12_31_2020">0001069530</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding id="Item-455" contextRef="As_Of_3_18_2021" unitRef="Unit1" decimals="INF">39898325</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus id="Item-500" contextRef="Duration_1_1_2020_To_12_31_2020">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityEmergingGrowthCompany id="Item-204" contextRef="Duration_1_1_2020_To_12_31_2020">false</dei:EntityEmergingGrowthCompany>
  <dei:EntityFileNumber id="Item-6" contextRef="Duration_1_1_2020_To_12_31_2020">000-29959</dei:EntityFileNumber>
  <dei:EntityFilerCategory id="Item-15" contextRef="Duration_1_1_2020_To_12_31_2020">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityIncorporationStateCountryCode id="Item-11" contextRef="Duration_1_1_2020_To_12_31_2020">DE</dei:EntityIncorporationStateCountryCode>
  <dei:EntityInteractiveDataCurrent id="Item-66" contextRef="Duration_1_1_2020_To_12_31_2020">Yes</dei:EntityInteractiveDataCurrent>
  <dei:EntityPublicFloat id="Item-200" contextRef="As_Of_6_30_2020" unitRef="Unit12" decimals="0">71146906</dei:EntityPublicFloat>
  <dei:EntityRegistrantName id="Item-199" contextRef="Duration_1_1_2020_To_12_31_2020">CASSAVA SCIENCES INC</dei:EntityRegistrantName>
  <dei:EntityShellCompany id="Item-113" contextRef="Duration_1_1_2020_To_12_31_2020">false</dei:EntityShellCompany>
  <dei:EntitySmallBusiness id="Item-190" contextRef="Duration_1_1_2020_To_12_31_2020">true</dei:EntitySmallBusiness>
  <dei:EntityTaxIdentificationNumber id="Item-274" contextRef="Duration_1_1_2020_To_12_31_2020">91-1911336</dei:EntityTaxIdentificationNumber>
  <dei:EntityVoluntaryFilers id="Item-499" contextRef="Duration_1_1_2020_To_12_31_2020">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer id="Item-501" contextRef="Duration_1_1_2020_To_12_31_2020">Yes</dei:EntityWellKnownSeasonedIssuer>
  <dei:IcfrAuditorAttestationFlag id="Item-7" contextRef="Duration_1_1_2020_To_12_31_2020">false</dei:IcfrAuditorAttestationFlag>
  <dei:LocalPhoneNumber id="Item-196" contextRef="Duration_1_1_2020_To_12_31_2020">501-2444</dei:LocalPhoneNumber>
  <dei:Security12bTitle id="Item-9" contextRef="Duration_1_1_2020_To_12_31_2020">Common Stock, $0.001 par value</dei:Security12bTitle>
  <dei:SecurityExchangeName id="Item-275" contextRef="Duration_1_1_2020_To_12_31_2020">NASDAQ</dei:SecurityExchangeName>
  <dei:TradingSymbol id="Item-502" contextRef="Duration_1_1_2020_To_12_31_2020">sava</dei:TradingSymbol>
  <sava:CashIncentiveBonusAward id="Item-26" contextRef="As_Of_10_13_2020_srt_StatementScenarioAxis_sava_FirstValuationMilestoneMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember" unitRef="Unit12" decimals="-5">7300000</sava:CashIncentiveBonusAward>
  <sava:CashIncentiveBonusAward id="Item-472" contextRef="As_Of_12_31_2020_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_sava_Exceeds5BillionMarketCapitalizationMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember" unitRef="Unit12" decimals="-5">322300000</sava:CashIncentiveBonusAward>
  <sava:CashIncentiveBonusAward id="Item-135" contextRef="As_Of_12_31_2020_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_sava_Exceeds5BillionMarketCapitalizationMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember" unitRef="Unit12" decimals="-5">137400000</sava:CashIncentiveBonusAward>
  <sava:CashIncentiveBonusAward id="Item-17" contextRef="As_Of_1_1_2021_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_sava_SecondThroughEighthValuationMilestonesMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit12" decimals="-5">145000000</sava:CashIncentiveBonusAward>
  <sava:CashIncentiveBonusAward id="Item-266" contextRef="As_Of_1_1_2021_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_sava_SecondThroughEighthValuationMilestonesMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit12" decimals="-5">59900000</sava:CashIncentiveBonusAward>
  <sava:CashIncentiveBonusPlanTextBlock id="Item-8" contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:10pt;"&gt;Note&amp;nbsp;8.&amp;nbsp; 2020 Cash Incentive Bonus Plan&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;On August&amp;nbsp;26, 2020, the Board approved the Plan. The Plan was established to promote the long-term success of the Company by creating an &amp;#x201C;at-risk&amp;#x201D; cash bonus program that rewards&amp;nbsp;Plan&amp;nbsp;participants with additional cash compensation in lockstep with significant increases in the Company&amp;#x2019;s market capitalization. The Plan is considered &amp;#x201C;at-risk&amp;#x201D; because Plan participants&amp;nbsp;will&amp;nbsp;not receive a cash bonus&amp;nbsp;unless&amp;nbsp;the Company&amp;#x2019;s market capitalization increases&amp;nbsp;significantly and&amp;nbsp;certain&amp;nbsp;other&amp;nbsp;conditions specified in the Plan&amp;nbsp;are met.&amp;nbsp;Specifically, Plan participants&amp;nbsp;will&amp;nbsp;not&amp;nbsp;be paid&amp;nbsp;any cash bonuses unless (1) the Company completes a&amp;nbsp;merger or acquisition transaction that constitutes a sale of ownership of the Company or its assets (a Merger Transaction) or (2) the Compensation Committee of the Board&amp;nbsp;(the Compensation Committee) determines the Company has sufficient cash on hand, as defined in the Plan. Because&amp;nbsp;of the inherent discretion and uncertainty regarding&amp;nbsp;these&amp;nbsp;requirements, the Company has concluded that&amp;nbsp;a&amp;nbsp;Plan&amp;nbsp;grant date has not occurred&amp;nbsp;as of December&amp;nbsp;31, 2020.&amp;nbsp;Plan participants will be paid all earned cash bonuses in the event of a Merger Transaction.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;The Company&amp;#x2019;s market capitalization for purposes of the Plan&amp;nbsp;is&amp;nbsp;determined based on either (1) the Company&amp;#x2019;s closing price&amp;nbsp;of one share&amp;nbsp;on the Nasdaq Capital&amp;nbsp;Market&amp;nbsp;multiplied by the total issued and outstanding shares and options to purchase shares of the Company or (2) the aggregate consideration payable to security holders of the Company in a&amp;nbsp;Merger Transaction.&amp;nbsp;This constitutes a market condition under applicable accounting guidance.&amp;nbsp; &amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;The Plan&amp;nbsp;triggers a potential cash bonus each time&amp;nbsp;the&amp;nbsp;Company&amp;#x2019;s market capitalization increases significantly, up to a maximum&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;$5&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;nbsp;billion in market capitalization. The Plan specifies 14&amp;nbsp;incremental&amp;nbsp;amounts&amp;nbsp;between&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;$200&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;nbsp;million and&amp;nbsp;$5&amp;nbsp;billion&amp;nbsp;&amp;nbsp;(each increment,&amp;nbsp;a &amp;#x201C;Valuation Milestone&amp;#x201D;). Each&amp;nbsp;Valuation Milestone&amp;nbsp;triggers&amp;nbsp;a potential cash bonus award in a pre-set amount defined in the Plan. Each&amp;nbsp;Valuation&amp;nbsp;Milestone&amp;nbsp;must be achieved and maintained for no less than 20 consecutive trading days for&amp;nbsp;Plan&amp;nbsp;participants to be eligible for a potential cash bonus award.&amp;nbsp;Approximately &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;59%&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt; of each&amp;nbsp;cash bonus award&amp;nbsp;associated with a Valuation Milestone&amp;nbsp;is subject to&amp;nbsp;adjustment and&amp;nbsp;approval&amp;nbsp;by the Compensation Committee.&amp;nbsp;Any amounts&amp;nbsp;not awarded by the Compensation Committee&amp;nbsp;are&amp;nbsp;no longer available for distribution.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;If the Company were to exceed a $5&amp;nbsp;billion market capitalization&amp;nbsp;for no less than 20 consecutive trading days, all&amp;nbsp;Valuation&amp;nbsp;Milestones would be deemed achieved, in which case cash bonus awards would&amp;nbsp;range from&amp;nbsp;a minimum of&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;$137.4&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;nbsp;million&amp;nbsp;up to&amp;nbsp;a hypothetical maximum of&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;$322.3&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;nbsp;million.&amp;nbsp;Payment of cash bonuses is deferred until such time as&amp;nbsp;(1)&amp;nbsp;the Company completes a Merger Transaction, or&amp;nbsp;(2)&amp;nbsp;the&amp;nbsp;Compensation Committee determines the&amp;nbsp;Company has sufficient cash&amp;nbsp;on hand&amp;nbsp;to render payment&amp;nbsp;(each, a &amp;#x201C;Performance Condition&amp;#x201D;),&amp;nbsp;neither&amp;nbsp;of which may ever occur. Accordingly, there can be no assurance that&amp;nbsp;Plan&amp;nbsp;participants will&amp;nbsp;ever&amp;nbsp;be&amp;nbsp;paid a cash bonus that is awarded under the Plan, even if the Company&amp;#x2019;s market capitalization increases&amp;nbsp;significantly.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;The Plan is accounted for as a liability award.&amp;nbsp;The fair value of each&amp;nbsp;Valuation&amp;nbsp;Milestone&amp;nbsp;award&amp;nbsp;will be&amp;nbsp;determined&amp;nbsp;once&amp;nbsp;a&amp;nbsp;grant date occurs and&amp;nbsp;will be&amp;nbsp;remeasured each reporting period.&amp;nbsp;Compensation expense associated with the Plan&amp;nbsp;will be&amp;nbsp;recognized over the expected achievement period for each&amp;nbsp;of the 14&amp;nbsp;Valuation&amp;nbsp;Milestones, when&amp;nbsp;a Performance Condition&amp;nbsp;is considered probable of being met. &amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;On October&amp;nbsp;13, 2020, the Company&amp;nbsp;achieved&amp;nbsp;the first&amp;nbsp;Valuation&amp;nbsp;Milestone.&amp;nbsp;Subsequently, the Compensation Committee&amp;nbsp;approved&amp;nbsp;a potential cash bonus&amp;nbsp;award&amp;nbsp;of&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;$7.3&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;nbsp;million&amp;nbsp;in total&amp;nbsp;for&amp;nbsp;all Plan participants, subject to future satisfaction of a Performance Condition.&amp;nbsp;However,&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;nbsp;compensation expense has been recorded&amp;nbsp;since no&amp;nbsp;grant date has occurred and no&amp;nbsp;Performance Conditions are considered probable of being met.&amp;nbsp;There is no continuing service requirement for Plan participants once&amp;nbsp;the Compensation Committee approves a cash&amp;nbsp;bonus award.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;Subsequent to December&amp;nbsp;31, 2020, the Company achieved eight additional Valuation Milestones triggering potential Company obligations to all Plan participants from a minimum of &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;$59.9&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;nbsp;million up to a hypothetical maximum of &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;$145.0&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;nbsp;million, to be determined by the Compensation Committee and contingent upon future satisfaction of a Performance Condition.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;No&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt; actual cash payments were authorized or made to participants under the Plan during the year ended December&amp;nbsp;31, 2020.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</sava:CashIncentiveBonusPlanTextBlock>
  <sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet id="Item-222" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3">2000</sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet>
  <sava:LeasesAndCommitmentsDisclosureTextBlock id="Item-14" contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;"&gt;7.&amp;nbsp;&amp;nbsp;Leases and Commitments&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;Right-of-use Asset and Liability&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The Company has a single non-cancelable operating lease for approximately &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;6,000&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; square feet of office space in Austin, Texas, which is used for the development of novel products. &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;On September&amp;nbsp;4, 2020, the Company entered into a lease amendment that extended&amp;nbsp;the&amp;nbsp;lease termination date to &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;April&amp;nbsp;30, 2024&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt; and set&amp;nbsp;new rental rates effective as of January&amp;nbsp;1, 2021.&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;Future lease payments are&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; (in thousands)&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt"&gt;
			&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt"&gt;
						&lt;font style="display: inline;font-family:Calibri;font-size:11pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;font-size:9pt;"&gt;For the year ending December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-size:9pt;"&gt;2021&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;66&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-size:9pt;"&gt;2022&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;102&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-size:9pt;"&gt;2023&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;107&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-size:9pt;"&gt;2024&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;36&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-size:9pt;"&gt;Total future lease payments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;311&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-size:9pt;"&gt;Less: imputed interest&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;(18)
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-size:9pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;293&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt"&gt;
						&lt;font style="display: inline;font-family:Calibri;font-size:11pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Rent expense was &lt;/font&gt;&lt;font style="display: inline;"&gt;$0.1&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;million for the year ended December&amp;nbsp;31, 2020 and 2019.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;The Company recorded a&amp;nbsp;right-of-use asset and lease liability&amp;nbsp;of &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;$316,000&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;nbsp;as a result of the lease&amp;nbsp;modification in September 2020. The Company utilized a discount rate of&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;3.25%&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;nbsp;for the modified lease&amp;nbsp;to determine the present value of the future lease payments, which&amp;nbsp;approximated the Company&amp;#x2019;s incremental borrowing rate&amp;nbsp;in September 2020. &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;There were &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; right-of-use assets exchanged for operating lease liabilities during the year ended December&amp;nbsp;31, 2019.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;Cash paid for operating lease liabilities totaled &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;$99,000&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;$95,000&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt; during the years ended December&amp;nbsp;31, 2020 and 2019, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;color:#000000;font-size:10pt;"&gt;Other Commitments&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The Company conducts its product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. It has contractual arrangements with these organizations, however these contracts are cancelable on thirty days&amp;#x2019; notice and the Company&amp;#x2019;s obligations under these contracts are largely based on services performed.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The Company is dependent on contract development and manufacturing organizations for the manufacture of all our materials for clinical studies.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</sava:LeasesAndCommitmentsDisclosureTextBlock>
  <sava:PaymentsForCashIncentiveBonus id="Item-258" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember" unitRef="Unit12" decimals="-5">0</sava:PaymentsForCashIncentiveBonus>
  <sava:PercentageOfCommissionAtmOffering id="Item-25" contextRef="As_Of_3_27_2020_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember" unitRef="Unit13" decimals="3">0.030</sava:PercentageOfCommissionAtmOffering>
  <sava:PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment id="Item-256" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember" unitRef="Unit13" decimals="2">0.59</sava:PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment>
  <sava:PerformancePlanValuationAmount id="Item-27" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember" unitRef="Unit12" decimals="-9">5000000000</sava:PerformancePlanValuationAmount>
  <sava:PerformancePlanValuationAmount id="Item-193" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember" unitRef="Unit12" decimals="-6">200000000</sava:PerformancePlanValuationAmount>
  <sava:ProceedsFromGrantsPolicyPolicyTextBlock id="Item-192" contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;Proceeds from Grants&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;In 2020, the Company received &lt;/font&gt;&lt;font style="display: inline;"&gt;$4.2&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;million of reimbursement from the National Institutes of Health and National Institute on Drug Abuse and &lt;/font&gt;&lt;font style="display: inline;"&gt;$4.7&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;million in 2019. The Company records the proceeds from these grants as reductions to its research and development expenses.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</sava:ProceedsFromGrantsPolicyPolicyTextBlock>
  <sava:ProceedsFromIssuanceFollowOnPublicOfferingNetOfIssuanceCosts id="Item-241" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3">70251000</sava:ProceedsFromIssuanceFollowOnPublicOfferingNetOfIssuanceCosts>
  <sava:ReductionToResearchAndDevelopmentExpense id="Item-198" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-5">4700000</sava:ReductionToResearchAndDevelopmentExpense>
  <sava:ReductionToResearchAndDevelopmentExpense id="Item-24" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-5">4200000</sava:ReductionToResearchAndDevelopmentExpense>
  <sava:ResearchAndDevelopmentExpenseNetOfGrantReimbursement id="Item-33" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3">1568000</sava:ResearchAndDevelopmentExpenseNetOfGrantReimbursement>
  <sava:ResearchAndDevelopmentExpenseNetOfGrantReimbursement id="Item-32" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3">3053000</sava:ResearchAndDevelopmentExpenseNetOfGrantReimbursement>
  <sava:ResearchContractCostsAndAccrualsPolicyPolicyTextBlock id="Item-276" contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;color:#000000;"&gt;Research Contract Costs and Accruals&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;The Company has entered into various research and development contracts with research institutions and other third-party vendors. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&amp;#x2019;s estimates. The Company&amp;#x2019;s historical accrual estimates have not been materially different from actual costs.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</sava:ResearchContractCostsAndAccrualsPolicyPolicyTextBlock>
  <sava:ShareBasedCompensationAdditionalExpenseExpectedOnVesting id="Item-283" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit12" decimals="-5">2300000</sava:ShareBasedCompensationAdditionalExpenseExpectedOnVesting>
  <sava:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm id="Item-67" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_sava_TwoThousandEighteenEquityIncentivePlanMember">P10Y</sava:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm>
  <sava:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod id="Item-291" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-5">1500000</sava:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod>
  <sava:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm id="Item-30" contextRef="Duration_1_1_2020_To_12_31_2020">P2Y1M6D</sava:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm>
  <sava:SummaryOfNonCashStockBasedCompensationTableTextBlock id="Item-123" contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Year ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Research and development&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.78%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;453&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;542&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;General and administrative&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;535&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;754&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Total non-cash stock-based compensation expense&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.78%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;988&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;1,296&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt"&gt;
						&lt;font style="display: inline;font-family:Calibri;font-size:11pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.78%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.20%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</sava:SummaryOfNonCashStockBasedCompensationTableTextBlock>
  <us-gaap:AccountsPayableCurrent id="Item-84" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">453000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent id="Item-83" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">911000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="Item-86" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">777000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="Item-85" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">719000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="Item-264" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" unitRef="Unit12" decimals="-3">878000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AdditionalPaidInCapital id="Item-106" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">190664000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital id="Item-105" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">267086000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition id="Item-387" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3">9000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition xsi:nil="true" id="Item-385" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" />
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition id="Item-384" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">9000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition xsi:nil="true" id="Item-382" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" />
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition xsi:nil="true" id="Item-386" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" />
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition id="Item-423" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3">27000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition xsi:nil="true" id="Item-421" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" />
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition id="Item-420" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">27000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition xsi:nil="true" id="Item-418" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" />
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition xsi:nil="true" id="Item-422" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" />
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="Item-393" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3">60000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts xsi:nil="true" id="Item-391" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" />
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="Item-390" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">60000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts xsi:nil="true" id="Item-388" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" />
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts xsi:nil="true" id="Item-392" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" />
  <us-gaap:AllocatedShareBasedCompensationExpense id="Item-129" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3">1296000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Item-127" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit12" decimals="-3">754000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Item-125" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3">542000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Item-128" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3">988000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Item-126" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit12" decimals="-3">535000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Item-124" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3">453000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Item-154" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="-3">2932000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Item-156" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" unitRef="Unit1" decimals="-3">4504000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Item-153" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="-3">2145000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Item-155" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" unitRef="Unit1" decimals="-3">554000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets id="Item-82" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">23486000</us-gaap:Assets>
  <us-gaap:Assets id="Item-81" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">94300000</us-gaap:Assets>
  <us-gaap:AssetsCurrent id="Item-76" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">23349000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="Item-75" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">93994000</us-gaap:AssetsCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Item-247" contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3">19807000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Item-249" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">23081000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Item-248" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">93506000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock id="Item-63" contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;Cash and Cash Equivalents and Concentration of Credit Risk&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The Company invests in cash and cash equivalents and, in the past, marketable securities. The Company considers highly-liquid financial instruments with original maturities of three months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts, money market funds and certificates of deposit. The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The Company&amp;#x2019;s investment policy allows for investments in marketable securities with active secondary or resale markets, establishes diversification and credit quality requirements and limits investments by maturity and issuer. The Company maintains its investments at one financial institution. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect id="Item-245" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3">3274000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect id="Item-244" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3">70425000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
  <us-gaap:CertificatesOfDepositAtCarryingValue id="Item-338" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-5">13000000</us-gaap:CertificatesOfDepositAtCarryingValue>
  <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable id="Item-463" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_sava_PlacementAgentWarrantsMember">2018-08-17</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
  <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable id="Item-458" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember">2018-08-17</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Item-465" contextRef="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_sava_PlacementAgentWarrantsMember" unitRef="Unit14" decimals="2">1.59</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Item-460" contextRef="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember" unitRef="Unit14" decimals="2">1.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="Item-468" contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="INF">4504091</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="Item-466" contextRef="As_Of_12_31_2019_us-gaap_ClassOfWarrantOrRightAxis_sava_PlacementAgentWarrantsMember" unitRef="Unit1" decimals="INF">7975</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="Item-462" contextRef="As_Of_12_31_2019_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember" unitRef="Unit1" decimals="INF">4496116</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="Item-119" contextRef="As_Of_12_31_2019_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_PlanNameAxis_sava_CommonStockWarrantsMember" unitRef="Unit1" decimals="-5">4600000</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="Item-467" contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="INF">554019</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="Item-461" contextRef="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember" unitRef="Unit1" decimals="INF">554019</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="Item-28" contextRef="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_PlanNameAxis_sava_CommonStockWarrantsMember" unitRef="Unit1" decimals="-5">4000000</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="Item-3" contextRef="As_Of_1_1_2021_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit1" decimals="-5">600000</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="Item-29" contextRef="As_Of_1_1_2021_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_PlanNameAxis_sava_CommonStockWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit1" decimals="-5">600000</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:CommitmentsAndContingencies xsi:nil="true" id="Item-100" contextRef="As_Of_12_31_2019" unitRef="Unit12" />
  <us-gaap:CommitmentsAndContingencies xsi:nil="true" id="Item-99" contextRef="As_Of_12_31_2020" unitRef="Unit12" />
  <us-gaap:CommonStockParOrStatedValuePerShare id="Item-477" contextRef="As_Of_12_31_2019" unitRef="Unit14" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="Item-476" contextRef="As_Of_12_31_2020" unitRef="Unit14" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="Item-268" contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_sava_TwoThousandEighteenEquityIncentivePlanMember" unitRef="Unit14" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="Item-69" contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="INF">120000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="Item-68" contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="INF">120000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="Item-471" contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_sava_TwoThousandEighteenEquityIncentivePlanMember" unitRef="Unit1" decimals="INF">1000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="Item-211" contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="INF">21841810</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="Item-292" contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="INF">35237987</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="Item-284" contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="INF">21841810</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="Item-51" contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="INF">35237987</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue id="Item-104" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">22000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue id="Item-103" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">35000</us-gaap:CommonStockValue>
  <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock id="Item-64" contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;"&gt;5.&amp;nbsp;&amp;nbsp;Employee 401(k) Benefit Plan&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers substantially all employees. Employees are eligible to participate in the plan the first day of the month after hire and may contribute up to the current statutory limits under Internal Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf of all employees. Through December&amp;nbsp;31, 2020, the Company has not made any matching contributions to the 401(k) plan.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
  <us-gaap:CompensationRelatedCostsPolicyTextBlock id="Item-5" contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;Stock-based Compensation&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each &lt;/font&gt;&lt;a name="_cp_text_1_372"&gt;&lt;/a&gt;&lt;font style="display: inline;"&gt;award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management's judgment. The Company recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally &lt;/font&gt;&lt;font style="display: inline;"&gt;four&lt;/font&gt;&lt;font style="display: inline;"&gt; years. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The Company has granted share-based awards that vest upon achievement of certain performance criteria, or performance awards. The Company multiplies the number of performance awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. The Company periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance awards vest and common stock is issued upon achievement of the performance criteria.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
  <us-gaap:DeferredIncomeTaxLiabilities id="Item-367" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">26000</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:DeferredIncomeTaxLiabilities id="Item-366" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">67000</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:DeferredTaxAssetsGross id="Item-357" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">29751000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross id="Item-356" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">28514000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsNet id="Item-361" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">26000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsNet id="Item-360" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">67000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="Item-349" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">17110000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="Item-348" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">18333000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOther id="Item-355" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">237000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsOther id="Item-354" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">264000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="Item-353" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">6587000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="Item-352" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">6687000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost id="Item-351" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">5817000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost id="Item-350" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">3230000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="Item-359" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">29725000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="Item-358" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">28447000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxLiabilities xsi:nil="true" id="Item-369" contextRef="As_Of_12_31_2019" unitRef="Unit12" />
  <us-gaap:DeferredTaxLiabilities xsi:nil="true" id="Item-368" contextRef="As_Of_12_31_2020" unitRef="Unit12" />
  <us-gaap:DeferredTaxLiabilitiesLeasingArrangements id="Item-365" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">19000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
  <us-gaap:DeferredTaxLiabilitiesLeasingArrangements id="Item-364" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">62000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
  <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment id="Item-363" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">7000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment id="Item-362" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">5000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
  <us-gaap:DepreciationDepletionAndAmortization id="Item-218" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3">58000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization id="Item-217" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3">22000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Item-152" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit14" decimals="2">-0.27</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Item-151" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit14" decimals="2">-0.24</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock id="Item-251" contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;Net Loss per Share&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Basic net loss per share is computed on the basis of the weighted-average number of common shares outstanding for the reporting period. Diluted net loss per share is computed on the basis of the weighted-average number of common shares outstanding plus dilutive potential common shares outstanding using the treasury-stock method. Potential dilutive common shares consist of outstanding equity awards and warrants. There is no difference between the Company&amp;#x2019;s net loss and comprehensive loss. The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands, except net loss per share data):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt"&gt;
			&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:24.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:24.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Year ended December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Numerator:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;(6,334)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;(4,631)
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Denominator:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Shares used in computing net loss per share, basic and diluted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;26,105&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;17,412&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Net loss per share, basic and diluted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;(0.24)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;(0.27)
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt; Dilutive common stock options excluded from net loss per share, diluted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;2,145&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;2,932&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt; Common stock warrants excluded from net loss per share, diluted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;554&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;4,504&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The Company excluded weighted equity awards and warrants outstanding to purchase common stock from the calculation of diluted net loss per share because the effect of including these shares in this calculation would be anti-dilutive.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations xsi:nil="true" id="Item-491" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit13" />
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations xsi:nil="true" id="Item-490" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit13" />
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="Item-481" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit13" decimals="3">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="Item-480" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit13" decimals="3">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="Item-489" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit13" decimals="3">-0.192</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="Item-488" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit13" decimals="3">0.202</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost id="Item-485" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit13" decimals="3">-0.024</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost id="Item-484" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit13" decimals="3">-0.428</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes xsi:nil="true" id="Item-483" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit13" />
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes xsi:nil="true" id="Item-482" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit13" />
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch id="Item-487" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit13" decimals="3">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch id="Item-486" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit13" decimals="3">0.016</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="Item-88" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">58000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="Item-87" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">83000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock id="Item-55" contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;Fair Value Measurements &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The Company reports its cash and cash equivalents at fair value as Level 1, Level 2 or Level 3 using the following inputs:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
				&lt;font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; &amp;#xB7;&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
			&lt;a name="_9eed50031d7a4ae08d8481e27454a126"&gt;&lt;/a&gt;&lt;a name="_a55395c9dddb484ab9d7fe2cd900ad3a"&gt;&lt;/a&gt;&lt;a name="_9c970aca55e541dc8a21fc5af6a42932"&gt;&lt;/a&gt;&lt;a name="_c95ddda386b84ea0a6341120a7f1021f"&gt;&lt;/a&gt;&lt;a name="_3c0ffcf4570c456cbc299897392e42d9"&gt;&lt;/a&gt;&lt;a name="_dee475e5298f41189ad89abce51b465d"&gt;&lt;/a&gt;&lt;a name="_56802d68c6a94dbe9fcf1274361e7f37"&gt;&lt;/a&gt;&lt;a name="_5121355f7d274c19a6859f83034a8dd4"&gt;&lt;/a&gt;&lt;a name="_adff7fd0d1df49cfbd1d486e06beadfa"&gt;&lt;/a&gt;&lt;a name="_d9e1ff57a6464ab6a179624ab81cda10"&gt;&lt;/a&gt;&lt;a name="_a6d0459d796849d2b1866055cd140477"&gt;&lt;/a&gt;&lt;a name="_6967f826ca9b4f0f9b986e3e324d9161"&gt;&lt;/a&gt;&lt;a name="_5a3701addc544c73a9d512b8e9743988"&gt;&lt;/a&gt;&lt;a name="_c3da333d461e4520b3a037507e639721"&gt;&lt;/a&gt;&lt;a name="_7878265e95384b81ae1b7f17224656fd"&gt;&lt;/a&gt;&lt;a name="_b691c60198414d559b1914e876b580a1"&gt;&lt;/a&gt;&lt;a name="_7fb1ed58d627447ab56cfbe9d52d6120"&gt;&lt;/a&gt;&lt;a name="_be8d133366f34f6686cef9d21c16f0a3"&gt;&lt;/a&gt;&lt;a name="_e3b5f0a49cfe4f04a7282b95d681b7ce"&gt;&lt;/a&gt;&lt;a name="_932ab8c8a3574e5a87e70dc56597bb6f"&gt;&lt;/a&gt;&lt;a name="_9fb551aa76e3415c984cffa1491a23ea"&gt;&lt;/a&gt;&lt;a name="_1746df8b27fc41ef992b25383e220984"&gt;&lt;/a&gt;&lt;a name="_0c3de46198274b128860550988ef844d"&gt;&lt;/a&gt;&lt;a name="_75dfd0ae686c45b99fde81a8d35908b3"&gt;&lt;/a&gt;&lt;a name="_d9318bc5124f4b7c97afcc172b32ae28"&gt;&lt;/a&gt;&lt;a name="_6310384476c740cf8e641c9a413eb968"&gt;&lt;/a&gt;&lt;a name="_91d164c9544945c48fd3a86929e64fd4"&gt;&lt;/a&gt;&lt;a name="_973c93b3770b4476a04247143aaf5d5a"&gt;&lt;/a&gt;&lt;a name="_9d4e208743764419adbb1942938e565a"&gt;&lt;/a&gt;&lt;a name="_e2f59ee1432249b792889c80e60b08d7"&gt;&lt;/a&gt;&lt;a name="_f6345b5294af4fef90374149482d4f46"&gt;&lt;/a&gt;&lt;a name="_d48429101312494397f78e2250f832e4"&gt;&lt;/a&gt;&lt;font style="display: inline;color:#000000;"&gt;Level 1 includes quoted prices in active markets. The Company bases the fair value of money market funds on Level 1 inputs.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
				&lt;font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; &amp;#xB7;&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;Level 2 includes significant observable inputs, such as quoted prices for identical or similar investments, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from third-party providers. It uses the bid price to establish fair value where a bid price is available. The Company bases the fair value of its certificates of deposit, if any, on Level 2 inputs.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
				&lt;font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; &amp;#xB7;&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;Level 3 includes unobservable inputs that are supported by little or no market activity. The Company does not have any investments where the fair value is based on Level 3 inputs.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. A certificate of deposit totaling &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;$13.0&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;million at December&amp;nbsp;31, 2019 was included within cash equivalents as a Level 2 input. The fair value of the remainder of cash and cash equivalents, including money market accounts, was based on Level 1 inputs at December&amp;nbsp;31, 2020 and 2019.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy id="Item-279" contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Financial instruments include cash and cash equivalents, accounts payable and accrued liabilities. The estimated fair value of financial instruments has been determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies may be material to the estimated fair value amounts. The carrying amounts of cash and cash equivalents, accounts payable and accrued liabilities are at cost, which approximates fair value due to the short maturity of those instruments.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment xsi:nil="true" id="Item-263" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" unitRef="Unit12" />
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="Item-219" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3">346000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="Item-294" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" unitRef="Unit12" decimals="-3">346000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:GeneralAndAdministrativeExpense id="Item-35" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3">3391000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="Item-34" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3">3739000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncomeTaxDisclosureTextBlock id="Item-118" contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;"&gt;6.&amp;nbsp;&amp;nbsp;Income Taxes&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The Company did not provide for income taxes in 2020 and 2019 because it had book and federal taxable losses in those years and the tax benefit that would have resulted from the pre-tax losses was fully offset by a change in the valuation allowance. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The reconciliation of the statutory federal income tax rate to the Company&amp;#x2019;s effective tax rate for the years ended December&amp;nbsp;31, 2020 and 2019 was as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt"&gt;
			&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="4" valign="bottom" style="width:30.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;Year ended December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Tax at federal statutory rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;21.0&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;21.0&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;State tax, net of federal benefit&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Share-based compensation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(42.8)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(2.4)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Research and development credits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1.6&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;0.6&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;20.2&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(19.2)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Effective income tax rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;Deferred tax assets and valuation allowance&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:15.15pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Deferred tax assets reflect the tax effects of net operating loss and tax credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company&amp;#x2019;s deferred taxes assets at December&amp;nbsp;31, 2020 and 2019 were valued at the corporate tax rate of 21%. The Company offsets its deferred tax assets by a valuation allowance because it is uncertain about the timing and amount of any future profits. Significant components of its deferred tax assets are as follows (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;December 31, &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Net operating loss carryforwards&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;18,333&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;17,110&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Share-based compensation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;3,230&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;5,817&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Research and development credit carryforwards&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;6,687&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;6,587&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;264&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;237&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Total deferred tax assets:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;28,514&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;29,751&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Valuation allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(28,447)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(29,725)
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Net deferred tax assets:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;67&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;26&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Deferred tax liabilities:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Property and equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(5)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(7)
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Operating lease right-of-use assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(62)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(19)
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Total deferred tax liabilities:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(67)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(26)
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Net deferred tax asset / (liability):&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:5.25pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:5.25pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:5.25pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:5.25pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:5.25pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:5.25pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The valuation allowance decreased by &lt;/font&gt;&lt;font style="display: inline;"&gt;$1.3&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;million in 2020. The valuation allowance decreased by &lt;/font&gt;&lt;font style="display: inline;"&gt;$2.4&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;million due to a write down of the share-based compensation deferred tax asset and is offset in part by a &lt;/font&gt;&lt;font style="display: inline;"&gt;$1.1&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;million increase due to additional book losses during the year. The valuation allowance increased by &lt;/font&gt;&lt;font style="display: inline;"&gt;$0.9&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;million in 2019 due to additional book losses during the year. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The Company&amp;#x2019;s pre-tax net operating loss carryforwards of &lt;/font&gt;&lt;font style="display: inline;"&gt;$87.3&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;million are federal, of which &lt;/font&gt;&lt;font style="display: inline;"&gt;$74.1&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;million expires between &lt;/font&gt;&lt;font style="display: inline;"&gt;2029&lt;/font&gt;&lt;font style="display: inline;"&gt; and &lt;/font&gt;&lt;font style="display: inline;"&gt;2039&lt;/font&gt;&lt;font style="display: inline;"&gt; and &lt;/font&gt;&lt;font style="display: inline;"&gt;$13.2&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;million carries forward indefinitely. As of December&amp;nbsp;31, 2020, the Company had federal research and development tax credits of approximately &lt;/font&gt;&lt;font style="display: inline;"&gt;$11.1&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;million, which expire in the years &lt;/font&gt;&lt;font style="display: inline;"&gt;2023&lt;/font&gt;&lt;font style="display: inline;"&gt; through &lt;/font&gt;&lt;font style="display: inline;"&gt;2040&lt;/font&gt;&lt;font style="display: inline;"&gt;. &amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;Unrecognized tax benefits&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:14.4pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;As of December&amp;nbsp;31, 2020 and 2019, the Company has unrecognized tax benefits related to tax credits of &lt;/font&gt;&lt;font style="display: inline;"&gt;$4.5&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;million and &lt;/font&gt;&lt;font style="display: inline;"&gt;$4.4&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;million, respectively. None of the unrecognized tax benefits as of December&amp;nbsp;31, 2020, if recognized, would impact the effective tax rate due to the valuation allowance and no interest or penalties have been recognized. A reconciliation of the beginning and ending balance of unrecognized tax benefits is as follows (in thousands): &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="4" valign="bottom" style="width:31.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;Year ended December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="middle" style="width:15.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="middle" style="width:15.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Beginning balance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;4,400&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;4,400&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Additions based on tax positions related to the current year&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;100&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Ending balance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;4,500&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;4,400&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;As of December&amp;nbsp;31, 2020, there were no unrecognized tax benefits that we expect would change significantly over the next 12 months.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The Company files U.S. and Texas income tax returns. In the United States, the statute of limitations with respect to the federal income tax returns for tax years after 2016&amp;nbsp;are open to audit; however, since the Company has net operating losses, the taxing authority has the ability to review tax returns prior to the 2017 tax year and make adjustments to these net operating loss carryforwards.&amp;nbsp;We are not under audit in any taxing jurisdiction at this time.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:IncomeTaxPolicyTextBlock id="Item-253" contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;Income Taxes&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The Company accounts for income taxes under the asset and liability method.&amp;nbsp;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. &amp;nbsp;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&amp;nbsp;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The Company accounts for uncertain tax positions in accordance with ASC 740, &amp;#x201C;Income Taxes&amp;#x201D;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&amp;#x2019;s financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="Item-224" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3">159000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="Item-223" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3">458000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="Item-226" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3">621000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="Item-225" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3">-58000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities id="Item-228" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3">-3000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities id="Item-227" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3">25000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherCurrentAssets id="Item-221" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3">23000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
  <us-gaap:IncreaseDecreaseInOtherCurrentAssets id="Item-220" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3">220000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
  <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities id="Item-230" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3">9000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
  <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities id="Item-229" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3">85000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
  <us-gaap:InterestAndOtherIncome id="Item-42" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3">328000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome id="Item-41" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3">112000</us-gaap:InterestAndOtherIncome>
  <us-gaap:LeaseAndRentalExpense id="Item-261" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-5">100000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:LeaseAndRentalExpense id="Item-262" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-5">100000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:LeaseExpirationDate1 id="Item-58" contextRef="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_sava_AustinMember">2024-04-30</us-gaap:LeaseExpirationDate1>
  <us-gaap:LesseeLeasesPolicyTextBlock id="Item-346" contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;Leases&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The Company recognizes&amp;nbsp;assets and liabilities that arise from leases.&amp;nbsp;For operating leases, the Company is required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, in the&amp;nbsp;statements&amp;nbsp;of financial position.&amp;nbsp;As the Company`s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
  <us-gaap:LesseeOperatingLeaseDiscountRate id="Item-252" contextRef="As_Of_9_30_2020" unitRef="Unit13" decimals="4">0.0325</us-gaap:LesseeOperatingLeaseDiscountRate>
  <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock id="Item-137" contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt"&gt;
						&lt;font style="display: inline;font-family:Calibri;font-size:11pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;font-size:9pt;"&gt;For the year ending December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-size:9pt;"&gt;2021&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;66&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-size:9pt;"&gt;2022&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;102&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-size:9pt;"&gt;2023&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;107&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-size:9pt;"&gt;2024&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;36&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-size:9pt;"&gt;Total future lease payments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;311&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-size:9pt;"&gt;Less: imputed interest&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;(18)
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-size:9pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;293&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt"&gt;
						&lt;font style="display: inline;font-family:Calibri;font-size:11pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue id="Item-142" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">311000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths id="Item-138" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">66000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour id="Item-141" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">36000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree id="Item-140" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">107000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo id="Item-139" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">102000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
  <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount id="Item-143" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">18000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
  <us-gaap:Liabilities id="Item-98" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">1387000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="Item-97" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">2100000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity id="Item-112" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">23486000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="Item-111" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">94300000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent id="Item-94" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">1387000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="Item-93" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">1865000</us-gaap:LiabilitiesCurrent>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="Item-243" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3">5806000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="Item-242" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3">75447000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="Item-236" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3">-18000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="Item-235" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3">360000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="Item-232" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3">-2514000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="Item-231" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3">-5382000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss id="Item-405" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3">-4631000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss xsi:nil="true" id="Item-403" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" />
  <us-gaap:NetIncomeLoss xsi:nil="true" id="Item-402" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" />
  <us-gaap:NetIncomeLoss xsi:nil="true" id="Item-400" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" />
  <us-gaap:NetIncomeLoss id="Item-404" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-4631000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="Item-447" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3">-6334000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss xsi:nil="true" id="Item-445" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" />
  <us-gaap:NetIncomeLoss xsi:nil="true" id="Item-444" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" />
  <us-gaap:NetIncomeLoss xsi:nil="true" id="Item-442" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" />
  <us-gaap:NetIncomeLoss id="Item-446" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-6334000</us-gaap:NetIncomeLoss>
  <us-gaap:NetRentableArea id="Item-271" contextRef="As_Of_12_31_2020_srt_StatementGeographicalAxis_sava_AustinMember" unitRef="Unit15" decimals="0">6000</us-gaap:NetRentableArea>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="Item-281" contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;Recent Accounting Pronouncements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The Company reviewed recently issued accounting pronouncements and plan to adopt those that are applicable to it, and does not expect the adoption of these pronouncements to have a material impact on its financial position, results of operations or cash flows. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;In December 2019, the FABS issued ASU No. 2019-12, &lt;/font&gt;&lt;font style="display: inline;font-style:italic;"&gt;Income Taxes (Topic 740) Simplifying Accounting for Income Taxes &lt;/font&gt;&lt;font style="display: inline;"&gt;as part of its initiative to reduce complexity in the accounting standards. The guidance amended certain disclosure requirements that had become redundant, outdated or superseded. Additionally, this guidance amends accounting for the interim period effects of changes in tax laws or rates and simplifies aspects of the accounting for franchise taxes. The guidance is effective for annual periods beginning after December&amp;nbsp;15, 2020, and is applicable for the Company in fiscal year 2021. Early adoption is permitted. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;In November 2018, the FASB issued ASU No. 2018-18, &lt;/font&gt;&lt;font style="display: inline;font-style:italic;color:#000000;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606. &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;The amendments in this update provide guidance on how to assess whether certain transactions between collaborative arrangement participants should be accounted for within the revenue recognition standard. The amendments in this update are effective for interim and annual periods for the Company beginning on January&amp;nbsp;1, 2020. &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;The adoption of this guidance did not have a material impact on&amp;nbsp;the Company&amp;#x2019;s&amp;nbsp;financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;In August 2018, the FASB issued ASU &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;No. 2018-13,&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-style:italic;color:#000000;"&gt;Fair Value Measurement (Topic 820) - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt; (ASU &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;2018-13),&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt; which is designed to improve the effectiveness of disclosures by removing, modifying and adding disclosures related to fair value measurements. ASU &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;2018-13&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt; is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The adoption of ASU 2018-13 did not have a material impact on&amp;nbsp;the Company&amp;#x2019;s&amp;nbsp;financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:NumberOfOperatingSegments id="Item-115" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit16" decimals="INF">1</us-gaap:NumberOfOperatingSegments>
  <us-gaap:OperatingExpenses id="Item-38" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3">4959000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="Item-37" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3">6446000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="Item-40" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3">-4959000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="Item-39" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3">-6446000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingLeaseLiability id="Item-473" contextRef="As_Of_9_30_2020" unitRef="Unit12" decimals="-3">316000</us-gaap:OperatingLeaseLiability>
  <us-gaap:OperatingLeaseLiability id="Item-144" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">293000</us-gaap:OperatingLeaseLiability>
  <us-gaap:OperatingLeaseLiabilityCurrent id="Item-90" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">90000</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:OperatingLeaseLiabilityCurrent id="Item-89" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">58000</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent xsi:nil="true" id="Item-96" contextRef="As_Of_12_31_2019" unitRef="Unit12" />
  <us-gaap:OperatingLeaseLiabilityNoncurrent id="Item-95" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">235000</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:OperatingLeasePayments id="Item-57" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3">95000</us-gaap:OperatingLeasePayments>
  <us-gaap:OperatingLeasePayments id="Item-18" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3">99000</us-gaap:OperatingLeasePayments>
  <us-gaap:OperatingLeaseRightOfUseAsset id="Item-78" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">90000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OperatingLeaseRightOfUseAsset id="Item-280" contextRef="As_Of_9_30_2020" unitRef="Unit12" decimals="-3">316000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OperatingLeaseRightOfUseAsset id="Item-77" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">295000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OperatingLossCarryforwards id="Item-293" contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" unitRef="Unit12" decimals="-5">87300000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards id="Item-454" contextRef="As_Of_12_31_2020_srt_StatementScenarioAxis_sava_ExpiresBetween2029And2039Member_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" unitRef="Unit12" decimals="-5">74100000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards id="Item-61" contextRef="As_Of_12_31_2020_srt_StatementScenarioAxis_sava_IndefinitelyMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" unitRef="Unit12" decimals="-5">13200000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwardsExpirationDate id="Item-136" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_sava_ExpiresBetween2029And2039Member_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">2039-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
  <us-gaap:OperatingLossCarryforwardsExpirationDate id="Item-59" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_sava_ExpiresBetween2029And2039Member_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">2029-01-01</us-gaap:OperatingLossCarryforwardsExpirationDate>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock id="Item-21" contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;"&gt;1.&amp;nbsp;&amp;nbsp;General and Liquidity&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Cassava Sciences, Inc. (the Company), formerly known as Pain Therapeutics, Inc., develops proprietary products that offer significant improvements to patients and healthcare professionals. The Company generally focuses its product development efforts on disorders of the nervous system. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Coronavirus Disease 2019 (COVID-19)&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The&lt;/font&gt;&lt;font style="display: inline;"&gt; recent, widespread outbreak of a novel infectious disease called Coronavirus Disease 2019, or COVID-19, has not significantly impacted the Company&amp;#x2019;s operations or financial condition as of March&amp;nbsp;23, 2021. &lt;/font&gt;&lt;font style="display: inline;"&gt;However, this pandemic has created a dynamic and uncertain situation in the national economy. The Company continues to closely monitor the latest information to make timely, informed business decisions and public disclosures regarding the potential impact of pandemic on its operations and financial condition. The scope of pandemic is unprecedented and its long-term impact on the Company&amp;#x2019;s operations and financial condition cannot be reasonably estimated at this time.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;Liquidity&amp;nbsp; &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The Company has incurred significant net losses and negative cash flows since inception, and as a result has an accumulated deficit of $174.9&amp;nbsp;million at December&amp;nbsp;31, 2020. The Company expects its cash requirements to be significant in the future. The amount and timing of its future cash requirements will depend on regulatory and market acceptance of the Company&amp;#x2019;s product candidates and the resources it devotes to researching and developing, formulating, manufacturing, commercializing and supporting its products. The Company may seek additional future funding through public or private financing in the future, if such funding is available and on terms acceptable to the Company. There are no assurances that additional financing will be available on favorable terms, or at all. However, management believes that the current working capital position will be sufficient to meet the Company&amp;#x2019;s working capital needs for at least the next 12 months.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:OtherAssetsCurrent id="Item-74" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">268000</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsCurrent id="Item-73" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">488000</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherLiabilitiesCurrent id="Item-92" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">9000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesCurrent id="Item-91" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">94000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:PaymentsOfStockIssuanceCosts id="Item-237" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3">60000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Item-233" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3">18000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="Item-269" contextRef="As_Of_12_31_2019" unitRef="Unit14" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="Item-270" contextRef="As_Of_12_31_2020" unitRef="Unit14" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized id="Item-273" contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized id="Item-272" contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued id="Item-288" contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued id="Item-287" contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding id="Item-469" contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding id="Item-470" contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockValue xsi:nil="true" id="Item-102" contextRef="As_Of_12_31_2019" unitRef="Unit12" />
  <us-gaap:PreferredStockValue xsi:nil="true" id="Item-101" contextRef="As_Of_12_31_2020" unitRef="Unit12" />
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="Item-120" contextRef="Duration_11_13_2020_To_11_13_2020_us-gaap_PlanNameAxis_sava_PublicOfferingMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">70251000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="Item-474" contextRef="Duration_2_12_2021_To_2_12_2021_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit12" decimals="-5">189700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromSaleOfMachineryAndEquipment id="Item-114" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" unitRef="Unit12" decimals="-3">360000</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="Item-234" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3">360000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:ProceedsFromStockOptionsExercised id="Item-238" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3">256000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromWarrantExercises id="Item-240" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3">5866000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromWarrantExercises id="Item-212" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_PlanNameAxis_sava_CommonStockWarrantsMember" unitRef="Unit12" decimals="-5">5900000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromWarrantExercises id="Item-239" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3">4940000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromWarrantExercises id="Item-53" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_PlanNameAxis_sava_CommonStockWarrantsMember" unitRef="Unit12" decimals="-5">4900000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromWarrantExercises id="Item-2" contextRef="Duration_1_1_2021_To_1_1_2021_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit12" decimals="-5">700000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromWarrantExercises id="Item-197" contextRef="Duration_1_1_2021_To_1_1_2021_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_PlanNameAxis_sava_CommonStockWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit12" decimals="-5">700000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock id="Item-337" contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;"&gt;3.&amp;nbsp;&amp;nbsp;Property and Equipment&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The Company&amp;#x2019;s property and equipment&lt;/font&gt;&lt;font style="display: inline;"&gt; include furniture and equipment&lt;/font&gt;&lt;font style="display: inline;"&gt;. Depreciation is recognized using the straight-line method over the expected life of the property and equipment.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;During the&amp;nbsp;year ended&amp;nbsp;December&amp;nbsp;31, 2020, the Company sold surplus manufacturing equipment to an independent third party and received proceeds totaling &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;$360,000&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;.&amp;nbsp;The original&amp;nbsp;cost of the property and equipment was &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;$892,000&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&amp;nbsp;and accumulated depreciation was &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;$878,000&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;,&amp;nbsp;resulting a gain on sale&amp;nbsp;of property and equipment of &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;$346,000&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&amp;nbsp;during the&amp;nbsp;year ended&amp;nbsp;December&amp;nbsp;31, 2020. There were &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; sales of property and equipment during year ended&amp;nbsp;December&amp;nbsp;31, 2019.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentGross id="Item-60" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" unitRef="Unit12" decimals="-3">892000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentNet id="Item-80" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">47000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="Item-79" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">11000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="Item-108" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">-168587000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="Item-107" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">-174921000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability id="Item-189" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
  <us-gaap:SaleOfStockConsiderationReceivedPerTransaction id="Item-54" contextRef="Duration_3_27_2020_To_3_27_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember" unitRef="Unit12" decimals="-6">100000000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction id="Item-191" contextRef="Duration_8_1_2018_To_8_31_2018_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_PlanNameAxis_sava_CommonStockWarrantsMember" unitRef="Unit1" decimals="-5">9100000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction id="Item-134" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember" unitRef="Unit1" decimals="INF">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction id="Item-260" contextRef="Duration_11_13_2020_To_11_13_2020_us-gaap_PlanNameAxis_sava_PublicOfferingMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">9375000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction id="Item-194" contextRef="Duration_2_12_2021_To_2_12_2021_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit1" decimals="INF">4081633</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SaleOfStockPricePerShare id="Item-250" contextRef="As_Of_11_13_2020_us-gaap_PlanNameAxis_sava_PublicOfferingMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit14" decimals="2">8.00</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:SaleOfStockPricePerShare id="Item-20" contextRef="As_Of_2_12_2021_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit14" decimals="2">49.00</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock id="Item-347" contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;December 31, &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Net operating loss carryforwards&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;18,333&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;17,110&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Share-based compensation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;3,230&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;5,817&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Research and development credit carryforwards&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;6,687&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;6,587&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;264&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;237&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Total deferred tax assets:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;28,514&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;29,751&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Valuation allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(28,447)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(29,725)
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Net deferred tax assets:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;67&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;26&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Deferred tax liabilities:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Property and equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(5)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(7)
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Operating lease right-of-use assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(62)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(19)
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Total deferred tax liabilities:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(67)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(26)
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Net deferred tax asset / (liability):&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:5.25pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:5.25pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:5.25pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:5.25pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:5.25pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:5.25pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock id="Item-146" contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:24.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:24.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Year ended December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Numerator:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;(6,334)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;(4,631)
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Denominator:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Shares used in computing net loss per share, basic and diluted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;26,105&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;17,412&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Net loss per share, basic and diluted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;(0.24)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;(0.27)
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt; Dilutive common stock options excluded from net loss per share, diluted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;2,145&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;2,932&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt; Common stock warrants excluded from net loss per share, diluted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;554&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;4,504&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock id="Item-479" contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="4" valign="bottom" style="width:30.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;Year ended December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Tax at federal statutory rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;21.0&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;21.0&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;State tax, net of federal benefit&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Share-based compensation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(42.8)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(2.4)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Research and development credits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1.6&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;0.6&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;20.2&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(19.2)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Effective income tax rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock id="Item-205" contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Number of Performance Awards&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Outstanding as of December 31, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;138,055&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 30pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 30pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Vested performance awards&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 30pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Forfeited/Canceled&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Outstanding as of December 31, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;138,055&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.58%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock id="Item-295" contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="6" valign="bottom" style="width:37.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Options outstanding&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="4" valign="bottom" style="width:24.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Options exercisable&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;average&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Number of&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;remaining&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;average&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Number of&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;average&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:23.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Range of exercise prices&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;outstanding&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;contractual&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;exercise&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt; vested&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;exercise&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;From&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;To&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;life (in years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;0.95&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;1.88&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;659,688&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;8.4&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;1.47&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;251,613&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;1.31&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;3.24&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;4.09&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;812,094&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;6.7&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;3.51&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;643,377&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;3.48&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;4.10&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;13.09&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;598,462&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;5.0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;10.89&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;525,383&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;11.42&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;14.21&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;35.00&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;619,599&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;2.8&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;24.02&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;619,599&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;24.02&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;36.40&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;53.55&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;127,661&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;0.7&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;51.72&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;127,661&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;51.72&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;2,817,504&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;5.6&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;11.30&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;2,167,633&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;13.86&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="Item-165" contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Number of Options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Weighted Average Exercise Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Weighted Average Remaining Contractual Term&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Aggregate Intrinsic Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;text-decoration:underline;"&gt;In years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;text-decoration:underline;"&gt;In millions&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Outstanding as of December 31, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;3,210,965&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt; 12.27&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;6.05&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;4.2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Options granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;60,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt; 7.25&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Options exercised&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;(71,105)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt; 3.60&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Options forfeited/canceled&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;(382,356)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt; 20.31&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Outstanding as of December 31, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;2,817,504&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt; 11.30&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;5.60&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;6.4&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#FF0000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Vested and expected to vest at December 31, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;2,817,504&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt; 11.30&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;5.60&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;6.4&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#FF0000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Exercisable at December 31, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;2,167,633&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt; 13.86&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;4.85&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;3.7&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock id="Item-339" contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt"&gt;
						&lt;font style="display: inline;font-family:Calibri;font-size:11pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt"&gt;
						&lt;font style="display: inline;font-family:Calibri;font-size:11pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;Volatility&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:15.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;123%&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; to &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;139%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:14.74%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;118%&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; to &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;119%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt"&gt;
						&lt;font style="display: inline;font-family:Calibri;font-size:11pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;Risk-free interest rates&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;0.46%&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; to &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;0.78%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;1.7%&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; to &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;2.5%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt"&gt;
						&lt;font style="display: inline;font-family:Calibri;font-size:11pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;Expected life of option&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;7&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;7&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt"&gt;
						&lt;font style="display: inline;font-family:Calibri;font-size:11pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;Dividend yield&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;zero&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;zero&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt"&gt;
						&lt;font style="display: inline;font-family:Calibri;font-size:11pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;Forfeiture rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;zero&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;zero&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt"&gt;
						&lt;font style="display: inline;font-family:Calibri;font-size:11pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;Weighted average fair value of stock options granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$6.69&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$1.60&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt"&gt;
						&lt;font style="display: inline;font-family:Calibri;font-size:11pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock id="Item-457" contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:41.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;Number of Shares Outstanding under Warrant&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:41.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;Issuance Date&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;Expiration Date&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;Exercise Price Per Share&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:17.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;August 17, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;February 17, 2021&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1.25&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;554,019&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;4,496,116&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;August 17, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;February 17, 2021&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1.59&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;7,975&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;554,019&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;4,504,091&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.26%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.80%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock id="Item-13" contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;Business Segments&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&amp;#x2019;s operations are confined to &lt;/font&gt;&lt;font style="display: inline;"&gt;one&lt;/font&gt;&lt;font style="display: inline;"&gt; business segment: the development of novel drugs and diagnostics.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:ShareBasedCompensation id="Item-216" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3">1296000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="Item-215" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3">988000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="Item-265" contextRef="Duration_1_1_2020_To_12_31_2020">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="Item-52" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_sava_TwoThousandEightEquityIncentivePlanMember">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod xsi:nil="true" id="Item-209" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit1" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod xsi:nil="true" id="Item-207" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit1" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="Item-206" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit1" decimals="INF">138055</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="Item-210" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit1" decimals="INF">138055</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod xsi:nil="true" id="Item-208" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit1" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate id="Item-121" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">2026-12-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate id="Item-16" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">2022-01-01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions id="Item-343" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit13" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions id="Item-342" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit13" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="Item-341" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit13" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="Item-340" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit13" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="Item-4" contextRef="Duration_1_1_2019_To_12_31_2019">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="Item-31" contextRef="Duration_1_1_2020_To_12_31_2020">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum id="Item-188" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit13" decimals="2">1.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum id="Item-202" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit13" decimals="2">1.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum id="Item-290" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit13" decimals="2">1.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum id="Item-133" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit13" decimals="2">1.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum id="Item-145" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit13" decimals="3">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum id="Item-195" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit13" decimals="4">0.0078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum id="Item-56" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit13" decimals="3">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum id="Item-70" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit13" decimals="4">0.0046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="Item-187" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-5">3700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="Item-184" contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="INF">2167633</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="Item-185" contextRef="As_Of_12_31_2020" unitRef="Unit14" decimals="2">13.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="Item-186" contextRef="Duration_1_1_2020_To_12_31_2020">P4Y10M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="Item-174" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit1" decimals="INF">382356</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Item-170" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit1" decimals="INF">60000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="Item-345" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit14" decimals="2">1.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="Item-344" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit14" decimals="2">6.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="Item-169" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-5">4200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="Item-179" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-5">6400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Item-166" contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="INF">3210965</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Item-176" contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="INF">2817504</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Item-167" contextRef="As_Of_12_31_2019" unitRef="Unit14" decimals="2">12.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Item-177" contextRef="As_Of_12_31_2020" unitRef="Unit14" decimals="2">11.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="Item-168" contextRef="Duration_1_1_2019_To_12_31_2019">P6Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="Item-178" contextRef="Duration_1_1_2020_To_12_31_2020">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue id="Item-183" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-5">6400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber id="Item-180" contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="INF">2817504</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice id="Item-181" contextRef="As_Of_12_31_2020" unitRef="Unit14" decimals="2">11.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 id="Item-182" contextRef="Duration_1_1_2020_To_12_31_2020">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="Item-173" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit14" decimals="2">3.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="Item-175" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit14" decimals="2">20.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="Item-171" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit14" decimals="2">7.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy id="Item-203" contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;color:#000000;"&gt;Incentive Bonus Plan&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;In 2020, the Company established the 2020 Cash Incentive Bonus Plan (the &amp;#x201C;Plan&amp;#x201D;) to incentivize Plan participants.&amp;nbsp;&amp;nbsp;Awards under the Plan are accounted for as liability awards under ASC 718 &amp;#x201C;&lt;/font&gt;&lt;font style="display: inline;font-style:italic;color:#000000;"&gt;Stock-based Compensation&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;&amp;#x201D;.&amp;nbsp;The fair value of each&amp;nbsp;potential Plan&amp;nbsp;award&amp;nbsp;will be&amp;nbsp;determined&amp;nbsp;once&amp;nbsp;a&amp;nbsp;grant date occurs and&amp;nbsp;will be&amp;nbsp;remeasured each reporting period.&amp;nbsp;Compensation expense associated with the Plan&amp;nbsp;will be&amp;nbsp;recognized over the expected achievement period for each&amp;nbsp;Plan award, when&amp;nbsp;a Performance Condition&amp;nbsp;is considered probable of being met.&amp;nbsp;&amp;nbsp;See Note 8 for further discussion of the Plan.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="Item-335" contextRef="As_Of_12_31_2020" unitRef="Unit14" decimals="2">13.86</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="Item-330" contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFiveMember" unitRef="Unit14" decimals="2">51.72</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="Item-323" contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFourMember" unitRef="Unit14" decimals="2">24.02</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="Item-302" contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeOneMember" unitRef="Unit14" decimals="2">1.31</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="Item-316" contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeThreeMember" unitRef="Unit14" decimals="2">11.42</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="Item-309" contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeTwoMember" unitRef="Unit14" decimals="2">3.48</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="Item-324" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFiveMember" unitRef="Unit14" decimals="2">36.40</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="Item-317" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFourMember" unitRef="Unit14" decimals="2">14.21</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="Item-296" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeOneMember" unitRef="Unit14" decimals="2">0.95</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="Item-310" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeThreeMember" unitRef="Unit14" decimals="2">4.10</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="Item-303" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeTwoMember" unitRef="Unit14" decimals="2">3.24</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="Item-334" contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="INF">2167633</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="Item-329" contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFiveMember" unitRef="Unit1" decimals="INF">127661</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="Item-322" contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFourMember" unitRef="Unit1" decimals="INF">619599</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="Item-301" contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeOneMember" unitRef="Unit1" decimals="INF">251613</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="Item-315" contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeThreeMember" unitRef="Unit1" decimals="INF">525383</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="Item-308" contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeTwoMember" unitRef="Unit1" decimals="INF">643377</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="Item-331" contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="INF">2817504</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="Item-326" contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFiveMember" unitRef="Unit1" decimals="INF">127661</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="Item-319" contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFourMember" unitRef="Unit1" decimals="INF">619599</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="Item-298" contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeOneMember" unitRef="Unit1" decimals="INF">659688</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="Item-312" contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeThreeMember" unitRef="Unit1" decimals="INF">598462</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="Item-305" contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeTwoMember" unitRef="Unit1" decimals="INF">812094</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 id="Item-333" contextRef="As_Of_12_31_2020" unitRef="Unit14" decimals="2">11.30</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 id="Item-328" contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFiveMember" unitRef="Unit14" decimals="2">51.72</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 id="Item-321" contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFourMember" unitRef="Unit14" decimals="2">24.02</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 id="Item-300" contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeOneMember" unitRef="Unit14" decimals="2">1.47</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 id="Item-314" contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeThreeMember" unitRef="Unit14" decimals="2">10.89</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 id="Item-307" contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeTwoMember" unitRef="Unit14" decimals="2">3.51</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="Item-332" contextRef="Duration_1_1_2020_To_12_31_2020">P5Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="Item-327" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFiveMember">P8M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="Item-320" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFourMember">P2Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="Item-299" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeOneMember">P8Y4M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="Item-313" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeThreeMember">P5Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="Item-306" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeTwoMember">P6Y8M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="Item-325" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFiveMember" unitRef="Unit14" decimals="2">53.55</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="Item-318" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFourMember" unitRef="Unit14" decimals="2">35.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="Item-297" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeOneMember" unitRef="Unit14" decimals="2">1.88</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="Item-311" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeThreeMember" unitRef="Unit14" decimals="2">13.09</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="Item-304" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeTwoMember" unitRef="Unit14" decimals="2">4.09</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock id="Item-282" contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;"&gt;4.&amp;nbsp;&amp;nbsp;Stockholders' Equity and Stock-Based Compensation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;Preferred Stock&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The Company&amp;#x2019;s Board of Directors (the &amp;#x201C;Board&amp;#x201D;) has the authority to issue preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number of shares constituting any series or the designation of the series.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;color:#000000;"&gt;2021 Registered Direct Offering&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;On February&amp;nbsp;12, 2021, the Company completed a common stock offering pursuant to which certain investors purchased &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;4,081,633&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; shares of common stock at a price of &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;$49.00&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; per share. Net proceeds of the offering were approximately &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;$189.7&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;million after deducting offering expenses.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;2020 Follow-on Public Offering&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;text-decoration:underline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;On November&amp;nbsp;13, 2020, the Company completed the sale of&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;9,375,000&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;shares of Cassava common stock in an underwritten public offering at a price of&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;$8.00&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;per share. The Company received net proceeds from the offering of&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;$70,251,000&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;after deducting underwriting discounts and offering expenses.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;line-height:106.67%;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Common Stock Warrants&lt;/font&gt;&lt;font style="display: inline;font-style:italic;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;In August 2018, the Company issued warrants to&amp;nbsp;purchase up to an aggregate of&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;9.1&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;million shares of its common stock in conjunction with an offering of its common stock.&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;During 2020, the Company received proceeds of &lt;/font&gt;&lt;font style="display: inline;"&gt;$4.9&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;million from the exercise of &lt;/font&gt;&lt;font style="display: inline;"&gt;4.0&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;million shares pursuant to warrants. During 2019, the Company received proceeds of &lt;/font&gt;&lt;font style="display: inline;"&gt;$5.9&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;million from the exercise of &lt;/font&gt;&lt;font style="display: inline;"&gt;4.6&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;million shares pursuant to warrants. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Subsequent to December&amp;nbsp;31, 2020, the Company received proceeds of &lt;/font&gt;&lt;font style="display: inline;"&gt;$0.7&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;million from the exercise of an additional &lt;/font&gt;&lt;font style="display: inline;"&gt;0.6&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;million shares pursuant to warrants. There were no warrants outstanding following the 2021 exercises.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Warrants outstanding as of December&amp;nbsp;31, 2020 and 2019 were as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt"&gt;
			&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:41.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;Number of Shares Outstanding under Warrant&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:41.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;Issuance Date&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;Expiration Date&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;Exercise Price Per Share&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:17.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;August 17, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;February 17, 2021&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1.25&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;554,019&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;4,496,116&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;August 17, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;February 17, 2021&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1.59&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;7,975&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;554,019&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;4,504,091&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.26%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.80%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;At the Market (ATM) Common Stock Issuance &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;On March&amp;nbsp;27, 2020, the Company established an at-the-market offering program (ATM) to sell, from time to time, shares of Company common stock having an aggregate offering price of up to&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;$100&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;nbsp;million&amp;nbsp;in transactions pursuant to a shelf registration statement that was declared effective by the&amp;nbsp;U.S. Securities and Exchange Commission (the SEC)&amp;nbsp;on May&amp;nbsp;5, 2020. The Company is obligated to pay a commission of&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;3.0%&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;nbsp;of the gross proceeds from the sale of shares of common stock in the offering. The Company is not obligated to sell any shares in the offering.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;There were&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;nbsp;common stock sales under the ATM during the year ended December&amp;nbsp;31, 2020.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 2.5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 2.5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;2008 Equity Incentive Plan &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Under the Company&amp;#x2019;s &lt;/font&gt;&lt;font style="display: inline;"&gt;2008 Equity Incentive Plan, or 2008 Equity Plan,&lt;/font&gt;&lt;font style="display: inline;"&gt; its employees, directors and consultants received share-based awards, including grants of stock options and performance awards. The &lt;/font&gt;&lt;font style="display: inline;"&gt;2008 Equity Plan&lt;/font&gt;&lt;font style="display: inline;"&gt; expired in December 2017. Share-based awards generally expire &lt;/font&gt;&lt;font style="display: inline;"&gt;ten&lt;/font&gt;&lt;font style="display: inline;"&gt; years from the date of grant.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 2.5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;2018 Equity Incentive Plan &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;In January 2018, the Company&amp;#x2019;s Board approved the Company&amp;#x2019;s 2018 Omnibus Incentive Plan (the 2018 Plan). The Company&amp;#x2019;s Board or a designated Committee of the Board is responsible for administration of the 2018 Plan and determined the terms and conditions of each option granted, consistent with the terms of the 2018 Plan. The Company&amp;#x2019;s employees, directors, and consultants are eligible to receive awards under the 2018 Plan, including grants of stock options and performance awards. Share-based awards generally expire &lt;/font&gt;&lt;font style="display: inline;"&gt;ten&lt;/font&gt;&lt;font style="display: inline;"&gt; years from the date of grant. The 2018 Plan provides for issuance of up to &lt;/font&gt;&lt;font style="display: inline;"&gt;1,000,000&lt;/font&gt;&lt;font style="display: inline;"&gt; shares of common stock, par value &lt;/font&gt;&lt;font style="display: inline;"&gt;$0.001&lt;/font&gt;&lt;font style="display: inline;"&gt; per share under the 2018 Plan, subject to adjustment as provided in the 2018 Plan. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;When stock options or performance awards are exercised net of the exercise price and taxes, the number of shares of stock issued is reduced by the number of shares equal to the amount of taxes owed by the award recipient and that number of shares are cancelled. The Company then uses its cash to pay tax authorities the amount of statutory taxes owed by and on behalf of the award recipient.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;Stock Options&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 2.5pt 0pt 0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 2.5pt 0pt 0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The following summarizes information about stock option activity during 2020:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 2.5pt 0pt 0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Number of Options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Weighted Average Exercise Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Weighted Average Remaining Contractual Term&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Aggregate Intrinsic Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;text-decoration:underline;"&gt;In years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;text-decoration:underline;"&gt;In millions&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Outstanding as of December 31, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;3,210,965&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt; 12.27&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;6.05&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;4.2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Options granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;60,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt; 7.25&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Options exercised&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;(71,105)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt; 3.60&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Options forfeited/canceled&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;(382,356)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt; 20.31&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Outstanding as of December 31, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;2,817,504&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt; 11.30&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;5.60&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;6.4&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#FF0000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Vested and expected to vest at December 31, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;2,817,504&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt; 11.30&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;5.60&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;6.4&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#FF0000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Exercisable at December 31, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;2,167,633&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt; 13.86&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;4.85&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;3.7&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The following summarizes information about stock options at December&amp;nbsp;31, 2020 by a range of exercise prices:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 14.4pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt"&gt;
			&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="6" valign="bottom" style="width:37.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Options outstanding&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="4" valign="bottom" style="width:24.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Options exercisable&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;average&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Number of&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;remaining&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;average&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Number of&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;average&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:23.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Range of exercise prices&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;outstanding&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;contractual&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;exercise&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt; vested&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;exercise&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;From&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;To&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;life (in years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;0.95&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;1.88&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;659,688&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;8.4&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;1.47&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;251,613&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;1.31&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;3.24&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;4.09&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;812,094&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;6.7&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;3.51&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;643,377&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;3.48&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;4.10&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;13.09&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;598,462&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;5.0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;10.89&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;525,383&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;11.42&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;14.21&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;35.00&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;619,599&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;2.8&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;24.02&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;619,599&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;24.02&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;36.40&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;53.55&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;127,661&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;0.7&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;51.72&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;127,661&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;51.72&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;2,817,504&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;5.6&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;11.30&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;2,167,633&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;13.86&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The Company uses Black-Scholes to estimate the fair value of options granted. Black-Scholes considers a number of factors, including the market price of the Company&amp;#x2019;s common stock. It used certain factors to value each stock option granted, which resulted in a weighted average fair value of options granted during 2020 and 2019, as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt"&gt;
			&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt"&gt;
						&lt;font style="display: inline;font-family:Calibri;font-size:11pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt"&gt;
						&lt;font style="display: inline;font-family:Calibri;font-size:11pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;Volatility&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:15.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;123%&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; to &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;139%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:14.74%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;118%&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; to &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;119%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt"&gt;
						&lt;font style="display: inline;font-family:Calibri;font-size:11pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;Risk-free interest rates&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;0.46%&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; to &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;0.78%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;1.7%&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; to &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;2.5%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt"&gt;
						&lt;font style="display: inline;font-family:Calibri;font-size:11pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;Expected life of option&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;7&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;7&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt"&gt;
						&lt;font style="display: inline;font-family:Calibri;font-size:11pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;Dividend yield&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;zero&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;zero&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt"&gt;
						&lt;font style="display: inline;font-family:Calibri;font-size:11pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;Forfeiture rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;zero&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;zero&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt"&gt;
						&lt;font style="display: inline;font-family:Calibri;font-size:11pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;Weighted average fair value of stock options granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$6.69&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$1.60&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt"&gt;
						&lt;font style="display: inline;font-family:Calibri;font-size:11pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Volatility&lt;/font&gt;&lt;font style="display: inline;"&gt; is based on reviews of the historical volatility of the Company&amp;#x2019;s common stock. Risk-free interest rates are based on yields of U.S. treasury notes in effect at the date of grant. Expected life of option is based on actual historical option exercises. Dividend yield is &lt;/font&gt;&lt;font style="display: inline;"&gt;zero&lt;/font&gt;&lt;font style="display: inline;"&gt; because the Company does not anticipate paying cash dividends in the foreseeable future. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;As of December&amp;nbsp;31, 2020, the Company expects to recognize compensation expense of &lt;/font&gt;&lt;font style="display: inline;"&gt;$&lt;/font&gt;&lt;font style="display: inline;"&gt;1.5&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;million related to non-vested options held by equity plan participants over the weighted average remaining recognition period of &lt;/font&gt;&lt;font style="display: inline;"&gt;2.1&lt;/font&gt;&lt;font style="display: inline;"&gt; years.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Subsequent to &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;December&amp;nbsp;31, 2020, there &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;were&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;20,385&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;stock options exercised resulting in proceeds to the Company &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;totaling&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;$169,000&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;Performance Awards&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The following summarizes information about performance award activity during 2020:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt"&gt;
			&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Number of Performance Awards&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Outstanding as of December 31, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;138,055&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 30pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 30pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Vested performance awards&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 30pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Forfeited/Canceled&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Outstanding as of December 31, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;138,055&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.58%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;"&gt;If and when outstanding performance awards vest, the Company would recognize &lt;/font&gt;&lt;font style="display: inline;"&gt;$&lt;/font&gt;&lt;font style="display: inline;"&gt;2.3&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;million in non-cash stock-based compensation expense. These performance awards expire between &lt;/font&gt;&lt;font style="display: inline;"&gt;2022&lt;/font&gt;&lt;font style="display: inline;"&gt; and &lt;/font&gt;&lt;font style="display: inline;"&gt;2026&lt;/font&gt;&lt;font style="display: inline;"&gt;.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;Stock-Based Compensation Expense&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The following summarizes information about non-cash stock-based compensation expense, in thousands:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt"&gt;
			&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Year ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Research and development&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.78%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;453&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;542&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;General and administrative&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;535&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;754&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Arial;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Total non-cash stock-based compensation expense&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.78%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;988&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;1,296&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt"&gt;
						&lt;font style="display: inline;font-family:Calibri;font-size:11pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.78%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.20%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
  <us-gaap:SharesIssued id="Item-370" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">17219300</us-gaap:SharesIssued>
  <us-gaap:SharesIssued id="Item-406" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">21841810</us-gaap:SharesIssued>
  <us-gaap:SharesIssued id="Item-448" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">35237987</us-gaap:SharesIssued>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="Item-267" contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;"&gt;2.&amp;nbsp;&amp;nbsp;Summary of Significant Accounting Policies&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;Use of Estimates&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. Actual results could differ from those estimates.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;Proceeds from Grants&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;In 2020, the Company received &lt;/font&gt;&lt;font style="display: inline;"&gt;$4.2&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;million of reimbursement from the National Institutes of Health and National Institute on Drug Abuse and &lt;/font&gt;&lt;font style="display: inline;"&gt;$4.7&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;million in 2019. The Company records the proceeds from these grants as reductions to its research and development expenses.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;Cash and Cash Equivalents and Concentration of Credit Risk&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The Company invests in cash and cash equivalents and, in the past, marketable securities. The Company considers highly-liquid financial instruments with original maturities of three months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts, money market funds and certificates of deposit. The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The Company&amp;#x2019;s investment policy allows for investments in marketable securities with active secondary or resale markets, establishes diversification and credit quality requirements and limits investments by maturity and issuer. The Company maintains its investments at one financial institution. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;Fair Value Measurements &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The Company reports its cash and cash equivalents at fair value as Level 1, Level 2 or Level 3 using the following inputs:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
				&lt;font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; &amp;#xB7;&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
			&lt;a name="_9eed50031d7a4ae08d8481e27454a126"&gt;&lt;/a&gt;&lt;a name="_a55395c9dddb484ab9d7fe2cd900ad3a"&gt;&lt;/a&gt;&lt;a name="_9c970aca55e541dc8a21fc5af6a42932"&gt;&lt;/a&gt;&lt;a name="_c95ddda386b84ea0a6341120a7f1021f"&gt;&lt;/a&gt;&lt;a name="_3c0ffcf4570c456cbc299897392e42d9"&gt;&lt;/a&gt;&lt;a name="_dee475e5298f41189ad89abce51b465d"&gt;&lt;/a&gt;&lt;a name="_56802d68c6a94dbe9fcf1274361e7f37"&gt;&lt;/a&gt;&lt;a name="_5121355f7d274c19a6859f83034a8dd4"&gt;&lt;/a&gt;&lt;a name="_adff7fd0d1df49cfbd1d486e06beadfa"&gt;&lt;/a&gt;&lt;a name="_d9e1ff57a6464ab6a179624ab81cda10"&gt;&lt;/a&gt;&lt;a name="_a6d0459d796849d2b1866055cd140477"&gt;&lt;/a&gt;&lt;a name="_6967f826ca9b4f0f9b986e3e324d9161"&gt;&lt;/a&gt;&lt;a name="_5a3701addc544c73a9d512b8e9743988"&gt;&lt;/a&gt;&lt;a name="_c3da333d461e4520b3a037507e639721"&gt;&lt;/a&gt;&lt;a name="_7878265e95384b81ae1b7f17224656fd"&gt;&lt;/a&gt;&lt;a name="_b691c60198414d559b1914e876b580a1"&gt;&lt;/a&gt;&lt;a name="_7fb1ed58d627447ab56cfbe9d52d6120"&gt;&lt;/a&gt;&lt;a name="_be8d133366f34f6686cef9d21c16f0a3"&gt;&lt;/a&gt;&lt;a name="_e3b5f0a49cfe4f04a7282b95d681b7ce"&gt;&lt;/a&gt;&lt;a name="_932ab8c8a3574e5a87e70dc56597bb6f"&gt;&lt;/a&gt;&lt;a name="_9fb551aa76e3415c984cffa1491a23ea"&gt;&lt;/a&gt;&lt;a name="_1746df8b27fc41ef992b25383e220984"&gt;&lt;/a&gt;&lt;a name="_0c3de46198274b128860550988ef844d"&gt;&lt;/a&gt;&lt;a name="_75dfd0ae686c45b99fde81a8d35908b3"&gt;&lt;/a&gt;&lt;a name="_d9318bc5124f4b7c97afcc172b32ae28"&gt;&lt;/a&gt;&lt;a name="_6310384476c740cf8e641c9a413eb968"&gt;&lt;/a&gt;&lt;a name="_91d164c9544945c48fd3a86929e64fd4"&gt;&lt;/a&gt;&lt;a name="_973c93b3770b4476a04247143aaf5d5a"&gt;&lt;/a&gt;&lt;a name="_9d4e208743764419adbb1942938e565a"&gt;&lt;/a&gt;&lt;a name="_e2f59ee1432249b792889c80e60b08d7"&gt;&lt;/a&gt;&lt;a name="_f6345b5294af4fef90374149482d4f46"&gt;&lt;/a&gt;&lt;a name="_d48429101312494397f78e2250f832e4"&gt;&lt;/a&gt;&lt;a name="_bdc2c9f8bbfb466e81aff2540dc06056"&gt;&lt;/a&gt;&lt;font style="display: inline;color:#000000;"&gt;Level 1 includes quoted prices in active markets. The Company bases the fair value of money market funds on Level 1 inputs.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
				&lt;font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; &amp;#xB7;&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;Level 2 includes significant observable inputs, such as quoted prices for identical or similar investments, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from third-party providers. It uses the bid price to establish fair value where a bid price is available. The Company bases the fair value of its certificates of deposit, if any, on Level 2 inputs.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
				&lt;font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; &amp;#xB7;&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;Level 3 includes unobservable inputs that are supported by little or no market activity. The Company does not have any investments where the fair value is based on Level 3 inputs.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. A certificate of deposit totaling &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;$13.0&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;million at December&amp;nbsp;31, 2019 was included within cash equivalents as a Level 2 input. The fair value of the remainder of cash and cash equivalents, including money market accounts, was based on Level 1 inputs at December&amp;nbsp;31, 2020 and 2019.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;color:#000000;"&gt;Business Segments&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&amp;#x2019;s operations are confined to &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;one&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; business segment: the development of novel drugs and diagnostics.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;color:#000000;"&gt;Stock-based Compensation&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;The Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each &lt;/font&gt;&lt;a name="_cp_text_1_372"&gt;&lt;/a&gt;&lt;font style="display: inline;color:#000000;"&gt;award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management's judgment. The Company recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;four&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; years. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;The Company has granted share-based awards that vest upon achievement of certain performance criteria, or performance awards. The Company multiplies the number of performance awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. The Company periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance awards vest and common stock is issued upon achievement of the performance criteria.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;color:#000000;"&gt;Net Loss per Share&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;Basic net loss per share is computed on the basis of the weighted-average number of common shares outstanding for the reporting period. Diluted net loss per share is computed on the basis of the weighted-average number of common shares outstanding plus dilutive potential common shares outstanding using the treasury-stock method. Potential dilutive common shares consist of outstanding equity awards and warrants. There is no difference between the Company&amp;#x2019;s net loss and comprehensive loss. The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands, except net loss per share data):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt"&gt;
			&lt;font style="display: inline;font-size:1pt;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:24.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:24.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Year ended December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Numerator:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;(6,334)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;(4,631)
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Denominator:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Shares used in computing net loss per share, basic and diluted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;26,105&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;17,412&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;Net loss per share, basic and diluted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;(0.24)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;(0.27)
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt; Dilutive common stock options excluded from net loss per share, diluted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;2,145&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;2,932&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt; Common stock warrants excluded from net loss per share, diluted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;554&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap"&gt;4,504&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;The Company excluded weighted equity awards and warrants outstanding to purchase common stock from the calculation of diluted net loss per share because the effect of including these shares in this calculation would be anti-dilutive.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 6pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt"&gt;
			&lt;font style="display: inline;font-family:Tahoma;font-size:1pt;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-size:1pt;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;color:#000000;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;Financial instruments include cash and cash equivalents, accounts payable and accrued liabilities. The estimated fair value of financial instruments has been determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies may be material to the estimated fair value amounts. The carrying amounts of cash and cash equivalents, accounts payable and accrued liabilities are at cost, which approximates fair value due to the short maturity of those instruments.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;color:#000000;"&gt;Research Contract Costs and Accruals&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;The Company has entered into various research and development contracts with research institutions and other third-party vendors. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&amp;#x2019;s estimates. The Company&amp;#x2019;s historical accrual estimates have not been materially different from actual costs.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;color:#000000;"&gt;Incentive Bonus Plan&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;In 2020, the Company established the 2020 Cash Incentive Bonus Plan (the &amp;#x201C;Plan&amp;#x201D;) to incentivize Plan participants.&amp;nbsp;&amp;nbsp;Awards under the Plan are accounted for as liability awards under ASC 718 &amp;#x201C;&lt;/font&gt;&lt;font style="display: inline;font-style:italic;color:#000000;"&gt;Stock-based Compensation&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;&amp;#x201D;.&amp;nbsp;The fair value of each&amp;nbsp;potential Plan&amp;nbsp;award&amp;nbsp;will be&amp;nbsp;determined&amp;nbsp;once&amp;nbsp;a&amp;nbsp;grant date occurs and&amp;nbsp;will be&amp;nbsp;remeasured each reporting period.&amp;nbsp;Compensation expense associated with the Plan&amp;nbsp;will be&amp;nbsp;recognized over the expected achievement period for each&amp;nbsp;Plan award, when&amp;nbsp;a Performance Condition&amp;nbsp;is considered probable of being met.&amp;nbsp;&amp;nbsp;See Note 8 for further discussion of the Plan.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;color:#000000;"&gt;Leases&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;The Company recognizes&amp;nbsp;assets and liabilities that arise from leases.&amp;nbsp;For operating leases, the Company is required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, in the&amp;nbsp;statements&amp;nbsp;of financial position.&amp;nbsp;As the Company`s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;color:#000000;"&gt;Income Taxes&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;The Company accounts for income taxes under the asset and liability method.&amp;nbsp;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. &amp;nbsp;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&amp;nbsp;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;The Company accounts for uncertain tax positions in accordance with ASC 740, &amp;#x201C;Income Taxes&amp;#x201D;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&amp;#x2019;s financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;color:#000000;"&gt;Recent Accounting Pronouncements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;The Company reviewed recently issued accounting pronouncements and plan to adopt those that are applicable to it, and does not expect the adoption of these pronouncements to have a material impact on its financial position, results of operations or cash flows. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;In December 2019, the FABS issued ASU No. 2019-12, &lt;/font&gt;&lt;font style="display: inline;font-style:italic;color:#000000;"&gt;Income Taxes (Topic 740) Simplifying Accounting for Income Taxes &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;as part of its initiative to reduce complexity in the accounting standards. The guidance amended certain disclosure requirements that had become redundant, outdated or superseded. Additionally, this guidance amends accounting for the interim period effects of changes in tax laws or rates and simplifies aspects of the accounting for franchise taxes. The guidance is effective for annual periods beginning after December&amp;nbsp;15, 2020, and is applicable for the Company in fiscal year 2021. Early adoption is permitted. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;In November 2018, the FASB issued ASU No. 2018-18, &lt;/font&gt;&lt;font style="display: inline;font-style:italic;color:#000000;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606. &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;The amendments in this update provide guidance on how to assess whether certain transactions between collaborative arrangement participants should be accounted for within the revenue recognition standard. The amendments in this update are effective for interim and annual periods for the Company beginning on January&amp;nbsp;1, 2020. &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;The adoption of this guidance did not have a material impact on&amp;nbsp;the Company&amp;#x2019;s&amp;nbsp;financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;In August 2018, the FASB issued ASU &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;No. 2018-13,&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-style:italic;color:#000000;"&gt;Fair Value Measurement (Topic 820) - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt; (ASU &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;2018-13),&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt; which is designed to improve the effectiveness of disclosures by removing, modifying and adding disclosures related to fair value measurements. ASU &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;2018-13&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt; is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The adoption of ASU 2018-13 did not have a material impact on&amp;nbsp;the Company&amp;#x2019;s&amp;nbsp;financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:StockholdersEquity id="Item-375" contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3">19628000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity xsi:nil="true" id="Item-373" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" />
  <us-gaap:StockholdersEquity id="Item-372" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">183567000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Item-371" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">17000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Item-374" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-163956000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Item-411" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">22099000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity xsi:nil="true" id="Item-409" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" />
  <us-gaap:StockholdersEquity id="Item-408" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">190664000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Item-407" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">22000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Item-410" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-168587000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Item-453" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">92200000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity xsi:nil="true" id="Item-451" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" />
  <us-gaap:StockholdersEquity id="Item-450" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">267086000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Item-449" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">35000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Item-452" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-174921000</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="Item-436" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">9375000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesOther id="Item-394" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">4622510</us-gaap:StockIssuedDuringPeriodSharesOther>
  <us-gaap:StockIssuedDuringPeriodSharesOther id="Item-430" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">3950072</us-gaap:StockIssuedDuringPeriodSharesOther>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="Item-172" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit1" decimals="INF">71105</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="Item-424" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">71105</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="Item-285" contextRef="Duration_1_1_2021_To_1_1_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit1" decimals="INF">20385</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan id="Item-381" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3">1287000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan xsi:nil="true" id="Item-379" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" />
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan id="Item-378" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">1287000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan xsi:nil="true" id="Item-376" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" />
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan xsi:nil="true" id="Item-380" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" />
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan id="Item-417" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3">961000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan xsi:nil="true" id="Item-415" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" />
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan id="Item-414" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">961000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan xsi:nil="true" id="Item-412" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" />
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan xsi:nil="true" id="Item-416" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" />
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="Item-441" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3">70251000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues xsi:nil="true" id="Item-439" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" />
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="Item-438" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">70242000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="Item-437" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">9000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues xsi:nil="true" id="Item-440" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" />
  <us-gaap:StockIssuedDuringPeriodValueOther id="Item-399" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3">5866000</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:StockIssuedDuringPeriodValueOther xsi:nil="true" id="Item-397" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" />
  <us-gaap:StockIssuedDuringPeriodValueOther id="Item-396" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">5861000</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:StockIssuedDuringPeriodValueOther id="Item-395" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">5000</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:StockIssuedDuringPeriodValueOther xsi:nil="true" id="Item-398" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" />
  <us-gaap:StockIssuedDuringPeriodValueOther id="Item-435" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3">4940000</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:StockIssuedDuringPeriodValueOther xsi:nil="true" id="Item-433" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" />
  <us-gaap:StockIssuedDuringPeriodValueOther id="Item-432" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">4936000</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:StockIssuedDuringPeriodValueOther id="Item-431" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">4000</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:StockIssuedDuringPeriodValueOther xsi:nil="true" id="Item-434" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" />
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Item-429" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3">256000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised xsi:nil="true" id="Item-427" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" />
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Item-426" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">256000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised xsi:nil="true" id="Item-425" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" />
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised xsi:nil="true" id="Item-428" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" />
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Item-257" contextRef="Duration_1_1_2021_To_1_1_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit12" decimals="0">169000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock id="Item-158" contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="4" valign="bottom" style="width:31.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;Year ended December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="middle" style="width:15.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="middle" style="width:15.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Beginning balance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;4,400&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;4,400&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Additions based on tax positions related to the current year&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;100&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Ending balance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;4,500&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;4,400&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
  <us-gaap:TaxCreditCarryforwardAmount id="Item-255" contextRef="As_Of_12_31_2020_srt_StatementScenarioAxis_sava_ExpiresBetween2023And2039Member_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" unitRef="Unit12" decimals="-5">11100000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:TaxCreditCarryforwardExpirationDate id="Item-65" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_sava_ExpiresBetween2023And2039Member_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">2040-12-31</us-gaap:TaxCreditCarryforwardExpirationDate>
  <us-gaap:TaxCreditCarryforwardExpirationDate id="Item-286" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_sava_ExpiresBetween2023And2039Member_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">2023-01-01</us-gaap:TaxCreditCarryforwardExpirationDate>
  <us-gaap:UnrecognizedTaxBenefits id="Item-160" contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3">4400000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits id="Item-164" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">4400000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits id="Item-163" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3">4500000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions xsi:nil="true" id="Item-162" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" />
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions id="Item-161" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3">100000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:UseOfEstimates id="Item-456" contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;Use of Estimates&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. Actual results could differ from those estimates.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="Item-278" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_sava_BookLossesMember" unitRef="Unit12" decimals="-5">900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="Item-49" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-5">-1300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="Item-277" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_sava_BookLossesMember" unitRef="Unit12" decimals="-5">1100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="Item-50" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_sava_WriteDownOfShareBasedCompensationMember" unitRef="Unit12" decimals="-5">-2400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:WarrantsAndRightsOutstandingMaturityDate id="Item-464" contextRef="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_sava_PlacementAgentWarrantsMember">2021-02-17</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
  <us-gaap:WarrantsAndRightsOutstandingMaturityDate id="Item-459" contextRef="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember">2021-02-17</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Item-150" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">17412000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Item-149" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit1" decimals="-3">26105000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <!--Extensible List Section-->
  <!--Footnote Section-->
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>16
<FILENAME>sava-20201231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created by Certent Disclosure Management 6.39.2.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/23/2021 3:59:27 PM-->
<!--Modified on: 3/23/2021 3:59:27 PM-->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" targetNamespace="http://www.cassavasciences.com/20201231" elementFormDefault="qualified" attributeFormDefault="unqualified" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:sava="http://www.cassavasciences.com/20201231">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.cassavasciences.com/role/StatementBalanceSheets" id="StatementBalanceSheets">
        <link:definition>00100 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/StatementStatementsOfOperations" id="StatementStatementsOfOperations">
        <link:definition>00200 - Statement - Statements Of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/StatementStatementsOfCashFlows" id="StatementStatementsOfCashFlows">
        <link:definition>00500 - Statement - Statements Of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>40602 - Disclosure - Income Taxes (Schedule Of Effective Income Tax Rate Reconciliation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails" id="DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails">
        <link:definition>40603 - Disclosure - Income Taxes (Schedule Of Deferred Tax Assets And Valuation Allowance) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsFutureMinimumLeasePaymentsDetails" id="DisclosureLeasesAndCommitmentsFutureMinimumLeasePaymentsDetails">
        <link:definition>40702 - Disclosure - Leases And Commitments (Future Minimum Lease Payments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/StatementBalanceSheetsParenthetical" id="StatementBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/StatementStatementsOfStockholdersEquity" id="StatementStatementsOfStockholdersEquity">
        <link:definition>00400 - Statement - Statements Of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureGeneralAndLiquidity" id="DisclosureGeneralAndLiquidity">
        <link:definition>10101 - Disclosure - General And Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary Of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipment" id="DisclosurePropertyAndEquipment">
        <link:definition>10301 - Disclosure - Property And Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensation" id="DisclosureStockholdersEquityAndStockBasedCompensation">
        <link:definition>10401 - Disclosure - Stockholders' Equity And Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureEmployee401KBenefitPlan" id="DisclosureEmployee401KBenefitPlan">
        <link:definition>10501 - Disclosure - Employee 401(k) Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>10601 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureLeasesAndCommitments" id="DisclosureLeasesAndCommitments">
        <link:definition>10701 - Disclosure - Leases And Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlan" id="Disclosure2020CashIncentiveBonusPlan">
        <link:definition>10801 - Disclosure - 2020 Cash Incentive Bonus Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicy">
        <link:definition>20202 - Disclosure - Summary Of Significant Accounting Policies (Policy)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30203 - Disclosure - Summary Of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationTables" id="DisclosureStockholdersEquityAndStockBasedCompensationTables">
        <link:definition>30403 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>30603 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsTables" id="DisclosureLeasesAndCommitmentsTables">
        <link:definition>30703 - Disclosure - Leases And Commitments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureGeneralAndLiquidityNarrativeDetails" id="DisclosureGeneralAndLiquidityNarrativeDetails">
        <link:definition>40101 - Disclosure - General And Liquidity (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>40201 - Disclosure - Summary Of Significant Accounting Policies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails">
        <link:definition>40202 - Disclosure - Summary Of Significant Accounting Policies (Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentNarrativeDetails" id="DisclosurePropertyAndEquipmentNarrativeDetails">
        <link:definition>40301 - Disclosure - Property And Equipment (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails" id="DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails">
        <link:definition>40401 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationWarrantsOutstandingDetails" id="DisclosureStockholdersEquityAndStockBasedCompensationWarrantsOutstandingDetails">
        <link:definition>40402 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Warrants Outstanding) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockOptionActivityDetails" id="DisclosureStockholdersEquityAndStockBasedCompensationStockOptionActivityDetails">
        <link:definition>40403 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Stock Option Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails" id="DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails">
        <link:definition>40404 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Information About Stock Options Outstanding) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationWeightedAverageFairValueOfOptionsGrantedDetails" id="DisclosureStockholdersEquityAndStockBasedCompensationWeightedAverageFairValueOfOptionsGrantedDetails">
        <link:definition>40405 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Weighted Average Fair Value Of Options Granted) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationSummaryOfPerformanceAwardActivityDetails" id="DisclosureStockholdersEquityAndStockBasedCompensationSummaryOfPerformanceAwardActivityDetails">
        <link:definition>40406 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Summary Of Performance Award Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNonCashStockBasedCompensationExpensesDetails" id="DisclosureStockholdersEquityAndStockBasedCompensationNonCashStockBasedCompensationExpensesDetails">
        <link:definition>40407 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Non-Cash Stock-Based Compensation Expenses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails" id="DisclosureIncomeTaxesNarrativeDetails">
        <link:definition>40601 - Disclosure - Income Taxes (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" id="DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails">
        <link:definition>40604 - Disclosure - Income Taxes (Schedule Of Unrecognized Tax Benefits) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsNarrativeDetails" id="DisclosureLeasesAndCommitmentsNarrativeDetails">
        <link:definition>40701 - Disclosure - Leases And Commitments (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails" id="Disclosure2020CashIncentiveBonusPlanNarrativeDetails">
        <link:definition>40801 - Disclosure - 2020 Cash Incentive Bonus Plan (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="sava-20201231_cal.xml" xlink:title="Calculation Links, all" />
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="sava-20201231_def.xml" xlink:title="Definition Links, all" />
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="sava-20201231_lab.xml" xlink:title="Label Links, all" />
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="sava-20201231_pre.xml" xlink:title="Presentation Links, all" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
  <element name="AustinMember" id="sava_AustinMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
  <element id="sava_TwoThousandEightEquityIncentivePlanMember" name="TwoThousandEightEquityIncentivePlanMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting" name="ShareBasedCompensationAdditionalExpenseExpectedOnVesting" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="sava_RangeOneMember" name="RangeOneMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="sava_RangeTwoMember" name="RangeTwoMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="sava_RangeThreeMember" name="RangeThreeMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="sava_RangeFourMember" name="RangeFourMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="sava_RangeFiveMember" name="RangeFiveMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="sava_LeasesAndCommitmentsAbstract" name="LeasesAndCommitmentsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="sava_LeasesAndCommitmentsDisclosureTextBlock" name="LeasesAndCommitmentsDisclosureTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="sava_LeasesAndCommitmentsTable" name="LeasesAndCommitmentsTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <element id="sava_LeasesAndCommitmentsLineItems" name="LeasesAndCommitmentsLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="sava_SummaryOfNonCashStockBasedCompensationTableTextBlock" name="SummaryOfNonCashStockBasedCompensationTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="sava_AtMarketEquityProgramMember" name="AtMarketEquityProgramMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="sava_WarrantsMember" name="WarrantsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="sava_PlacementAgentWarrantsMember" name="PlacementAgentWarrantsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="sava_ReductionToResearchAndDevelopmentExpense" name="ReductionToResearchAndDevelopmentExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="sava_TwoThousandEighteenEquityIncentivePlanMember" name="TwoThousandEighteenEquityIncentivePlanMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement" name="ResearchAndDevelopmentExpenseNetOfGrantReimbursement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="sava_ProceedsFromGrantsPolicyPolicyTextBlock" name="ProceedsFromGrantsPolicyPolicyTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock" name="ResearchContractCostsAndAccrualsPolicyPolicyTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="sava_IndefinitelyMember" name="IndefinitelyMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="sava_PercentageOfCommissionAtmOffering" name="PercentageOfCommissionAtmOffering" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="sava_CashIncentiveBonusPlanTextBlock" name="CashIncentiveBonusPlanTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="sava_CashIncentiveBonusPlanAbstract" name="CashIncentiveBonusPlanAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="sava_PerformancePlanValuationAmount" name="PerformancePlanValuationAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="sava_CashIncentiveBonusAward" name="CashIncentiveBonusAward" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="sava_CashIncentiveBonusPlanTable" name="CashIncentiveBonusPlanTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <element id="sava_CashIncentiveBonusPlanLineItems" name="CashIncentiveBonusPlanLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="sava_CashIncentiveBonusPlanMember" name="CashIncentiveBonusPlanMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="sava_Exceeds5BillionMarketCapitalizationMember" name="Exceeds5BillionMarketCapitalizationMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" name="PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="sava_ProceedsFromIssuanceFollowOnPublicOfferingNetOfIssuanceCosts" name="ProceedsFromIssuanceFollowOnPublicOfferingNetOfIssuanceCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="sava_ExpiresBetween2023And2039Member" name="ExpiresBetween2023And2039Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="sava_ExpiresBetween2029And2039Member" name="ExpiresBetween2029And2039Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="sava_PublicOfferingMember" name="PublicOfferingMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="sava_CommonStockWarrantsMember" name="CommonStockWarrantsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="sava_RegisteredDirectOffering2021Member" name="RegisteredDirectOffering2021Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="sava_FirstValuationMilestoneMember" name="FirstValuationMilestoneMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="sava_PaymentsForCashIncentiveBonus" name="PaymentsForCashIncentiveBonus" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="sava_BookLossesMember" name="BookLossesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="sava_WriteDownOfShareBasedCompensationMember" name="WriteDownOfShareBasedCompensationMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="sava_SecondThroughEighthValuationMilestonesMember" name="SecondThroughEighthValuationMilestonesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>17
<FILENAME>sava-20201231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created by Certent Disclosure Management 6.39.2.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/23/2021 3:59:27 PM-->
<!--Modified on: 3/23/2021 3:59:27 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#StatementBalanceSheets" roleURI="http://www.cassavasciences.com/role/StatementBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#StatementStatementsOfOperations" roleURI="http://www.cassavasciences.com/role/StatementStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#StatementStatementsOfCashFlows" roleURI="http://www.cassavasciences.com/role/StatementStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails" roleURI="http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureLeasesAndCommitmentsFutureMinimumLeasePaymentsDetails" roleURI="http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsFutureMinimumLeasePaymentsDetails" />
  <calculationLink xlink:role="http://www.cassavasciences.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Balance Sheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637521119669585901" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637521119669585901" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637521119669595881" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637521119669585901" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637521119669595881" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_637521119669595881" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637521119669585901" xlink:to="us-gaap_OtherAssetsCurrent_637521119669595881" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637521119669595881" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637521119669595881" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637521119669595881" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637521119669595881" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637521119669675672" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_637521119669675672" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637521119669675672" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637521119669675672" xlink:to="us-gaap_LiabilitiesCurrent_637521119669675672" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637521119669675672" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637521119669675672" xlink:to="us-gaap_AccountsPayableCurrent_637521119669675672" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637521119669675672" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637521119669675672" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637521119669675672" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_637521119669675672" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637521119669675672" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_637521119669675672" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_637521119669675672" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637521119669675672" xlink:to="us-gaap_OtherLiabilitiesCurrent_637521119669675672" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637521119669675672" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637521119669675672" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637521119669675672" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637521119669685653" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637521119669675672" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637521119669685653" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637521119669685653" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_637521119669685653" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637521119669685653" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637521119669685653" xlink:to="us-gaap_PreferredStockValue_637521119669685653" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637521119669685653" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637521119669685653" xlink:to="us-gaap_CommonStockValue_637521119669685653" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637521119669685653" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637521119669685653" xlink:to="us-gaap_AdditionalPaidInCapital_637521119669685653" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637521119669685653" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637521119669685653" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637521119669685653" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cassavasciences.com/role/StatementStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Statements Of Operations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome_637521119669685653" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestAndOtherIncome_637521119669685653" order="1" use="optional" weight="1" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637521119669685653" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_637521119669685653" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637521119669685653" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637521119669685653" xlink:to="us-gaap_OperatingExpenses_637521119669685653" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637521119669685653" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637521119669685653" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637521119669685653" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement" xlink:label="sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement_637521119669685653" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637521119669685653" xlink:to="sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement_637521119669685653" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637521119669685653" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637521119669685653" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637521119669685653" order="3" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cassavasciences.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - Statements Of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637521119669685653" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637521119669685653" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637521119669685653" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637521119669685653" xlink:to="us-gaap_NetIncomeLoss_637521119669685653" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637521119669685653" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637521119669685653" xlink:to="us-gaap_ShareBasedCompensation_637521119669685653" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637521119669685653" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637521119669685653" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637521119669685653" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_637521119669685653" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637521119669685653" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_637521119669685653" order="4" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637521119669685653" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637521119669685653" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637521119669685653" order="5" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637521119669685653" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637521119669685653" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637521119669685653" order="6" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_637521119669685653" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637521119669685653" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_637521119669685653" order="7" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_637521119669685653" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637521119669685653" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_637521119669685653" order="8" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637521119669685653" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637521119669685653" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637521119669685653" order="9" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_637521119669685653" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637521119669685653" xlink:to="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_637521119669685653" order="10" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637521119669685653" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637521119669685653" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637521119669685653" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637521119669685653" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637521119669685653" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_637521119669695619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637521119669685653" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_637521119669695619" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637521119669695619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637521119669695619" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637521119669695619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637521119669695619" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637521119669695619" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637521119669695619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637521119669695619" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637521119669695619" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637521119669695619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637521119669695619" xlink:to="us-gaap_ProceedsFromWarrantExercises_637521119669695619" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637521119669695619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637521119669695619" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637521119669695619" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_ProceedsFromIssuanceFollowOnPublicOfferingNetOfIssuanceCosts" xlink:label="sava_ProceedsFromIssuanceFollowOnPublicOfferingNetOfIssuanceCosts_637521119669695619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637521119669695619" xlink:to="sava_ProceedsFromIssuanceFollowOnPublicOfferingNetOfIssuanceCosts_637521119669695619" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Income Taxes (Schedule Of Effective Income Tax Rate Reconciliation) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637521119669695619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637521119669695619" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637521119669695619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637521119669695619" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_637521119669695619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_637521119669695619" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637521119669695619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637521119669695619" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_637521119669695619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_637521119669695619" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Income Taxes (Schedule Of Deferred Tax Assets And Valuation Allowance) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637521119669695619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637521119669695619" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637521119669695619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross_637521119669695619" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_637521119669695619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637521119669695619" xlink:to="us-gaap_DeferredTaxAssetsOther_637521119669695619" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637521119669695619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637521119669695619" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637521119669695619" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637521119669695619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637521119669695619" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637521119669695619" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637521119669695619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637521119669695619" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637521119669695619" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_637521119669695619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_637521119669695619" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_637521119669695619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_637521119669695619" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsFutureMinimumLeasePaymentsDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Leases And Commitments (Future Minimum Lease Payments) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637472758052522425" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637521119669695619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637472758052522425" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637521119669695619" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637521119669695619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637472758052522425" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637521119669695619" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637521119669695619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637472758052522425" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637521119669695619" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637521119669705591" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637472758052522425" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637521119669705591" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>18
<FILENAME>sava-20201231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created by Certent Disclosure Management 6.39.2.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/23/2021 3:59:27 PM-->
<!--Modified on: 3/23/2021 3:59:28 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#StatementStatementsOfStockholdersEquity" roleURI="http://www.cassavasciences.com/role/StatementStatementsOfStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails" roleURI="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosurePropertyAndEquipmentNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureStockholdersEquityAndStockBasedCompensationWarrantsOutstandingDetails" roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationWarrantsOutstandingDetails" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails" roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureStockholdersEquityAndStockBasedCompensationSummaryOfPerformanceAwardActivityDetails" roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationSummaryOfPerformanceAwardActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureStockholdersEquityAndStockBasedCompensationNonCashStockBasedCompensationExpensesDetails" roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNonCashStockBasedCompensationExpensesDetails" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureLeasesAndCommitmentsNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#Disclosure2020CashIncentiveBonusPlanNarrativeDetails" roleURI="http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <definitionLink xlink:role="http://www.cassavasciences.com/role/StatementStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00400 - Statement - Statements Of Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637521119669954930" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_637521119669954930" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary Of Significant Accounting Policies (Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637521119669984863" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637521119669984863" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_NetIncomeLossAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentNarrativeDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Property And Equipment (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637521119669994809" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637521119669994809" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637521119669994809" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637521119669994809" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_WarrantsMember" xlink:label="sava_WarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sava_WarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_PlacementAgentWarrantsMember" xlink:label="sava_PlacementAgentWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sava_PlacementAgentWarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637521119669994809" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_637521119669994809" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637521119670004783" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_637521119670004783" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_RegisteredDirectOffering2021Member" xlink:label="sava_RegisteredDirectOffering2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_RegisteredDirectOffering2021Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_PublicOfferingMember" xlink:label="sava_PublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_PublicOfferingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_CommonStockWarrantsMember" xlink:label="sava_CommonStockWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_CommonStockWarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_AtMarketEquityProgramMember" xlink:label="sava_AtMarketEquityProgramMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_AtMarketEquityProgramMember" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_TwoThousandEightEquityIncentivePlanMember" xlink:label="sava_TwoThousandEightEquityIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_TwoThousandEightEquityIncentivePlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_TwoThousandEighteenEquityIncentivePlanMember" xlink:label="sava_TwoThousandEighteenEquityIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_TwoThousandEighteenEquityIncentivePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637521119670004783" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637521119670004783" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637521119670014764" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_637521119670014764" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637521119670014764" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_637521119670014764" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_PercentageOfCommissionAtmOffering" xlink:label="sava_PercentageOfCommissionAtmOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sava_PercentageOfCommissionAtmOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting" xlink:label="sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesIssued" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationWarrantsOutstandingDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Warrants Outstanding) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_WarrantsMember" xlink:label="sava_WarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sava_WarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_PlacementAgentWarrantsMember" xlink:label="sava_PlacementAgentWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sava_PlacementAgentWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails" xlink:type="extended" xlink:title="40404 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Information About Stock Options Outstanding) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637521119670054656" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637521119670054656" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_RangeOneMember" xlink:label="sava_RangeOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sava_RangeOneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_RangeTwoMember" xlink:label="sava_RangeTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sava_RangeTwoMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_RangeThreeMember" xlink:label="sava_RangeThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sava_RangeThreeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_RangeFourMember" xlink:label="sava_RangeFourMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sava_RangeFourMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_RangeFiveMember" xlink:label="sava_RangeFiveMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sava_RangeFiveMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationSummaryOfPerformanceAwardActivityDetails" xlink:type="extended" xlink:title="40406 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Summary Of Performance Award Activity) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNonCashStockBasedCompensationExpensesDetails" xlink:type="extended" xlink:title="40407 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Non-Cash Stock-Based Compensation Expenses) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637521119670074600" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_637521119670074600" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Income Taxes (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_637521119670084571" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_637521119670084571" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:label="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="us-gaap_DeferredTaxAssetDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="us-gaap_DeferredTaxAssetDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="us-gaap_DeferredTaxAssetDomain_637521119670084571" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="us-gaap_DeferredTaxAssetDomain_637521119670084571" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_WriteDownOfShareBasedCompensationMember" xlink:label="sava_WriteDownOfShareBasedCompensationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DeferredTaxAssetDomain" xlink:to="sava_WriteDownOfShareBasedCompensationMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_BookLossesMember" xlink:label="sava_BookLossesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DeferredTaxAssetDomain" xlink:to="sava_BookLossesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637521119670084571" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_637521119670084571" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_ExpiresBetween2029And2039Member" xlink:label="sava_ExpiresBetween2029And2039Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="sava_ExpiresBetween2029And2039Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_IndefinitelyMember" xlink:label="sava_IndefinitelyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="sava_IndefinitelyMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_ExpiresBetween2023And2039Member" xlink:label="sava_ExpiresBetween2023And2039Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="sava_ExpiresBetween2023And2039Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardExpirationDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsNarrativeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Leases And Commitments (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_LeasesAndCommitmentsTable" xlink:label="sava_LeasesAndCommitmentsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="sava_LeasesAndCommitmentsTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637521119670104519" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_637521119670104519" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_AustinMember" xlink:label="sava_AustinMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="sava_AustinMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_LeasesAndCommitmentsLineItems" xlink:label="sava_LeasesAndCommitmentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="sava_LeasesAndCommitmentsLineItems" xlink:to="sava_LeasesAndCommitmentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="sava_LeasesAndCommitmentsLineItems" xlink:to="us-gaap_NetRentableArea" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="sava_LeasesAndCommitmentsLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="sava_LeasesAndCommitmentsLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="sava_LeasesAndCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="sava_LeasesAndCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="sava_LeasesAndCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="sava_LeasesAndCommitmentsLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="sava_LeasesAndCommitmentsLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails" xlink:type="extended" xlink:title="40801 - Disclosure - 2020 Cash Incentive Bonus Plan (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_CashIncentiveBonusPlanTable" xlink:label="sava_CashIncentiveBonusPlanTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="sava_CashIncentiveBonusPlanTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_CashIncentiveBonusPlanMember" xlink:label="sava_CashIncentiveBonusPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_CashIncentiveBonusPlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="sava_CashIncentiveBonusPlanTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="sava_CashIncentiveBonusPlanTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_Exceeds5BillionMarketCapitalizationMember" xlink:label="sava_Exceeds5BillionMarketCapitalizationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="sava_Exceeds5BillionMarketCapitalizationMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_FirstValuationMilestoneMember" xlink:label="sava_FirstValuationMilestoneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="sava_FirstValuationMilestoneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_SecondThroughEighthValuationMilestonesMember" xlink:label="sava_SecondThroughEighthValuationMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="sava_SecondThroughEighthValuationMilestonesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="sava_CashIncentiveBonusPlanTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_CashIncentiveBonusPlanLineItems" xlink:label="sava_CashIncentiveBonusPlanLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="sava_CashIncentiveBonusPlanLineItems" xlink:to="sava_CashIncentiveBonusPlanTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_PerformancePlanValuationAmount" xlink:label="sava_PerformancePlanValuationAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="sava_CashIncentiveBonusPlanLineItems" xlink:to="sava_PerformancePlanValuationAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="sava_CashIncentiveBonusPlanLineItems" xlink:to="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_CashIncentiveBonusAward" xlink:label="sava_CashIncentiveBonusAward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="sava_CashIncentiveBonusPlanLineItems" xlink:to="sava_CashIncentiveBonusAward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_PaymentsForCashIncentiveBonus" xlink:label="sava_PaymentsForCashIncentiveBonus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="sava_CashIncentiveBonusPlanLineItems" xlink:to="sava_PaymentsForCashIncentiveBonus" priority="1" use="optional" />
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>19
<FILENAME>sava-20201231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created by Certent Disclosure Management 6.39.2.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/23/2021 3:59:27 PM-->
<!--Modified on: 3/23/2021 3:59:27 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document And Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Balance Sheets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash And Cash Equivalents At Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Development Expense Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued development expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employee Related Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued compensation and benefits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities, current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities, non-current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments And Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 7 and 8)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $.001 par value; 10,000,000 shares authorized, none issued and outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $.001 par value; 120,000,000 shares authorized; 35,237,987 and 21,841,810 shares issued and outstanding at December 31, 2020 and 2019, respectively</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional Paid In Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings Accumulated Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities And Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Par value per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Offering of common stock shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Statements Of Operations [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement" xlink:label="sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement" xlink:to="sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement_lbl" xml:lang="en-US">Research and Development Expense, Net Of Grant Reimbursement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement_lbl" xml:lang="en-US">Research and Development Expense, Net Of Grant Reimbursement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement_lbl" xml:lang="en-US">Research and development, net of grant reimbursement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General And Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain on sale of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain on sale of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xml:lang="en-US">Interest And Other Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xml:lang="en-US">Interest income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Earnings Per Share Basic And Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share, basic and diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted Average Number Of Share Outstanding Basic And Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Shares used in computing net loss per share, basic and diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statements Of Stockholders' Equity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Balance, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Balance, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_lbl" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Ownership Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_lbl" xml:lang="en-US">Stock options for employees</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock options for non-employees</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock pursuant to exercise of stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from stock options exercised</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock pursuant to exercise of stock options, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Stock options exercised</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Issuance costs from 2018 sale of common stock and warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of common stock pursuant to exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of common stock pursuant to exercise of warrants, shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Common stock issued in conjunction with follow-on public offering, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Common stock issued in conjunction with follow-on public offering, net of issuance costs, shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statements Of Cash Flows [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Non-cash stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation Depletion And Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase Decrease In Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Increase Decrease In Other Current Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Other current assets</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:to="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_lbl" xml:lang="en-US">Increase Decrease In Operating Lease Right Of Use Assets and Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_lbl" xml:lang="en-US">Increase Decrease In Operating Lease Right Of Use Assets and Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_lbl" xml:lang="en-US">Operating lease right-of-use assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Increase Decrease In Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Increase Decrease In Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued development expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Increase Decrease In Employee Related Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Accrued compensation and benefits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">Increase Decrease In Other Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">Other current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided By Used In Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from sale of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided By Used In Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided By Used In Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Issuance costs from 2018 sale of common stock and warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds From Issuance Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net proceeds from offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of common stock and warrants, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of common stock warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_ProceedsFromIssuanceFollowOnPublicOfferingNetOfIssuanceCosts" xlink:label="sava_ProceedsFromIssuanceFollowOnPublicOfferingNetOfIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ProceedsFromIssuanceFollowOnPublicOfferingNetOfIssuanceCosts" xlink:to="sava_ProceedsFromIssuanceFollowOnPublicOfferingNetOfIssuanceCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_ProceedsFromIssuanceFollowOnPublicOfferingNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds From Issuance Follow On Public Offering, Net Of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_ProceedsFromIssuanceFollowOnPublicOfferingNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds From Issuance Follow On Public Offering, Net Of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_ProceedsFromIssuanceFollowOnPublicOfferingNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from follow-on public offering, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided By Used In Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">General And Liquidity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">General And Liquidity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary Of Significant Accounting Policies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary Of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property And Equipment [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property And Equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Stockholders' Equity And Stock-Based Compensation [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Shareholders' Equity and Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stockholders' Equity And Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Employee 401(k) Benefit Plan [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">Employee 401(k) Benefit Plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_LeasesAndCommitmentsAbstract" xlink:label="sava_LeasesAndCommitmentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_LeasesAndCommitmentsAbstract" xlink:to="sava_LeasesAndCommitmentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_LeasesAndCommitmentsAbstract_lbl" xml:lang="en-US">Leases And Commitments [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_LeasesAndCommitmentsAbstract_lbl" xml:lang="en-US">Leases And Commitments [Abstract]</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_LeasesAndCommitmentsDisclosureTextBlock" xlink:label="sava_LeasesAndCommitmentsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_LeasesAndCommitmentsDisclosureTextBlock" xlink:to="sava_LeasesAndCommitmentsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_LeasesAndCommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Leases and commitments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_LeasesAndCommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Leases And Commitments Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_LeasesAndCommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Leases And Commitments</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_CashIncentiveBonusPlanAbstract" xlink:label="sava_CashIncentiveBonusPlanAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashIncentiveBonusPlanAbstract" xlink:to="sava_CashIncentiveBonusPlanAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_CashIncentiveBonusPlanAbstract_lbl" xml:lang="en-US">2020 Cash Incentive Bonus Plan [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_CashIncentiveBonusPlanAbstract_lbl" xml:lang="en-US">Cash Incentive Bonus Plan [Abstract]</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_CashIncentiveBonusPlanTextBlock" xlink:label="sava_CashIncentiveBonusPlanTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashIncentiveBonusPlanTextBlock" xlink:to="sava_CashIncentiveBonusPlanTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_CashIncentiveBonusPlanTextBlock_lbl" xml:lang="en-US">Cash Incentive Bonus Plan [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_CashIncentiveBonusPlanTextBlock_lbl" xml:lang="en-US">Cash Incentive Bonus Plan [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_CashIncentiveBonusPlanTextBlock_lbl" xml:lang="en-US">2020 Cash Incentive Bonus Plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use Of Estimates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use Of Estimates</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_ProceedsFromGrantsPolicyPolicyTextBlock" xlink:label="sava_ProceedsFromGrantsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ProceedsFromGrantsPolicyPolicyTextBlock" xlink:to="sava_ProceedsFromGrantsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_ProceedsFromGrantsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Proceeds From Grants Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_ProceedsFromGrantsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Proceeds From Grants Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_ProceedsFromGrantsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Proceeds From Grants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash And Cash Equivalents Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash And Cash Equivalents And Concentration Of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Business Segments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Compensation Related Costs Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value Of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock" xlink:label="sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock" xlink:to="sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Research Contract Costs And Accruals Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Research Contract Costs And Accruals Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Research Contract Costs And Accruals</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Incentive Bonus Plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Tax Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Warrants Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Stock Option Activity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Information About Stock Options Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Weighted Average Fair Value Of Options Granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Nonvested Performance-based Units Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Summary Of Performance Award Activity</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_SummaryOfNonCashStockBasedCompensationTableTextBlock" xlink:label="sava_SummaryOfNonCashStockBasedCompensationTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_SummaryOfNonCashStockBasedCompensationTableTextBlock" xlink:to="sava_SummaryOfNonCashStockBasedCompensationTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_SummaryOfNonCashStockBasedCompensationTableTextBlock_lbl" xml:lang="en-US">Summary Of Non-Cash Stock-Based Compensation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_SummaryOfNonCashStockBasedCompensationTableTextBlock_lbl" xml:lang="en-US">Summary Of Non Cash Stock Based Compensation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_SummaryOfNonCashStockBasedCompensationTableTextBlock_lbl" xml:lang="en-US">Non-Cash Stock-Based Compensation Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule Of Effective Income Tax Rate Reconciliation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule Of Deferred Tax Assets And Valuation Allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xml:lang="en-US">Schedule Of Unrecognized Tax Benefits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Future Minimum Lease Payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositAtCarryingValue" xlink:label="us-gaap_CertificatesOfDepositAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositAtCarryingValue" xlink:to="us-gaap_CertificatesOfDepositAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CertificatesOfDepositAtCarryingValue_lbl" xml:lang="en-US">Certificates of Deposit, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CertificatesOfDepositAtCarryingValue_lbl" xml:lang="en-US">Certificate of deposit</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_ReductionToResearchAndDevelopmentExpense" xlink:label="sava_ReductionToResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ReductionToResearchAndDevelopmentExpense" xlink:to="sava_ReductionToResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_ReductionToResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Reduction To Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_ReductionToResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Reduction To Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sava_ReductionToResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Reimbursement from National Institutes of Health research grants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of business segments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period of stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Award expiration period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Net Income Loss [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Numerator:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xml:lang="en-US">Weighted Average Number Of Shares Outstanding Basic [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xml:lang="en-US">Denominator:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Common stock excluded from net loss per share, diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_lbl" xml:lang="en-US">Proceeds from Sale of Machinery and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_lbl" xml:lang="en-US">Proceeds from sale of equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, original cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class Of Warrant Or Right [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_WarrantsMember" xlink:label="sava_WarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_WarrantsMember" xlink:to="sava_WarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_WarrantsMember_lbl" xml:lang="en-US">Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_WarrantsMember_lbl" xml:lang="en-US">Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_WarrantsMember_lbl" xml:lang="en-US">Warrants [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_PlacementAgentWarrantsMember" xlink:label="sava_PlacementAgentWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PlacementAgentWarrantsMember" xlink:to="sava_PlacementAgentWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_PlacementAgentWarrantsMember_lbl" xml:lang="en-US">Placement Agent Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_PlacementAgentWarrantsMember_lbl" xml:lang="en-US">Placement Agent Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_PlacementAgentWarrantsMember_lbl" xml:lang="en-US">Placement Agent Warrants [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class Of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US">Performance Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US">Performance Award [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_RegisteredDirectOffering2021Member" xlink:label="sava_RegisteredDirectOffering2021Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_RegisteredDirectOffering2021Member" xlink:to="sava_RegisteredDirectOffering2021Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_RegisteredDirectOffering2021Member_lbl" xml:lang="en-US">Registered Direct Offering 2021 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_RegisteredDirectOffering2021Member_lbl" xml:lang="en-US">Registered Direct Offering2021 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_RegisteredDirectOffering2021Member_lbl" xml:lang="en-US">2021 Registered Direct Offering [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_PublicOfferingMember" xlink:label="sava_PublicOfferingMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PublicOfferingMember" xlink:to="sava_PublicOfferingMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_PublicOfferingMember_lbl" xml:lang="en-US">Public Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_PublicOfferingMember_lbl" xml:lang="en-US">Public Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_PublicOfferingMember_lbl" xml:lang="en-US">Public Offering [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_CommonStockWarrantsMember" xlink:label="sava_CommonStockWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CommonStockWarrantsMember" xlink:to="sava_CommonStockWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_CommonStockWarrantsMember_lbl" xml:lang="en-US">Common Stock Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_CommonStockWarrantsMember_lbl" xml:lang="en-US">Common Stock Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_CommonStockWarrantsMember_lbl" xml:lang="en-US">Common Stock Warrants [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_TwoThousandEightEquityIncentivePlanMember" xlink:label="sava_TwoThousandEightEquityIncentivePlanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_TwoThousandEightEquityIncentivePlanMember" xlink:to="sava_TwoThousandEightEquityIncentivePlanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_TwoThousandEightEquityIncentivePlanMember_lbl" xml:lang="en-US">2008 Equity Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_TwoThousandEightEquityIncentivePlanMember_lbl" xml:lang="en-US">Two Thousand Eight Equity Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_TwoThousandEightEquityIncentivePlanMember_lbl" xml:lang="en-US">2008 Equity Incentive Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_TwoThousandEighteenEquityIncentivePlanMember" xlink:label="sava_TwoThousandEighteenEquityIncentivePlanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_TwoThousandEighteenEquityIncentivePlanMember" xlink:to="sava_TwoThousandEighteenEquityIncentivePlanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_TwoThousandEighteenEquityIncentivePlanMember_lbl" xml:lang="en-US">Two Thousand Eighteen Equity Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_TwoThousandEighteenEquityIncentivePlanMember_lbl" xml:lang="en-US">Two Thousand Eighteen Equity Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_TwoThousandEighteenEquityIncentivePlanMember_lbl" xml:lang="en-US">2018 Equity Incentive Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Price per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Number of Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Number of shares execrise</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US">Aggregate offering price</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_PercentageOfCommissionAtmOffering" xlink:label="sava_PercentageOfCommissionAtmOffering" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PercentageOfCommissionAtmOffering" xlink:to="sava_PercentageOfCommissionAtmOffering_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_PercentageOfCommissionAtmOffering_lbl" xml:lang="en-US">Percentage Of Commission ATM Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_PercentageOfCommissionAtmOffering_lbl" xml:lang="en-US">Percentage Of Commission ATM Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_PercentageOfCommissionAtmOffering_lbl" xml:lang="en-US">Percentage of commission in ATM offering</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:to="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Share based compensation arrangement by share based payment award options grant in period weighted average remaining contractual term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grant In Period Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Expiration period of stock options granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod" xlink:to="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod_lbl" xml:lang="en-US">Share based compensation arrangement by share based payment award options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Forfeitures In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod_lbl" xml:lang="en-US">Compensation costs prior to forfeiture</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm" xlink:to="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm_lbl" xml:lang="en-US">Share based compensation arrangement by share based payment award options nonvested forfeitures in period weighted average contractual term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Forfeitures In Period Weighted Average Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm_lbl" xml:lang="en-US">Weighted average remaining recognition period</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting" xlink:label="sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting" xlink:to="sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting_lbl" xml:lang="en-US">Share Based Compensation Additional Expense Expected On Vesting.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting_lbl" xml:lang="en-US">Share Based Compensation Additional Expense Expected On Vesting</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting_lbl" xml:lang="en-US">Additional stock compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Vested performance awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Performance awards vested</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xml:lang="en-US">Performance awards expiration date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xml:lang="en-US">Class of Warrant or Right, Date from which Warrants or Rights Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xml:lang="en-US">Issuance Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Warrants and Rights Outstanding, Maturity Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Expiration Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise Price Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding as of, Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding as of, Beginning</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Options forfeited/canceled</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Vested and expected to vest at December 31, 2020</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Exercisable at December 31, 2020</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding as of, Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding as of, Beginning</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options exercised</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options forfeited/cancelled</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Vested and expected to vest at December 31, 2020</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable at December 31, 2020</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term, Vested and expected to vest at December 31, 2020</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term, Exercisable at December 31, 2020</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Outstanding, Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Vested and expected to vest at December 31, 2020</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable at December 31, 2020</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_RangeOneMember" xlink:label="sava_RangeOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_RangeOneMember" xlink:to="sava_RangeOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_RangeOneMember_lbl" xml:lang="en-US">Range One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_RangeOneMember_lbl" xml:lang="en-US">Range One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_RangeOneMember_lbl" xml:lang="en-US">$0.95 - $1.88 [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_RangeTwoMember" xlink:label="sava_RangeTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_RangeTwoMember" xlink:to="sava_RangeTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_RangeTwoMember_lbl" xml:lang="en-US">Range Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_RangeTwoMember_lbl" xml:lang="en-US">Range Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_RangeTwoMember_lbl" xml:lang="en-US">$3.24 - $4.09 [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_RangeThreeMember" xlink:label="sava_RangeThreeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_RangeThreeMember" xlink:to="sava_RangeThreeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_RangeThreeMember_lbl" xml:lang="en-US">Range Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_RangeThreeMember_lbl" xml:lang="en-US">Range Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_RangeThreeMember_lbl" xml:lang="en-US">$4.10 - $13.09 [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_RangeFourMember" xlink:label="sava_RangeFourMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_RangeFourMember" xlink:to="sava_RangeFourMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_RangeFourMember_lbl" xml:lang="en-US">Range Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_RangeFourMember_lbl" xml:lang="en-US">Range Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_RangeFourMember_lbl" xml:lang="en-US">$14.21 - $35.00 [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_RangeFiveMember" xlink:label="sava_RangeFiveMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_RangeFiveMember" xlink:to="sava_RangeFiveMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_RangeFiveMember_lbl" xml:lang="en-US">Range Five [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_RangeFiveMember_lbl" xml:lang="en-US">Range Five [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_RangeFiveMember_lbl" xml:lang="en-US">$36.40 - $53.55 [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Range of exercise prices, Minimum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Range of exercise prices, Maximum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Number of outstanding options, Options outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life (in years), Options outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Weighted average exercise price, Options outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Number of vested options, Options exercisable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Weighted average exercise price, Options exercisable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Volatility, Minimum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Volatility, Maximum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free interest rates, Minimum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk-free interest rates, Maximum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life of option</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl" xml:lang="en-US">Forfeiture rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average fair value of stock options granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Outstanding as of, Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Outstanding as of, Beginning</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Forfeited/Cancelled</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General And Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share Based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total non-cash stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Country [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Federal [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario Unspecified [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_ExpiresBetween2029And2039Member" xlink:label="sava_ExpiresBetween2029And2039Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ExpiresBetween2029And2039Member" xlink:to="sava_ExpiresBetween2029And2039Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_ExpiresBetween2029And2039Member_lbl" xml:lang="en-US">Expires Between 2029 And 2039 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_ExpiresBetween2029And2039Member_lbl" xml:lang="en-US">Expires Between2029 And2039 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_ExpiresBetween2029And2039Member_lbl" xml:lang="en-US">Expires Between 2029 And 2039 [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_IndefinitelyMember" xlink:label="sava_IndefinitelyMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_IndefinitelyMember" xlink:to="sava_IndefinitelyMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_IndefinitelyMember_lbl" xml:lang="en-US">Indefinitely [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_IndefinitelyMember_lbl" xml:lang="en-US">Indefinitely [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_IndefinitelyMember_lbl" xml:lang="en-US">Indefinitely [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_ExpiresBetween2023And2039Member" xlink:label="sava_ExpiresBetween2023And2039Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ExpiresBetween2023And2039Member" xlink:to="sava_ExpiresBetween2023And2039Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_ExpiresBetween2023And2039Member_lbl" xml:lang="en-US">Expires Between 2023 And 2039 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_ExpiresBetween2023And2039Member_lbl" xml:lang="en-US">Expires Between2023 And2039 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_ExpiresBetween2023And2039Member_lbl" xml:lang="en-US">Expires Between 2023 And 2039 [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Tax at federal statutory rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U.S federal corporate tax rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Change in Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation allowance increase (decrease)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Pre-tax net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl" xml:lang="en-US">Operating Loss Carryforwards, Expiration Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl" xml:lang="en-US">Expiration date of pre-tax net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardExpirationDate" xlink:to="us-gaap_TaxCreditCarryforwardExpirationDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate_lbl" xml:lang="en-US">Tax Credit Carryforward, Expiration Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate_lbl" xml:lang="en-US">Expiration date of federal research and development tax credits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Federal research and development tax credits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized tax benefits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State tax, net of federal benefit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Research and development credits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective income tax rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and development credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred tax liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xml:lang="en-US">Operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total deferred tax liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US">Deferred Tax Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US">Net deferred tax asset / (liability):</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US">Additions based on tax positions related to the current year</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_LeasesAndCommitmentsTable" xlink:label="sava_LeasesAndCommitmentsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_LeasesAndCommitmentsTable" xlink:to="sava_LeasesAndCommitmentsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_LeasesAndCommitmentsTable_lbl" xml:lang="en-US">Leases And Commitments [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_LeasesAndCommitmentsTable_lbl" xml:lang="en-US">Leases And Commitments [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Segment Geographical [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_AustinMember" xlink:label="sava_AustinMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_AustinMember" xlink:to="sava_AustinMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_AustinMember_lbl" xml:lang="en-US">Austin [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_AustinMember_lbl" xml:lang="en-US">Austin [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_AustinMember_lbl" xml:lang="en-US">Austin [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_LeasesAndCommitmentsLineItems" xlink:label="sava_LeasesAndCommitmentsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_LeasesAndCommitmentsLineItems" xlink:to="sava_LeasesAndCommitmentsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_LeasesAndCommitmentsLineItems_lbl" xml:lang="en-US">Leases And Commitments [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_LeasesAndCommitmentsLineItems_lbl" xml:lang="en-US">Leases And Commitments [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetRentableArea" xlink:to="us-gaap_NetRentableArea_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetRentableArea_lbl" xml:lang="en-US">Net Rentable Area</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetRentableArea_lbl" xml:lang="en-US">Office space</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Lease Expiration Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Lease expiration date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Operating Leases, Rent Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Rent expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US">Leases, discount rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-use assets exchange for operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Cash paid for operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">For the year ending December 31,</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2021</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2022</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2023</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2024</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total future minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_CashIncentiveBonusPlanTable" xlink:label="sava_CashIncentiveBonusPlanTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashIncentiveBonusPlanTable" xlink:to="sava_CashIncentiveBonusPlanTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_CashIncentiveBonusPlanTable_lbl" xml:lang="en-US">Cash Incentive Bonus Plan [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_CashIncentiveBonusPlanTable_lbl" xml:lang="en-US">Cash Incentive Bonus Plan [Table]</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_CashIncentiveBonusPlanLineItems" xlink:label="sava_CashIncentiveBonusPlanLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashIncentiveBonusPlanLineItems" xlink:to="sava_CashIncentiveBonusPlanLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_CashIncentiveBonusPlanLineItems_lbl" xml:lang="en-US">Cash Incentive Bonus Plan [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_CashIncentiveBonusPlanLineItems_lbl" xml:lang="en-US">Cash Incentive Bonus Plan [Line Items]</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_PerformancePlanValuationAmount" xlink:label="sava_PerformancePlanValuationAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PerformancePlanValuationAmount" xlink:to="sava_PerformancePlanValuationAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_PerformancePlanValuationAmount_lbl" xml:lang="en-US">Performance Plan Valuation Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_PerformancePlanValuationAmount_lbl" xml:lang="en-US">Performance Plan Valuation Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_PerformancePlanValuationAmount_lbl" xml:lang="en-US">Valuation milestone amount in market capitalization</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:to="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment_lbl" xml:lang="en-US">Percentage Valuation Milestone Cash Bonus Award Subject To Approval And Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment_lbl" xml:lang="en-US">Percentage Valuation Milestone Cash Bonus Award Subject To Approval And Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment_lbl" xml:lang="en-US">Percentage of each cash bonus award associated with Valuation Milestone subject to adjustment and approval</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_CashIncentiveBonusAward" xlink:label="sava_CashIncentiveBonusAward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashIncentiveBonusAward" xlink:to="sava_CashIncentiveBonusAward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_CashIncentiveBonusAward_lbl" xml:lang="en-US">Cash Incentive Bonus Award</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_CashIncentiveBonusAward_lbl" xml:lang="en-US">Cash Incentive Bonus Award</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_CashIncentiveBonusAward_lbl" xml:lang="en-US">Cash bonus award</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_PaymentsForCashIncentiveBonus" xlink:label="sava_PaymentsForCashIncentiveBonus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PaymentsForCashIncentiveBonus" xlink:to="sava_PaymentsForCashIncentiveBonus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_PaymentsForCashIncentiveBonus_lbl" xml:lang="en-US">Payments For Cash Incentive Bonus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_PaymentsForCashIncentiveBonus_lbl" xml:lang="en-US">Payments For Cash Incentive Bonus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_PaymentsForCashIncentiveBonus_lbl" xml:lang="en-US">Payments authorized or made to participants under the Plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property Plant And Equipment Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Manufacturing Equipment [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_AtMarketEquityProgramMember" xlink:label="sava_AtMarketEquityProgramMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_AtMarketEquityProgramMember" xlink:to="sava_AtMarketEquityProgramMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_AtMarketEquityProgramMember_lbl" xml:lang="en-US">At-The-Market Equity Program [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_AtMarketEquityProgramMember_lbl" xml:lang="en-US">At Market Equity Program [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_AtMarketEquityProgramMember_lbl" xml:lang="en-US">ATM [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:label="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_lbl" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="us-gaap_DeferredTaxAssetDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetDomain" xlink:to="us-gaap_DeferredTaxAssetDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetDomain_lbl" xml:lang="en-US">Deferred Tax Asset [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetDomain_lbl" xml:lang="en-US">Deferred Tax Asset [Domain]</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_WriteDownOfShareBasedCompensationMember" xlink:label="sava_WriteDownOfShareBasedCompensationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_WriteDownOfShareBasedCompensationMember" xlink:to="sava_WriteDownOfShareBasedCompensationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_WriteDownOfShareBasedCompensationMember_lbl" xml:lang="en-US">Write Down Of Share Based Compensation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_WriteDownOfShareBasedCompensationMember_lbl" xml:lang="en-US">Write Down Of Share Based Compensation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_WriteDownOfShareBasedCompensationMember_lbl" xml:lang="en-US">Write Down Of Share-Based Compensation [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_BookLossesMember" xlink:label="sava_BookLossesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_BookLossesMember" xlink:to="sava_BookLossesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_BookLossesMember_lbl" xml:lang="en-US">Book Losses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_BookLossesMember_lbl" xml:lang="en-US">Book Losses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_BookLossesMember_lbl" xml:lang="en-US">Book Losses [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_CashIncentiveBonusPlanMember" xlink:label="sava_CashIncentiveBonusPlanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashIncentiveBonusPlanMember" xlink:to="sava_CashIncentiveBonusPlanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_CashIncentiveBonusPlanMember_lbl" xml:lang="en-US">Cash Incentive Bonus Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_CashIncentiveBonusPlanMember_lbl" xml:lang="en-US">Cash Incentive Bonus Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_CashIncentiveBonusPlanMember_lbl" xml:lang="en-US">Cash Incentive Bonus Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_Exceeds5BillionMarketCapitalizationMember" xlink:label="sava_Exceeds5BillionMarketCapitalizationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_Exceeds5BillionMarketCapitalizationMember" xlink:to="sava_Exceeds5BillionMarketCapitalizationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_Exceeds5BillionMarketCapitalizationMember_lbl" xml:lang="en-US">Exceeds 5 Billion Market Capitalization [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_Exceeds5BillionMarketCapitalizationMember_lbl" xml:lang="en-US">Exceeds5 Billion Market Capitalization [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_Exceeds5BillionMarketCapitalizationMember_lbl" xml:lang="en-US">Exceeds $5 Billion Market Capitalization For No Less Than 20 Consecutive Trading Days [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_FirstValuationMilestoneMember" xlink:label="sava_FirstValuationMilestoneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_FirstValuationMilestoneMember" xlink:to="sava_FirstValuationMilestoneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_FirstValuationMilestoneMember_lbl" xml:lang="en-US">First Valuation Milestone [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_FirstValuationMilestoneMember_lbl" xml:lang="en-US">First Valuation Milestone [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_FirstValuationMilestoneMember_lbl" xml:lang="en-US">First Valuation Milestone [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_SecondThroughEighthValuationMilestonesMember" xlink:label="sava_SecondThroughEighthValuationMilestonesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_SecondThroughEighthValuationMilestonesMember" xlink:to="sava_SecondThroughEighthValuationMilestonesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_SecondThroughEighthValuationMilestonesMember_lbl" xml:lang="en-US">Second Through Eighth Valuation Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_SecondThroughEighthValuationMilestonesMember_lbl" xml:lang="en-US">Second Through Eighth Valuation Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_SecondThroughEighthValuationMilestonesMember_lbl" xml:lang="en-US">Second Through Eighth Valuation Milestones [Member]</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>20
<FILENAME>sava-20201231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created by Certent Disclosure Management 6.39.2.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/23/2021 3:59:27 PM-->
<!--Modified on: 3/23/2021 3:59:27 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#StatementBalanceSheets" roleURI="http://www.cassavasciences.com/role/StatementBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#StatementBalanceSheetsParenthetical" roleURI="http://www.cassavasciences.com/role/StatementBalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#StatementStatementsOfOperations" roleURI="http://www.cassavasciences.com/role/StatementStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#StatementStatementsOfStockholdersEquity" roleURI="http://www.cassavasciences.com/role/StatementStatementsOfStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#StatementStatementsOfCashFlows" roleURI="http://www.cassavasciences.com/role/StatementStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureGeneralAndLiquidity" roleURI="http://www.cassavasciences.com/role/DisclosureGeneralAndLiquidity" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosurePropertyAndEquipment" roleURI="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipment" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureStockholdersEquityAndStockBasedCompensation" roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensation" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureEmployee401KBenefitPlan" roleURI="http://www.cassavasciences.com/role/DisclosureEmployee401KBenefitPlan" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureIncomeTaxes" roleURI="http://www.cassavasciences.com/role/DisclosureIncomeTaxes" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureLeasesAndCommitments" roleURI="http://www.cassavasciences.com/role/DisclosureLeasesAndCommitments" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#Disclosure2020CashIncentiveBonusPlan" roleURI="http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlan" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicy" roleURI="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureStockholdersEquityAndStockBasedCompensationTables" roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationTables" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.cassavasciences.com/role/DisclosureIncomeTaxesTables" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureLeasesAndCommitmentsTables" roleURI="http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsTables" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureGeneralAndLiquidityNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureGeneralAndLiquidityNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails" roleURI="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosurePropertyAndEquipmentNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureStockholdersEquityAndStockBasedCompensationWarrantsOutstandingDetails" roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationWarrantsOutstandingDetails" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureStockholdersEquityAndStockBasedCompensationStockOptionActivityDetails" roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockOptionActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails" roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureStockholdersEquityAndStockBasedCompensationWeightedAverageFairValueOfOptionsGrantedDetails" roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationWeightedAverageFairValueOfOptionsGrantedDetails" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureStockholdersEquityAndStockBasedCompensationSummaryOfPerformanceAwardActivityDetails" roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationSummaryOfPerformanceAwardActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureStockholdersEquityAndStockBasedCompensationNonCashStockBasedCompensationExpensesDetails" roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNonCashStockBasedCompensationExpensesDetails" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails" roleURI="http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" roleURI="http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureLeasesAndCommitmentsNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#DisclosureLeasesAndCommitmentsFutureMinimumLeasePaymentsDetails" roleURI="http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsFutureMinimumLeasePaymentsDetails" />
  <roleRef xlink:type="simple" xlink:href="sava-20201231.xsd#Disclosure2020CashIncentiveBonusPlanNarrativeDetails" roleURI="http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails" />
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document And Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637521119670294023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637521119670294023" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_637521119670304012" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport_637521119670304012" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637521119670313965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637521119670313965" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637521119670313965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637521119670313965" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637521119670313965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637521119670313965" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637521119670313965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637521119670313965" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637521119670313965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_637521119670313965" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637521119670313965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_637521119670313965" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637521119670313965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637521119670313965" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637521119670313965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637521119670313965" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637521119670313965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637521119670313965" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637521119670313965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637521119670313965" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_637521119670313965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_637521119670313965" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637521119670313965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637521119670313965" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637521119670313965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637521119670313965" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637521119670313965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637521119670313965" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637521119670313965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_637521119670313965" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637521119670313965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_637521119670313965" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637521119670313965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_637521119670313965" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637521119670313965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_637521119670313965" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637521119670313965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_637521119670313965" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_637521119670313965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_637521119670313965" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_637521119670313965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_637521119670313965" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637521119670313965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637521119670313965" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637521119670313965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637521119670313965" order="25" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637521119670313965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_637521119670313965" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637521119670313965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_637521119670313965" order="27" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637521119670313965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637521119670313965" order="28" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_637521119670323934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_637521119670323934" order="29" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637521119670323934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_637521119670323934" order="30" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_637521119670323934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_637521119670323934" order="31" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637521119670323934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637521119670323934" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_637521119670323934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_637521119670323934" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637521119670323934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637521119670323934" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637521119670323934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637521119670323934" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Balance Sheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637521119670323934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_637521119670323934" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637521119670323934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637521119670323934" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637521119670323934" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_637521119670323934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637521119670323934" xlink:to="us-gaap_OtherAssetsCurrent_637521119670323934" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637521119670323934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637521119670323934" xlink:to="us-gaap_AssetsCurrent_637521119670323934" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637521119670323934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637521119670323934" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637521119670323934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637521119670323934" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637521119670323934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets_637521119670323934" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637521119670323934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637521119670323934" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637521119670323934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637521119670323934" xlink:to="us-gaap_AccountsPayableCurrent_637521119670323934" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637521119670323934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637521119670323934" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637521119670323934" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_637521119670323934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637521119670323934" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_637521119670323934" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637521119670323934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637521119670323934" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637521119670323934" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_637521119670323934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637521119670323934" xlink:to="us-gaap_OtherLiabilitiesCurrent_637521119670323934" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637521119670323934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637521119670323934" xlink:to="us-gaap_LiabilitiesCurrent_637521119670323934" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637521119670323934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637521119670323934" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637521119670323934" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637521119670323934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities_637521119670323934" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637521119670323934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies_637521119670323934" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637521119670333917" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_637521119670333917" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637521119670333917" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637521119670333917" xlink:to="us-gaap_PreferredStockValue_637521119670333917" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637521119670333917" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637521119670333917" xlink:to="us-gaap_CommonStockValue_637521119670333917" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637521119670333917" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637521119670333917" xlink:to="us-gaap_AdditionalPaidInCapital_637521119670333917" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637521119670333917" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637521119670333917" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637521119670333917" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637521119670333917" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637521119670333917" xlink:to="us-gaap_StockholdersEquity_637521119670333917" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637521119670333917" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637521119670333917" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/StatementBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Balance Sheets (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637521119670333917" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637521119670333917" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637521119670333917" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_637521119670333917" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_637521119670333917" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_637521119670333917" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637521119670333917" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_637521119670333917" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637521119670333917" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637521119670333917" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637521119670333917" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_637521119670333917" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637521119670333917" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_637521119670333917" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637521119670333917" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_637521119670333917" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/StatementStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Statements Of Operations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_637521119670333917" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_637521119670333917" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement" xlink:label="sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement_637521119670333917" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637521119670333917" xlink:to="sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement_637521119670333917" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637521119670333917" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637521119670333917" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637521119670333917" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637521119670333917" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637521119670333917" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637521119670333917" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637521119670333917" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637521119670333917" xlink:to="us-gaap_OperatingExpenses_637521119670333917" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637521119670333917" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_637521119670333917" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome_637521119670333917" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestAndOtherIncome_637521119670333917" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637521119670333917" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_637521119670333917" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_637521119670333917" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_637521119670333917" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637521119670333917" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637521119670333917" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/StatementStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00400 - Statement - Statements Of Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637521119670333917" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_637521119670333917" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637521119670333917" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637521119670333917" xlink:to="us-gaap_StatementEquityComponentsAxis_637521119670333917" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637521119670343887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637521119670333917" xlink:to="us-gaap_CommonStockMember_637521119670343887" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637521119670343887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637521119670333917" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637521119670343887" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637521119670343887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637521119670333917" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637521119670343887" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637521119670343887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637521119670333917" xlink:to="us-gaap_RetainedEarningsMember_637521119670343887" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637521119670343887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637521119670333917" xlink:to="us-gaap_EquityComponentDomain_637521119670343887" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637521119670343887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637521119670333917" xlink:to="us-gaap_StatementLineItems_637521119670343887" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637521119670343887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637521119670343887" xlink:to="us-gaap_StockholdersEquity_637521119670343887" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_637521119670343887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637521119670343887" xlink:to="us-gaap_SharesIssued_637521119670343887" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_637521119670343887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637521119670343887" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_637521119670343887" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_637521119670343887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637521119670343887" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_637521119670343887" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637521119670343887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637521119670343887" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637521119670343887" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637521119670343887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637521119670343887" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637521119670343887" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_637521119670343887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637521119670343887" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_637521119670343887" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_637521119670343887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637521119670343887" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_637521119670343887" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_637521119670343887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637521119670343887" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_637521119670343887" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637521119670343887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637521119670343887" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637521119670343887" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637521119670343887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637521119670343887" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637521119670343887" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637521119670343887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637521119670343887" xlink:to="us-gaap_NetIncomeLoss_637521119670343887" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_6375211196703438871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637521119670343887" xlink:to="us-gaap_StockholdersEquity_6375211196703438871" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_6375211196703438871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637521119670343887" xlink:to="us-gaap_SharesIssued_6375211196703438871" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - Statements Of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637521119670343887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637521119670343887" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637521119670343887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637521119670343887" xlink:to="us-gaap_NetIncomeLoss_637521119670343887" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637521119670343887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637521119670343887" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637521119670343887" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637521119670343887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637521119670343887" xlink:to="us-gaap_ShareBasedCompensation_637521119670343887" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637521119670343887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637521119670343887" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637521119670343887" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637521119670343887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637521119670343887" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637521119670343887" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637521119670343887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637521119670343887" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637521119670343887" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_637521119670343887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637521119670343887" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_637521119670343887" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_637521119670343887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637521119670343887" xlink:to="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_637521119670343887" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637521119670343887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637521119670343887" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637521119670343887" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637521119670353872" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637521119670343887" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637521119670353872" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_637521119670353872" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637521119670343887" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_637521119670353872" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_637521119670353872" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637521119670343887" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_637521119670353872" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637521119670353872" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637521119670343887" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637521119670353872" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637521119670353872" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637521119670353872" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637521119670353872" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637521119670353872" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637521119670353872" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_637521119670353872" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637521119670353872" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_637521119670353872" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637521119670353872" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637521119670353872" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637521119670353872" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637521119670353872" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637521119670353872" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637521119670353872" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637521119670353872" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637521119670353872" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637521119670353872" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637521119670353872" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637521119670353872" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637521119670353872" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637521119670353872" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637521119670353872" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637521119670353872" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637521119670353872" xlink:to="us-gaap_ProceedsFromWarrantExercises_637521119670353872" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_ProceedsFromIssuanceFollowOnPublicOfferingNetOfIssuanceCosts" xlink:label="sava_ProceedsFromIssuanceFollowOnPublicOfferingNetOfIssuanceCosts_637521119670353872" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637521119670353872" xlink:to="sava_ProceedsFromIssuanceFollowOnPublicOfferingNetOfIssuanceCosts_637521119670353872" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637521119670353872" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637521119670353872" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637521119670353872" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_637521119670353872" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_637521119670353872" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637521119670353872" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637521119670353872" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_6375211196703538721" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_6375211196703538721" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureGeneralAndLiquidity" xlink:type="extended" xlink:title="10101 - Disclosure - General And Liquidity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637521119670353872" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637521119670353872" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary Of Significant Accounting Policies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_637521119670353872" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_637521119670353872" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipment" xlink:type="extended" xlink:title="10301 - Disclosure - Property And Equipment">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637521119670353872" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637521119670353872" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensation" xlink:type="extended" xlink:title="10401 - Disclosure - Stockholders' Equity And Stock-Based Compensation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_637521119670363849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_637521119670363849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureEmployee401KBenefitPlan" xlink:type="extended" xlink:title="10501 - Disclosure - Employee 401(k) Benefit Plan">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_637521119670363849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_637521119670363849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="10601 - Disclosure - Income Taxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_637521119670363849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_637521119670363849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureLeasesAndCommitments" xlink:type="extended" xlink:title="10701 - Disclosure - Leases And Commitments">
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_LeasesAndCommitmentsAbstract" xlink:label="sava_LeasesAndCommitmentsAbstract" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_LeasesAndCommitmentsDisclosureTextBlock" xlink:label="sava_LeasesAndCommitmentsDisclosureTextBlock_637521119670363849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsAbstract" xlink:to="sava_LeasesAndCommitmentsDisclosureTextBlock_637521119670363849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlan" xlink:type="extended" xlink:title="10801 - Disclosure - 2020 Cash Incentive Bonus Plan">
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_CashIncentiveBonusPlanAbstract" xlink:label="sava_CashIncentiveBonusPlanAbstract" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_CashIncentiveBonusPlanTextBlock" xlink:label="sava_CashIncentiveBonusPlanTextBlock_637521119670363849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanAbstract" xlink:to="sava_CashIncentiveBonusPlanTextBlock_637521119670363849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy" xlink:type="extended" xlink:title="20202 - Disclosure - Summary Of Significant Accounting Policies (Policy)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_637521119670363849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_637521119670363849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_ProceedsFromGrantsPolicyPolicyTextBlock" xlink:label="sava_ProceedsFromGrantsPolicyPolicyTextBlock_637521119670363849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sava_ProceedsFromGrantsPolicyPolicyTextBlock_637521119670363849" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637521119670363849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637521119670363849" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_637521119670363849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_637521119670363849" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_637521119670363849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_637521119670363849" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_637521119670363849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_637521119670363849" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637521119670363849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637521119670363849" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_637521119670363849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_637521119670363849" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock" xlink:label="sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock_637521119670363849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock_637521119670363849" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637521119670363849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637521119670363849" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_637521119670363849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_637521119670363849" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_637521119670363849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_637521119670363849" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637521119670363849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637521119670363849" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - Summary Of Significant Accounting Policies (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_637521119670363849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_637521119670363849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationTables" xlink:type="extended" xlink:title="30403 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_637521119670363849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_637521119670363849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637521119670363849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637521119670363849" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_637521119670363849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_637521119670363849" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_637521119670363849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_637521119670363849" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_637521119670363849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_637521119670363849" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_SummaryOfNonCashStockBasedCompensationTableTextBlock" xlink:label="sava_SummaryOfNonCashStockBasedCompensationTableTextBlock_637521119670373829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="sava_SummaryOfNonCashStockBasedCompensationTableTextBlock_637521119670373829" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="30603 - Disclosure - Income Taxes (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637521119670373829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637521119670373829" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637521119670373829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637521119670373829" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_637521119670373829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_637521119670373829" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsTables" xlink:type="extended" xlink:title="30703 - Disclosure - Leases And Commitments (Tables)">
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_LeasesAndCommitmentsAbstract" xlink:label="sava_LeasesAndCommitmentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637521119670373829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637521119670373829" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureGeneralAndLiquidityNarrativeDetails" xlink:type="extended" xlink:title="40101 - Disclosure - General And Liquidity (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637521119670373829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637521119670373829" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary Of Significant Accounting Policies (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositAtCarryingValue" xlink:label="us-gaap_CertificatesOfDepositAtCarryingValue_637521119670373829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CertificatesOfDepositAtCarryingValue_637521119670373829" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_ReductionToResearchAndDevelopmentExpense" xlink:label="sava_ReductionToResearchAndDevelopmentExpense_637521119670373829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sava_ReductionToResearchAndDevelopmentExpense_637521119670373829" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_637521119670373829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NumberOfOperatingSegments_637521119670373829" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637521119670373829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637521119670373829" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary Of Significant Accounting Policies (Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_635240128367044116" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637521119670373829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_635240128367044116" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637521119670373829" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637521119670373829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637521119670373829" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637521119670373829" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637521119670373829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637521119670373829" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637521119670373829" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637521119670373829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637521119670373829" xlink:to="us-gaap_EmployeeStockOptionMember_637521119670373829" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_637521119670373829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637521119670373829" xlink:to="us-gaap_WarrantMember_637521119670373829" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637521119670373829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637521119670373829" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637521119670373829" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract_637521119670373829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637521119670373829" xlink:to="us-gaap_NetIncomeLossAbstract_637521119670373829" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637521119670373829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_637521119670373829" xlink:to="us-gaap_NetIncomeLoss_637521119670373829" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_637521119670373829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637521119670373829" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_637521119670373829" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637521119670373829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_637521119670373829" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637521119670373829" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_637521119670373829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637521119670373829" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_637521119670373829" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637521119670373829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637521119670373829" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637521119670373829" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentNarrativeDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Property And Equipment (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637521119670373829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637521119670373829" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637521119670373829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637521119670373829" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637521119670373829" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637521119670373829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637521119670373829" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637521119670373829" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_637521119670383801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637521119670373829" xlink:to="us-gaap_EquipmentMember_637521119670383801" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637521119670383801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637521119670373829" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637521119670383801" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_637521119670383801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637521119670383801" xlink:to="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_637521119670383801" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637521119670383801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637521119670383801" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637521119670383801" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637521119670383801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637521119670383801" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637521119670383801" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637521119670383801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637521119670383801" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637521119670383801" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637521119670383801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637521119670383801" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637521119670383801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637521119670383801" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637521119670383801" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637521119670383801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637521119670383801" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637521119670383801" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_WarrantsMember" xlink:label="sava_WarrantsMember_637521119670383801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637521119670383801" xlink:to="sava_WarrantsMember_637521119670383801" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_PlacementAgentWarrantsMember" xlink:label="sava_PlacementAgentWarrantsMember_637521119670383801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637521119670383801" xlink:to="sava_PlacementAgentWarrantsMember_637521119670383801" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637521119670383801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637521119670383801" xlink:to="us-gaap_StatementClassOfStockAxis_637521119670383801" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637521119670383801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637521119670383801" xlink:to="us-gaap_ClassOfStockDomain_637521119670383801" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637521119670383801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637521119670383801" xlink:to="us-gaap_CommonStockMember_637521119670383801" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637521119670383801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637521119670383801" xlink:to="us-gaap_AwardTypeAxis_637521119670383801" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637521119670383801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637521119670383801" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637521119670383801" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_637521119670383801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637521119670383801" xlink:to="us-gaap_PerformanceSharesMember_637521119670383801" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637521119670383801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637521119670383801" xlink:to="us-gaap_PlanNameAxis_637521119670383801" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637521119670383801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637521119670383801" xlink:to="us-gaap_PlanNameDomain_637521119670383801" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_RegisteredDirectOffering2021Member" xlink:label="sava_RegisteredDirectOffering2021Member_637521119670383801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637521119670383801" xlink:to="sava_RegisteredDirectOffering2021Member_637521119670383801" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_PublicOfferingMember" xlink:label="sava_PublicOfferingMember_637521119670383801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637521119670383801" xlink:to="sava_PublicOfferingMember_637521119670383801" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_CommonStockWarrantsMember" xlink:label="sava_CommonStockWarrantsMember_637521119670383801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637521119670383801" xlink:to="sava_CommonStockWarrantsMember_637521119670383801" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_AtMarketEquityProgramMember" xlink:label="sava_AtMarketEquityProgramMember_637521119670383801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637521119670383801" xlink:to="sava_AtMarketEquityProgramMember_637521119670383801" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_TwoThousandEightEquityIncentivePlanMember" xlink:label="sava_TwoThousandEightEquityIncentivePlanMember_637521119670383801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637521119670383801" xlink:to="sava_TwoThousandEightEquityIncentivePlanMember_637521119670383801" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_TwoThousandEighteenEquityIncentivePlanMember" xlink:label="sava_TwoThousandEighteenEquityIncentivePlanMember_637521119670383801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637521119670383801" xlink:to="sava_TwoThousandEighteenEquityIncentivePlanMember_637521119670383801" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637521119670383801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637521119670383801" xlink:to="srt_RangeAxis_637521119670383801" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637521119670383801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637521119670383801" xlink:to="srt_RangeMember_637521119670383801" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637521119670383801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637521119670383801" xlink:to="srt_MaximumMember_637521119670383801" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637521119670383801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637521119670383801" xlink:to="srt_MinimumMember_637521119670383801" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637521119670393755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637521119670383801" xlink:to="us-gaap_SubsequentEventTypeAxis_637521119670393755" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637521119670393755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637521119670393755" xlink:to="us-gaap_SubsequentEventTypeDomain_637521119670393755" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637521119670393755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637521119670393755" xlink:to="us-gaap_SubsequentEventMember_637521119670393755" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670393755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637521119670383801" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670393755" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_637521119670393755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670393755" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_637521119670393755" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare_637521119670393755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670393755" xlink:to="us-gaap_SaleOfStockPricePerShare_637521119670393755" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637521119670393755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670393755" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637521119670393755" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637521119670393755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670393755" xlink:to="us-gaap_ProceedsFromWarrantExercises_637521119670393755" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_637521119670393755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670393755" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_637521119670393755" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_637521119670393755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670393755" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_637521119670393755" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_PercentageOfCommissionAtmOffering" xlink:label="sava_PercentageOfCommissionAtmOffering_637521119670393755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670393755" xlink:to="sava_PercentageOfCommissionAtmOffering_637521119670393755" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637521119670393755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670393755" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637521119670393755" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm_637521119670393755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670393755" xlink:to="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm_637521119670393755" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637521119670393755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670393755" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637521119670393755" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod_637521119670393755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670393755" xlink:to="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod_637521119670393755" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm_637521119670393755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670393755" xlink:to="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm_637521119670393755" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637521119670403724" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670393755" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637521119670403724" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637521119670403724" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670393755" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637521119670403724" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting" xlink:label="sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting_637521119670403724" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670393755" xlink:to="sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting_637521119670403724" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_637521119670403724" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670393755" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_637521119670403724" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_637521119670403724" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670393755" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_637521119670403724" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637521119670403724" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670393755" xlink:to="us-gaap_CommonStockSharesAuthorized_637521119670403724" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637521119670403724" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670393755" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637521119670403724" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_637521119670403724" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670393755" xlink:to="us-gaap_SharesIssued_637521119670403724" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationWarrantsOutstandingDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Warrants Outstanding) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637521119670423678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637521119670423678" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637521119670423678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637521119670423678" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637521119670423678" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637521119670423678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637521119670423678" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637521119670423678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_WarrantsMember" xlink:label="sava_WarrantsMember_637521119670423678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637521119670423678" xlink:to="sava_WarrantsMember_637521119670423678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_PlacementAgentWarrantsMember" xlink:label="sava_PlacementAgentWarrantsMember_637521119670423678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637521119670423678" xlink:to="sava_PlacementAgentWarrantsMember_637521119670423678" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670423678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637521119670423678" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670423678" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_637521119670423678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670423678" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_637521119670423678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_637521119670423678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670423678" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_637521119670423678" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637521119670423678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670423678" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637521119670423678" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_637521119670423678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670423678" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_637521119670423678" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockOptionActivityDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Stock Option Activity) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637521119670423678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637521119670423678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637521119670423678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637521119670423678" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637521119670423678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637521119670423678" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637521119670423678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637521119670423678" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6375211196704236781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6375211196704236781" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_637521119670423678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_637521119670423678" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637521119670423678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637521119670423678" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637521119670423678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637521119670423678" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637521119670423678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637521119670423678" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637521119670423678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637521119670423678" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637521119670423678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637521119670423678" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6375211196704236781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6375211196704236781" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_637521119670423678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_637521119670423678" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637521119670423678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637521119670423678" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637521119670423678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637521119670423678" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_637521119670423678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_637521119670423678" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637521119670433658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637521119670433658" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637521119670433658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637521119670433658" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_637521119670433658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_637521119670433658" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637521119670433658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637521119670433658" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails" xlink:type="extended" xlink:title="40404 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Information About Stock Options Outstanding) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_637521119670433658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_637521119670433658" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637521119670433658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_637521119670433658" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637521119670433658" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637521119670433658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637521119670433658" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637521119670433658" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_RangeOneMember" xlink:label="sava_RangeOneMember_637521119670433658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637521119670433658" xlink:to="sava_RangeOneMember_637521119670433658" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_RangeTwoMember" xlink:label="sava_RangeTwoMember_637521119670433658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637521119670433658" xlink:to="sava_RangeTwoMember_637521119670433658" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_RangeThreeMember" xlink:label="sava_RangeThreeMember_637521119670433658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637521119670433658" xlink:to="sava_RangeThreeMember_637521119670433658" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_RangeFourMember" xlink:label="sava_RangeFourMember_637521119670433658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637521119670433658" xlink:to="sava_RangeFourMember_637521119670433658" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_RangeFiveMember" xlink:label="sava_RangeFiveMember_637521119670433658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637521119670433658" xlink:to="sava_RangeFiveMember_637521119670433658" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637521119670433658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_637521119670433658" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637521119670433658" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_637521119670433658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637521119670433658" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_637521119670433658" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_637521119670433658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637521119670433658" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_637521119670433658" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_637521119670433658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637521119670433658" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_637521119670433658" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_637521119670433658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637521119670433658" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_637521119670433658" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_637521119670433658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637521119670433658" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_637521119670433658" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_637521119670433658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637521119670433658" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_637521119670433658" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_637521119670433658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637521119670433658" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_637521119670433658" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationWeightedAverageFairValueOfOptionsGrantedDetails" xlink:type="extended" xlink:title="40405 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Weighted Average Fair Value Of Options Granted) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_637521119670433658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_637521119670433658" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_637521119670433658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_637521119670433658" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_637521119670433658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_637521119670433658" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_637521119670433658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_637521119670433658" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637521119670433658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637521119670433658" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637521119670433658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637521119670433658" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_637521119670443637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_637521119670443637" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637521119670443637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637521119670443637" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationSummaryOfPerformanceAwardActivityDetails" xlink:type="extended" xlink:title="40406 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Summary Of Performance Award Activity) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637176597182574833" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637521119670443637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637176597182574833" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637521119670443637" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637521119670443637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637521119670443637" xlink:to="us-gaap_AwardTypeAxis_637521119670443637" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637521119670443637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637521119670443637" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637521119670443637" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_637521119670443637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637521119670443637" xlink:to="us-gaap_PerformanceSharesMember_637521119670443637" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670443637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637521119670443637" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670443637" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637521119670443637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670443637" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637521119670443637" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637521119670443637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670443637" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637521119670443637" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_637521119670443637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670443637" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_637521119670443637" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_637521119670443637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670443637" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_637521119670443637" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6375211196704436371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637521119670443637" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6375211196704436371" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNonCashStockBasedCompensationExpensesDetails" xlink:type="extended" xlink:title="40407 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Non-Cash Stock-Based Compensation Expenses) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637521119670443637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637521119670443637" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637521119670443637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637521119670443637" xlink:to="us-gaap_IncomeStatementLocationAxis_637521119670443637" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637521119670443637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637521119670443637" xlink:to="us-gaap_IncomeStatementLocationDomain_637521119670443637" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637521119670443637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637521119670443637" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637521119670443637" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_637521119670443637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637521119670443637" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_637521119670443637" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637521119670443637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637521119670443637" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637521119670443637" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637521119670443637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637521119670443637" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637521119670443637" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Income Taxes (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_637521119670443637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable_637521119670443637" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_637521119670443637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637521119670443637" xlink:to="us-gaap_IncomeTaxAuthorityAxis_637521119670443637" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_637521119670443637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_637521119670443637" xlink:to="us-gaap_IncomeTaxAuthorityDomain_637521119670443637" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_637521119670443637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637521119670443637" xlink:to="us-gaap_DomesticCountryMember_637521119670443637" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:label="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_637521119670443637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637521119670443637" xlink:to="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_637521119670443637" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="us-gaap_DeferredTaxAssetDomain_637521119670443637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_637521119670443637" xlink:to="us-gaap_DeferredTaxAssetDomain_637521119670443637" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_WriteDownOfShareBasedCompensationMember" xlink:label="sava_WriteDownOfShareBasedCompensationMember_637521119670443637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetDomain_637521119670443637" xlink:to="sava_WriteDownOfShareBasedCompensationMember_637521119670443637" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_BookLossesMember" xlink:label="sava_BookLossesMember_637521119670443637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetDomain_637521119670443637" xlink:to="sava_BookLossesMember_637521119670443637" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637521119670443637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637521119670443637" xlink:to="srt_RangeAxis_637521119670443637" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637521119670443637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637521119670443637" xlink:to="srt_RangeMember_637521119670443637" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637521119670443637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637521119670443637" xlink:to="srt_MinimumMember_637521119670443637" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637521119670443637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637521119670443637" xlink:to="srt_MaximumMember_637521119670443637" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637521119670453596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637521119670443637" xlink:to="srt_StatementScenarioAxis_637521119670453596" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637521119670453596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637521119670453596" xlink:to="srt_ScenarioUnspecifiedDomain_637521119670453596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_ExpiresBetween2029And2039Member" xlink:label="sava_ExpiresBetween2029And2039Member_637521119670453596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637521119670453596" xlink:to="sava_ExpiresBetween2029And2039Member_637521119670453596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_IndefinitelyMember" xlink:label="sava_IndefinitelyMember_637521119670453596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637521119670453596" xlink:to="sava_IndefinitelyMember_637521119670453596" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_ExpiresBetween2023And2039Member" xlink:label="sava_ExpiresBetween2023And2039Member_637521119670453596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637521119670453596" xlink:to="sava_ExpiresBetween2023And2039Member_637521119670453596" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_637521119670453596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637521119670443637" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_637521119670453596" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637521119670453596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637521119670453596" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637521119670453596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637521119670453596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637521119670453596" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637521119670453596" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_637521119670453596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637521119670453596" xlink:to="us-gaap_OperatingLossCarryforwards_637521119670453596" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate_637521119670453596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637521119670453596" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate_637521119670453596" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate_637521119670453596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637521119670453596" xlink:to="us-gaap_TaxCreditCarryforwardExpirationDate_637521119670453596" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_637521119670453596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637521119670453596" xlink:to="us-gaap_TaxCreditCarryforwardAmount_637521119670453596" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_637521119670453596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637521119670453596" xlink:to="us-gaap_UnrecognizedTaxBenefits_637521119670453596" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Income Taxes (Schedule Of Effective Income Tax Rate Reconciliation) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637521119670453596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637521119670453596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637521119670453596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637521119670453596" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_637521119670453596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_637521119670453596" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_637521119670453596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_637521119670453596" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637521119670453596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637521119670453596" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637521119670453596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637521119670453596" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Income Taxes (Schedule Of Deferred Tax Assets And Valuation Allowance) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_637521119670453596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_637521119670453596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637521119670453596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_637521119670453596" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637521119670453596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637521119670453596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637521119670453596" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637521119670453596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637521119670453596" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_637521119670453596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther_637521119670453596" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637521119670453596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross_637521119670453596" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637521119670453596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637521119670453596" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_637521119670463576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet_637521119670463576" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_637521119670463576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_637521119670463576" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_637521119670463576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_637521119670463576" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_637521119670463576" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_637521119670463576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_637521119670463576" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_637521119670463576" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_637521119670463576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_637521119670463576" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_637521119670463576" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities_637521119670463576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_637521119670463576" xlink:to="us-gaap_DeferredTaxLiabilities_637521119670463576" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="extended" xlink:title="40604 - Disclosure - Income Taxes (Schedule Of Unrecognized Tax Benefits) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_637521119670463576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_637521119670463576" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_637521119670463576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_637521119670463576" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_6375211196704635761" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_6375211196704635761" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsNarrativeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Leases And Commitments (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_LeasesAndCommitmentsAbstract" xlink:label="sava_LeasesAndCommitmentsAbstract" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_LeasesAndCommitmentsTable" xlink:label="sava_LeasesAndCommitmentsTable_637521119670463576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsAbstract" xlink:to="sava_LeasesAndCommitmentsTable_637521119670463576" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637521119670463576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsTable_637521119670463576" xlink:to="srt_StatementGeographicalAxis_637521119670463576" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637521119670463576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637521119670463576" xlink:to="srt_SegmentGeographicalDomain_637521119670463576" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_AustinMember" xlink:label="sava_AustinMember_637521119670463576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637521119670463576" xlink:to="sava_AustinMember_637521119670463576" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_LeasesAndCommitmentsLineItems" xlink:label="sava_LeasesAndCommitmentsLineItems_637521119670463576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsTable_637521119670463576" xlink:to="sava_LeasesAndCommitmentsLineItems_637521119670463576" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea_637521119670463576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsLineItems_637521119670463576" xlink:to="us-gaap_NetRentableArea_637521119670463576" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1_637521119670463576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsLineItems_637521119670463576" xlink:to="us-gaap_LeaseExpirationDate1_637521119670463576" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense_637521119670463576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsLineItems_637521119670463576" xlink:to="us-gaap_LeaseAndRentalExpense_637521119670463576" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637521119670463576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsLineItems_637521119670463576" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637521119670463576" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637521119670463576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsLineItems_637521119670463576" xlink:to="us-gaap_OperatingLeaseLiability_637521119670463576" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_637521119670463576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsLineItems_637521119670463576" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_637521119670463576" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637521119670463576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsLineItems_637521119670463576" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637521119670463576" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_637521119670463576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsLineItems_637521119670463576" xlink:to="us-gaap_OperatingLeasePayments_637521119670463576" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsFutureMinimumLeasePaymentsDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Leases And Commitments (Future Minimum Lease Payments) (Details)">
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_LeasesAndCommitmentsAbstract" xlink:label="sava_LeasesAndCommitmentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637521119670463576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637521119670463576" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637521119670463576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637521119670463576" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637521119670463576" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637521119670463576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637521119670463576" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637521119670463576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637521119670463576" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637521119670473539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637521119670473539" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637521119670473539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637521119670473539" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637521119670473539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637521119670473539" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637521119670473539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsAbstract" xlink:to="us-gaap_OperatingLeaseLiability_637521119670473539" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails" xlink:type="extended" xlink:title="40801 - Disclosure - 2020 Cash Incentive Bonus Plan (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_CashIncentiveBonusPlanAbstract" xlink:label="sava_CashIncentiveBonusPlanAbstract_637399223356820786" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_CashIncentiveBonusPlanTable" xlink:label="sava_CashIncentiveBonusPlanTable_637521119670473539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanAbstract_637399223356820786" xlink:to="sava_CashIncentiveBonusPlanTable_637521119670473539" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637521119670473539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanTable_637521119670473539" xlink:to="srt_RangeAxis_637521119670473539" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637521119670473539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637521119670473539" xlink:to="srt_RangeMember_637521119670473539" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637521119670473539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637521119670473539" xlink:to="srt_MinimumMember_637521119670473539" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637521119670473539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637521119670473539" xlink:to="srt_MaximumMember_637521119670473539" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637521119670473539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanTable_637521119670473539" xlink:to="us-gaap_PlanNameAxis_637521119670473539" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637521119670473539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637521119670473539" xlink:to="us-gaap_PlanNameDomain_637521119670473539" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_CashIncentiveBonusPlanMember" xlink:label="sava_CashIncentiveBonusPlanMember_637521119670473539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637521119670473539" xlink:to="sava_CashIncentiveBonusPlanMember_637521119670473539" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637521119670473539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanTable_637521119670473539" xlink:to="srt_StatementScenarioAxis_637521119670473539" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637521119670473539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637521119670473539" xlink:to="srt_ScenarioUnspecifiedDomain_637521119670473539" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_Exceeds5BillionMarketCapitalizationMember" xlink:label="sava_Exceeds5BillionMarketCapitalizationMember_637521119670473539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637521119670473539" xlink:to="sava_Exceeds5BillionMarketCapitalizationMember_637521119670473539" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_FirstValuationMilestoneMember" xlink:label="sava_FirstValuationMilestoneMember_637521119670473539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637521119670473539" xlink:to="sava_FirstValuationMilestoneMember_637521119670473539" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_SecondThroughEighthValuationMilestonesMember" xlink:label="sava_SecondThroughEighthValuationMilestonesMember_637521119670473539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637521119670473539" xlink:to="sava_SecondThroughEighthValuationMilestonesMember_637521119670473539" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637521119670473539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanTable_637521119670473539" xlink:to="us-gaap_SubsequentEventTypeAxis_637521119670473539" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637521119670473539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637521119670473539" xlink:to="us-gaap_SubsequentEventTypeDomain_637521119670473539" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637521119670473539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637521119670473539" xlink:to="us-gaap_SubsequentEventMember_637521119670473539" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_CashIncentiveBonusPlanLineItems" xlink:label="sava_CashIncentiveBonusPlanLineItems_637521119670473539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanTable_637521119670473539" xlink:to="sava_CashIncentiveBonusPlanLineItems_637521119670473539" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_PerformancePlanValuationAmount" xlink:label="sava_PerformancePlanValuationAmount_637521119670473539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanLineItems_637521119670473539" xlink:to="sava_PerformancePlanValuationAmount_637521119670473539" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment_637521119670473539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanLineItems_637521119670473539" xlink:to="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment_637521119670473539" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_CashIncentiveBonusAward" xlink:label="sava_CashIncentiveBonusAward_637521119670473539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanLineItems_637521119670473539" xlink:to="sava_CashIncentiveBonusAward_637521119670473539" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="sava-20201231.xsd#sava_PaymentsForCashIncentiveBonus" xlink:label="sava_PaymentsForCashIncentiveBonus_637521119670473539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanLineItems_637521119670473539" xlink:to="sava_PaymentsForCashIncentiveBonus_637521119670473539" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797649157896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 18, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-29959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CASSAVA SCIENCES INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">91-1911336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7801 N. Capital of Texas Highway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Austin<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">78731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">501-2444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">sava<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,146,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,898,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
			<font style="display: inline;font-size:8pt;">Portions of the Registrant's Proxy Statement for its 2021 Annual Meeting of Stockholders (the Proxy Statement), to be filed with the U.S. Securities and Exchange Commission, are incorporated by reference to Part III of this Form 10-K Report.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001069530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797649395096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 93,506<span></span>
</td>
<td class="nump">$ 23,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">488<span></span>
</td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">93,994<span></span>
</td>
<td class="nump">23,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">295<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">94,300<span></span>
</td>
<td class="nump">23,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">911<span></span>
</td>
<td class="nump">453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued development expense</a></td>
<td class="nump">719<span></span>
</td>
<td class="nump">777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,865<span></span>
</td>
<td class="nump">1,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">235<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">1,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7 and 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $.001 par value; 10,000,000 shares authorized, none issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.001 par value; 120,000,000 shares authorized; 35,237,987 and 21,841,810 shares issued and outstanding at December 31, 2020 and 2019, respectively</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">267,086<span></span>
</td>
<td class="nump">190,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(174,921)<span></span>
</td>
<td class="num">(168,587)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">92,200<span></span>
</td>
<td class="nump">22,099<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 94,300<span></span>
</td>
<td class="nump">$ 23,486<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797648993944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Balance Sheets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">35,237,987<span></span>
</td>
<td class="nump">21,841,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">35,237,987<span></span>
</td>
<td class="nump">21,841,810<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797649363368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements Of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement', window );">Research and development, net of grant reimbursement</a></td>
<td class="nump">$ 3,053<span></span>
</td>
<td class="nump">$ 1,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,739<span></span>
</td>
<td class="nump">3,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of property and equipment</a></td>
<td class="num">(346)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">6,446<span></span>
</td>
<td class="nump">4,959<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(6,446)<span></span>
</td>
<td class="num">(4,959)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest income</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,334)<span></span>
</td>
<td class="num">$ (4,631)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares used in computing net loss per share, basic and diluted</a></td>
<td class="nump">26,105<span></span>
</td>
<td class="nump">17,412<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Expense, Net Of Grant Reimbursement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797648921720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements Of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-In Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 183,567<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (163,956)<span></span>
</td>
<td class="nump">$ 19,628<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2018</a></td>
<td class="nump">17,219,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan', window );">Stock options for employees</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,287<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock options for non-employees</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs from 2018 sale of common stock and warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(60)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock pursuant to exercise of warrants</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">5,861<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock pursuant to exercise of warrants, shares</a></td>
<td class="nump">4,622,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,631)<span></span>
</td>
<td class="num">(4,631)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">190,664<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(168,587)<span></span>
</td>
<td class="nump">22,099<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2019</a></td>
<td class="nump">21,841,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan', window );">Stock options for employees</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">961<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock options for non-employees</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">256<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options, shares</a></td>
<td class="nump">71,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock pursuant to exercise of warrants</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">4,936<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock pursuant to exercise of warrants, shares</a></td>
<td class="nump">3,950,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued in conjunction with follow-on public offering, net of issuance costs</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">70,242<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">70,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued in conjunction with follow-on public offering, net of issuance costs, shares</a></td>
<td class="nump">9,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,334)<span></span>
</td>
<td class="num">(6,334)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 267,086<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (174,921)<span></span>
</td>
<td class="nump">$ 92,200<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2020</a></td>
<td class="nump">35,237,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109244457&amp;loc=d3e16649-113920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797649011848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements Of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,334)<span></span>
</td>
<td class="num">$ (4,631)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="nump">988<span></span>
</td>
<td class="nump">1,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of property and equipment</a></td>
<td class="num">(346)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="num">(220)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet', window );">Operating lease right-of-use assets and liabilities</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">458<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued development expense</a></td>
<td class="num">(58)<span></span>
</td>
<td class="nump">621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and benefits</a></td>
<td class="nump">25<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(5,382)<span></span>
</td>
<td class="num">(2,514)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">360<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs from 2018 sale of common stock and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of common stock warrants</a></td>
<td class="nump">4,940<span></span>
</td>
<td class="nump">5,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_ProceedsFromIssuanceFollowOnPublicOfferingNetOfIssuanceCosts', window );">Proceeds from follow-on public offering, net of issuance costs</a></td>
<td class="nump">70,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">75,447<span></span>
</td>
<td class="nump">5,806<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">70,425<span></span>
</td>
<td class="nump">3,274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">23,081<span></span>
</td>
<td class="nump">19,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 93,506<span></span>
</td>
<td class="nump">$ 23,081<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease In Operating Lease Right Of Use Assets and Liabilities, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ProceedsFromIssuanceFollowOnPublicOfferingNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Follow On Public Offering, Net Of Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ProceedsFromIssuanceFollowOnPublicOfferingNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797657444008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General And Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>General And Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">General And Liquidity</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">1.&nbsp;&nbsp;General and Liquidity</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Cassava Sciences, Inc. (the Company), formerly known as Pain Therapeutics, Inc., develops proprietary products that offer significant improvements to patients and healthcare professionals. The Company generally focuses its product development efforts on disorders of the nervous system. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">Coronavirus Disease 2019 (COVID-19)</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The</font><font style="display: inline;"> recent, widespread outbreak of a novel infectious disease called Coronavirus Disease 2019, or COVID-19, has not significantly impacted the Company&#x2019;s operations or financial condition as of March&nbsp;23, 2021. </font><font style="display: inline;">However, this pandemic has created a dynamic and uncertain situation in the national economy. The Company continues to closely monitor the latest information to make timely, informed business decisions and public disclosures regarding the potential impact of pandemic on its operations and financial condition. The scope of pandemic is unprecedented and its long-term impact on the Company&#x2019;s operations and financial condition cannot be reasonably estimated at this time.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Liquidity&nbsp; </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company has incurred significant net losses and negative cash flows since inception, and as a result has an accumulated deficit of $174.9&nbsp;million at December&nbsp;31, 2020. The Company expects its cash requirements to be significant in the future. The amount and timing of its future cash requirements will depend on regulatory and market acceptance of the Company&#x2019;s product candidates and the resources it devotes to researching and developing, formulating, manufacturing, commercializing and supporting its products. The Company may seek additional future funding through public or private financing in the future, if such funding is available and on terms acceptable to the Company. There are no assurances that additional financing will be available on favorable terms, or at all. However, management believes that the current working capital position will be sufficient to meet the Company&#x2019;s working capital needs for at least the next 12 months.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797650987672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary Of Significant Accounting Policies</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">2.&nbsp;&nbsp;Summary of Significant Accounting Policies</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Use of Estimates</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. Actual results could differ from those estimates.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Proceeds from Grants</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In 2020, the Company received </font><font style="display: inline;">$4.2</font><font style="display: inline;">&nbsp;million of reimbursement from the National Institutes of Health and National Institute on Drug Abuse and </font><font style="display: inline;">$4.7</font><font style="display: inline;">&nbsp;million in 2019. The Company records the proceeds from these grants as reductions to its research and development expenses.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Cash and Cash Equivalents and Concentration of Credit Risk</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company invests in cash and cash equivalents and, in the past, marketable securities. The Company considers highly-liquid financial instruments with original maturities of three months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts, money market funds and certificates of deposit. The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company&#x2019;s investment policy allows for investments in marketable securities with active secondary or resale markets, establishes diversification and credit quality requirements and limits investments by maturity and issuer. The Company maintains its investments at one financial institution. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Fair Value Measurements </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company reports its cash and cash equivalents at fair value as Level 1, Level 2 or Level 3 using the following inputs:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<a name="_9eed50031d7a4ae08d8481e27454a126"></a><a name="_a55395c9dddb484ab9d7fe2cd900ad3a"></a><a name="_9c970aca55e541dc8a21fc5af6a42932"></a><a name="_c95ddda386b84ea0a6341120a7f1021f"></a><a name="_3c0ffcf4570c456cbc299897392e42d9"></a><a name="_dee475e5298f41189ad89abce51b465d"></a><a name="_56802d68c6a94dbe9fcf1274361e7f37"></a><a name="_5121355f7d274c19a6859f83034a8dd4"></a><a name="_adff7fd0d1df49cfbd1d486e06beadfa"></a><a name="_d9e1ff57a6464ab6a179624ab81cda10"></a><a name="_a6d0459d796849d2b1866055cd140477"></a><a name="_6967f826ca9b4f0f9b986e3e324d9161"></a><a name="_5a3701addc544c73a9d512b8e9743988"></a><a name="_c3da333d461e4520b3a037507e639721"></a><a name="_7878265e95384b81ae1b7f17224656fd"></a><a name="_b691c60198414d559b1914e876b580a1"></a><a name="_7fb1ed58d627447ab56cfbe9d52d6120"></a><a name="_be8d133366f34f6686cef9d21c16f0a3"></a><a name="_e3b5f0a49cfe4f04a7282b95d681b7ce"></a><a name="_932ab8c8a3574e5a87e70dc56597bb6f"></a><a name="_9fb551aa76e3415c984cffa1491a23ea"></a><a name="_1746df8b27fc41ef992b25383e220984"></a><a name="_0c3de46198274b128860550988ef844d"></a><a name="_75dfd0ae686c45b99fde81a8d35908b3"></a><a name="_d9318bc5124f4b7c97afcc172b32ae28"></a><a name="_6310384476c740cf8e641c9a413eb968"></a><a name="_91d164c9544945c48fd3a86929e64fd4"></a><a name="_973c93b3770b4476a04247143aaf5d5a"></a><a name="_9d4e208743764419adbb1942938e565a"></a><a name="_e2f59ee1432249b792889c80e60b08d7"></a><a name="_f6345b5294af4fef90374149482d4f46"></a><a name="_d48429101312494397f78e2250f832e4"></a><a name="_bdc2c9f8bbfb466e81aff2540dc06056"></a><font style="display: inline;color:#000000;">Level 1 includes quoted prices in active markets. The Company bases the fair value of money market funds on Level 1 inputs.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Level 2 includes significant observable inputs, such as quoted prices for identical or similar investments, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from third-party providers. It uses the bid price to establish fair value where a bid price is available. The Company bases the fair value of its certificates of deposit, if any, on Level 2 inputs.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Level 3 includes unobservable inputs that are supported by little or no market activity. The Company does not have any investments where the fair value is based on Level 3 inputs.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. A certificate of deposit totaling </font><font style="display: inline;color:#000000;">$13.0</font><font style="display: inline;color:#000000;">&nbsp;million at December&nbsp;31, 2019 was included within cash equivalents as a Level 2 input. The fair value of the remainder of cash and cash equivalents, including money market accounts, was based on Level 1 inputs at December&nbsp;31, 2020 and 2019.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Business Segments</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&#x2019;s operations are confined to </font><font style="display: inline;color:#000000;">one</font><font style="display: inline;color:#000000;"> business segment: the development of novel drugs and diagnostics.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Stock-based Compensation</font><font style="display: inline;font-weight:bold;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each </font><a name="_cp_text_1_372"></a><font style="display: inline;color:#000000;">award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management's judgment. The Company recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally </font><font style="display: inline;color:#000000;">four</font><font style="display: inline;color:#000000;"> years. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The Company has granted share-based awards that vest upon achievement of certain performance criteria, or performance awards. The Company multiplies the number of performance awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. The Company periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance awards vest and common stock is issued upon achievement of the performance criteria.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Net Loss per Share</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Basic net loss per share is computed on the basis of the weighted-average number of common shares outstanding for the reporting period. Diluted net loss per share is computed on the basis of the weighted-average number of common shares outstanding plus dilutive potential common shares outstanding using the treasury-stock method. Potential dilutive common shares consist of outstanding equity awards and warrants. There is no difference between the Company&#x2019;s net loss and comprehensive loss. The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands, except net loss per share data):</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:24.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:24.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Year ended December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;">Numerator:</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">(6,334)
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">(4,631)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;">Denominator:</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;">Shares used in computing net loss per share, basic and diluted</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">26,105&nbsp;
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">17,412&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;">Net loss per share, basic and diluted</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">(0.24)
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">(0.27)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;"> Dilutive common stock options excluded from net loss per share, diluted</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">2,145&nbsp;
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">2,932&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;"> Common stock warrants excluded from net loss per share, diluted</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">554&nbsp;
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">4,504&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The Company excluded weighted equity awards and warrants outstanding to purchase common stock from the calculation of diluted net loss per share because the effect of including these shares in this calculation would be anti-dilutive.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-family:Tahoma;font-size:1pt;color:#000000;">&#xFEFF;</font><font style="display: inline;font-size:1pt;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Fair Value of Financial Instruments</font><font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Financial instruments include cash and cash equivalents, accounts payable and accrued liabilities. The estimated fair value of financial instruments has been determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies may be material to the estimated fair value amounts. The carrying amounts of cash and cash equivalents, accounts payable and accrued liabilities are at cost, which approximates fair value due to the short maturity of those instruments.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Research Contract Costs and Accruals</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The Company has entered into various research and development contracts with research institutions and other third-party vendors. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical accrual estimates have not been materially different from actual costs.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Incentive Bonus Plan</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">In 2020, the Company established the 2020 Cash Incentive Bonus Plan (the &#x201C;Plan&#x201D;) to incentivize Plan participants.&nbsp;&nbsp;Awards under the Plan are accounted for as liability awards under ASC 718 &#x201C;</font><font style="display: inline;font-style:italic;color:#000000;">Stock-based Compensation</font><font style="display: inline;color:#000000;">&#x201D;.&nbsp;The fair value of each&nbsp;potential Plan&nbsp;award&nbsp;will be&nbsp;determined&nbsp;once&nbsp;a&nbsp;grant date occurs and&nbsp;will be&nbsp;remeasured each reporting period.&nbsp;Compensation expense associated with the Plan&nbsp;will be&nbsp;recognized over the expected achievement period for each&nbsp;Plan award, when&nbsp;a Performance Condition&nbsp;is considered probable of being met.&nbsp;&nbsp;See Note 8 for further discussion of the Plan.</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Leases</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The Company recognizes&nbsp;assets and liabilities that arise from leases.&nbsp;For operating leases, the Company is required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, in the&nbsp;statements&nbsp;of financial position.&nbsp;As the Company`s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Income Taxes</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The Company accounts for income taxes under the asset and liability method.&nbsp;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. &nbsp;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&nbsp;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The Company accounts for uncertain tax positions in accordance with ASC 740, &#x201C;Income Taxes&#x201D;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&#x2019;s financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Recent Accounting Pronouncements</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The Company reviewed recently issued accounting pronouncements and plan to adopt those that are applicable to it, and does not expect the adoption of these pronouncements to have a material impact on its financial position, results of operations or cash flows. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">In December 2019, the FABS issued ASU No. 2019-12, </font><font style="display: inline;font-style:italic;color:#000000;">Income Taxes (Topic 740) Simplifying Accounting for Income Taxes </font><font style="display: inline;color:#000000;">as part of its initiative to reduce complexity in the accounting standards. The guidance amended certain disclosure requirements that had become redundant, outdated or superseded. Additionally, this guidance amends accounting for the interim period effects of changes in tax laws or rates and simplifies aspects of the accounting for franchise taxes. The guidance is effective for annual periods beginning after December&nbsp;15, 2020, and is applicable for the Company in fiscal year 2021. Early adoption is permitted. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">In November 2018, the FASB issued ASU No. 2018-18, </font><font style="display: inline;font-style:italic;color:#000000;">Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606. </font><font style="display: inline;color:#000000;">The amendments in this update provide guidance on how to assess whether certain transactions between collaborative arrangement participants should be accounted for within the revenue recognition standard. The amendments in this update are effective for interim and annual periods for the Company beginning on January&nbsp;1, 2020. </font><font style="display: inline;color:#000000;">The adoption of this guidance did not have a material impact on&nbsp;the Company&#x2019;s&nbsp;financial statements.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;background-color: #FFFFFF;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;background-color: #FFFFFF;">In August 2018, the FASB issued ASU </font><font style="display: inline;color:#000000;">No. 2018-13,</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">&nbsp;</font><font style="display: inline;font-style:italic;color:#000000;">Fair Value Measurement (Topic 820) - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</font><font style="display: inline;color:#000000;background-color: #FFFFFF;"> (ASU </font><font style="display: inline;color:#000000;">2018-13),</font><font style="display: inline;color:#000000;background-color: #FFFFFF;"> which is designed to improve the effectiveness of disclosures by removing, modifying and adding disclosures related to fair value measurements. ASU </font><font style="display: inline;color:#000000;">2018-13</font><font style="display: inline;color:#000000;background-color: #FFFFFF;"> is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The adoption of ASU 2018-13 did not have a material impact on&nbsp;the Company&#x2019;s&nbsp;financial statements.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797657402344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property And Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property And Equipment</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">3.&nbsp;&nbsp;Property and Equipment</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company&#x2019;s property and equipment</font><font style="display: inline;"> include furniture and equipment</font><font style="display: inline;">. Depreciation is recognized using the straight-line method over the expected life of the property and equipment.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">During the&nbsp;year ended&nbsp;December&nbsp;31, 2020, the Company sold surplus manufacturing equipment to an independent third party and received proceeds totaling </font><font style="display: inline;color:#000000;font-size:10pt;">$360,000</font><font style="display: inline;color:#000000;font-size:10pt;">.&nbsp;The original&nbsp;cost of the property and equipment was </font><font style="display: inline;font-size:10pt;">$892,000</font><font style="display: inline;font-size:10pt;">&nbsp;and accumulated depreciation was </font><font style="display: inline;font-size:10pt;">$878,000</font><font style="display: inline;font-size:10pt;">,&nbsp;resulting a gain on sale&nbsp;of property and equipment of </font><font style="display: inline;font-size:10pt;">$346,000</font><font style="display: inline;font-size:10pt;">&nbsp;during the&nbsp;year ended&nbsp;December&nbsp;31, 2020. There were </font><font style="display: inline;font-size:10pt;">no</font><font style="display: inline;font-size:10pt;"> sales of property and equipment during year ended&nbsp;December&nbsp;31, 2019.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797664660488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity And Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stockholders' Equity And Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Stockholders' Equity And Stock-Based Compensation</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">4.&nbsp;&nbsp;Stockholders' Equity and Stock-Based Compensation</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Preferred Stock</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company&#x2019;s Board of Directors (the &#x201C;Board&#x201D;) has the authority to issue preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number of shares constituting any series or the designation of the series.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">2021 Registered Direct Offering</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">On February&nbsp;12, 2021, the Company completed a common stock offering pursuant to which certain investors purchased </font><font style="display: inline;color:#000000;">4,081,633</font><font style="display: inline;color:#000000;"> shares of common stock at a price of </font><font style="display: inline;color:#000000;">$49.00</font><font style="display: inline;color:#000000;"> per share. Net proceeds of the offering were approximately </font><font style="display: inline;color:#000000;">$189.7</font><font style="display: inline;color:#000000;">&nbsp;million after deducting offering expenses.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">2020 Follow-on Public Offering</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;text-decoration:underline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">On November&nbsp;13, 2020, the Company completed the sale of&nbsp;</font><font style="display: inline;color:#000000;">9,375,000</font><font style="display: inline;color:#000000;">&nbsp;shares of Cassava common stock in an underwritten public offering at a price of&nbsp;</font><font style="display: inline;color:#000000;">$8.00</font><font style="display: inline;color:#000000;">&nbsp;per share. The Company received net proceeds from the offering of&nbsp;</font><font style="display: inline;color:#000000;">$70,251,000</font><font style="display: inline;color:#000000;">&nbsp;after deducting underwriting discounts and offering expenses.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 10pt;line-height:106.67%;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">Common Stock Warrants</font><font style="display: inline;font-style:italic;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">In August 2018, the Company issued warrants to&nbsp;purchase up to an aggregate of&nbsp;</font><font style="display: inline;color:#000000;">9.1</font><font style="display: inline;color:#000000;">&nbsp;million shares of its common stock in conjunction with an offering of its common stock.&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">During 2020, the Company received proceeds of </font><font style="display: inline;">$4.9</font><font style="display: inline;">&nbsp;million from the exercise of </font><font style="display: inline;">4.0</font><font style="display: inline;">&nbsp;million shares pursuant to warrants. During 2019, the Company received proceeds of </font><font style="display: inline;">$5.9</font><font style="display: inline;">&nbsp;million from the exercise of </font><font style="display: inline;">4.6</font><font style="display: inline;">&nbsp;million shares pursuant to warrants. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Subsequent to December&nbsp;31, 2020, the Company received proceeds of </font><font style="display: inline;">$0.7</font><font style="display: inline;">&nbsp;million from the exercise of an additional </font><font style="display: inline;">0.6</font><font style="display: inline;">&nbsp;million shares pursuant to warrants. There were no warrants outstanding following the 2021 exercises.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Warrants outstanding as of December&nbsp;31, 2020 and 2019 were as follows:</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:41.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">Number of Shares Outstanding under Warrant</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:41.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:8pt;">Issuance Date</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">Expiration Date</font></p>
				</td>
				<td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">Exercise Price Per Share</font></p>
				</td>
				<td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:17.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">August 17, 2018</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">February 17, 2021</font></p>
				</td>
				<td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.25&nbsp;
				</td>
				<td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">554,019&nbsp;
				</td>
				<td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,496,116&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">August 17, 2018</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">February 17, 2021</font></p>
				</td>
				<td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.59&nbsp;
				</td>
				<td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">7,975&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">554,019&nbsp;
				</td>
				<td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,504,091&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.26%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.80%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">At the Market (ATM) Common Stock Issuance </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">On March&nbsp;27, 2020, the Company established an at-the-market offering program (ATM) to sell, from time to time, shares of Company common stock having an aggregate offering price of up to&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">$100</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;million&nbsp;in transactions pursuant to a shelf registration statement that was declared effective by the&nbsp;U.S. Securities and Exchange Commission (the SEC)&nbsp;on May&nbsp;5, 2020. The Company is obligated to pay a commission of&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">3.0%</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;of the gross proceeds from the sale of shares of common stock in the offering. The Company is not obligated to sell any shares in the offering.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">There were&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">no</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;common stock sales under the ATM during the year ended December&nbsp;31, 2020.</font>
		</p>
		<p style="margin:0pt 2.5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 2.5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">2008 Equity Incentive Plan </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Under the Company&#x2019;s </font><font style="display: inline;">2008 Equity Incentive Plan, or 2008 Equity Plan,</font><font style="display: inline;"> its employees, directors and consultants received share-based awards, including grants of stock options and performance awards. The </font><font style="display: inline;">2008 Equity Plan</font><font style="display: inline;"> expired in December 2017. Share-based awards generally expire </font><font style="display: inline;">ten</font><font style="display: inline;"> years from the date of grant.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 2.5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">2018 Equity Incentive Plan </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In January 2018, the Company&#x2019;s Board approved the Company&#x2019;s 2018 Omnibus Incentive Plan (the 2018 Plan). The Company&#x2019;s Board or a designated Committee of the Board is responsible for administration of the 2018 Plan and determined the terms and conditions of each option granted, consistent with the terms of the 2018 Plan. The Company&#x2019;s employees, directors, and consultants are eligible to receive awards under the 2018 Plan, including grants of stock options and performance awards. Share-based awards generally expire </font><font style="display: inline;">ten</font><font style="display: inline;"> years from the date of grant. The 2018 Plan provides for issuance of up to </font><font style="display: inline;">1,000,000</font><font style="display: inline;"> shares of common stock, par value </font><font style="display: inline;">$0.001</font><font style="display: inline;"> per share under the 2018 Plan, subject to adjustment as provided in the 2018 Plan. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">When stock options or performance awards are exercised net of the exercise price and taxes, the number of shares of stock issued is reduced by the number of shares equal to the amount of taxes owed by the award recipient and that number of shares are cancelled. The Company then uses its cash to pay tax authorities the amount of statutory taxes owed by and on behalf of the award recipient.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Stock Options</font>
		</p>
		<p style="margin:0pt 2.5pt 0pt 0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 2.5pt 0pt 0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The following summarizes information about stock option activity during 2020:</font>
		</p>
		<p style="margin:0pt 2.5pt 0pt 0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Number of Options</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Weighted Average Exercise Price</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Weighted Average Remaining Contractual Term</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Aggregate Intrinsic Value</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;text-decoration:underline;">In years</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;text-decoration:underline;">In millions</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Outstanding as of December 31, 2019</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">3,210,965&nbsp;
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> 12.27&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">6.05</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">4.2</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Options granted</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">60,000&nbsp;
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> 7.25&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Options exercised</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">(71,105)
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> 3.60&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Options forfeited/canceled</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">(382,356)
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> 20.31&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Outstanding as of December 31, 2020</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">2,817,504&nbsp;
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> 11.30&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">5.60</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">6.4</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#FF0000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Vested and expected to vest at December 31, 2020</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">2,817,504&nbsp;
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> 11.30&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">5.60</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">6.4</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#FF0000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Exercisable at December 31, 2020</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">2,167,633&nbsp;
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> 13.86&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">4.85</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">3.7</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The following summarizes information about stock options at December&nbsp;31, 2020 by a range of exercise prices:</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 14.4pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="6" valign="bottom" style="width:37.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Options outstanding</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="4" valign="bottom" style="width:24.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Options exercisable</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Weighted</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">average</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Weighted</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Weighted</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Number of</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">remaining</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">average</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Number of</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">average</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:23.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Range of exercise prices</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">outstanding</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">contractual</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">exercise</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"> vested</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">exercise</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">From</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">To</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">options</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">life (in years)</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">price</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">options</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">price</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">0.95</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">1.88</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">659,688&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">8.4</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">1.47</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">251,613&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">1.31</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">3.24</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">4.09</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">812,094&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">6.7</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">3.51</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">643,377&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">3.48</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">4.10</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">13.09</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">598,462&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">5.0</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10.89</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">525,383&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">11.42</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">14.21</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">35.00</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">619,599&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">2.8</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">24.02</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">619,599&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">24.02</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">36.40</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">53.55</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">127,661&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">0.7</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">51.72</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">127,661&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">51.72</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,817,504&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">5.6</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">11.30</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,167,633&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">13.86</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company uses Black-Scholes to estimate the fair value of options granted. Black-Scholes considers a number of factors, including the market price of the Company&#x2019;s common stock. It used certain factors to value each stock option granted, which resulted in a weighted average fair value of options granted during 2020 and 2019, as follows:</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">2020</font></p>
				</td>
				<td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Volatility</font></p>
				</td>
				<td valign="middle" style="width:15.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">123%</font><font style="display: inline;color:#000000;"> to </font><font style="display: inline;color:#000000;">139%</font></p>
				</td>
				<td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.74%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">118%</font><font style="display: inline;color:#000000;"> to </font><font style="display: inline;color:#000000;">119%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Risk-free interest rates</font></p>
				</td>
				<td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">0.46%</font><font style="display: inline;color:#000000;"> to </font><font style="display: inline;color:#000000;">0.78%</font></p>
				</td>
				<td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">1.7%</font><font style="display: inline;color:#000000;"> to </font><font style="display: inline;color:#000000;">2.5%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Expected life of option</font></p>
				</td>
				<td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">7</font><font style="display: inline;color:#000000;"> years</font></p>
				</td>
				<td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">7</font><font style="display: inline;color:#000000;"> years</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Dividend yield</font></p>
				</td>
				<td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">zero</font></p>
				</td>
				<td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">zero</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Forfeiture rate</font></p>
				</td>
				<td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">zero</font></p>
				</td>
				<td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">zero</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Weighted average fair value of stock options granted</font></p>
				</td>
				<td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$6.69</font></p>
				</td>
				<td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$1.60</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Volatility</font><font style="display: inline;"> is based on reviews of the historical volatility of the Company&#x2019;s common stock. Risk-free interest rates are based on yields of U.S. treasury notes in effect at the date of grant. Expected life of option is based on actual historical option exercises. Dividend yield is </font><font style="display: inline;">zero</font><font style="display: inline;"> because the Company does not anticipate paying cash dividends in the foreseeable future. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">As of December&nbsp;31, 2020, the Company expects to recognize compensation expense of </font><font style="display: inline;">$</font><font style="display: inline;">1.5</font><font style="display: inline;">&nbsp;million related to non-vested options held by equity plan participants over the weighted average remaining recognition period of </font><font style="display: inline;">2.1</font><font style="display: inline;"> years.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Subsequent to </font><font style="display: inline;color:#000000;">December&nbsp;31, 2020, there </font><font style="display: inline;color:#000000;">were&nbsp;</font><font style="display: inline;color:#000000;">20,385</font><font style="display: inline;">&nbsp;</font><font style="display: inline;color:#000000;">stock options exercised resulting in proceeds to the Company </font><font style="display: inline;color:#000000;">totaling&nbsp;</font><font style="display: inline;color:#000000;">$169,000</font><font style="display: inline;color:#000000;">.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Performance Awards</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The following summarizes information about performance award activity during 2020:</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Number of Performance Awards</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;">Outstanding as of December 31, 2019</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">138,055&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;">Granted</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;">Vested performance awards</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;">Forfeited/Canceled</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;">Outstanding as of December 31, 2020</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">138,055&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.58%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font><font style="display: inline;">If and when outstanding performance awards vest, the Company would recognize </font><font style="display: inline;">$</font><font style="display: inline;">2.3</font><font style="display: inline;">&nbsp;million in non-cash stock-based compensation expense. These performance awards expire between </font><font style="display: inline;">2022</font><font style="display: inline;"> and </font><font style="display: inline;">2026</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Stock-Based Compensation Expense</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The following summarizes information about non-cash stock-based compensation expense, in thousands:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Year ended</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">December 31,</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;">Research and development</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.78%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">453&nbsp;
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">542&nbsp;
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;">General and administrative</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">535&nbsp;
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">754&nbsp;
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;">Total non-cash stock-based compensation expense</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.78%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">988&nbsp;
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">1,296&nbsp;
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.78%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.20%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797657454040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee 401(k) Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee 401(k) Benefit Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee 401(k) Benefit Plan</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">5.&nbsp;&nbsp;Employee 401(k) Benefit Plan</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers substantially all employees. Employees are eligible to participate in the plan the first day of the month after hire and may contribute up to the current statutory limits under Internal Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf of all employees. Through December&nbsp;31, 2020, the Company has not made any matching contributions to the 401(k) plan.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797657406776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">6.&nbsp;&nbsp;Income Taxes</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company did not provide for income taxes in 2020 and 2019 because it had book and federal taxable losses in those years and the tax benefit that would have resulted from the pre-tax losses was fully offset by a change in the valuation allowance. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The reconciliation of the statutory federal income tax rate to the Company&#x2019;s effective tax rate for the years ended December&nbsp;31, 2020 and 2019 was as follows:</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="4" valign="bottom" style="width:30.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Year ended December 31,</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Tax at federal statutory rate</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">21.0&nbsp;
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">%</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">21.0&nbsp;
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">%</font></p>
				</td>
				<td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">State tax, net of federal benefit</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Share-based compensation</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(42.8)
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(2.4)
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Research and development credits</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.6&nbsp;
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">0.6&nbsp;
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Change in valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">20.2&nbsp;
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(19.2)
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Effective income tax rate</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">%</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">%</font></p>
				</td>
				<td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Deferred tax assets and valuation allowance</font>
		</p>
		<p style="margin:0pt;text-indent:15.15pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Deferred tax assets reflect the tax effects of net operating loss and tax credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company&#x2019;s deferred taxes assets at December&nbsp;31, 2020 and 2019 were valued at the corporate tax rate of 21%. The Company offsets its deferred tax assets by a valuation allowance because it is uncertain about the timing and amount of any future profits. Significant components of its deferred tax assets are as follows (in thousands):</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">December 31, </font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Deferred tax assets:</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Net operating loss carryforwards</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">18,333&nbsp;
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">17,110&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Share-based compensation</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,230&nbsp;
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5,817&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Research and development credit carryforwards</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">6,687&nbsp;
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">6,587&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Other</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">264&nbsp;
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">237&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Total deferred tax assets:</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">28,514&nbsp;
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">29,751&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(28,447)
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(29,725)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Net deferred tax assets:</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">67&nbsp;
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">26&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Deferred tax liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Property and equipment</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(5)
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(7)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Operating lease right-of-use assets</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(62)
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(19)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Total deferred tax liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(67)
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(26)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Net deferred tax asset / (liability):</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The valuation allowance decreased by </font><font style="display: inline;">$1.3</font><font style="display: inline;">&nbsp;million in 2020. The valuation allowance decreased by </font><font style="display: inline;">$2.4</font><font style="display: inline;">&nbsp;million due to a write down of the share-based compensation deferred tax asset and is offset in part by a </font><font style="display: inline;">$1.1</font><font style="display: inline;">&nbsp;million increase due to additional book losses during the year. The valuation allowance increased by </font><font style="display: inline;">$0.9</font><font style="display: inline;">&nbsp;million in 2019 due to additional book losses during the year. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company&#x2019;s pre-tax net operating loss carryforwards of </font><font style="display: inline;">$87.3</font><font style="display: inline;">&nbsp;million are federal, of which </font><font style="display: inline;">$74.1</font><font style="display: inline;">&nbsp;million expires between </font><font style="display: inline;">2029</font><font style="display: inline;"> and </font><font style="display: inline;">2039</font><font style="display: inline;"> and </font><font style="display: inline;">$13.2</font><font style="display: inline;">&nbsp;million carries forward indefinitely. As of December&nbsp;31, 2020, the Company had federal research and development tax credits of approximately </font><font style="display: inline;">$11.1</font><font style="display: inline;">&nbsp;million, which expire in the years </font><font style="display: inline;">2023</font><font style="display: inline;"> through </font><font style="display: inline;">2040</font><font style="display: inline;">. &nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Unrecognized tax benefits</font>
		</p>
		<p style="margin:0pt;text-indent:14.4pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">As of December&nbsp;31, 2020 and 2019, the Company has unrecognized tax benefits related to tax credits of </font><font style="display: inline;">$4.5</font><font style="display: inline;">&nbsp;million and </font><font style="display: inline;">$4.4</font><font style="display: inline;">&nbsp;million, respectively. None of the unrecognized tax benefits as of December&nbsp;31, 2020, if recognized, would impact the effective tax rate due to the valuation allowance and no interest or penalties have been recognized. A reconciliation of the beginning and ending balance of unrecognized tax benefits is as follows (in thousands): </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="4" valign="bottom" style="width:31.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Year ended December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:15.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:15.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Beginning balance</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,400&nbsp;
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,400&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Additions based on tax positions related to the current year</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">100&nbsp;
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Ending balance</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,500&nbsp;
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,400&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">As of December&nbsp;31, 2020, there were no unrecognized tax benefits that we expect would change significantly over the next 12 months.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company files U.S. and Texas income tax returns. In the United States, the statute of limitations with respect to the federal income tax returns for tax years after 2016&nbsp;are open to audit; however, since the Company has net operating losses, the taxing authority has the ability to review tax returns prior to the 2017 tax year and make adjustments to these net operating loss carryforwards.&nbsp;We are not under audit in any taxing jurisdiction at this time.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797651173640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases And Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_LeasesAndCommitmentsAbstract', window );"><strong>Leases And Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_LeasesAndCommitmentsDisclosureTextBlock', window );">Leases And Commitments</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">7.&nbsp;&nbsp;Leases and Commitments</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Right-of-use Asset and Liability</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The Company has a single non-cancelable operating lease for approximately </font><font style="display: inline;font-size:10pt;">6,000</font><font style="display: inline;font-size:10pt;"> square feet of office space in Austin, Texas, which is used for the development of novel products. </font><font style="display: inline;color:#000000;font-size:10pt;">On September&nbsp;4, 2020, the Company entered into a lease amendment that extended&nbsp;the&nbsp;lease termination date to </font><font style="display: inline;color:#000000;font-size:10pt;">April&nbsp;30, 2024</font><font style="display: inline;color:#000000;font-size:10pt;"> and set&nbsp;new rental rates effective as of January&nbsp;1, 2021.&nbsp;</font><font style="display: inline;font-size:10pt;">Future lease payments are</font><font style="display: inline;font-size:10pt;"> (in thousands)</font><font style="display: inline;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-size:9pt;">&#xFEFF;</font><font style="display: inline;font-weight:bold;font-size:9pt;">For the year ending December 31,</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">&#xFEFF;</font><font style="display: inline;font-size:9pt;">2021</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">66&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">&#xFEFF;</font><font style="display: inline;font-size:9pt;">2022</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">102&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">&#xFEFF;</font><font style="display: inline;font-size:9pt;">2023</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">107&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">&#xFEFF;</font><font style="display: inline;font-size:9pt;">2024</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">36&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">&#xFEFF;</font><font style="display: inline;font-size:9pt;">Total future lease payments</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">311&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">&#xFEFF;</font><font style="display: inline;font-size:9pt;">Less: imputed interest</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">(18)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">&#xFEFF;</font><font style="display: inline;font-size:9pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">293&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Rent expense was </font><font style="display: inline;">$0.1</font><font style="display: inline;">&nbsp;million for the year ended December&nbsp;31, 2020 and 2019.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">The Company recorded a&nbsp;right-of-use asset and lease liability&nbsp;of </font><font style="display: inline;color:#000000;font-size:10pt;">$316,000</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;as a result of the lease&nbsp;modification in September 2020. The Company utilized a discount rate of&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">3.25%</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;for the modified lease&nbsp;to determine the present value of the future lease payments, which&nbsp;approximated the Company&#x2019;s incremental borrowing rate&nbsp;in September 2020. </font><font style="display: inline;font-size:10pt;">There were </font><font style="display: inline;font-size:10pt;">no</font><font style="display: inline;font-size:10pt;"> right-of-use assets exchanged for operating lease liabilities during the year ended December&nbsp;31, 2019.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">Cash paid for operating lease liabilities totaled </font><font style="display: inline;color:#000000;font-size:10pt;">$99,000</font><font style="display: inline;color:#000000;font-size:10pt;"> and </font><font style="display: inline;color:#000000;font-size:10pt;">$95,000</font><font style="display: inline;color:#000000;font-size:10pt;"> during the years ended December&nbsp;31, 2020 and 2019, respectively.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;color:#000000;font-size:10pt;">Other Commitments</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company conducts its product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. It has contractual arrangements with these organizations, however these contracts are cancelable on thirty days&#x2019; notice and the Company&#x2019;s obligations under these contracts are largely based on services performed.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company is dependent on contract development and manufacturing organizations for the manufacture of all our materials for clinical studies.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_LeasesAndCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Leases And Commitments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_LeasesAndCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_LeasesAndCommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Leases and commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_LeasesAndCommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797650939080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>2020 Cash Incentive Bonus Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanAbstract', window );"><strong>Cash Incentive Bonus Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanTextBlock', window );">2020 Cash Incentive Bonus Plan</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;font-size:10pt;">Note&nbsp;8.&nbsp; 2020 Cash Incentive Bonus Plan</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">On August&nbsp;26, 2020, the Board approved the Plan. The Plan was established to promote the long-term success of the Company by creating an &#x201C;at-risk&#x201D; cash bonus program that rewards&nbsp;Plan&nbsp;participants with additional cash compensation in lockstep with significant increases in the Company&#x2019;s market capitalization. The Plan is considered &#x201C;at-risk&#x201D; because Plan participants&nbsp;will&nbsp;not receive a cash bonus&nbsp;unless&nbsp;the Company&#x2019;s market capitalization increases&nbsp;significantly and&nbsp;certain&nbsp;other&nbsp;conditions specified in the Plan&nbsp;are met.&nbsp;Specifically, Plan participants&nbsp;will&nbsp;not&nbsp;be paid&nbsp;any cash bonuses unless (1) the Company completes a&nbsp;merger or acquisition transaction that constitutes a sale of ownership of the Company or its assets (a Merger Transaction) or (2) the Compensation Committee of the Board&nbsp;(the Compensation Committee) determines the Company has sufficient cash on hand, as defined in the Plan. Because&nbsp;of the inherent discretion and uncertainty regarding&nbsp;these&nbsp;requirements, the Company has concluded that&nbsp;a&nbsp;Plan&nbsp;grant date has not occurred&nbsp;as of December&nbsp;31, 2020.&nbsp;Plan participants will be paid all earned cash bonuses in the event of a Merger Transaction.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">The Company&#x2019;s market capitalization for purposes of the Plan&nbsp;is&nbsp;determined based on either (1) the Company&#x2019;s closing price&nbsp;of one share&nbsp;on the Nasdaq Capital&nbsp;Market&nbsp;multiplied by the total issued and outstanding shares and options to purchase shares of the Company or (2) the aggregate consideration payable to security holders of the Company in a&nbsp;Merger Transaction.&nbsp;This constitutes a market condition under applicable accounting guidance.&nbsp; &nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">The Plan&nbsp;triggers a potential cash bonus each time&nbsp;the&nbsp;Company&#x2019;s market capitalization increases significantly, up to a maximum&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">$5</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;billion in market capitalization. The Plan specifies 14&nbsp;incremental&nbsp;amounts&nbsp;between&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">$200</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;million and&nbsp;$5&nbsp;billion&nbsp;&nbsp;(each increment,&nbsp;a &#x201C;Valuation Milestone&#x201D;). Each&nbsp;Valuation Milestone&nbsp;triggers&nbsp;a potential cash bonus award in a pre-set amount defined in the Plan. Each&nbsp;Valuation&nbsp;Milestone&nbsp;must be achieved and maintained for no less than 20 consecutive trading days for&nbsp;Plan&nbsp;participants to be eligible for a potential cash bonus award.&nbsp;Approximately </font><font style="display: inline;color:#000000;font-size:10pt;">59%</font><font style="display: inline;color:#000000;font-size:10pt;"> of each&nbsp;cash bonus award&nbsp;associated with a Valuation Milestone&nbsp;is subject to&nbsp;adjustment and&nbsp;approval&nbsp;by the Compensation Committee.&nbsp;Any amounts&nbsp;not awarded by the Compensation Committee&nbsp;are&nbsp;no longer available for distribution.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">If the Company were to exceed a $5&nbsp;billion market capitalization&nbsp;for no less than 20 consecutive trading days, all&nbsp;Valuation&nbsp;Milestones would be deemed achieved, in which case cash bonus awards would&nbsp;range from&nbsp;a minimum of&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">$137.4</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;million&nbsp;up to&nbsp;a hypothetical maximum of&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">$322.3</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;million.&nbsp;Payment of cash bonuses is deferred until such time as&nbsp;(1)&nbsp;the Company completes a Merger Transaction, or&nbsp;(2)&nbsp;the&nbsp;Compensation Committee determines the&nbsp;Company has sufficient cash&nbsp;on hand&nbsp;to render payment&nbsp;(each, a &#x201C;Performance Condition&#x201D;),&nbsp;neither&nbsp;of which may ever occur. Accordingly, there can be no assurance that&nbsp;Plan&nbsp;participants will&nbsp;ever&nbsp;be&nbsp;paid a cash bonus that is awarded under the Plan, even if the Company&#x2019;s market capitalization increases&nbsp;significantly.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">The Plan is accounted for as a liability award.&nbsp;The fair value of each&nbsp;Valuation&nbsp;Milestone&nbsp;award&nbsp;will be&nbsp;determined&nbsp;once&nbsp;a&nbsp;grant date occurs and&nbsp;will be&nbsp;remeasured each reporting period.&nbsp;Compensation expense associated with the Plan&nbsp;will be&nbsp;recognized over the expected achievement period for each&nbsp;of the 14&nbsp;Valuation&nbsp;Milestones, when&nbsp;a Performance Condition&nbsp;is considered probable of being met. &nbsp;&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">On October&nbsp;13, 2020, the Company&nbsp;achieved&nbsp;the first&nbsp;Valuation&nbsp;Milestone.&nbsp;Subsequently, the Compensation Committee&nbsp;approved&nbsp;a potential cash bonus&nbsp;award&nbsp;of&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">$7.3</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;million&nbsp;in total&nbsp;for&nbsp;all Plan participants, subject to future satisfaction of a Performance Condition.&nbsp;However,&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">no</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;compensation expense has been recorded&nbsp;since no&nbsp;grant date has occurred and no&nbsp;Performance Conditions are considered probable of being met.&nbsp;There is no continuing service requirement for Plan participants once&nbsp;the Compensation Committee approves a cash&nbsp;bonus award.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">Subsequent to December&nbsp;31, 2020, the Company achieved eight additional Valuation Milestones triggering potential Company obligations to all Plan participants from a minimum of </font><font style="display: inline;color:#000000;font-size:10pt;">$59.9</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;million up to a hypothetical maximum of </font><font style="display: inline;color:#000000;font-size:10pt;">$145.0</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;million, to be determined by the Compensation Committee and contingent upon future satisfaction of a Performance Condition.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">No</font><font style="display: inline;color:#000000;font-size:10pt;"> actual cash payments were authorized or made to participants under the Plan during the year ended December&nbsp;31, 2020.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_CashIncentiveBonusPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>2020 Cash Incentive Bonus Plan [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_CashIncentiveBonusPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_CashIncentiveBonusPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Incentive Bonus Plan [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_CashIncentiveBonusPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797648884968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policies (Policy)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use Of Estimates</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Use of Estimates</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. Actual results could differ from those estimates.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_ProceedsFromGrantsPolicyPolicyTextBlock', window );">Proceeds From Grants</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Proceeds from Grants</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In 2020, the Company received </font><font style="display: inline;">$4.2</font><font style="display: inline;">&nbsp;million of reimbursement from the National Institutes of Health and National Institute on Drug Abuse and </font><font style="display: inline;">$4.7</font><font style="display: inline;">&nbsp;million in 2019. The Company records the proceeds from these grants as reductions to its research and development expenses.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash And Cash Equivalents And Concentration Of Credit Risk</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Cash and Cash Equivalents and Concentration of Credit Risk</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company invests in cash and cash equivalents and, in the past, marketable securities. The Company considers highly-liquid financial instruments with original maturities of three months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts, money market funds and certificates of deposit. The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company&#x2019;s investment policy allows for investments in marketable securities with active secondary or resale markets, establishes diversification and credit quality requirements and limits investments by maturity and issuer. The Company maintains its investments at one financial institution. </font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Fair Value Measurements </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company reports its cash and cash equivalents at fair value as Level 1, Level 2 or Level 3 using the following inputs:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<a name="_9eed50031d7a4ae08d8481e27454a126"></a><a name="_a55395c9dddb484ab9d7fe2cd900ad3a"></a><a name="_9c970aca55e541dc8a21fc5af6a42932"></a><a name="_c95ddda386b84ea0a6341120a7f1021f"></a><a name="_3c0ffcf4570c456cbc299897392e42d9"></a><a name="_dee475e5298f41189ad89abce51b465d"></a><a name="_56802d68c6a94dbe9fcf1274361e7f37"></a><a name="_5121355f7d274c19a6859f83034a8dd4"></a><a name="_adff7fd0d1df49cfbd1d486e06beadfa"></a><a name="_d9e1ff57a6464ab6a179624ab81cda10"></a><a name="_a6d0459d796849d2b1866055cd140477"></a><a name="_6967f826ca9b4f0f9b986e3e324d9161"></a><a name="_5a3701addc544c73a9d512b8e9743988"></a><a name="_c3da333d461e4520b3a037507e639721"></a><a name="_7878265e95384b81ae1b7f17224656fd"></a><a name="_b691c60198414d559b1914e876b580a1"></a><a name="_7fb1ed58d627447ab56cfbe9d52d6120"></a><a name="_be8d133366f34f6686cef9d21c16f0a3"></a><a name="_e3b5f0a49cfe4f04a7282b95d681b7ce"></a><a name="_932ab8c8a3574e5a87e70dc56597bb6f"></a><a name="_9fb551aa76e3415c984cffa1491a23ea"></a><a name="_1746df8b27fc41ef992b25383e220984"></a><a name="_0c3de46198274b128860550988ef844d"></a><a name="_75dfd0ae686c45b99fde81a8d35908b3"></a><a name="_d9318bc5124f4b7c97afcc172b32ae28"></a><a name="_6310384476c740cf8e641c9a413eb968"></a><a name="_91d164c9544945c48fd3a86929e64fd4"></a><a name="_973c93b3770b4476a04247143aaf5d5a"></a><a name="_9d4e208743764419adbb1942938e565a"></a><a name="_e2f59ee1432249b792889c80e60b08d7"></a><a name="_f6345b5294af4fef90374149482d4f46"></a><a name="_d48429101312494397f78e2250f832e4"></a><font style="display: inline;color:#000000;">Level 1 includes quoted prices in active markets. The Company bases the fair value of money market funds on Level 1 inputs.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Level 2 includes significant observable inputs, such as quoted prices for identical or similar investments, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from third-party providers. It uses the bid price to establish fair value where a bid price is available. The Company bases the fair value of its certificates of deposit, if any, on Level 2 inputs.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Level 3 includes unobservable inputs that are supported by little or no market activity. The Company does not have any investments where the fair value is based on Level 3 inputs.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. A certificate of deposit totaling </font><font style="display: inline;color:#000000;">$13.0</font><font style="display: inline;color:#000000;">&nbsp;million at December&nbsp;31, 2019 was included within cash equivalents as a Level 2 input. The fair value of the remainder of cash and cash equivalents, including money market accounts, was based on Level 1 inputs at December&nbsp;31, 2020 and 2019.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Business Segments</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Business Segments</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&#x2019;s operations are confined to </font><font style="display: inline;">one</font><font style="display: inline;"> business segment: the development of novel drugs and diagnostics.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Stock-based Compensation</font><font style="display: inline;font-weight:bold;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each </font><a name="_cp_text_1_372"></a><font style="display: inline;">award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management's judgment. The Company recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally </font><font style="display: inline;">four</font><font style="display: inline;"> years. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company has granted share-based awards that vest upon achievement of certain performance criteria, or performance awards. The Company multiplies the number of performance awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. The Company periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance awards vest and common stock is issued upon achievement of the performance criteria.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Net Loss per Share</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Basic net loss per share is computed on the basis of the weighted-average number of common shares outstanding for the reporting period. Diluted net loss per share is computed on the basis of the weighted-average number of common shares outstanding plus dilutive potential common shares outstanding using the treasury-stock method. Potential dilutive common shares consist of outstanding equity awards and warrants. There is no difference between the Company&#x2019;s net loss and comprehensive loss. The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands, except net loss per share data):</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:24.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:24.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Year ended December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;">Numerator:</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">(6,334)
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">(4,631)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;">Denominator:</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;">Shares used in computing net loss per share, basic and diluted</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">26,105&nbsp;
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">17,412&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;">Net loss per share, basic and diluted</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">(0.24)
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">(0.27)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;"> Dilutive common stock options excluded from net loss per share, diluted</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">2,145&nbsp;
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">2,932&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;"> Common stock warrants excluded from net loss per share, diluted</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">554&nbsp;
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">4,504&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company excluded weighted equity awards and warrants outstanding to purchase common stock from the calculation of diluted net loss per share because the effect of including these shares in this calculation would be anti-dilutive.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Of Financial Instruments</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Fair Value of Financial Instruments</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Financial instruments include cash and cash equivalents, accounts payable and accrued liabilities. The estimated fair value of financial instruments has been determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies may be material to the estimated fair value amounts. The carrying amounts of cash and cash equivalents, accounts payable and accrued liabilities are at cost, which approximates fair value due to the short maturity of those instruments.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock', window );">Research Contract Costs And Accruals</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Research Contract Costs and Accruals</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The Company has entered into various research and development contracts with research institutions and other third-party vendors. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical accrual estimates have not been materially different from actual costs.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Incentive Bonus Plan</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Incentive Bonus Plan</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">In 2020, the Company established the 2020 Cash Incentive Bonus Plan (the &#x201C;Plan&#x201D;) to incentivize Plan participants.&nbsp;&nbsp;Awards under the Plan are accounted for as liability awards under ASC 718 &#x201C;</font><font style="display: inline;font-style:italic;color:#000000;">Stock-based Compensation</font><font style="display: inline;color:#000000;">&#x201D;.&nbsp;The fair value of each&nbsp;potential Plan&nbsp;award&nbsp;will be&nbsp;determined&nbsp;once&nbsp;a&nbsp;grant date occurs and&nbsp;will be&nbsp;remeasured each reporting period.&nbsp;Compensation expense associated with the Plan&nbsp;will be&nbsp;recognized over the expected achievement period for each&nbsp;Plan award, when&nbsp;a Performance Condition&nbsp;is considered probable of being met.&nbsp;&nbsp;See Note 8 for further discussion of the Plan.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Leases</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company recognizes&nbsp;assets and liabilities that arise from leases.&nbsp;For operating leases, the Company is required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, in the&nbsp;statements&nbsp;of financial position.&nbsp;As the Company`s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Income Taxes</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company accounts for income taxes under the asset and liability method.&nbsp;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. &nbsp;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&nbsp;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company accounts for uncertain tax positions in accordance with ASC 740, &#x201C;Income Taxes&#x201D;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&#x2019;s financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt 72pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Recent Accounting Pronouncements</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company reviewed recently issued accounting pronouncements and plan to adopt those that are applicable to it, and does not expect the adoption of these pronouncements to have a material impact on its financial position, results of operations or cash flows. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In December 2019, the FABS issued ASU No. 2019-12, </font><font style="display: inline;font-style:italic;">Income Taxes (Topic 740) Simplifying Accounting for Income Taxes </font><font style="display: inline;">as part of its initiative to reduce complexity in the accounting standards. The guidance amended certain disclosure requirements that had become redundant, outdated or superseded. Additionally, this guidance amends accounting for the interim period effects of changes in tax laws or rates and simplifies aspects of the accounting for franchise taxes. The guidance is effective for annual periods beginning after December&nbsp;15, 2020, and is applicable for the Company in fiscal year 2021. Early adoption is permitted. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">In November 2018, the FASB issued ASU No. 2018-18, </font><font style="display: inline;font-style:italic;color:#000000;">Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606. </font><font style="display: inline;color:#000000;">The amendments in this update provide guidance on how to assess whether certain transactions between collaborative arrangement participants should be accounted for within the revenue recognition standard. The amendments in this update are effective for interim and annual periods for the Company beginning on January&nbsp;1, 2020. </font><font style="display: inline;color:#000000;">The adoption of this guidance did not have a material impact on&nbsp;the Company&#x2019;s&nbsp;financial statements.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;background-color: #FFFFFF;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;background-color: #FFFFFF;">In August 2018, the FASB issued ASU </font><font style="display: inline;color:#000000;">No. 2018-13,</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">&nbsp;</font><font style="display: inline;font-style:italic;color:#000000;">Fair Value Measurement (Topic 820) - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</font><font style="display: inline;color:#000000;background-color: #FFFFFF;"> (ASU </font><font style="display: inline;color:#000000;">2018-13),</font><font style="display: inline;color:#000000;background-color: #FFFFFF;"> which is designed to improve the effectiveness of disclosures by removing, modifying and adding disclosures related to fair value measurements. ASU </font><font style="display: inline;color:#000000;">2018-13</font><font style="display: inline;color:#000000;background-color: #FFFFFF;"> is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The adoption of ASU 2018-13 did not have a material impact on&nbsp;the Company&#x2019;s&nbsp;financial statements.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ProceedsFromGrantsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Grants Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ProceedsFromGrantsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research Contract Costs And Accruals Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797650941960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:24.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:24.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Year ended December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;">Numerator:</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">(6,334)
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">(4,631)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;">Denominator:</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;">Shares used in computing net loss per share, basic and diluted</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">26,105&nbsp;
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">17,412&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;">Net loss per share, basic and diluted</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">(0.24)
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">(0.27)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;"> Dilutive common stock options excluded from net loss per share, diluted</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">2,145&nbsp;
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">2,932&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;"> Common stock warrants excluded from net loss per share, diluted</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">554&nbsp;
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">4,504&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797651196888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity And Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stockholders' Equity And Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Warrants Outstanding</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:41.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">Number of Shares Outstanding under Warrant</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:41.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:8pt;">Issuance Date</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">Expiration Date</font></p>
				</td>
				<td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">Exercise Price Per Share</font></p>
				</td>
				<td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:17.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">August 17, 2018</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">February 17, 2021</font></p>
				</td>
				<td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.25&nbsp;
				</td>
				<td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">554,019&nbsp;
				</td>
				<td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,496,116&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">August 17, 2018</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">February 17, 2021</font></p>
				</td>
				<td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.59&nbsp;
				</td>
				<td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">7,975&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">554,019&nbsp;
				</td>
				<td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,504,091&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.26%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.80%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Number of Options</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Weighted Average Exercise Price</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Weighted Average Remaining Contractual Term</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Aggregate Intrinsic Value</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;text-decoration:underline;">In years</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;text-decoration:underline;">In millions</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Outstanding as of December 31, 2019</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">3,210,965&nbsp;
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> 12.27&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">6.05</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">4.2</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Options granted</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">60,000&nbsp;
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> 7.25&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Options exercised</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">(71,105)
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> 3.60&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Options forfeited/canceled</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">(382,356)
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> 20.31&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Outstanding as of December 31, 2020</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">2,817,504&nbsp;
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> 11.30&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">5.60</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">6.4</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#FF0000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Vested and expected to vest at December 31, 2020</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">2,817,504&nbsp;
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> 11.30&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">5.60</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">6.4</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#FF0000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Exercisable at December 31, 2020</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">2,167,633&nbsp;
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> 13.86&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">4.85</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">3.7</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:40.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Information About Stock Options Outstanding</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="6" valign="bottom" style="width:37.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Options outstanding</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="4" valign="bottom" style="width:24.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Options exercisable</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Weighted</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">average</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Weighted</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Weighted</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Number of</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">remaining</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">average</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Number of</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">average</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:23.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Range of exercise prices</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">outstanding</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">contractual</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">exercise</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"> vested</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">exercise</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">From</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">To</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">options</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">life (in years)</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">price</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">options</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">price</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">0.95</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">1.88</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">659,688&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">8.4</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">1.47</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">251,613&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">1.31</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">3.24</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">4.09</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">812,094&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">6.7</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">3.51</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">643,377&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">3.48</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">4.10</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">13.09</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">598,462&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">5.0</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10.89</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">525,383&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">11.42</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">14.21</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">35.00</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">619,599&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">2.8</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">24.02</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">619,599&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">24.02</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">36.40</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">53.55</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">127,661&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">0.7</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">51.72</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">127,661&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">51.72</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,817,504&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">5.6</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">11.30</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,167,633&nbsp;
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">13.86</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Weighted Average Fair Value Of Options Granted</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">2020</font></p>
				</td>
				<td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Volatility</font></p>
				</td>
				<td valign="middle" style="width:15.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">123%</font><font style="display: inline;color:#000000;"> to </font><font style="display: inline;color:#000000;">139%</font></p>
				</td>
				<td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.74%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">118%</font><font style="display: inline;color:#000000;"> to </font><font style="display: inline;color:#000000;">119%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Risk-free interest rates</font></p>
				</td>
				<td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">0.46%</font><font style="display: inline;color:#000000;"> to </font><font style="display: inline;color:#000000;">0.78%</font></p>
				</td>
				<td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">1.7%</font><font style="display: inline;color:#000000;"> to </font><font style="display: inline;color:#000000;">2.5%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Expected life of option</font></p>
				</td>
				<td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">7</font><font style="display: inline;color:#000000;"> years</font></p>
				</td>
				<td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">7</font><font style="display: inline;color:#000000;"> years</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Dividend yield</font></p>
				</td>
				<td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">zero</font></p>
				</td>
				<td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">zero</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Forfeiture rate</font></p>
				</td>
				<td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">zero</font></p>
				</td>
				<td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">zero</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Weighted average fair value of stock options granted</font></p>
				</td>
				<td valign="middle" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$6.69</font></p>
				</td>
				<td valign="middle" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$1.60</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock', window );">Summary Of Performance Award Activity</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Number of Performance Awards</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;">Outstanding as of December 31, 2019</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">138,055&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;">Granted</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;">Vested performance awards</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;">Forfeited/Canceled</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;">Outstanding as of December 31, 2020</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">138,055&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.58%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_SummaryOfNonCashStockBasedCompensationTableTextBlock', window );">Non-Cash Stock-Based Compensation Expenses</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Year ended</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">December 31,</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;">Research and development</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.78%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">453&nbsp;
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">542&nbsp;
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;">General and administrative</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">535&nbsp;
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">754&nbsp;
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:9pt;">Total non-cash stock-based compensation expense</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.78%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">988&nbsp;
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">1,296&nbsp;
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.78%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.20%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_SummaryOfNonCashStockBasedCompensationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Non-Cash Stock-Based Compensation [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_SummaryOfNonCashStockBasedCompensationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797651128904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule Of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="4" valign="bottom" style="width:30.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Year ended December 31,</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Tax at federal statutory rate</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">21.0&nbsp;
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">%</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">21.0&nbsp;
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">%</font></p>
				</td>
				<td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">State tax, net of federal benefit</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Share-based compensation</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(42.8)
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(2.4)
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Research and development credits</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.6&nbsp;
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">0.6&nbsp;
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Change in valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">20.2&nbsp;
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(19.2)
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Effective income tax rate</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">%</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">%</font></p>
				</td>
				<td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule Of Deferred Tax Assets And Valuation Allowance</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">December 31, </font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Deferred tax assets:</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Net operating loss carryforwards</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">18,333&nbsp;
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">17,110&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Share-based compensation</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,230&nbsp;
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5,817&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Research and development credit carryforwards</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">6,687&nbsp;
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">6,587&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Other</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">264&nbsp;
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">237&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Total deferred tax assets:</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">28,514&nbsp;
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">29,751&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(28,447)
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(29,725)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Net deferred tax assets:</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">67&nbsp;
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">26&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Deferred tax liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Property and equipment</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(5)
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(7)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Operating lease right-of-use assets</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(62)
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(19)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Total deferred tax liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(67)
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(26)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Net deferred tax asset / (liability):</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Schedule Of Unrecognized Tax Benefits</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="4" valign="bottom" style="width:31.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Year ended December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:15.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:15.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Beginning balance</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,400&nbsp;
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,400&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Additions based on tax positions related to the current year</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">100&nbsp;
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Ending balance</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,500&nbsp;
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,400&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797657503016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases And Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_LeasesAndCommitmentsAbstract', window );"><strong>Leases And Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Future Minimum Lease Payments</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-size:9pt;">&#xFEFF;</font><font style="display: inline;font-weight:bold;font-size:9pt;">For the year ending December 31,</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">&#xFEFF;</font><font style="display: inline;font-size:9pt;">2021</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">66&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">&#xFEFF;</font><font style="display: inline;font-size:9pt;">2022</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">102&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">&#xFEFF;</font><font style="display: inline;font-size:9pt;">2023</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">107&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">&#xFEFF;</font><font style="display: inline;font-size:9pt;">2024</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">36&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">&#xFEFF;</font><font style="display: inline;font-size:9pt;">Total future lease payments</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">311&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">&#xFEFF;</font><font style="display: inline;font-size:9pt;">Less: imputed interest</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">(18)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">&#xFEFF;</font><font style="display: inline;font-size:9pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">293&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_LeasesAndCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Leases And Commitments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_LeasesAndCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797657622856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>General And Liquidity (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>General And Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 174,921<span></span>
</td>
<td class="nump">$ 168,587<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797650910696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policies (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CertificatesOfDepositAtCarryingValue', window );">Certificate of deposit</a></td>
<td class="nump">$ 13.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_ReductionToResearchAndDevelopmentExpense', window );">Reimbursement from National Institutes of Health research grants</a></td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="nump">$ 4.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of stock options</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ReductionToResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction To Research And Development Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ReductionToResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CertificatesOfDepositAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A savings certificate entitling the Entity (that is, bearer) to receive interest at an established maturity date, based upon a fixed interest rate.  A certificate of deposit may be issued in any denomination. Certificates of deposit are generally issued by commercial banks and, therefore, insured by the FDIC (up to the prescribed limit).  Certificates of deposit generally restrict holders from withdrawing funds on demand without the incurrence of penalties.  Generally, only certificates of deposit with original maturities of three months or less qualify as cash equivalents. Original maturity means original maturity to the entity holding the investment. As a related example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CertificatesOfDepositAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797649115656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policies (Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share) (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,334)<span></span>
</td>
<td class="num">$ (4,631)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares used in computing net loss per share, basic and diluted</a></td>
<td class="nump">26,105<span></span>
</td>
<td class="nump">17,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock excluded from net loss per share, diluted</a></td>
<td class="nump">2,145<span></span>
</td>
<td class="nump">2,932<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock excluded from net loss per share, diluted</a></td>
<td class="nump">554<span></span>
</td>
<td class="nump">4,504<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797649116312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property And Equipment (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of property and equipment</a></td>
<td class="nump">$ 346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Manufacturing Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment', window );">Proceeds from sale of equipment</a></td>
<td class="nump">360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, original cost</a></td>
<td class="nump">892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of property and equipment</a></td>
<td class="nump">$ 346<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sale of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797574983672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity And Stock-Based Compensation (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 12, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Nov. 13, 2020</div></th>
<th class="th"><div>Mar. 27, 2020</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,940,000<span></span>
</td>
<td class="nump">$ 5,866,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares execrise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">554,019<span></span>
</td>
<td class="nump">4,504,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod', window );">Compensation costs prior to forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm', window );">Weighted average remaining recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds from stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 256,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Offering of common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds from stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 169,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sava_AtMarketEquityProgramMember', window );">ATM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_PercentageOfCommissionAtmOffering', window );">Percentage of commission in ATM offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sava_AtMarketEquityProgramMember', window );">ATM [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sava_TwoThousandEightEquityIncentivePlanMember', window );">2008 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sava_TwoThousandEighteenEquityIncentivePlanMember', window );">2018 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm', window );">Expiration period of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Offering of common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Award [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting', window );">Additional stock compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Performance awards vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Award [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Performance awards expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Award [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Performance awards expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | 2021 Registered Direct Offering [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="nump">4,081,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share</a></td>
<td class="nump">$ 49.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from offering</a></td>
<td class="nump">$ 189,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,251,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares execrise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">554,019<span></span>
</td>
<td class="nump">4,496,116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsMember', window );">Warrants [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares execrise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsMember', window );">Warrants [Member] | Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares execrise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsMember', window );">Warrants [Member] | Common Stock Warrants [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares execrise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sava_PlacementAgentWarrantsMember', window );">Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares execrise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,975<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PercentageOfCommissionAtmOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Commission ATM Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PercentageOfCommissionAtmOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Additional Expense Expected On Vesting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options grant in period weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options nonvested forfeitures in period weighted average contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sava_AtMarketEquityProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sava_AtMarketEquityProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sava_TwoThousandEightEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sava_TwoThousandEightEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sava_TwoThousandEighteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sava_TwoThousandEighteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sava_RegisteredDirectOffering2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sava_RegisteredDirectOffering2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sava_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sava_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sava_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sava_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sava_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sava_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797645037080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity And Stock-Based Compensation (Warrants Outstanding) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares Outstanding</a></td>
<td class="nump">554,019<span></span>
</td>
<td class="nump">4,504,091<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Issuance Date</a></td>
<td class="text">Aug. 17,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration Date</a></td>
<td class="text">Feb. 17,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price Per Share</a></td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares Outstanding</a></td>
<td class="nump">554,019<span></span>
</td>
<td class="nump">4,496,116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sava_PlacementAgentWarrantsMember', window );">Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Issuance Date</a></td>
<td class="text">Aug. 17,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration Date</a></td>
<td class="text">Feb. 17,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price Per Share</a></td>
<td class="nump">$ 1.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,975<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sava_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sava_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797649411288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity And Stock-Based Compensation (Stock Option Activity) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stockholders' Equity And Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of, Beginning</a></td>
<td class="nump">3,210,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="num">(71,105)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited/canceled</a></td>
<td class="num">(382,356)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of, Ending</a></td>
<td class="nump">2,817,504<span></span>
</td>
<td class="nump">3,210,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at December 31, 2020</a></td>
<td class="nump">2,817,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at December 31, 2020</a></td>
<td class="nump">2,167,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding as of, Beginning</a></td>
<td class="nump">$ 12.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options granted</a></td>
<td class="nump">7.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options exercised</a></td>
<td class="nump">3.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options forfeited/cancelled</a></td>
<td class="nump">20.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding as of, Ending</a></td>
<td class="nump">11.30<span></span>
</td>
<td class="nump">$ 12.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested and expected to vest at December 31, 2020</a></td>
<td class="nump">11.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable at December 31, 2020</a></td>
<td class="nump">$ 13.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">6 years 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Vested and expected to vest at December 31, 2020</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Exercisable at December 31, 2020</a></td>
<td class="text">4 years 10 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 6.4<span></span>
</td>
<td class="nump">$ 4.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest at December 31, 2020</a></td>
<td class="nump">6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable at December 31, 2020</a></td>
<td class="nump">$ 3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797647837368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity And Stock-Based Compensation (Information About Stock Options Outstanding) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of outstanding options, Options outstanding | shares</a></td>
<td class="nump">2,817,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years), Options outstanding</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price, Options outstanding</a></td>
<td class="nump">$ 11.30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of vested options, Options exercisable | shares</a></td>
<td class="nump">2,167,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price, Options exercisable</a></td>
<td class="nump">$ 13.86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeOneMember', window );">$0.95 - $1.88 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, Minimum</a></td>
<td class="nump">0.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, Maximum</a></td>
<td class="nump">$ 1.88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of outstanding options, Options outstanding | shares</a></td>
<td class="nump">659,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years), Options outstanding</a></td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price, Options outstanding</a></td>
<td class="nump">$ 1.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of vested options, Options exercisable | shares</a></td>
<td class="nump">251,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price, Options exercisable</a></td>
<td class="nump">$ 1.31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeTwoMember', window );">$3.24 - $4.09 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, Minimum</a></td>
<td class="nump">3.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, Maximum</a></td>
<td class="nump">$ 4.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of outstanding options, Options outstanding | shares</a></td>
<td class="nump">812,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years), Options outstanding</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price, Options outstanding</a></td>
<td class="nump">$ 3.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of vested options, Options exercisable | shares</a></td>
<td class="nump">643,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price, Options exercisable</a></td>
<td class="nump">$ 3.48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeThreeMember', window );">$4.10 - $13.09 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, Minimum</a></td>
<td class="nump">4.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, Maximum</a></td>
<td class="nump">$ 13.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of outstanding options, Options outstanding | shares</a></td>
<td class="nump">598,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years), Options outstanding</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price, Options outstanding</a></td>
<td class="nump">$ 10.89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of vested options, Options exercisable | shares</a></td>
<td class="nump">525,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price, Options exercisable</a></td>
<td class="nump">$ 11.42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeFourMember', window );">$14.21 - $35.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, Minimum</a></td>
<td class="nump">14.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, Maximum</a></td>
<td class="nump">$ 35.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of outstanding options, Options outstanding | shares</a></td>
<td class="nump">619,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years), Options outstanding</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price, Options outstanding</a></td>
<td class="nump">$ 24.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of vested options, Options exercisable | shares</a></td>
<td class="nump">619,599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price, Options exercisable</a></td>
<td class="nump">$ 24.02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeFiveMember', window );">$36.40 - $53.55 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, Minimum</a></td>
<td class="nump">36.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, Maximum</a></td>
<td class="nump">$ 53.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of outstanding options, Options outstanding | shares</a></td>
<td class="nump">127,661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years), Options outstanding</a></td>
<td class="text">8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price, Options outstanding</a></td>
<td class="nump">$ 51.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of vested options, Options exercisable | shares</a></td>
<td class="nump">127,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price, Options exercisable</a></td>
<td class="nump">$ 51.72<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797648882504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity And Stock-Based Compensation (Weighted Average Fair Value Of Options Granted) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stockholders' Equity And Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, Minimum</a></td>
<td class="nump">123.00%<span></span>
</td>
<td class="nump">118.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, Maximum</a></td>
<td class="nump">139.00%<span></span>
</td>
<td class="nump">119.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rates, Minimum</a></td>
<td class="nump">0.46%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rates, Maximum</a></td>
<td class="nump">0.78%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of option</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Forfeiture rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of stock options granted</a></td>
<td class="nump">$ 6.69<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797657778600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity And Stock-Based Compensation (Summary Of Performance Award Activity) (Details) - Performance Award [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding as of, Beginning</a></td>
<td class="nump">138,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested performance awards</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited/Cancelled</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding as of, Ending</a></td>
<td class="nump">138,055<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797658489048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity And Stock-Based Compensation (Non-Cash Stock-Based Compensation Expenses) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total non-cash stock-based compensation expense</a></td>
<td class="nump">$ 988<span></span>
</td>
<td class="nump">$ 1,296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total non-cash stock-based compensation expense</a></td>
<td class="nump">453<span></span>
</td>
<td class="nump">542<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total non-cash stock-based compensation expense</a></td>
<td class="nump">$ 535<span></span>
</td>
<td class="nump">$ 754<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797574904072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S federal corporate tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance increase (decrease)</a></td>
<td class="num">$ (1,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">4,500<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=sava_WriteDownOfShareBasedCompensationMember', window );">Write Down Of Share-Based Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance increase (decrease)</a></td>
<td class="num">(2,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=sava_BookLossesMember', window );">Book Losses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance increase (decrease)</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Pre-tax net operating loss carryforwards</a></td>
<td class="nump">87,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Expires Between 2029 And 2039 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Pre-tax net operating loss carryforwards</a></td>
<td class="nump">74,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Indefinitely [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Pre-tax net operating loss carryforwards</a></td>
<td class="nump">13,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Expires Between 2023 And 2039 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Federal research and development tax credits</a></td>
<td class="nump">$ 11,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Minimum [Member] | Expires Between 2029 And 2039 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Expiration date of pre-tax net operating loss carryforwards</a></td>
<td class="text">Jan.  01,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Minimum [Member] | Expires Between 2023 And 2039 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardExpirationDate', window );">Expiration date of federal research and development tax credits</a></td>
<td class="text">Jan.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Maximum [Member] | Expires Between 2029 And 2039 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Expiration date of pre-tax net operating loss carryforwards</a></td>
<td class="text">Dec. 31,  2039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Maximum [Member] | Expires Between 2023 And 2039 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardExpirationDate', window );">Expiration date of federal research and development tax credits</a></td>
<td class="text">Dec. 31,  2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of each operating loss carryforward included in operating loss carryforward, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of the tax credit carryforward, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=sava_WriteDownOfShareBasedCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=sava_WriteDownOfShareBasedCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=sava_BookLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=sava_BookLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=sava_ExpiresBetween2029And2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=sava_ExpiresBetween2029And2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=sava_IndefinitelyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=sava_IndefinitelyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=sava_ExpiresBetween2023And2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=sava_ExpiresBetween2023And2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797664652632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule Of Effective Income Tax Rate Reconciliation) (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax at federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of federal benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="num">(42.80%)<span></span>
</td>
<td class="num">(2.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">20.20%<span></span>
</td>
<td class="num">(19.20%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797646752584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Schedule Of Deferred Tax Assets And Valuation Allowance) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 18,333<span></span>
</td>
<td class="nump">$ 17,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">3,230<span></span>
</td>
<td class="nump">5,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">6,687<span></span>
</td>
<td class="nump">6,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">28,514<span></span>
</td>
<td class="nump">29,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(28,447)<span></span>
</td>
<td class="num">(29,725)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets:</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease right-of-use assets</a></td>
<td class="num">(62)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities:</a></td>
<td class="num">(67)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax asset / (liability):</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797649519768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule Of Unrecognized Tax Benefits) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current year</a></td>
<td class="nump">100<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending Balance</a></td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797648978760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases And Commitments (Narrative) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_LeasesAndCommitmentsLineItems', window );"><strong>Leases And Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">295<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="nump">$ 316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Leases, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets exchange for operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease liabilities</a></td>
<td class="nump">$ 99<span></span>
</td>
<td class="nump">$ 95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=sava_AustinMember', window );">Austin [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_LeasesAndCommitmentsLineItems', window );"><strong>Leases And Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Office space | ft&#178;</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">Apr. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_LeasesAndCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Leases And Commitments [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_LeasesAndCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sava_AustinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sava_AustinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797675586392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases And Commitments (Future Minimum Lease Payments) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>For the year ending December 31,</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 293<span></span>
</td>
<td class="nump">$ 316<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139797647780232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>2020 Cash Incentive Bonus Plan (Narrative) (Details) - Cash Incentive Bonus Plan [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Oct. 13, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanLineItems', window );"><strong>Cash Incentive Bonus Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment', window );">Percentage of each cash bonus award associated with Valuation Milestone subject to adjustment and approval</a></td>
<td class="nump">59.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_PaymentsForCashIncentiveBonus', window );">Payments authorized or made to participants under the Plan</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sava_CashIncentiveBonusPlanMember', window );">First Valuation Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanLineItems', window );"><strong>Cash Incentive Bonus Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_CashIncentiveBonusAward', window );">Cash bonus award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanLineItems', window );"><strong>Cash Incentive Bonus Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_PerformancePlanValuationAmount', window );">Valuation milestone amount in market capitalization</a></td>
<td class="nump">200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Exceeds $5 Billion Market Capitalization For No Less Than 20 Consecutive Trading Days [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanLineItems', window );"><strong>Cash Incentive Bonus Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_CashIncentiveBonusAward', window );">Cash bonus award</a></td>
<td class="nump">137.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Second Through Eighth Valuation Milestones [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanLineItems', window );"><strong>Cash Incentive Bonus Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_CashIncentiveBonusAward', window );">Cash bonus award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanLineItems', window );"><strong>Cash Incentive Bonus Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_PerformancePlanValuationAmount', window );">Valuation milestone amount in market capitalization</a></td>
<td class="nump">5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Exceeds $5 Billion Market Capitalization For No Less Than 20 Consecutive Trading Days [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanLineItems', window );"><strong>Cash Incentive Bonus Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_CashIncentiveBonusAward', window );">Cash bonus award</a></td>
<td class="nump">$ 322.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Second Through Eighth Valuation Milestones [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanLineItems', window );"><strong>Cash Incentive Bonus Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sava_CashIncentiveBonusAward', window );">Cash bonus award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_CashIncentiveBonusAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Incentive Bonus Award</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_CashIncentiveBonusAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_CashIncentiveBonusPlanLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Incentive Bonus Plan [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_CashIncentiveBonusPlanLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PaymentsForCashIncentiveBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Cash Incentive Bonus</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PaymentsForCashIncentiveBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Valuation Milestone Cash Bonus Award Subject To Approval And Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PerformancePlanValuationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Performance Plan Valuation Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PerformancePlanValuationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sava_CashIncentiveBonusPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sava_CashIncentiveBonusPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=sava_FirstValuationMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=sava_FirstValuationMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=sava_Exceeds5BillionMarketCapitalizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=sava_Exceeds5BillionMarketCapitalizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=sava_SecondThroughEighthValuationMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=sava_SecondThroughEighthValuationMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>58
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M[ONI/[0&V1M?.=OIHVMBI[*4\M'>S*++EF,9L9B%QD)0^/?$)BR.+1+P^*<
M;1W&M(;'UWOTVVSR,)DEU6PBXV\\,IO+UK!%(K:B:6SNY>X#*R;4MWBAC'7V
ME^SR=WN]%@E3;612& .#A(O\/WTN''%D,'1.&'B%@??*P#TU@E\8^$T->H5!
M+_-,/I7,#U-JZ-6%DCNB[-N 9B\R9V;6,'TN;-P#H^!7#G;F:BK#%,)HR%A$
MY$88;E[(3.3KR<:E3;X$4_+VS;N+KH'AK%$W+*"O<VCO!+3KD3LIS$8#;L2B
M'P&ZP/- UMN3O?90Q"D+.\1WSXCG>$X%H0EN?D=5A[C#S-RM,)_BYK^E D9W
MJD;_83;^P?5^AN?_3]?_-5YJHV!C_(T,UCL,ULL&Z]4-]O"R956QQ,U=I_T1
M8=$_L.@W8S$6(J4QN6=;J4P5'1S'J)0A= 8'.H-F=&ZY#H'.@BDN(W(+CW45
M*1SM]CM"Z?Q Z1P%F:1*'3'ZSJBRVX? YJX,&X[6;KM>VW<17L,#K^%_<E5&
M[*2C<*R:_3,Z4!HUHU2$#7-3#5*A*S__]%,--]<I==5IN.$4A2R9[>C3R[T&
M;$5CC2UX]TCN712IT)E;'C,R3Y,E4Y5T<!#'<=K>:-0?892\DI+7A-(]6W.K
M=^"R.4TJHU@#-!D'P?CKF 23V<U\<A.0V7R",2R%VO6;,)R)4"J(8";/9R0P
ML-B(5&0B4V'4"_R/JFGCZ-,;C&0I\"XNT07)!_I,9A$L/+[B89Y(D#CCD".W
M[8Y<U_<'&,-2_%U<M0N&XRA23.NS_07Y!.^1SZ+:=SCD^=!QR;Q#)G3+#<B2
M7)$']DPU^0#UWHZ^8+S++.'BPH[R?MC)2MXX9)!R6#O> -6:,F>XN,R_)CBQ
M=[ P'^1.5)+#X<90=G*!,2NSAHM+_6MFASVS4/*)B[ ZYCCFPQ\8M3)[N+CH
MOZ:VD-JNH#_Y]O1&QA'/A^=HKO7*Y.'A>I\%< SGN)-4:@#ZKH<1*=.%ARO]
M)YG511LIL'11 ])WW+;7Z_4P1F6V\'"1?^ &4A?L<]=[NWQ' A:F"KQ52:LF
M7<@D 74,C P?S\@;I^. EFRAK'FB,5I>>F7B\'!IA]P?<;$FP4NRE'$E1QQ
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M9Q2H-Y;7^W+=D:PT6]N:2;51FF:FSC+ =8"ZOV%,OG3T;MF>CN)_4$L#!!0
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M?UU*#DXYYD3ZDD.V?A<W)(,CLZUCQI_M5-*0\A%1:._E>X;IZK4797(^P$F
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M- #?+YQKXP=BD'[M^.:_ 5!+ P04    " "GB'=2CM0*)_T"  #]!@  &
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MO4><;7!F#4ZZ!Z>;PJU6KK!PHSCRWP%B(M4R2[?,9NE!Q#EF'>AU3R%-TN0
M7J]5V@MXO7]2"M^G2^L,'8X?!W+TVQS]D*/_W]4\C-/K0 O%=J'>G1R=GZ6#
MBZMWGPN$:UU63+V<' W3[N#*0K4;@ZU$H3)9<X2\-DJXVN ?]@[,D6YT)EBX
M*,+2;<OT2HF?R*&V0JW 439?)G_&WWNV4*(K- ?]A"98\;FBBT8!4N0(.@^+
M;Q/JO*J8UV8+_X+, /K#0W0R+)<$O-W^T^"QD0M62TY=Q%2RMG075)W3]C5
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M%^>O(' LKO(UG*"4I,?G%Q7(TN:+N2'Q2I,([R$1A.)]GE6K4KS)8A7W#[@
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M9@0'+0O@^]( &\T#;]#=BE_]'U!+ P04    " "GB'=2\BPICDD4   )0
M&0   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6R]6WN/VT:2_]^?HC$)<C:@
M>4@S8X^?P,PXOOB0> U/LHO#X8!KD2V),<56V.2,M9]^?U75W6Q*%.W-+@[(
M@T-U5U77^]%\]6#KSVYE3*.^K,O*O3Y:-<WFQ>FIRU9FK=V)W9@*ORQLO=8-
M_JR7IVY3&YWSIG5Y.CL[>WJZUD5U].85O_M8OWEEVZ8L*O.Q5JY=KW6]O3&E
M?7A]-#T*+SX5RU5#+T[?O-KHI;DSS6^;CS7^.HU0\F)M*E?82M5F\?KH>OKB
M9OJ4-O"*OQ;FP27/BHXRM_8S_?$^?WUT1A29TF0-@=#XW[VY-65)D$#''Q[H
M4<1)&]/G /T='QZ'F6MG;FWYMR)O5J^/KHY4;A:Z+9M/]N$GXP]T2? R6SK^
MKWJ0M9?/CU36NL:N_690L"XJ^;_^XAF1;+@Z.[!AYC?,F&Y!Q%2^U8U^\ZJV
M#ZJFU8!&#WQ4W@WBBHJD<M?4^+7 ON;-G4A#_66A[HIE52R*3%>-NLXRVU9-
M42W51UL666&<>LQ/VR>O3AL@INVGF4=R(TAF!Y!,9^H76S4KIWZL<I/W 9R"
MXDCV+)!],QN%^-9D)^I\.E&SL]G9"+SSR(9SAG?^K[/A?Z[GKJFA3?\[@O<B
MXKU@O!<'\/[F#.'\T34%-,RX(=Z.0B"K?>$V.C.OCV"6SM3WYHC!V@3LHQ^^
M>WHY>_;\Y:-?5T9AW4;7FJT"JQ9%I:NLT*5R#1;#Y!JGBDIEMB*K+YHM=+)9
MP8 B,S9U@1V;$NQ8FLK4NBRW]+O9-":GO0W0_%85]-<= 76PX#_: @3B)]U
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M&G3ZV/5D/8W5&RV6=@*:"XWSE%WF.,""- +X/A-"[S;&0#,2C_\%4$L#!!0
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M.I16P9QOA=#/&WM!.R;._P-02P,$%     @ IXAW4DNP!A#C @  3 @  !D
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MF 4HZ]@/>-;C!*73PQ:GZ09:PT!O# FWC&;PGNQ10"Q]'?:#C7H;!D)YSRS
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M )J>+(X&%AR_6A+?Z/._;$G^&<^$Y&I'_&LQWZW,=XWY;HOYGVLI),GC)%\
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M0E78>/&MHFA(MC+7_1F3DF7F<4F)NDSJ >K]G#'YWM &JB]&H_\ 4$L#!!0
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M'!SL.5BLQHYP,-+R@LZ4EYX<K-P$!]5*#0R"M$0@NT0,Q\'*T8% $XS'!IE
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MRAK0?BJEV4_L <V3&?T"4$L#!!0    ( *>(=U(*SD[C!P,  #$)   9
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M(Q)Y?\X7BJ]LBYMSI1NFG:;Z30/"".CS!>=JMS .RE=2[S]02P,$%     @
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MM>*B)A)6,^^>3A[HT"A8B>\<]NKLF1A77H3X:19?\ID7&"(H(=/&!,._'3Q
M61I+R/&K,>JU>QK%\^>C];^M\^C,"U/P(,H?/-?%S$L]DL.*;4O])/;_0.-0
M;.QEHE3VE^P;V< CV59I437*2%#Q^O#/7IM G"F@HVZ%L%$(/ZH0-0J1=?1
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M >2X8"MA[]3F*S9Z^@XO4\+X7]@TOE$ V<I853;!Q*#DLOYG3TT>=@(ZR9&
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M  T8$L?-/KBW'X7K?2K<_/\U^@U02P,$%     @ IXAW4I>*NQS     $P(
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MH]ZL0&]&O5F!WHQZLP*]&?5F!7HSZLT*]&;4FQ7HS:@W*]!;4&]1H+>@WJ)
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ IXAW4IE<G",0!@  G"<  !,
M             ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M" "GB'=2EV*^VX$&  ",&@  &               @($-"   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ IXAW4G\)K3@$!0  R!,  !@
M             ("!Q X  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4
M Q0    ( *>(=U*#*88(H (  "D)   8              " @?X3  !X;"]W
M;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " "GB'=2E^1#^F8#  !E
M"@  &               @('4%@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL
M4$L! A0#%     @ IXAW4CD;&*>+!0  -AX  !@              ("!<!H
M 'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( *>(=U)94B?4
M7P4  ,,4   8              " @3$@  !X;"]W;W)K<VAE971S+W-H965T
M-BYX;6Q02P$"% ,4    " "GB'=2JV!=&8X%  !6#   &
M@('&)0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ IXAW
M4A!-HBL^$P  ^3@  !@              ("!BBL  'AL+W=O<FMS:&5E=',O
M<VAE970X+GAM;%!+ 0(4 Q0    ( *>(=U*.U HG_0(  /T&   8
M      " @?X^  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *>(=U+9]"318 @  "$7   9              "
M@;E?  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ IXAW
M4O(L*8Y)%   "4   !D              ("!4&@  'AL+W=O<FMS:&5E=',O
M<VAE970Q-2YX;6Q02P$"% ,4    " "GB'=2UHJDJ_("  #6!@  &0
M        @('0?   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0
M   ( *>(=U)/-"U .P8  .81   9              " @?E_  !X;"]W;W)K
M<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ IXAW4J]A>>0V!   '@L
M !D              ("!:X8  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q0
M2P$"% ,4    " "GB'=2&==CE7("  !M!0  &0              @('8B@
M>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( *>(=U*%\$SD
M#0(  '@$   9              " @8&-  !X;"]W;W)K<VAE971S+W-H965T
M,C N>&UL4$L! A0#%     @ IXAW4B$T5&/, @  &0<  !D
M ("!Q8\  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " "G
MB'=2S30:>UT#   R"@  &0              @('(D@  >&PO=V]R:W-H965T
M<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( *>(=U)+L 80XP(  $P(   9
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M970R-RYX;6Q02P$"% ,4    " "GB'=2$OMA)DL#   2"P  &0
M    @(&XKP  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (
M *>(=U+GN]/3N@(  #X'   9              " @3JS  !X;"]W;W)K<VAE
M971S+W-H965T,CDN>&UL4$L! A0#%     @ IXAW4@K.3N,' P  ,0D  !D
M             ("!*[8  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"
M% ,4    " "GB'=2>4R?CK$$  #6%@  &0              @(%IN0  >&PO
M=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( *>(=U(NO5@J"0,
M )H)   9              " @5&^  !X;"]W;W)K<VAE971S+W-H965T,S(N
M>&UL4$L! A0#%     @ IXAW4LWT'&V. P  U@L  !D              ("!
MD<$  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " "GB'=2
MC&B-D*4"  "G!@  &0              @(%6Q0  >&PO=V]R:W-H965T<R]S
M:&5E=#,T+GAM;%!+ 0(4 Q0    ( *>(=U*.SI;I7@,  ,D*   9
M      " @3+(  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%
M  @ IXAW4DH,(-6/ @  *@<  !D              ("!Q\L  'AL+W=O<FMS
M:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " "GB'=2HRS 8T($  #;$
M&0              @(&-S@  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+
M 0(4 Q0    ( *>(=U*FD79]*@,   P3   -              "  0;3  !X
M;"]S='EL97,N>&UL4$L! A0#%     @ IXAW4I>*NQS     $P(   L
M         ( !6]8  %]R96QS+RYR96QS4$L! A0#%     @ IXAW4K5 L F(
M P  2QD   \              ( !1-<  'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0    ( *>(=U*9/J*$? $  )86   :              "  ?G:  !X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( *>(=U*J9Q1AF $
M  L7   3              "  :W<  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@     M "T ,@P  ';>      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>101</ContextCount>
  <ElementCount>297</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>38</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Statements Of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/StatementStatementsOfOperations</Role>
      <ShortName>Statements Of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00400 - Statement - Statements Of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/StatementStatementsOfStockholdersEquity</Role>
      <ShortName>Statements Of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00500 - Statement - Statements Of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/StatementStatementsOfCashFlows</Role>
      <ShortName>Statements Of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - General And Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureGeneralAndLiquidity</Role>
      <ShortName>General And Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary Of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary Of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Property And Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property And Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Stockholders' Equity And Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensation</Role>
      <ShortName>Stockholders' Equity And Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Employee 401(k) Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureEmployee401KBenefitPlan</Role>
      <ShortName>Employee 401(k) Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Leases And Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureLeasesAndCommitments</Role>
      <ShortName>Leases And Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - 2020 Cash Incentive Bonus Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlan</Role>
      <ShortName>2020 Cash Incentive Bonus Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary Of Significant Accounting Policies (Policy)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy</Role>
      <ShortName>Summary Of Significant Accounting Policies (Policy)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Summary Of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary Of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationTables</Role>
      <ShortName>Stockholders' Equity And Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensation</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Leases And Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsTables</Role>
      <ShortName>Leases And Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureLeasesAndCommitments</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>40101 - Disclosure - General And Liquidity (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureGeneralAndLiquidityNarrativeDetails</Role>
      <ShortName>General And Liquidity (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureGeneralAndLiquidity</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Summary Of Significant Accounting Policies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary Of Significant Accounting Policies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Summary Of Significant Accounting Policies (Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Summary Of Significant Accounting Policies (Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Property And Equipment (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentNarrativeDetails</Role>
      <ShortName>Property And Equipment (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stockholders' Equity And Stock-Based Compensation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Warrants Outstanding) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationWarrantsOutstandingDetails</Role>
      <ShortName>Stockholders' Equity And Stock-Based Compensation (Warrants Outstanding) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>40403 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Stock Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stockholders' Equity And Stock-Based Compensation (Stock Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40404 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Information About Stock Options Outstanding) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails</Role>
      <ShortName>Stockholders' Equity And Stock-Based Compensation (Information About Stock Options Outstanding) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40405 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Weighted Average Fair Value Of Options Granted) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationWeightedAverageFairValueOfOptionsGrantedDetails</Role>
      <ShortName>Stockholders' Equity And Stock-Based Compensation (Weighted Average Fair Value Of Options Granted) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40406 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Summary Of Performance Award Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationSummaryOfPerformanceAwardActivityDetails</Role>
      <ShortName>Stockholders' Equity And Stock-Based Compensation (Summary Of Performance Award Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40407 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Non-Cash Stock-Based Compensation Expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNonCashStockBasedCompensationExpensesDetails</Role>
      <ShortName>Stockholders' Equity And Stock-Based Compensation (Non-Cash Stock-Based Compensation Expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Income Taxes (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40602 - Disclosure - Income Taxes (Schedule Of Effective Income Tax Rate Reconciliation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes (Schedule Of Effective Income Tax Rate Reconciliation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40603 - Disclosure - Income Taxes (Schedule Of Deferred Tax Assets And Valuation Allowance) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails</Role>
      <ShortName>Income Taxes (Schedule Of Deferred Tax Assets And Valuation Allowance) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40604 - Disclosure - Income Taxes (Schedule Of Unrecognized Tax Benefits) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes (Schedule Of Unrecognized Tax Benefits) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Leases And Commitments (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsNarrativeDetails</Role>
      <ShortName>Leases And Commitments (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40702 - Disclosure - Leases And Commitments (Future Minimum Lease Payments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases And Commitments (Future Minimum Lease Payments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="sava-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40801 - Disclosure - 2020 Cash Incentive Bonus Plan (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails</Role>
      <ShortName>2020 Cash Incentive Bonus Plan (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlan</ParentRole>
      <Position>37</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>sava-20201231.xml</File>
    <File>sava-20201231.xsd</File>
    <File>sava-20201231_cal.xml</File>
    <File>sava-20201231_def.xml</File>
    <File>sava-20201231_lab.xml</File>
    <File>sava-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>63
<FILENAME>0001069530-21-000020-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001069530-21-000020-xbrl.zip
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M_A-@#J _,7SA.%BIHI:$>UOC5AOK:B+3<R<4%SG^E3VZ/&(ALV_<D%G1K>/
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M5P"/[7HQIK#OF!6';N0R_N&[Y<4VLS^&P1AOBXTC,=BMD_9=_<)">9_L=/D
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M9Y\@F(]<RYU@MR:Y9T-GMPG),2V A_E<F!4@($'[PR,VD4]SX*18@&)^Q4>
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M#W[U8/@H&1.E,1J%C)$QH#6"SR'Q&.<D"LB0+8#:('\7DY%D,HF>G"(:T8A
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M$]J5$U1DB;)FH9%?G=PPA\%2VI97%-S3[\I%SLIF^/I*C6U2F?DS9^NF?1F
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MKGQ[-M7[Z?UTPJZ^NWSV[.RWWT2,LZ0\\,V+D,JP, H&#IL*%%OM;JY"<3N
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MMT%#%VRR$P9CX@E>*WG>CT&HYF+%S_EDH3M+QR2IXF1R0HFP#1>!<Q%S=5.
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MQ/W-R_ I)O1%\;%M<?$T];Y0%T3CFD[PKO6R<2C6OZ0@#O#U./!%$/,RN!5
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M?/.#9Y]03K[@KN+]" 1@PF)0_^3%<_!$3\P+)APW*2>ARR(:3O%O.[;2"H[
M<5A(,&7L.JY%<=$DD\:STJH)Z.&LI&O$J!>-+-PGA*<<QKFHY^#Y(H1'*8T
MHQ-8L<@S13R=.(5*;! P!]#!L@Q1:"+N99C5:, 83T',"9]RL!"Z&*L42[7I
M;HQ#550J=^?,+/1U$()P/;DA" $X#W$S-"[@R(_7M__X='-A#'YZ7:HMOV!G
M?R2;HT>]K1\8D.)E<$E%ZCEY!A#Y)&34QO*S(?SQ#>T(!5Z!M8%WQ"X/FA,[
MD20+#!2SR2HA.\=2LE3.SLF(RK(JQ5)B&:S8E<&ML!5[,7.UI=F&#,0ZLA@.
M#3@ ^AL-K5'FS\W6>5+Y59PF?P^>P<*&284=@&2SL6L)#"R@"X)+B3WU*7Z+
M1ATW861I"G>CF,H*,UE,XE-9L$<8 !R,IWD[CP&;Z\=R[Q9C.UA3D7$ ZZ"D
M- 3W"7F$U >G)0>&)\?T&R,1" ^6 <K? *9AS%VQ-XGK)RXH)HJ(XR'8A[G]
MQT<(5--:H$D0@02H>V1.AG12RZ9P <=<P@:)&+?@R=P 6!OC3U#*4&>0=%C
M!T-Z@?]X ;HQ5LKFMI&"%?.#./HH7T,LW*$<:#X$6F(T/Y8<2RKXD&SU*D&I
M56G)MF<'LAA]IO(ZOCDR[%1+B,;5E;E_.Q=-^RP"4X&%@$+S?3!=HM@@.V4
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M%I2OF?"]&Z83GRD5A58L."TX?$4B1A)+,_MK6-@%7UG82@KV,H,&4S?L76C
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M8!DU=L)MW$G%1' ]WNL[%H1S+\!4,%HIY, 5,S#( 4P$=X@#B$)-<P!1"-/
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MEHI<K5QYWV==LRC/5'0DJ24]DSN1[FJP$LT8#'L#RU(C$=9Y:48.*.&<-YV
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M/*]+HVIP^AOGJ&1>S]6]_L89(+=*Y=M01+M%\AF<'I%9K$6W,*!0K$@+5>N
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M^CN>3OI]@](A"(1M /B,;&<ZI88]-JAIL8/R; SM@3L=3<SAU+$-F.K8G)C
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MTPKR#U4'/%)Q;*T3_33X@NO4^:5PU'!=GZK;D;',4\8B\ C+V@!!3+?G7K!
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MOWAXP@!6T/\P7$^ZA[ ,R&NWHSN^V+9GV6"=R4N_?WAY<LS/_P=02P,$%
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M;3PQZ[N3;'>Q@$Y%GA_HX6DK/-3XY7]02P,$%     @ IXAW4L6/JN^;"@
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MA7A% R]@>EZ^PDR+&3GMCY43JJ[NN( Z^$:;.!/&-])XQ2(.A0,W40B_W.,
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MRT+()FS^?6<R2:],:T%U@C,37#'F:J4A1*R;F8"RB-"6O$)QOV-QN+JJ$(2
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MJ/K&1IA817+V#X$=+2O4-(!8"[-XSK:IN:3SGM$"1D3 F/X#"P)&%2*3;9I
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MR$1'Y MJKM,7R&*ZLV<*9<9SB,AITK-G#FK>XR"39.J3Y=D)^/1'B #F&!'
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M2R&ZWI!*A8#U!/4#&]9<X?B$XHD-2Y8@O,/\)H7*1<!>V)A*G*ZSA':D[+B
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M/#>XP24FIOE 'V:FI]]LU%QFR3*.BUVTMC]%&-@0P)G"*)';$X9!K<"<-XR
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MD?X=)Y^S!!>?Z#.77$W71 7EV5,G#>6&:OA6\U#/W)T"!3XOJNP$OUE[]!\
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MU/)0Z)(!(XR=_,LTNDO7:95BAX,N*1.X$VA$4;B#A /2,91P]"XBL 5XVC5
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MEUFR3/ZZ*RM)D=V)VX:)#9,J1HPBDS0,%F\F1"_SZKIYP9_;#A ;YOC@QOI
M=2?H-D=--^SV[;XC[Z'L_ZO''"4]Z2A?(1S%#R1Z$KW<,;U$3"]16>9QRFII
M?4FK!ZDRRUIW58ZBMD]69SFJT<RZEF *L)L@UJ1!K!TZL#5K!D87REI! &,W
MLV8,T.N"@%#K'7X =,%9IYSLU+O4[_.BCTD:JO0,$-,2&Q'V<PT=-= $P@RI
M'])K'D232V6F[7F0/QH1# /Q&#FB7?60%ZR8)Y%H$R68CI3;J*C2.-U&E&27
M)9@G ]/5$-S1D/)1A;.G6]*WI-R?$R?,L8^#4.(ACP6;]R,=:TS*YR^D+WLL
M$.6>NGK@=-9'T4EK"CIQ!F9]?:&LK&_/%H[U'6)2/[["C6\I&E]M>R"%":>3
M3.M7(ZH73N-9+2)IO4,E%8S'*,"*WG% XMT3I/WW;&-OXC E!MW0?HBRW2J*
MJUU!C_?-V,?4WJP^L,U:V@EQNH)6^MQH2G'JR"$J<YKA[PMUJFF!ZG:: /4K
M4%8GMP_XA+,ASH=J1JCBG@.$0  "&*I_NDMQ^V&4/TXSFO1?R3U[.GQ/5+-4
ML&>'&7]<Q1,')EM>[R.6&S#-T5O+C^Z>4/^I6_!%Q*%0VG6#BAC\]2()=-V3
MR$ + AT,BV>1@2?]<Z$?,3'Z2Y%69+WQ);M:?7J("GQ&7S<YSS>T<!T__E%.
MDJQ9 29,CF*UDR=+/IB)E!.XGCTQ;D39T=4*L080:P&)30!-KXY?-/W$:W+Y
M3ASD&Q$>SO+\]\N<!)]2'0?Z-  .KP+:>O8A 8P+RU'T/C@E0YP.R"%# ZIW
MKPG13IYTK'8</7T0*0-] 0RYQI#.94;DDIL+XG;'(X)K6L$,<HQP57K]!B?E
MCV?I>DU'7[8K<MY)Y%3[K0,S@!,[B]9ZM#4GC'L[PNMOCG-^]".J6VCVY[IM
M 'G^1-*!"J>/"5-]OS^89*1I'!]S1._/H=L'$D!>O203Y:S$\8Z%EMLBXJ7/
MHJ=9Y@'OTZ*L^OF3ZH!B8  ((E8BM(%#2PT3+"P@]<OC41YIOBE,2#@B&?2>
M[T>0$1[["1.'2&X?BGQW__".EO-]Z,/5+('=^ '\>8B K7N[,,-XNSM"R>.5
MM E4MX%X(S+[@UJ1/R,9]=$"7M#ZWY<$&?EO\E_D'_39[W__?U!+ P04
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M2-^:.8>_3N/'Z#5DZ>4CY4"UPA"@U,FF+:-OG>#)<1K?Q=&+GU\ I2IF+?E
MM<,C1:FB30M%WRJZBY+4"?[7?Z:NWYH2#U0];!E*Y6S:'?JPT**6QL AJ*/Z
M]7 4P&QU";D6TP"Z8![<+:*0;!I83S(<Z+E:7L*OQ3;P -PLA@39/WAZ1*?:
M#?"O)QD._%PM+^'?- CT /]C["!OUH?WY5,4-&!?^WXXP+.;71ZM;F[*C3;#
ME(RZ?',73C@'!%-:4[+A:(^[]:42->[9_P!!\/<0+L8?@)/ <=:[3I*,8EDA
MI!^.<L3%*+6D<?_^>Q1D$+\86\GCIA/2QG1#TPI/\TMM:-RS%T?S^5D1&J8A
MAHW'UK3D0].-@!2EBC1NX:]#.+$YV%'[PDF=HO$4"W]3\J&I2$"*4D4:M_"X
MCY\[*9A'\3OU0'.5:F@*83>^U,/ O 1R\1Z63A"<98D?@H0\_-52#4V#[,:7
M&M3H%W"Y!/$<#LG?XN@U7: [14Y([E&-J8>F%WXA2OUHL0Y<N[-XDGD^+&V2
MIB#)(;P*G'F#>LB)ZX(=C$_'AX9J1U"&4CE:; =%#U_ K0"KSU03#4<9G&TO
MG8$UGN_?94^![UX%D4->HU72#$T%K*:7&M!H!T"7I(H+]CB"1O6N.'EG0\DT
M-!T)RU(J;=,L8/32K?1Y3#X<@8!W]GZ/FHPN>CV"M_0,5O=G@]:Y\PY'^=U$
M*CDPL(L4$RBQA]W1FU<BM>^'HTMVLTM]#>RB1#%"0<EB)[@./?#V=T!>K*RE
M&X[^^)M?ZE'^'8E?OZS?CY5T:Y849[H*./&>[/X>NB>[*@+^7I0R*HH1YF!)
MP9F3/&%0LN3SW'&><QZ"($W*3]8)67S\CU5KIK,K/X2-\9W@+LK=Z GW9\6R
MBG>L[D+EL0P*RQE#BL:TQO2V-FI"'5%<.B-NZG97/;I&CZ(%P!\HC,N+$Z!E
MP20]=^+X'2X"<3 @ A6X\AI'#7X5;]*CO<0*Z/(<^Q$Z<,57C75P9YHNX+16
MA9- E,V$5K&"4SSBO? !4X!'^_8JGEOGG7=*4>H$INB\>,<BG.-0,O<H?MQT
M]B,!& W2"$#+8QPGVJX>Q*54,";HH$09R!6%X$EKT5R)C*!EL880PD(:$:)"
MUK1 G0^LT3%%'%D!*BJCOPYMWOC.DQ] ( #G'I&<P1JM"XIH1'0+"?TZCUR>
MW#GO*"@_8]W7F-@X!@AJLF$ X)?3QET@%#_.8,,W8"33HCF]E<P0$-7&_6'Y
MK-,]"- 1$S=)F/GL(TL[D14L&+63IKZ-*H%X9]B8J)GLHTL+>17$2_O@RJ%&
M&R3WL$)(;2$[! 15L#;5/H1P,V(;R"#&@\Y.V>;:*E>CY&T4NFUFDX]\]K&D
MG<C$^' #GE,J4+)'#>.((,&BT=?PH.7 ^R,N/HZ2C]]A Z%+5C8EAS7*%Y51
M0;?708:&5VQ8/CRD#'68QN-3%!ACB%00%)$8HG)83+@K6XO%IWF]-*0T4/="
M.FPZN.(34I)!\P7$3U'# N!$WQQ1>,53_9_6DME' RX)E=HM3S49M3W/S\6X
M<WP/O<+Z[*?.>JP51FK[^" BJ(V6R7OTJE (O$LG#N$"*9FX;K;,L+WV LQ\
MUR>M&]@9[2-+2YF56BDU#2>;6'*O+^WC!:>,LLR2)IFC*GOL\KE,'E:PLAG(
MD<XV"'Y!985FWS!,]'PKY@[#N@"I[WZL-)A79(ZH5V1&/]5*_=ONRHR2_2($
M>1KCQN+G0,$=B/%U6JXM)"FS-;VZ@[B6W+*I(Y#?M)YDZ0+.1G]]]&HJ2]8S
M6<H.+C&M\9K>E!Q'Y!-A1)[!:C901+3$7[I):G(H"LY<5G."):<1;P-*M40*
MKC$X<EI#D+:R6N*5O1'$A;FTH.2PD10BBPJ],0D5D(&ZHB"DMI<$[+7$T,^T
M!6):\62QEPJ<2PCY)]OJ[4JK7Y+IK/#KBD+>L"L'&V%7/HH;36>C2H$:Z(TB
M5BW!JD4, Q(QM59GQ,NW9Q F<$:B-YZ8WK@^R5!*HYLAEU#:[3^HHV%][A\4
MVD2?_.,>0@SA0<% +L +"")\J[<0Z1; L>D;>D[T'OC+IPS6O=QT-6U=CG':
M%U/I!R7D(J#T;MV^GA'C&P@AM '$9N(M_1 _4HL"G1?P$,8-1BYK^--%7ALO
MVWUS_/ F2I)I^. $8#JK11]8A1X@D88KLWW<:2]V5]OC:4ZA$,SQ?;]U$GTU
M9)'"NSBQCAI\$BJ(\:!](%E)GJ_K4/]@L> CI7$\:+,X98@C:_;0?!<"/YT"
M$A29!E\8S*4F;J6:$@]9VP(267+.!-?3S"Y=2S-D];(%L20^3^E@69YUG#F)
M[Z+]E!]D*='TR\@U9,VW$<V2LZ _ (HZ![S)"YS)YL4#LM,9AJ%B\.2C2+O"
MALP<B1(K.T_JUWQ,=E)EF)$/&6;D:L'_,2J*UNN>V.(Z(%=>/2[G1=,>45 J
M5OMQ(N,ZKI!JZB[F3+DHYD+-NZ]5XW,YT2-&48AOYK[YI$4;-8^Y>B6KAZ)3
M;A'-57'E+/([:'B_GIBN+N?A^.3$%%5R:X5Z,DN14OM1D-*;A50:4/-820EQ
MB2WQ":Y<DL,V"81>#!8@3/P7D"]DZ53AS6\G;3I);XF19_W>)94OS8FM)(>
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MPS2-1+6U@4"<%&:^+6)2*RB4^H\90*:R0\%1_2/L/ >9&O-M)YGXH5 <,L\
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M,#(P,3(S,2YX;6Q02P$"% ,4    " "GB'=2S*N=%I<,  !"?@  $0
M        @ &^WP  <V%V82TR,#(P,3(S,2YX<V102P$"% ,4    " "GB'=2
MQ8^J[YL*  !WD0  %0              @ &$[   <V%V82TR,#(P,3(S,5]C
M86PN>&UL4$L! A0#%     @ IXAW4IAL(E)U&   G8L! !4
M ( !4O<  '-A=F$M,C R,#$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( *>(=U(H
M%#T;$DT  "G'!  5              "  ?H/ 0!S879A+3(P,C Q,C,Q7VQA
M8BYX;6Q02P$"% ,4    " "GB'=2 *C/JGPS   9U , %0
M@ $_70$ <V%V82TR,#(P,3(S,5]P<F4N>&UL4$L%!@     &  8 B@$  .Z0
$ 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
